although
high
regulatori
cell
popul
repres
peripher
blood
cell
contain
one
third
class
ii
express
cell
peripher
blood
highli
purifi
facssort
dr
dr
high
dr
high
high
high
treg
cell
demonstr
equival
suppress
activ
driven
vitro
dmicrot
cocultur
system
type
high
treg
cell
exhibit
cell
contactdepend
suppress
anergi
express
mrna
slightli
differ
level
substanti
differ
inhibitori
natur
dr
high
high
popul
uncov
cell
provid
differ
strength
costimulatori
signal
upon
costimul
dr
high
cocultur
exhibit
strong
earli
suppress
prolifer
cytokin
product
high
cocultur
exhibit
much
delay
suppress
late
accompani
preferenti
inhibit
cytokin
ifng
often
induct
importantli
contrast
effect
regul
two
differ
type
treg
cell
underscor
anoth
major
differ
two
type
high
treg
cell
unlik
usual
effect
reduc
immun
respons
actual
inhibit
suppress
dr
high
thu
enhanc
cocultur
respons
contrast
appear
compon
suppress
mechan
high
cell
possibl
due
differenti
involv
dr
high
high
popul
cross
regul
vitro
may
vivo
well
importantli
differ
kinet
suppress
skew
involv
dr
high
high
popul
seen
two
popul
studi
distinct
popul
thu
appar
studi
heterogen
combin
treg
popul
would
obscur
possibl
contrast
respons
possibl
differ
function
featur
may
reflect
tempor
order
util
differ
regulatori
subset
vivo
immun
respons
switch
innat
adapt
immun
chronic
progress
relaps
experiment
autoimmun
encephalomyel
reae
sjl
mous
depend
activ
cell
endogen
myelin
epitop
ie
epitop
spread
play
major
patholog
role
diseas
progress
use
transfer
naiv
cfselabel
tcr
transgen
cell
mix
bone
marrow
chimera
show
activ
naiv
cell
sjl
mice
undergo
reae
occur
directli
cn
cervic
lymph
node
spleen
peripher
lymphoid
organ
flow
cytometr
histolog
examin
cn
reae
reveal
infiltr
signific
number
dendrit
cell
dc
includ
myeloid
lymphoid
plamacytoid
subset
seen
healthi
cn
function
examin
antigen
present
capac
apc
popul
purifi
cn
mice
establish
reae
show
dc
effici
present
endogen
antigen
result
activ
naiv
tg
cell
contrast
dc
well
macrophag
microglia
capac
activ
memori
cell
current
result
indic
naiv
cell
gain
access
inflam
cn
bypass
need
activ
peripher
lymphoid
site
epitop
spread
initi
princip
within
cn
target
organ
activ
naiv
cell
involv
chronic
reae
mediat
cn
dc
infiltr
macrophag
resid
microglia
consequ
block
recruit
differenti
dc
may
viabl
target
inhibit
relaps
diseas
progress
murin
ms
model
possibl
ms
patient
author
contribut
equal
work
multipl
sclerosi
ms
inflammatori
diseas
central
nervou
system
cn
character
local
area
inflamm
demyelin
ms
present
variou
clinic
form
relapsingremit
cours
progress
cours
unusu
progress
like
devict
diseas
lesion
found
optic
nerv
spinal
cord
brain
addit
first
clinic
present
signific
proport
ms
patient
often
isol
optic
neuriti
underli
immunolog
basi
differ
form
ms
associ
diseas
like
optic
neuriti
well
defin
experiment
autoimmun
encephalomyel
eae
cell
mediat
diseas
share
mani
clinic
histolog
featur
ms
howev
date
develop
alway
associ
eae
spontan
anim
model
devict
diseas
although
myelinspecif
cell
abl
induc
eae
unimmun
mice
studi
ms
eae
suggest
b
cell
antibodi
may
play
role
demyelin
develop
tcr
transgen
mous
specif
minor
protein
cn
myelin
call
myelin
oligodendrocyt
glycoprotein
mog
previous
report
larg
proport
tcr
transgen
mice
develop
spontan
isol
cross
tcr
transgen
mice
igh
knockin
mutant
mous
th
b
cell
specif
mog
produc
mogspecif
antibodi
knockin
mice
spontan
develop
eae
howev
mice
express
mogspecif
b
cell
develop
earli
sever
form
eae
histolog
examin
central
nervou
system
anim
reveal
select
distribut
inflammatori
foci
lesion
restrict
spinal
cord
optic
nerv
lesion
pattern
typic
devict
subform
ms
import
mog
specif
b
cell
cooper
role
antibodi
develop
devict
diseas
discuss
antibodyinduc
demyelin
import
compon
patholog
multipl
sclerosi
ms
particular
antibodi
myelin
oligodendrocyt
glycoprotein
mog
elev
ms
patient
implic
mediat
demyelin
aim
studi
elucid
mechan
antimog
mediat
demyelin
show
antibodi
crosslink
mog
oligodendrocyt
result
repartit
mog
lipid
raft
lead
chang
phosphoryl
specif
protein
culmin
rapid
morpholog
alter
use
proteom
analys
identifi
target
protein
whose
phosphoryl
state
alter
upon
antimog
treatment
protein
fell
function
categori
relat
regul
signal
transduct
lead
cellular
stress
respons
cytoskelet
instabl
chang
specif
antimog
although
crosslink
myelin
associ
glycoprotein
mag
also
instig
signal
modif
distinct
observ
mog
result
oligodendrocyt
morpholog
alter
next
appli
find
eae
model
analyz
antibodi
mog
develop
immun
mice
mog
rat
human
origin
interestingli
although
regimen
result
eae
similar
antimog
antibodi
titer
evalu
elisa
human
mog
requir
b
cell
diseas
induct
igg
human
rat
mog
bound
unfix
rodent
oligodendrocyt
induc
repartit
mog
lipid
raft
morpholog
alter
data
suggest
novel
mechan
antibodi
pathogen
b
cell
mediat
eae
provid
vitro
tool
determin
whether
autoimmun
antibodi
pathogen
may
use
evalu
pathogen
antibodi
ms
patient
adjunct
diagnosi
treatment
although
high
regulatori
cell
popul
repres
peripher
blood
cell
contain
one
third
class
ii
express
cell
peripher
blood
highli
purifi
facssort
dr
dr
high
dr
high
high
high
treg
cell
demonstr
equival
suppress
activ
driven
vitro
dmicrot
cocultur
system
type
high
treg
cell
exhibit
cell
contactdepend
suppress
anergi
express
mrna
slightli
differ
level
substanti
differ
inhibitori
natur
dr
high
high
popul
uncov
cell
provid
differ
strength
costimulatori
signal
upon
costimul
dr
high
cocultur
exhibit
strong
earli
suppress
prolifer
cytokin
product
high
cocultur
exhibit
much
delay
suppress
late
accompani
preferenti
inhibit
cytokin
ifng
often
induct
importantli
contrast
effect
regul
two
differ
type
treg
cell
underscor
anoth
major
differ
two
type
high
treg
cell
unlik
usual
effect
reduc
immun
respons
actual
inhibit
suppress
dr
high
thu
enhanc
cocultur
respons
contrast
appear
compon
suppress
mechan
high
cell
possibl
due
differenti
involv
dr
high
high
popul
cross
regul
vitro
may
vivo
well
importantli
differ
kinet
suppress
skew
involv
dr
high
high
popul
seen
two
popul
studi
distinct
popul
thu
appar
studi
heterogen
combin
treg
popul
would
obscur
possibl
contrast
respons
possibl
differ
function
featur
may
reflect
tempor
order
util
differ
regulatori
subset
vivo
immun
respons
switch
innat
adapt
immun
chronic
progress
relaps
experiment
autoimmun
encephalomyel
reae
sjl
mous
depend
activ
cell
endogen
myelin
epitop
ie
epitop
spread
play
major
patholog
role
diseas
progress
use
transfer
naiv
cfselabel
tcr
transgen
cell
mix
bone
marrow
chimera
show
activ
naiv
cell
sjl
mice
undergo
reae
occur
directli
cn
cervic
lymph
node
spleen
peripher
lymphoid
organ
flow
cytometr
histolog
examin
cn
reae
reveal
infiltr
signific
number
dendrit
cell
dc
includ
myeloid
lymphoid
plamacytoid
subset
seen
healthi
cn
function
examin
antigen
present
capac
apc
popul
purifi
cn
mice
establish
reae
show
dc
effici
present
endogen
antigen
result
activ
naiv
tg
cell
contrast
dc
well
macrophag
microglia
capac
activ
memori
cell
current
result
indic
naiv
cell
gain
access
inflam
cn
bypass
need
activ
peripher
lymphoid
site
epitop
spread
initi
princip
within
cn
target
organ
activ
naiv
cell
involv
chronic
reae
mediat
cn
dc
infiltr
macrophag
resid
microglia
consequ
block
recruit
differenti
dc
may
viabl
target
inhibit
relaps
diseas
progress
murin
ms
model
possibl
ms
patient
multipl
sclerosi
ms
inflammatori
diseas
central
nervou
system
cn
character
local
area
inflamm
demyelin
ms
present
variou
clinic
form
relapsingremit
cours
progress
cours
unusu
progress
like
devict
diseas
lesion
found
optic
nerv
spinal
cord
brain
addit
first
clinic
present
signific
proport
ms
patient
often
isol
optic
neuriti
underli
immunolog
basi
differ
form
ms
associ
diseas
like
optic
neuriti
well
defin
experiment
autoimmun
encephalomyel
eae
cell
mediat
diseas
share
mani
clinic
histolog
featur
ms
howev
date
develop
alway
associ
eae
spontan
anim
model
devict
diseas
although
myelinspecif
cell
abl
induc
eae
unimmun
mice
studi
ms
eae
suggest
b
cell
antibodi
may
play
role
demyelin
develop
tcr
transgen
mous
specif
minor
protein
cn
myelin
call
myelin
oligodendrocyt
glycoprotein
mog
previous
report
larg
proport
tcr
transgen
mice
develop
spontan
isol
cross
tcr
transgen
mice
igh
knockin
mutant
mous
th
b
cell
specif
mog
produc
mogspecif
antibodi
knockin
mice
spontan
develop
eae
howev
mice
express
mogspecif
b
cell
develop
earli
sever
form
eae
histolog
examin
central
nervou
system
anim
reveal
select
distribut
inflammatori
foci
lesion
restrict
spinal
cord
optic
nerv
lesion
pattern
typic
devict
subform
ms
import
mog
specif
b
cell
cooper
role
antibodi
develop
devict
diseas
discuss
antibodyinduc
demyelin
import
compon
patholog
multipl
sclerosi
ms
particular
antibodi
myelin
oligodendrocyt
glycoprotein
mog
elev
ms
patient
implic
mediat
demyelin
aim
studi
elucid
mechan
antimog
mediat
demyelin
show
antibodi
crosslink
mog
oligodendrocyt
result
repartit
mog
lipid
raft
lead
chang
phosphoryl
specif
protein
culmin
rapid
morpholog
alter
use
proteom
analys
identifi
target
protein
whose
phosphoryl
state
alter
upon
antimog
treatment
protein
fell
function
categori
relat
regul
signal
transduct
lead
cellular
stress
respons
cytoskelet
instabl
chang
specif
antimog
although
crosslink
myelin
associ
glycoprotein
mag
also
instig
signal
modif
distinct
observ
mog
result
oligodendrocyt
morpholog
alter
next
appli
find
eae
model
analyz
antibodi
mog
develop
immun
mice
mog
rat
human
origin
interestingli
although
regimen
result
eae
similar
antimog
antibodi
titer
evalu
elisa
human
mog
requir
b
cell
diseas
induct
igg
human
rat
mog
bound
unfix
rodent
oligodendrocyt
induc
repartit
mog
lipid
raft
morpholog
alter
data
suggest
novel
mechan
antibodi
pathogen
b
cell
mediat
eae
provid
vitro
tool
determin
whether
autoimmun
antibodi
pathogen
may
use
evalu
pathogen
antibodi
ms
patient
adjunct
diagnosi
treatment
support
cm
rg
nr
nation
ms
societi
nih
sp
coloc
peptidyl
arginin
deiminas
pathophysiolog
relev
antigen
determin
rheumatoid
arthritisspecif
humor
autoimmun
elisa
serum
synovi
fluid
relat
anticitrullin
stain
synovium
presenc
hladr
share
epitop
result
use
differ
anticitrullin
antibodi
confirm
raspecif
presenc
synovi
intracellular
citrullin
protein
differ
previous
identifi
non
raspecif
deimin
protein
fibrin
vimentin
raspecif
relat
distinct
presenc
citrullin
peptidyl
arginin
deiminas
type
enzym
ra
synovium
addit
synovi
intracellular
citrullin
protein
detect
ra
synovium
determin
directli
system
acpa
level
well
local
acpa
product
joint
relat
raspecif
intracellular
citrullin
protein
acpa
depend
presenc
load
hladr
share
epitop
conclus
data
identifi
raspecif
synovi
intracellular
citrullin
protein
primari
antigen
target
acpa
vivo
provid
pathophysiolog
rational
specif
autoimmun
process
human
ra
antibodi
citrullinemodifi
protein
enhanc
tissu
injuri
inflammatori
arthriti
k
kuhn
l
kulik
k
j
braschler
w
p
arend
v
holer
immunolog
medicin
univers
colorado
health
scienc
center
denver
co
usa
antibodi
citrullinemodifi
protein
shown
specif
predict
marker
rheumatoid
arthriti
ra
although
patholog
relev
antibodi
unclear
similar
observ
ra
murin
collageninduc
arthriti
cia
model
ra
identifi
serum
antibodi
reactiv
specif
citrullinemodifi
protein
preced
clinic
appar
diseas
understand
role
antibodi
citrullinemodifi
protein
diseas
examin
whether
toler
antigen
could
protect
mice
cia
mice
toler
intraven
administr
mg
citrullinemodifi
peptid
noncitrullin
control
peptid
bovin
type
ii
collagen
cii
ovalbumin
day
three
day
final
dose
tolerogen
mice
challeng
cii
complet
freundt
adjuv
mice
toler
citrullinemodifi
peptid
demonstr
reduc
diseas
sever
compar
control
peptid
ovalbumin
f
f
f
respect
p
b
data
suggest
immun
respons
citrullinemodifi
protein
import
develop
inflammatori
arthriti
second
demonstr
pathogen
potenti
antibodi
citrullinemodifi
protein
determin
whether
antibodi
autoantigen
could
enhanc
diseas
accomplish
first
identifi
igm
monoclon
antibodi
design
specif
citrullinemodifi
fibrinogen
transfer
mice
alon
combin
submaxim
dose
arthritisinduc
anticii
monoclon
antibodi
combin
anticii
antibodi
substanti
enhanc
diseas
sever
f
vs
f
without
p
b
also
creat
two
addit
monoclon
antibodi
igg
class
specif
citrullin
fibrinogen
also
substanti
enhanc
diseas
sever
combin
anticii
antibodi
f
f
p
b
compar
anticii
antibodi
alon
result
demonstr
antibodi
specif
citrullinemodifi
protein
pathogen
like
play
import
role
joint
destruct
human
ra
u
deshmukh
h
bagav
fu
rheumatolog
immunolog
univers
virginia
charlottesvil
va
usa
autoantibodi
reactiv
differ
polypeptid
within
small
nuclear
ribonucleoprotein
complex
snrnp
often
present
patient
system
lupu
erythematosu
although
mechan
initi
antisnrnp
autoantibodi
respons
known
well
accept
complex
respons
achiev
intra
intermolecular
epitop
spread
establish
model
intermolecular
epitop
spread
within
small
nuclear
ribonucleoprotein
snrnp
complex
use
recombin
smd
protein
previous
demonstr
initi
antigen
interact
mhc
non
mhc
gene
influenc
intermolecular
epitop
spread
elucid
mechan
intermolecular
epitop
spread
within
snrnp
complex
immun
mice
synthet
peptid
contain
cell
epitop
smd
peptid
induc
cell
reactiv
immunogen
aj
strain
mice
peptid
smd
smd
consist
induc
intermolecular
epitop
spread
arnp
consist
epitop
spread
observ
mice
immun
peptid
smd
although
group
mice
high
titer
antibodi
reactiv
peptid
immunogen
antibodi
capabl
immunoprecipit
smd
antigen
minim
present
data
contrast
obtain
whole
protein
immun
wherein
immunoprecipit
antismd
antibodi
readili
gener
data
suggest
smd
peptid
immun
mice
b
cell
epitop
spread
respons
gener
antiarnp
antibodi
thu
molecular
mimicri
respons
initi
antisnrnp
autoantibodi
data
indic
cell
mimic
suffici
gener
diversifi
antibodi
respons
within
snrnp
complex
use
pool
igg
immunoglobulin
deriv
patient
primari
sjogrent
syndrom
screen
random
peptid
librari
identifi
diseas
relev
autoantigen
peptid
among
identifi
peptid
one
recognis
patientst
sera
elisa
assay
employ
solid
phase
peptid
peptid
recogn
sera
normal
donor
patient
affect
autoimmun
diseas
system
lupu
erythemathosu
rheumatoid
arthriti
system
sclerosi
therefor
reactiv
peptid
appear
confin
within
primari
sjogrent
syndrom
patient
identifi
peptid
show
homolog
ebv
encod
earli
antigen
protein
ebv
infect
associ
sjogrent
syndrom
find
suggest
ebv
infect
may
involv
diseas
pathogenesi
put
incit
stimulu
peptid
share
similar
tear
lipocalin
protein
highli
express
tear
saliva
alphafodrin
cytoskeleton
protein
consid
import
autoantigen
target
sjogrent
syndrom
antipeptid
antibodi
affin
purifi
patientst
sera
recogn
tear
lipocalin
western
blot
moreov
antibodi
abl
bind
alphafodrin
known
cleav
sever
fragment
expos
cell
surfac
apoptosi
find
suggest
tear
lipocalin
may
consid
novel
yet
unidentifi
autoantigen
sjogrent
syndrom
investig
function
role
play
autoantibodi
popul
pathogenesi
diseas
recent
studi
suggest
increas
cell
autoantibodi
reactiv
lipid
may
present
multipl
sclerosi
ms
patient
compar
control
creat
lipid
order
array
contain
duplic
spot
brain
myelin
microbi
lipid
glycolipid
repres
potenti
target
autoimmun
respons
ms
use
lipid
array
test
cerebrospin
fluid
ms
patient
neurolog
diseas
ond
control
presenc
antilipid
antibodi
lipid
array
reactiv
quantifi
signific
analysi
microarray
sam
appli
identifi
lipid
statisticallysignific
differ
array
reactiv
ms
control
sampl
lipid
signific
differ
array
reactiv
order
use
hierarch
cluster
algorithm
display
heat
map
use
treeview
lipid
array
demonstr
increas
autoantibodi
reactiv
lipid
includ
sulfatid
oxid
form
cholesterol
two
separ
form
oxid
phosphatidylcholin
lysophosphatidylethanolamin
sphingomyelin
ms
patient
csf
base
arraydetermin
antilipid
antibodi
profil
patientst
sampl
cluster
group
ms
ond
control
result
suggest
lipid
autoantigen
target
ms
antilipid
antibodi
could
diagnost
predict
valu
ms
array
demonstr
increas
antibodi
brain
polar
lipid
extract
oxid
lipid
sulfatid
mice
acut
eae
current
explor
role
lipid
demyelin
diseas
vivo
mice
rosi
ms
inflammatori
demyelin
disord
cn
share
clinic
patholog
characterist
role
autoantibodi
relat
diseas
pathophysiolog
diagnosi
unknown
character
myelin
autoantibodi
diseas
studi
humor
respons
panel
candid
autoantigen
use
protein
array
confirm
data
use
novel
solid
solut
phase
antibodi
bind
assay
serum
csf
sampl
patient
adem
reveal
robust
bind
wide
rang
autoantigen
minor
subset
sampl
ms
enceph
normal
control
demonstr
bind
distinguish
background
confirm
data
two
myelin
antigen
myelin
basi
protein
mbp
myelin
oligodendrocyt
glycoprotein
mog
evalu
use
tradit
solid
novel
fluid
phase
assay
solidphas
bind
antigen
observ
minor
subset
patient
ms
enceph
solutionphas
bind
characterist
higher
affin
antibodi
absent
match
serum
csf
patient
adem
contain
autoantibodi
direct
toward
mbp
mog
contrast
counterpart
found
ms
autoantibodi
demonstr
robust
solut
phase
bind
data
highlight
fundament
differ
humor
respons
clinic
similar
diseas
reflect
underli
differ
pathogenesi
adem
ms
role
human
b
cell
evid
function
physic
associ
deaglio
vaisitti
f
malavasi
lab
immunogenet
cerm
dept
genet
univers
torino
torino
itali
human
kd
surfac
glycoprotein
endow
ectoenzymat
receptori
activ
studi
function
nk
cell
indic
molecul
bypass
intrins
structur
inabl
transduc
signal
physic
function
associ
tcr
show
membran
local
critic
signal
human
b
cell
membran
fraction
indic
relev
fraction
molecul
costitut
present
raft
normal
tonsil
neoplast
raji
daudi
namalwa
ramo
cell
upon
crosslink
molecul
transloc
raft
togeth
fraction
b
suggest
becom
physic
associ
later
associ
two
receptor
confirm
live
cell
use
cocap
biochem
coimmunoprecipit
experi
associ
also
function
natur
inde
ligat
transduc
signal
cell
present
activ
wit
lack
flux
formal
proof
function
interplay
obtain
loss
signal
upon
gene
silenc
lastli
event
independ
enzymat
activ
present
cell
line
analyz
unmodifi
silenc
togeth
data
stress
notion
uniqu
type
receptor
work
synergi
b
cell
ii
enzym
receptor
function
distinct
independ
tolllik
receptor
tlr
evolutionarili
conserv
patternrecognit
receptor
central
innat
immun
tlr
initi
innat
respons
infect
select
recognit
conserv
pathogenassoci
motif
signal
cytokin
induct
address
whether
endogen
signal
via
tlr
direct
central
nervou
system
cn
respons
axon
injuri
stereotact
lesion
axon
entorhin
cortex
caus
axon
degener
rapid
activ
cnsresid
cell
microglia
astrocyt
specif
region
hippocampu
found
constitut
express
hippocampu
specif
upregul
microglia
denerv
zone
prior
leukocyt
recruit
detect
inba
mrna
suggest
engag
downstream
signal
pathway
reduc
cytokin
tnfa
chemokin
level
caus
delay
cell
infiltr
macrophag
infiltr
suggest
pathway
direct
macrophag
cell
entri
differenti
regul
later
expans
microgli
popul
requir
signal
wherea
astrocyt
activ
unaffect
respons
alter
mice
argu
endotoxin
effect
find
suggest
signal
direct
endogen
respons
cn
axon
injuri
select
regul
earli
cytokinechemokin
express
drive
later
cellular
respons
implic
regener
repair
work
fund
multipl
sclerosi
societi
canada
link
innat
immun
autoimmun
role
tlr
signal
pathway
p
p
ho
j
mitchel
l
lee
w
h
robinson
l
steinman
frequent
associ
microbi
infect
autoimmun
diseas
human
infect
often
exacerb
ongo
autoimmun
respons
lead
chronic
inflamm
tissu
destruct
degener
correspond
target
organ
innat
immun
system
first
line
defens
pathogen
insult
tolllik
receptor
tlr
innat
immun
system
abil
recogn
pathogen
pathogenderiv
product
initi
signal
cascad
trigger
macrophag
dendrit
cell
produc
proinflammatori
cytokin
lead
stimul
adapt
immun
respons
known
tlr
ligand
activ
intracellular
signal
pathway
lead
nuclear
transloc
reltyp
transcript
factor
nfkb
activ
map
kinas
induc
gene
express
proinflammatori
cytokin
hypothes
blockad
innat
immun
system
tlr
would
tangibl
method
attenu
inflammatori
cascad
due
inabl
signal
signal
pathway
studi
investig
involv
progress
experiment
autoimmun
encephalomyel
eae
prototyp
model
multipl
sclerosi
found
mice
defici
express
resist
mog
induc
eae
diseas
bypass
need
bind
administ
cpg
ligand
activ
signal
pathway
show
mice
receiv
singl
dose
cpg
time
diseas
induct
overal
mean
diseas
sever
similar
wildtyp
mice
therefor
manipul
innat
immun
system
tlr
signal
pathway
offer
uniqu
opportun
suppress
destruct
inflammatori
respons
may
provid
novel
approach
treatment
autoimmun
diseas
inflammatori
arthriti
link
innat
adapt
immun
transcript
factor
tbet
tbox
express
cell
play
major
role
adapt
immun
tbet
control
develop
mous
human
type
helper
lymphocyt
howev
role
tbet
innat
immun
system
larg
unexplor
demonstr
essenti
function
tbet
dendrit
cell
dc
control
inflammatori
arthriti
describ
collagen
antibodyinduc
arthriti
caia
bipartit
diseas
character
earli
compon
intact
mice
mediat
innat
immun
system
later
phase
influenc
adapt
immun
system
mice
markedli
reduc
joint
inflamm
earli
late
time
point
tbet
doubl
knockout
mice
essenextracellular
heat
shock
protein
hsp
consid
proinflammatori
bdanger
signalq
yet
also
downregul
experiment
immun
arthriti
diabet
model
specif
inhibit
respons
report
vitro
differenti
modul
express
transcript
factor
human
cell
downregul
tbet
nfatp
lead
decreas
secret
tnfa
ifng
enhanc
secret
effect
depend
could
attribut
lp
contamin
balbc
mice
vivo
inhibit
clinic
histolog
serolog
manifest
conainduc
hepat
associ
upregul
tcell
express
downregul
tbet
express
result
provid
molecular
explan
effect
treatment
tcell
inflamm
via
innat
regul
inflammatori
respons
enhanc
immun
respons
immunodepress
cutan
tcell
lymphoma
patient
patient
advanc
cutan
tcell
lymphoma
ctcl
exhibit
profound
defect
cell
mediat
immun
partial
result
mark
defici
number
peripher
blood
dendrit
cell
dc
capac
make
dc
deriv
cytokin
ifna
host
immun
function
appear
play
integr
role
mediat
diseasecontrol
respons
ctcl
investig
effect
synthet
imidazoquinolin
recogn
immun
stimulatori
virtu
activ
dc
follow
bind
toll
like
receptor
tlr
tlr
bind
compound
cultur
freshli
isol
peripher
blood
mononuclear
cell
pbmc
patient
advanc
ctcl
erythroderma
circul
malign
tcell
normal
volunt
broad
panel
immun
function
assess
three
tlr
ligand
significantli
induc
high
level
ifna
tlr
ligand
induc
ifng
cytokin
induc
effect
associ
mark
activ
nk
tcell
assess
express
cytolyt
activ
furthermor
strike
upregul
express
dc
monocyt
also
occur
thu
imidazoquinolin
exhibit
abil
potent
broadli
enhanc
immun
respons
patient
advanc
ctcl
preclin
find
typic
associ
signific
clinic
improv
put
clinic
practic
therefor
import
implic
potenti
enhanc
antitumor
immun
among
patient
advanc
ctcl
betaadrenerg
tolllik
receptor
signal
epiderm
keratinocyt
drive
skin
immun
respons
solubl
protein
dermat
contact
hypersensit
lichen
planu
alopecia
areata
vitiligo
show
precondit
skin
hadrenerg
antagonist
tolllik
receptor
agonist
aureu
peptidoglycan
pgn
result
increas
local
express
interleukin
il
gene
turn
instruct
thelper
adapt
respons
solubl
protein
antigen
contrari
agonist
e
coli
lipopolysaccharid
lp
use
presenc
hadrenerg
antagonist
effect
effect
conson
pattern
tlr
express
shown
epiderm
keratinocyt
skin
dendrit
cell
hadrenerg
signal
defect
togeth
saureu
infect
thought
serv
initi
andor
persist
factor
numer
th
inflammatori
skin
diseas
might
disclos
least
part
relev
pathogenet
mechan
reg
regul
immun
vargasroja
j
c
crispin
j
alcocervarela
depart
immunolog
rheumatolog
instituto
nacion
de
ciencia
medica
nutricion
salvador
zubiran
mexico
citi
mexico
last
decad
role
activ
suppress
gain
import
place
oper
model
immun
respons
regulatori
treg
cell
consid
essenti
part
normal
immun
respons
absenc
malfunct
causal
link
diseas
anim
model
clinic
scenario
recent
group
other
report
treg
cell
numer
defici
patient
system
lupu
erythematosu
sle
system
autoimmun
diseas
treg
cell
found
function
abnorm
autoimmun
diseas
howev
function
compet
explor
patient
sle
thu
aim
work
isol
treg
cell
patient
sle
order
investig
suppress
capac
normal
patient
method
fifteen
patient
sle
accord
acr
criteria
ageand
sexmatch
control
includ
moment
studi
patient
receiv
corticosteroid
immunosuppress
drug
patient
activ
diseas
treg
cell
quantifi
flow
cytometri
result
express
percentag
cell
within
total
lymphocyt
popul
intracellular
quantifi
isol
magnet
separ
suppress
capac
quantifi
hour
cocultur
treg
cell
ad
cell
cultur
stimul
platebound
solubl
cell
prolifer
calcul
accord
cfse
dilut
prolifer
result
express
index
consid
number
cell
divis
per
cell
cell
prolifer
method
issu
anoth
abstract
result
treg
cell
quantit
lower
patient
control
activ
sle
f
inact
sle
f
control
f
p
b
expect
intracellular
exclus
observ
convers
intracellular
regularli
observ
cell
treg
cell
obtain
healthi
individu
prolifer
neither
basal
stimul
condit
convers
treg
cell
sle
patient
prolifer
stimul
p
b
compar
cell
obtain
normal
control
sle
patient
prolifer
spontan
less
stimul
p
b
cocultur
treg
cell
healthi
control
inhibit
prolifer
hand
inhibit
observ
cell
patient
sle
p
conclus
treg
suppress
function
defici
patient
sle
mediat
expans
mainten
tgfb
induc
treg
inflamm
novel
role
c
fantini
c
becker
tubb
h
lehar
p
r
gall
f
nerath
laboratori
immunolog
imed
clinic
johann
gutenberg
univers
mainz
germani
institut
patholog
johann
gutenberg
univers
mainz
germani
regulatori
cell
implic
mainten
self
toler
mani
anim
model
human
diseas
cell
subdivid
acquir
natur
regulatori
cell
base
origin
first
group
includ
regulatori
cell
gener
peripheri
result
antigen
specif
toler
protocol
second
repres
natur
occur
regulatori
cell
gener
thymu
first
day
birth
last
group
cell
character
express
wing
helix
transcript
factor
implic
direct
genet
program
determin
regulatori
potenti
natur
occur
regulatori
cell
recent
shown
regulatori
phenotyp
also
induc
cell
upon
tgfh
stimul
suppress
capac
tgfh
induc
treg
titreg
extens
describ
vitro
role
vivo
poorli
investig
order
shed
light
vivo
physiolog
titreg
analyz
expans
phenotyp
stabil
cell
vivo
brief
titreg
adopt
transfer
scid
mice
alon
togeth
colitogen
narv
cell
order
provid
inflammatori
environ
result
obtain
seri
experi
indic
titreg
depend
surviv
expans
presenc
ongo
inflammatori
respons
indic
loss
express
regulatori
capac
titreg
transfer
scid
mice
absenc
colitogen
cell
investig
vivo
titreg
requir
lead
identif
exogen
provid
ongo
inflammatori
respons
main
respons
titreg
expans
suppress
activ
limit
site
inflamm
moreov
shown
alon
suffici
maintain
express
regulatori
phenotyp
titreg
cell
requir
presenc
propos
tgfh
induc
regulatori
cell
titreg
new
class
acquir
regulatori
cell
highli
inflamm
depend
expans
surviv
make
action
limit
space
immun
respons
occur
limit
time
respons
last
properti
shown
titreg
cell
offer
new
insight
normal
occur
immun
respons
physiolog
control
also
offer
possibl
gener
regulatori
cell
vitro
therapeut
tool
circumv
problem
relat
prolong
gener
state
immunodepress
r
torgerson
e
gambineri
vijay
anov
h
och
pediatr
univers
washington
seattl
wa
usa
pediatr
ba
meyerq
childrent
hospit
florenc
itali
member
forkhead
wingedhelix
famili
transcript
regul
shown
play
key
role
develop
function
regulatori
cell
mice
human
defect
gene
lead
diseas
system
autoimmun
character
sever
autoimmun
enteropathi
endocrinopathi
skin
diseas
known
ipex
immun
dysregul
polyendocrinopathi
enteropathi
xlink
defin
region
domain
may
function
import
sequenc
gene
patient
clinic
phenotyp
suggest
ipex
syndrom
cohort
identifi
uniqu
mutat
patient
remain
patient
normal
sequenc
genom
dna
level
half
low
mrna
express
clinic
patient
mutat
sever
diseas
triad
enteropathi
dermat
endocrinopathi
often
combin
autoimmun
phenomena
wherea
patient
normal
sequenc
tend
milder
diseas
appear
geneotypephenotyp
correl
mutat
particular
region
gene
specif
complex
symptom
mutat
identifi
thu
far
cluster
one
three
region
carboxytermin
forkhead
domain
leucin
zipper
aminotermin
prolinerich
domain
particularli
near
end
exon
interestingli
mutat
identifi
zinc
finger
domain
introduc
mutat
identifi
patient
cdna
express
exogen
cell
assess
effect
nuclear
import
dimer
dnabind
transcript
control
use
approach
identifi
region
carboxytermin
portion
protein
requir
nuclear
import
dna
bind
region
central
portion
requir
oligomer
region
import
control
transcript
grail
express
associ
biolog
activ
regulatori
cell
mackenzi
c
seroogi
pediatr
univers
wisconsin
madison
wi
usa
regulatori
cell
treg
subset
cell
anerg
phenotyp
suppress
immun
respons
antigenspecif
fashion
poorli
understood
mechan
date
specif
gene
marker
subset
cell
transcript
factor
observ
link
treg
cell
grail
ubiquitin
ligas
necessari
develop
cell
anergi
vivo
hypothes
grail
import
develop
function
natur
occur
induc
treg
cell
sever
line
evid
support
hypothesi
grail
express
natur
occur
treg
cell
level
greater
cell
toler
immun
vivo
lead
induct
longliv
express
antigenspecif
toler
cell
gene
express
analysi
cell
reveal
grail
mrna
upregul
increas
vs
cell
increas
vs
natur
occur
treg
cell
moreov
grail
express
link
express
strongli
suggest
suppressor
phenotyp
induc
toler
popul
initi
step
understand
role
grail
treg
cell
suppressor
function
demonstr
enforc
express
grail
antigenspecif
cell
line
suffici
convey
suppressor
phenotyp
vitro
data
link
grail
express
biolog
activ
treg
cell
mechanist
studi
ongo
discuss
induct
treg
toleranceinduc
antigenpres
cell
deriv
bone
marrow
cultur
initi
object
rel
ubiquit
express
cell
surfac
molecul
deliv
immunoregulatori
signal
follow
engag
receptor
famili
describ
sever
group
isoform
design
tissuerestrict
distribut
isoform
describ
splenic
tissu
express
predominantli
bone
marrow
tissu
show
predomin
express
littl
known
date
concern
function
activ
express
cell
differ
tissu
use
number
isoformspecif
agonist
mab
investig
effect
signal
via
express
splenic
cell
vs
bone
marrow
dendrit
cell
dc
precursor
materi
method
investig
effect
agonist
mab
three
independ
function
assay
gener
alloimmun
primari
mlc
gener
allostimulatori
dendrit
cell
dc
bone
marrow
cell
cultur
vitro
presenc
induct
treg
cona
activ
thymocyt
vitro
primari
mlc
cultur
set
stimul
spleen
cell
mitomycinc
treat
stimul
cell
cultur
contain
mab
cytokin
assay
supernat
elisa
ctl
assay
day
second
assay
bone
marrow
cell
cultur
day
gmcsf
withwithout
gener
dc
dc
matur
induc
overnight
lp
mitomycinc
treat
dc
use
activ
fresh
splenocyt
mlc
induc
treg
splenocyt
cultur
dc
reg
also
induc
cona
activ
thymocyt
cultur
mab
treg
assay
fac
cell
use
realtim
pcr
express
abil
suppress
ctl
cytokin
product
fresh
primari
mlc
cultur
result
mab
suppress
cytokin
product
gener
ctl
directli
fresh
mlc
cultur
contrast
addit
caus
signific
perturb
develop
allostimulatori
dc
bone
marrow
cultur
howev
presenc
mab
function
allostimulatori
dc
develop
bone
marrow
cultur
instead
cultur
popul
dc
develop
induc
treg
splenocyt
similar
treg
popul
induc
thymocyt
activ
cona
presenc
popul
treg
inhibit
antigenspecif
regulatori
cell
dysfunct
uniqu
autoreact
cell
popul
may
associ
develop
coliti
waspdefici
mice
v
cottadealmeida
f
takeshima
maillard
p
michetti
b
snapper
depart
medicin
massachusett
gener
hospitalharvard
medic
school
boston
usa
depart
cell
biolog
oswaldo
cruz
foundat
rio
de
janeiro
rj
brazil
nagasaki
univers
school
medicin
nagasaki
japan
lausann
univers
hospit
lausann
switzerland
background
wiskottaldrich
syndrom
sever
immunodefici
associ
autoimmun
patient
develop
inflammatori
bowel
diseas
ibd
major
waspdefici
wko
mice
also
manifest
sever
coliti
object
aim
determin
whether
ibd
result
aberr
regulatori
cell
function
method
lymphoid
organ
obtain
wt
wko
mice
analyz
flow
cytometri
number
regulatori
cell
treg
determin
directli
assess
role
treg
coliti
develop
adopt
transfer
wt
wko
hi
rb
hi
lo
rb
lo
cell
alon
combin
scid
recipi
clinic
score
histopatholog
analys
perform
result
wko
mice
reduc
number
treg
peripher
lymphoid
organ
find
alreadi
evid
onset
clinic
coliti
interestingli
also
demonstr
decreas
number
treg
thymu
expect
adopt
transfer
approach
demonstr
wt
rb
hi
cell
induc
coliti
block
concomit
transfer
wt
rb
lo
cell
howev
wt
rb
hi
cell
transfer
diseas
even
presenc
wko
rb
lo
cell
also
found
wko
rb
hi
cell
colitogen
caus
diseas
late
incid
lower
sever
surprisingli
cotransf
wko
rb
hi
wko
rb
lo
cell
result
develop
sever
diseas
furthermor
wko
rb
lo
cell
alon
wt
rb
lo
cell
abl
induc
coliti
conclus
data
indic
aberr
develop
function
treg
wko
mice
furthermor
transfer
studi
suggest
presenc
uniqu
colitogen
effector
cell
within
wko
rb
lo
popul
aberr
treg
function
uniqu
autoreact
effector
cell
popul
may
account
autoimmun
ibd
patient
waspdefici
mice
mhc
class
ii
control
regulatori
toler
allogen
transplant
g
benich
k
germana
akiyama
k
tanaka
c
leguern
surgeri
mghtranplant
unit
boston
usa
surgeri
mghtbrc
boston
usa
mhc
class
ii
gene
function
close
associ
regul
cell
immun
although
mechan
control
remain
unknown
previous
demonstr
transfer
donortyp
mhc
class
ii
gene
bone
marrow
miniatur
swine
recipi
subsequ
renal
allograft
induc
immun
toler
due
delet
alloreact
cell
order
assess
whether
toler
mechan
would
implic
regulatori
pathway
notabl
regulatori
cell
treg
examin
effect
somat
transgenesi
donor
class
ii
iab
gene
bone
marrow
cba
mice
surviv
subsequ
heart
graft
model
donorspecif
toler
well
indefinit
surviv
fulli
allogen
graft
achiev
without
use
immunosuppress
class
iimedi
toler
spread
cell
respons
graft
antigen
seventi
seven
percent
longterm
accept
heart
analyz
day
transplant
present
sign
chronic
allograft
vasculopathi
addit
singl
inject
treg
naiv
immunocompet
cba
mice
prolong
surviv
graft
result
indic
class
iimedi
toler
affect
regulatori
treg
pathway
like
emerg
class
iispecif
treg
suppress
whole
allorespons
therebi
achiev
graft
surviv
also
provid
mechan
class
ii
express
may
control
regul
cell
immun
transplant
lipid
metabol
inflammatori
respons
use
affymetrix
oligonucleotid
array
demonstr
also
express
human
bronchial
epitheli
cell
hbe
show
strike
upregul
follow
stimul
epitheli
cell
helper
cytokin
hbe
significantli
downregul
cytokin
ifngamma
upregul
downregul
strongli
implic
particip
allerg
inflamm
consist
hypothesi
express
markedli
enhanc
bronchial
epitheli
cell
lung
mice
undergo
allerg
inflamm
strong
stain
also
identifi
respiratori
epithelium
human
inferior
turbin
biopsi
defici
mice
test
model
allerg
airway
inflamm
found
strongli
protect
reduct
airway
eosinophilia
peribronchovascular
inflamm
pulmonari
cytokin
product
thu
critic
regul
allerg
airway
inflamm
current
investig
mechan
action
final
data
suggest
molecular
mechan
explain
relationship
fatti
acid
metabol
diet
obes
asthma
xiaochun
wan
shijun
zheng
salaheddin
lamhamedicherradi
lingyun
xu
brendan
hilliard
youhai
h
chen
depart
patholog
laboratori
medicin
school
medicin
univers
pennsylvania
philadelphia
pa
usa
tumor
suppressor
regul
apoptosi
cell
cycl
oncogenesi
explor
role
autoimmun
diseas
studi
autoimmun
inflamm
innat
immun
function
use
mice
defici
found
mice
suscept
experiment
autoimmun
encephalomyel
eae
streptozotocininduc
type
diabet
control
mice
produc
higher
level
upon
activ
vitro
cell
macrophag
produc
significantli
elev
level
inflammatori
cytokin
innat
immun
respons
lipopolysaccharid
interferoni
also
significantli
enhanc
accompani
increas
level
total
phosphoryl
signal
transduc
activ
transcript
stat
result
indic
inhibit
autoimmun
inflamm
innat
immun
downregul
proinflammatori
cytokin
syndrom
associ
autoantigen
ringdepend
ligas
suppress
cellular
prolifer
espinosa
hedlund
brauner
v
k
kuchroo
wahrenherleniu
object
determin
function
background
ligas
group
protein
mediat
posttransl
modif
ubiquitin
ligas
implic
mani
cellular
process
includ
apoptosi
prolifer
signal
ligas
eg
cblb
grail
itch
regul
import
signal
pathway
immun
cell
indirect
evid
uncharacter
ligas
involv
regul
immun
respons
rossa
main
autoantigen
target
autoimmun
rheumat
diseas
sjfgrent
syndrom
function
known
base
sequenc
homolog
hypothes
protein
ligas
method
result
investig
ligas
ubiquitin
assay
perform
vivo
vitro
lack
ring
domain
coexpress
ubiquitin
cell
ubiquitin
protein
purifi
ninta
resin
ubiquitin
visual
immunoblot
antiflag
antibodi
polyubiquitin
suggest
autoubiquitin
ring
depend
manner
vitro
mediat
polyubiquitin
togeth
sever
ubiquitin
conjug
enzym
notabl
function
consequ
ubiquitin
investig
stabli
b
cell
lymphoma
cell
line
express
b
lymphoma
cell
result
decreas
prolifer
five
independ
clone
compar
five
gfp
express
clone
parent
cell
line
furthermor
express
cell
activ
antibodi
increas
cell
death
express
cell
compar
gfp
express
parent
cell
conclus
data
demonstr
novel
ringfing
depend
ligas
inhibit
prolifer
promot
activ
induc
cell
death
donor
lymphocyt
infus
dli
reliabl
induc
durabl
remiss
patient
relaps
cml
follow
allogen
bone
marrow
transplant
identifi
immunolog
target
graftversusleukemia
effect
dli
use
cml
postdli
respond
sera
screen
cml
cdna
express
librari
two
identifi
target
deriv
gene
encod
protein
kd
kd
develop
high
titer
specif
igg
respons
antigen
dli
respond
correl
immuneinduc
remiss
known
homolog
code
region
contain
known
function
motif
ident
compon
human
exosom
involv
process
rna
human
exosom
contain
known
autoantigen
pm
autoantibodi
target
patient
polymyos
scleroderma
present
studi
undertaken
character
express
primari
normal
malign
hematopoiet
tissu
northern
blot
show
highlevel
express
varieti
leukemia
cell
line
normal
tissu
except
testi
specif
monoclon
antibodi
develop
util
detect
antigen
express
leukemia
cell
line
primari
leukemia
tissu
western
blot
immunohistochemistri
express
pattern
confirm
antigenspecif
realtim
pcr
highli
express
leukem
blast
patient
aml
cml
blast
crisi
bare
detect
normal
bone
marrow
normal
peripher
blood
leukem
cell
patient
stabl
phase
cml
contrast
purifi
progenitor
normal
individu
patient
stabl
phase
cml
express
high
level
transcript
protein
immunohistochem
stain
confirm
rare
stain
myeloid
precursor
normal
marrow
diffus
stain
myeloblast
cell
aml
blast
crisi
cml
marrow
express
pattern
similar
leukemia
associ
antigen
includ
wilm
tumor
gene
suggest
abund
express
malign
myeloid
progenitor
cell
may
common
antigen
target
humor
immun
respons
follow
dli
strike
similar
express
pattern
support
notion
dli
exert
cur
effect
target
antigen
present
selfrenew
malign
progenitor
popul
cml
contribut
suppress
lethal
intestin
inflam
yasuyo
shimomura
emiko
mizoguchi
atul
k
bhan
atsushi
mizoguchi
expans
accumul
b
cell
commonli
observ
inflam
intestin
ibd
patient
well
experiment
coliti
model
interestingli
expand
b
cell
shown
play
regulatori
role
certain
intestin
inflammatori
condit
immun
gastroenterolog
howev
molecular
event
lead
inflammationassoci
expans
regulatori
b
cell
elucid
yet
therefor
studi
design
defin
molecular
mechan
use
acut
coliti
model
coliti
induc
addit
dextran
sodium
sulfat
dss
drink
water
day
interestingli
flow
cytometr
immunohistochem
analys
show
mark
expans
b
cell
colon
lamina
propria
lp
recoveri
phase
day
four
day
cessat
dss
intak
acut
phase
day
dss
coliti
expand
b
cell
repres
prematur
phenotyp
similar
splenic
transit
type
b
cell
subset
addit
analysi
igh
chain
divers
show
b
cell
polyclon
expand
surprisingli
lymphotoxin
lt
pathway
necessari
develop
galt
format
normal
condit
requir
inflammationinduc
b
cell
expans
indic
mark
expans
b
cell
colon
dsstreat
lt
knockout
ko
mice
therefor
identifi
factor
involv
b
cell
expans
realtim
pcr
purifi
b
cell
use
seri
primer
set
detect
broad
rang
b
cellassoci
signal
molecul
molecul
perform
signific
upregul
baffr
b
cellactiv
factor
belong
tnf
familyreceptor
btk
brutont
tyrosin
kinas
observ
colon
b
cell
day
compar
day
day
function
role
molecul
inflammationinduc
b
cell
expans
examin
use
specif
ko
mice
treat
dss
recoveri
phase
dssinduc
acut
coliti
expans
b
cell
colon
observ
baffr
defici
mice
reduc
btk
ko
mice
contrast
absenc
affect
b
cell
expans
baffmedi
activ
nf
k
b
shown
enhanc
surviv
b
cell
inde
western
blot
analysi
show
activ
nf
n
b
precursor
nf
n
b
day
b
cell
addit
mark
increas
apoptosi
colon
b
cell
observ
baffr
defici
mice
compar
wt
mice
final
examin
function
role
b
cell
dss
induc
coliti
coliti
induc
b
celldefici
mice
note
b
celldefici
mice
die
coliti
day
wherea
wt
mice
surviv
sign
recoveri
acut
coliti
studi
indic
intestin
inflammationinduc
b
cell
expans
baff
lt
pathway
contribut
suppress
acut
lethal
coliti
increas
constitut
activ
nfkb
patient
multipl
sclerosi
j
yan
b
pat
c
winterford
h
ingli
p
pender
j
greer
school
medicin
univers
queensland
brisban
qld
australia
multipl
sclerosi
ms
character
inflamm
demyelin
central
nervou
system
cn
current
evid
suggest
ms
result
autoimmun
respons
mediat
lymphocyt
activ
peripher
lymphoid
organ
migrat
cn
recent
studi
suggest
transcript
factor
nfnb
might
play
import
role
develop
chronic
autoimmun
attack
diseas
ms
nfnb
normal
found
cytoplasm
cell
inflammatori
condit
move
nucleu
initi
gene
express
produc
proinflammatori
molecul
activ
nfnb
regul
group
inhibitor
molecul
known
inb
sever
inb
famili
member
polymorph
associ
suscept
ms
causasian
immun
cell
peopl
rheumatoid
arthriti
asthma
nfnb
found
aberr
constitut
nuclear
local
enhanc
transcript
proinflammatori
gene
observ
nfnb
inba
coloc
macrophag
nuclei
activ
ms
lesion
howev
unknown
nfnb
constitut
activ
immun
cell
ms
patient
aim
current
studi
investig
question
peripher
blood
mononuclear
cell
pbmc
collect
untreat
patient
ms
healthi
control
cell
fix
pellet
embed
paraffin
section
immunohistochemistri
use
antibodi
specif
cell
b
cell
macrophag
nfnb
rela
subunit
remaind
cell
lyse
cytoplasm
nuclear
fraction
purifi
lysat
fraction
analys
polyacrylamid
gel
electrophoresi
immunoblot
use
antibodi
specif
nfnb
subunit
inba
percentag
transloc
nfnb
defin
rel
amount
nfnb
found
nucleu
divid
total
amount
present
whole
cell
determin
sampl
sixtyeight
percent
sampl
untreat
ms
patient
increas
nfnb
transloc
nucleu
compar
pbmc
healthi
control
p
b
immunohistochem
studi
confirm
transloc
nfnb
nucleu
show
patient
sampl
increas
nfnb
activ
cell
monocyt
rather
b
cell
addit
level
inba
protein
reduc
cytoplasm
untreat
ms
patient
compar
healthi
control
although
statist
signific
degre
result
indic
cell
macrophag
untreat
ms
patient
show
higher
level
constitut
activ
nfnb
healthi
control
activ
may
lead
enhanc
transcript
proinflammatori
gene
relat
chronic
natur
ms
investig
contribut
novel
gene
product
fibrinogen
like
protein
prothrombinas
mediat
immun
injuri
experiment
human
acut
allograft
reject
method
result
use
mous
heterotop
cardiac
transplant
model
mous
fibroleukin
mrna
transcript
protein
highli
express
macrophag
posit
lymphocyt
endotheli
cell
reject
cardiac
allograft
associ
deposit
fibrin
defici
mice
reject
allograft
similar
rate
litterm
control
surviv
graft
defici
mice
markedli
prolong
larg
devoid
intravascular
fibrin
furthermor
treatment
wild
type
mice
neutral
polyclon
antibodi
amelior
histolog
evid
alloreject
intravascular
fibrin
deposit
result
increas
graft
surviv
compar
graft
surviv
untreat
mice
mice
inject
irrelev
antibodi
address
relev
human
fibroleukin
acut
allograft
reject
examin
kidney
biopsi
patient
undergon
renal
transplant
mrna
transcript
protein
markedli
express
mainli
renal
tubul
cell
infiltr
lymphoid
cell
includ
macrophag
cell
matur
b
cell
plasma
cell
endotheli
cell
dual
stain
show
fibrin
deposit
local
mainli
blood
vessel
glomerulu
interstitium
lumen
tubul
occur
associ
express
conclus
data
collect
suggest
account
fibrin
deposit
seen
experiment
human
allograft
reject
provid
rational
target
adjunct
therapi
treat
allograft
reject
work
support
nation
scienc
fund
distinguish
young
investig
dr
q
ning
dr
xp
luo
natur
scienc
foundat
china
nsfc
nsfc
oper
fund
canadian
institut
health
research
cihr
grant
pm
glycolipid
mediat
activ
inkt
cell
suffici
induc
airway
hyperreact
independ
convent
cell
depend
ahr
inkt
cell
produc
eosinophil
b
cell
ige
requir
induc
ahr
sinc
ahr
develop
b
cell
defici
jhd
mice
mice
treat
mab
elimin
eosinophil
moreov
mhc
class
ii
defici
mice
lack
convent
cell
inkt
cell
show
exagger
glycolipid
induc
ahr
clearli
demonstr
convent
cell
requir
ahr
therefor
activ
pulmonari
inkt
necessari
suffici
induc
ahr
complet
absenc
convent
cell
suggest
inkt
cell
central
critic
pathogenesi
ahr
therapi
target
inkt
cell
may
clinic
effect
limit
develop
ahr
asthma
involv
nkt
cell
pathogenesi
collageninduc
antibodyinduc
arthriti
kaieda
chiba
oki
yamamura
miyak
immunolog
nation
institut
neurosci
ncnp
tokyo
japan
natur
killer
nk
cell
uniqu
subset
lymphocyt
express
cell
receptor
variou
nk
receptor
produc
larg
amount
cytokin
includ
ifng
stimul
glycolipid
ligand
galactosylceramid
agc
previous
shown
administr
och
synthet
analogu
agc
prevent
collageninduc
arthriti
cia
preferenti
induc
product
nkt
cell
howev
role
nkt
cell
natur
cours
arthriti
model
remain
unclear
present
studi
investig
role
nkt
cell
collageninduc
antibodyinduc
arthriti
induc
collageninduc
arthriti
mice
immun
intraderm
base
tail
ag
bovin
chiken
type
ii
collagen
cii
emulsifi
equal
volum
cfa
mice
boost
intraderm
inject
antigen
prepar
day
arthriti
develop
monitor
inspect
three
time
week
start
day
mice
inject
intraperion
twice
per
week
antibodi
induc
antibodyinduc
arthriti
mice
inject
either
mixtur
anticii
monoclon
antibodi
mab
arthrogencia
mab
chondrex
llc
seattl
usa
follow
lp
inject
serum
krn
cell
receptor
transgen
mice
cross
nonobes
diabet
mice
kbxn
detect
nkt
cell
cell
stain
agalactosylceramideload
dimer
analyz
use
flowcytometri
anticii
antibodi
measur
enzymelink
immunosorb
assay
elisa
histopatholog
examin
perform
evalu
arthriti
number
nkt
cell
increas
liver
peak
clinic
cours
cia
antibodyinduc
arthriti
administr
mab
inhibit
develop
cia
induc
mice
next
induc
mice
nkt
cell
defici
knockout
mice
sever
arthriti
significantli
reduc
nkt
defici
mice
compar
wild
type
mice
level
anticollagen
antibodi
differ
group
ratio
anticii
mab
elev
ifng
product
drain
lymph
node
cell
reduc
nkt
celldefici
mice
elucid
role
nkt
cell
effector
phase
arthriti
next
examin
antibodyinduc
arthriti
nkt
defici
mice
wild
type
mice
clinic
arthriti
score
patholog
examin
reveal
sever
arthriti
significantli
lower
nkt
defici
knockout
knockout
mice
compar
wild
type
mice
nkt
cell
play
import
role
pathogenesi
arthriti
particularli
effector
phase
arthriti
consid
fact
skew
glycolipid
ligand
och
inhibit
develop
arthriti
nkt
cell
could
new
target
treatment
rheumatoid
arthriti
effect
natur
killer
nk
cell
allogen
bone
marrow
transplant
swati
bhattacharyya
morton
j
cowan
depart
pediatr
ucsf
san
francisco
ca
usa
specif
object
studi
stdi
want
defin
role
nk
cell
myeloabl
mhc
mismatch
condit
nk
cell
capabl
receptor
mediat
lysi
target
cell
lack
self
class
mhc
molecul
thu
use
effect
mhc
mismatch
allogen
bonemarrow
transplant
creat
myeloabl
instead
lymphocyt
advantag
use
nk
cell
achiev
creation
space
without
develop
gvhd
materi
method
result
preliminari
experi
done
assess
myeloabl
properti
nk
cell
adult
nk
cell
inject
ip
day
old
balbc
newborn
bone
marrow
harvest
set
invitro
assay
studi
show
allogen
nk
cell
destroy
erythroid
myeloid
stem
cell
next
set
experi
inject
nk
cell
f
bonemarrow
old
balbc
fetus
howev
due
toxic
move
restrict
usag
nk
cell
postnat
seven
ten
recipi
linbm
allogen
nk
cell
multilineag
engraft
week
post
transplant
engraft
inhibit
coadministr
anti
nk
mab
antitgf
beta
antibodi
indic
transplant
nk
cell
play
import
role
engraft
b
engraft
occur
mostli
secret
tgfbeta
result
addit
nk
cell
transplant
cell
mass
use
immunodefici
tbnk
scida
model
studi
repopul
marrow
follow
transplant
nk
cell
found
signific
repopul
cell
significantli
lower
amount
b
cell
blood
genotyp
pcr
thymocyt
show
success
reconstitut
thymu
cell
follow
nk
cell
wt
bm
transplant
adult
anim
engraft
cell
show
normal
tcr
rearrang
featur
lack
knockout
anim
bonemarrow
analysi
show
signific
engraft
b
cell
normal
igg
heavi
chain
rearrang
posttranspl
unlik
scida
develop
b
cell
halt
earli
stage
conclus
nk
cell
use
effect
cytotherapeut
myeloabl
agent
immunosuppress
condit
work
support
grant
nih
niaid
exogen
promot
product
human
nkt
cell
clone
role
immun
regul
k
sakuishi
miyak
yamamura
immunolog
nation
institut
neurosci
nation
center
neurolog
psychiatri
kodaira
tokyo
japan
abil
nkt
cell
produc
cytokin
well
describ
howev
potenti
human
nkt
cell
produc
cytokin
variou
immun
respons
need
yet
delin
analyz
cytokin
product
nkt
cell
clone
deriv
human
pbmc
healthi
subject
multipl
sclerosi
patient
found
exogen
would
promot
product
method
nkt
cell
clone
gener
initi
stimul
fresh
pbmc
agalactosylceramid
agc
analogu
och
nkt
cell
sort
base
reactiv
mab
maintain
clone
cell
sort
stimul
pha
monthli
basi
nkt
cell
stimul
agc
och
load
monocytederiv
immatur
dendrit
cell
without
exogen
supernat
evalu
hour
later
cytomer
bead
array
cba
result
clone
produc
amount
higher
case
exogen
enhanc
cytokin
product
respons
glycolipid
clone
presenc
clone
produc
remark
amount
even
absenc
agc
och
conclus
data
impli
presenc
human
nkt
cell
could
exhibit
potenti
produc
abund
respons
weak
endogen
antigen
stimul
show
interest
connect
nkt
cellmedi
immun
regul
specif
nkt
cell
gangliosid
dianna
wu
paul
b
chapman
depart
medicin
memori
sloankett
cancer
center
new
york
ny
usa
shown
previous
gangliosid
express
melanoma
present
antigenpres
cell
immun
induc
nkt
cell
current
studi
evalu
specif
nkt
cell
gangliosid
differ
carbohydr
compon
interact
nkt
cell
tcell
receptor
tcr
elispot
found
subset
nkt
cell
mice
also
recogn
lactosylceramid
interpret
result
mean
presenc
nacetylgalactosamin
galnc
inhibit
interact
tcr
sinc
nkt
cell
recogn
glucosegalactos
sialic
acid
galncglucosegalactos
sialic
acid
galncglucosegalactosesial
acid
also
found
lactosylceramid
glucosegalactos
recogn
nkt
cell
suggest
least
one
sialic
acid
molecul
necessari
tcr
bind
conclus
begun
character
epitop
recogn
nkt
cell
find
tcr
nkt
requir
glucosegalactos
link
least
one
sialic
acid
recognit
galnc
block
tcr
bind
support
nci
requir
develop
airwayhyperreact
ahr
cardin
featur
asthma
show
human
subject
asthma
major
cell
bronchoalveolar
lavag
bal
fluid
convent
cell
rather
nkt
cell
express
invari
cell
receptor
inkt
cell
bal
fluid
asthmat
subject
cell
inkt
cell
wherea
patient
sarcoidosi
anoth
pulmonari
inflammatori
diseas
inkt
cell
similar
result
obtain
use
immunofluoresc
confoc
laser
scan
microscopi
endobronchi
biopsi
specimen
patient
asthma
sarcodosi
like
inkt
cell
mous
model
asthma
inkt
lung
patient
asthma
produc
littl
ifng
contrast
inkt
cell
peripher
blood
subject
asthmat
sarcoidosi
normal
individu
produc
three
cytokin
suggest
compartment
subset
inkt
cell
lung
patient
bronchial
asthma
taken
togeth
studi
demonstr
lung
patient
asthma
sarcoidosi
contain
predominantli
inkt
cell
rather
convent
cell
pulmonari
inkt
cell
produc
cytokin
profil
known
amplifi
inflammatori
respons
asthma
strongli
suggest
inkt
cell
play
central
role
pathogenesi
human
asthma
initi
identifi
atopi
suscept
gene
posit
clone
congen
mous
model
asthma
mous
distinct
genet
variant
found
associ
develop
immun
respons
allergeninduc
airway
hyperreact
human
also
found
signific
atopi
suscept
gene
specif
allel
associ
protect
atopi
examin
immunolog
function
use
specif
monoclon
antibodi
mab
demonstr
potent
cell
costimulatori
molecul
critic
role
regul
immun
system
express
cell
earli
activ
express
sustain
preferenti
cell
vitro
stimul
cell
specif
mab
combin
cell
receptor
activ
markedli
increas
cell
prolifer
indic
signal
provid
robust
posit
costimulatori
signal
cell
administr
mab
vivo
combin
antigen
strikingli
enhanc
product
cytokin
prevent
develop
respiratori
toler
increas
pulmonari
inflamm
studi
indic
novel
signific
costimulatori
molecul
alter
function
immun
respons
could
provid
potent
immunomodulatori
therapi
varieti
immunolog
disord
tlr
nk
innat
immun
pm
vivo
homeostat
prolifer
naiv
tcell
restrain
tcr
repertoir
healthi
human
adult
kohler
u
wagner
pierer
kimmig
b
oppmann
b
moew
k
juelk
c
romagnani
thiel
clinic
immunolog
drfz
berlin
berlin
germani
medicin
iv
univers
leipzig
leipzig
sachsen
germani
molecular
biolog
mpi
infect
biolog
berlin
berlin
germani
object
human
naiv
tcell
previous
shown
postthym
prolifer
constitut
major
naiv
tcell
elderli
take
advantag
new
phenotyp
marker
want
analys
possibl
consequ
postthym
prolifer
naiv
thcell
pool
elucid
drive
forc
process
human
method
absolut
number
peripher
blood
tcell
determin
donor
differ
age
addit
tcell
healthi
donor
highli
purifi
subject
detail
repertoir
analysi
spectratyp
final
rna
isol
purifi
tcell
cdna
prepar
subsequ
express
analys
rtpcr
result
show
absolut
number
naiv
tcell
remain
fairli
stabl
adult
peripher
blood
exclud
thymu
depend
regul
central
naiv
tcell
pool
contrari
thymic
naiv
tcell
decreas
age
impli
depend
thymic
function
importantli
demonstr
naiv
tcell
isol
healthi
adult
characteris
highli
restrict
oligoclon
tcell
receptor
repertoir
order
elucid
drive
forc
postthym
naiv
tcell
expans
evalu
signatur
recent
tcr
engag
purifi
thymic
naiv
naiv
tcell
ex
vivo
rtpcr
analysi
reveal
upregul
among
naiv
tcell
gene
shown
express
exclus
upon
tcr
conclus
result
demonstr
first
time
presum
tcr
driven
peripher
homeostat
prolifer
naiv
tcell
healthi
human
individu
caus
signific
contract
peripher
tcr
repertoir
given
import
highli
divers
repertoir
abil
mount
effici
immun
respons
agedepend
deterior
tcell
immun
could
entail
ageingassoci
increas
suscept
infect
cancer
decreas
effici
vaccin
moreov
preferenti
expans
selfreact
naiv
cell
could
contribut
autoimmun
transcript
factor
express
describ
uniqu
marker
regulatori
cell
treg
tgfh
seem
play
crucial
role
induct
express
recent
describ
intragraft
express
latent
tgfh
associ
stabl
kidney
allograft
function
monkey
longer
receiv
immunosuppress
thu
interest
tgfh
express
stabl
graft
function
correl
intragraft
express
stain
kidney
biopsi
kidney
tissu
time
graft
reject
obtain
monkey
treat
antibodi
specif
anim
treat
atg
csa
combin
drug
polyclon
goatantihuman
antibodi
use
addit
tissu
stain
latent
activ
tgfh
anim
clinic
reject
serum
creatinin
higher
show
signific
graft
infiltr
express
nucleu
lymphocyt
cell
one
except
one
anim
reject
still
csa
treatment
show
nuclear
express
earli
biopsi
day
post
transplant
anim
treat
approxim
anim
show
nuclear
express
graft
infiltr
cell
anim
show
signific
interstiti
infiltr
without
loss
graft
function
five
anim
treat
atg
time
transplant
follow
treatment
none
anim
show
nuclear
express
day
later
anim
also
show
clinic
graft
reject
could
found
infiltr
cell
anim
n
delay
csa
treatment
combin
show
express
express
evid
prior
csa
treatment
three
anim
stabl
graft
function
year
immunosuppress
withdrawn
show
low
level
nuclear
express
nuclear
express
tgfh
found
almost
tissu
sampl
examin
direct
correl
amount
either
latent
tgfh
activ
tgfh
present
graft
presenc
nuclear
conclud
nuclear
intragraft
express
uniqu
toler
graft
rather
posit
cell
treg
must
consid
part
normal
immun
respons
graft
reject
nuclear
express
inhibit
csa
atg
treatment
may
indic
drug
prevent
treg
develop
insulin
essenti
develop
autoimmun
diabet
creat
nod
mice
without
nativ
insulin
gene
mutat
insulin
sequenc
mutat
insulin
replac
tyrosin
alanin
b
chain
amino
acid
ala
insulin
mutat
abrog
autoreact
multupl
insulin
cell
clone
eg
preserv
hormon
activ
four
founder
strain
ala
insulintransgen
mice
establish
directli
nod
mice
combin
insulin
knockout
nod
mice
nod
mice
lack
insulin
gene
mutat
insulin
transgen
develop
antiinsulin
autoantibodi
wherea
mice
bear
least
one
copi
nativ
insulin
gene
without
insulin
gene
develop
insulin
autoantibodi
remark
initi
two
doubl
insulin
knockout
mice
sacrif
strain
b
f
week
age
show
insliti
howev
sialiti
observ
suggest
protect
autoimmun
delet
nativ
insulin
organspecif
almost
mice
nativ
insulin
gene
sacrif
week
age
intraislet
insul
without
transgen
n
consist
lack
insul
none
nativ
insulin
null
nod
mice
develop
diabet
founder
strain
alatransgen
nod
mice
develop
diabet
insul
nativ
insulin
gene
also
present
suggest
prevent
effect
depend
absenc
nativ
insulin
splenocyt
protect
transgen
nativ
insulin
null
nod
mice
show
delay
transfer
diabet
nodscid
mice
transfer
week
compar
standard
nod
splenocyt
transfer
transfer
week
nodscid
mice
nativ
insulin
gene
splenocyt
diabet
nodscid
recipi
show
immunolog
memori
transfer
diabet
second
nodscid
mous
mous
develop
diabet
week
post
splenocyt
transfer
observ
nativ
insulin
null
nod
mice
mutat
insulin
sequenc
abrog
antiislet
autoimmun
suggest
insulin
essenti
autoantigen
type
diabet
nod
mice
insulin
peptid
like
critic
determin
abil
transfer
diseas
splenocyt
protect
mice
like
due
express
nativ
insulin
sequenc
recipi
indic
splenocyt
protect
nativ
insulin
null
mice
compet
rapidli
transfer
diabet
host
appropri
target
yet
undetermin
factor
new
zealand
nz
mous
model
compris
new
zealand
black
nzb
new
zealand
white
nzw
strain
spontan
develop
system
autoimmun
consid
excel
model
sle
numer
slelink
loci
identifi
throughout
nz
genometh
challeng
determin
gene
underli
linkag
region
role
sle
pathogenesi
end
assay
utilis
affymetrix
genechip
system
global
gene
express
splenic
bcell
tcell
sampl
lupuspron
nzb
nonautoimmun
balbc
mice
investig
along
two
congen
mous
strain
carri
nzbderiv
diseaselink
region
balbc
genom
name
distal
chromosom
proxim
chromosom
differenti
express
gene
nzb
balbc
identifi
combin
result
two
methodsa
foldchang
analysi
signific
analysi
microarray
sam
gene
observ
result
analys
consid
differenti
express
base
threshold
f
compar
balbc
fold
chang
analysi
cutoff
valu
sam
analysi
gene
transcript
differenti
express
nzb
balbc
bcell
gene
transcript
differenti
express
nzb
balbc
tcell
attempt
defin
diseas
suscept
gene
within
congen
interv
transcript
profil
gene
map
within
congen
interv
compar
balb
c
success
identifi
number
differenti
express
gene
specif
congen
interv
exampl
interferoninduc
ifi
gene
cluster
site
distal
chromosom
show
consider
degre
differenti
express
nzb
congen
strain
compar
balbc
replic
find
seen
investig
gene
express
splenic
tissu
nzb
relat
locu
proxim
chromosom
upregul
btb
cnc
homolog
gene
present
bcell
congen
strain
compar
balbc
transcript
factor
key
role
bcell
class
switch
somat
hypermut
evid
humor
immun
respons
defin
sequenc
variant
across
gene
order
characteris
haplotyp
structur
inbr
mous
strain
impact
lupu
suscept
locu
b
cell
toler
k
raman
l
li
bhaskarabhatla
r
samudrala
k
hsu
c
mohan
intern
medicinerheumatolog
ut
southwestern
medic
center
dalla
tx
usa
purpos
wherea
mice
autoantibodi
free
mice
render
congen
allel
lupu
suscept
interv
develop
high
titr
antinucleosom
antibodi
henc
tip
balanc
toler
toward
autoimmun
studi
design
understand
might
breach
b
cell
toler
method
mice
bred
heligmhel
heligshel
transgen
mice
mice
examin
breach
b
cell
toler
use
variou
method
includ
flow
cytometri
serolog
calcium
flux
analysi
vitro
cultur
result
presenc
helig
transgen
bcure
q
associ
autoimmun
phenotyp
includ
splenomegali
f
mg
vs
f
mg
n
age
month
b
mfi
ia
b
f
unit
vs
f
unit
n
age
month
cell
activ
number
cell
f
vs
f
n
antinuclear
antibodi
product
antidnahiston
igg
f
uml
vs
f
uml
n
age
month
p
glomerulonephr
studi
impact
central
delet
bred
heligmhel
mice
n
mice
compar
diminut
splenic
igm
hel
transgen
b
cell
serum
antihel
antibodi
indic
sle
abrog
central
delet
high
avid
antiself
b
cell
studi
impact
clonal
anergi
bred
heligshel
mice
model
although
selfreact
b
cell
allow
escap
peripheri
function
anergis
importantli
breach
toler
model
sinc
mice
increas
number
b
cell
f
vs
f
p
b
n
age
month
also
significantli
higher
level
antihel
antibodi
f
uml
vs
f
uml
n
age
month
p
interestingli
mice
age
month
also
produc
antissdna
igm
antibodi
ex
vivo
overnight
cultur
whole
splenocyt
demonstr
spontan
activ
b
cell
absenc
stimulu
activ
enhanc
presenc
antiigm
n
age
month
prolifer
assay
use
cfdase
dilut
reveal
increas
respons
b
cell
antiigm
shel
undivid
b
cell
vs
n
age
month
examin
presenc
rescu
delet
helig
b
cell
shel
mice
b
cell
adopt
transfer
shel
mice
howev
compar
delet
either
b
cell
conclus
find
support
conclus
though
may
capac
thwart
central
delet
high
avid
antiself
b
cell
certainli
abrog
effect
danergizationt
lowavid
antiself
b
cell
molecular
base
differ
current
examin
aim
studi
determin
whether
insvntr
polymorph
modul
function
phenotyp
cell
respons
pin
subject
high
risk
patient
ab
subject
without
control
subject
betacel
autoimmun
subject
type
insvntr
class
class
iii
allel
peripher
blood
lymphocyt
cell
subset
naiiv
recent
prime
memori
stimul
immunodomin
epitop
cytokin
secret
ifng
tnfa
determin
analysi
reveal
predomin
cell
subject
protect
vntr
class
iii
allel
subject
vntr
class
allel
cell
phenotyp
associ
regulatori
function
subject
experiment
model
autoimmun
analysi
show
first
time
transcript
effect
vntr
gene
subject
high
risk
affect
select
pin
specif
lymphocyt
peripheri
influenc
predisposit
suscept
inflammatori
bowel
diseas
inflammatori
bowel
diseas
ibd
complex
genet
disord
caus
combin
genet
environment
factor
recent
evid
implic
compon
innat
immun
system
pathogenesi
ibd
mutat
human
associ
suscept
ibd
data
prompt
us
undertak
thorough
investig
one
innat
immun
pathway
involv
extracellular
pathogenassoci
molecular
pattern
recognit
tolllik
receptor
pathway
select
gene
tlr
gene
famili
well
compon
downstream
signal
pathway
perform
haplotypebas
associ
analysi
gene
assess
common
genet
variat
found
tlr
pathway
reveal
suggest
evid
associ
polymorph
tirap
ibd
screen
canadian
popul
ibd
trio
case
control
howev
result
replic
independ
belgian
sampl
collect
ibd
trio
case
control
second
replic
effort
consist
ibd
trio
ibd
tetrad
conclud
shortli
allow
us
make
definit
conclus
regard
observ
associ
two
polymorph
previous
associ
ibd
nfkb
promot
indel
also
assess
use
metaanalys
publish
studi
studi
popul
nfkb
polymorph
fail
show
definit
associ
metaanalysi
howev
definit
show
allel
associ
suscept
ibd
explor
phenotyp
associ
allel
final
found
human
baffr
defici
caus
hypogammaglobulinemia
k
warnatz
u
salzer
gutenberg
schlesier
b
grimbach
h
h
peter
h
eibel
dep
rheumatolog
clinic
immunolog
univers
clinic
freiburg
germani
introduct
baffr
member
tnfr
superfamili
express
mainli
matur
b
cell
baff
synonym
bli
baffrmic
exhibit
sever
defect
peripher
b
cell
homeostasi
indic
promin
role
baffrbaff
interact
peripher
b
cell
develop
mous
hypogammaglobulinemia
disturb
germin
center
format
impair
antibodi
respons
baffdefici
mice
render
baff
receptor
clear
candid
gene
search
etiolog
cvid
report
first
patient
homozyg
mutat
baffr
caus
clinic
phenotyp
cvid
method
patient
screen
surfac
express
baffr
flowcytometri
suspect
defect
confirm
genom
dna
sequenc
rtpcr
western
blot
analysi
extens
immunolog
phenotyp
peripher
blood
cell
perform
patientderiv
b
cell
compar
normal
control
vitro
activ
via
bcr
f
baff
result
yr
old
patient
hypogammaglobulinemia
igg
iga
gl
igm
gl
famili
histori
immunodefici
identifi
fac
analysi
express
baffr
b
cell
due
genom
homozyg
delet
transmembran
region
exon
immun
phenotyp
distinct
may
permit
screen
baffbaffr
defici
function
assay
still
ongo
besid
recurr
pneumonia
suffer
unusu
fungal
infect
upper
respiratori
tract
conclus
first
patient
genom
baffr
defect
confirm
role
baff
master
regul
peripher
b
cell
homeostasi
also
human
immun
phenotyp
patient
may
allow
identif
patient
relat
defect
support
dfg
grant
b
c
purpos
cytotox
lymphocyt
associ
protein
may
widespread
signific
aetiolog
sever
autoimmun
diseas
aid
good
candid
gene
sle
part
suggest
linkag
interv
lupu
two
genomewid
linkag
scan
linkag
region
associ
differ
polymorph
also
report
type
diabet
gravest
diseas
coeliac
diseas
function
import
inhibit
cell
activ
cooper
two
cell
costimulatori
molecul
ico
key
regul
cell
activ
encod
region
homolog
lupu
linkag
interv
mous
chromosom
bxsb
mice
report
associ
sever
aid
polymorph
utr
exon
flank
region
gene
howev
result
sle
aid
inconsist
larg
small
frequenc
african
european
warrant
potenti
inclus
map
experiment
valid
involv
genotyp
new
popul
sampl
nucleas
assay
taqman
assaysondemand
primeroligo
base
extent
assay
resolv
malditof
mass
spectrometri
chip
massarray
sequenom
marker
chosen
genotyp
success
least
west
african
european
american
hardyweinberg
equilibrium
parent
popul
minim
level
ancestri
inform
shannon
inform
content
sic
maximum
similar
frequenc
within
contin
current
use
subset
marker
valid
map
screen
risk
factor
diseas
patient
multipl
sclerosi
prostat
cancer
hallmark
atop
allergi
product
allergenspecif
ige
turn
requir
cytokin
interleukin
il
product
allergenspecif
type
cell
addit
respons
activ
releas
inflammatori
mediat
mast
cell
basophil
allergenspecif
ige
abl
form
complex
allergen
effici
process
present
igereceptor
express
antigen
present
cell
apc
captur
present
allergen
via
mechan
shown
result
reduct
concentr
allergen
requir
trigger
tcell
activ
bind
allergenig
complex
surfac
human
b
lymphocyt
demonstr
previous
flow
cytometri
use
fluoresc
label
antiig
antibodi
investig
bind
allergenig
complex
surfac
splenic
bcell
isol
balbc
mice
method
bcell
isol
spleen
naiv
balbc
mice
use
magnet
bead
miltenyi
serial
dilut
sera
ovalbuminsensit
mice
immun
intraperiton
inject
naiv
untreat
control
incub
alon
presenc
ag
ovalbumin
ova
hour
subsequ
bcell
ad
sampl
incub
hour
follow
incub
seraallergen
bcell
wash
twice
pb
contain
bovin
serum
albumin
bsa
stain
ice
minut
monoclon
fluorescentlylabel
antiig
antibodi
addit
experi
fluorescentlylabel
ova
use
reveal
bind
ovaantibodi
complex
cell
analyz
wash
use
facscalibur
flow
cytomet
sampl
minimum
cell
analyz
result
absenc
serum
allergen
small
percentag
bcell
ige
posit
incub
bcell
allergen
ova
sera
ova
sensit
mice
higher
serum
concentr
result
mark
increas
ige
bcell
increas
bcell
alreadi
detect
low
serum
concentr
bind
ige
depend
upon
presenc
allergen
allergenspecif
antibodi
sinc
incub
sera
ovasensit
mice
irrelev
allergen
naiv
mice
ova
result
similar
increas
antibodi
posit
bcell
furthermor
bind
ovaig
complex
shown
inhibit
markedli
treatment
fcerii
antibodi
vitro
conclus
data
demonstr
mous
splenic
bcell
bind
allergenspecif
ige
low
affin
ige
receptor
fcerii
effici
bind
occur
presenc
allergenig
complex
may
form
basi
approach
character
identif
ige
contain
sera
novel
candid
marker
multipl
sclerosi
use
phage
cdna
display
v
somer
c
govart
k
somer
p
stinissen
biomedisch
onderzoeksinstituut
biom
limburg
universitair
centrum
luc
transnat
univers
limburg
tul
diepenbeek
belgium
multipl
sclerosi
ms
chronic
inflammatori
diseas
central
nervou
system
character
presenc
focal
lesion
result
myelin
breakdown
past
year
import
contribut
b
cell
autoreact
antibodi
demonstr
pathogenesi
ms
fulli
explor
complex
inform
present
within
antibodi
repertoir
patient
develop
novel
power
molecular
approach
dserolog
antigen
selectiont
involv
display
cdna
express
librari
filament
phage
subsequ
select
patient
igg
aim
studi
appli
sa
technolog
identifi
antigen
specif
recogn
antibodi
igg
present
cerebrospin
fluid
csf
ms
patient
first
construct
cdna
display
librari
clone
normal
cdna
librari
prepar
activ
chronic
ms
plaqu
vari
degre
demyelin
inflammatori
activ
soar
et
al
express
fusion
protein
filament
phage
minor
coat
protein
pvi
parallel
select
perform
pool
csf
n
relapsingremit
ms
patient
affin
select
reveal
panel
differ
clone
reactiv
first
csf
pool
detail
serolog
analysi
differ
antigen
larg
panel
n
individu
patient
control
csf
show
exclus
reactiv
ms
patient
csf
seven
differ
antigen
sequenc
analysi
reveal
clone
never
associ
ms
antigen
cdna
second
pool
csf
current
investig
conclus
find
demonstr
novel
molecular
approach
use
identifi
novel
candid
antigen
ms
use
diagnost
marker
use
studi
humor
immun
respons
ms
allohsct
v
bajzik
n
dulphi
saadaduchenoy
l
leca
c
scieux
e
gluckman
g
soci
charron
toubert
h
moinsteisserenc
recognit
viral
antigen
immun
system
induc
coordin
number
chang
lymphocyt
subset
involv
chang
express
cell
surfac
molecul
lymphocyt
migratori
properti
abil
prolifer
exert
tcell
mediat
cytotox
primari
infect
human
cytomegaloviru
hcmv
follow
lifelong
persist
viral
latenc
cell
myeloid
lineag
cmv
specif
cell
maintain
high
frequenc
healthi
cmv
carrier
reflect
perman
control
cmv
reactiv
subclin
level
host
immun
respons
primari
cmv
infect
usual
clinic
silent
littl
known
longitudin
evolut
specif
cell
cours
antigen
challeng
due
latenc
immun
reconstitut
patient
allogen
haematopoiet
stem
cell
transplant
allohsct
high
risk
cmv
reactiv
first
three
month
design
strategi
follow
cmv
reactiv
context
combin
weekli
determin
viral
load
quantif
cmv
specif
immun
respons
took
advantag
monitor
explor
complex
hostpathogen
relat
cours
infect
latenc
focus
immun
domin
respons
tegument
protein
character
cell
respons
use
combin
phenotyp
hlaclass
tetram
function
elispot
assay
twelv
patient
select
abil
mount
cmv
respons
total
cell
specif
cell
detect
time
reactiv
earli
day
allohsct
underw
phase
expans
stabil
respons
depend
intens
antigen
challeng
recipi
seroneg
donor
phenotyp
predomin
first
wave
reactiv
rapidli
follow
progress
though
phenotyp
although
molecul
observ
late
phenotyp
express
correl
stage
defin
express
patient
reactiv
twice
enrich
cell
differ
phenotyp
observ
consist
differ
stage
differenti
cell
perforin
posit
wherea
granzym
express
seem
restrict
tetram
posit
tcell
compart
conclus
studi
show
specif
effect
anticmv
respons
mount
earli
allohsct
even
donor
seroneg
gave
insight
evolut
cmvspecif
cell
respons
human
onset
reactiv
stage
chronic
infect
reproduc
protein
analysi
method
compli
glp
gmp
part
requir
loac
technolog
offer
benefit
sinc
protein
analysi
integr
sampl
handl
separ
stain
destain
detect
digit
data
analysi
addit
due
integr
sever
individu
procedur
increas
throughput
reproduc
achiev
compar
chipbas
protein
analysi
regard
sensit
size
accuraci
reproduc
sdspage
data
compar
obtain
coomassiestain
page
gel
benefit
work
microfluid
scale
includ
speed
analysi
sampl
size
fulli
autom
data
evalu
ten
sampl
run
thirti
minut
electropherogram
plot
fluoresc
intens
separ
time
gener
sampl
data
individu
constitu
complex
mixtur
shown
along
calcul
concentr
percent
total
protein
trace
analysi
sampl
take
thirti
minut
use
four
microlit
sampl
data
analysi
automat
perform
realtim
store
archiv
digit
format
iq
oqpv
tool
servic
well
part
compliant
softwar
tailor
instrument
use
regul
environ
n
kenyon
x
xu
han
c
heali
koester
baidal
c
ricordi
r
alejandro
insulin
independ
achiev
via
allogen
islet
transplant
patient
type
diabet
aim
determin
immunophenotyp
islet
transplant
recipi
determin
alter
immun
profil
ip
correl
graft
statu
thirteen
islet
allograft
recipi
longterm
n
year
type
diabet
treat
steroid
free
immun
suppress
rapamycin
induct
therapi
zenapax
monitor
serial
chang
ip
twelv
patient
receiv
islet
infus
patient
receiv
islet
donor
patient
experienc
insulin
independ
eventu
return
reduc
dosag
exogen
insulin
peripher
blood
pb
sampl
collect
pre
post
transplant
color
stain
multiparametr
analysi
lymphocyt
subset
b
nk
cell
activ
marker
hla
dr
similar
observ
cytotox
lymphocyt
gene
clg
express
pb
variabl
chang
ip
occur
earli
posttranspl
period
infus
initi
appear
correl
graft
statu
differ
howev
subsequ
observ
overal
white
blood
cell
count
wbc
ip
stabl
recipi
vs
patient
partial
islet
allograft
loss
previous
shown
elev
clg
predict
islet
reject
studi
compar
ip
clg
data
result
antidonor
mix
lymphocyt
reaction
mlr
data
show
wbc
decreas
less
baselin
stabl
patient
remain
rel
low
patient
experienc
reject
wbc
increas
subsequ
elev
clg
remain
higher
stabl
recipi
cell
drop
less
baselin
remain
level
similar
wbc
cell
count
includ
cell
subset
drop
initi
increas
evid
reject
indic
clg
elev
onset
hyperglycemia
initi
exogen
insulin
patient
despit
zenapax
therapi
patient
partial
graft
loss
show
elev
cell
appar
reject
show
elev
cell
stabl
patient
show
clear
stabl
decreas
baselin
experienc
gradual
increas
time
regard
nk
b
cell
subset
trend
toward
count
remain
baselin
seen
stabl
patient
increas
evid
reject
observ
patient
partial
graft
loss
suggest
chang
post
transplant
ip
indic
alter
recipientt
immun
respons
transplant
islet
support
clg
mlr
clinic
data
stabl
vs
reject
patient
work
establish
flow
base
method
assess
function
statu
recipi
cell
respons
nonspecif
donor
cell
stimul
ultim
tailor
patient
therapi
autoimmun
children
atyp
type
type
diabet
l
k
gilliam
j
p
palmer
b
brooksworrel
c
j
greenbaum
c
pihok
medicin
univers
washington
seattl
wa
usa
benaroya
research
institut
seattl
wa
usa
pediatr
univers
washington
seattl
wa
usa
aim
incid
type
type
diabet
mellitu
increas
children
although
classic
thought
separ
pathogenes
present
often
admixtur
featur
present
diagnosi
aim
examin
relationship
autoimmun
measur
hla
clinic
cours
method
subject
atyp
present
featur
obes
acanthosi
nigrican
absenc
dka
andor
absenc
weight
loss
subject
clinic
diagnosi
studi
time
diagnosi
diabetesassoci
autoantibodi
daa
includ
islet
cell
insulin
autoantibodi
measur
subject
underw
hla
genotyp
classifi
high
risk
protect
low
risk
hla
haplotyp
subject
year
age
diagnosi
clinic
cours
follow
subject
mean
period
f
month
result
atyp
atyp
subject
posit
least
one
daa
hla
type
one
high
risk
hla
allel
prescrib
insulin
diagnosi
remain
insulin
throughout
followup
period
insulinrequir
subject
lost
followup
insulinrequir
subject
daa
posit
diagnosi
hlatyp
insulinrequir
subject
high
risk
hla
genotyp
low
risk
hla
genotyp
initi
noninsulinrequir
subject
remain
oral
agent
daa
neg
one
type
subject
hla
low
risk
subject
initi
treat
oral
agent
subsequ
requir
insulin
glucos
control
subject
high
risk
hla
one
daa
posit
subject
daa
posit
diagnosi
hlatyp
subject
high
risk
hla
genotyp
combin
high
risk
protect
allel
remain
low
risk
protect
allel
diagnosi
subject
treat
oral
agent
one
insulin
followup
inform
obtain
subject
subject
initi
treat
insulin
remain
insulin
individu
daa
neg
hla
type
subject
initi
treat
oral
agent
remain
oral
agent
followup
three
daa
posit
one
high
risk
hla
subject
group
posit
daa
high
risk
hla
two
three
subject
initi
treat
oral
agent
subsequ
requir
insulin
glucos
control
daa
posit
high
risk
hla
conclus
children
clinic
classifi
atyp
present
high
frequenc
autoimmun
marker
hla
haplotyp
addit
autoimmun
marker
children
clinic
featur
appear
indic
aggress
diabet
diseas
process
previous
shown
children
typic
develop
clinic
assay
evalu
tolllik
receptor
function
r
p
deer
j
orang
immunolog
childrent
hospit
philadelphia
philadelphia
pa
usa
tolllik
receptor
tlr
transmembran
pattern
recognit
protein
particip
innat
immun
respons
number
genet
defect
influenc
function
receptor
identifi
associ
recurr
andor
sever
infect
goal
develop
reproduc
assay
tlr
respons
evalu
tlr
function
patient
recurr
infect
peripher
blood
mononuclear
cell
pbmc
isol
incub
ligand
tlr
tumor
necrosi
factor
tnf
cell
supernat
evalu
enzymelink
immunosorb
assay
elisa
measur
immun
respons
optim
concentr
mean
respons
individu
ligand
establish
healthi
adult
control
donor
number
variabl
assess
could
affect
assay
includ
blood
anticoagul
blood
storag
time
pbmc
cryopreserv
assay
media
incub
period
assay
reproduc
media
contain
fetal
bovin
serum
neither
serumfre
human
serumcontain
media
could
effect
substitut
cryopreserv
pbmc
result
consider
higher
tnf
product
respons
ligand
freshli
isol
cell
mean
increas
amongst
ligand
test
use
optim
assay
condit
three
patient
mutat
ikbkg
gene
encod
nfkappab
essenti
modul
nemo
protein
ultim
studi
diseas
control
tnf
respons
patient
ikbkg
mutat
predict
exon
delet
alter
nemo
n
correspond
control
respect
although
number
variabl
influenc
tnf
tlr
respons
assay
optim
clinic
use
screen
patient
affect
primari
immun
defici
influenc
tlr
function
aim
studi
inhal
innocu
protein
induc
develop
toler
immun
respons
character
develop
reg
cell
absenc
airway
hyperrespons
ahr
airway
inflamm
reason
protein
promot
allerg
sensit
instead
toler
studi
extens
still
controversi
mani
allergen
possess
serin
proteinas
activ
allergensserin
proteinas
hous
dust
mite
cockroach
mediat
effect
proteinaseactiv
previous
shown
exogen
activ
allergen
challeng
enhanc
allergenmedi
ahr
airway
inflamm
current
hypothesi
activ
time
encount
inhal
protein
may
mediat
allerg
sensit
prevent
develop
tolerogen
respons
methodolog
use
balbc
mous
model
toler
intranas
administ
ovalbumin
ova
balbc
mice
administ
ova
consecut
day
mice
administ
ova
activ
peptid
sligrlnh
mimic
inhal
allergen
activ
potenti
control
mice
receiv
ova
control
peptid
lsigrlnh
administ
salin
alon
mice
subsequ
receiv
interperiton
ip
immun
ova
al
oh
ten
day
last
administr
five
day
follow
immun
mice
euthan
cell
isol
spleen
cultur
vitro
antigen
present
cell
narv
mous
ova
day
prolifer
assess
group
mice
challeng
twice
ova
altern
day
day
ip
immun
assess
ahr
eosinophil
inflamm
lung
day
last
challeng
result
cell
isol
mice
treat
initi
ova
alon
prolifer
poorli
ova
vitro
indic
develop
toler
ova
cell
mice
treat
salin
alon
ova
prolifer
vigor
furthermor
mice
treat
initi
salin
alon
ova
develop
ahr
eosinophil
inflamm
follow
ova
challeng
mice
treat
ova
alon
show
sign
either
conclus
activ
airway
prevent
develop
tolerogen
respons
toward
administ
ova
observ
indic
inhal
allergensserin
proteinas
may
induc
allerg
sensit
activ
airway
nasal
vaccin
proteosomebas
adjuv
glatiram
acet
clear
alzheimert
bamyloid
antibodyindepend
fashion
result
reduct
thioflavin
posit
fibrillar
amyloid
hippocampu
reduct
total
brain
ah
level
vs
non
treat
mice
effect
requir
antibodi
observ
bcell
defici
mice
vaccin
anim
develop
activ
microglia
cell
coloc
ah
fibril
extent
microgli
activ
correl
strongli
decreas
ah
fibril
also
notic
strong
correl
cell
ifng
secret
cell
increas
number
cell
r
may
play
role
promot
microgli
activ
result
defin
antibodyindepend
therapeut
approach
treatment
alzheimert
diseas
util
compound
safe
test
current
use
human
collabor
central
toler
peripher
regul
control
autoimmun
z
chen
c
benoist
mathi
immunolog
immunogenet
joslin
diabet
centerharvard
medic
school
boston
usa
varieti
mechan
propos
immunolog
toler
self
tissu
promin
role
attribut
central
toler
illumin
role
air
thymic
delet
autoreact
lymphocyt
peripher
regul
exemplifi
function
gener
regulatori
cell
suppress
pathogen
effector
report
fulmin
autoimmun
earli
life
grave
shorten
lifespan
mice
defici
air
anim
lack
either
air
exacerb
inflammatori
damag
air
doubledefici
anim
particularli
promin
lung
liver
also
involv
sever
organ
despit
massiv
lymphoprolifer
littl
inflammatori
infiltr
occcur
mani
organ
possibl
protect
aireand
mechan
studi
highlight
critic
import
central
toler
peripher
regul
maintain
self
toler
suggest
still
learn
eye
immun
privileg
tissu
constitut
produc
neuropeptid
cytokin
factor
activ
suppress
inflamm
mediat
innat
adapt
immun
neural
retina
nr
retin
pigment
epitheli
rpe
cell
document
support
immun
privileg
howev
understand
mechan
ocular
immun
analyz
anterior
chamber
eye
therefor
begin
identifi
factor
import
regul
immun
retina
investig
effect
secret
factor
nr
rpe
activ
rest
activ
macrophag
nr
healthi
mice
dissect
place
cultur
hour
cultur
media
place
result
posterior
eye
cup
contain
rpe
incub
hour
condit
media
cm
use
treat
rest
endotoxinstimul
macrophag
cell
line
hour
macrophag
supernat
assay
multiplex
analysi
tnfalpha
gmcsf
addit
rpecm
nrcm
assay
multiplex
analysi
found
gmcsf
rpecm
nrcm
nrcm
stimul
gmcsf
product
rest
macrophag
suppress
endotoxinstimul
macrophag
rpecm
nrcm
suppress
tnfalpha
product
endotoxinstimul
macrophag
induc
signific
level
product
macrophag
nr
may
support
macrophag
differenti
gmcsf
nr
rpe
suppress
product
inflammatori
cytokin
tnfalpha
endotoxinstimul
macrophag
caus
macrophag
produc
antiinflammatori
cytokin
result
suggest
mechan
immunosuppress
retina
may
involv
factor
suppress
classic
activ
promot
altern
activ
macrophag
therefor
neuroretina
rpe
contribut
mechan
retin
immun
privileg
support
grant
usamrmc
treatment
donorspecif
transfus
mab
induc
nonrespons
popul
cell
recogn
alloantigen
via
indirect
antigen
present
n
e
phillip
l
greiner
j
p
mord
rossini
medicinediabet
univers
massachusett
medic
school
worcest
viet
nam
treatment
donorspecif
transfus
dst
monoclon
antibodi
mab
induc
prolong
allograft
surviv
mice
part
delet
host
cell
recogn
alloantigen
direct
antigen
present
fate
host
cell
recogn
alloantigen
via
indirect
antigen
present
mice
treat
costimul
blockad
unclear
studi
investig
fate
tcr
transgen
cell
recogn
alloantigen
via
indirect
antigen
present
use
cfselabel
first
document
transgen
cell
prolifer
vitro
vivo
respons
allostimul
treatment
mice
circul
cell
dst
plu
mab
howev
fail
delet
alloreact
cell
instead
render
nonrespons
rechalleng
alloantigen
mice
circul
nonrespons
alloreact
cell
also
fail
reject
skin
allograft
nonrespons
state
cell
revers
addit
mab
agonist
mab
presenc
antigen
protocol
success
revers
clonal
adapt
anerg
state
toler
cell
nonrespons
alloreact
cell
arecap
activ
howev
evidenc
robust
vitro
prolifer
respons
mab
presenc
costimul
data
document
nondelet
mechan
costimul
blockad
block
host
alloreact
cell
respons
prolong
graft
surviv
use
b
cell
defici
mice
evalu
abil
toler
presensit
cell
via
mix
chimer
induct
bone
marrow
transplant
bmt
b
cell
defici
wildtyp
b
mice
presensit
tail
skin
receiv
nonmyeloabl
condit
nk
monoclon
antibodi
gy
total
bodi
irradi
bmt
bone
marrow
cell
bmc
twelv
week
reject
presenc
antidonor
igg
serum
presensit
mice
confirm
indirect
stain
flow
cytometri
multilineag
chimer
monitor
week
postbmt
flow
cytometri
presensit
wildtyp
mice
reject
donor
bmc
week
thu
antidonor
igg
antibodi
present
wildtyp
mice
presensit
pose
strong
barrier
donor
marrow
engraft
contrast
amt
mice
show
engraft
donor
bmc
stabl
longterm
multilineag
donor
chimer
importantli
chimer
amt
mice
accept
donor
graft
longterm
third
parti
graft
reject
week
thu
result
show
preexist
cell
immun
bmc
donor
antigen
may
overcom
nonmyeloabl
mix
chimer
induct
presensit
mice
previous
shown
cellular
necrosi
augment
secret
human
monocytederiv
dendrit
cell
present
studi
compar
dendrit
cell
respons
cellular
necrosi
atop
individu
nonatop
control
subject
use
vitro
cultur
system
monocytederiv
dendrit
cell
stimul
either
necrot
cell
combin
tnfalpha
demonstr
dendrit
cell
atop
individu
secret
significantli
less
respons
necrot
cell
product
compar
dendrit
cell
nonatop
subject
upon
stimul
necrot
cell
crosslink
dendrit
cell
atop
subject
secret
significantli
less
furthermor
upregul
necrosi
significantli
less
dendrit
cell
atop
individu
compar
normal
subject
contrast
respons
dendrit
cell
atop
subject
tnfalpha
significantli
differ
normal
individu
conclud
atopi
associ
defect
respons
dendrit
cell
necrot
cell
death
may
play
role
mechan
atop
sensitis
pathway
monocytederiv
dendrit
cell
b
rethi
p
gogolak
e
rajnavolgyi
c
terhorst
lanyi
institut
immunolog
univers
debrecen
medic
health
scienc
center
debrecen
hungari
divis
immunolog
beth
israel
deaco
medic
center
boston
usa
microbiolog
tumor
biolog
center
karolinska
institut
stockholm
sweden
slam
signal
lymphocyt
activ
molecul
selfligand
receptor
surfac
activ
tand
blymphocyt
macrophag
dendrit
cell
dc
import
interfac
adapt
innat
immun
respons
underscor
slam
receptor
measl
viru
induc
immunosuppress
moreov
recent
report
indic
high
express
level
slam
tlymphocyt
patient
infect
tuberculosi
lepra
associ
milder
patholog
function
slam
surfac
human
dendrit
cell
poorli
understood
examin
effect
slam
slam
interact
activ
signal
human
peripher
blood
monocytederiv
dendrit
cell
effect
slam
dc
activ
analyz
cocultur
dc
cell
express
alon
combin
slam
product
strongli
inhibit
slam
engag
result
dc
phenotyp
less
potent
induc
differenti
naiv
lymphocyt
ifng
produc
effector
cell
interestingli
abil
bslameducatedq
dc
support
prolifer
naiv
cell
significantli
increas
determin
effect
slam
differ
tlrinduc
dc
activ
cell
cell
express
slam
cocultur
immatur
dendrit
cell
presenc
lp
polyic
unlik
product
tlr
induc
secret
augment
slam
engag
dc
activ
lp
slam
engag
reduc
product
level
cultur
activ
lp
slam
indic
slam
modul
pathway
independ
thu
find
suggest
dual
function
slam
monocytederiv
dc
allow
slam
exert
oppos
effect
function
base
receiv
activ
signal
activ
human
nk
cell
plasmacytoid
dc
modul
cell
hi
regulatori
cell
c
romagnani
della
chiesa
kohler
l
moretta
moretta
thiel
clinic
immunolog
german
rheumat
research
center
drfz
berlin
germani
dipartimento
di
medicina
sperimental
universita
di
genova
genova
itali
istituto
g
gaslini
genova
itali
background
plasmacytoid
dendrit
cell
pdc
repres
special
cell
popul
produc
type
interferon
respons
viru
howev
although
pdcderiv
type
interferon
potent
modul
nk
cell
function
nk
cell
essenti
antivir
immun
role
pdc
coordin
nk
cell
function
yet
elucid
detail
especi
human
object
studi
investig
interplay
human
pdc
nk
cell
evalu
th
hi
regulatori
treg
cell
modul
interact
method
highli
purifi
facssort
human
pdc
nk
cell
hi
treg
cell
neg
cell
cocultur
nk
cell
analys
express
prolifer
stain
cfse
cytokin
product
use
bioplex
cytotox
cr
releas
assay
pdc
activ
cpga
cocultur
nk
cell
result
pdc
follow
engag
activ
autolog
nk
cell
indic
induct
surfac
express
condit
pdc
also
enhanc
nk
cell
effector
function
includ
cytotox
cytokin
product
moreov
induc
prolifer
bright
dim
nk
cell
activ
highli
upregul
fashion
autolog
cell
strikingli
hi
treg
cell
inhibit
prolifer
nk
cell
induc
interplay
pdc
helper
cell
influenc
nk
cell
activ
prolifer
induc
pdc
alon
conclus
first
demonstr
human
pdc
activ
nk
cell
enhanc
effector
function
induc
prolifer
addit
first
demonstr
th
hi
treg
cell
modul
nk
cell
prolifer
impli
direct
role
adapt
immun
respons
amplifi
inhibit
innat
immun
hepat
c
viru
core
protein
induc
monocytemedi
mechan
reduc
ifna
plasmacytoid
dendrit
cell
loss
patient
chronic
hcv
infect
dolganiuc
g
baki
k
kodi
g
szabo
medicin
univers
massachusett
medic
school
worcest
usa
immun
respons
acut
hepat
c
viru
infect
insuffici
individu
lead
chronic
infect
major
infect
individu
current
success
therapi
hcv
infect
base
use
ifna
type
interferon
ifn
includ
ifnalpha
ifna
inhibit
viral
replic
promot
antivir
immun
respons
limit
controversi
inform
avail
relat
capac
hcvinfect
patient
produc
endogen
ifna
purpos
studi
investig
function
capac
plasmacytoid
dendrit
cell
pdc
main
produc
ifna
patient
chronic
hcv
infect
compar
control
found
significantli
decreas
product
ifna
determin
elisa
pbmc
hcv
patient
upon
stimul
pdcspecif
ligand
cpga
dna
hsv
ko
correl
decreas
frequenc
circul
pdc
determin
flow
cytometri
hcv
patient
compar
control
hcv
f
control
f
pdc
purifi
hcv
patient
produc
lower
level
ifna
compar
control
apoptot
determin
stain
annexin
v
dna
ladder
vitro
stimul
cpga
dna
hsv
ko
lead
increas
cell
death
pdc
hcv
patient
compar
control
correl
loss
pdc
hcv
viral
count
genotyp
liver
function
importantli
reduct
pdc
frequenc
ifna
product
patient
sustain
virolog
respons
hcv
elimin
therapi
suggest
role
viral
deriv
mechan
dc
defect
found
recombin
hcv
core
protein
directli
affect
pdc
function
significantli
reduc
ifna
product
pbmc
determin
hcv
core
protein
activ
monocyt
produc
tnfa
vitro
tnfa
induc
pdc
apoptosi
inhibit
ifna
product
normal
pdc
antitnfa
neutral
antibodi
addit
restor
ifna
product
core
stimul
pbmc
deplet
monocyt
pbmc
abolish
tnfa
product
prevent
hcv
coreinduc
inhibit
pdc
ifna
product
result
show
hcv
core
protein
modul
hostt
abil
produc
ifna
indirectli
interf
pdc
function
via
monocytederiv
cytokin
reveal
viralinduc
mechan
pdc
loss
ifna
product
defect
like
contribut
chronic
viral
persist
may
provid
mechanist
explan
therapeut
benefit
ifna
therapi
hcv
infect
delay
induc
human
tolerogen
dc
inhibit
naiv
cell
prolifer
mechan
exagger
induct
f
li
k
laudanski
l
perez
c
l
millergraziano
surgeri
univers
rochest
medic
center
rochest
ny
usa
previou
data
indic
treat
human
monocyt
mo
differenti
macrophag
mac
express
elev
mac
marker
like
addit
monocyt
partial
differenti
dendrit
cell
mo
gmcsf
day
ad
addit
day
induc
tolerogen
dendrit
cell
tol
dc
diminish
cell
activ
mechan
tolerogen
dc
inhibit
cell
still
undefin
suggest
relat
upregul
inhibitori
costimul
ligandreceptor
combin
tol
dc
gener
control
donorst
mo
ad
day
cultur
mo
gmcsf
induc
addit
day
addit
dc
differenti
cultur
significantli
decreas
dc
level
f
posit
versu
classic
dc
control
f
posit
level
f
versu
f
posit
increas
mac
characterist
f
versu
f
posit
posit
express
howev
tol
dc
express
inhibitori
costimulatori
ligand
significantli
increas
f
classic
dc
f
posit
mean
fluoresc
intens
mfi
also
significantli
increas
tol
dc
previous
shown
tol
dc
unabl
act
adequ
antigen
present
cell
apc
assess
inhibitori
activ
tol
dc
ad
autolog
cell
cultur
presenc
immobil
anti
plu
sinc
stimul
cell
prolifer
absenc
apc
diminish
prolifer
presenc
tol
dc
would
indic
cell
inhibitori
rather
diminish
apc
effect
addit
dc
significantli
p
reduc
cell
prolifer
anti
compar
cell
cultur
classic
dc
howev
correl
degre
increas
tol
dc
express
mediat
decreas
cell
prolifer
tol
dc
highest
increas
exhibit
highest
inhibitori
activ
data
suggest
tol
dc
function
reduc
autolog
naiv
cell
prolifer
cell
receptor
stimul
result
induct
inhibitori
costimulatori
receptor
rather
induct
nevertheless
induc
augment
dc
express
may
still
contribut
cell
inhibit
anergi
induct
tol
dc
interact
previous
activ
cell
whose
upregul
level
trigger
exagger
tol
dc
level
induct
heme
inhibit
dendrit
cell
differenti
adapt
immun
j
j
listopad
ritter
r
sabat
k
asadullah
wd
dock
crba
dermatolog
schere
ag
berlin
germani
institut
medic
immunolog
charit
humboldt
univers
berlin
germani
strong
immunosuppress
potenc
stress
protein
proven
sever
model
autoimmun
transplant
underli
immun
mechan
howev
poorli
character
studi
potent
induc
cobalt
protoporphyrin
ix
coppix
strongli
suppress
cell
prolifer
mix
lymphocyt
reaction
mlr
possibl
mechan
demonstr
select
coppix
induc
increas
express
monocyt
associ
depress
accessori
molecul
express
stimulatori
cytokin
secret
likewis
induct
monocytederiv
dendrit
cell
mddc
copppix
associ
almost
complet
inhibit
differenti
matur
function
mddc
strong
decreas
express
dc
marker
accessori
molecul
hladr
observ
wherea
secret
inhibit
product
increas
antigenpres
capac
coppix
treat
mddc
strongli
diminish
lymphocyt
transform
assay
mlr
specif
effect
demonstr
transduct
immatur
mddc
togeth
chang
indic
switch
dc
immatur
nonstimulatori
phenotyp
vivo
coppix
treatment
challeng
dosedepend
depress
ear
inflamm
dnfb
type
tma
type
induc
contact
dermat
mice
remark
coppix
even
strongli
inhibit
tcelldepend
inflamm
appli
around
sensit
hypothes
inhibit
dc
differenti
matur
function
crucial
mechan
suppress
adapt
immun
induct
vitro
vivo
donorspecif
allograft
toler
administr
recipientderiv
immatur
dendrit
cell
suboptim
immunosuppress
g
beriou
h
pech
c
guillonneau
e
merieau
c
cuturi
inserm
nant
franc
introduct
benefit
allogen
immatur
bone
marrowderiv
dendrit
cell
ibmdc
allograft
surviv
report
sever
studi
howev
contrast
protocol
base
inject
donorderiv
dc
administr
recipientderiv
dc
would
much
applic
cadaver
organ
transplant
recent
show
inject
recipienttyp
ibmdc
day
transplant
induc
signific
prolong
allograft
surviv
present
studi
aim
improv
protocol
induc
allograft
toler
method
ibmdc
gener
rat
bone
marrow
precursor
lowdos
gmcsf
day
cultur
adher
cell
display
immatur
phenotyp
character
low
mhcii
express
variou
amount
ibmdc
cell
administ
iv
syngen
rat
transplant
allogen
heart
without
addit
suboptim
immunosuppress
consist
rapamycin
oral
new
deoxyspergulalin
analog
ip
result
allograft
surviv
improv
repeat
inject
syngen
ibmdc
addit
treatment
low
dose
rapamycin
interestingli
combin
inject
ibmdc
strike
synergist
effect
induc
definit
allograft
accept
recipi
toler
treat
recipi
accept
donortyp
third
partytyp
skin
graft
demonstr
toler
donorspecif
hypothes
treatment
ibmdc
could
maintain
immatur
phenotyp
function
inde
show
vitro
decreas
mhcii
express
rat
bmdc
effect
treatment
vivo
matur
administ
ibmdc
current
investig
conclus
thu
demonstr
donorspecif
allograft
toler
induc
singl
inject
syngen
ibmdc
one
day
prior
transplant
suboptim
immunosuppress
treatment
report
find
may
contribut
develop
new
therapeut
strategi
induc
transplant
toler
clinic
set
among
dc
subset
reconstitut
natur
type
iinterferonproduc
pdc
propos
play
major
role
establish
immun
compet
therefor
investig
impact
circul
pdc
measur
month
reduc
intens
condit
ric
fludarabinebas
condit
allosct
patient
hematolog
nonhematolog
malign
receiv
ricallosct
hlaident
sibl
order
determin
whether
could
provid
indic
long
term
outcom
median
absolut
count
pdc
measur
month
rang
multipl
logist
regress
analysi
includ
relev
paramet
demograph
graft
characterist
ric
regimen
cmv
infect
acut
gvhd
absenc
grade
iiiv
acut
gvhd
associ
improv
pdc
recoveri
month
p
ci
major
type
ifnsecret
cell
also
investig
whether
pdc
recov
allosct
function
respons
viral
stimul
patient
experienc
grade
agvhd
could
secret
significantli
higher
amount
ifnalpha
compar
patient
grade
iiiv
agvhd
mean
vs
pgml
respect
p
like
highlight
deleteri
impact
corticosteroid
therapi
pdc
function
stem
cell
dose
lymphoid
subset
infus
allograft
affect
pdc
recoveri
though
pdc
count
could
predict
death
progress
relaps
patient
bhighq
pdc
recoveri
profil
improv
overal
surviv
os
p
contrast
patient
blowq
pdc
recoveri
profil
increas
incid
late
transplantrel
mortal
gvhd
infect
p
addit
overal
incid
late
infect
viral
fungal
bacteri
significantli
higher
blowq
pdc
recoveri
group
compar
bhighq
pdc
recoveri
group
vs
p
illustr
import
pdc
antiinfecti
immun
respons
multivari
analysi
bhighq
pdc
count
significantli
predict
decreas
risk
death
p
ci
role
rare
immun
effector
cell
would
tend
evid
truli
ric
less
toxic
regimen
studi
could
show
monitor
pdc
may
use
patientst
manag
closer
surveil
infect
prophylaxi
may
signific
impact
probabl
favor
outcom
context
ricallosct
sever
combin
immunodefici
syndrom
scid
characteris
absent
tand
blymphocyt
function
scid
usual
fatal
earli
infanc
without
success
immun
reconstitut
previous
report
patient
affect
xlink
scid
receiv
late
bone
marrow
transplant
year
age
followup
short
statur
due
peripher
growth
hormon
gh
hyporespons
abnorm
protein
phosphoryl
event
follow
gh
receptor
ghr
stimul
observ
mutat
screen
expression
analysi
fail
reveal
molecular
alter
ghr
gene
sinc
hypothes
role
g
chain
ghr
signal
studi
evalu
ghrg
element
function
interact
ebv
transform
lymphocyt
bcl
xscid
pt
ctr
function
respons
gh
pattern
ghr
induc
ptyr
nucleu
transloc
studi
gh
enhanc
prolifer
ctr
bcl
dosedepend
fashion
maxim
effect
ngml
contrast
pt
cell
prolifer
cytofluorimetr
analysi
reveal
differ
ghr
express
ptst
cell
gh
stimul
fail
induc
phosphoryl
protein
kda
correspond
stat
molecul
contrast
observ
ctr
peak
phosphoryl
min
observ
cell
line
examin
b
protein
express
compar
addit
ctr
cell
gh
induc
nuclear
transloc
evalu
confoc
microscopi
contrast
pt
cell
effici
transloc
occur
gh
stimul
report
previous
unappreci
function
interact
gc
ghr
eventu
lead
activ
intranuclear
transloc
protein
novel
humor
immunodefici
human
associ
deleteri
homozyg
mutat
castano
p
j
patino
c
woellner
u
salzer
b
grimbach
c
j
montoya
j
c
orrego
c
rugel
j
l
franco
group
primari
immunodefici
siuunivers
antioquia
medellin
colombia
clinic
immunolog
rheumatolog
univers
freiburg
freiburg
germani
b
cell
found
complex
complement
receptor
tetraspan
membran
protein
critic
balanc
antigeninduc
bcrmediat
signal
threshold
b
cell
function
link
bcr
follow
corecognit
ag
kd
transmembran
protein
two
extracellular
ig
domain
cytoplasm
tail
contain
sever
tyrosin
residu
becom
phosphoryl
crosslink
bcr
allow
interact
cytoplasm
protein
link
downstream
signal
cascad
mice
mutat
lead
hypogammaglobulinemia
impair
bcell
memori
low
b
cell
decreas
germin
center
format
human
select
defect
express
yet
describ
present
three
adult
sibl
one
male
two
femal
affect
recurr
respiratori
gastrointestin
tract
infect
sinc
childhood
low
serum
igg
iga
igm
peripher
blood
b
cell
within
normal
rang
fac
show
profoundli
reduc
surfac
express
three
patient
dna
sequenc
reveal
homozyg
delet
two
nucleotid
exon
lead
frameshift
prematur
stop
codon
patient
six
rel
famili
heterozyg
bcell
subpopul
pbl
show
signific
decreas
isotypeswitch
memori
cell
low
cell
patient
isohemagglutinin
decreas
solubl
level
slightli
increas
patient
tonsilt
morpholog
cellular
one
patient
normal
highli
activ
lymphoid
follicl
result
show
mutat
lead
novel
humor
immunodefici
human
affect
immunoglobulin
product
lead
increas
suscept
recurr
infect
support
colciencia
codi
deutsch
forschungsgemeinschaft
dfg
mutat
taci
associ
immunodefici
phenotyp
human
affect
individu
mutat
first
famili
affect
highli
conserv
cystein
residu
extracellular
domain
taci
mutat
observ
second
famili
nonsens
mutat
posit
lead
put
truncat
taci
protein
consist
extracellular
domain
extend
screen
patient
sporad
cvid
found
patient
carri
heterozyg
mutat
two
affect
conserv
cystein
residu
seven
locat
within
transmembran
region
two
intracellular
part
protein
fac
stain
b
cell
heterozyg
mutat
reveal
normal
taci
surfac
stain
stimul
common
mitogen
igm
b
cell
patient
mutat
taci
prolifer
normal
tonsil
biopsi
one
patient
reveal
promin
enlarg
germin
center
hypercellular
b
cell
clinic
patient
present
hypogammagloblobulinemia
especi
low
igm
display
sign
lymphoprolifer
autoimmun
high
frequenc
conclus
evalu
taci
candid
gene
patient
cvid
found
homozyg
heterozyg
mutat
famili
sporad
cvid
case
three
mutat
lead
substitut
highli
conserv
amino
acid
two
nonsens
mutat
human
tacidefici
phenotyp
consist
primarili
humor
immunodefici
thu
differ
murin
model
howev
sign
autoimmun
lymphoprolifer
also
evid
matern
engraft
cell
occur
patient
scid
variabl
extent
often
absenc
clinic
sign
gvhd
report
describ
matern
engraft
tcrgi
cell
two
children
rk
jr
artemi
common
chain
defici
respect
children
clinic
symptom
gvhd
purpos
studi
characteris
popul
detail
peripher
blood
children
phenotyp
function
characteris
respons
mitogen
children
deliv
term
normal
pregnanc
vaccin
accord
protocol
addit
rk
receiv
bcg
birth
present
month
pcp
low
serum
immunoglobulin
lymphopenia
failur
lymphocyt
respond
mitogen
rk
present
lymphocyt
count
l
posit
tcrgi
b
cell
found
jr
present
lymphocyt
count
l
posit
tcrgi
b
cell
number
l
dna
isol
peripher
blood
cell
amplifi
biom
primer
tcrg
tcri
children
clonal
tcrg
tcri
rearrang
found
compat
tcrgi
cell
utilis
tcr
tcr
tcr
tcr
vy
gene
respect
present
evid
two
children
significantli
rais
tcrgi
popul
matern
origin
blood
neither
children
clinic
evid
gvhd
rk
receiv
bcg
birth
experienc
bcg
lymphaden
skin
gut
biopsi
child
found
infiltr
tcrgi
cell
shown
clonal
ident
tcrgi
cell
blood
case
possibl
clone
aros
direct
respons
bcg
vaccin
birth
howev
cell
investig
mother
respons
bcg
data
confirm
previou
report
clonal
tcrgi
cell
found
cross
placenta
fail
initi
gvhd
neonat
child
scid
clonal
tcrgi
cell
also
shown
present
mother
abstract
origin
cell
resolv
cell
receptor
variabl
beta
chain
tcrbv
pcr
frequent
use
investig
tcrbv
usag
autoimmun
diseas
infect
cancer
tcrbv
locu
contain
variabl
region
larg
number
forward
primer
use
cover
tcrbv
segment
previou
studi
simplifi
tcrbv
analysi
perform
multiplex
pcr
primer
divid
group
approach
work
singl
cell
rtpcr
time
consum
costli
hardli
appli
larg
scale
screen
simplifi
tcrbv
analysi
establish
new
seminest
rtpcr
method
two
set
degener
primer
cover
tcrbv
gene
respect
singl
cell
analysi
extend
rtpcr
design
nest
primer
locat
tcrbv
constant
region
specif
prime
confirm
screen
cdna
cell
clone
previous
defin
tcrbv
usag
flow
cytometri
convent
tcrbv
rtpcr
retriev
tcrbv
gene
segment
compris
sampl
primer
set
high
sensit
demonstr
success
amplif
rearrang
tcrbv
gene
singl
cell
sort
bodi
fluid
dissect
tissu
new
approach
allow
fast
costeffect
high
throughput
analysi
cell
receptor
rearrang
singl
cell
level
facilit
studi
cell
respons
human
diseas
singl
cell
directli
clone
mitogen
well
plate
pancreat
drain
lymph
node
pln
human
subject
type
diabet
control
subject
gener
independ
cell
clone
sequenc
cell
receptor
alpha
beta
chain
clone
modest
expans
tcr
chain
seen
pln
nondiseas
subject
includ
subject
type
diabet
high
degre
cell
expans
observ
longterm
diabet
recent
onset
diabet
cell
infiltr
islet
use
candid
antigen
screen
approach
ebv
transform
b
cell
antigen
present
cell
clonal
expand
cell
clone
pln
longterm
diabet
respond
insulin
chain
context
context
insulin
peptid
specif
block
antidr
antibodi
cell
clone
pln
normal
cerebrospin
fluid
multipl
sclerosi
patient
reactiv
cell
clone
peripheri
multipl
sclerosi
patient
nonexpand
cell
one
long
term
diabet
pln
recogn
insulin
peptid
context
result
first
establish
cell
clonal
expans
human
pancreat
drain
lymph
node
subject
type
diabet
identif
cognat
autoantigen
experi
demonstr
feasibl
nonbias
cell
clone
drain
lymph
node
organ
target
autoimmun
diseas
identifi
put
autoantigen
moreov
result
confirm
human
result
nod
mous
model
identifi
insulin
critic
autoantigen
diabet
interact
neg
regul
cell
respons
necessari
transplant
toler
induct
toler
induct
may
therefor
facilit
select
inhibit
pathway
without
block
studi
select
inhibit
interact
use
modul
monoclon
antibodi
rat
model
acut
kidney
graft
reject
induct
treatment
day
abrog
reject
long
term
day
kidney
graft
function
normal
stabl
toler
recipi
absenc
histolog
lesion
chronic
reject
toler
recipi
develop
alloantibodi
donor
mhc
class
ii
molecul
unlik
untreat
reject
control
develop
antibodi
mhc
class
ii
molecul
pbmc
spleen
cell
toler
anim
prolifer
donor
cell
mlr
prolifer
third
parti
cell
howev
purifi
cell
fulli
reactiv
suggest
regul
cell
nont
cell
popul
deplet
pbmc
either
nont
cell
fulli
restor
reactiv
wherea
deplet
b
cell
mhc
ii
cell
effect
repres
nk
cell
express
found
partial
respons
suppress
effect
antidonor
reactiv
could
restor
vitro
block
indoleamin
ido
ino
vivo
pharmacolog
inhibit
enzym
led
reject
otherwis
toler
transplant
studi
demonstr
initi
select
blockad
gener
nont
regulatori
cell
kidney
transplant
toler
sustain
activ
ido
ino
contrast
granuloma
detect
tcra
doubl
knockout
dko
b
celldefici
tcra
aa
dko
mice
coliti
tcra
ko
mice
character
mark
increas
product
wherea
tko
mice
show
signific
increas
ifng
product
interestingli
develop
granulomat
coliti
associ
increas
immatur
myeloid
dendrit
cell
dc
indic
presenc
dc
phenotyp
colon
lp
dc
produc
larg
amount
associ
mark
increas
express
cell
tko
mice
compar
ko
mice
product
colon
lp
dc
upregul
tolllik
receptor
ligand
cpg
significantli
downregul
well
igg
fc
fraction
vivo
neutral
activ
administr
specif
mab
suppress
develop
granuloma
tko
mice
test
abil
immatur
myeloid
dc
induc
granuloma
purifi
immatur
myeloid
dc
isol
granuloma
tko
mice
month
age
bone
marrowderiv
immatur
matur
myeloid
dc
wt
mice
directli
inject
ileocec
valv
recipi
young
tko
mice
week
age
follow
laparotomi
importantli
transfer
colon
myeloid
dc
well
also
bone
marrowderiv
wt
immatur
myeloid
dc
led
develop
granuloma
recipi
tko
mice
contrast
transfer
matur
myeloid
dc
fail
find
indic
immatur
myeloid
dc
abil
induc
granuloma
specif
intestin
inflammatori
condit
character
domin
immun
respons
absenc
environ
impair
b
cell
function
multipl
sclerosi
ms
demyelin
diseas
central
nervou
system
cn
character
plaqu
infiltr
cell
although
eae
anim
model
ms
consid
cell
mediat
diseas
recent
report
suggest
myelinspecif
cell
also
caus
eae
suscept
strain
mice
among
genet
factor
link
ms
strongest
associ
found
hla
class
class
ii
gene
howev
role
hla
class
pathogenesi
ms
well
defin
due
lack
proper
anim
model
studi
gener
hla
class
transgen
mice
investig
function
molecul
diseas
pathogenesi
eae
transgen
introduc
class
defici
mice
breed
elimin
effect
endogen
class
molecul
use
softwar
program
propr
select
bind
epitop
myelin
proteolipid
protein
plp
immun
transgen
mice
express
control
mice
peptid
plp
cell
tg
mice
respond
plp
peptid
dose
depend
manner
respons
seen
kbodbo
mice
express
mous
class
ii
use
vitro
antibodi
block
experi
cell
respons
tg
mice
shown
mediat
cell
well
cell
restrict
hla
class
transgen
molecul
plp
peptid
also
induc
pronounc
neurolog
diseas
tg
mice
character
brain
ataxia
spin
spastic
reflex
head
tilt
mice
also
show
cn
patholog
consist
heavi
inflamm
menengi
cerebellum
region
brain
first
anim
model
describ
encephalitogen
role
hla
class
irestrict
cell
studi
underway
understand
role
hla
class
molecul
predisposit
onset
eae
usa
medicin
divis
immunolog
rheumatolog
stanford
univers
school
medicin
stanford
ca
usa
palo
alto
va
health
care
system
palo
alto
ca
usa
patholog
stanford
univers
school
medicin
stanford
ca
usa
pathogenesi
rheumatoid
arthriti
ra
involv
deposit
excess
local
gener
fibrin
inflam
joint
beliv
imbal
fibrinolysi
coagul
within
rheumatoid
joint
differenti
ra
joint
diseas
recent
studi
identifi
deimin
fibrin
candid
autoantigen
human
ra
develop
fibrinogeninduc
arthriti
mous
model
ra
use
human
fibrinogen
immun
antigen
model
demonstr
strong
cell
reactiv
fibrinogen
crossreact
collagen
type
ii
use
proteom
microarray
contain
protein
peptid
repres
put
autoantigen
ra
also
find
strong
b
cell
reactiv
fibrinogen
robust
autoreact
b
cell
spread
collagen
type
ii
v
human
cartilag
glycoprotein
citrullinesubstitut
peptid
deriv
filaggrin
also
show
arthriti
adopt
transfer
naiv
mice
either
sera
whole
splenocyt
diseas
mice
clinic
symptom
immun
adopt
transfer
mice
includ
erythema
mild
swell
encompass
ankl
foot
digit
histopatholog
analysi
h
e
stain
joint
section
indic
mononuclear
infiltr
within
inflam
synovi
membran
new
fibrinogeninduc
arthriti
mous
model
may
provid
addit
insight
understand
diseas
mechan
develop
novel
therpeut
intervent
rheumatoid
arthriti
materi
method
group
week
old
mice
transgen
extracellular
domain
immun
subcutan
ug
maltos
bind
fusion
protein
ribonucleoprotein
ul
either
pb
ugul
cfa
control
group
also
includ
mice
inject
ug
maltos
bind
protein
lack
cfa
sera
mice
examin
autoantibodi
use
immunoblot
elisa
tissu
obtain
necropsi
stain
hemotoxylin
eosin
examin
blind
fashion
result
antiribonucleoprotein
rnp
antibodi
develop
mice
immun
cfa
mctdlike
interstiti
perivascular
lung
diseas
develop
group
mice
immun
either
cfa
rna
antirnp
antibodi
lung
diseas
observ
control
mice
inject
singl
dose
rnp
physiolog
associ
adequ
induc
autoimmun
mice
transgen
allel
associ
suscept
mctd
conclus
singl
inject
transgen
mice
cfa
inducedantirnp
autoimmun
interstit
lung
diseas
thu
model
replic
central
immunolog
clinic
featur
mctd
proteoglycaninduc
arthriti
new
uniqu
tcr
transgen
arthriti
model
character
pathogen
effector
cell
arthrit
mice
map
cell
recognit
site
human
mous
cartilag
proteoglycan
pg
gener
pgspecif
cell
hybridoma
recogn
dominantarthritogen
cell
epitop
among
immort
cell
hybridoma
specif
consensu
sequenc
grvrvnsay
human
cartilag
pg
induc
arthriti
upon
adopt
transfer
show
high
similar
histopatholog
primari
form
pginduc
arthriti
pgia
describ
peripher
joint
patient
rheumatoid
arthriti
ra
better
understand
role
antigenspecif
cell
develop
autoimmun
model
arthriti
insert
chain
cell
receptor
tcr
hybridoma
vivo
express
vector
gener
transgen
tg
mice
constitut
express
tcr
chain
mice
backcross
arthriti
suscept
balbc
strain
immun
cartilag
pg
interestingli
rapid
onset
arthriti
sever
clinic
symptom
detect
mice
immun
pg
never
occur
wildtyp
balbc
mice
arthriti
character
chronic
progress
diseas
cours
intermitt
spontan
exacerb
remiss
reminisc
clinic
appear
ra
histolog
analysi
inflam
joint
show
extens
cartilag
bone
eros
similar
seen
arthrit
joint
human
patient
ifng
cytokineproduc
cell
predomin
cell
detect
prearthrit
stage
initi
phase
arthriti
shift
significantli
toward
bia
time
onset
arthriti
also
demonstr
adopt
transfer
splenocyt
arthrit
nonarthrit
donor
mice
syngen
balbcscid
knockout
recipi
mice
could
induc
arthriti
conclus
presenc
larg
number
arthritogen
epitopespecif
cell
high
express
level
epitopespecif
tcr
suffici
induc
arthriti
arthritogen
epitopespecif
mice
valuabl
power
tool
use
develop
cell
direct
immun
modul
strategi
seri
studi
suggest
insulin
key
target
develop
antiislet
autoimmun
type
diabet
mous
man
major
wegmann
cell
clone
islet
nod
mice
react
insulin
react
specif
insulin
peptid
use
prototyp
ia
restrict
cell
receptor
tcr
bdc
clone
produc
separ
combin
h
tcr
transgen
express
va
chain
verifi
rtpcr
splenic
mrna
sequenc
entir
chain
flow
cytometri
peripher
blood
mononuclear
cell
demonstr
good
express
h
chain
transgen
cell
approxim
peripher
cell
tg
fvb
mice
express
transgen
hchain
compar
nontransgen
mice
transgen
fvb
mice
cross
backcross
nod
homozyg
ragtcr
mice
lymphopen
compar
heterozyg
rag
f
tcr
mice
mean
lymphocyt
count
lymphocytesul
versu
lymphocytesul
p
heterozyg
rag
f
tcr
transgen
mice
show
insul
everi
age
test
week
progress
diabet
develop
insulin
autoantibodi
tcr
ragtg
mice
develop
diabet
older
age
eg
week
sinc
gene
express
thymu
gene
express
minim
thymu
tcr
transgen
mice
bred
nod
knockout
mice
creat
tcr
diabet
develop
much
earlier
mice
week
first
diabet
observ
partial
restor
peripher
lymphocyt
believ
acceler
diabet
higher
peripher
lymphocyt
count
knockout
transgen
mice
due
lymphocyt
escap
neg
thymic
select
due
lack
insulin
express
autoantigen
thymu
current
produc
bdc
tcr
congen
nod
background
analyz
clonal
cell
receptor
infiltr
cell
insulit
lesion
experi
indic
transgen
cell
receptor
confer
diabet
suscept
immunecompromis
mice
confer
insul
suscept
immunocompet
mice
implic
pathogenesi
immunoregul
murin
model
sarcoidosi
sarcoidosi
system
granulomat
diseas
unclear
etiolog
limit
treatment
cell
activ
play
promin
role
multiorgan
inflamm
sarcoidosi
mechanist
studi
therapeut
progress
hamper
lack
experiment
anim
model
recent
report
cell
produc
chronic
intestin
inflamm
transfer
studi
demonstr
retransf
splenic
cell
recipi
induc
progress
systemat
granulomat
diseas
inflamm
involv
skin
lung
pancrea
intestin
environment
microb
requir
diseas
develop
flow
cytometri
lymphocyt
recov
mice
diseas
increas
cell
featur
surprisingli
cotransf
wildtyp
mesenter
node
mln
b
cell
prevent
cell
expans
inflamm
diseas
activ
induc
immunopathogen
lymphocyt
protect
function
mln
b
cell
requir
genet
suffici
result
establish
mous
model
sarcoidosi
reveal
new
set
protect
b
cell
immunoregul
via
cognat
interact
product
model
provid
experiment
system
delin
immun
target
immunoregulatori
deficit
may
underlay
pathogenesi
sarcoidosi
support
nih
crohnt
coliti
foundat
america
background
shown
sjlj
mice
given
ioniz
irradi
develop
acut
myelomonocyt
leukemia
one
yearincid
radiationinduc
aml
riaml
markedli
increas
irradi
follow
treatment
corticosteroid
leukemogenesi
shown
due
delet
one
copi
chromosom
induc
preleukem
state
secondari
prolif
stimulu
result
leukem
transform
aim
studi
initi
investig
whether
allogen
bone
marrow
transplant
allo
bmt
use
prolif
stimulu
irradi
sjlj
mice
therebi
creat
model
endogen
post
transplant
leukemia
relaps
materi
method
sjlj
mice
subleth
irradi
gy
transplant
tcell
deplet
balbc
bm
cell
anim
monitor
weight
loss
sign
leukem
diseas
surviv
regular
time
interv
peripher
blood
collect
evalu
donor
chimer
differ
cell
lineag
flowcytometri
moribund
anim
sacrif
lymphoid
tissu
prelev
flowcytometr
ckit
vb
ia
histopatholog
immunohistochem
studi
stain
mpo
result
bmt
led
develop
mix
chimer
f
f
f
tcell
bcell
myeloid
cell
lineag
respect
week
bmt
onward
mice
develop
weight
loss
overt
malais
n
result
mortal
day
post
bmt
autopsi
mice
show
enlarg
spleen
nodul
brownish
discolor
liver
necrosi
microscop
studi
show
destruct
splenic
architectur
uniform
cell
popul
also
found
liver
hosttyp
origin
immatur
myeloid
natur
popul
demonstr
use
immunohistochemistri
mpo
flowcytometri
lo
lo
spleen
liver
bone
marrow
ex
vivo
mlr
fail
reveal
increas
alloreact
vivo
expans
alloreact
cell
frequenc
absent
argu
graftversushost
diseas
conclus
describ
new
model
endogen
leukemia
irradi
allo
bmt
sjlj
mice
give
rise
fatal
aml
model
like
involv
radiationinduc
defect
endogen
growth
factor
produc
allo
bmt
play
facilit
role
leukemogenesi
model
valu
studi
leukemogenesi
immunotherapi
aml
b
cell
neg
regul
function
upregul
vivo
patient
rheumatoid
arthriti
ra
mice
collagen
induc
arthriti
cia
suggest
target
might
new
therapeut
option
ra
method
analys
vitro
ex
vivo
vivo
effect
mab
particularli
memori
cell
function
physiolog
pathophysiolog
cia
model
condit
result
antibodi
target
vitro
significantli
inhibit
memori
cell
respons
recal
antigen
vitro
inhibit
delay
type
hypersensit
respons
vivo
mous
importantli
dab
mice
establish
collageninduc
arthriti
cia
treat
mab
alon
combin
tnfalpha
receptorigfus
protein
antibodi
administr
demonstr
signific
therapeut
efficaci
establish
cia
monotherapi
moreov
combin
antibodi
tnf
alpha
receptorfus
protein
reveal
addit
therapeut
effect
establish
arthriti
mice
mice
treat
mab
also
show
signific
reduct
anticollagen
antibodi
respons
togeth
reduc
b
cell
number
conclus
treatment
autoimmun
diseas
ra
associ
exagger
b
cell
respons
mab
might
uniqu
target
result
modul
b
cell
respons
moreov
unlik
therapeut
pathway
antibodi
therapi
exhibit
signific
inhibitori
effect
memori
cell
activ
target
could
offer
novel
therapeut
strategi
ra
patient
synerg
tnf
alpha
receptor
therapi
combin
signal
pathway
tnf
alpha
blockad
might
import
clinic
use
larg
group
nonrespond
antitnf
alpha
target
therapi
exist
also
known
one
ligand
program
death
neg
regul
lymphocyt
activ
broadli
express
mice
may
contribut
peripher
toler
interact
base
immuneinhibitori
function
investig
prevent
andor
therapeut
potenti
autoimmun
diabet
stimul
experi
prolif
respons
splenocyt
nonobes
diabet
nod
mice
downregul
dosedepend
manner
gener
transgen
nod
mice
overexpress
pancreat
cell
character
protect
potenti
mice
transgen
mice
observ
isletspecif
transgen
express
transcript
translat
level
strikingli
sever
insul
transgen
mice
significantli
decreas
moreov
diseas
onset
delay
well
diabet
incid
decreas
mice
assay
whether
protect
diabet
mice
differenti
regul
develop
cross
transgen
mice
doubli
transgen
nod
mice
directli
investig
express
profil
tripli
transgen
mice
higher
marker
express
suggest
overexpress
may
indirectli
trigger
develop
enhanc
function
origin
autoimmun
respons
suppress
transgen
mice
furthermor
transgen
islet
higher
transplant
success
rate
surviv
longer
wildtyp
islet
result
support
theoret
basi
genet
manipul
organspecif
manner
provid
potenti
therapeut
approach
mediat
islet
transplant
member
famili
costimulatori
molecul
express
activ
b
cell
play
role
regul
toler
autoimmun
two
ligand
wide
express
immun
nonimmun
cell
restrict
express
primarili
found
macrophag
dendrit
cell
upregul
islet
cell
diabet
nod
mice
investig
role
progress
autoimmun
diabet
cross
defici
mice
onto
nod
background
loss
precipit
earli
onset
diabet
male
femal
nod
mice
defici
mice
becom
diabet
week
age
comparison
week
wild
type
control
wild
type
defici
cell
diabetogen
adopt
transfer
defici
nod
scid
host
wild
type
defici
cell
induc
diabet
adopt
transfer
wild
type
nod
scid
host
data
indic
express
requir
host
tissu
islet
cell
endothelium
dendrit
cell
order
dampen
autoreact
cell
respons
respiratori
virus
influenza
elicit
immun
respons
involv
activ
prolifer
recruit
cell
lung
major
site
viral
infect
major
featur
antivir
respons
secret
ifng
signatur
cytokin
activ
effector
cell
previous
observ
cell
persist
spontan
secret
ifng
lung
day
follow
viral
infect
report
ifng
induc
viral
infect
contribut
major
quantit
qualit
alter
pulmonari
dendrit
cell
nat
immunol
current
studi
determin
induc
costimulatori
molecul
ico
regul
cell
respons
follow
influenza
infect
substanti
level
ico
observ
cell
acut
influenza
viral
infect
persist
least
day
postinfect
subsid
gradual
manner
parallel
express
ifng
neutral
icosico
ligand
interact
acut
influenza
viral
infect
balbc
mice
use
either
recombin
icosig
fusion
protein
neutral
antiico
mab
although
initi
delay
recruit
cell
follow
substanti
increas
number
cell
lung
moreov
intracellular
stain
cell
demonstr
elev
level
spontan
product
ifng
immunoregulatori
cytokin
day
postinfluenza
infect
thu
transient
ico
blockad
dramat
alter
normal
tempor
express
ifng
cell
investig
effect
icosico
ligand
interact
vitro
activ
ovalbumin
ova
specif
cell
cocultur
antigen
dendrit
cell
presenc
blockad
icosicosligand
interact
blockad
enhanc
antigenspecif
prolifer
cell
secret
ifng
vitro
prime
cell
receiv
ico
blockad
adopt
transfer
vivo
recipi
mice
sensit
challeng
intranas
inject
ova
cell
purifi
pulmonari
lavag
mice
adopt
transfer
cell
found
express
higher
level
ifng
compar
adopt
transfer
cell
subject
icosicosligand
blockad
togeth
result
suggest
novel
previous
unappreci
role
ico
neg
regul
regulatori
cytokin
product
cell
newli
identifi
tim
cell
immunoglobulin
mucin
domaincontain
molecul
gene
famili
associ
regul
immun
respons
genet
link
asthma
diseas
howev
endogen
ligand
identifi
found
express
antigenpres
cell
ligand
interact
observ
vivoderiv
cell
specif
block
antibodi
vivo
administr
solubl
fusion
protein
either
immun
respons
result
hyperprolifer
preferenti
expans
cell
furthermor
solubl
costimul
cell
expans
vitro
vivo
data
suggest
interact
deliv
signal
necessari
expans
cell
aim
mix
chimer
donorspecif
toler
achiev
bone
marrow
transplant
bmt
nonmyeloabl
condit
use
gy
total
bodi
irradi
tbi
mab
cell
need
first
week
cell
toler
induct
investig
earli
ctl
activ
role
variou
donor
cell
popul
toler
model
method
recipi
mice
treat
tbi
gy
day
one
dose
mab
day
bmt
fulli
allogen
donor
induc
mix
lymphohematopoiet
chimer
ctl
function
assess
cr
releas
assay
day
bmt
assess
role
specif
donor
cell
popul
toler
induct
recipi
mice
receiv
condit
follow
bmt
fulli
allogen
b
cellor
celldefici
mice
mt
tcrh
background
experi
transgen
mice
express
diphtheria
toxin
receptor
promotor
use
donor
mice
diphtheria
toxin
inject
lead
rapid
deplet
dendrit
cell
result
earlier
studi
show
donorspecif
cell
delet
peripher
repertoir
within
day
bmt
regimen
demonstr
donorspecif
loss
ctl
function
cr
releas
assay
alreadi
day
bmt
mice
receiv
toler
protocol
receiv
condit
without
bmt
find
suggest
earli
phase
donorreact
cell
anergi
delet
search
tolerogen
donor
cell
popul
use
either
b
cellor
celldefici
donor
mice
also
test
dendrit
cell
deplet
transgen
model
system
absenc
cell
popul
donor
marrow
interfer
establish
lymphohematopoiet
chimer
toler
shown
durabl
mix
chimer
accept
donor
skin
prompt
reject
third
parti
skin
conclus
donorspecif
alloreact
cell
unrespons
within
day
delet
peripheri
within
day
bmt
tbi
day
mab
treatment
neither
b
cell
cell
dendrit
cell
donor
origin
critic
requir
toler
induct
model
effect
immun
tumor
often
result
develop
vigor
cellmedi
immun
respons
effect
antitumor
immun
larg
predic
contribut
cytokin
ie
ifng
tnfa
differenti
cell
toward
phenotyp
involv
complex
chain
event
member
novel
class
molecul
call
tim
cell
immunoglobulin
mucin
domaincontain
protein
recent
shown
exert
great
influenc
immun
phenotyp
balanc
vivo
manipul
action
one
member
novel
protein
famili
previous
found
profoundli
affect
diseas
sever
outcom
anim
model
autoimmun
allograft
transplant
promot
hyperprolifer
antigenactiv
cell
spontan
product
cytokin
result
strongli
suggest
agent
target
pathway
could
also
enhanc
effect
antitumor
immun
respons
vivo
presum
one
mechan
favor
cell
promot
cellmedi
immun
studi
describ
antibodi
specif
investig
abil
promot
antitumor
effect
mice
use
thymoma
tumor
model
deliv
either
standalon
therapeut
agent
follow
establish
tumor
skin
adjuv
irradi
tumor
cell
vaccin
prior
live
tumor
challeng
antibodi
promot
signific
reduct
challeng
tumor
growth
time
furthermor
includ
adjuv
tumor
vaccin
also
allow
treat
mice
fulli
reject
subsequ
live
tumor
challeng
neither
tumor
reject
limit
tumor
growth
seen
mice
receiv
isotypematch
control
antibodi
either
experiment
protocol
demonstr
power
capac
antibodi
chang
cours
tumor
progress
treat
mice
experi
support
prospect
role
act
critic
regul
cellmedi
immun
function
respons
ms
inflammatori
diseas
cn
white
matter
presum
autoimmun
etiolog
therapi
current
use
show
benefit
ms
target
tcell
autoimmun
respons
apoptosi
autoreact
tcell
fundament
immunoregulatori
mechan
autoimmun
tcell
predispos
death
ms
could
allevi
increas
express
inhibitor
apoptosi
iap
protein
protect
cell
apoptosi
particular
xlink
iap
xiap
interrupt
apoptot
cascad
tcell
directli
inhibit
effector
caspas
inhibit
xiap
prime
cell
apoptosi
induc
multipl
stimuli
use
repeat
interperiton
ip
inject
xiap
antisens
oligonucleotid
mice
reduc
xiap
protein
level
peripher
blood
leukocyt
similarli
administ
treat
mog
induc
eae
mice
given
daili
via
ip
inject
time
symptomat
onset
reduc
clinic
score
within
day
prevent
diseas
progress
anim
compar
control
group
receiv
random
scrambl
oligonucleotid
salin
show
continu
diseas
increas
sever
n
antixiap
treat
anim
show
evid
consider
increas
leukocyt
apoptosi
high
number
tunel
posit
cell
spinal
cord
prophylact
treatment
prior
induct
eae
follow
daili
treatment
reduc
incid
mild
diseas
anim
n
sever
diseas
n
analysi
tissu
day
immun
indic
limit
inflammatori
infiltr
antixiap
protect
anim
correl
diseas
chemokin
express
cn
reduc
treat
anim
amelior
diseas
due
immun
suppress
evid
shift
treat
anim
data
establish
xiap
critic
control
suscept
cnsinfiltr
cell
apoptosi
experiment
modul
xiap
prevent
cure
eae
studi
increas
understand
regul
inflammatori
patholog
cn
support
xiap
novel
target
therapeut
intervent
ms
prolifer
recallantigen
respons
autoreact
human
cell
benhorin
goldstein
koltakov
l
chess
bank
medicin
chaim
sheba
medic
center
tel
aviv
univers
ramat
gan
israel
medicin
columbia
univers
new
york
ny
usa
late
antigen
vla
integrin
receptor
collagen
induc
surfac
membran
activ
tcell
tc
remain
preferenti
express
effectormemori
cell
recent
show
cell
site
chronic
autoimmun
inflammatori
arthriti
express
restrict
uniqu
cell
receptor
tcr
vh
repertoir
suggest
respond
uniqu
set
autoantigen
tissu
sinc
immunocyt
critic
immun
mediat
diseas
amelior
monoclon
antibodi
mab
tnfa
explor
anti
tnfa
mab
affect
tc
subset
anti
tnfa
mab
infliximab
agml
control
immunoglobulin
neutral
tnfa
ex
vivo
mitogen
pha
trigger
activ
blood
pb
mononuclear
cell
mc
pbmc
significantli
reduc
percentag
tc
day
cultur
f
f
tc
n
affect
subset
furthermor
cfsedy
intracellular
label
reveal
reduct
due
preferenti
inhibit
express
among
tc
induc
divid
presenc
anti
thu
divid
cell
cultur
reduc
f
nondivid
tc
slightli
increas
contrast
anti
respons
subset
inhibit
lesser
extent
tnfa
blockad
inhibit
n
addit
cell
cell
ratio
wash
mc
day
cultur
pbmc
activ
anti
mab
plu
anti
tnfa
control
trigger
cell
absenc
anti
tnfa
likewis
decreas
subset
emerg
autolog
de
novo
day
cultur
suggest
preferenti
inhibit
tc
divis
anti
tnfa
may
involv
mc
activ
presenc
anti
tnfa
n
experi
importantli
anti
tnfa
mab
also
preferenti
inhibit
pb
deriv
tc
divid
ex
vivo
respons
recal
antigen
tetanu
toxoid
less
potent
inhibit
subset
final
nonantigen
mitogen
stimul
spontan
divid
thu
presum
autoreact
synovi
fluid
sf
neither
tc
patient
autoimmun
arthriti
also
dramat
preferenti
reduc
anti
tnfa
inhibit
n
ex
vivo
cultur
data
suggest
critic
immunomodulatori
effect
anti
tnfa
mediat
abil
preferenti
target
inhibit
mitogen
antigen
autoantigen
induc
expans
effector
memori
subset
antibodi
endow
specif
recognit
properti
hladisplay
tumor
associ
antigen
recent
produc
shown
directli
detect
express
hlatumor
associ
antigen
surfac
cancer
cell
applic
reagent
valid
cell
epitop
would
greatli
facilit
vaccin
develop
yet
mani
technic
obstacl
stand
way
develop
consist
approach
make
antibodi
cell
receptor
tcr
like
specif
particularli
import
would
develop
immunogen
form
immunogen
could
use
rapid
reproduc
immun
mice
gener
polyclon
antibodi
respons
reactiv
epitop
develop
technolog
might
lead
effici
creation
monoclon
antibodi
mab
specif
hlapeptid
hypothes
immunogen
present
immun
system
tetraval
form
rather
monoval
form
would
display
enhanc
immunogen
promot
consist
gener
high
titer
igg
polyclon
antibodi
respons
specif
immunogen
test
hypothesi
refold
e
coli
produc
insolubl
protein
prepar
purifi
form
monom
tetram
peptid
complex
display
either
human
eukaryot
transcript
initi
factor
vlmtedikl
selfprotein
found
upregul
hiv
infect
cell
human
tumor
suppressor
protein
llgrnsfev
selfprotein
wide
express
mani
cancer
immun
group
balbc
mice
time
interv
either
monom
tetram
form
immunogen
assay
mous
sera
polyclon
igg
antibodi
respons
reactiv
hlapeptid
competit
elisa
mice
group
immun
tetram
immunogen
show
specif
igg
antibodi
respons
contrast
specif
polyclon
antibodi
respons
detect
mice
immun
monom
immunogen
confirm
specif
polyclon
respons
evalu
antibodi
mice
immun
tetram
immunogen
stain
cell
posit
puls
either
competit
bind
assay
cell
assay
result
support
elisa
data
indic
immunogen
formul
tetram
immunogen
abl
gener
specif
antibodi
respons
mice
furthermor
demonstr
elisa
cell
stain
tetram
form
immunogen
effici
elicit
igg
polyclon
antibodi
respons
reactiv
within
week
initi
immun
collect
find
support
hypothesi
tetraval
form
immunogen
consist
lead
specif
antibodi
respons
epitop
addit
abil
gener
probe
rapid
reproduc
manner
invalu
hla
class
epitop
valid
etanercept
recombin
human
tnf
receptor
fusion
protein
fda
approv
psoriasi
psoriat
arthriti
tnfa
increas
synthesi
proinflammatori
cytokin
lead
activ
multipl
signal
pathway
includ
nfkb
relnfkb
transcript
factor
play
central
role
numer
cellular
process
includ
stress
respons
keratinocyt
prolifer
differenti
util
phosphoryl
specif
antibodi
examin
express
activ
nuclear
nfkbrela
via
immunohistochemistri
normal
skin
nonlesion
psoriat
skin
lesion
psoriat
skin
lesion
skin
patient
treat
etanercept
express
activ
nuclear
nfkb
normal
epidermi
wherea
basal
level
constitut
activ
phosphoryl
nfkbrela
present
uninvolv
epidermi
psoriasi
patient
also
signific
upregul
activ
phosphoryl
nfkbrela
epidermi
psoriat
plaqu
serial
biopsi
psoriasi
patient
treat
etanercept
month
month
month
demonstr
signific
regul
phosphoryl
nfkbrela
correl
decreas
epiderm
thick
restor
normal
marker
keratinocyt
differenti
clinic
outcom
data
suggest
activ
nfkb
play
signific
role
pathogenesi
psoriasi
potenti
mechan
action
tnftarget
agent
downregul
nfkb
transcript
activ
therapi
altern
strategi
regul
express
j
shen
j
snyder
h
azmi
j
ragheb
laboratori
immunolog
nei
nation
institut
health
bethesda
md
usa
monoclon
antibodi
direct
alpha
chain
tac
receptor
emerg
therapi
transplant
autoimmun
diseas
cohort
patient
autoimmun
uveiti
treat
multipl
immunosuppress
medic
monotherapi
daclizumab
human
antitac
antibodi
suffici
control
diseas
without
seriou
side
effect
basi
antibodyt
therapeut
efficaci
establish
meanwhil
antibodi
shown
efficaci
primat
transplant
model
withdrawn
clinic
use
due
seriou
side
effect
associ
administr
report
express
activ
human
cell
biphas
consist
earli
peak
subsequ
nadir
second
peak
hr
transient
express
critic
physiolog
function
costimulatori
pathway
yet
mechan
underli
biphas
pattern
express
larg
unknown
also
report
second
phase
express
sever
inhibit
vitro
daclizumab
show
primari
pbmc
cultur
use
block
antibodi
flow
cytometri
impact
late
phase
act
indirectli
regul
andor
cytokin
neither
appreci
effect
either
earli
late
express
addit
signal
necessari
late
phase
express
recombin
agonist
mab
could
substitut
costimul
final
contrast
earlier
report
observ
regul
earli
express
depend
upon
interact
find
mark
contradistinct
report
mous
collect
data
indic
regul
late
express
like
direct
consequ
signal
result
suggest
daclizumab
combin
agent
block
earli
express
may
viabl
altern
use
antibodi
clinic
background
object
rheumatoid
arthriti
ra
autoreact
diseas
activ
cell
play
import
role
orchestr
autoimmun
respons
give
rise
inflammatori
cascad
respons
joint
inflamm
bone
destruct
costimulatori
pathway
critic
full
cell
activ
modul
pathway
shown
inhibit
tcell
activ
lead
inhibit
immun
respons
abatacept
modul
cell
activ
interf
engag
abatacept
shown
provid
signific
improv
sign
symptom
rheumatoid
arthriti
phase
ii
trial
examin
effect
abatacept
administr
diseas
induct
anticollagen
antibodi
product
bone
destruct
rat
model
collagen
induc
arthriti
method
femal
da
rat
immun
sc
day
ug
bovin
type
ii
collagen
incomplet
freundt
adjuv
base
tail
immun
rat
administ
either
mgkg
abatacept
control
human
igg
ip
day
diseas
progress
monitor
measur
paw
volum
ml
plethysmomet
hind
paw
measur
chang
volum
baselin
measur
day
record
conclus
studi
day
serum
sampl
collect
anim
measur
collagen
specif
antibodi
elisa
well
serum
cytokin
measur
leg
rat
remov
place
formalin
prepar
histolog
analysi
well
analysi
bone
morpholog
micro
ct
summari
day
studi
signific
paw
swell
observ
igg
treat
control
anim
continu
increas
throughout
studi
reach
plateau
ml
day
administr
abatacept
abrog
paw
swell
throughout
cours
studi
igg
treat
rat
reach
incid
incid
observ
abatacept
treat
group
serum
anticollagen
antibodi
level
correl
well
paw
swell
data
abatacept
administr
result
inhibit
collagen
specif
antibodi
also
found
abatacept
decreas
express
mani
circul
cytokin
chemokin
upregul
diseas
anim
microct
data
reveal
abatacept
treatment
protect
bone
destruct
knee
ankl
rat
appear
normal
conclus
abatacept
select
costimul
modul
significantli
inhibit
onset
progress
diseas
rat
cia
model
studi
paw
swell
collagen
specif
antibodi
bone
destruct
inhibit
treatment
abatacept
modul
human
tcell
prolifer
cytokin
product
affect
tnfa
product
monocyt
p
davi
g
nadler
k
rouleau
j
suchard
immunolog
inflamm
drug
discoveri
bristolmy
squibb
princeton
nj
usa
background
object
activ
cell
play
central
role
inflammatori
cascad
lead
joint
inflamm
destruct
characterist
rheumatoid
arthriti
ra
cytokin
secret
activ
cell
initi
propag
immunolog
driven
inflamm
associ
ra
abatacept
first
new
class
agent
select
modul
costimulatori
signal
requir
full
tcell
activ
evalu
vitro
abil
regul
human
tcell
prolifer
cytokin
product
effect
abatacept
immun
complex
ic
lpsinduc
tnfa
releas
monocyt
also
evalu
distinguish
impact
abatacept
innat
versu
adapt
antigenspecif
respons
method
cell
isol
normal
healthi
volunt
effect
abatacept
antigendepend
tcell
activ
evalu
use
either
irradi
human
bcell
line
pmlcl
antigenpres
cell
apc
primari
mix
lymphocyt
reaction
mlr
autolog
epbmc
apc
recal
respons
tetanu
toxin
tt
cytokin
measur
variou
time
post
activ
prolifer
determin
day
monocyt
isol
elutri
challeng
lp
ic
tnfa
level
measur
h
chi
includ
nonspecif
ig
fusion
protein
control
summari
abatacept
significantli
modul
tcell
prolifer
primari
recal
respons
concentr
agml
maxim
inhibit
observ
agml
concentr
abatacept
trough
plasma
level
observ
patient
receiv
clinic
effect
dose
condit
maxim
inhibit
prolifer
similar
trough
plasma
level
patient
agml
abatacept
inhibit
cytokin
product
primari
ttdepend
recal
respons
howev
extent
rank
order
cytokin
inhibit
abatacept
markedli
differ
two
respons
specif
inhibit
n
tnfa
n
ifng
primari
respons
wherea
inhibit
ifng
z
minim
effect
tnfa
product
tt
recal
respons
contrast
abatacept
inhibit
icor
lpsinduc
tnfa
product
human
monocyt
conclus
abatacept
select
costimul
modul
significantli
inhibit
activ
measur
cytokin
product
prolifer
human
cell
context
primari
mlr
ttdepend
memori
respons
inhibit
occur
concentr
serum
c
min
level
observ
patient
receiv
clinic
effect
dose
abatacept
mgkg
monthli
consist
suppress
tcell
activ
vivo
effect
abatacept
tnfa
product
monocyt
challeng
lp
ic
indic
agent
may
larg
preserv
innat
immun
respons
kremer
jm
et
al
nejm
essenti
role
restrict
immun
chronic
viral
infect
mett
ejrna
matthia
von
herrath
immun
regul
lab
la
jolla
institut
san
diego
ca
usa
virus
use
varieti
strategi
suppress
antivir
immun
respons
lead
persist
host
induct
immun
suppress
one
mechan
virus
escap
clearanc
establish
persist
infect
cytokin
immunomodulatori
properti
downregul
cellular
immun
respons
act
apc
cell
gain
insight
role
viral
persist
studi
lymphocyt
choriomening
viru
lcmv
infect
natur
host
lcmv
isol
clone
establish
prolong
infect
balbc
mice
associ
less
effect
antivir
immun
respons
studi
condit
dendrit
cell
result
report
signific
amount
gener
lymphocyt
class
apc
persist
lcmv
infect
treatment
neutral
antibodi
day
post
clone
infect
result
acceler
viral
clearanc
associ
numer
increas
total
spleen
cell
comparison
nontreat
mice
decreas
level
gener
splenocyt
lastli
overal
clinic
appear
improv
intervent
reflect
increas
bodyweight
healthi
shini
coat
increas
physic
activ
conclus
studi
indic
persist
viral
infect
play
essenti
role
suppress
antivir
respons
system
blockad
improv
clinic
outcom
similar
strategi
might
benefici
chronic
infect
associ
increas
level
exampl
hepat
c
viru
infect
work
support
ada
mentor
grant
program
project
grant
niaid
matthia
von
herrath
pm
effect
natalizumab
antibodi
immun
cell
adhes
migrat
patient
ms
object
establish
biolog
dproof
conceptt
vivo
treatment
patient
multipl
sclerosi
ms
result
decreas
function
express
migratori
capac
immun
cell
develop
simpl
vitro
assay
could
appli
monitor
therapeut
respons
background
natalizumab
tysabrir
human
monoclon
antibodi
direct
adhes
molecul
recent
approv
treatment
patient
relaps
remit
ms
presum
benefici
effect
ms
would
base
bind
natalizumab
surfac
circul
immun
cell
therebi
inhibit
capac
migrat
cn
date
impact
vivo
therapi
natalizumab
function
express
immun
cell
ms
patient
report
develop
simpl
assay
measur
effect
could
prove
use
immun
monitor
patient
emerg
therapi
designmethod
consent
patient
particip
openlabel
phase
clinic
trial
natalizumab
relaps
remit
ms
provid
venou
blood
immedi
prior
preinfus
one
hour
follow
postinfus
monthli
natalizumab
infus
iv
level
surfac
express
circul
immun
cell
subset
assess
flow
cytometri
migratori
capac
immun
cell
evalu
establish
twocompart
boyden
chamber
known
captur
mediat
migrat
human
immun
cell
result
observ
express
circul
immun
cell
significantli
reduc
vivo
natalizumab
infus
p
n
effect
observ
immun
cell
subset
greatest
cell
compar
b
cell
p
monocyt
p
function
assay
migrat
postinfus
immun
cell
significantli
decreas
compar
migrat
correspond
preinfus
cell
p
decreas
observ
surfac
express
correl
well
decreas
migratori
function
correspond
immun
cell
follow
infus
r
p
b
confirm
migrat
assay
carri
frozen
mononuclear
cell
pbmc
provid
mean
monitor
patientst
respons
time
plan
present
batch
analysi
prospect
collect
sampl
patient
provid
insight
kinet
stabil
vivo
effect
conclus
studi
provid
first
biolog
dproof
conceptt
vivo
natalizumab
therapi
result
diminish
function
express
migratori
capac
circul
immun
cell
abil
reproduc
captur
effect
rel
simpl
bioassay
valid
assay
appli
frozen
pbmc
could
provid
use
mean
monitor
patient
promis
therapi
infiltr
autoreact
tcell
central
nervou
system
cn
requir
complex
molecular
interplay
immun
cell
blood
brain
barrier
bbb
especi
involv
vascular
cell
adhes
molecul
vcam
intercellular
adhes
molecul
icam
develop
new
ultrasound
base
approach
quantif
ultrasound
contrast
media
high
concentr
sensit
particl
acoust
quantif
spaq
combin
spaq
specif
gasfil
microparticl
mp
target
vcam
icam
vcammp
icammp
aim
monitor
molecular
chang
bloodbrainbarri
cours
activ
induc
adopt
transfer
myelin
basic
protein
mbp
eae
ex
vivo
imag
express
atea
diseas
maximum
prove
high
sensit
specif
spatial
resolut
method
possibl
videodensitometr
quantif
result
could
reproduc
vivo
clear
periventricular
cerebellar
upregul
express
maximum
atea
could
suppress
pretreat
rat
corticosteroid
p
b
imag
result
confirm
parallel
immunohistochemistri
subsequ
applic
icammp
icammp
vcammp
inject
influenc
followup
measur
sequenti
imag
icammp
vivo
cours
activ
mbpeae
reveal
signific
upregul
icam
respect
onset
diseas
day
atea
day
activ
eae
point
time
signal
chang
observ
magnet
reson
imag
mri
albumin
stain
detect
bbb
integr
gadolinium
enhanc
mri
sonif
reveal
disturb
bbb
therebi
prove
safeti
method
vivo
conclus
base
data
molecular
imag
adhes
molecul
spaq
platform
technolog
quantif
chang
bbb
vivo
sensit
superior
convent
mri
experiment
autoimmun
encephalomyel
eae
cell
mediat
autoimmun
diseas
cell
chemoattract
cytokin
infiltr
cn
cell
preced
onset
relaps
experiment
autoimmun
encephalomyel
eae
report
sjl
bs
mice
sever
relapsingremit
diseas
extens
infiltr
cell
compar
b
mice
develop
mild
lowrelaps
diseas
respons
myelin
oligodendrocyt
peptid
observ
led
us
search
mechan
specif
regul
traffick
cell
relaps
bs
mice
report
show
cell
chemoattract
cytokin
import
role
regul
relaps
eae
induc
mog
sjl
bs
mice
found
product
within
cn
mice
eae
level
cn
correl
well
promin
infiltr
cell
b
cell
acut
relaps
diseas
infiltr
cell
occassionali
cell
b
cell
contain
immunoreact
kd
cleav
kd
found
spinal
cord
mice
activ
diseas
remiss
level
significantli
decreas
relaps
mice
cn
level
peak
parallel
activ
cell
infiltr
identifi
cell
withn
cn
infiltr
co
immunoprecipit
coreceptor
abund
form
found
relaps
data
suggest
produc
infiltr
cell
depend
mechan
also
indic
function
relationship
consist
specif
chemoattract
properti
cytokin
base
observ
treat
eae
mice
neutral
antibodi
treatment
neutral
antibodi
success
revers
paralysi
amelior
relaps
diseas
treat
mice
diminish
infiltr
cell
lesser
demyelin
spare
axon
observ
taken
togeth
show
import
role
regul
relaps
eae
describ
novel
therapeut
approach
specif
imped
cell
chemoattract
eae
base
neutral
immun
respons
involv
multipl
cellcel
interact
use
explant
intravit
confoc
multiphoton
microscopi
collect
xyz
time
data
interact
antigen
ag
specif
cell
agbear
dendrit
cell
dc
intact
lymph
node
ln
narv
cell
move
rapidli
absenc
ag
show
prolong
adher
agbear
dc
accompani
immunolog
synaps
format
activ
detach
antigenbear
dc
follow
along
cell
divis
data
suggest
cell
activ
follow
prolong
lymphocyt
associ
individu
antigenbear
dc
rather
summat
signal
brief
encount
present
cell
cell
associ
singl
dc
antigen
present
direct
cell
contact
also
seen
format
cluster
appear
nonrandom
natur
rapid
movement
dc
dendrit
readili
visual
tdc
contact
process
follow
movement
cell
toward
dc
bodi
quantit
analysi
suggest
impact
selfmhc
recognit
time
narv
celldc
interact
intravit
method
permit
visual
dc
migrat
ln
egress
lymphocyt
hev
initi
contact
dc
fluoresc
report
construct
eg
egfp
control
promot
reveal
consequ
tdc
interact
real
time
within
ln
fluoresc
chimer
protein
use
track
redistribut
key
protein
cell
movement
interact
differenti
migratori
behavior
lymphocyt
dc
distinct
region
lymph
node
observ
failur
rapidli
move
b
lymphocyt
cross
rather
strict
border
cell
zone
b
cell
follicl
dc
distribut
function
examin
nonlymphoid
tissu
liver
steadyst
condit
inflamm
kidney
behavior
subepitheli
dc
small
bowel
visual
steadyst
condit
follow
infect
salmonella
elicit
activ
protrus
respons
dc
studi
contribut
accur
pictur
molecular
cellular
spatial
tempor
aspect
cell
interact
signal
event
host
immun
respons
regulatori
cell
treg
fundament
function
suppress
immun
respons
howev
compart
exert
suppress
function
vivo
known
integrin
e
h
unravel
fundament
dichotomi
naivelik
effectormemorylik
treg
latter
capabl
suppress
inflammatori
immun
respons
strikingli
suppress
action
e
treg
complet
depend
inflammationseek
capac
treg
fucosyltransferasedefici
anim
lack
selectinligand
fail
migrat
inflam
site
unabl
mediat
suppress
contrast
naivelik
e
treg
show
enhanc
recircul
lymph
node
effici
prevent
prime
naiv
cell
find
provid
first
conclus
evid
appropri
local
crucial
vivo
activ
treg
lowdos
methotrex
mtx
establish
highli
effect
treatment
sever
psoriasi
rheumatoid
arthriti
howev
mechan
action
remain
unclear
use
treatment
psoriasi
mtx
thought
act
directli
epiderm
hyperprolifer
howev
poor
efficaci
local
administ
mtx
effect
agent
target
cell
strongli
suggest
antiprolif
effect
mtx
respons
efficaci
psoriasi
therefor
investig
effect
lowdos
mtx
cell
explor
cellular
pathway
effect
mediat
peripher
blood
mononuclear
cell
isol
stimul
streptococc
antigen
superantigen
mitogen
pha
presenc
mm
mtx
cell
express
adhes
molecul
activ
marker
amount
cell
apoptosi
cultur
determin
flow
cytometr
folateand
adenosinedepend
pathway
mtx
action
manipul
use
specif
agonist
antagonist
show
mtx
caus
dosedepend
suppress
cell
activ
adhes
molecul
express
due
cell
apoptosi
suppress
intercellular
adhes
molecul
icam
adenosin
folatedepend
mtx
suppress
skinhom
cutan
lymphocyteassoci
antigen
cla
adenosineindepend
effect
mtx
cla
requir
constant
presenc
mtx
cultur
suppress
cell
activ
cell
adhes
molecul
express
rather
apoptosi
mediat
part
adenosin
polyglutam
mtx
import
mechan
antiinflammatori
action
mtx
integrin
heterodimer
transmembran
protein
regul
cellcel
cellmatrix
interact
alpha
v
contain
integrin
repres
major
famili
rgdbind
integrin
shown
import
role
angiogenesi
tumorigenesi
neural
develop
wound
heal
alpha
v
beta
express
mani
immun
cell
surfac
express
highest
tissu
resid
cell
gy
cell
b
cell
variou
alpha
v
integrin
express
monocyt
macrophag
dc
shown
antibodi
blockad
regul
monocyt
transmigr
phagocytosi
apoptot
cell
macrophag
dc
howev
definit
vivo
studi
role
alpha
v
immun
system
limit
lethal
alpha
v
knockout
mice
describ
gener
condit
knockout
mice
studi
role
adhes
molecul
regul
leukocyt
function
condit
delet
alpha
v
use
mice
express
cre
promot
gener
mice
lack
alpha
v
endotheli
cell
hematopoiet
cell
although
mice
appear
normal
birth
develop
sign
chronic
diseas
weight
loss
begin
week
progress
experiment
anim
die
week
patholog
examin
reveal
mice
develop
spontan
transmur
gastrointestin
gi
respiratori
tract
inflamm
ulcer
epitheli
cell
hyperplasia
histolog
find
combin
clinic
observ
wast
gi
obstruct
consist
chronic
progress
inflammatori
bowel
diseas
ibd
defin
phenotyp
select
delet
alpha
v
specif
leukocyt
compart
result
suggest
alpha
v
integrin
regul
cell
migrat
cell
respons
pathogen
deriv
ligand
conclus
data
demonstr
alpha
v
play
essenti
role
regul
immun
homeostasi
gi
respiratori
tract
delet
alpha
v
gener
new
model
spontan
chronic
ibd
therefor
propos
novel
function
alpha
v
integrin
normal
regul
inflammatori
respons
immun
homeostasi
food
allergi
signific
health
problem
particularli
western
countri
uk
usa
peanut
common
caus
food
allergi
associ
usual
high
titer
ige
antibodi
consist
preferenti
activ
helper
th
type
cell
use
high
ige
respond
balbc
strain
mice
previous
shown
sensit
peanut
lectin
minor
peanut
allergen
associ
increas
allergenspecif
ige
chang
cytokin
protein
mrna
express
indic
select
type
respons
elev
level
ifng
cytokin
express
use
flow
cytometr
analys
intracellular
cytokin
express
pattern
determin
rel
contribut
lymphocyt
immun
phenotyp
develop
follow
exposur
peanut
lectin
method
mice
immun
intraderm
inject
peanut
lectin
fourteen
day
follow
initi
exposur
drain
auricular
lymph
node
excis
singl
cell
suspens
prepar
drain
lymph
node
cell
peanut
prime
naiv
mice
label
carboxyfluoresein
succinimidyl
ester
cfse
identifi
prolifer
cell
restimul
vitro
peanut
lectin
cell
mitogen
concanavalin
con
variou
period
time
cell
stain
fluorescentlylabel
antibodi
follow
saponin
permeabil
fluorescentlylabel
anticytokin
antibodi
result
vitro
stimul
peanutprim
cell
peanut
lectin
con
induc
prolifer
cell
hr
contrast
cell
narv
mice
respond
con
moreov
allergenspecif
cell
express
profil
increas
frequenc
rel
low
level
ifng
posit
cell
compar
unstimul
control
cell
cultur
con
hr
cultur
cell
display
phenotyp
high
level
ifng
posit
cell
posit
cell
regardless
whether
restimul
con
allergen
conclus
data
suggest
rather
lymphocyt
skew
toward
select
type
cytokin
phenotyp
mous
model
peanut
allergi
tgfh
highli
conserv
multifunct
cytokin
divers
regulatori
role
immun
system
regulatori
cell
secret
tgfh
variabl
amount
term
induc
oral
administr
myelin
protein
mediat
recoveri
eae
littl
known
differenti
phenotyp
function
cell
creat
induc
transgen
tg
mous
model
tgfh
link
promot
thu
allow
tissu
specif
express
tgfh
upon
tcr
stimul
found
antigen
specif
stimul
narv
peripher
cell
tgfh
tg
mice
induc
cell
hyporespons
potent
suppress
activ
vitro
vivo
tgfh
tg
cell
secret
ifng
earli
express
tgfh
critic
differenti
cell
mog
peptid
tcr
tg
adopt
transfer
model
cell
tgfh
tg
mice
prevent
gener
pathogen
cell
wild
type
anim
induct
eae
also
greatli
inhibit
effector
function
transfer
time
diseas
onset
use
twostep
vitro
cultur
system
found
antigenpres
dendrit
cell
act
dtempor
bridgest
relay
inhibitori
signal
cell
naiv
cell
furthermor
cell
inhibit
cell
induc
upregul
costimulatori
signal
activ
matur
thu
suppress
cell
mediat
matur
dendrit
cell
alter
antigenpres
function
previous
show
treatment
hmgcoa
reductas
inhibitor
atorvastatin
prevent
differenti
myelinreact
cell
amelior
clinic
symptom
mice
experiment
autoimmun
encephalomyel
eae
youssef
et
al
natur
hmgcoa
reductas
critic
enzym
mevalon
biosynthet
pathway
gener
cholesterol
also
isoprenoid
deriv
function
attach
certain
signal
protein
ubiquinon
cell
membran
aim
present
studi
distinguish
pathway
intermedi
regulatori
function
differenti
develop
eae
provid
firsttim
evid
oral
administr
induc
bia
cell
compromis
product
isoprenoid
lipid
farnesylpyrophosph
pp
geranylgeranylpp
vivo
deplet
metabol
precursor
caus
transient
ie
hd
redistribut
farnesyl
ra
geranylgeranyl
rhoa
gtpase
membran
cytosol
cell
accompani
reduct
phosphoryl
erk
dna
bind
cfo
respons
cell
receptor
activ
also
show
select
inhibit
erk
pathway
mek
inhibitor
shift
balanc
cell
cytokin
product
toward
sinc
erk
activ
shown
requir
transactiv
ifng
repress
promot
jorritsma
et
al
j
immunol
result
thu
explain
cell
undergo
differenti
activ
antigen
presenc
chronic
inflamm
rheumatoid
arthriti
ra
mediat
repeatedli
activ
proinflammatori
cell
contrast
cell
might
downmodul
chronic
autoimmun
respons
rare
found
ra
previous
document
ra
cell
sever
impair
abil
differenti
effector
exert
enhanc
differenti
mechan
underli
function
abnorm
howev
delin
critic
determin
regul
immun
respons
promot
cell
develop
inhibit
cell
differenti
analyz
role
singl
nucleotid
polymorph
snp
receptor
achain
critic
bind
signal
transduct
differenti
human
cell
healthi
individu
genotyp
allel
specif
pcr
two
achain
snp
locat
function
import
region
achainth
domain
respect
naiv
memori
posit
cell
isol
peripher
blood
individu
homozyg
either
allel
prime
five
day
mab
andor
presenc
absenc
exogen
phenotyp
result
differenti
effector
cell
analyz
flow
cytometr
analysi
cytoplasm
cytokin
allel
affect
cell
differenti
contrast
inhibitori
effect
cell
differenti
significantli
diminish
cell
homozyg
mutant
allel
compar
wild
type
allel
likewis
augment
effect
cell
differenti
enhanc
cell
homozyg
wild
type
allel
compar
cell
express
mutant
allel
data
indic
mutant
allel
achain
associ
decreas
cell
respons
delin
potenti
mechan
differ
respons
cell
express
differ
allel
cell
form
individu
homozyg
either
wildtyp
mutant
allel
prime
differ
concentr
analyz
flow
cytometri
phosphoryl
wherea
concentr
differ
cell
express
phosphoryl
respons
stimul
significantli
reduc
cell
express
allel
compar
cell
express
thu
allel
achain
might
regul
cell
differenti
diminish
cell
respons
result
reduc
phosphoryl
subsequ
diminish
cell
differenti
allel
might
therebi
contribut
develop
unbalanc
th
subset
activ
characterist
autoimmun
diseas
ra
cytokin
famili
consist
propos
mediat
immun
respons
therefor
util
subunitspecif
neutral
monoclon
antibodi
genet
knockout
mice
distinguish
individu
contribut
establish
murin
model
autoimmun
pathogen
respons
name
experiment
autoimmun
encephalomyel
eae
leishmania
major
infect
specif
neutral
mice
genet
defici
demonstr
protect
incid
sever
eae
howev
exhibit
transient
suscept
l
major
infect
demonstr
increas
lesion
size
data
suggest
contribut
l
major
immun
although
requir
eae
contrast
specif
vivo
neutral
provid
signific
longlast
therapi
eae
antibodi
administ
prior
diseas
induct
onset
establish
eae
suppress
central
nervou
system
inflamm
patholog
even
though
antigenspecif
prolifer
cytokin
restimul
respons
influenc
vivo
antibodi
treatment
fac
analysi
demonstr
vivo
neutral
preserv
naiv
hi
hi
lo
cell
phenotyp
thu
appear
particip
vivo
activ
andor
traffick
encephalitogen
cell
mice
treat
specif
neutral
antibodi
maintain
protect
cell
immun
l
major
infect
thu
despit
critic
role
eae
appear
contribut
effect
l
major
resist
overal
seem
close
relat
function
investig
like
continu
delin
role
autoimmun
diseas
pathogen
immun
object
develop
arthriti
kbxn
mous
model
depend
induct
high
titer
antibodi
ab
glycolyt
enzym
isomeras
gpi
promot
cell
express
transgeneencod
cell
receptor
tcr
specif
gpi
goal
determin
whether
unusu
strong
autoab
respons
presum
reflect
unusu
potent
help
depend
cell
differenti
helper
th
phenotyp
answer
question
might
gener
import
insight
human
arthritid
rheumatoid
arthriti
ra
associ
product
autoab
method
role
cytokin
known
control
th
phenotyp
investig
introduc
interleukin
il
knockout
mutat
kbxn
model
evalu
impact
defici
clinic
arthriti
autoab
product
cell
activ
celltyp
kbxn
mice
reveal
cross
knockin
alter
result
green
fluoresc
protein
gfp
express
control
endogen
gene
regulatori
element
transfer
experi
permit
identif
celltyp
requir
arthriti
develop
final
quantit
rtpcr
allow
determin
cytokin
profil
kbxn
cell
result
appear
dispens
develop
arthriti
crucial
full
diseas
develop
kbxn
mice
greatli
reduc
titer
antigpi
ab
gpireact
tcr
standard
kbxn
mice
induc
transcript
activ
locu
cell
eosinophil
yet
kbxn
arthriti
pure
diseas
cytokin
upregul
kbxn
cell
express
pattern
sever
cytokin
kbxn
cell
match
convent
cell
conclus
crucial
develop
antigpiabmedi
arthriti
kbxn
mous
model
howev
cytokin
profil
initi
antigpi
cell
fit
classic
diseas
potenti
promot
develop
inflammatori
arthriti
rais
caution
propos
therapi
ra
aim
bias
cell
toward
product
genotyp
reveal
two
distinct
pathway
lead
arthriti
mice
h
hess
molecular
pharmacolog
physiolog
biogen
inc
cambridg
usa
collageninduc
arthriti
cia
inflammatori
joint
diseas
rodent
etiolog
involv
pathogen
autoimmun
respons
provok
immun
collagen
type
ii
cii
togeth
adjuv
mycobacteria
part
complet
freundt
adjuv
cfa
potent
induc
product
macrophag
dc
key
cytokin
instruct
naiv
cell
upon
activ
differenti
along
helper
type
pathway
cia
like
ra
claim
regard
predominantli
autoimmun
diseas
howev
diseas
progress
certain
featur
becom
detect
appear
cia
perhap
ra
mix
type
immun
respons
recent
describ
heterodimer
cytokin
share
subunit
cytokin
implic
either
initi
sustain
respons
initi
studi
shown
cia
develop
mice
markedli
reduc
extend
studi
found
provid
mice
sensit
pristan
prior
prime
cii
sever
cia
develop
incid
pristan
sensit
preced
ciiadjuv
immun
mycobacteria
becom
dispens
cia
induct
cia
incid
sever
wildtyp
mice
immun
cii
compar
diseas
observ
pristanesensit
mice
notebl
wildtyp
mice
repetit
immun
cfa
substitut
requir
pristanesensit
maxim
cia
sever
mice
respond
provoc
signific
cia
develop
taken
togeth
data
suggest
pristan
trigger
pathway
capabl
enhanc
autoimmunogen
stimulu
set
cii
final
appear
suffici
necessari
trigger
sever
arthriti
background
system
onset
juvenil
idiopath
arthriti
sojia
remain
enigmat
pediatr
rheumat
diseas
patient
requir
system
corticosteroid
prolong
period
control
system
manifest
half
patient
develop
chronic
arthriti
difficult
control
even
methotrex
antitnf
agent
antagonist
anakinra
partial
effect
treatment
inflammatori
chronic
arthriti
evalu
sojia
patient
system
symptom
method
healthi
pbmc
incub
serum
sojia
patient
chang
gene
transcript
assess
use
oligonucleotid
microarray
realtim
pcr
gene
whose
express
significantli
alter
identifi
analyz
pbmc
sojia
patient
healthi
control
addit
perform
global
gene
express
analysi
use
blood
pbmc
rna
sojia
patient
hybrid
affymetrix
gene
array
one
third
patient
remiss
one
third
system
symptom
remain
one
third
polyarticular
arthriti
system
involv
time
analysi
also
compar
gene
express
patient
children
system
infect
pbmc
healthi
control
sojia
patient
expos
vitro
pmaionomycin
assess
cytokin
secret
capac
twelv
sojia
patient
treat
anakinra
month
result
sojia
serum
increas
transcript
innat
immun
gene
sever
gene
upregul
vivo
pbmc
sojia
patient
pma
induc
releas
pbmc
sojia
patient
healthi
pbmc
treatment
sojia
patient
system
andor
arthrit
phase
diseas
anakinra
period
month
induc
complet
diseas
remiss
patient
partial
respons
remain
patient
conclus
sojia
patient
show
dysregul
product
effect
treatment
diseas
human
tumour
overexpress
varieti
taa
tumour
associ
antigen
either
absent
express
low
level
normal
tissu
peptid
deriv
taa
present
surfac
tumour
cell
class
hla
molecul
repres
target
cytotox
immunotherapeut
anticanc
agent
nyeso
taa
unknown
function
overexpress
number
tumour
type
includ
melanoma
bladder
gener
solubl
tcr
cell
receptor
specif
nyeso
peptid
present
tcr
lack
transmembran
domain
stabilis
novel
disulphid
bond
express
e
coli
separ
h
chain
refold
inclus
bodi
natur
affin
tcr
order
gener
molecul
suitabl
target
tumour
tcr
affin
matur
use
phage
display
technolog
tcr
variant
use
subsequ
studi
estim
affin
biacor
analysi
half
life
hla
complex
hour
highli
specif
hla
show
data
demonstr
tcr
bind
specif
nyeso
peptid
puls
cell
fac
analysi
also
target
tumour
cell
express
nyeso
fluoresc
microscopi
furthermor
tcr
specif
inhibit
activ
cell
clone
nyeso
tumour
cell
measur
infg
elispot
immun
activ
includ
cytokin
fuse
tcr
h
chain
c
terminu
fusion
protein
suitabl
develop
immunotherapeut
agent
treat
nyeso
tumour
type
diabet
major
loss
insulin
produc
beta
cell
caus
autoreact
tcell
specif
antigen
express
pancreat
islet
autoantibodi
insulin
glutam
decarboxylas
strongli
associ
type
diabet
studi
analyz
preval
proinsulinspecif
tcell
type
diabet
patient
prediabet
subject
posit
two
autoantibodi
hlagenotyp
match
isletcel
autoantibodi
ica
neg
healthi
children
peripher
blood
mononuclear
cell
posit
children
three
studi
group
cultur
presenc
two
differ
peptid
aa
aa
proinsulin
aa
peptid
day
thereaft
cell
restimul
mhc
class
ii
monom
day
monom
contain
peptid
use
primari
stimul
bind
tcell
proinsulincontain
mhc
class
ii
tetram
analyz
flow
cytometri
result
show
type
diabet
patient
prediabet
subject
posit
one
proinsulincontain
tetram
wherea
ica
neg
healthi
control
tetram
bind
cell
differ
type
diabet
patient
healthi
control
statist
signific
p
chisquar
test
frequenc
tetram
posit
cell
proinsulin
activ
cell
higher
type
diabet
patient
prediabet
subject
control
subject
p
p
respect
studi
group
mannwhitney
utest
conclus
type
diabet
patient
prediabet
subject
higher
preval
proinsulinspecif
tcell
hlagenotyp
match
healthi
control
skin
prick
test
spt
seri
common
allergen
extract
includ
grass
weed
tree
hous
dust
mite
mould
result
subject
posit
spt
least
one
aeroallergen
male
femal
ratio
mean
age
year
preval
rate
allergen
group
pollen
mite
mould
mast
cell
play
pivot
role
immediatetyp
inflammatori
allerg
reaction
result
asthma
crosslink
highaffin
receptor
ige
fcri
mast
cell
activ
signal
pathway
lead
ca
mobil
follow
degranul
releas
histamin
preform
mediat
well
de
novo
synthesi
arachidon
acid
metabolit
ie
leukotrien
prostaglandin
investig
possibl
effect
heat
shock
immunolog
function
bone
marorow
deriv
mast
cell
bmmc
studi
degranul
leukotrien
product
found
heat
shock
inhibit
degranul
bmmc
without
effect
leukotrien
product
elucid
mechan
suppress
degranul
studi
effect
heat
shock
calcium
influx
tyrosin
phosphoryl
found
heat
shock
inhibit
calcium
influx
tyrosin
phosphoryl
syk
ship
sinc
degranul
mast
cell
play
role
allerg
nonallerg
reaction
find
may
relev
respect
protect
effect
heat
shock
respons
addit
convent
beffectorq
function
eosinophil
evid
eosinophil
function
antigenpres
cell
apc
increas
major
distinct
amongst
potenti
apc
type
amateur
profession
apc
amateur
apc
stimul
previous
activ
cell
cell
hybridoma
wherea
profession
apc
capabl
initi
cell
respons
investig
whether
eosinophil
capabl
initi
cell
respons
vivo
eosinophil
isol
spleen
transgen
balbc
mice
percol
follow
mac
contamin
apc
includ
dendrit
cell
exclud
cocultur
eosinophil
gmcsf
increas
express
costimulatori
molecul
includ
mhcii
gmcsf
stimul
eosinophil
allow
take
ova
vitro
intratrach
inject
wildtyp
balbc
mice
receiv
intraven
inject
agspecif
cell
ova
tcr
transgen
balbc
mice
h
earlier
altern
use
gfplabel
eosinophil
gfp
doubl
transgen
mice
fluoresc
conjug
ovabead
demonstr
fluoresc
microscopi
agload
eosinophil
apc
physic
interact
naiv
ova
tcr
cell
drain
paratrach
lymph
node
pln
h
eosinophil
transfer
agfre
eosinophil
randomli
distribut
across
pln
donor
cell
physic
interact
agload
eosinophil
agspecif
cell
result
activ
naiv
cell
measur
earli
cell
activ
marker
flow
cytometri
howev
eosinophil
apc
function
complet
impair
eosinophil
pretreat
rbc
lysi
buffer
contain
ammonium
chlorid
inhibit
antigen
process
eosinophil
data
suggest
eosinophil
may
function
profession
apc
initi
cell
respons
given
antigen
background
multifunct
cytokin
shown
suppress
immunoglobulin
product
anim
experi
plasma
tgfh
observ
higher
asthmat
compar
normal
control
joseph
et
al
ann
asthma
allergi
effect
tgf
cytokin
product
human
peripher
blood
mononuclear
cell
pbmc
investig
method
pbmc
asthmat
normal
control
isol
heparin
blood
densitygradi
centrifug
ficollpaqu
wash
three
time
phosphat
buffer
salin
resuspend
cellsml
serum
free
medium
aimv
cytokin
measur
pbmcml
cultur
medium
incub
ionophor
presenc
tgf
alon
antibodi
tgf
follow
hour
cell
cultur
supernat
collect
store
assay
cytokin
elisa
kit
pharmingen
usa
use
determin
ifng
supernat
pbmc
cultur
result
far
result
control
patient
analyz
median
ifng
product
unstimul
cell
pgml
increas
significantli
follow
exposur
tgf
pgml
p
b
upon
ad
antibodi
tgf
median
ifng
reduc
p
b
follow
stimul
pma
ionomycin
basal
median
ifng
product
pbmc
pgml
significantli
increas
upon
exposur
tgf
p
b
upon
ad
specif
antibodi
tgf
median
ifng
level
decreas
pgml
p
b
rest
state
trend
pbmc
asthmat
produc
higher
amount
ifng
compar
pbmc
control
conclus
tgf
may
regul
product
ifng
rest
stimul
pbmc
normal
control
asthmat
respons
abrog
specif
antibodi
tgf
molecul
cell
atop
asthmat
children
preliminari
report
n
e
martinezjimenez
e
rojasramo
b
garfia
e
g
zenteno
r
l
lascurain
clinic
immunolog
allergi
issst
mexico
mexico
citi
mexico
biochemistri
iner
ssa
mexico
mexico
citi
mexico
background
phenotyp
cell
accumul
chronic
inflam
tissu
allerg
process
found
mainli
memori
cell
express
surfac
marker
associ
product
howev
process
cell
surfac
marker
peripher
blood
clearli
determin
object
studi
perform
frecuenc
surfac
marker
cell
product
peripher
blood
atop
asthmat
children
method
cross
section
studi
trial
carri
atop
asthmat
children
healthi
children
control
proport
peripher
mononuclear
cell
surfac
molecul
studi
flow
cytometri
identifi
surfac
molecul
cell
analysi
perform
pbmc
pmaionomycin
stimul
examin
infg
product
result
median
percentil
median
percentil
cell
show
increas
product
correlationship
product
atop
asthmat
children
conclus
although
cell
peripher
blood
observ
atop
dermat
patient
work
identifi
similar
cellular
popul
respiratori
atop
diseas
also
cell
cell
seem
correspond
cell
express
stimuli
express
marker
could
correspond
earli
activ
atop
asthma
allerg
process
number
studi
analys
phenotyp
cell
express
surfac
marker
preferenti
associ
product
howev
repercuss
nasal
challeng
cell
peripher
blood
clearli
determin
found
cell
correl
posit
product
conclus
hous
dust
mite
prime
cell
allerg
rhiniti
patient
express
correl
product
local
challeng
repercuss
peripher
cell
could
observ
cell
stimul
pmai
mugwort
pollen
allergen
repres
main
caus
pollinosi
late
summer
europ
ninetyf
percent
mugwortallerg
patient
sensit
major
allergen
art
v
contrast
common
pollen
allergen
contain
multipl
cell
epitop
art
v
contain
one
singl
immunodomin
cell
epitop
art
v
character
minim
epitop
art
v
investig
possibl
associ
art
v
hla
class
iiphenotyp
art
v
cell
line
clone
establish
patient
clinic
defin
mugwort
pollen
allergi
ige
specif
art
v
patient
cellular
respons
art
v
obtain
core
region
amino
acid
contain
amino
acid
essenti
cell
reactiv
defin
use
truncat
singlesubstitut
analog
peptid
cell
stimul
frequenc
patient
recogn
art
v
significantli
increas
compar
healthi
control
vs
odd
ratio
p
b
identifi
main
restrict
element
present
immunodomin
epitop
use
monoclon
antihla
antibodi
apc
defin
hladrb
conclus
allergi
art
v
character
uniform
cell
repons
diseas
associ
therefor
mugwort
pollinosi
repres
ideal
candid
peptidebas
immunotherapi
includ
possibl
monitor
antigenspecif
cell
respons
therapi
use
hladrtetram
vitro
gener
mast
cell
hemopoiet
antigen
chemokin
receptor
activ
marker
tetraspanin
mirkina
schweighoff
rdadv
novarti
institut
biomed
research
vienna
austria
mast
cell
mc
play
pathogen
role
allerg
inflamm
via
releas
broad
spectrum
inflammatori
mediat
gener
mc
human
cord
blood
hemopoiet
precursor
cultur
rhscf
stem
span
medium
better
character
differenti
process
map
express
hemopoiet
marker
chemokin
receptor
adhes
molecul
receptor
aminopeptidas
n
present
mc
precursor
earli
hemopoiet
marker
bright
freshli
isol
precursor
disappear
within
week
differenti
develop
matur
mc
enhanc
cell
underw
freezingthaw
cycl
follow
cultur
presenc
human
serum
week
display
typic
featur
matur
mc
methachromat
stain
gimsamay
gruenwald
abund
express
granular
mast
cell
tryptas
surfac
express
mc
antigen
ckit
fceria
degranul
crosslink
fceria
ige
ag
mc
precursor
markedli
express
surfac
neg
low
undetect
precursor
absent
matur
mc
report
mc
precursor
substanti
express
surfac
interestingli
detect
chemoattract
receptor
homolog
molecul
express
cell
surfac
mc
precursor
second
receptor
prostaglandin
major
prostanoid
releas
agactiv
mc
data
suggest
possibl
autocrin
function
mc
find
sensit
marker
mc
reactiv
ag
explor
correl
mc
degranul
express
activ
marker
tetraspanin
use
test
reactiv
basophil
allergen
found
marker
hardli
detect
surfac
mc
precursor
high
matur
mc
surfac
intracellularli
first
evid
presenc
cord
bloodderiv
mc
express
increas
igedepend
independ
stimul
increas
mirror
degranul
process
determin
member
tetraspanin
famili
high
surfac
mc
precursor
express
augment
fold
differenti
matur
mc
contrast
surfac
express
diminish
stimul
pmaionomycin
trigger
ige
ag
therefor
member
btetraspanin
webq
could
differenti
involv
mc
activ
studi
defin
potenti
target
antiallerg
intervent
sensit
tool
monitor
mc
activ
rational
abpa
hypersensit
lung
diseas
result
bronchial
colon
aspergillu
fumigatu
asthmat
cystic
fibrosi
patient
previous
report
restrict
abpa
patient
propos
singl
nucleotid
polymorph
snp
also
play
role
develop
abpa
asthmat
cf
patient
method
dna
extract
cultur
bcell
line
abpa
nonabpa
patient
sequenc
polymorph
includ
extracellular
cytoplasm
snp
stimul
pbl
abpa
control
subject
examin
express
b
cell
flow
cytometri
hladr
genotyp
perform
use
standard
techniqu
result
frequenc
snp
significantli
increas
abpa
patient
compar
nonabpa
subject
vs
snp
identifi
abpa
patient
homozyg
cytoplasm
snp
identifi
abpa
patient
coexist
extracellular
plu
cytoplasm
snp
observ
abpa
patient
abpa
subject
also
significantli
increas
express
molecul
per
b
cell
stimul
pbl
cultur
compar
control
two
abpa
patient
identifi
previous
unreport
snp
bind
region
c
one
abpa
patient
snp
associ
snp
patient
snp
isol
also
associ
upregul
express
b
cell
stimul
conclus
presenc
snp
particularli
allel
locat
within
bind
region
may
confer
suscept
develop
abpa
addit
new
snp
bind
region
identifi
abpa
background
hous
dust
mite
hdm
allergen
involv
sensit
develop
allerg
airway
diseas
particularli
bronchial
asthma
allerg
rhiniti
dermatophagoid
pteronyssinu
dp
blomia
tropicali
bt
predomin
inhal
allergen
part
world
aim
measur
allergen
level
asthmaticst
home
hongkong
method
seventi
hous
enrol
mite
indoor
environ
studi
dust
sampl
obtain
two
site
subjectst
hous
bed
floor
level
quantifi
twosit
monoclon
antibodybas
elisa
techniqu
result
level
allergen
found
bed
gm
ugg
dust
ci
ugg
floor
gm
ugg
dust
ci
ugg
signific
differ
p
howev
level
allergen
also
found
bed
gm
ugg
dust
ci
ugg
floor
gm
ugg
dust
ci
ugg
statist
signific
differ
allergen
found
differ
site
addit
concern
exposur
index
allergen
found
bed
floor
bed
floor
level
ugg
dust
higher
obtain
bed
floor
respect
p
b
hand
higher
percentag
bed
floor
observ
level
dust
compar
bed
floor
respect
p
b
conclus
der
blot
major
sensit
allergen
region
blot
potent
one
hongkong
probabl
reflect
high
level
exposur
bt
uniqu
major
bt
dp
allergen
includ
precis
diagnosi
effect
immunotherapeut
treatment
mite
allergi
hongkong
cytokin
bronchial
epitheli
cell
object
investig
whether
der
f
allergen
proteas
induc
cytokin
product
epitheli
cell
line
method
cell
expos
four
differ
concentr
serial
addit
der
f
ugml
incub
h
h
compar
without
incub
allergen
cytokin
supernat
assay
elisa
revers
transcriptionpcr
also
perform
result
cell
treat
der
f
allergen
show
serial
chang
cohes
monolay
signific
increas
level
cytokin
product
compar
untrea
sampl
statist
significantli
increas
addit
der
f
caus
releas
time
concentrationdepend
manner
p
b
respect
level
elev
h
h
allergen
exposur
increas
time
continu
increas
level
present
supernat
h
h
time
show
concentr
depend
induct
express
well
increas
express
conclus
hdminduc
airway
inflamm
may
includ
der
fmediat
releas
inflammatori
mediat
proteolyt
activ
allergen
may
stimul
releas
proinflammatori
cytokin
human
bronchial
epithelium
suggest
product
bronchial
epitheli
cell
may
play
role
pathogenesi
allerg
asthma
introduct
pathogenesi
airway
remodel
involv
alter
interact
epitheli
mesenchym
cell
lead
air
wall
thicken
edema
davi
et
al
j
allergi
clin
immunol
frieri
allergi
asthma
proc
airway
remodel
associ
increas
vegf
increas
vascular
permeabl
pulmonari
submucosa
lee
ks
et
al
j
allergi
clin
immunol
auml
dialyz
pteronyssinu
extract
dpe
stimul
secret
vegf
serumfre
condit
media
cm
rel
dpe
without
control
media
ctlm
hour
capetand
et
al
j
clin
path
rational
determin
mediat
secret
cm
dpetreat
stimul
nhlf
secret
vegf
rel
ctlm
method
subconflu
nhlf
cultur
hour
cm
ctlm
gener
without
respect
plu
auml
dpe
cm
ctlm
assay
vegf
elisa
cell
number
measur
mtt
incorpor
data
express
mean
f
analyz
twotail
test
two
group
anova
z
three
group
result
nhlf
serumfre
media
secret
vegf
rel
control
f
pgml
n
versu
f
pgml
n
p
b
test
ctlm
stimul
nhlf
secret
vegf
control
n
absolut
vegf
level
increas
follow
condit
cm
nhlf
f
pgml
n
n
cm
wo
nhlf
f
pgml
n
n
ctlm
nhlf
f
n
p
b
anova
ctlm
caus
decreas
nhlf
cell
number
rel
cm
studi
perform
evalu
probabl
effect
allergi
children
without
otiti
media
effus
ome
allergi
common
ome
patient
allerg
patient
might
help
allergi
treatment
otiti
media
effus
common
childhood
ear
diseas
variou
predispos
factor
one
may
allergi
skin
prick
test
spt
abl
determin
allerg
patient
common
aeroallergen
studi
perform
children
ome
khalili
hospit
teach
hospit
affili
shiraz
univers
medic
scienc
iran
myringotomi
without
ventil
tube
insert
plu
adenoidectomi
done
group
pateint
age
rang
year
normal
middl
ear
underw
adenoidectomi
select
control
skin
prick
test
common
aeroallergen
mold
grass
weed
tree
mite
done
presenc
peripher
eosinophilia
also
investig
group
peripher
eosinophil
count
significantli
higher
case
group
p
b
patient
ome
group
posit
spt
weed
spt
neg
children
control
group
howev
skin
reactiv
two
group
significantli
differ
abl
demonstr
strong
correl
ome
posit
skin
test
common
aeroallergen
suggest
spt
evalu
children
ome
recurr
angioedema
blastocysti
homini
success
treat
paromomycin
micheloud
j
jensen
e
fernandezcruz
j
carbon
clinic
immunolog
unit
univers
hospit
gregorio
maranon
madrid
spain
background
publish
report
urticaria
associ
parasit
blastocysti
homini
uncommon
report
case
angioedema
blastocysti
homini
materi
clinic
immunolog
data
patient
associ
case
report
subject
femal
histori
episod
attack
swell
mouth
face
upper
extrem
accompani
recurr
urticaria
treat
differ
antihistamin
oral
corticosteroid
partial
respons
inmunolog
test
perform
peripher
blood
disclos
normal
immunoglobulin
level
igg
mgdl
iga
mgdl
igm
mgdl
normal
percentag
lymphocyt
subset
normal
level
complement
factor
mgdl
mgdl
fb
mgdl
mgdl
well
neg
circul
immun
complex
function
activ
also
normal
ige
specif
ascari
echinococcu
anisaki
neg
serolog
hepat
viru
b
hepat
viru
c
hiv
neg
complet
blood
differenti
analysi
biochem
serum
paramet
around
normal
rang
urinalysi
normal
stool
examin
reveal
blastocysti
homini
consecut
determin
intestin
parasit
well
urticariaangiedema
respond
success
paromomycin
sulfat
remiss
urticariaangioedema
maintain
clinic
followup
conclus
diagnosi
blastocysti
homini
infect
must
suspect
patient
otherwis
frustrat
chronic
allerg
skin
disord
paromomycin
might
benefit
chronic
persist
urticariaangioedema
associ
parasit
infect
two
group
recent
report
variou
mous
monoclon
ige
antibodi
induc
mous
bone
marrow
deriv
mast
cell
secret
mediat
absenc
known
specif
antigen
studi
investig
whether
exposur
purifi
human
myeloma
ige
catalog
number
biodesign
intern
kennebunk
absenc
known
specif
antigen
detect
effect
mediat
secret
human
mast
cell
gener
vitro
umbil
cord
blood
cell
exposur
ige
microgramsml
igg
significantli
enhanc
releas
chemokin
histamin
cysteinyl
leukotrien
human
mast
cell
result
obtain
microcentrifug
prepar
ige
lack
larg
aggreg
ige
accord
hplc
mass
spectrometri
hplcpurifi
prepar
ige
monom
devoid
ige
dimer
accord
mass
spectrometri
howev
condit
challeng
test
chemokin
product
respons
ige
alon
significantli
less
induc
aliquot
igesensit
popul
human
mast
cell
stimul
antiig
product
chemokin
respons
exposur
ige
presenc
absenc
antiig
inhibit
preincub
cell
dexamethason
overal
result
indic
exposur
human
myeloma
ige
vitro
absenc
known
specif
antigen
induc
chemokin
product
human
mast
cell
concentr
test
clinic
relev
find
remain
determin
one
might
specul
effect
ige
mast
cell
independ
known
specif
antigen
contribut
pathogenesi
mast
cellassoci
disord
particularli
subject
high
level
ige
recent
show
intranas
phototherapi
use
mix
low
dose
uvb
uva
visibl
light
muvvi
effect
treat
season
allerg
rhiniti
aim
present
studi
compar
clinic
efficaci
rhinophototherapi
fexofenadin
hydroclorid
perform
open
studi
ragweedallerg
patient
ragwe
season
szege
patient
receiv
intranas
irradi
increas
dose
muvvi
light
week
patient
receiv
mg
fexofenadin
hcl
daili
period
time
individu
symptom
score
total
nasal
score
tn
record
rhinophototherapi
result
significantli
better
reduct
individu
symptom
score
rhinorrea
p
nasal
obstruct
p
tn
p
compar
fexofenadin
hcl
signific
differ
two
treatment
observ
reduc
symptom
score
sneez
nasal
itch
palat
itch
eye
symptom
addit
measur
wheal
format
skin
prick
test
spt
digit
planimetri
start
studi
day
end
therapi
interestingli
ten
day
end
treatment
rhinophototherapi
group
allergeninduc
wheal
format
significantli
reduc
compar
baselin
p
contrast
fexofenadin
treat
group
differ
observ
chang
histamineinduc
wheal
format
observ
studi
rhinophototherapi
significantli
effect
fexofenadin
treat
allerg
rhiniti
prolong
inhibitori
effect
rhinophototherapi
spt
suggest
long
last
effect
seen
fexofenadin
treatment
eosinophil
eo
promin
cell
asthmat
inflamm
lung
airway
eo
show
significantli
prolong
surviv
antiapoptot
activ
mediat
cytokin
gmcsf
markedli
increas
asthmat
lung
select
induct
eo
apoptosi
propos
therapeut
approach
asthma
previou
studi
shown
ppias
cyclophilin
fkbp
inhibitor
suppress
gmcsf
tnfa
express
function
data
implic
ppias
mediat
ci
tran
isomer
pserpthrpro
bond
target
protein
potenti
key
regul
cytokin
express
recent
shown
inhibit
anoth
ppias
block
prosurviv
effect
either
gmcsf
hyaluron
acid
ha
identifi
mechan
underli
eo
apoptosi
induc
inhibit
examin
activ
eo
treat
inhibitor
juglon
cell
lysat
examin
fulllength
proenzym
activ
subunit
western
blot
analysi
shown
previous
publish
data
rest
eo
underw
spontan
baselin
activ
h
cultur
complet
block
rhgmcsf
pgml
treatment
eo
ha
agml
markedli
increas
airway
asthmat
lung
prevent
spontan
activ
well
howev
treatment
eo
juglon
induc
activ
even
presenc
rhgmcsf
ha
furthermor
apoptot
initi
inhibit
appar
eo
preactiv
rhgmcsf
preincub
high
concentr
rhgmcsf
ha
also
fail
block
juglon
induc
activ
cell
death
kinet
analysi
show
within
minut
juglon
trigger
extrem
intens
activ
activ
sensit
earli
marker
ultim
apoptosi
eo
trypan
blue
exclus
indic
eo
viabil
remain
high
h
despit
juglon
treatment
data
indic
enzymat
activ
requir
prevent
activ
initi
apoptosi
downstream
gmcsf
receptor
object
defin
balbc
mous
vitro
model
domin
cell
epitop
major
cat
allergen
fel
test
effect
natur
regulatori
cell
reg
respons
cell
naiv
mice
mice
immun
fel
materi
method
analysi
prolif
immun
respons
naiv
mice
immun
mice
use
vitro
system
myeloidderiv
antigenpuls
dendrit
cell
dc
induc
cell
prolifer
immatur
dc
harvest
mous
bonemarrow
matur
vitro
day
puls
antigen
day
lymphocyt
obtain
mous
spleen
cell
ad
dc
cell
day
h
thymidin
addit
harvest
cell
prolifer
measur
unsepar
spleen
lymphocyt
separ
cell
subpopul
cell
separ
magnet
bead
check
puriti
fac
cell
stimul
measur
whole
fel
overlap
peptid
immun
balbc
mice
inject
time
fel
al
oh
result
unsepar
splenic
lymphocyt
naiv
mice
give
signific
prolifer
stimul
fel
allergen
synthet
peptid
unsepar
lymphocyt
immun
mice
gave
signific
stimul
index
fel
peptid
f
aa
chain
purifi
lymphocyt
fel
mice
gave
signific
stimul
fel
peptid
f
reg
ad
cell
prolifer
inhibit
purifi
cell
naiv
mice
gave
also
posit
stimul
index
expos
fel
f
peptid
prolifer
abolish
addit
reg
naiv
mice
ratio
reg
cell
cell
major
cat
allergen
fel
seem
harbour
one
major
cell
epitop
contain
region
test
immun
balbc
mice
natur
reg
immun
mice
inhibit
lymphocyt
prolifer
stimul
fel
f
dc
natur
reg
naiv
mice
inhibit
prolifer
naiv
immun
balbc
mice
test
fel
f
peptidepuls
dendrit
cell
background
omalizumab
oma
novel
human
monoclon
antiig
antibodi
allerg
asthma
oma
bind
circul
ige
lead
reduct
high
affin
ige
receptor
mast
cell
mc
therebi
reduc
mc
degranul
upon
specif
allergen
exposur
result
decreas
mc
releas
allerg
mediat
histamin
leukotrien
lt
ltra
block
effect
cysteinyl
lt
respons
featur
allerg
asthma
howev
block
mediat
categori
lt
releas
mc
examin
effect
oma
moderatesever
allerg
asthma
patient
use
ltra
evalu
asthma
exacerb
need
burst
system
steroid
pool
analysi
two
recent
complet
clinic
trial
method
innov
week
random
doubleblind
placebocontrol
studi
etopa
week
open
label
trial
allow
concurr
ltra
use
use
analysi
entri
criteria
clinic
outcom
similar
allow
pool
analysi
total
patient
intenttotreat
itt
popul
two
studi
patient
receiv
inhal
steroid
longactingbetaagonistswer
use
patient
innov
patient
etopa
receiv
concurr
ltra
overal
ltra
use
baselin
patient
innov
etopa
group
compar
use
poisson
regress
base
itt
popul
adjust
baselin
sex
age
use
oral
steroid
studi
treatment
treatmentbyltra
interact
result
patient
ltra
tend
exhibit
greater
level
asthma
sever
evidenc
baselin
histori
trial
incid
clinic
exacerb
irrespect
treatment
rel
risk
rr
asthma
exacerb
primari
outcom
oma
vs
control
ltra
subgroup
ci
somewhat
lower
observ
overal
studi
popul
similarli
rr
use
system
steroid
secondari
outcom
oma
vs
control
ltra
subgroup
ci
similar
effect
size
observ
overal
popul
conclus
patient
moder
sever
asthma
oma
demonstr
efficaci
ltra
subgroup
similar
improv
shown
overal
popul
asthma
morbid
assess
clinic
exacerb
improv
conjunct
signific
reduct
system
steroid
burst
inflamm
allerg
asthma
gener
activ
endogen
proinflammatori
cytokin
includ
produc
lymphocyt
allergeninduc
respons
enhanc
airway
hyperreact
mous
model
studi
shown
develop
immun
respons
significantli
downregul
respons
elicit
ifng
product
experiment
induc
ova
albumin
ova
allerg
balbc
mice
inhal
chitin
made
mice
given
chitin
intraven
ovasensit
allergeninduc
immunopatholog
respons
balf
cytolog
antiova
humor
respons
ovadriven
cytokin
product
assess
administr
chitin
significantli
suppress
immunopatholog
symptom
ovasensit
mice
dissect
inhibitori
mechan
respons
spleen
cell
isol
chitintr
nontreat
ovasensit
mice
cultur
presenc
ova
andor
chitin
day
ova
alon
stimul
product
associ
cytokin
group
contrast
ovachitin
stimul
result
significantli
increas
product
ifng
moreov
spleen
cell
isol
chitintr
mice
show
abund
amount
ifng
product
stimul
chitin
less
amount
cytokin
without
ovastimul
suggest
inhibit
respons
might
explain
potenti
mechan
due
chang
antibodi
isotyp
cytokin
produc
splenocyt
mice
receiv
chitin
summari
result
indic
chitininduc
ifng
respons
success
downregul
ige
product
lung
eosinophilia
ova
allerg
anim
purpos
idea
enlighten
seri
allerg
toxic
manifest
unexpect
onset
ingest
cook
mushroom
cortinariu
orellanu
gyromitra
gyromitra
poison
also
occur
ingest
commerci
avail
morel
contamin
g
esculenta
method
case
age
sex
notifi
treatment
emerg
depart
aljunaid
hospit
ingest
cook
mushroom
veget
toxic
speci
confus
edibl
speci
follow
advers
reaction
allergictox
variabl
sever
allerg
manifest
ie
itch
burn
flush
tingl
sensat
bodi
urticaria
variabl
sever
toxic
manifest
acut
onset
result
neurotoxin
releas
ie
nausea
min
vomit
min
abdomin
cramp
bloat
feel
wateri
diarrhea
h
proster
dehydr
profus
sweat
coma
convuls
hallucin
excit
depress
spastic
colon
seizur
h
extrem
thirst
lack
urin
product
symptom
includ
feel
warmth
clammi
numb
tongu
extrem
thirst
one
case
seri
concomit
intak
alcohol
beverag
toxic
syndrom
clinic
test
procedur
ie
use
ria
test
kit
evidenc
subnanogram
level
toxin
urin
plasma
patient
surviv
earli
phase
recov
without
complic
meticul
follow
much
sever
manifestationsdelay
notif
treatment
appear
recov
short
time
period
gener
follow
rapid
sever
loss
strength
prostrat
paincaus
restless
sudden
onset
abdomin
discomfort
feel
full
aggress
therapi
result
surviv
variabl
degre
liver
enlarg
rest
succumb
death
irrevers
damag
vital
organ
hepatoren
insuffici
cardiac
skelet
muscl
toxin
affect
primarili
liver
addit
disturb
blood
cell
central
nervou
system
result
degre
revers
advers
effect
depend
upon
urgenc
therapeut
notif
absenc
dietari
histori
allergictox
manifest
could
mistaken
symptom
hepat
renal
impair
consequ
caus
eg
viral
hepat
therefor
urgent
distinct
made
delay
onset
symptom
mistaken
behind
idea
organ
previous
damag
import
rapid
diagnosi
evid
victim
hospit
given
aggress
support
therapi
immedi
ingest
mortal
rate
wherea
admit
beyond
ingest
mortal
rate
conclus
mushroom
per
name
alik
dissimilar
nutrit
toxic
natur
haphazard
selectionconsumpt
could
cost
life
consum
tacrolimu
macrolid
immunosuppress
use
prevent
graft
reject
transplant
patient
treatment
atop
dermat
drug
inhibit
tlymphocyt
activ
prevent
transcript
wish
investig
whether
tacrolimu
also
indirectli
suppress
natur
killer
nk
cell
eosinophil
activ
inhibit
tcell
lymphocyt
assay
heparin
blood
collect
healthi
adult
donor
layer
ficolhypaqu
densiti
gradient
isol
lymphocyt
cell
cultur
invitro
concentr
cellsml
increas
amount
tacrolimu
drug
cytokin
ad
biweekli
maintain
appropri
cell
concentr
weekli
flow
cytometr
analys
perform
detect
tacrolimust
effect
thelper
cell
tcytotox
cell
nk
cell
cd
popul
cd
also
measur
assess
lymphocyt
activ
doubl
stain
cd
cd
weekli
assess
cr
discharg
cell
perform
detect
nk
cell
activ
eosinophil
assay
tacrolimu
effect
eosinophil
viabil
investig
isol
white
blood
cell
eosinophilia
patient
whole
blood
collect
patient
layer
percol
gradient
isol
white
blood
cell
kept
concentr
cellsml
treat
vari
amount
drug
concentr
ad
specif
cultur
order
studi
differ
effect
cell
activ
cytokin
drug
ad
biweekli
flow
cytometri
perform
day
increment
monitor
eosinophil
activ
express
fluoresc
lymphocyt
activ
inhibit
observ
tlymphocyt
eosinophil
popul
well
nk
cell
activ
flow
cytometri
analysi
stain
express
indic
increas
time
concentr
tacrolimu
tlymphocyt
activ
decreas
compar
control
cultur
treat
alon
cultur
week
treat
tacrolimu
display
decreas
respect
week
decreas
activ
level
tacrolimu
ngml
respect
overal
activ
level
unaffect
increas
treatment
drug
time
cr
assay
suggest
overal
decreas
nk
cell
activ
eosinophil
activ
compar
control
flow
cytometri
result
stain
cd
indic
decreas
eosinophil
activ
day
incub
day
decreas
cell
activ
tacrolimu
ngml
ngml
increas
time
concentr
mean
fluoresc
cell
express
cd
activ
marker
decreas
conclus
although
primari
effect
tacrolimu
tcell
also
may
affect
nk
cell
eosinophil
activ
effect
eosinophil
may
explain
drugt
benefici
effect
atop
dermat
patient
background
hemopoiesi
import
factor
pathogenesi
allerg
asthma
sever
studi
suggest
extramedullari
hemopoiet
cell
present
insid
asthmat
lung
contribut
chronic
airway
inflamm
defin
factor
respons
emerg
cell
relationship
allerg
inflamm
isol
intrapulmonari
hemopoiet
cell
lung
allerg
balbc
mice
show
presenc
strictli
depend
airway
challeng
ovalbuminsensit
mice
chest
b
differ
hemopoiet
cell
bonemarrow
growth
properti
sensit
steroid
intl
immunopharmacol
press
evalu
possibl
contribut
intrapulmonari
hemopoiet
cell
accumul
made
system
activ
signal
origin
challeng
lung
local
allerg
reaction
object
defin
whether
allergenchalleng
lung
releas
factor
respons
intrapulmonari
accumul
hemopoiet
cell
b
whether
product
activ
factor
dissoci
allergeninduc
lung
injuri
method
develop
transplant
model
fragment
allergenchalleng
sensit
lung
donor
ectop
implant
syngen
recipi
hemopoiet
cell
insid
recipientst
lung
quantit
without
allergen
exposur
recipi
contribut
releas
graft
assess
elisa
neutral
graft
result
balbc
mice
accumul
hemopoiet
cell
occur
donor
sensit
challeng
airway
b
recipi
sensit
sc
allergen
inject
airwaychalleng
media
condit
lung
fragment
appropri
donor
contain
biolog
activ
well
immunoreact
eotaxin
induc
intrapulmonari
accumul
hemopoiet
cell
sensit
recipi
effect
appropri
donorrecipi
combin
prevent
antibodi
unlik
balbc
lung
transgen
cbaca
mice
contain
larg
number
hemopoiet
cell
independ
sensit
challeng
lung
fragment
naiv
transgen
donor
condit
media
induc
intrapulmonari
accumul
hemopoiet
cell
nontransgen
ovalbuminsensit
recipi
conclus
intrapulmonari
accumul
hemopoiet
cell
independ
local
immunolog
injuri
induc
allergen
challeng
b
lung
graft
system
releas
requir
accumul
hemopoiet
cell
recipientst
lung
c
fulli
effect
sensit
anim
tradit
consid
termin
effector
cell
eosinophl
current
emerg
subtl
role
relat
influenc
tissu
milieu
immunomodul
rel
new
appreci
stem
part
realiz
eosinophil
store
arsen
preform
cytokin
chemokin
welldefin
immunomodulatori
properti
capabl
rapid
releas
potent
mediat
respons
specif
stimuli
although
multipl
mediat
store
close
proxim
within
eosinophil
specif
granul
releas
appear
independ
regul
ie
eotaxin
induc
releas
ifng
induc
secret
rant
without
detect
releas
date
mechan
govern
select
elus
interestingli
eosinophil
respons
mani
factor
reservoir
indic
cognat
receptor
ligand
also
express
despit
dual
express
receptorligand
pair
eosinophil
studi
address
receptor
express
relat
storag
releas
cognat
ligand
studi
util
flow
cytometr
analysi
monitor
intraand
extracellular
express
receptor
approach
combin
electron
microscopi
light
microscopi
subcellular
fraction
visual
local
receptor
throughout
eotaxininduc
secret
ligand
surprisingli
discov
addit
nomin
surfac
express
compon
function
type
ii
receptor
complex
preform
store
within
freshli
isol
eosinophil
demonstr
bind
compon
receptor
chain
select
mobil
concert
like
particip
traffick
granul
vesicular
compart
work
repres
first
indic
preform
intern
store
cytokin
receptor
within
human
eosinophil
propos
novel
mechan
select
mediat
releas
cyclosporin
child
success
desensit
hypersensit
reaction
cylosporin
rare
cyclosporin
formul
parent
oral
use
vital
drug
bone
marrow
transplant
bmt
thu
recognit
hypersensit
reaction
guidelin
subsequ
use
import
transplant
surveil
purpos
paper
report
case
anaphylaxi
intraven
oral
cyclosporin
success
manag
oral
desensit
also
present
review
differ
formul
cyclosporin
least
drug
reaction
case
report
girl
thalassemia
major
admit
post
bmt
develop
anaphylact
reaction
respiratori
distress
hypotens
gener
urticaria
second
exposur
intraven
oral
cyclosporin
fortun
good
respons
immedi
rescu
treatment
immunosuppress
drug
effect
cyclosporin
engraft
two
avail
formul
cyclosporin
iran
contain
cremophorel
polyoxyethyl
caster
oil
iv
chemic
similar
compound
cremophorel
oral
compound
previou
report
case
cyclosporin
hypersensit
confirm
due
solubil
agent
rather
cyclosporin
safest
suggest
formul
cornoilbas
soft
gelatin
capsul
avail
us
thu
oral
desensit
start
accord
classic
penicillin
desensit
protocol
toler
appropri
patient
report
cyclosporin
desensit
literatur
cyclosporin
anaphylaxi
rare
possibl
face
unavail
suitabl
formul
desensit
consid
skin
reactiv
aeroallergen
relat
nasal
polyp
tissu
eosinophil
inflamm
fardin
eghtedari
sey
reza
cheraghzadeh
sara
kashef
ahmad
monabati
elham
shoraka
role
allergi
pathogenesi
nasal
polyposi
clear
studi
investig
possibl
correl
skin
reactiv
aeroallergen
polyp
tissu
eosinophil
inflamm
twentyf
patient
nasal
polyposi
candid
polypectomi
gener
anesthesia
enrol
polyp
tissu
stain
hematoxilineosin
eosinophil
count
skin
prick
test
spt
least
common
aeroallergen
allergopharma
germani
includ
pollen
mite
mold
done
patient
posit
spt
defin
reaction
least
larger
neg
control
glycerol
patient
least
one
posit
spt
patient
eosinophil
count
polyp
tissu
percent
cell
count
field
find
signific
correl
polyp
eosinophil
count
compar
skin
reactiv
seem
polyp
eosinophil
inflamm
consequ
allergi
aeroallergen
nasal
polyposi
allergen
immunotherapi
treatment
allerg
rhiniti
asthma
revers
immun
imbal
patient
igemedi
disord
form
therapi
involv
gradual
administr
increas
dose
allergen
patient
found
possess
allergenspecif
ige
reactiv
treatment
effect
reduc
allergi
symptom
medic
use
improv
qualiti
life
allergi
suffer
allergen
immunotherapi
aqueou
allergen
howev
carri
risk
system
reaction
use
questionnair
membership
immunotherapi
committe
american
academi
allergi
asthma
immunolog
verifi
potenti
risk
death
near
death
reaction
immedi
follow
administr
aqueou
allergen
find
confirm
near
death
reaction
death
associ
aqueou
immunotherapi
reduc
lifethreaten
reaction
allergen
immunotherapi
patterson
develop
techniqu
glutaraldehyd
polymer
ragwe
grass
allergen
multipl
studi
polymer
vaccin
found
effect
aqueou
allergen
extract
devoid
system
respons
extend
pattersont
find
demonstr
polymer
ragwe
grass
vaccin
superior
safeti
aqueou
materi
allergi
patient
given
inject
polymer
ragwe
grass
allergen
zero
system
respons
elimin
risk
death
associ
aqueou
allergen
immunotherapi
retain
effect
strongli
recommend
allergi
patient
receiv
polymer
ragwe
grass
vaccin
given
use
aqueou
allergen
immunotherapi
untrain
physician
nurs
practition
increas
nationwid
may
safer
patient
fda
either
elimin
avail
aqueou
ragwe
grass
allergen
altogeth
restrict
use
physician
board
certifi
allergyimmunolog
l
chini
f
angelini
c
chatgilialoglu
dellont
v
mosches
corrent
r
iannini
chianca
p
rossi
c
ferreri
pediatr
policlinico
tor
vergata
univers
rome
tor
vergata
rome
itali
isof
consiglio
nazional
dell
ricerch
bologna
itali
format
tran
fatti
acid
residu
membran
lipid
due
radicalcatalys
isomer
process
natur
occur
ci
fatti
acid
moieti
radic
stress
well
document
atop
diseas
data
still
avail
possibl
associ
high
level
tran
fatti
acid
patient
investig
presenc
tran
lipid
isom
erythrocyt
tlymphocyt
membran
children
affect
atop
eczemadermat
syndrom
a
take
advantag
tran
lipid
librari
avail
radic
process
model
vitro
found
tran
fatti
acid
erythrocyt
lymphocyt
membran
total
content
reach
highest
valu
main
fatti
acid
residu
high
tran
fatti
acid
level
correl
significantli
increas
amount
palmit
acid
decreas
stearic
acid
fatti
acid
also
correl
decreas
arachidon
level
scenario
fit
imhibit
elongas
enzymat
activ
moreov
highest
tran
fatti
acid
level
detect
children
atop
dermat
mediat
ige
prickrast
neg
new
signific
lipid
impair
a
propos
gener
involv
role
tran
isom
human
patholog
studi
aim
contribut
lipidom
research
regard
doubl
bond
structur
influenc
geometr
chang
membran
lipid
physiolog
diseas
boleslaw
kalicki
anna
jung
wanda
stankiewicz
marek
dabrowski
janusz
zuber
paediatr
militari
medic
institut
warsaw
poland
immunolog
institut
hygien
epidemiolog
warsaw
poland
proinflammatori
cytokin
nitrici
oxiden
play
import
role
exacerb
asthma
aim
studi
determin
level
exhal
breath
condes
asthmat
children
materi
method
sampl
exhal
breath
condens
collect
children
asthma
femal
male
age
mean
breath
frozen
examin
exhal
breath
condens
done
ecoscreen
equip
jaeger
comp
result
compar
group
asthmat
children
children
asthma
exacerb
ii
children
without
exacerb
asthma
well
control
steroid
drug
iii
children
asthma
improv
without
drug
longer
month
control
ivth
healthi
children
age
mean
result
highest
valu
found
group
children
paramet
shown
signific
differ
examin
group
conclus
mean
concentr
cytokin
strong
correl
exacerb
asthma
children
examin
exhal
breath
condens
especi
also
cytokin
use
noninvas
method
monitor
exacerb
asthma
children
introduct
children
probabl
peanut
allergi
skin
prick
test
spt
report
specif
aim
determin
sensit
specif
peanut
allergi
skin
test
peanut
specificig
combin
children
lower
preexist
probabl
peanut
allergi
method
children
attend
allergi
clinic
posit
peanut
spt
n
age
rang
year
mean
year
includ
studi
immedi
skin
applic
food
test
isaft
use
gram
peanut
butter
posit
wheal
detect
minut
peanut
specificig
level
openlabel
peanut
food
challeng
perform
result
fiftytwo
peanut
challeng
posit
spt
specif
mm
isaft
alon
specif
peanut
specificig
level
kul
alon
sensit
specif
level
kul
specif
combin
spt
posit
isaft
peanut
specificig
n
kul
specif
conclus
spt
predict
peanut
allergi
children
without
high
preexist
probabl
peanut
allergi
child
without
recent
histori
peanut
reaction
spt
b
diamet
peanut
specificig
measur
challeng
necessari
level
b
n
kul
allergi
test
result
interpret
context
histori
suspicion
food
allergi
cowt
milk
allergi
consid
caus
infantil
colic
clinician
frequent
chang
diet
infant
cowt
milk
free
diet
studi
evalu
role
cowt
milk
allergi
infantil
colic
group
exclus
breast
fed
infant
exclus
breast
fed
infant
three
week
three
month
age
refer
infantil
colic
enrol
studi
skin
prick
test
cowt
milk
extract
allergopharma
stool
exam
occult
blood
done
babi
randomli
select
two
group
case
control
case
group
includ
two
babi
posit
skin
prick
test
advis
mother
consum
cowt
milk
dairi
product
two
week
control
group
chang
diet
mother
babi
came
back
follow
babi
case
babi
control
group
infant
colic
whose
mother
take
dairi
product
improv
significantli
comparison
control
group
preval
posit
skin
prick
test
colicki
infant
nearli
similar
preval
cowt
milk
allergi
popul
infant
one
year
age
basi
previou
studi
occult
bleed
stool
significantli
higher
colicki
infant
comparison
noncolicki
infant
cowt
milk
allergi
seem
common
caus
infantil
colic
advis
elimin
dairi
product
diet
nurs
mother
paracrin
intracrin
role
inflamm
differ
cell
may
variabl
present
cytosol
andor
nucleu
may
undergo
activationdepend
transloc
site
includ
nuclear
envelop
lipid
bodi
organel
leukocyt
cell
role
local
format
cyclooxygenas
pathwayderiv
eicosanoid
evalu
express
rat
basophil
leukemia
cell
rest
rbl
cell
contain
numer
lipid
bodi
identifi
stain
oil
red
incorpor
fluoresc
fatti
acid
analog
immunocytochemistri
present
cytosol
nucleu
rest
rbl
cell
well
punctat
cytosol
site
costain
lipid
bodi
rest
rbl
cell
disrupt
nitrogen
cavit
subject
subcellular
fraction
protocol
design
isol
buoyant
lipid
bodi
western
blot
subcellular
fraction
present
lipid
bodi
well
cytosol
nuclear
fraction
investig
local
within
rbl
cell
cell
transfect
plasmid
encod
fusion
protein
examin
cell
soon
hr
transfect
demonstr
promin
focal
green
fluoresc
punctat
cytosol
site
stain
lipid
bodi
oil
red
fluoresc
remain
larg
lipid
bodi
associ
hr
posttransfect
lesser
number
cell
also
began
exhibit
diffus
cytosol
fluoresc
ascertain
whether
cell
activ
alter
distribut
cell
sensit
antidnp
ige
activ
dnp
hr
igemedi
activ
lipid
bodi
number
per
cell
hr
activ
fluoresc
exhibit
almost
exclus
punctat
cytosol
local
lipid
bodi
thu
lipid
bodi
rbl
cell
constitut
discret
pool
especi
enrich
newli
synthes
find
provid
addit
evid
function
lipid
bodi
organel
format
eicosanoid
pertin
inflamm
categori
potenti
seriou
immun
reaction
loss
treatment
effect
may
result
repeat
exposur
patient
therapeut
protein
peptid
even
human
sourc
base
human
sequenc
object
object
investig
studi
approach
taken
develop
human
proteinpeptid
product
avail
unit
state
respect
immunogen
potenti
materi
method
packag
insert
twenti
therapeut
human
proteinpeptid
product
examin
follow
inform
alter
peptid
sequenc
polysaccharid
attach
manufactur
process
choic
excipi
viral
valid
assay
antibodi
develop
vitro
vivo
correl
cell
mediat
immun
precaut
contraind
specif
patient
popul
therapeut
effect
advers
reaction
product
includ
hormon
cytokin
coagul
factor
immun
globulin
well
blood
compon
result
inform
chang
potenti
affect
immunogen
differ
conform
therapeut
agent
molecul
possibl
adjuv
effect
certain
excipi
rare
present
except
recombin
product
immunogen
often
studi
develop
serum
antibodi
therapeut
agent
rare
term
cellmedi
immun
respons
skinsensit
antibodi
unless
rout
administr
dermal
applic
instruct
test
antibodi
therapeut
agent
often
dictat
chang
treatment
effect
occasion
manifest
advers
reaction
anaphylaxi
special
popul
suscept
develop
immun
respons
therapeut
agent
gener
address
precaut
warn
contraind
section
label
howev
systemat
studi
explor
immunogen
specif
popul
often
lack
conclus
inform
regard
immun
reaction
human
proteinspeptid
remain
inadequ
pursu
present
mani
avail
therapeut
product
greater
attent
need
focus
import
issu
bear
safeti
effect
product
solubl
receptor
function
decoy
receptor
inhibit
action
aim
studi
evalu
serum
concentr
asthma
patient
bronchial
challeng
dp
allergen
studi
perform
asthma
patient
posit
histori
dust
allergi
symptom
posit
skin
prick
test
result
dp
extract
signific
bronchoconstrict
respons
bronchial
dp
challeng
ten
healthi
person
neg
skin
prick
test
common
aeroallergen
use
control
bronchial
provoc
challeng
dp
extract
perform
asthma
patient
blood
sampl
collect
hour
ear
hour
lar
hour
allergen
challeng
plasma
concentr
evalu
elisa
r
system
mean
plasma
concentr
greater
asthma
patient
f
pgml
healthi
control
f
pgml
differ
mean
plasma
concentr
patient
respond
allergen
challeng
isol
earli
asthmat
respons
singl
responderssr
respond
earli
late
asthmat
respons
dual
respondersdr
ear
signific
fall
plasma
concentr
found
dr
f
pgml
p
b
sr
f
pgml
mean
plasma
concentr
significantli
greater
sr
f
pgml
dr
f
pgml
significantli
differ
baselin
level
fall
plasma
concentr
dr
seen
ear
may
result
increas
activ
turn
may
particip
develop
sustain
allerg
inflamm
patient
background
splice
variant
known
antagon
mani
biolog
activ
aim
studi
compar
express
ratio
patient
asthma
versu
healthi
subject
materi
method
eight
healthi
subject
eight
patient
atop
asthma
confirm
case
histori
skin
test
rast
involv
studi
inform
consent
patient
healthi
subject
particip
studi
obtain
rna
extract
pbmc
obtain
ficollurographin
gradient
centrifug
cdna
use
quantit
pcr
specif
formdiscrimin
primer
sybr
green
perform
use
icycl
iq
biorad
hercul
usa
result
express
ratio
f
f
patient
atop
asthma
healthi
subject
respect
ratio
correl
age
sex
total
serum
ige
level
presenc
eczema
rhiniti
anaphylaxi
patient
asthma
conclus
differ
rel
express
splice
variant
healthi
subject
versu
atop
asthma
patient
natur
altern
splice
form
human
deriv
mrna
elimin
second
exon
encod
amino
acid
residu
structur
biolog
properti
poorli
understood
direct
nonmrna
quantit
measur
current
possibl
major
purpos
studi
compar
structur
parent
cytokin
b
attempt
reveal
domin
b
epitop
sequenc
loop
region
use
synthet
peptid
computerassist
model
c
prepar
monoclon
antibodi
mab
specif
cytokin
form
evalu
bind
affin
antibodi
peptid
synthes
solidphas
method
character
analyt
hplc
massspectrometri
increas
immunogen
peptid
conjug
keyhol
limpet
hemocyanin
klh
use
immunogen
polyclon
monoclon
antibodi
peptid
addit
whole
recombin
protein
produc
balbc
mice
analysi
reactiv
mous
antisera
produc
show
low
reactiv
synthet
peptid
antipeptid
antisera
obtain
demonstr
notic
reactiv
especi
antiserum
peptid
mimick
splice
fragment
consist
sequenc
immunodot
elisa
demonstr
mab
produc
abl
recogn
peptid
reactiv
peptid
antisera
complet
absent
model
use
templat
design
peptid
mimick
uniqu
b
epitop
emerg
splice
site
assay
antibodi
bind
mab
label
cytokin
show
valu
vari
techniqu
may
allow
identif
character
differ
includ
quantit
qualit
function
aspect
endotoxin
shown
power
effect
adapt
immun
although
endotoxin
particular
lp
import
adjuv
prime
allerg
immun
respons
shown
suppress
recal
immun
respons
test
effect
lp
vivo
prime
memori
respons
model
allerg
asthma
induc
without
adjuv
mice
immun
twice
day
mcg
ovalbumin
ova
intraperiton
one
week
later
mice
challeng
seri
aerosol
ova
consecut
day
group
mice
either
evalu
acut
diseas
recuper
least
month
rechalleng
relaps
diseas
found
mice
sensit
intraperiton
ova
low
lp
content
remov
detoxigel
contain
pgml
endotoxin
rechalleng
ova
sigma
grade
v
contain
ngml
endotoxin
develop
minim
allerg
lung
inflamm
mucu
secret
ovaspecif
ige
compar
anim
immun
high
lp
contain
ova
support
previou
data
result
demonstr
lp
influenc
ova
prime
howev
mice
immun
use
protocol
lowfat
milk
powder
contain
endotoxin
ngml
aerosol
milk
solut
respons
significantli
higher
low
endotoxin
contain
ova
prime
mice
data
indic
lp
may
critic
induc
respons
ova
necessari
prime
milk
protein
test
effect
lp
vivo
memori
respons
lead
diseas
relaps
challeng
recuper
mice
ova
titrat
dose
lp
ngml
aerosol
ova
solut
found
inhibit
allerg
inflamm
mucu
product
immunoglobulin
ngml
ad
lp
ngml
determin
whether
lp
suppress
memori
respons
low
high
lp
dose
involv
b
cell
experi
b
cell
defici
mice
interestingli
absenc
b
cell
found
suppress
intermedi
lp
dose
effect
high
low
dose
suggest
b
cell
play
role
lp
effect
recal
memori
respons
summari
result
show
lp
necessari
prime
certain
protein
ova
other
milk
addit
lp
inhibitori
effect
memori
respons
appear
involv
b
cell
cowt
milk
allergi
signific
health
problem
infanc
childhood
patient
usual
allerg
major
milk
protein
cowt
milk
formula
includ
casein
betalactoglobulin
alphalactalbumin
result
develop
dermat
asthma
anaphylaxi
current
anim
model
milkinduc
allerg
asthma
advantag
milk
allergen
experiment
model
natur
clinic
relev
broaden
scope
gener
applic
mous
model
allerg
asthma
induc
allerg
respons
combin
protein
cost
effect
kg
milk
powder
vienna
eur
g
ovalbumin
eur
establish
model
acut
relaps
milkinduc
allerg
asthma
mice
inject
either
balbc
mice
mcg
lowfat
milk
powder
dissolv
pb
intraperiton
three
week
apart
one
week
later
expos
mice
seri
milkaerosol
challeng
solut
milk
powder
pb
two
consecut
day
mice
either
evalu
diseas
acut
onset
diseas
recuper
follow
month
reexpos
milk
similar
seri
aerosol
challeng
gener
diseas
relaps
observ
increas
lung
inflamm
mucu
secret
milkspecif
ige
acut
onset
diseas
day
relaps
day
balbc
mice
howev
milk
sensit
aerosol
induc
higher
infiltr
inflammatori
cell
bronchoalveolar
lavag
fluid
compar
balbc
mice
percent
eosinophil
airway
f
f
balbc
mice
compar
eosinophil
naiv
recov
mice
furthermor
number
perivascular
peribronchi
infiltr
eosinophil
within
lung
tissu
section
reflect
differ
similarli
mucu
hypersecret
milkspecif
ige
level
higher
compar
balbc
mice
observ
differ
strain
appar
acut
relaps
diseas
recuper
balbc
mice
lymphocyt
infiltr
lung
previous
demonstr
ovalbumininduc
model
contrast
ovalbumininduc
allerg
asthma
milk
sensit
aerosol
result
larg
differ
mous
strain
yet
fulli
understood
present
use
inexpens
clinic
relev
mous
model
milk
allergi
mice
demonstr
signific
genet
differ
immun
respons
balbc
cowt
milk
background
asthma
older
adult
underrecogn
often
associ
allerg
trigger
antiimmunoglobulin
e
ige
therapi
omalizumab
oma
indic
patient
z
year
moder
sever
allerg
asthma
continu
inadequ
control
despit
treatment
inhal
corticosteroid
previou
analys
focus
specif
efficaci
older
adult
examin
treatment
respons
oma
asthma
exacerb
well
patientreport
investigatorreport
global
treatment
effect
patient
year
older
method
data
combin
random
doubl
blind
placebocontrol
pbo
trial
patient
moder
sever
allerg
asthma
confirm
skin
test
rast
test
week
week
durat
pool
studi
popul
involv
total
patient
treat
oma
treat
pbo
met
entri
criteria
includ
baselin
need
treatment
moder
high
dose
inhal
corticosteroid
subject
year
age
rel
risk
rr
clinic
signific
asthma
exacerb
oma
vs
pbo
primari
endpoint
determin
use
poisson
regress
control
age
categori
studi
sex
baselin
ige
prior
histori
asthma
exacerb
overal
popul
patient
year
similar
approach
taken
evalu
patientand
investigatorreport
global
treatment
effect
excel
good
moder
poor
worsen
use
cumul
logist
regress
two
group
compar
oma
pbo
result
mean
age
older
subgroup
year
femal
mean
ige
level
iudl
rang
overal
studi
popul
mean
age
year
rang
femal
mean
ige
level
iudl
rang
oma
associ
reduc
risk
clinic
signific
asthma
exacerb
trial
review
pool
analysi
overal
studi
popul
reveal
rr
oma
vs
pbo
ci
subgroup
patient
older
rr
ci
improv
shown
oma
agreement
patientand
investigatorreport
global
effect
demonstr
significantli
greater
respons
p
b
measur
patient
assign
oma
rel
pbo
irrespect
age
conclus
patient
year
age
omalizumab
associ
rr
reduct
clinic
signific
asthma
exacerb
significantli
better
patientand
investigatorreport
global
effect
rate
compar
placebo
suggest
omalizumab
effect
older
patient
moder
sever
allerg
asthma
treatment
gener
well
toler
laboratori
demonstr
human
b
lymphocyt
synthes
autocrin
product
cytokin
appear
essenti
maintain
ige
product
cell
initi
ige
synthesi
contact
b
cell
ligand
cell
necessari
cultur
system
use
murin
fibroblast
ltk
establish
propag
human
b
cell
vitro
object
develop
model
b
cell
use
cocultur
system
method
human
b
lymphocyt
isol
tonsil
purifi
sheep
red
blood
cell
roset
ltk
cell
stabli
transfect
cdna
encod
wildtyp
form
human
protein
cocultur
system
b
cell
coincub
untransfect
ltk
cell
transfect
cell
seed
plate
isol
b
cell
also
stimul
solubl
antibodi
recombin
ad
cultur
incub
day
induc
ige
product
day
cocultur
detect
intracellular
b
cell
assess
flow
cytometri
also
measur
level
phosphoryl
flow
cytometri
resultat
use
brdu
stain
demonstr
effici
support
surviv
b
lymphocyt
increas
prolifer
versu
compar
solubl
antibodi
block
apoptosi
b
lymphocyt
effici
solubl
vs
importantli
day
cultur
number
b
cell
significantli
higher
versu
compar
solubl
ab
product
ige
human
b
lymphocyt
cultur
assess
elisa
also
increas
significantli
ng
ml
versu
ngml
compar
b
cell
stimul
solubl
antibodi
contrast
receptor
signal
equal
influenc
cultur
system
phosphoryl
respons
exogen
nearli
equal
hour
cocultur
solubl
compar
untransfect
ltk
control
posit
cell
cocultur
solubl
versu
ltk
conclus
induc
effici
cross
link
solubl
antibodi
lead
turn
high
level
posit
b
cell
previous
demonstr
like
suggest
product
b
cell
import
vivo
cytokin
product
human
b
lymphocyt
may
underreport
due
incomplet
stimul
via
rational
daclizumab
zenapaxr
human
monoclon
antibodi
direct
receptor
chain
approv
prevent
renal
allograft
reject
evalu
treatment
asthma
multipl
sclerosi
autoimmun
diseas
daclizumab
inhibit
activ
human
lymphocyt
block
cell
prolifer
reduc
product
cytokin
natur
occur
regulatori
cell
reg
thought
play
import
role
prevent
autoimmun
diseas
man
mous
sakaguchi
annu
rev
immunol
sinc
reg
character
constitut
express
high
level
evalu
vitro
effect
daclizumab
function
cell
method
cell
enrich
whole
blood
obtain
healthi
human
donor
use
stemcel
technolog
rosettesepk
system
reg
flow
sort
bright
top
stain
intens
effector
cell
eff
sort
bottom
stain
intens
inhibitori
activ
reg
assess
standard
cocultur
system
briefli
eff
alon
reg
alon
eff
reg
stimul
day
presenc
immobil
presenc
irradi
autolog
apc
prolifer
measur
hthymidin
incorpor
last
hour
cultur
result
reg
stimul
day
presenc
daclizumab
agml
show
littl
prolifer
similar
reg
stimul
absenc
dac
eff
stimul
alon
demonstr
substanti
prolifer
inhibit
daclizumab
averag
expect
reg
suppress
prolifer
eff
cocultur
system
system
preincub
reg
daclizumab
affect
suppress
activ
cell
cocultur
experi
daclizumab
effect
function
reg
cell
inhibit
eff
cell
healthi
human
volunt
respiratori
exposur
environment
antigen
ova
induc
rapid
expans
antigen
specif
helper
cell
popul
mice
primari
intranas
challeng
ova
also
induc
differenti
activ
ova
specif
effector
th
cell
narv
precursor
effector
function
demonstr
shortterm
cultur
antigen
restimul
effector
th
cell
found
drain
lymph
node
circul
howev
secondari
intranas
challeng
ova
fail
induc
inflamm
lung
even
size
th
cell
popul
peak
base
observ
th
cell
prime
respiratori
system
environment
antigen
absenc
adjuv
view
defect
anerg
studi
demonstr
express
effector
function
intranas
prime
th
cell
lung
follow
challeng
antigenbead
emboli
mice
importantli
secondari
intranas
challeng
solubl
antigen
induc
th
cell
mediat
inflamm
lung
result
suggest
th
cell
prime
via
respiratori
rout
environment
antigen
anerg
importantli
clear
express
th
cell
effector
function
tightli
control
innat
respons
lung
bead
emboli
solubl
ova
induc
rapid
increas
chemokin
express
rapid
increas
number
activ
dendrit
cell
lung
howev
clear
innat
event
critic
express
th
cell
effector
function
lung
propos
loss
innat
regul
th
cell
effector
function
peripher
organ
necessari
cell
mediat
organ
specif
disord
extracellular
adenosin
atp
local
physiolog
regul
previous
shown
atp
stimul
bronchopulmonari
vagal
sensori
termin
nocicept
c
stretchsensit
fiber
action
mediat
receptor
r
j
physiol
lond
ditto
stimulatori
action
atp
c
fiber
could
involv
atpinduc
bronchoconstrict
cough
vagal
sensori
neuron
nodos
ganglion
express
homomer
well
heteromer
explor
subtyp
mediat
atpinduc
action
potenti
ap
nodos
c
fiber
termin
lung
effect
potent
select
antagonist
site
proc
natl
acad
sci
usa
activ
guineapig
intrapulmonari
vagal
sensori
nerv
termin
hmethyleneatp
h
matp
potent
select
agonist
site
studi
perfus
isol
lung
prepar
ap
c
n
fiber
n
induc
h
matp
bolu
absenc
presenc
um
min
quantifi
dischargesec
data
mean
sd
h
matp
induc
ap
nondesensit
manner
c
fiber
frequenc
f
f
respect
reduc
respons
f
f
respect
p
b
um
significantli
inhibit
action
h
matp
fiber
f
inhibitori
effect
c
fiber
conclus
h
matp
stimul
nocicept
c
stretchsensit
fiber
act
present
data
could
also
indic
differ
natur
subtyp
express
two
fiber
phenotyp
addit
sinc
aerosol
atp
induc
bronchoconstrict
cough
human
subject
patient
asthma
copd
could
constitut
novel
therapeut
modal
manag
patient
chronic
obstruct
airway
diseas
support
duska
therapeut
inc
bala
cynwyd
pennsylvania
sulfur
dioxid
known
induc
bronchoconstrict
asthmat
particularli
sensit
cell
physiolog
basi
unknown
investig
biolog
basi
sulfit
sensit
mast
cell
line
human
peripher
blood
basophil
airway
epitheli
cell
cell
expos
vari
concentr
sodium
sulfit
presenc
absenc
antioxid
inhibitor
redox
pathway
sodium
sulfit
induc
mast
cell
basophil
degranul
level
equival
induc
ige
crosslink
ionomycin
respons
independ
extracellular
calcium
influx
use
redox
sensit
fluoresc
dye
diacet
sulfit
shown
increas
gener
intracellular
reactiv
oxygen
speci
ro
upregul
sulfiteinduc
ro
gener
also
demonstr
airway
epitheli
cell
line
ro
degranul
induc
sulfit
inhibit
free
radic
scaveng
tetramethylthiourea
flavoenzym
inhibitor
diphenyleneiodinium
overal
data
suggest
one
potenti
mechan
sulfiteinduc
asthmat
symptom
may
due
activ
airway
mast
cell
epitheli
cell
gener
ro
via
activ
nadph
oxidas
complex
increas
gener
superoxid
anion
cedar
pollen
hypersensit
major
caus
season
airway
symptom
sever
region
northern
hemispher
group
allergen
isol
clone
sequenc
pollen
least
six
cedar
speci
recent
resolv
crystal
structur
map
known
ige
epitop
jun
mountain
cedar
mc
given
high
degre
amino
acid
sequenc
ident
evid
immunolog
crossreact
cedar
allergen
investig
structur
basi
share
ige
epitop
two
group
allergen
crossreact
jun
cri
j
japanes
cedar
jc
probe
sera
jcallerg
patient
immunocap
inhibit
linear
ige
epitop
identifi
cri
j
array
overlap
jun
peptid
use
sera
patient
allerg
jc
bind
mous
monoclon
anticri
j
antibodi
peptid
also
test
model
cri
j
protein
prepar
mpack
suit
use
crystal
structur
jun
templat
immunocap
inhibit
indic
ige
antijc
pollen
antibodi
sera
jcallerg
patient
react
jun
peptid
repres
jun
epitop
bound
human
ige
anticri
j
antibodi
epitop
map
region
cri
j
model
similar
surfac
exposur
homolog
region
jun
crystal
structur
one
epitop
map
betahel
core
jun
recogn
sera
jc
patient
despit
complet
sequenc
ident
appar
similar
surfac
exposur
monoclon
antibodi
cri
j
identifi
anoth
share
epitop
probabl
conform
one
uniqu
cri
j
epitop
may
glycopeptid
structur
find
indic
ige
antibodi
sever
linear
conform
ige
epitop
group
cedar
allergen
crossreact
homolog
allergen
share
respons
may
recogn
structur
element
common
mani
plant
allergen
find
suggest
patient
genet
divers
popul
respond
similar
linear
conform
epitop
homolog
allergen
understand
similar
differ
immun
respons
group
allergen
aid
develop
effect
allergi
vaccin
allergi
admiss
admiss
relat
acut
allerg
diseas
method
databas
acut
hospit
new
york
state
examin
statewid
plan
cooper
research
system
sparc
databas
compil
mandatori
report
acut
care
hospit
inform
input
regard
diagnos
disposit
procedur
insur
demograph
charg
patient
admiss
diagnosi
princip
otherwis
food
allergi
use
code
allerg
diseas
includ
anaphylaxi
urticaria
allergi
unspecifi
code
extract
demograph
characterist
tabul
hospit
pattern
examin
admiss
food
allergi
compar
admiss
acut
allerg
diseas
result
decad
examin
admiss
new
york
state
hospit
code
allerg
diseas
exclus
food
relat
code
increas
less
howev
number
admiss
allerg
condit
involv
food
allergi
tripl
median
age
allerg
diseas
relat
admiss
increas
year
studi
howev
median
age
food
allergi
admiss
actual
decreas
increas
age
nonfood
relat
allerg
diseas
admiss
appear
primarili
due
increas
angioedema
admiss
age
greater
food
allergi
relat
admiss
increas
nonafrican
american
patient
african
american
patient
decad
studi
contrast
allergi
relat
admiss
exclus
food
relat
code
increas
african
american
especi
angioedema
age
relat
differ
observ
respect
specif
food
caus
anaphylaxi
conclus
food
allergi
relat
hospit
increasingli
report
new
york
state
whether
increas
food
allergi
relat
hospit
relat
increas
food
allergi
greater
awar
condit
determin
research
pattern
food
allergi
relat
hospit
clearli
warrant
asthma
chronic
inflammatori
diseas
establish
oxidantantioxid
imbal
antioxid
therapi
might
better
strategi
augment
endogen
antioxid
better
manag
asthma
vitamin
e
strong
lipophil
antioxid
multipl
action
biochem
cellular
level
effect
supplement
standard
therapi
explor
asthmat
conduct
doubl
blind
standard
therapycontrol
studi
assess
role
exogen
supplement
vitamin
e
endogen
oxidantantioxid
balanc
asthmat
fifti
six
patient
divid
two
group
placebo
group
patient
standard
therapi
vitamin
esuppl
group
patient
standard
therapi
plu
iu
vitamin
e
capsul
twice
daili
venou
blood
collect
day
baselin
week
respect
treatment
present
studi
show
standard
therapi
well
vitamin
esuppl
group
lower
level
superoxid
anion
gener
compar
baselin
plasma
glutathion
peroxidas
gshpx
increas
standard
therapi
group
wherea
differ
found
plasma
gshpx
baselin
vitamin
esuppl
group
plasma
lipid
peroxid
increas
total
antioxid
capac
decreas
standard
therapi
group
wherea
vitamin
esuppl
group
significantli
lower
level
lipid
peroxid
higher
total
antioxid
capac
total
blood
glutathion
also
decreas
standard
therapi
group
wherea
signific
differ
found
vitamin
esuppl
group
plasma
nitrat
nitrit
nox
decreas
standard
therapi
group
wherea
increas
vitamin
esuppl
group
plasma
protein
sulfhydryl
red
cell
superoxid
dismutas
sod
level
increas
standard
therapi
group
chang
baselin
red
cell
sod
activ
vitamin
esuppl
group
level
former
remain
increas
group
also
signific
differ
found
plasma
protein
carbonyl
red
cell
catalas
either
standard
therapi
group
vitamin
esuppl
group
plasma
vitamin
e
level
increas
two
fold
vitamin
e
supplement
chang
observ
standard
therapi
group
signific
improv
predict
group
week
respect
treatment
vitamin
esuppl
group
greater
degre
improv
term
increas
baselin
studi
provid
biochem
clinic
evid
first
time
vitamin
e
augment
endogen
antioxid
screen
improv
lung
function
may
use
adjunct
therapi
treatment
asthmat
ric
regimen
includ
highli
immunosuppress
nonmyeloabl
therapi
replac
high
dose
chemotherapi
radiotherapi
allosct
explor
good
result
concern
feasibl
engraft
howev
littl
known
immun
recoveri
pattern
patient
especi
differ
lymphoid
cell
subset
assess
differ
time
point
allosct
kinet
recoveri
narv
central
memori
termin
differenti
lymphocyt
patient
singl
center
receiv
hlaident
ric
allosct
patient
graft
characterist
age
diagnos
myeloid
malign
lymphoid
malign
metastat
solid
tumor
pt
consid
high
risk
pt
receiv
fludarabin
busulfan
antithymocyt
globulinbas
ric
pt
receiv
low
dose
irradiationbas
ric
patient
receiv
peripher
blood
stem
cell
graft
receiv
cyclosporin
csa
alon
gvhd
prophylaxi
receiv
csa
mmf
pt
develop
grade
acut
gvhd
median
seri
contrast
cell
subset
cell
subset
progress
sustain
recoveri
first
month
allosct
acquisit
function
marker
perforin
among
differ
subset
analyz
recoveri
narv
cell
central
memori
cell
measur
day
allosct
onset
grade
acut
gvhd
show
signific
correl
risk
grade
acut
gvhd
p
p
p
respect
patient
develop
grade
acut
gvhd
recov
median
narv
cellsal
prior
onset
gvhd
compar
cellsal
patient
grade
acut
gvhd
narv
cell
level
significantli
decreas
appropri
acut
gvhd
treatment
cox
multivari
analysi
take
account
relev
risk
factor
acut
gvhd
earli
recoveri
narv
cell
first
month
allosct
strongest
paramet
significantli
predict
grade
acut
gvhd
develop
p
rr
ci
interestingli
signific
correl
total
number
cell
infus
allogen
graft
earli
recoveri
narv
cell
p
suggest
graft
manipul
might
repres
attract
tool
toward
har
alloreact
ricallosct
lymphocyt
ctl
play
major
role
mediat
allograft
reject
mhcident
solid
bone
marrow
transplant
set
instanc
alloreact
direct
toward
either
donor
solid
organ
recipi
bone
marrow
deriv
antigen
often
repres
minor
variat
self
alloantigen
call
minor
histocompat
minor
h
antigen
variant
minor
h
antigen
elicit
robust
ctl
respons
sever
case
lead
graft
versu
host
diseas
gvhd
graft
reject
may
result
death
molecular
mechan
minor
h
antigen
process
present
donor
recipi
ctl
remain
poorli
understood
studi
exploit
mice
defici
variou
aspect
antigen
present
demonstr
role
donorand
recipientderiv
dendrit
cell
proteasom
aquisit
process
crosspresent
minor
h
antigen
find
reveal
import
role
recipi
dendrit
cell
donor
proteasom
gener
effect
minor
h
antigen
respons
find
import
implic
understand
gvhd
viral
tumor
vaccin
design
well
l
stephan
j
p
tremblay
human
genet
crchul
quebec
qc
canada
human
genet
crchul
quebec
qc
canada
duchenn
muscular
dystrophi
dmd
fatal
neuromuscular
recess
diseas
character
widespread
muscl
damag
throughout
bodi
cure
current
avail
dmd
research
group
pursu
research
program
develop
treatment
base
healthi
donor
myoblast
transplant
mt
sustain
immunosuppress
current
requir
prevent
reject
allogen
human
mt
howev
major
draw
back
mt
longterm
use
immunosuppress
treatment
associ
advers
effect
nephrotox
increas
cancer
risk
etc
last
year
transplant
toler
obtain
develop
stabl
donorspecif
chimer
result
bone
marrow
transplant
bmt
induct
stabl
multilineag
chimer
smlc
across
fulli
mhcmismatch
barrier
establish
busulfan
myelosuppress
treatment
mice
prime
allogen
spleen
cell
transfus
follow
singl
cyclophosphamid
cyp
dose
immunosuppress
drug
develop
protocol
obtain
smlc
donor
bmt
follow
condit
regimen
involv
treatment
singl
cyp
dose
low
treosulfan
treo
dose
less
toxic
busulfan
analog
tri
obtain
similar
chimeri
level
mdx
mice
dystroph
mous
model
cyptreo
base
protocol
order
prevent
reject
allogen
healthi
balbc
myoblast
muscl
fiber
form
graft
tibiali
anterior
ta
mice
treat
variabl
mix
chimer
level
leukocyt
cell
popul
day
bmt
treat
mice
chimer
treat
mice
variabl
chimer
level
tcell
popul
proport
popul
consequ
mice
develop
smlc
dystrophin
posit
fiber
present
chimer
ta
mice
day
mt
hybrid
fiber
number
equival
one
observ
ta
section
mdx
mice
treat
immunosuppress
infiltr
tcell
observ
around
dystrophin
posit
fiber
day
mt
test
toler
ddresistancett
capac
done
challeng
initi
graft
donor
myoblast
mice
left
ta
use
cyptreo
protocol
develop
one
hundr
day
later
second
mt
donor
strain
perform
right
ta
without
addit
therapi
mice
sacrif
day
second
mt
ta
graft
observ
dystrophin
posit
fiber
tcell
infiltr
thu
conclud
first
graft
surviv
challeng
donor
antigenmt
without
addit
treatment
taken
togeth
show
treo
low
toxic
associ
protocol
requir
irradi
use
clinic
use
approv
drug
would
permit
obtain
safe
sustain
immunolog
toler
dmd
patient
donor
mt
accordingli
could
appli
condit
regimen
sever
organ
tissu
transplant
neonat
cellsag
restrict
develop
immun
toler
specialis
cell
cell
best
defin
subset
regulatori
function
essenti
maintain
immun
balanc
mice
shown
regulatori
capac
man
prerequisit
develop
still
controversi
howev
understand
development
need
immun
toler
might
facilit
manipul
shown
neonat
phase
pivot
induc
domin
toler
peripher
antigen
built
syngen
bone
marrow
transplant
model
determin
whether
develop
regulatori
cell
restrict
certain
development
window
reason
ragmic
transplant
cell
deplet
rag
f
bone
marrow
reconstitut
nonirradi
recipi
show
immun
dysregul
die
wast
diseas
diseas
driven
host
deriv
cell
bone
marrow
deriv
cell
abolish
diseas
wherea
tcr
transgen
neonat
recipi
protect
deplet
cell
alon
resembl
whole
cell
deplet
wherea
addit
bone
marrow
deriv
cell
prevent
even
cure
diseas
bmt
strikingli
cell
develop
bone
marrow
chimera
ineffect
taken
togeth
result
demonstr
regulatori
cell
might
help
tool
treat
immun
dysregul
howev
develop
restrict
certain
development
window
earli
live
larg
diminish
adult
bmt
understand
develop
role
regulatori
cell
immun
reconstitut
allow
us
improv
gvt
reaction
avoid
gvhd
model
acut
gvhd
use
model
vivo
ctl
develop
previous
demonstr
antihost
ctl
characterist
acut
gvhd
model
impair
select
blockad
either
ifng
surprisingli
preliminari
experi
indic
day
donor
transfer
mice
receiv
combin
ifng
blockad
exhibit
sever
lymphopenia
untreat
acut
gvhd
suggest
paradox
worsen
diseas
compar
select
blockad
either
ifng
alon
address
mechan
involv
acut
gvhd
induc
mice
inject
million
wild
type
wt
parent
spleen
cell
million
ifng
donor
plu
neutral
antiifng
mab
mg
iv
weekli
neutral
achiev
mg
mab
weekli
iv
control
consist
normal
mice
gvhd
mice
receiv
ifng
blockad
alon
control
mab
alon
day
parent
cell
transfer
mice
assess
splenic
lymphocyt
subpopul
flow
cytometri
ex
vivo
antihost
ctl
activ
result
indic
peak
donor
cell
expans
day
greater
gvhd
mice
receiv
combin
ifng
blockad
compar
untreat
control
mab
treat
wt
gvhd
mice
importantli
combin
ifng
blockad
acceler
gvhd
phenotyp
peak
antihost
ctl
activ
seen
day
vs
day
wt
gvhd
complet
host
b
cell
elimin
ctl
downregul
seen
day
vs
day
wt
gvhd
note
day
gvhd
mice
receiv
combin
ifng
blockad
differ
ifng
blockad
gvhd
mice
respect
donor
cell
engraft
host
b
cell
elimin
result
support
hypothesi
earli
absenc
ifng
acceler
ctl
develop
regardless
presenc
contrast
absenc
day
permit
greater
cell
expans
consist
loss
depend
regulatori
mechan
extracorpor
photopheresi
ecp
immunomodulatori
cell
therapi
investig
treatment
variou
immunemedi
inflammatori
disord
clinic
ecp
involv
intraven
reinfus
autolog
apoptot
peripher
blood
leukocyt
anim
model
deliveri
apoptot
cell
shown
regul
immun
respons
modul
cytokin
gener
regulatori
cell
downregul
antigenpres
cell
apc
function
other
shown
activ
narv
cell
presenc
apc
engulf
ecptreat
apoptot
cell
lead
gener
cell
popul
suppress
activ
present
studi
demonstr
direct
interact
ecptreat
peripher
blood
mononuclear
cell
pbmc
narv
human
cell
vitro
promot
cell
phenotyp
regulatori
activ
gener
human
regulatori
cell
ecp
depend
apc
revers
addit
express
upregul
regulatori
cell
prolifer
respons
concanavalina
howev
regulatori
cell
express
increas
level
secret
signific
level
proinflammatori
cytokin
ifng
tnfa
transfer
ecpderiv
regulatori
cell
secondari
mix
lymphocyt
reaction
result
greater
inhibit
syngen
respond
cell
prolifer
ifng
product
treg
respond
ratio
addit
transwel
assay
demonstr
inhibit
respond
cell
ecpderiv
regulatori
cell
contactdepend
addit
studi
underway
character
phenotyp
regulatori
cell
determin
suppress
capac
vivo
laboratori
shown
transplant
hematopoiet
stem
cell
hsc
fetal
sheep
result
longterm
multilineag
hematopoiet
chimer
observ
demonstr
toler
induc
prenat
period
earli
inject
hsc
optim
age
transplant
day
gestat
term
day
howev
relationship
hematopoiet
chimer
toler
remain
obscur
order
understand
ontogeni
immun
system
fetal
sheep
analyz
variou
cell
popul
thymu
spleen
bone
marrow
bm
small
intestin
site
peyert
patch
format
liver
peripher
blood
pb
fetal
sheep
day
gestat
flowcytometeri
observ
demonstr
day
thymu
contain
cell
popul
minim
detect
day
howev
increas
day
diminish
day
day
day
gestat
peak
cell
popul
pb
bm
liver
well
cell
seen
bm
small
intestin
spleen
day
gestat
liver
pb
express
small
intestin
increas
day
day
howev
bm
spleen
express
diminish
day
gestat
cell
popul
peripher
lymphoid
organ
earli
gestat
age
express
like
memori
phenotyp
cell
describ
cooper
et
al
journal
immunolog
immunohistochemistri
studi
day
show
cell
abruptli
increas
medulla
thymu
decreas
day
gradual
increas
day
data
suggest
popul
cell
phenotyp
consist
regulatori
cell
primari
secondari
lymphoid
organ
earli
gestat
data
support
establish
peripher
toler
earli
gestat
may
role
toler
induct
follow
utero
hsc
transplant
background
surprisingli
antitumor
respons
occur
patient
reject
donor
graft
follow
nonmyeloabl
hematopoiet
cell
transplant
dey
et
al
biol
blood
marrow
transplant
murin
mix
chimera
prepar
nonmyeloabl
condit
previous
show
recipi
leukocyt
infus
rli
induc
antitumor
respons
hosttyp
tumor
rubio
et
al
blood
investig
clinic
relev
rli
model
evalu
effect
rli
tumorbear
mice
compar
rli
allogen
lymphocyt
infus
untreat
mice
method
mix
chimer
achiev
balbc
mice
condit
deplet
mab
cyclophosphamid
mgkg
day
gy
thymic
irradi
day
prior
transplant
k
bone
marrow
cell
group
receiv
rli
balbc
spleen
cell
seven
week
postbmt
rli
donor
mice
receiv
balbc
b
cell
lymphoma
cell
two
week
rli
group
receiv
rli
deplet
b
cell
mac
column
purg
tumor
cell
cell
given
iv
one
week
rli
chimera
allogen
lymphocyt
infus
spleen
cell
untreat
balbc
mice
clinic
set
rli
would
obtain
tumorbear
host
therefor
examin
whether
rli
still
effect
lymphocyt
obtain
tumorbear
mice
recipi
rli
tumorbear
mice
show
similar
tumor
surviv
compar
recipi
rli
naiv
donor
thu
purg
procedur
antitumor
effect
achiev
rli
tumorbear
host
nontumorbear
host
allogen
lymphocyt
inject
potenti
feasibl
antitumor
therapi
therefor
compar
antitumor
effect
allogen
lymphocyt
infus
naiv
mice
rli
given
mix
chimera
rli
recipi
longer
surviv
naiv
mice
receiv
allogen
lymphocyt
result
suggest
antitumor
effect
rli
therapi
stronger
allogen
lymphocyt
infus
therapi
also
suggest
reject
allogen
cell
insuffici
mix
chimer
requir
prior
induc
reject
achiev
maximum
antitumor
effect
conclus
togeth
data
reinforc
potenti
rli
therapi
new
hsct
strategi
risk
graftversushost
diseas
thymoglobulinr
rabbit
antihuman
thymocyt
globulin
fda
approv
use
acut
transplant
reject
posit
result
set
suggest
thymoglobulinr
would
like
effect
graftversushost
diseas
test
hyothesi
preclin
gener
antimous
thymocyt
antiserum
matg
immun
rabbit
mous
thymocyt
purifi
igg
result
immuneserum
method
perform
ident
use
gener
thymoglobulinr
human
counterpart
atg
addit
model
acut
graftversushost
diseas
gvhd
develop
gvhd
induc
transfer
spleen
cell
mice
nonirradi
balbc
defici
mice
lack
matur
b
cell
follow
transfer
allogen
cell
host
display
progress
weight
loss
accompani
increas
product
varieti
proinflammatori
cytokin
detect
serum
hepat
necrosi
inflamm
sever
organ
absenc
therapeut
intervent
control
mice
display
signific
diseas
within
week
appli
matg
variou
time
point
follow
cell
transfer
gvhd
model
evalu
effect
diseas
preventionrevers
administr
matg
day
post
allogen
cell
transfer
deplet
cell
circul
fac
analysi
complet
prevent
evid
acut
gvhd
gvh
mice
treat
matg
show
evid
weight
loss
elev
cytokin
level
target
organ
patholog
protect
effect
matg
acut
gvhd
persist
least
week
also
test
effect
mous
atg
treatment
given
acut
gvhd
well
establish
contrast
matg
administr
initi
diseas
treatment
day
follow
allogen
cell
transfer
show
evid
gvhd
amelior
thu
show
depend
upon
time
dose
matg
treatment
quit
effect
prevent
acut
gvh
murin
model
diseas
result
suggest
explor
thymoglobulinr
dose
relat
bone
marrow
transplant
human
patient
prophylaxi
gvhd
warrant
work
support
genzym
corpor
role
ifng
induct
graftversushost
diseas
gvhd
allogen
hematopoiet
cell
transplant
allohct
elus
ifng
protect
lethal
irradi
mice
receiv
allogen
cell
plu
marrow
cell
deleteri
noncondit
subleth
irradi
recipi
allogen
cell
alon
ie
without
marrow
cell
recent
observ
cell
ifng
ko
donor
induc
sever
damag
parenchym
gvhd
target
tissu
reduc
abil
elimin
recipi
hematopoiet
cell
lethal
irradi
murin
allohct
model
result
suggest
deleteri
effect
ifng
allohct
recipi
donor
cell
alon
might
due
facilit
antihost
lymphohematopoiet
gvh
reaction
result
destruct
host
type
hematopoiet
cell
hematopoiet
failur
recipi
test
hypothesi
compar
develop
gvhd
subleth
irradi
gy
mice
receiv
splenocyt
alon
along
bone
marrow
cell
bmc
ifng
ko
wildtyp
wt
donor
mice
receiv
subleth
irradi
alon
use
nongvhd
control
surviv
longterm
consist
publish
studi
recipi
wt
splenocyt
alon
without
bmc
inoculum
contain
minim
number
hematopoiet
stem
cell
develop
sever
gvhd
compar
mice
receiv
similar
number
splenocyt
ko
donor
p
b
contrast
mice
receiv
donor
spleen
cell
along
bmc
recipi
ko
allohct
develop
sever
acut
gvhd
succumb
death
week
recipi
wt
allohct
surviv
longterm
p
b
unlik
recipi
wt
allohct
addit
bmc
splenocyt
significantli
delay
gvhd
death
recipi
gko
allohct
order
quantit
evalu
abil
wt
vs
ifng
ko
donor
cell
induc
lethal
gvhd
compar
surviv
lethal
irradi
mice
receiv
fix
number
bmc
along
titrat
number
splenocyt
wt
ifng
ko
mice
minim
number
splenocyt
need
induc
lethal
gvhd
approxim
fold
less
ko
wt
donor
cell
taken
togeth
result
indic
wt
allohct
mediat
stronger
lymphohematopoiet
gvh
reaction
gko
allohct
latter
caus
sever
damag
parenchym
tissu
sinc
lymphohematopoiet
gvh
reaction
may
select
elimin
host
lymphohematopoiet
cell
includ
lymphoma
cell
better
understand
mechan
ifng
separ
two
type
gvh
reaction
could
lead
novel
approach
separ
gvhd
graftvsleukem
effect
background
shown
blockad
earli
murin
mhcdispar
allogen
bone
marrow
transplant
bmt
result
augment
donor
host
alloreact
graftvshost
diseas
gvhd
resp
reject
later
bmt
blockad
combin
dli
induc
graftvsleukemia
gvl
effect
slightli
increas
risk
gvhd
aim
explor
model
mhccompat
mihcdispar
allo
bmt
blockad
use
modul
gvhd
induc
gvl
effect
materi
method
akr
gy
radiat
bm
chimera
treat
block
moab
irrelev
hamster
igg
earli
late
mice
monitor
weight
chang
clinic
sign
gvhd
surviv
moribund
anim
sacrif
histopatholog
fac
use
studi
cell
chimer
hostdonorreact
cellfrequ
mlr
studi
ex
vivo
alloreact
elisa
determin
circul
antidna
ab
result
earli
nont
cell
deplet
tcd
allo
bmt
induc
acut
lethal
gvhd
increas
donor
cell
chimer
alloreact
cell
histopatholog
confirm
late
nontcd
allo
bmt
howev
induc
weight
loss
alopecia
splenomegali
lymphadenopathi
cachexia
mortal
treat
nontreat
anim
show
differ
chimer
alloreact
cellfrequ
histopatholog
show
lymphoprolifer
spleen
lymph
node
also
stomach
intestin
salivari
gland
liver
liver
periport
infiltr
show
numer
plasmacel
antidna
ab
liverenzym
abnorm
detect
treat
group
ex
vivo
splenocyt
diseas
anim
show
strikingli
strong
spontan
prolifer
mlr
reactiv
toward
hostor
donortyp
antigen
equal
toler
nontreat
chimera
conclus
mihcdispar
context
earli
nontcd
bmt
induc
vigor
acut
gvhd
consist
activ
alloreact
cell
bm
inoculum
contrast
blockad
day
onward
give
rise
break
transplant
toler
howev
induc
lymphoprolif
syndrom
autoimmun
manifestationsour
data
suggest
nontcd
allo
mihcdispar
bmt
donorhost
toler
reli
clonal
delet
insensit
ab
contrast
toler
self
maintain
peripher
toler
mechan
signal
appear
play
major
rolew
current
investig
blockad
elicit
antileukem
reactiv
balanc
autoimmun
antitumor
immun
modul
kamachi
nakamura
hama
k
kudo
yoshimi
n
watanab
tsuge
kojima
pediatr
nagoya
univers
graduat
school
medicin
nagoya
aichi
japan
pediatr
fujita
health
univers
toyoak
aichi
japan
whim
syndrom
rare
primari
immunodefici
diseas
character
wart
hypogammaglobulinemia
infect
myelokathexi
report
patient
whim
syndrom
treat
allogen
bone
marrow
transplant
bmt
perform
nonmyeloabl
bmt
femal
patient
nonsens
mutat
chemokin
receptor
identifi
caus
gene
whim
syndrom
healthi
hlamatch
sister
mutat
gene
patient
experienc
recurr
middl
ear
sinopulmonari
urinari
tract
infect
sinc
year
age
recogn
leukopen
white
blood
cell
count
l
neutropen
l
hypogammaglobulinem
dl
admit
local
hospit
year
age
aim
oper
chronic
otiti
media
refer
hospit
investig
leukopenia
examin
bone
marrow
aspir
reveal
mark
granulocyt
hyperplasia
bone
marrow
neutrophil
contain
extrem
pyknot
nuclei
vacuol
cytoplasm
diseas
diagnos
whim
syndrom
treatment
daili
subcutan
inject
recombin
human
gcsf
increas
mildli
blood
neutrophil
decreas
frequenc
febril
episod
four
month
later
therapi
discontinu
develop
splenomegali
myelofibrosi
worn
hear
aid
due
intract
otiti
media
sinc
year
age
deaf
gradual
aggrav
consid
allogen
bmt
year
age
treatment
plan
approv
institut
review
board
nagoya
univers
graduat
school
medicin
written
inform
consent
obtain
patient
parent
sister
condit
regimen
consist
fludarabin
day
tbi
gy
day
incompat
redcel
group
total
kg
erythrocytesdeplet
bone
marrow
mononuclear
cell
infus
patient
sister
januari
gvhd
prophylaxi
consist
tacrolimu
shortterm
methotrex
absolut
granulocyt
count
peripher
blood
day
although
evid
infect
sign
acut
gvhd
mild
eczemat
lesion
observ
bodi
day
diagnosi
chronic
gvhd
confirm
skin
biopsi
skin
lesion
improv
day
continu
oral
administr
tacrolimu
donor
cell
peripher
blood
determin
microsatellit
type
day
thirti
six
month
bmt
well
normal
blood
cell
count
need
therapi
allogen
bmt
potenti
cure
primari
immunodefici
diseas
affect
marrowderiv
cell
consid
nonmyeloabl
bmt
treatment
choic
patient
whim
syndrom
hlamatch
sibl
donor
human
leukocyt
respond
vigor
encount
murin
cell
one
outcom
respons
develop
xenogen
gvhd
human
pbmnc
use
reconstitut
immunodefici
recipi
mice
hypothes
prevent
xenogen
gvhd
would
permit
long
term
reconstitut
immunodefici
mice
function
human
cell
two
propos
approach
prevent
xenogen
gvhd
deplet
xenoreact
cell
prior
inject
pbmnc
recipi
mice
gener
recipi
mice
lack
antigen
stimul
xenogen
gvhd
respons
human
leukocyt
character
human
antimurin
respons
abil
unfraction
human
pbmnc
prolifer
respons
murin
stimul
cell
lack
express
murin
class
ii
test
absenc
antigen
express
murin
stimul
cell
interfer
prolif
respons
human
pbmnc
stimul
cell
find
suggest
number
human
leukocyt
subpopul
abl
prolifer
respons
antigen
antigen
xenogen
murin
cell
character
respons
cell
surfac
marker
express
activ
human
leukocyt
incub
murin
stimul
cell
analyz
result
indic
activ
popul
cell
includ
b
nk
nkt
cell
deplet
activ
cell
result
inhibit
prolif
respons
origin
stimul
cell
upon
restimul
cell
remain
deplet
howev
deplet
cell
still
abl
prolifer
xenogen
stimul
cell
mous
strain
allogen
pbmnc
addit
studi
character
antigen
respons
induc
respond
lymphoid
popul
test
administr
deplet
popul
prevent
develop
xenogen
gvhd
dysfunct
normal
pregnanc
predomin
type
cytokin
prevail
consid
protect
foetu
increas
type
cytokin
may
deleteri
effect
studi
want
evalu
possibl
role
certain
cytokin
develop
iugr
analyz
gene
express
gene
polymorph
protein
level
cytokin
iugr
noniugr
pregnanc
pakistani
popul
iugr
common
materi
method
iugr
control
motherinf
pair
studi
mrna
express
level
tnfa
tgfh
infg
matern
decidua
foetal
trophoblast
side
placenta
quantifi
rtpcr
cytokin
cytokin
receptor
gene
polymorph
determin
genom
dna
combin
pcr
restrict
enzym
cleavag
serum
level
tnfa
tgfh
quantifi
matern
umbil
cord
blood
elisa
luminex
result
signific
decreas
p
b
p
b
increas
tgfh
p
b
decidua
similarli
decreas
p
b
increas
tgfh
p
b
trophoblast
iugr
placenta
compar
noniugr
placenta
found
significantli
lower
level
serum
mother
iugr
infant
p
b
tgfh
serum
infant
iugr
p
b
compar
noniugr
infant
conclus
note
mrna
express
decidua
downregul
tgfh
mrna
upregul
iugr
placenta
mother
popul
multipl
risk
factor
iugr
propos
low
placenta
may
involv
pathogenesi
iugr
might
possibl
treatabl
background
infertil
affect
coupl
desir
children
immunolog
factor
propos
involv
mani
otherwis
unexplain
case
infertil
due
import
antisperm
antibodi
diagnosi
immunoinfertil
main
aim
studi
setup
igg
mar
determin
preval
asa
zanjan
provinceiran
method
introduct
endometri
growth
seem
depend
uterin
arteri
blood
flow
import
endometri
develop
pregnanc
outcom
previous
report
nk
cytotox
report
predict
subsequ
pregnanc
loss
women
recurr
spontan
abort
rsa
sildenafil
citrat
viagra
type
phosphodiesteras
inhibitor
augment
vasodilatori
effect
prevent
degrad
cgmp
vagin
sildenafil
improv
uterin
arteri
blood
flow
sonograph
endometri
thick
patient
prior
fail
assist
reproduct
cycl
due
poor
endometri
respons
improv
uterin
blood
flow
prolif
phase
may
detriment
effect
level
endometrium
implant
window
nomedi
releas
cytokin
tumour
necrosi
factorfrom
activ
natur
killer
cell
implic
caus
implant
failur
therefor
purpos
studi
establish
effect
sildenafil
nk
cell
activ
women
histori
rsa
includ
women
multipl
invitro
fertil
failur
materi
method
fifteen
nonpregn
women
histori
rsa
ten
normal
healthi
women
previou
success
pregnanc
outcom
studi
measur
uterin
arteri
blood
flow
pulsatil
index
pi
record
use
doppler
ultrasound
intravagin
probe
studi
women
natur
killer
cell
activ
measur
use
flow
cytometri
follow
peripher
blood
nk
cellst
surfac
antigen
also
studi
use
flow
cytometri
nk
cell
activ
sildenafil
therapi
rsa
women
studi
addit
influenc
ng
sildenafil
nk
cell
activ
vitro
cultur
perform
result
determin
posit
correl
increas
natur
killer
cell
activ
pi
women
histori
rsa
compar
normal
healthi
women
r
n
p
b
preliminari
data
suggest
sildenafil
signific
influenc
nk
cell
activ
conclus
data
suggest
increas
natur
killer
cell
activ
associ
diminish
uterin
arteri
blood
flow
sildenafil
might
interest
therapeut
option
women
reproduct
failur
howev
studi
need
determin
role
therapi
human
reproduct
work
support
grant
nr
object
high
level
serum
ige
hallmark
immun
respons
allerg
patient
epidemiolog
studi
indic
prenat
environ
play
import
decis
role
develop
allergi
later
life
test
whether
impact
matern
atopi
could
transmit
maternalfet
interfac
experi
conduct
method
anim
model
develop
administr
allergen
mate
studi
impact
matern
allergi
develop
allerg
immun
respons
earli
life
healthi
pregnant
women
approv
placenta
collect
medic
investig
invit
give
birth
univers
hospit
twentyf
pregnant
women
demonstr
atop
base
clinic
symptom
atop
diseas
togeth
posit
phadiatop
andor
skin
prick
test
gave
birth
hospit
placenta
collect
mous
human
group
kept
prepar
slide
carri
slide
doublestain
analysi
immunohistochemistri
detect
macrophag
murin
human
placenta
monoclon
antibodi
ab
employ
immunohistochem
procedur
result
placent
macrophag
show
intens
posit
reaction
antiig
monoclon
antibodi
surprisingli
remark
differ
healthi
mous
atop
model
mous
well
human
counterpart
distribut
pattern
ige
placenta
conclus
ige
distribut
macrophag
murin
human
term
placenta
atop
mother
could
patholog
impos
babi
high
level
serum
ige
pregnanc
women
unit
state
suffer
recurr
miscarriag
concept
fail
recent
identifi
novel
role
complement
activ
antiphospholipid
antibodyinduc
pregnanc
loss
j
clin
invest
test
hypothesi
complement
activ
necessari
intermedi
pathogenesi
recurr
spontan
miscarriag
femal
cbaj
mice
wellstudi
model
immunologicallymedi
periimplant
pregnanc
loss
share
mani
featur
human
recurr
miscarriag
embryo
mate
cbaj
femal
male
show
increas
rate
resorpt
compar
rate
observ
control
group
cbaj
balbc
p
b
histolog
studi
show
extens
deposit
inflammatori
infiltr
fetal
debri
decidua
earli
day
gestat
contrast
evid
complement
decidua
cbaj
balbc
provid
direct
evid
complement
fact
critic
mediat
model
spontan
pregnanc
loss
attempt
rescu
fetus
cbaj
mice
complement
inhibitor
block
activ
altern
classic
pathway
treat
mice
recombin
convertas
inhibitor
crryig
mg
ip
day
crryig
complet
rescu
pregnanc
cbaj
mice
crryig
vs
untreat
f
resorpt
vs
f
p
b
inadequ
express
complement
regulatori
protein
possibl
caus
increas
complement
deposit
embryon
death
western
blot
embryo
decidua
show
defici
examin
import
complement
activ
level
treat
cbaj
pregnant
mice
mab
administr
mab
mg
ip
day
prevent
pregnanc
loss
f
resorpt
p
b
distinguish
role
receptor
mac
seed
treat
pregnant
mice
highli
specif
peptid
antagonist
receptor
acph
lornithineprodcyclohexylalaninetrparg
ag
ip
day
significantli
improv
pregnanc
outcom
f
fetal
resorpt
p
b
suggest
interact
play
critic
role
fetal
loss
given
import
altern
pathway
ischem
antibodytrig
injuri
consid
role
factor
b
model
treatment
pregnant
cbaj
mice
block
antifb
mab
improv
outcom
control
f
fetal
resorpt
p
b
result
show
complement
activ
play
essenti
caus
role
damag
fetalplacent
unit
factor
b
requir
miscarrriag
studi
identifi
key
innat
immun
effector
mediat
poor
pregnanc
outcom
provid
novel
import
target
prevent
recurr
pregnanc
loss
patient
fetu
although
semiallogen
usual
accept
matern
immun
system
howev
complic
includ
allorespons
mechan
thought
potenti
detriment
success
pregnanc
therefor
use
mix
lymphocyt
cultur
mlc
reaction
compar
allogen
tcell
respons
nonpregn
women
n
respons
healthi
pregnant
n
pregnant
women
affect
differ
gestationassoci
diseas
prolong
preterm
ruptur
fetal
membran
pprom
n
uncontrol
preterm
labor
pl
n
preeclampsia
n
intrauterin
growth
retard
iugr
n
peripher
blood
mononuclear
cell
pbmc
three
group
stimul
pbmc
unrel
volunt
pregnant
women
significantli
reduc
stimul
indic
si
median
valu
rang
compar
nonpregn
women
median
valu
rang
expos
pbmc
pregnant
women
pbmc
fetu
led
signific
decreas
si
median
valu
rang
among
two
group
pregnant
individu
si
women
prolong
preterm
ruptur
fetal
membran
pprom
significantli
higher
median
valu
rang
comparison
women
uncontrol
pl
median
valu
rang
women
preeclampsia
median
valu
rang
women
iugr
median
valu
rang
women
normal
term
deliveri
median
valu
rang
matern
pbmc
stimul
pbmc
fetu
phenomenon
could
observ
stimul
pbmc
unrel
volunt
addit
increas
humor
immun
respons
assess
women
pprom
women
antihlaantibodi
posit
comparison
women
uncontrol
pl
women
antihlaantibodi
posit
result
reveal
strongli
reduc
allogen
cell
respons
pbmc
pregnant
women
downregul
pbmc
fetu
use
stimul
find
could
observ
pregnant
women
suffer
differ
gestationassoci
diseas
except
women
pprom
exhibit
compar
high
allorespons
impli
increas
antifet
reaction
condit
object
signal
transduc
activ
transcript
involv
invas
carcinoma
cell
earlier
studi
found
invas
correl
bind
activ
trophoblast
choriocarcinoma
cell
aim
investig
verifi
role
observ
rna
interfer
induc
knock
method
use
short
interfer
rna
sirna
knock
choriocarcinoma
cell
line
oligonucleotid
design
interfer
exclus
mrna
control
scrambl
oligonucleotid
design
interfer
known
human
protein
success
knock
analyz
polyacrylamid
gel
electrophoresi
western
blot
matrigel
use
vitro
invas
assay
invas
cell
measur
count
cell
filter
beyond
matrigel
well
medium
beyond
filter
result
appli
concentr
sirna
oligonucleotid
invas
choriocarcinoma
cell
reduc
invas
nontransfect
cell
increas
stimul
leukemia
inhibitori
factor
lif
cell
effect
complet
block
significantli
reduc
lif
invas
conclus
play
key
role
invas
choriocarcinoma
cell
slight
remain
invas
capac
knock
cell
may
due
complet
elimin
invas
trigger
pathway
introduct
one
import
problem
detect
antisperm
antibodi
asa
design
internatin
correct
method
least
fals
answer
seem
enzymelink
immunosorb
assay
elisa
sensit
specif
diagnost
valu
detect
asa
use
sperm
surfac
antigen
without
contamin
sperm
insid
antigen
nonsperm
antigen
coat
antigen
elisa
techniqu
way
techniqu
use
differ
specif
deterg
recommend
studi
focus
differ
method
sperm
surfac
antigen
extract
determin
better
method
antigen
extract
elisa
techniqu
materi
method
extract
sperm
surfac
antigen
four
differ
method
sonic
method
use
nacl
salt
sd
deterg
use
li
deterg
sperm
prior
treat
biotin
evalu
four
extract
method
blot
elisa
techniqu
assess
better
expos
surfac
antigen
result
conclus
result
demonstr
extract
method
li
deterg
expos
sperm
surfac
antigen
better
three
method
conclud
method
superior
use
elisa
techniqu
chang
lymphocyt
cd
marker
patient
expos
mustard
ga
introduct
immunodepress
effect
mustard
ga
detect
previou
studiesth
present
studi
perform
iranian
chemic
casual
year
exposur
mustard
ga
determin
chang
absolut
lymphocyt
count
cell
cd
marker
compar
normal
control
group
method
cbc
absolut
lymphocyt
count
determind
h
automat
systemt
cell
cd
marker
analyz
flow
cytometr
methodus
conjug
monoclon
antibodi
result
absolut
lymphocyt
count
increas
lymphocyt
marker
decreas
significantli
p
b
compar
normal
control
group
decreas
marker
report
investig
previous
conclus
increas
susept
respiratori
infect
patient
could
due
decreas
lymphocyt
subsetsincreas
absolut
lymphocyt
count
could
due
lymphoprolif
chang
b
nk
lymphocyt
lineag
requir
anoth
investig
display
phage
gener
enhanc
function
affin
partner
studi
ligandreceptor
signal
monocyt
cell
line
cellular
morpholog
chang
incub
multival
phage
observ
sinc
h
cultiv
cell
propag
ceas
h
phenomenon
presum
relat
anchor
multival
phage
surfac
molecul
proven
either
elisa
immunocytochemistri
interestingli
apoptot
nucleu
found
coordin
phage
cytotox
activ
phage
analyz
doubl
stain
contrast
wildtyp
phage
dualcolour
fluoresc
induc
recombin
phage
associ
apoptot
characterist
indic
level
cleav
incub
multival
phage
high
stimul
cisplatin
determin
flow
cytometri
nevertheless
signal
appar
stronger
uninduc
quantifi
immunocytochemistri
multival
apoptot
nucleu
harbor
substanti
amount
cleav
wherea
result
cisplatininduc
accordingli
caspas
depend
pathway
suppos
partial
involv
cell
death
program
novel
function
trigger
apoptosi
impli
exist
counterreceptor
membran
pollut
day
termend
threat
univers
progress
differ
scientif
field
help
one
side
world
technologist
hand
caus
great
danger
effect
human
plant
heavi
metal
pollut
hanaeklau
aquat
system
becom
seriou
threat
today
heavi
metal
wide
spread
pollut
great
environment
concern
non
degrad
thu
persist
truebyp
mani
bacteria
facult
anaerob
nitrogenfix
facult
bacteria
gener
capabl
fix
nitrogen
grow
anaerob
environ
exampl
bacteria
includ
enterobacteriacea
enterobact
speci
camb
univ
press
chemic
treatment
water
resourc
expens
endeavour
microbi
biomass
emerg
option
develop
econom
ecofriendli
wast
water
treatment
process
presenc
heavi
metal
damag
microbi
lifeth
present
studi
carri
check
toxic
cd
cadmium
metal
bean
plant
physiolog
process
relat
nitrifi
bacteria
soil
root
shoot
plant
methodolog
plant
analys
day
germin
content
chlorophyl
b
carbohyder
protein
amino
acid
determiend
stander
method
miner
ion
analys
flame
photometri
atom
absorpt
techniqeth
toxic
differ
concentr
cd
metal
nitrifi
bacteria
determin
spc
standard
plate
count
method
cd
found
highli
toxic
seedl
well
microbi
life
present
rhizopspher
bean
plant
concentr
usedmorpholog
plant
effect
colour
plant
turn
yellow
growth
plant
inhibit
length
root
shoot
found
decreas
cmpare
control
plantsreduct
proces
photosynthesi
observ
yellow
colour
leav
appear
instead
green
colour
declin
chlorophyl
b
content
nutrit
valu
plant
decreas
increas
concentr
cd
metal
may
due
absenc
nitrifi
bacteria
normal
found
symbiot
associ
plant
fix
atmospher
nitrogen
root
legumin
plant
dakora
donald
presenc
cd
metal
nodul
format
inhibit
result
decreas
protien
content
absenc
amino
acid
high
concentr
cd
potassium
sodium
investig
low
percentag
show
accumal
cd
higher
root
compar
miner
ion
due
plant
abl
stand
errect
positioniron
magnesium
magnes
respons
metabol
activ
transpir
transloc
also
effect
percentag
also
found
decreas
higher
concentr
cd
introduct
mannanbind
lectin
mbl
pathway
innat
immun
import
host
defens
pathogen
major
surgic
trauma
known
influenc
variou
immun
function
present
studi
investig
effect
major
surgeri
two
central
compon
mbl
pathway
mbl
associ
proteas
compar
effect
crp
level
method
sixti
patient
random
open
laparoscop
colectomi
benign
malign
diseas
serum
level
mbl
crp
determin
preoper
hour
follow
incis
postop
day
result
four
paramet
show
slight
decreas
serum
level
within
first
two
hour
incis
mbl
minor
signific
p
p
respect
peak
found
postop
day
compar
preoper
level
signific
increas
found
hour
incis
p
level
significantli
lower
day
p
crp
signific
increas
seen
postop
day
p
wherea
level
day
statist
differ
preoper
level
p
level
crp
significantli
correl
r
p
b
wherea
signific
correl
detect
paramet
signific
differ
respons
two
surgic
techniqu
reveal
conclus
contrast
mark
effect
level
crp
major
surgeri
margin
influenc
mbl
pathway
differ
respons
two
differ
surgic
techniqu
object
studi
theori
hemaimmun
reaction
method
cancer
cell
yeast
cell
ns
ad
human
fresh
anticoagul
whole
blood
blood
cell
plasma
treat
citric
acid
incub
minut
main
outcom
index
adher
rate
darc
et
al
result
found
cancer
cell
dead
cell
yeast
cell
activ
war
hemaimmun
reaction
hir
time
war
cancer
cell
yeast
cell
level
index
adher
rate
significantli
higher
time
peac
ns
control
group
time
war
cancer
cell
yeast
cell
level
hir
white
blood
cell
group
plasma
ad
significantli
higher
white
blood
cell
group
without
plasma
level
hir
white
cell
group
red
blood
cell
ad
significantli
higher
white
blood
cell
group
without
red
blood
cell
ad
conclus
human
hemaimmun
reaction
look
like
modern
war
bodi
result
suggest
complement
red
blood
cell
play
vital
role
blood
immun
reaction
road
map
hemaimmun
reaction
antigen
cancer
cell
yeast
cell
activ
complement
plasma
antigen
opson
complement
mainli
adher
red
blood
cell
adher
white
blood
cell
activ
hemaimmun
reaction
system
see
figur
l
furthermor
provid
use
inform
studi
innat
adapt
immun
establish
experiment
war
type
system
hemaimmun
reaction
road
map
novel
apc
imprint
uniqu
pattern
nk
receptor
gut
mucos
cell
identifi
novel
antigen
present
cell
popul
intestin
lamina
propria
constitut
express
costimulatori
molecul
show
stimul
via
apc
induc
uniqu
pattern
nk
receptor
mucos
cell
resid
cell
gut
mucosa
narv
mice
exhibit
activ
phenotyp
express
ig
famili
nk
receptor
express
lectinlik
heterodimer
receptor
contrast
activ
cell
periton
exud
lymphocyt
spleen
follow
vaccinia
listeria
infect
express
express
similar
differ
nkr
express
also
found
antigenspecif
cell
gener
differ
site
infect
nkr
express
profil
gut
mucosa
depend
stimul
via
apc
sinc
express
could
dramat
reduc
administr
block
antibodi
antibodi
treatment
howev
effect
nkr
express
activ
cell
peripher
site
apc
occur
howev
mice
intraperiton
immun
express
allogen
cell
induc
cell
accumul
periton
caviti
thu
costimul
via
apc
imprint
uniqu
nk
receptor
mucos
cell
demonstr
applic
bayesian
network
comput
elucid
causal
intermolecular
influenc
signal
network
use
simultan
multivari
measur
phosphoryl
protein
phospholipid
popul
singl
human
primari
cell
select
perturb
activ
inhibit
import
infer
direct
influenc
signal
compon
identifi
classic
report
signal
relationship
predict
novel
influenc
connect
includ
interpathway
crosstalk
kinas
kinas
akt
confirm
experiment
result
manifest
feasibl
datadriven
construct
causal
signal
network
model
primari
cell
data
singl
cell
level
may
util
understand
patient
specif
signal
alter
diseas
state
immunophenotyp
peripher
blood
mononuclear
cell
pbmc
limit
valu
assess
clinic
state
inform
altern
immunophenotyp
may
combin
function
assay
correl
clinic
statu
function
assay
howev
tediou
requir
prolong
cultur
period
one
simpl
highli
inform
rapid
approach
examin
cell
signal
within
individu
cell
follow
brief
stimul
abnorm
within
signal
pathway
specif
cell
type
could
provid
import
insight
concern
patholog
condit
studi
focus
jakstat
pathway
central
host
defens
cell
growth
apoptosi
dysfunct
pathway
observ
within
cancer
cell
variou
type
develop
condit
allow
dual
label
cell
surfac
marker
intracellular
phosphoryl
stat
member
within
individu
normal
pbmc
undergon
rapid
cytokin
stimul
vitro
pbmc
first
incub
primari
antibodi
cell
surfac
cytokin
ifng
treatment
appli
induc
stat
phosphoryl
cell
immedi
fix
pfa
permeabl
cocktail
saponin
methanol
ethanol
isopropanol
aceton
vari
concentr
cell
label
primari
antibodi
sever
pstat
protein
analysi
efficaci
extracellular
intracellular
label
complet
use
bd
facsarray
flow
cytomet
reagent
test
appear
tradeoff
intracellular
extracellular
label
cell
methanol
previous
use
lab
lab
other
give
good
signal
phosphostat
allow
identif
mani
cell
surfac
molecul
permeabil
method
saponin
lower
alcohol
concentr
allow
better
cell
surfac
label
simultan
caus
decreas
pstat
signal
reagent
test
methanol
allow
best
dual
label
intracellular
extracellular
protein
method
permit
rapid
analysi
complex
cell
popul
includ
pbmc
interrog
signal
pathway
individu
cell
type
allow
profound
evalu
gain
addit
insight
abnorm
caus
aris
presenc
immun
dysfunct
dendrit
cell
dc
key
regul
innat
acquir
immun
dc
matur
critic
event
dc
life
cycl
confer
capac
simul
cell
prolifer
polar
dc
may
matur
toll
receptor
ligand
like
lp
well
cell
depend
mechan
via
ligandmedi
activ
previous
demonstr
cigarett
smoke
extract
cse
inhibit
sever
matur
event
induc
lipopolysaccharid
lp
includ
upregul
costimulatori
molecul
product
key
polar
cytokin
current
studi
hypothes
cse
also
impair
dc
matur
mediat
cell
depend
pathway
stimul
cse
gener
bubbl
smoke
one
cigarett
univers
kentucki
ml
pb
immatur
dc
gener
human
monocyt
cultur
gmcsf
final
hour
cultur
dc
incub
cse
concentr
diminish
cellular
viabil
measur
annexin
v
propridium
iodid
stain
final
hour
dc
matur
interferongamma
express
costimulatori
molecul
determin
flow
cytometri
concentr
determin
elisa
pge
level
also
analyz
elisa
csecondit
dc
matur
express
lower
level
compar
control
dc
addit
product
matur
dc
inhibit
dosedepend
fashion
cse
condit
csecondit
dc
produc
pge
control
suggest
mechan
cse
alter
dc
matur
data
illustr
cse
alter
dc
matur
induc
lp
inhibit
product
cse
illustr
import
mechan
smoke
inhibit
essenti
adapt
immun
respons
relev
pathogenesi
cancer
certain
infect
tanveer
khanum
nadia
noor
nasra
jalil
sadaf
hedayat
microbiolog
jinnah
univers
women
karachi
sindh
pakistan
microbiolog
jinnah
univers
women
karachi
sindh
pakistan
bacteriocin
low
molecular
weight
singl
polypeptid
polypeptid
complex
antibacteri
activ
synthes
ribosom
secret
bacteri
cell
bthe
group
heterogen
substanc
rang
low
molecular
weight
compound
high
molecular
particl
resembl
bacteriophag
protein
compon
rasool
khan
q
bradli
classifi
bacteriocin
two
broad
type
group
low
molecular
weight
trypsin
sensit
thermost
bateriocin
b
group
high
molecular
weight
trypsin
resist
thermost
beteriocin
microorgan
yogurt
subsequ
creation
organ
acid
bioactiv
protein
inhibit
growth
growth
mani
pathogen
microorgan
methodolog
differ
yogurt
sampl
use
isol
bacteri
strain
make
dilut
yougurt
sampl
dilut
sampl
spread
nutrient
agar
incub
isol
coloni
identifi
use
differ
convent
method
ten
refer
strain
use
check
bacteriocinogen
activ
isol
includ
e
coli
staphaureu
klebsiella
salmonella
enterococcu
micrococcu
bacillu
staph
epidermidi
pseudomona
bacteriocin
product
detect
againt
refer
strain
use
agar
well
cross
streak
method
titr
bacteriocin
produc
quantifi
two
fold
serial
dilut
bacteriocin
result
disscuss
averag
coloni
form
unit
per
ml
calcul
cfuml
bacteria
isol
identifi
use
differ
convent
method
bacteriocin
lactobacilli
activ
shigella
bacillu
micrococcu
bacteriocin
bacillu
activ
aureu
st
epidermidi
enterococcu
e
coli
bacteriocin
pseudomonu
activ
shigella
aureu
st
epidermidi
entercoccu
micrococcu
bacillu
typhi
arbitrari
unit
bacteriocin
lactobacilli
shigella
aureu
st
epidermidi
entercoccu
bacillu
arbitrari
unit
bacteriocin
pseudomona
shigella
aureu
st
epidermidi
arbitrari
unit
bacteriocin
bacillu
found
found
yougurt
contain
high
number
bacteria
includ
gram
neg
posit
speci
bacteria
bacteriocin
lactobacilli
broad
spectrum
activ
gram
neg
posit
bacteria
best
inhibitori
activ
observ
st
epidermidi
pseudomona
produc
power
bacteriocin
inhibit
growth
major
clinic
isol
bacteriocin
bacillu
lactobacilli
effect
also
observ
bacteria
produc
bacteriocin
line
diffus
remov
growth
also
bacteriocin
activ
best
observ
plate
first
refriger
cross
streak
indic
refriger
temperatur
facilit
diffus
bacteriocin
medium
brussel
belgium
laboraori
physiolog
vrije
universiteit
brussel
brussel
belgium
previous
show
fasl
retrovir
transduc
bone
marrowderiv
dc
increas
allospecif
cytotox
activ
cytokin
product
vivo
thank
fasl
depend
neutrophil
recruit
aim
studi
test
express
fasl
dc
promot
stronger
cytotox
activ
better
antitumor
immun
compar
dc
express
control
ag
use
tymoma
isol
mice
transfect
cdna
encod
ovalbumin
predomin
ag
express
tumor
first
evalu
therapeut
approach
consist
subcutan
inject
tumor
cell
fasl
controldc
mice
studi
consequ
treatment
tumor
growth
realis
histolog
analysi
tumor
site
measur
antitumor
cell
respons
observ
coinject
fasldc
cell
inhibit
tumor
growth
histolog
tumor
site
harvest
mice
coinject
controldc
cell
show
moder
inflammatori
infiltr
compos
essenti
mononuclear
cell
contrast
tumor
site
come
mice
coinject
fasldc
cell
reveal
massiv
destruct
tumor
associ
apoptosi
neutrophil
recruit
demonstr
vivo
apoptosi
could
explain
tumoricid
activ
fasldc
sinc
observ
tumor
cell
lyse
fasldc
vitro
demonstr
neutrophil
contribut
tumor
erad
fasldc
coinject
mice
monoclon
antibodi
treatment
restor
tumor
growth
final
mice
coinocul
fasldc
tumor
cell
display
higher
cytokin
product
protect
tumor
challeng
inde
observ
antitumor
protect
respons
mediat
ovaspecif
cell
evalu
role
neutrophil
recruit
fasldc
induct
ovaspecif
cell
respons
tumor
vaccin
target
tcell
capabl
differenti
activ
effector
cell
mediat
tumordestruct
memori
cell
crucial
longterm
tumorimmun
surveil
heterodim
repres
predomin
form
peripher
blood
circul
although
tcell
express
homodimer
recent
data
suggest
cell
may
repres
biolog
import
subset
memori
tcell
test
longitudin
sampl
peripher
blood
mononuclear
cell
pbmc
patient
melanoma
vaccin
differenti
antigen
presenc
express
tcell
ii
tcell
differenti
home
marker
iii
antigenspecif
tcell
use
aagigiltv
natur
process
peptid
elagigiltv
superagonist
peptid
load
tetram
reactiv
tcell
present
express
tcell
although
cell
show
differ
composit
base
express
examin
tetram
specif
tcell
two
subset
show
termin
differenti
phenotyp
maintain
time
data
suggest
cell
repres
memori
tcell
pool
contribut
longliv
immun
protect
could
consolid
hypothesi
use
transfect
recipi
surrog
cell
express
either
specif
tcr
transgen
tcr
interact
complex
show
differ
requir
cell
compar
cell
vitro
cultur
pbl
vaccin
patient
melanoma
use
differ
cytokin
peptid
stimul
show
lead
differenti
expans
specif
tcell
popul
respect
repres
first
ex
vivo
report
antitumor
direct
tcell
patient
melanoma
undergo
peptid
vaccin
asses
memori
tcell
popul
relev
immunomonitor
patient
tumor
aid
design
improv
tumor
vaccin
capabl
stimul
longliv
cellular
immun
respons
immun
laurenc
hoareau
mariepaul
gonthier
regi
roch
franck
festi
christian
lefebvr
hellencourt
maya
cesari
jeanpierr
rivier
marieamede
dijoux
sandrin
beshoutmann
univers
reunion
lbgm
saint
deni
reunion
franc
laboratoir
dtanapathologi
chd
felix
guyon
saint
deni
reunion
franc
introduct
addit
well
know
role
adipocyt
energi
homeostasi
recent
studi
suggest
cell
also
involv
immun
investig
immun
capac
adipocyt
studi
express
toll
like
receptor
tlr
import
player
innat
immun
addit
function
test
use
one
tlr
ligand
adipocyt
cultur
method
human
subcutan
primari
preadipocyt
matur
adipocyt
use
cellular
model
presenc
differ
tlr
determin
rna
level
revers
transcriptas
polymeras
chain
reaction
rtpcr
protein
level
western
blot
immunocytochemistri
furthermor
cell
stimul
lipopolysaccharid
lp
cytokin
gene
express
quantifi
differ
time
real
time
pcr
order
assess
adipocyt
respons
one
tlr
ligand
result
demonstr
human
subcutan
adipos
cell
tissu
express
tlr
mrna
result
confirm
presenc
correspond
protein
result
observ
matur
adipocyt
tissu
stimul
lp
increas
mrna
level
interleukin
observ
cultur
conclus
result
show
first
time
presenc
adipocyt
tlr
two
import
receptor
involv
innat
immun
receptor
present
preadipocyt
also
matur
adipocyt
adipos
tissu
furthermor
demonstr
receptor
adipocyt
abl
signal
immun
respons
cytokin
product
result
suggest
adipos
cell
could
respond
bacteri
infect
via
interact
bacteri
compon
tlr
particip
innat
immun
final
better
understand
mechan
adipocyt
respons
infect
analysi
tlr
signal
pathway
subcutan
adipocyt
progress
transduct
tcell
fulop
larbi
khalil
n
douziech
c
fortin
g
dupui
research
center
age
universit
de
sherbrook
sherbrook
qc
canada
deapart
biochemistri
universit
de
sherbrook
sherbrook
qc
canada
hdlmediat
revers
cholesterol
transport
rct
serv
regul
plasma
cholesterol
level
well
cholesterol
exchang
circul
cell
previous
shown
membran
cholesterol
increas
tcell
elderli
donor
accompani
defect
cellular
activ
lead
immun
senesc
rct
wellknown
case
atherosclerosi
role
tcell
cholesterol
metabol
well
tcell
signal
still
unknown
rct
lipid
raftsdepend
mechan
involv
fast
slow
pool
membran
cholesterol
studi
sought
determin
role
hdl
cholesterol
metabol
tcell
separ
tcell
young
year
elderli
year
healthi
senieur
subject
studi
cholesterol
uptak
tritiat
cholesterol
extrus
hdldriven
revers
cholesterol
transport
cholesterol
uptak
decreas
tcell
elderli
fast
cholesterol
pool
extract
lipid
raft
microdomain
separ
lipid
raft
elderli
donor
still
contain
high
amount
cholesterol
incub
tcell
hdl
induc
signalis
involv
min
corrobor
fast
pool
cholesterol
lipid
raft
long
last
activ
erk
observ
corrobor
slow
pool
cholesterol
nonraft
case
elderli
donor
activ
pathway
differenti
alter
data
first
show
hdlmediat
rct
impair
age
explain
chang
lipid
raft
properti
moreov
suggest
recent
lipid
raft
play
import
role
cholesterol
exchang
mediat
hdl
thu
lipid
raft
may
autoregul
cholesterol
content
chang
lipid
raft
properti
age
may
explain
defect
tcell
activ
evita
niedrit
ingmar
mikazan
guna
feldman
arija
volrat
dept
dermatovenereolog
riga
stradint
univers
riga
latvia
institut
microbiolog
virolog
riga
latvia
introduct
viral
infect
herp
captur
grow
attent
last
decad
shall
explain
everincreas
herp
virus
throughout
world
frequent
relaps
unsatisfactori
result
usual
prescrib
therapi
herp
simplex
virus
variou
research
deal
immunolog
herp
viru
attempt
accur
defin
impact
immun
regul
factor
therapi
herp
simplex
infect
excess
suggest
immun
model
remedi
directli
indirectli
affect
respons
immun
compet
cell
aim
research
evalu
effici
safeti
larifan
rectal
suppositori
treatment
frequent
relaps
infect
simpl
herp
well
detect
concentr
circul
interferon
therapi
method
research
compromis
analysi
varieti
larifansuppositori
gener
local
antivir
medicin
synthes
latvia
larifan
medicin
natur
origin
doubli
spiral
ribonuclein
acid
form
escherichia
coli
cell
infect
bacteriofag
larifan
wide
scope
antivir
medicin
vitro
prove
capabl
slow
reproduct
encephalomyel
venezuela
hors
virus
reduc
output
virus
time
anim
involv
experi
prove
prevent
therapeut
affect
case
tick
enceph
mice
encephalomyocard
rabi
influenza
viral
infect
total
number
patient
involv
research
frequent
relaps
simpl
herp
time
per
year
n
genit
herp
n
labial
herp
involv
patient
rang
year
age
rectal
suppositori
consist
mg
activ
substanc
sleep
st
nd
th
th
th
day
patient
cours
week
without
treatment
circul
interferon
detect
sera
patient
therapi
th
day
st
cours
circul
interferon
detect
biolog
standart
micromethod
result
patient
end
therapi
complet
discontinu
therapi
variou
reason
none
discontinu
therapi
side
effect
larifan
n
patient
relaps
therapi
n
patient
relaps
n
relaps
n
relaps
n
relaps
increas
circul
interferon
detect
n
patient
n
patient
remain
low
conclus
result
prove
suppositori
varieti
larifan
combin
local
system
immun
model
properti
larifan
would
effici
medicin
treat
frequent
recur
herp
infect
aggrav
evalu
signific
larifan
suppositori
treatment
frequent
recur
herp
infect
long
term
research
need
carri
apffel
adler
sana
j
garcia
r
kincaid
udiavar
molecular
technolog
laboratori
agil
laboratori
palo
alto
ca
usa
field
express
proteom
domin
separ
technolog
two
dimension
gel
electrophoresi
frequent
coupl
mass
spectrometr
identif
method
although
extrem
power
separ
techniqu
suffer
number
drawback
includ
lack
speed
autom
poor
reproduc
quantit
fundament
limit
linear
result
bia
toward
highli
express
protein
altern
approach
base
multidimension
hplc
separ
proteolyt
digest
complex
sampl
emerg
combin
nanoscal
revers
phase
separ
strong
cation
exchang
fraction
although
approach
demonstr
util
complex
result
mixtur
repres
consider
chromatograph
challeng
furthermor
pool
proteolyt
fragment
larg
number
protein
elimin
associ
given
peptid
parent
protein
thu
configur
multipl
post
translat
modif
effort
overcom
limit
exist
techniqu
evalu
use
multidimension
liquid
phase
separ
intact
protein
altern
approach
fraction
first
dimens
collect
refraction
second
orthogon
separ
mechan
collect
fraction
result
total
fraction
per
sampl
st
dimens
mode
coupl
strong
anion
exchang
chromatographi
nd
dimens
base
high
speed
separ
use
macropor
revers
phase
materi
high
temperatur
high
resolut
recoveri
materi
allow
rapid
diffus
larg
molecular
protein
result
revers
phase
cycl
time
minutesfract
combin
chromatograph
mode
larg
orthogon
util
compat
mobil
phase
yield
resolut
sever
hundr
protein
singl
analysi
follow
fraction
intact
protein
collect
fraction
reduc
alkyl
proteolyt
digest
subsequ
analysi
nanoscal
electrospray
lc
ms
base
microfluid
chipm
system
ion
trap
mass
spectrometri
although
fraction
gener
contain
multipl
protein
feasibl
identifi
compon
use
rapid
nanospray
lcmsm
inform
workflow
lcm
ms
time
consum
key
featur
approach
develop
tool
visual
compar
separ
intact
protein
identifi
priorit
fraction
subsequ
analysi
lcmsm
follow
collect
msm
data
pool
spectra
process
compar
protein
librari
data
base
use
spectrummil
softwar
identifi
protein
present
sampl
method
demonstr
analysi
protein
extract
murin
immunodeplet
sera
nod
mice
discuss
made
optim
current
limit
method
well
futur
potenti
oligosaccharid
involv
host
cellcel
process
play
key
role
immun
system
chang
glycosyl
format
aberr
oligosaccharid
accompani
host
diseas
infect
cancer
eg
ovarian
cancer
diabet
cystic
fibrosi
arthriti
autoimmun
respiratori
capac
diseas
present
introduc
new
fulli
autom
integr
analyt
platform
oligosaccharid
profil
consist
chipbas
chromatographi
system
conjunct
timeofflight
mass
spectrometri
microfluid
hplc
chip
made
laser
ablat
lamin
biocompat
polyimid
film
sampl
enrich
separ
nanoelectrospray
tip
fulli
integr
chip
devic
high
resolut
separ
oligosaccharid
achiev
porou
graphit
carbon
pgc
column
materi
pack
chip
devic
oligosaccharid
isom
readili
separ
resolv
specif
oligosaccharid
structur
identifi
accur
mass
measur
highli
reproduc
retent
time
way
differ
oligosaccharid
simultan
identifi
monitor
known
immunostimulatori
effect
unambigu
identifi
new
advanc
chipbas
analyt
platform
also
capabl
analyz
aspect
relat
diseas
like
chang
phosphoryl
pattern
chang
metabolom
level
ischemiareperfus
ir
injuri
consist
acut
inflammatori
respons
involv
complement
activ
upon
recognit
natur
igm
selfantigen
expos
ischemia
studi
dissect
role
lectin
versu
classic
complement
pathway
intestin
ir
model
reconstitut
irspecif
clonal
igm
mannosebind
lectin
mbl
coloc
igm
injur
tissu
mblmice
protect
ir
injuri
ischemia
reperfus
absenc
igm
deposit
contrast
injur
similarli
wt
anim
deposit
mbl
igm
damag
tissu
reperfus
mblmice
show
igm
deposit
intestin
villi
subsequ
proteom
analysi
identifi
specif
selfantigen
bound
igm
preliminari
result
vitro
studi
show
murin
mbl
bind
igm
studi
reveal
ir
pathogenesi
initi
igm
respons
ischem
antigen
follow
direct
activ
downstream
lectin
pathway
complement
chikovani
kvezer
g
burkadz
giorgadz
v
bakhutashvili
microbilog
virolog
immunolog
tbilisi
state
medic
univers
tbilisi
georgia
biomedicin
institut
medic
biotechnolog
tbilisi
georgia
axon
repair
matur
neuron
involv
complex
molecular
chang
critic
role
play
schwann
cell
well
macrophag
inflammatori
cell
one
import
molecul
determin
degenerationregener
process
damag
nerv
nitric
oxid
influenc
mani
aspect
nervou
system
physiolog
either
detriment
benefici
alreadi
reveal
possibl
target
neurofila
myelin
sheath
interrupt
axon
newli
form
neuromuscular
endplat
schwann
cell
distal
nerv
stump
manipul
suppli
may
offer
interest
therapeut
option
peripher
nerv
lesion
recoveri
possibl
regener
transect
sciatic
nerv
axon
influenc
plaferon
lb
plb
inhibit
induc
nitric
oxid
synthas
activ
vitro
investig
experi
conduct
twenti
white
rat
anim
daili
treat
plb
salin
treatment
begun
three
day
transect
ten
anim
treat
plb
other
undergon
cours
salin
treatment
oper
carri
microsurgeon
sciatic
nerv
transect
sew
anim
sacrif
seven
thirti
day
oper
nerv
remov
nitric
oxid
measur
day
morpholog
examin
month
measur
electron
spin
reson
method
use
trap
morpholog
investig
prepar
stain
hematoxylineosin
method
neurohistolog
methodnil
immunocytochem
method
use
monoclon
antibodi
find
suggest
plb
may
play
import
role
regener
injur
peripher
nerv
injur
nerv
intens
increas
product
well
quantiti
shwann
mast
cell
observ
accord
result
plb
prevent
induct
product
axotom
sciatic
nerv
quantit
analysi
show
influenc
plb
increas
shwann
mast
cell
statist
high
reliabl
iga
nephropathi
igan
character
glomerular
codeposit
iga
complement
compon
complement
system
activ
via
three
activ
pathway
classic
pathway
altern
pathway
recent
identifi
lectin
pathway
complement
activ
lead
tissu
deposit
activ
complement
compon
releas
proinflammatori
factor
iga
activ
complement
system
via
altern
pathway
classic
pathway
furthermor
recent
data
indic
involv
lectin
pathway
complement
igan
lp
activ
bind
mannosebind
lectin
mbl
lficolin
hficolin
carbohydr
ligand
follow
activ
mblassoci
serin
proteas
masp
studi
potenti
role
lectin
pathway
igan
interact
mbl
human
iga
possibl
explan
lectin
pathway
activ
igan
renal
biopsi
igan
patient
n
stain
mbl
lficolin
complement
polymer
monomer
serum
iga
igan
patient
n
healthi
control
n
purifi
affin
chromatographi
gel
filtrat
bind
mbl
iga
studi
elisa
igan
case
show
mesangi
deposit
glomerular
deposit
mbl
observ
case
igan
show
mesangi
pattern
mblposit
case
none
mblneg
case
also
show
glomerular
deposit
lficolin
protein
glomerular
deposit
mbl
lficolin
associ
significantli
mesangi
prolifer
interstiti
damag
proteinuria
vitro
studi
demonstr
bind
mbl
iga
healthi
control
igan
patient
strong
interindividu
variat
mbl
bind
observ
polymer
monomer
iga
interact
mbl
iga
dosedepend
could
inhibit
edta
dmannos
lmannos
indic
involv
lectin
domain
mbl
togeth
find
strongli
point
role
lectin
pathway
complement
glomerular
activ
igan
suggest
contribut
mbl
lficolin
progress
diseas
furthermor
find
support
hypothesi
glomerular
mbl
bind
complement
activ
igan
base
interact
mbl
iga
characteris
antibodi
titr
intraven
immunoglobulin
concentr
flebogammar
lopez
j
jorquera
r
area
instituto
grifol
sa
paret
del
vall
barcelona
spain
evalu
igg
antibodi
level
intraven
immunoglobulin
concentr
flebogammar
sever
pathogen
lot
flebogammar
product
igg
concentr
contain
sorbitol
excipi
studi
titr
cytomegaloviru
cmv
hepat
b
measl
varicella
vzv
parvoviru
polioviru
type
ii
iii
rubella
epstein
barr
ebv
herp
simplex
type
influenza
b
parainfluenza
type
adenoviru
mump
coxsacki
echoviru
tetanu
diphtheria
streptococcu
pneumonia
candida
albican
bordetella
pertussi
helicobact
pylori
campylobact
jejuni
chlamydia
borrelia
burgdorferi
toxoplasma
gondii
studi
elisa
test
use
except
antibodi
polioviru
type
ii
iii
diphtheria
measl
perform
neutral
test
result
shown
iuml
elisa
unit
uml
intern
refer
avail
determin
polioviru
measl
diphtheria
cber
lot
us
diphtheria
antitoxin
standard
refer
prepar
use
relev
result
obtain
follow
hepat
b
f
f
iuml
respect
vzv
f
iu
ml
tetanu
f
iuml
parvoviru
f
iuml
cmv
f
iuml
agent
titr
final
product
valu
observ
start
plasma
result
obtain
neutral
antibodi
polioviru
type
ii
iii
measl
f
f
f
f
samplerefer
ratio
respect
diphtheria
f
uml
presenc
neutral
antibodi
demonstr
result
meet
fdat
requir
prepar
regard
antibodi
studi
sinc
intern
refer
avail
quantit
perform
relat
cutoff
posit
limit
elisa
method
use
thu
activ
ebv
f
uml
herp
f
uml
mump
f
uml
helycobact
f
uml
adenoviru
f
uml
rubella
f
uml
st
pneumonia
f
mgl
influenza
etc
cutoff
limit
final
antibodi
also
detect
even
though
lower
extent
candida
f
uml
bordetella
f
uml
campylobact
uml
coxiella
f
uml
coxsacki
f
uml
flebogammar
contain
igg
antibodi
wide
panel
pathogen
normal
plasma
valu
high
number
agent
h
biesca
r
gajardo
vandermeeren
esteban
j
jorquera
research
develop
area
instituto
grifol
barcelona
spain
centro
nacion
de
biotecnologia
csic
campu
universidad
autonoma
madrid
spain
immunocompromis
individu
may
risk
vaccinia
infect
widespread
smallpoximmun
program
need
aim
studi
determin
level
neutral
antibodi
vaccinia
viru
human
intraven
immunoglobulin
ivig
manufactur
instituto
grifol
thirteen
batch
flebogammar
evalu
presenc
antivaccinia
antibodi
vaccinia
plaqu
reduct
neutral
assay
vaccinia
viru
work
stock
western
reservewr
strain
mix
ivig
prepar
incub
inocul
onto
monkey
cell
detect
intern
standard
nibsc
potenc
iuml
use
antibodyposit
control
prepar
sera
nonsmallpox
vaccin
donor
neg
control
prepar
use
linear
correl
rate
viru
neutral
antibodi
concentr
neutral
titer
specif
sampl
express
sampl
dilut
reduc
number
viru
plaqu
determin
triplic
compar
number
seen
viru
posit
control
without
ivig
ad
result
experi
provid
neutral
potenc
rang
antivaccinia
iuml
ivig
antivaccinia
antibodi
product
also
determin
elisa
wb
techniqu
reveal
product
abl
react
sever
vaccinia
viru
protein
relev
differ
among
batch
antivaccinia
titer
result
studi
consist
work
goldsmith
et
al
vox
sang
titer
antivaccinia
antibodi
found
prepar
biolog
relev
sinc
provid
protect
vaccinia
infect
immunocompromis
mice
lopez
costa
j
jorquera
r
area
instituto
grifol
sa
paret
del
vall
barcelona
spain
custom
intraven
immunoglobulin
ivig
therapeut
dose
patientt
need
unifi
content
sever
bottl
singl
contain
frequent
studi
deal
compat
two
ivig
prepar
share
formul
sorbitol
two
type
plastic
contain
nine
lot
two
prepar
manufactur
grifol
flebogammar
licens
clinic
trial
contain
sorbitol
excipi
fill
griflexpolypropylen
pp
gribagpvc
steril
bag
rate
ml
ml
bag
impli
worst
case
condit
refer
productplast
contact
ratio
grifillr
system
ensur
steril
fill
use
product
fill
plastic
contain
store
period
day
temperatur
test
transfer
origin
contain
glass
bottl
plastic
contain
pvc
pp
well
differ
storag
time
point
schedul
follow
paramet
evalu
appear
ph
turbid
osmol
total
protein
biorad
molecular
distribut
hplc
anticomplementari
activ
aca
prekallikrein
activ
pka
antibodi
titrat
tetanu
hepat
b
elisa
antibodi
polioviru
type
neutral
dehp
ga
chromatographi
mass
spectrometri
polypropylen
plastic
addit
bht
irganox
ethanox
hplc
sorbitol
hplc
pyrogen
inject
rabbit
toxic
intraperiton
inject
guinea
pig
mice
steril
steritest
system
millipor
bag
weight
control
result
test
perform
show
signific
variat
productst
characterist
transfer
plastic
contain
result
temperatur
show
sign
incompat
plastic
materi
antibodi
titr
studi
remain
perfectli
stabl
marker
use
assess
possibl
migrat
plastic
compon
product
dehp
pvc
pp
addit
undetect
low
dehp
content
show
valu
agml
instanc
pp
marker
undetect
mean
weight
loss
day
storag
acceler
temperatur
studi
higher
weight
loss
notic
signific
variat
detect
paramet
studi
sorbitolformul
ivig
show
compat
pvc
pp
short
time
period
introduct
autoimmun
hepat
aih
rare
diseas
character
progress
necroinflammatori
hepatocyt
injuri
caus
breakdown
immun
toler
selfantigen
howev
pathogen
mechan
underli
develop
aih
still
unclearth
aim
studi
complex
analysi
autoimmun
phenomena
involv
activ
apoptosi
well
transfer
costimulatori
signal
particular
lymphocyt
subpopul
peripher
blood
patient
aih
differ
stage
immunosuppress
therapi
materi
method
examin
carri
aih
patient
divid
two
group
first
group
consist
patient
denovo
diagnos
aih
immunophenotyp
peripher
blood
lymphocyt
done
twice
ie
five
month
immunosuppress
therapi
second
group
consist
patient
show
clinic
laboratori
featur
aih
remiss
singl
immunophenotyp
function
state
lymphocyt
examin
use
threecolor
flow
cytometri
techniqu
monoclon
antibodi
repertoir
refer
rang
activ
apoptosi
marker
obtain
immunophenotyp
healthi
volunt
result
percentag
cell
tc
surfac
marker
significantli
lower
aih
denovo
diagnos
patient
healthi
subject
percentag
activ
th
well
b
cell
significantli
higher
aih
denovo
diagnos
healthi
subject
five
month
immunosuppress
therapi
follow
chang
comparison
initi
data
found
increas
percentag
th
tc
cell
b
increas
percentag
th
cell
surfac
c
decreas
percentag
nk
cell
decreas
percentag
activ
b
cell
year
immunosuppress
therapi
signific
differ
percentag
th
tc
nk
cell
found
aih
patient
healthi
subject
conclus
activ
lymphocyt
appear
clinic
exacerb
aih
percentag
peripher
blood
nk
cell
decreas
month
immunosuppress
treatment
normal
year
treatment
percentag
activ
b
cell
increas
activ
phase
diseas
significantli
decreas
follow
month
year
immunosuppress
therapi
exacerb
aih
associ
decreas
number
activ
tc
lymphocyt
probabl
result
accumul
cell
liver
activ
lymphocyt
via
antigen
seem
princip
immun
event
pathogenesi
aih
exacerb
immunosuppress
therapi
last
year
lead
normal
amount
basic
lymphocyt
popul
peripher
blood
effect
observ
month
immunosuppress
therapi
identifi
common
binnat
signatureq
gene
express
profil
innat
vs
adapt
lymphocyt
yamagata
c
benoist
mathi
section
immunolog
immunogenet
joslin
diabet
center
boston
usa
innat
adapt
immun
respons
two
radic
differ
strategi
host
immun
system
take
pathogen
assault
dichotom
view
immun
respons
wide
accept
howev
clear
definit
hallmark
innat
immun
realli
distinguish
adapt
immun
order
address
question
took
broad
approach
compar
geneexpress
profil
innat
vs
adapt
immun
cell
popul
player
innat
immun
respons
includ
neutrophil
macrophag
natur
killer
nk
cell
dendrit
cell
dc
wherea
adapt
respons
includ
classic
b
cell
howev
compar
two
extrem
celltyp
eg
neutrophil
vs
cell
could
end
highlight
superfici
differ
tcr
downstream
gene
therefor
explor
differ
gene
express
compar
close
distinct
pair
innat
vs
adapt
popul
cell
nkt
vs
cell
igm
hi
igd
int
b
cell
vs
igm
int
igd
hi
cell
tcrb
vs
tcrb
cell
six
popul
sort
wildtyp
mice
tcr
transgen
mice
mrna
hybrid
affymetrix
chip
genom
analys
done
two
way
mathematicalgeometr
analysi
cell
popul
coordin
base
gene
express
refer
popul
plot
rpp
bioinformat
analysi
overexpress
gene
base
molecular
function
rpp
indic
innat
lymphocyt
activ
memori
nk
regulatorylik
charact
found
gene
overexpress
fold
intersect
three
innat
vs
adapt
comparison
number
significantli
higher
background
level
gene
random
dataset
also
defin
gene
underexpress
innat
cell
two
set
gene
success
sort
multipl
lymphocyt
popul
innat
adapt
subgroup
rpp
indic
express
level
gene
design
bunbiasedq
innat
signatur
molecular
character
gene
induc
innat
popul
point
multipl
molecular
pathway
activ
found
limit
set
function
entiti
enhanc
across
popul
innat
lymphocyt
essenti
intracellular
vacuol
traffick
interferoninduc
gtpase
system
find
prompt
one
specul
innat
immun
system
might
deploy
uniqu
intracellular
recognit
system
detect
subtl
chang
tissu
environ
analys
reveal
share
gene
pathway
induc
innat
lymphocyt
thu
common
binnat
signatureq
distinguish
innat
lymphocyt
adapt
one
find
instrument
genom
definit
classif
binnatenessq
variou
immun
celltyp
also
implic
understand
origin
evolut
innat
immun
previous
report
saccharid
structur
gal
galnac
recogn
amaranthu
leucocarpu
lectin
express
activ
cell
gal
galnac
structur
also
recogn
peneaut
agglutinin
pna
object
work
determin
structur
recogn
similar
structur
recogn
pna
pbmc
obtain
form
healthi
donor
cultur
presenc
mgml
concanavalin
con
cell
recov
everi
h
day
cell
label
fitc
conjugatedlectin
amaranthu
leucocarpu
peneaut
agglutinin
pna
differ
mab
case
cell
treat
neuraminidas
elimin
sialic
acid
camouflag
result
analyz
flow
cytometri
result
stimul
con
percentag
cell
increas
h
diminish
gradual
wherea
percentag
cell
pna
cell
increas
h
maintain
percentag
h
express
observ
express
time
cell
howev
neuraminidas
treat
cell
express
disminish
pna
cell
conclus
result
suggest
saccharid
structur
recongn
differ
saccharid
structur
recogn
pna
statin
class
hmg
coa
reductas
inhibitor
use
million
american
high
cholesterol
sever
line
evid
suggest
drug
possess
antiinflammatori
immunomodulatori
properti
beyond
cholesterollow
effect
recent
report
shown
statin
affect
immun
respons
skew
h
h
balanc
interf
mhc
class
ii
express
inhibit
inflammatori
process
protect
suppress
immun
respons
antigen
present
may
weaken
host
defens
determin
whether
hmg
coa
reductas
inhibitor
treatment
effect
vivo
acut
phase
respons
antibodi
product
follow
tetanu
vaccin
normal
healthi
volunt
doubl
blind
parallel
placebo
control
studi
twenti
healthi
volunt
random
receiv
atorvastatin
mg
calcium
placebo
pl
day
volunt
receiv
tetanu
toxoid
tt
vaccin
day
studi
acut
phase
respons
evalu
determin
chang
esr
cbc
differenti
serum
concentr
acut
phase
protein
antitrypsin
creactiv
protein
glycoprotein
cytokin
ifn
g
humor
respons
vaccin
assess
measur
total
immunoglobulin
specif
antitt
antibodi
baselin
measur
variabl
similar
group
follow
tenday
studi
drug
placebo
subject
atorvastatin
group
signific
reduct
total
cholesterol
f
mgdl
pl
f
mgdl
p
b
ldl
cholesterol
f
mgdl
pl
f
mgdl
p
compar
control
group
demonstr
effect
atorvastatin
baselin
antitt
antibodi
concentr
number
year
elaps
sinc
last
vaccin
similar
group
unexpectedli
product
specif
antibodi
tt
predomin
igg
fold
higher
volunt
treat
atorvastatin
day
postvaccin
f
unit
pl
f
unit
p
atorvastatin
suppress
postvaccin
rise
platelet
count
f
pl
f
p
lymphocyt
count
f
pl
f
p
consist
antiinflammatori
properti
signific
chang
esr
serum
level
acut
phase
reactant
cytokin
treatment
control
group
studi
demonstr
statin
augment
specif
immun
respons
follow
vaccin
healthi
volunt
rather
suppress
beyond
applic
reduc
cholesterol
suppress
inflamm
possibl
statin
may
benefit
group
respond
poorli
vaccin
elderli
immunocompromis
patient
clinic
studi
need
determin
group
demonstr
similar
respons
atorvastatin
well
determin
mechan
mediat
effect
osmel
gaspar
guerra
segura
immunolog
lab
teach
gen
hosp
dr
neto
guantanamo
guantanamo
cuba
pedagog
diagnost
knowledg
immunolog
student
second
year
medicin
teach
topic
microbiolog
patholog
diagnost
done
six
year
student
intern
medicin
resid
accomplish
objet
design
pedagog
instrument
interview
question
testt
knowledg
student
proffesor
wich
taught
reciev
subject
knowledg
adquir
second
year
student
intern
medicin
resid
obtain
lowest
mark
highest
integr
content
immunolog
subject
thatt
right
propos
immunolog
syllabu
agreement
social
profession
need
cuban
doctor
countri
inhibitor
defici
rare
condit
either
inherit
hereditari
angioedema
hae
acquir
acquir
angioedema
aae
clinic
character
recurr
selflimit
skin
intestin
edema
lifethreaten
upper
airway
obstruct
replac
therapi
concentr
treatment
choic
sever
acut
attack
angioedema
europ
report
need
efficaci
concentr
patient
hae
aae
observ
year
patient
efficaci
evalu
time
begin
resolut
symptom
side
effect
record
concentr
use
hae
patient
total
infus
mean
infusionpati
rang
aae
patient
total
infus
mean
infus
patient
rang
dose
rang
hae
aae
laryng
attack
time
begin
resolut
minut
episod
hour
episod
one
hae
patient
underw
tracheostomi
laryng
edema
despit
treatment
concentr
abdomin
attack
time
begin
resolut
within
one
hour
episod
hour
hour
episod
among
episod
edema
oral
mucosa
time
begin
resolut
within
one
hour
hour
facial
attack
time
begin
resolut
within
min
hour
hour
peripher
attack
time
resolut
within
one
hour
episod
hour
episod
hour
episod
patient
aae
infus
begin
resolut
alway
within
one
hour
remain
patient
infus
respons
becam
progress
slow
hour
requir
higher
dose
concentr
two
anaphylactoid
reaction
report
hae
patient
preval
hcv
treat
patient
drop
introduct
virucid
method
hiv
infect
ever
detect
data
indic
treatment
concentr
highli
effect
angioedema
laryng
abdomin
mucosa
effect
reduc
skin
involv
particularli
peripher
attack
patient
aae
may
becom
resist
treatment
safeti
gener
good
transmiss
blood
born
infect
drastic
reduc
sinc
viral
inactiv
procedur
introduc
osmel
gaspar
guerra
segura
neri
noa
rdguez
immunolog
lab
teach
gen
hosp
dr
aneto
guantanamo
guantanamo
cuba
qualiti
control
provinci
blood
bank
guantanamo
guantanamo
cuba
prospect
studi
special
plasmat
donor
year
plasmapheresi
program
hiperimmun
anti
tt
tetan
toxoid
plasma
provinci
blood
bank
guantanamo
evalu
donor
nutritionali
cere
program
hygen
food
institut
hanvana
wich
special
form
collect
data
relat
high
weight
race
immunohematolog
biochemist
point
view
valu
fraction
protein
electrophoresi
eritro
hemoglobin
particular
specif
antibodi
anti
tt
posit
antigen
hepat
b
c
hiv
test
nutrit
point
view
lipid
suppli
defici
donat
antropometr
hematolog
paramet
agre
literatur
specif
antibodi
titl
anti
tt
vari
donor
antigenloop
scaffold
induc
specif
antibodi
respons
mice
genet
immun
neckermann
j
lohrmann
w
zimmermann
tumor
immunolog
laboratori
depart
urolog
univers
clinic
grosshadern
ludwigmaximiliansunivers
munich
germani
genovac
gmbh
freiburg
germani
protein
belong
wide
distribut
protein
famili
found
mammal
bacteria
conserv
speci
exhibit
low
immunogen
properti
advantag
fusion
protein
use
genet
immun
antibodi
fusion
partner
gener
spontan
form
heptafold
scaffold
subunit
scaffold
display
expos
polypeptid
loop
nativ
loop
replac
foreign
loop
sequenc
import
applic
bloop
replacementq
strategi
lie
present
extracellular
loop
transmembran
protein
like
gprotein
coupl
receptor
gpcr
prove
difficult
gener
antisera
short
extracellular
loop
broad
interest
gpcr
famili
base
upon
fact
approv
drug
elicit
therapeut
effect
select
address
gpcr
proof
principl
applic
scaffold
replac
loop
baq
determin
hepat
b
surfac
antigen
hbsag
baq
determin
small
loop
nine
amino
acid
highli
immunogen
present
context
full
length
hbsag
studi
want
analyz
whether
present
hbsag
loop
scaffold
elicit
specif
immun
respons
upon
genet
immun
whether
scaffold
abl
mimic
nativ
conform
therefor
immun
mice
plasmid
code
scaffold
analyz
antisera
specif
antihbsag
antibodi
method
murin
cdna
nucleotid
code
baq
determin
clone
optim
immun
vector
balbc
mice
immun
two
week
interv
period
week
use
heliosr
gene
gun
blood
sampl
taken
anim
everi
two
week
analys
presenc
specif
antibodi
use
cellbas
elisa
assay
result
screen
antisera
cellbas
elisa
show
mice
elicit
specif
antibodi
plasmidencod
antigen
could
also
demonstr
immun
respons
direct
scaffold
prove
low
immunogen
scaffold
murin
system
therefor
detect
antibodi
respons
seem
specif
baq
determin
hbsag
discussionconclus
could
show
first
time
murin
scaffold
use
genet
immun
experi
present
foreign
peptid
loop
elicit
immun
respons
encod
antigenloop
whether
scaffold
allow
format
nativ
loop
conform
need
investig
elisa
recombin
hbsag
protein
detect
sera
futher
experi
perform
establish
whether
approach
extend
use
eg
direct
gener
antibodi
gpcr
loop
angioedema
without
major
urticaria
flare
poorli
character
caus
differ
condit
data
exist
underli
etiopathogenet
mechan
report
experi
patient
symptom
propos
diagnostictherapeut
approach
method
consecut
patient
examin
outpati
clinic
recurr
angioedema
without
urticaria
known
caus
angioedema
identifi
clinic
histori
detail
inform
person
famili
allergi
relationship
angioedema
potenti
caus
agent
search
food
drug
insect
sting
complet
physic
examin
routin
laboratori
test
blood
cell
count
protein
electrophoresi
erythrosediment
rate
stool
ova
parasit
pharyng
urin
cultur
sinu
dental
film
antitissu
autoantibodi
rheumatoid
factor
complement
paramet
inhibitor
perform
test
done
pertin
base
clinic
find
neg
respons
consid
result
accord
test
angioedema
classifi
follow
relat
extern
agent
drug
insect
sting
food
particular
relat
treatment
aceinhibitor
associ
autoimmun
diseas
infect
hereditari
inhibitor
defici
acquir
inhibitor
defici
idiopath
histaminerg
idiopath
non
histaminerg
patient
drop
studi
could
classifi
base
frequenc
differ
diagnosi
propos
follow
progress
test
anamnest
identif
caus
agent
test
complement
abnorm
antagonist
treatment
complet
diagnost
workup
cell
activ
intestin
dendrit
cell
dc
induc
guttrop
show
reciproc
dc
peripher
lymph
node
plndc
induc
home
receptor
promot
cell
accumul
inflam
skin
particularli
ligand
pand
eselectin
differenti
imprint
tissuetrop
independ
cytokin
restrict
particular
dc
subset
fix
plndc
retain
capac
induc
selectin
ligand
cell
suppress
addit
live
intestin
dc
contrast
fix
intestin
dc
fail
promot
guttrop
instead
induc
skinhom
receptor
moreov
induct
selectin
ligand
driven
antigenpuls
plndc
could
suppress
din
transt
ad
live
intestin
dc
plndc
suppress
gut
home
receptor
induc
intestin
dc
reactiv
tissuecommit
memori
cell
modifi
tissuetrop
accord
last
activ
dct
origin
thu
cell
activ
dc
acquir
selectin
ligand
default
unless
encount
fixationsensit
signal
guttrop
intestin
dc
memori
cell
remain
respons
signal
allow
dynam
migratori
reprogram
skinand
gutassoci
dc
prospect
studi
carri
studi
bacteriocin
produc
abilil
water
isol
total
isol
screen
bacteriocinogen
potenti
intragen
intergen
microorgan
isol
found
exert
broad
rang
bacteriocinogenesi
bioactiv
howev
none
produc
antagonist
relat
streptococc
strain
bacteriocinogenesi
demonstr
stab
lay
cross
streak
patch
agar
welltitr
bacteriocin
done
arbitari
unit
au
methodin
first
method
test
strain
stab
luria
agar
plate
incub
hr
chloroform
use
kill
bacteria
plate
overlaid
soft
agar
contain
micro
liter
hour
grown
indic
strainsand
incub
hr
examin
zone
inhibit
second
test
strain
streak
across
surfac
luria
agar
plate
incub
night
growth
test
strain
remov
plate
expos
chloroform
describ
earlier
indic
strain
cross
streakedpl
incub
night
examin
inhibit
growthin
luria
agar
plate
overlaid
ml
soft
agar
contain
micro
liter
indic
strain
plate
kept
hr
dri
fresh
coloni
strain
stab
indic
lawnplat
incub
hr
test
strain
grown
luria
broth
cultur
centrifug
rpm
min
supernat
collect
luria
agar
plate
overlaid
ml
soft
agar
contain
micro
liter
indic
strain
well
made
micro
liter
supern
ad
well
plate
incub
hr
zone
inhibit
indic
strain
around
well
measur
titrat
inocul
nutrient
broth
differ
produc
strain
incub
next
day
centrifug
tube
minut
make
fold
dilut
nutrient
agar
make
well
mark
accord
dilut
tube
take
micro
liter
dilut
tube
transfer
mark
well
processwa
repeat
dilut
next
day
check
zone
inhibitionamong
mani
result
appropri
result
obtain
listeria
monicylogen
strepptococcu
pyogen
bacteriocinogen
organ
gave
activ
gram
neg
stain
ecoli
styphi
klebsiella
pseudomana
gve
stain
saureu
sfecali
mleutu
bsubtilu
streptococcin
titer
estim
au
lacuna
percentag
determin
number
streptococcin
produc
clone
popul
found
elev
temperatur
mediat
cure
produc
isol
reveal
chromosom
locat
bacteriocinogen
determinantsa
report
past
studi
cardiac
surgeri
usual
follow
adhes
still
repres
incomplet
solv
problem
differ
treatment
propos
fibrin
seal
probabl
best
far
reduc
adhes
entamoeba
histolytica
produc
antiinflammatori
peptid
metglncysasns
term
monocyt
locomot
inhibitori
factor
mlif
first
describ
effect
monocyt
key
cell
late
inflamm
also
modul
cicatr
stage
woundheal
process
thu
mlif
could
regul
woundheal
purpos
studi
prevent
format
experiment
induc
pericard
adhes
rat
model
origin
develop
induc
cardiac
colater
circul
epicardiectomi
soft
sandpap
scratch
cm
apic
area
heart
perform
four
group
eight
male
wistar
rat
anesthesia
steril
condit
group
receiv
either
mlif
ag
ml
pyrogen
free
salin
solut
fibrin
seal
solut
ml
none
final
volum
adjust
ml
salin
solut
anim
recov
humanli
sacrif
day
ten
anesthet
overdos
systemat
necropsi
photograph
regist
done
blindli
evalu
three
independ
particip
control
anim
without
milf
fibrin
seal
develop
strong
nodular
extens
adhes
fibrin
seal
allow
focal
yet
strongadhes
mlif
inhibit
strong
adhes
p
b
allow
develop
soft
extensiveadhes
p
n
sig
mlif
togeth
fibrin
seal
complet
inhibit
pericard
adhes
model
combin
mlif
fibrin
seal
inhibit
adhes
either
substanc
alon
induc
partialand
qualit
differentreduct
adhes
suggest
factor
differ
target
mechan
act
synerg
name
mlif
reduc
activ
signal
monocyt
fibroblast
fibrin
seal
modul
pomp
diseas
autosom
recess
lysosom
storag
disord
character
defici
acid
alphaglucosidas
gaa
absenc
decreas
express
gaa
result
accumul
glycogen
muscl
tissu
infantil
pomp
patient
experi
lifethreaten
manifest
cardiomegali
lateonset
patient
experi
progress
myopathi
without
respiratori
insuffici
use
recombin
human
alphaglucosidas
rhgaa
investig
therapeut
agent
pomp
diseas
clinic
studi
observ
patient
treat
rhgaa
seroconvert
respons
therapeut
protein
role
rhgaaspecif
antibodi
unclear
could
potenti
inhibit
activ
therapeut
protein
alter
biodistribut
therebi
decreas
enzym
efficaci
previous
demonstr
weekli
intraperiton
administr
rhgaa
neo
neo
gaa
knockout
gaa
ko
mice
result
high
rhgaaspecif
igg
titer
shown
high
dose
methotrex
mtx
abl
suppress
titer
tenfold
administ
hour
follow
first
eight
weekli
rhgaa
treatment
studi
conduct
gaa
ko
mice
model
intraven
administr
rhgaa
clinic
rout
therapeut
administr
identifi
lower
efficaci
dose
methotrex
observ
intraven
deliveri
rhgaa
gaa
ko
mice
significantli
reduc
rhgaaspecif
igg
titer
observ
upon
intraperiton
administr
rhgaa
addit
demonstr
mtx
effect
reduc
immun
respons
administ
hour
follow
first
eight
weekli
rhgaa
treatment
moreov
lower
weekli
dose
mtx
effect
higher
dose
inhibit
rhgaaspecif
immun
respons
given
follow
rhgaa
treatment
studi
suggest
time
mtx
treatment
influenc
abil
inhibit
rhgaaspecif
immun
respons
approach
may
effect
minim
drugspecif
antibodi
respons
patient
receiv
protein
therapeut
releas
metal
ion
dental
metal
fill
support
presenc
galvan
cell
oral
caviti
way
caus
local
gener
patholog
problem
sensit
genet
suscept
individu
aim
studi
investig
vitro
lymphocyt
respons
metal
replac
electro
activ
dental
metal
fill
patient
oral
discomfort
method
sixtyeight
patient
oral
discomfort
dental
metal
fill
investig
divid
two
group
group
person
patient
patholog
level
galvan
current
group
b
person
patient
physiolog
level
galvan
current
voltag
galvan
measur
perform
equip
odontolog
embitron
cz
lymphocyt
activ
test
lymphocyt
prolifer
method
modifi
metal
melisa
patient
group
patient
group
b
electro
activ
metal
fill
replac
perform
patient
group
follow
melisa
least
half
year
fill
replac
perform
result
higher
lymphocyt
activ
metal
discov
examin
group
highest
level
prolifer
activ
found
ni
hg
mo
group
hg
ni
au
group
b
gener
lymphocyt
patient
group
b
sensit
one
group
follow
result
electro
activ
fill
remov
show
lymphocyt
reactiv
least
metal
test
decreas
highest
decreas
found
reaction
inorgan
mercuri
conclus
longtim
influenc
galvan
sensit
genet
suscept
individu
influenc
lymphocyt
prolifer
benefici
effect
dental
metal
fill
replac
confirm
decreas
lymphocyt
reactiv
metal
find
support
hypothesi
suffer
oral
discomfort
subject
feel
patient
base
real
cell
discomfort
due
releas
metal
ion
dental
metal
fill
due
galvan
activ
lymphocyt
metal
influenc
coupl
factor
well
acknowledg
studi
support
grant
czech
ministri
health
nr
nr
introduct
variou
untoward
reaction
allergictox
observ
cours
treatment
patient
pulmonaryextra
pulmonari
tuberculosi
method
old
theme
tuberculosi
duntreatablet
replac
dcurablet
introduct
effect
antituberculosi
drug
still
effect
limit
care
assess
patient
atdallerg
toxic
manifest
rifampicin
urticaria
red
skin
orang
discolor
febril
reaction
hepato
neuro
nephrotox
blood
dyscrasia
haemolysi
shock
blur
vision
confus
ataxiaperipher
neuriti
pseudomembran
coliti
ethambutol
r
skin
rash
itchingburn
sensat
anaphylactoid
reaction
nausea
vomit
abdomin
pain
anorexia
head
ach
peripher
neuropathi
hallucin
disorienatt
mental
confus
visual
disturb
transient
impair
liver
function
gouti
arthriti
isoniazid
r
itchingskin
rash
slur
speech
hallucin
coma
gener
convuls
statu
epilepticu
peripher
neuropathi
hypotens
respiratori
failur
sever
metabol
acidosi
fever
nausea
vomit
hepat
r
hemolyt
anemia
pyrazinamid
r
skin
rash
hepatox
gouti
arthriti
streptomycin
wide
spread
skin
rash
hive
nausea
vomit
headach
hypotens
ear
kidney
damag
rare
paralysi
interf
calcium
transport
central
nervu
system
ethionamid
sever
skin
rash
acn
alopecia
photosensit
nausea
vomit
anorexia
diarrhea
excess
saliv
metal
tast
hepatotox
mental
depress
anxieti
psychosi
system
encephalopathi
pellagralik
symptom
dizzi
drowsi
headach
convuls
peripher
neuropathi
tremor
paresthesia
optic
neuriti
optic
atrophi
diplopia
olefactori
disturb
deaf
r
hypothyroid
impot
menorrhagia
gynaecomastia
r
hypoglycemia
hypotens
r
thrombocytopenia
rheumat
pain
thiacetazon
skin
rash
nausea
vomit
jaundic
giddi
bone
marrow
suppress
agranulocytosi
incid
advers
reaction
observ
result
care
select
appropri
diagnosi
infecti
patient
less
like
associ
advers
effect
conclus
incid
advers
effect
rel
less
frequent
first
line
second
line
atd
treatment
background
wiskottaldrich
syndrom
protein
wasp
famili
member
wasp
nwasp
wave
key
molecul
regul
cytoskelet
chang
respons
cell
surfac
signal
event
critic
variou
biolog
process
includ
cell
migrat
immun
synaps
format
recent
gener
chimer
mice
defici
nwasp
nwko
mice
doubledefici
wasp
nwasp
dko
employ
blastocyst
complement
nwko
chimer
mice
like
wasp
ko
wko
mice
demonstr
chang
cell
develop
contrast
waspnwasp
dko
mice
mark
defect
cell
matur
associ
block
doubleneg
stage
consequ
decreas
cell
number
peripher
lymphoid
organ
aim
elucid
mechan
underli
aberr
cell
develop
waspnwasp
doubledefici
mice
method
delet
nwasp
select
tcell
wko
mice
use
creloxp
system
approach
mate
condit
nwaspko
wko
lckcre
transgen
mice
credko
lymphoid
organ
process
phenotyp
analysi
employ
standard
development
activ
marker
also
assess
thymocyt
migratori
function
driven
transwel
migrat
assay
thymoct
apoptosi
annexin
v
stain
colon
sampl
obtain
histolog
analys
cytokin
measur
result
lckdriven
nwasp
delet
wko
mice
credko
cell
develop
result
signific
decreas
thymic
cellular
also
found
increas
apoptot
cell
death
credko
anim
compar
wt
wko
mice
cell
substanti
decreas
singleposit
thymocyt
credko
micewhich
may
correl
directli
increas
apoptosi
addit
credko
thymocyt
signific
migrat
defect
compar
wko
thymocyt
also
defect
migrat
compar
wt
thymocyt
consequ
found
significantli
decreas
number
cell
spleen
credko
mice
howev
observ
major
cell
present
effector
phenotyp
interestingli
credko
mice
present
coliti
earlier
onset
may
associ
increas
sever
conclus
studi
demonstr
redund
function
wasp
nwasp
critic
combin
role
protein
cell
develop
function
togeth
function
analys
credko
thymocyt
suggest
decreas
migratori
activ
cell
might
relat
decreas
signal
result
increas
cell
death
consequ
reduc
thymocyt
number
furthermor
find
signific
increas
proport
effector
cell
peripheri
credko
may
associ
earli
onset
inflammatori
bowel
diseas
h
kalinski
chajut
khan
r
skalit
research
develop
quark
biotech
inc
fremont
ca
usa
fa
induc
apoptosi
key
signal
pathway
mani
diseas
studi
use
function
genom
approach
joint
studi
quark
biotech
agil
technolog
quarkt
proprietari
bifar
tm
platform
base
discoveri
essenti
function
gene
use
gene
inhibitori
element
gie
antisens
shrna
domin
neg
peptid
abund
gie
expect
chang
base
abil
inhibit
certain
gene
gie
protect
certain
treatment
enrich
gie
sensit
certain
treatment
deplet
studi
cell
tranduc
gie
librari
propag
expos
high
subleth
dose
antifa
antibodi
use
custom
oligonucleotid
agil
microarray
design
match
specif
gie
librari
rel
abund
gie
antifa
treatment
measur
analysi
function
gie
identifi
gie
protect
fa
other
sensit
treatment
protect
gie
inhibit
gene
involv
interferon
respons
phosphoinositol
metabol
vesicl
transport
chaperon
found
sensit
gie
includ
inhibit
antiapoptot
gene
bifar
platform
implement
agilentt
microarray
allow
function
dissect
fa
induc
apoptosi
process
known
particip
kill
viral
infect
cell
transform
cell
peripher
autoreact
tcell
well
physiolog
process
discoveri
inhibit
gene
lead
acceler
fa
induc
apoptosi
implement
therapeut
aim
enhanc
tumor
suppress
toler
basic
approach
appli
varieti
function
system
use
varieti
gie
type
prolifer
cell
well
fulli
differenti
cell
elucid
signal
transduct
pathway
identifi
novel
drug
target
chronic
brain
inflamm
persist
infect
traumat
extens
surgeri
eg
tumor
resect
main
caus
secondari
epilepsi
evalu
preserv
function
neural
tissu
chronic
administ
antifibrot
immunomodul
drug
damag
brain
induc
granuloma
cerebr
amygdala
wistar
rat
stereotax
inject
aluminum
silic
interaur
mm
later
mm
height
mm
accord
paxinot
atla
randomli
distribut
group
n
treat
vehicl
water
alcoholicwat
maiz
oil
methylprednisolon
acet
mgkgweek
im
colchicin
agkg
day
oral
thalidomid
mgkgday
oral
cyclosporin
mgkgday
oral
mixtur
colchicinemethylprednisolon
mgkgweek
thalidomidemethylprednisolon
mgkgweek
cyclosporinemethylprednisolon
mgkgweek
forti
five
day
two
week
end
treatment
experiment
epilepsi
induc
ptz
subthreshold
increas
dose
mgkg
administ
accord
hour
interv
develop
gener
seizur
cortic
electrod
implant
three
anim
group
electr
activ
regist
minut
time
elaps
sinc
applic
drug
first
myoclon
tonicclon
seizur
latenc
well
number
durat
afterdischarg
measur
compar
group
histolog
imag
analys
collagen
quantif
granulomat
lesion
also
made
evid
contrast
measur
found
rat
receiv
thalidomid
dose
requir
develop
tonicclon
seizur
group
higher
p
b
requir
rest
group
latenc
gener
tonicclon
seizur
also
longer
thalidomid
treat
rat
control
afterdischarg
control
group
frequent
thalidomid
group
also
found
sleeplik
high
voltag
slow
wave
isol
spike
didntt
burst
real
afterdischarg
thalidomid
seem
preserv
function
brain
tissu
surround
granulomat
lesion
would
promissori
altern
prevent
secondari
epilepsi
object
studi
ifng
proinflammatori
effector
cytokin
cellmedi
immun
play
essenti
role
innat
adapt
phase
immun
respons
interestingli
sever
depend
autoimmun
model
lack
ifng
associ
acceler
diseas
aim
studi
investig
ifng
could
involv
regul
depend
inflamm
materi
method
studi
influenc
ifng
effector
cell
use
adopt
transfer
model
differenti
antigenspecif
cell
differenti
impact
ifng
analyz
antigen
specif
delay
type
hypersensit
dth
reaction
differ
ko
strain
result
ifng
display
dual
function
immun
reaction
earli
phase
ifng
acceler
inflamm
wherea
late
phase
mediat
process
selflimit
ifng
neg
regul
homeostasi
antigen
challeng
studi
ifng
r
ko
ino
ko
mice
reveal
ifng
could
act
via
receptor
host
cell
involv
downstream
transfer
experi
ifng
ko
mice
show
cell
control
correspond
inflamm
conclus
result
show
ifng
import
player
regul
depend
inflamm
proinflammatori
cytokin
act
neg
feedback
regul
control
selflimit
depend
inflamm
object
studi
regulatori
cell
treg
increasingli
recognis
play
import
role
mainten
cell
homeostasi
selftoler
recent
report
phenotyp
function
dichotomi
among
natur
occur
murin
treg
subset
characteris
express
integrin
e
e
express
treg
correl
effectormemorylik
phenotyp
contrast
naivelik
e
treg
phenotyp
characterist
crucial
impact
migratori
properti
treg
vivo
ultim
result
differenti
potenc
suppress
immun
respons
within
distinct
anatom
compart
current
studi
intend
elucid
relationship
e
e
treg
subset
want
clarifi
whether
e
treg
origin
thymu
distinct
lineag
whether
gener
peripheri
certain
condit
materi
method
perform
brdulabel
experi
follow
vivo
prolifer
differ
treg
subset
normal
athym
condit
transfer
experi
investig
stabil
phenotyp
condit
gener
result
effectormemorylik
phenotyp
e
express
treg
suggest
antigenspecif
differenti
expans
peripheri
inde
brdulabel
experi
normal
thymectomis
mice
reveal
high
frequenc
prolifer
cell
within
subset
interestingli
e
express
treg
compar
enrich
adultthymectomis
mice
sustain
stabl
cell
number
even
absenc
thymic
output
mild
lymphopenia
observ
remain
cell
compart
transfer
distinct
treg
subset
nonlymphopen
recipi
observ
condit
e
express
treg
repres
stabl
subset
differenti
stage
treg
rather
transient
popul
transfer
tcr
transgen
cell
subsequ
appli
antigen
want
identifi
cellular
precursor
e
express
treg
condit
gener
vivo
initi
experi
indic
e
express
inde
induc
fraction
transfer
cell
tolerogen
condit
interestingli
induct
appear
confin
certain
compart
conclus
e
express
effectormemorylik
treg
repres
stabl
popul
normal
immun
system
contain
cell
constantli
cycl
presum
respons
selfantigen
andor
environment
antigen
effector
memorylik
treg
potenti
maintain
stabl
popul
size
peripheri
even
absenc
thymic
output
preliminari
result
suggest
phenotyp
induc
peripheri
antigenspecif
differenti
distinct
condit
better
understand
fundament
physiolog
gener
treg
subset
may
aid
design
futur
therapeut
strategi
treatment
ongo
autoimmun
diseas
mandana
sattari
shidehmehr
mofakham
saeed
khalili
immunolog
shahe
beheshti
univers
medic
school
tehran
islam
republ
iran
aim
accord
presenc
immun
system
factor
chronic
periap
lesion
hypersensit
reaction
may
role
pathogenesi
lesion
among
factor
particip
type
hypersensit
reaction
one
studi
aim
studi
evalu
relationship
presenc
ige
number
mast
cell
presenc
ige
histamin
human
dental
chronic
periap
lesion
materi
method
specimen
collect
patient
extract
lesion
divid
two
section
half
section
use
explant
cultur
maintain
day
sandwich
enzym
link
immunosorb
assay
elisa
use
determin
presenc
concentr
ige
histamin
base
presenc
ige
sampl
divid
case
ige
control
without
ige
groupsth
section
use
estim
number
mast
cell
histopatholog
techniqu
result
averag
percent
mast
cell
case
control
group
respect
f
f
statist
analysi
mann
whitneyu
test
spearman
correl
coeffici
show
differ
case
control
group
regard
number
mast
cell
histamin
concentr
also
correl
ige
mast
cell
ige
histamin
conclus
conclud
hypersensit
reaction
type
possibl
role
pathogenesi
chronic
periap
lesion
mandana
sattari
saeed
khalili
maryam
basirat
immunolog
shahe
beheshti
univers
medic
scienc
tehran
islam
republ
iran
aim
addit
microorgan
sever
factor
host
immun
respons
also
involv
pathogenesi
dental
cari
among
factor
immun
system
role
neutrophil
prevent
pathogenesi
dental
cari
well
studi
aim
studi
investig
neutrophil
chemotaxi
patient
dental
cari
materi
method
purpos
fifti
dental
student
dental
cari
select
ml
heparin
blood
collect
subject
neutrophil
chemotaxi
test
modifi
boyden
chamber
method
result
amount
neutrophil
chemotaxi
subject
f
micromet
statist
analysi
show
signific
differ
regard
neutrophil
chemotaxi
deffer
degre
dmf
compar
neutrophil
chemotaxi
degre
activ
cari
signific
differ
shown
degre
degre
activ
cari
regard
mean
neutrophil
chemotaxi
conclus
suggest
defici
neutrophil
chemotaxi
assum
pathogenesi
dental
cari
also
direct
correl
neutrophil
chemotaxi
degre
activ
cari
cours
studi
need
order
prove
hypothesi
mandana
sattari
saeed
khalili
immunolog
dept
shaeed
beheshti
univers
medic
scienc
tehren
islam
republ
iran
object
well
defin
part
gingiva
suscept
periodont
diseas
sinc
region
adjac
foramen
nerv
path
regard
import
role
neuropeptid
inflamm
special
gingiv
periodont
inflamm
hand
shown
substanc
p
sp
calcitonin
gene
relat
peptid
cgrp
role
periodont
diseas
sinc
establish
neutrophil
one
import
defens
line
periodont
diseas
aim
studi
determin
correl
concentr
neuropeptid
differ
region
human
healthi
gingiv
effect
neutrophil
death
materi
method
first
section
twenti
gingiv
sampl
first
maxillari
incisor
molar
region
twenti
gingiv
sampl
region
collect
periodont
surgeri
tissu
sampl
immedi
transport
steril
tube
fill
tissu
cultur
media
cultur
hr
supernat
fluid
extract
dive
microtub
frozen
degre
centigrad
eia
use
detect
neuropeptid
second
section
collect
heparin
blood
healthi
individu
neutrophil
collect
purpos
heparin
blood
mix
five
ml
dextran
maintain
laboratori
temperatur
minut
high
concentr
low
concentr
extract
neuropeptid
regard
concentr
sp
cgrp
first
section
collect
neutrophil
annexin
v
flou
stan
kit
use
detect
death
neutrophil
flourec
microscop
find
find
signific
differ
differ
gingiv
region
regard
cgrp
concentr
also
signific
revers
correl
cgrp
differ
gingiva
could
find
signific
correl
sp
differ
region
gingiva
sp
cgrp
present
sampl
second
part
find
sp
cgrp
significantli
induc
apoptosi
neutrophil
conclus
conclud
neuropeptid
probabl
particip
regul
maintanc
gingiv
health
base
low
level
cgrp
gingiv
upper
lower
dental
region
preval
local
aggress
priodont
distribut
low
level
cgrp
sp
region
could
suggest
possibl
role
suscept
region
local
priodont
second
part
studi
conclud
sp
cgrp
induc
apoptosi
instead
necrosi
neutrophil
also
may
parallel
regulatori
role
neuropeptid
first
adaptor
protein
discov
possess
tirdomain
interact
tolllik
receptor
lead
activ
nfkb
jnksignal
system
highli
conserv
natur
mous
human
gene
reveal
homolog
protein
level
human
murin
gene
organ
five
exon
four
intron
splice
variant
lack
exon
call
report
mous
protein
isoform
regul
lp
signal
pathway
trough
inabl
bind
activ
downstream
signal
molecul
murin
splice
establish
gener
inform
yet
human
process
nucleotid
sequenc
analysi
human
peripher
blood
mononuclear
cell
notic
human
splice
compar
report
mous
human
result
exon
excis
therefor
lack
id
domain
aa
human
mononuclear
cell
test
constitut
express
transcript
protein
murin
human
similar
process
compar
way
howev
regulatori
mechan
involv
could
exquisit
differ
background
pediatr
system
lupu
erythematosu
sle
multisystem
diseas
significantli
impact
qualiti
life
qol
children
sle
impact
school
attend
import
outcom
potenti
predictor
outcom
receiv
littl
attent
object
examin
relationship
school
attend
qol
physic
function
sle
activ
damag
children
sle
designmethod
crosssect
studi
children
sle
year
parent
complet
childpar
version
childhood
health
assess
questionnair
chaq
pediatr
qol
inventori
pedsql
gener
rheumatolog
modul
physician
complet
sle
diseas
activ
index
sledai
system
lupu
intern
collabor
clinicsacr
damag
index
slicc
number
day
prior
child
miss
school
due
physicalment
health
reason
record
use
pedsql
famili
inform
form
spearman
correl
determin
number
miss
school
day
variabl
result
children
girl
sle
mean
age
f
year
mean
educ
th
grade
mean
sle
durat
f
month
sledai
slicc
median
chaq
mean
pedsqlgener
f
parent
median
chaq
mean
pedsqlgener
f
particip
children
exclud
school
attend
inapplic
day
prior
particip
children
miss
school
mean
f
day
mean
number
day
ill
play
f
mean
number
day
need
someon
f
day
number
miss
school
day
moder
correl
decreas
qol
report
parent
measur
pedsqlgener
modul
r
p
correl
significantli
rheumatolog
modul
chaq
sledai
slicc
child
report
score
conclus
number
miss
school
day
correl
decreas
gener
qol
children
sle
perceiv
parent
howev
parallel
correl
miss
school
day
overal
qol
perceiv
children
identifi
discrep
percept
parent
children
warrant
investig
larger
cohort
lack
correl
school
attend
scale
suggest
gener
scale
captur
less
tangibl
element
sle
improv
antimycobacteri
therapi
due
activ
blockag
strain
depend
roqu
c
r
appelberg
correianev
laboratori
microbiolog
immunolog
infect
institut
molecular
cell
biolog
ibmc
porto
mestrado
de
imunologia
clinica
universidad
da
beira
interior
instituto
superior
de
saud
alto
ave
isav
fontarcada
portug
mycobacterium
avium
infect
common
opportunist
infect
immunocompromis
patient
treatment
infect
complex
alway
effect
antimycobacteri
treatment
impli
combin
two
drug
administ
long
period
furthermor
chemotherapi
repeatedli
fail
induc
steril
cure
occurr
antibioticresist
bacteria
rare
event
cytokin
pleiotrop
activ
major
effect
associ
antiinflammatori
immunosuppress
properti
particular
interest
result
abil
increas
suscept
infect
sever
mous
model
fact
previou
studi
group
shown
abrog
activ
improv
efficaci
antimycobacteri
drug
balbc
mice
surprisingli
present
studi
show
effect
seem
strain
specif
combin
receptor
mab
administr
antimycobacteri
therapi
clarithromycin
rifampicin
ethambutol
balbc
chronic
infect
avium
strain
increas
respons
treatment
balbc
strain
whether
repres
strain
differ
immun
respons
avium
antimycobacteri
treatment
current
investig
samar
lightfoot
han
brunnert
carsten
buhlmann
paig
anderson
agil
technolog
palo
alto
usa
agil
technolog
waldbronn
germani
compar
genom
hybrid
cgh
measur
copi
number
variat
multipl
loci
simultan
provid
import
tool
studi
cancer
development
disord
develop
diagnost
therapeut
target
recent
develop
oligonucleotid
array
platform
array
base
compar
genom
hybrid
acgh
analys
detect
map
copi
number
alter
human
genom
includ
singl
copi
loss
gene
specif
homozyg
delet
well
amplicon
vari
size
applic
technolog
studi
human
diseas
requir
adequ
qualiti
control
dna
sampl
prepar
prior
hybrid
agil
bioanalyz
associ
rna
assay
establish
industri
standard
check
integr
rna
sampl
howev
addit
rna
sampl
analys
bioanalyz
onchip
electrophoresi
capabl
dna
analysi
investig
use
bioanalyz
monitor
critic
step
workflow
acgh
experi
includ
dna
amplif
digest
templat
label
result
demonstr
bioanalyz
robustli
monitor
qualiti
quantiti
dna
templat
use
acgh
experi
multipl
sclerosi
chronic
autoimmun
diseas
mediat
cell
reactiv
differ
antigen
peptid
myelin
sheath
experiment
autoimmun
encephalomyel
induc
peptid
mbp
mog
plp
emulsifi
cfa
recapitul
human
diseas
mice
cell
redirect
antigenspecif
tlymphocyt
mediat
immunopatholog
previous
shown
select
effect
target
therapi
experiment
autoimmun
encephalomyel
mekala
et
al
natur
biotechnolog
develop
human
receptor
capabl
redirect
therapeut
lymphocyt
potenti
diseasecaus
cell
link
immunodomin
epitop
human
myelin
basic
protein
mbp
extracellular
transmembran
domain
beta
chain
tcrzeta
cytoplasm
domain
similarli
link
alpha
chain
dra
tcrzeta
alpha
beta
chain
construct
denot
link
use
tmv
sequenc
subclon
mscvigfp
retrovir
vector
gfp
posit
retrovir
transduc
hybridoma
cell
cell
isol
flow
cytometri
western
flow
cytometr
analysi
show
express
construct
order
assay
specif
effector
cell
use
two
differ
type
target
cell
ob
hybridoma
specif
human
peptid
mbp
mhc
ii
courtesi
dr
lar
fugger
skejbi
hospit
hmbp
cell
line
deriv
human
doubletransgen
mice
recognit
chimer
receptor
hmbpspecif
cell
shown
product
specif
cytokin
interferongamma
cell
recognit
target
cell
cell
also
induc
prolifer
transduc
therapeut
cell
also
shown
cytotox
cell
could
specif
recogn
cognat
tcr
mbp
reactiv
target
cell
kill
target
cell
vitro
vivo
studi
human
murin
model
system
valid
use
modifi
cell
cellular
immunotherapeut
agent
capabl
select
target
patholog
antigenspecif
cell
ongo
lif
neurotroph
cytokin
belong
famili
cytokin
play
role
oligodendrocyt
surviv
also
stem
cell
biolog
search
possibl
immun
function
lif
rtpcr
analysi
prove
presenc
lif
receptor
beta
murin
macrophag
dendrit
cell
tcell
upregul
activ
studi
myelinoligodendrocyt
glycoprotein
peptid
aa
mog
induc
eae
lif
knockout
mice
lif
mice
lif
mice
suffer
less
sever
cours
eae
comparison
wildtyp
mice
day
pi
n
primari
lymph
node
prolifer
assay
lymphocyt
lif
mice
respond
less
mog
wildtyp
mice
exhibit
similar
mitogen
respons
defect
antigenspecif
prolifer
could
restor
addit
lif
cell
cultur
supernat
primari
lymph
node
cultur
use
investig
cytokin
product
immun
mog
lif
mice
display
decreas
level
ifng
wherea
differ
product
observ
final
histolog
analysi
perform
investig
inflammatori
reaction
situ
immun
mog
blind
quantif
posit
cell
reveal
significantli
lower
number
tcell
macrophag
spinal
cord
lif
mice
day
pi
result
parallel
decreas
gmcsf
mrna
level
spinal
cord
lif
mice
day
pi
summari
result
line
defect
antigenspecif
tcell
prime
select
defect
cytokinechemokin
product
lif
mice
may
result
impair
recruit
antigen
present
cell
apc
disturb
apctcel
interact
overal
lead
less
sever
cours
mog
eae
direct
effect
lif
tcell
current
investig
consist
gelonin
acetylcholin
receptor
fragment
potenti
immunotherapeut
agent
treatment
myasthenia
gravi
hossann
z
li
shi
u
kreiling
j
buettner
p
vogel
jingm
j
g
wise
w
e
trommer
chemistri
tu
kaiserslautern
kaiserslautern
germani
biotechnolog
shanxi
univers
taiyuan
china
continu
attempt
antigenspecif
suppress
immun
system
urbatsch
il
sterz
rkm
peper
k
trommer
eur
j
immunol
fusion
protein
compos
amino
acid
extracellular
domain
asubunit
human
muscl
acetylcholin
receptor
plant
toxin
gelonin
express
ecoli
fusion
protein
form
inclus
bodi
could
solubil
presenc
guanidinium
chlorid
exhibit
rather
nativ
structur
shown
antibodi
recogn
conform
epitop
half
maxim
inhibit
translat
achiev
ngml
compar
ngml
nativ
recombin
gelonin
use
therapeut
agent
treatment
myasthenia
gravi
investig
anim
model
femal
lewi
rat
immun
complet
acetylcholin
receptor
electr
ray
torpedo
californica
develop
thereaft
experiment
autommun
myasthenia
gravi
quantit
assess
diseas
achiev
repetit
stimul
sciatic
nerv
rat
show
symptom
myasthenia
gravi
neither
visual
electrophysiolog
treatment
fusion
protein
determin
one
seven
week
second
applic
schill
goelz
r
linker
f
luhder
r
gold
institut
multipl
sclerosi
research
univers
goettingen
gemeinnuetzig
hertiestiftung
goettingen
germani
biogen
idec
cambridg
usa
background
treatment
fumar
acid
deriv
well
establish
effect
therapi
sever
psoriasi
mediat
skin
diseas
propos
one
underli
way
fumar
acid
work
induc
shift
studi
investig
clinic
molecular
effect
dimethyl
fumar
dmf
monomethyl
fumar
mmf
chronic
eae
model
multipl
sclerosi
method
mice
immun
myelinoligodendrocyt
glycoprotein
peptid
aa
mog
cfa
receiv
pertussi
toxin
group
micegroup
treat
day
day
twice
day
mgkg
bodi
weight
dimethyl
fumar
dmf
monomethyl
fumar
mmf
vehicl
alon
medic
administ
oral
gavag
anim
weigh
score
clinic
sign
diseas
daili
basi
day
mice
reach
paraplegia
sacrif
due
anim
experiment
law
blood
sampl
taken
mice
immun
peak
diseas
day
partial
remiss
day
plasma
protein
concentr
cytokin
chemokin
marker
measur
multianalyt
profil
map
test
result
control
group
mmf
treat
group
mice
suffer
paraplegia
wherea
dmf
group
mice
reach
clinic
endpoint
onset
diseas
earlier
mmf
treat
group
mean
day
compar
dmf
mean
day
control
group
mean
day
signific
dmf
treat
mice
significantli
less
sever
clinic
cours
prevent
treatment
approach
blood
sampl
current
analyz
use
multianalyt
profil
includ
cytokin
chemokin
histolog
studi
ongo
conclus
data
suggest
dmf
benefici
effect
chronic
eae
present
cytokin
histolog
result
pend
analys
benefici
autoimmun
restrain
destruct
immun
regulatori
manner
nathan
karin
yaniv
zohar
uri
weinberg
rachel
anunu
gizi
wildbaum
immunolog
rappaport
faculti
medicin
technion
haifa
israel
previou
studi
shown
target
dna
vaccin
encod
select
proinflammatori
mediat
particularli
chemokin
cytokin
could
effect
suppress
experiment
induc
autoimmun
diseas
select
manner
exampl
target
dna
vaccin
encod
cc
chemokin
rant
could
select
suppress
experiment
induc
rheumatoid
arthriti
benefici
effect
experiment
autoimmun
encephalomyel
eae
wherea
dna
vaccin
encod
effect
suppress
diseas
benefici
effect
vaccin
could
transfer
chemokinespecif
autoantibodi
develop
protect
donor
throughout
studi
repeatedli
observ
unexpect
phenomena
elicit
benefici
autoantibodi
product
ongo
autoimmun
rapid
current
present
shall
show
rapid
respons
result
amplif
regulatori
respons
induc
diseas
shall
show
high
relev
regulatori
mechan
human
diseas
therapeut
implic
autoimmun
cancer
key
refer
wildbaum
g
nahir
karin
n
benefici
autoimmun
proinflammatori
mediat
restrain
consequ
selfdestruct
immun
immun
regulatori
tcell
suppress
human
murin
tcell
function
role
regulatori
cell
human
diseas
modul
major
interest
enhanc
surviv
expans
regulatori
cell
would
benefici
autoimmun
diseas
contrast
increas
deplet
apoptosi
would
advantag
cancer
addit
describ
sensit
depriv
show
freshli
isol
facssort
human
regulatori
cell
highli
sensit
toward
apoptosi
contrast
cell
counterpart
howev
restimul
expand
regulatori
cell
reveal
reduc
sensit
toward
activ
induc
cell
death
aicd
contrast
aicdsensit
cell
simultan
expand
regulatori
cell
remain
highli
sensit
toward
apoptosi
murin
regulatori
cell
display
similar
sensit
data
suggest
model
cell
could
modul
number
regulatori
cell
via
system
contract
phase
immun
respons
furthermor
found
defect
suppress
function
regulatori
cell
multipl
sclerosi
ms
patient
given
known
alter
system
ms
investig
whether
alter
sensit
regulatori
cell
toward
apoptosi
could
critic
modul
defect
regulatori
respons
multipl
sclerosi
accumul
regulatori
cell
cn
recoveri
eae
mani
studi
focu
role
regulatori
cell
treg
prevent
onset
autoimmun
investig
regul
activ
pathogen
cell
spontan
remit
model
autoimmun
diseaseexperiment
autoimmun
encephalomyel
eae
eae
induc
immun
mice
central
nervou
system
cn
autoantigen
peptid
mog
hand
lead
develop
eae
day
postimmun
peak
diseas
second
week
follow
recoveri
phase
mice
free
clinic
sign
day
postimmun
mice
subsequ
resist
second
round
diseas
reimmun
mog
spinal
cord
drain
lymph
node
ln
cell
purifi
mice
differ
timepoint
diseas
cell
phenotyp
examin
fac
analysi
function
test
abil
prolifer
suppress
prolifer
cytokin
product
narv
prime
cell
vitro
found
proport
cell
express
cn
increas
cours
diseas
correl
recoveri
cell
preferenti
produc
ifngsecret
cell
vitro
cn
cell
anerg
prolifer
respons
presenc
cell
could
also
suppress
prolifer
respond
vitro
antibodi
use
deplet
cell
vivo
day
prior
eae
induct
deplet
led
exacerb
diseas
greatli
delay
recoveri
support
function
role
treg
remiss
interestingli
recoveri
render
mice
fulli
suscept
reinduct
moreov
transfer
cnsderiv
cell
led
acceler
recoveri
subsequ
eae
conclus
accumul
treg
produc
cn
recoveri
phase
eae
suggest
role
control
myelinreact
pathogen
cell
hypothesi
autoantigenreact
regulatori
cell
expand
induc
drain
lymph
node
recruit
effector
site
aid
resolut
autoimmun
diseas
multipl
sclerosi
defin
inflammatori
demyelin
diseas
white
matter
central
nervou
system
function
neurolog
deficit
patient
acut
relapsingremit
ms
explain
focal
white
matter
lesion
cn
case
patient
primari
secondari
progress
ms
experi
gradual
accumul
clinic
deficit
far
patholog
featur
diseas
describ
clearli
distinguish
relapsingremit
progress
diseas
ms
patient
present
studi
systemat
analyz
cortic
white
matter
patholog
larg
sampl
multipl
sclerosi
brain
differ
diseas
cours
case
acut
ms
rrm
spm
ppm
hemispher
doubl
hemisper
tissu
section
examin
cortic
demyelin
patholog
chang
white
matter
offer
uniqu
opportun
evalu
diseas
involv
larg
tissu
area
cortic
demyelin
plaqu
abund
patient
primari
secondari
progress
ms
virtual
absent
patient
acut
rrm
percentag
demyelin
cortic
area
acut
ms
rrm
ppm
spm
p
focal
load
demyelin
lesion
white
matter
almost
four
group
similar
result
obtain
analysi
cerebellar
cortex
percentag
demyelin
cortic
area
acut
ms
rrm
ppm
spm
p
especi
primari
also
secondari
progress
ms
case
myelin
pallor
observ
normal
appear
white
matter
associ
signific
inflamm
well
microglia
macrophag
activ
patholog
chang
spars
acut
rrm
brain
inflammatori
infiltr
per
mm
acm
rrm
ppm
spm
p
correl
size
locat
white
matter
plaqu
cortic
demyelin
diffus
white
matter
damag
observ
conclus
suggest
ms
brain
three
differ
patholog
process
occur
stagespecif
occur
least
part
independ
focal
white
matter
plaqu
cortic
demyelin
diffus
damag
white
matter
patholog
occur
background
inflamm
although
type
inflamm
differ
focal
white
matter
lesion
seem
due
new
wave
inflamm
enter
brain
bbb
damag
chronic
diseas
inflammatori
cell
accumul
gradual
throughout
whole
cn
lead
diffus
damag
bnormalq
white
matter
cortex
use
mous
model
distinct
hereditari
demyelin
neuropathi
heterocyg
homocyg
could
recent
demonstr
tcell
macrophag
involv
pathogenesi
hereditari
demyelin
disord
beyond
immun
cell
also
found
bloodderiv
fibroblastlik
cell
endoneurium
suppos
fibroblastlik
cell
might
ident
recent
describ
popul
peripher
blood
fibrocyt
might
therefor
compris
anoth
cell
type
potenti
import
immun
regul
hereditari
demyelin
neuropathi
studi
character
novel
cell
popul
endoneurium
observ
fibroblastlik
cell
show
close
contact
endoneuri
macrophag
contact
site
two
cell
popul
found
regularli
normal
demyelin
condit
interact
two
cell
popul
seem
play
role
immun
regul
within
peripher
nerv
sinc
immunodefici
lack
agerel
increas
cell
parallel
occurr
patholog
chang
within
peripher
nerv
suppos
lack
fibroblastlik
cell
might
result
alter
macrophag
activ
conclus
could
show
macrophag
fibroblastlik
cell
close
contact
within
endoneurium
accord
morpholog
observ
hypothes
fibroblastlik
cell
involv
regul
macrophag
function
demyelin
condit
introduct
increas
evid
indic
infect
epsteinbarr
viru
ebv
role
pathogenesi
mani
human
chronic
autoimmun
diseas
includ
multipl
sclerosi
ms
propos
new
hypothesi
chronic
autoimmun
diseas
occur
individu
genet
suscept
effect
bcell
infect
ebv
ebvinfect
b
cell
produc
autoantibodi
also
inhibit
activationinduc
apoptosi
autoreact
cell
target
organ
trend
immunol
http
eprintuqeduau
aim
studi
aim
determin
whether
patient
ms
increas
frequenc
ebvinfect
immort
b
cell
defect
immun
latent
ebv
infect
may
lead
develop
ms
method
sera
patient
ms
immunomodulatori
therapi
healthi
control
test
presenc
antiebv
viral
capsid
antigen
vca
igg
antiebv
nuclear
antigen
ebna
igg
use
elisa
use
realtim
pcr
quantifi
ebv
dna
load
cerebrospin
fluid
csf
peripher
blood
mononuclear
cell
pbmc
patient
ms
also
perform
ifngamma
elispot
assay
measur
peripher
blood
tcell
reactiv
major
histocompat
complex
mhc
classirestrict
latent
lytic
ebv
peptid
mhc
classiirestrict
ebv
peptid
human
cytomegaloviru
hcmv
peptid
result
preliminari
result
show
detect
level
ebv
dna
csf
patient
ms
furthermor
result
ifngamma
elispot
assay
indic
reduct
tcell
respons
mhc
classirestrict
latent
ebv
peptid
ms
patient
compar
healthi
control
conclus
find
presenc
ebv
csf
ms
patient
reduc
tcell
immun
latent
ebv
antigen
may
shed
light
role
ebv
infect
pathogenesi
ms
associ
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
femal
male
cidp
inflammatori
demyelin
diseas
affect
peripher
nervou
system
relat
syndrom
gb
chronic
condit
distinguish
gb
tempor
pattern
potenti
clinic
relaps
cidp
occur
commonli
male
femal
thought
autoimmun
natur
although
still
remain
unproven
thought
cidp
might
autoimmun
compon
sever
studi
investig
hla
molecul
carri
patient
cidp
studi
shown
trend
toward
increas
carriag
hla
howev
sinc
cidp
rel
uncommon
number
individu
studi
small
major
patient
male
studi
autoimmun
diseas
shown
sexrel
factor
appear
influenc
risk
associ
carriag
differ
hla
molecul
set
test
larger
cohort
patient
determin
hla
associ
cidp
whether
differ
depend
gender
patient
investig
carriag
class
ii
hla
molecul
cohort
cidp
patient
male
compar
carriag
molecul
healthi
control
patient
gb
dna
extract
ml
whole
blood
collect
written
inform
consent
obtain
dynal
lowresolut
ssp
kit
use
type
hladr
dqa
dqb
molecul
resolut
equival
serotyp
subgroup
comparison
femal
healthi
control
increas
carriag
femal
patient
cidp
p
b
femal
patient
gb
upon
subtyp
individu
major
individu
group
found
carri
differ
frequenc
carriag
male
group
trend
male
cidp
patient
toward
increas
carriag
compar
male
control
wherea
trend
toward
decreas
carriag
femal
cidp
patient
compar
control
result
confirm
associ
carriag
develop
cidp
signific
differ
frequenc
carriag
dqa
dqb
molecul
healthi
control
cidp
patient
gb
patient
group
consid
whole
subdivid
base
gender
result
show
genderspecif
hladr
associ
occur
cidp
reflect
similar
find
studi
autoimmun
diseas
provid
addit
evid
autoimmun
diseas
mechan
cidp
hla
type
studi
done
low
resolut
associ
cidp
particularli
male
carriag
particular
hla
molecul
may
becom
appar
type
done
molecular
level
j
greer
p
pender
school
medicin
univers
queensland
brisban
queensland
australia
myelin
proteolipid
protein
plp
abund
protein
central
nervou
system
myelin
put
target
antigen
multipl
sclerosi
ms
increas
level
cell
reactiv
direct
plp
welldocu
ms
found
also
increas
level
antibodi
specif
plp
particularli
extracellular
loop
consist
amino
acid
patient
ms
compar
healthi
control
patient
neurolog
diseas
ond
aim
current
studi
determin
whether
antibodi
could
pathogen
relev
ms
sera
patient
ms
primari
progress
ms
secondari
progress
ms
establish
relapsingremit
ms
first
attack
ms
patient
ond
healthi
control
screen
abil
opson
diilabel
purifi
human
myelin
therebi
increas
uptak
myelin
macrophag
percentag
individu
group
whose
sera
induc
level
myelin
uptak
greater
standard
deviat
higher
mean
healthi
control
group
ms
healthi
control
ond
patient
sera
secondari
primari
progress
ms
patient
induc
increas
level
myelin
uptak
macrophag
percentag
patient
establish
relapsingremit
ms
first
attack
whose
sera
induc
increas
level
myelin
uptak
macrophag
slightli
lower
sera
induc
increas
myelin
uptak
contain
antibodi
specif
region
assess
elisa
preadsorpt
sera
peptid
region
plp
molecul
found
abl
inhibit
partli
whole
opson
potenti
sera
show
plp
reactiv
elisa
thu
approxim
patient
ms
contain
plpspecif
antibodi
sera
opson
myelin
phagocytosi
antibodi
could
function
pathogen
effect
ms
via
varieti
mechan
caus
demyelin
antibodydepend
cellmedi
cytotox
complementdepend
lysi
via
opson
myelin
result
phagocytosi
addit
may
induc
upregul
mhc
costimulatori
molecul
cn
inhibit
remyelin
caus
axon
damag
modul
synapt
transmiss
antibodi
could
bind
extracellular
epitop
intact
myelin
would
like
directli
pathogen
one
recogn
disrupt
myelin
although
later
could
involv
escal
inflamm
activ
complement
cascad
result
show
plpspecif
antibodi
exhibit
least
one
potenti
pathogen
effect
identif
ms
patient
exhibit
elev
pathogen
antibodi
respons
may
import
step
select
patient
treatment
intraven
immunoglobulin
plasmapheresi
decreas
activ
korn
magnu
jung
depart
neurolog
universitaet
de
saarland
homburg
germani
stem
cell
section
laboratori
neurosci
nation
institut
age
nation
institut
health
baltimor
md
usa
glutam
excitotox
increasingli
recogn
pathogen
mechan
autoimmun
inflammatori
disord
central
nervou
system
cn
astrocyt
predomin
player
clear
extracellular
space
glutam
normal
extens
spare
capac
term
glutam
uptak
ask
might
basi
glutam
accumul
celltrigg
autoimmun
inflamm
vitro
exposur
primari
rat
astrocyt
antigenactiv
myelin
basic
protein
mbp
specif
cell
result
decreas
astrocyt
glutam
uptak
rate
far
v
max
concern
parallel
amount
astrocyt
na
depend
glutam
transport
glast
reduc
time
rang
h
similar
decreas
glast
protein
observ
astrocyt
reisol
cocultur
cell
activ
mbp
astrocyt
antigen
present
cell
apc
cocultur
cell
blast
preactiv
presenc
splenocyt
beforehand
sinc
incub
astrocyt
cellfre
supernat
mbpactiv
cell
also
result
reduc
express
glast
humor
factor
appear
drive
agent
block
experi
use
neutral
antibodi
exposur
astrocyt
recombin
cytokin
tumor
necrosi
factora
tnfa
identifi
respons
downmodul
glast
glast
also
downregul
cn
autoimmun
encephalit
rat
anim
suffer
system
inflamm
sinc
loss
glast
confin
inflammatori
infiltr
humor
factor
seem
caus
conclus
cellderiv
tnfa
impair
glutam
clearanc
capac
astrocyt
vitro
probabl
also
vivo
autoimmun
inflammatori
disord
provid
pathogen
link
glutam
excitotox
may
respons
earli
axon
dysfunct
remot
activ
inflammatori
demyelin
full
activ
tcell
requir
costimulatori
signal
interact
besid
mhcpeptidetcr
signal
previous
shown
dko
mice
genet
background
sjlj
versu
determin
requir
costimul
induct
eae
wherea
dko
background
highli
resist
develop
eae
follow
immun
encephalitogen
mog
peptid
dko
mice
sjl
mice
remain
suscept
eae
immun
plp
peptid
sinc
two
strain
differ
mhc
molecul
thu
differ
peptid
bind
select
expans
encephalitogen
cell
repertoir
examin
role
mhc
determin
requir
costimul
inea
sjlx
dko
backcross
mice
found
homozygos
haplotyp
strong
suscept
factor
clinic
histolog
eae
mice
order
detect
suscept
region
studi
mog
eae
dko
mice
select
least
one
b
allel
mhc
locu
addit
suscept
region
identifi
result
indic
express
class
ii
molecul
homozygos
allel
locu
major
suscept
factor
determin
requir
depend
induct
eae
object
induc
toler
immunecompet
anim
plasmid
express
membranebound
singlechain
antibodi
materi
method
thirti
old
immunecompet
mice
divid
three
group
ten
mice
receiv
intramuscular
inject
endotoxinfre
plasmid
pcblacz
left
anterior
tibiali
plasmid
encod
potent
immunogen
escherichia
coli
betagalactosidas
ten
mice
receiv
coinject
pcblacz
anoth
ten
mice
receiv
five
consecut
intramuscular
inject
plasmid
five
receiv
inject
pcblacz
alon
five
receiv
coinject
two
plasmid
result
singl
inject
examin
express
betagalactosidas
muscl
fiber
th
th
day
inject
signific
differ
transduc
muscl
fiber
found
day
singl
inject
howev
serum
igg
betagalactosidas
much
lower
anim
receiv
consecut
inject
two
plasmid
compar
control
group
conclus
express
antibodi
muscl
cell
protect
express
betagalactosidas
immunecompet
mice
membran
bound
singlechain
antibodi
attenu
host
humor
immun
respons
repeat
immun
probabl
mechan
peripher
toler
induc
anergi
activ
cell
interact
singlechain
antibodi
novel
strategi
target
activ
cell
may
use
treatment
acquir
autoimmun
diseas
memori
cell
eae
memori
cell
pool
function
dynam
repositori
antigenexperienc
lymphocyt
accumul
lifetim
individu
previou
studi
indic
cell
reactiv
myelin
antigen
mainli
memori
cell
ms
patient
hypothes
specif
mechan
diseas
mediat
memori
cell
develop
anim
model
memori
cellinduc
eae
wildtyp
wt
mog
tcr
transgen
memori
cell
gener
wt
transgen
mice
respect
immun
mogcfa
day
cell
sort
immedi
transfer
tcr
ab
mice
follow
immun
mogcfa
control
group
mice
immun
mog
peptid
use
gener
effector
cell
data
indic
diseas
induc
memori
cell
sever
compar
induc
effector
cell
confoc
doublelabel
imag
show
cn
infiltr
memori
cell
associ
astrocyt
activ
dramat
demyelin
shown
gfapposit
cell
stain
respect
furthermor
sort
memori
accord
express
either
provid
central
tcm
effector
tem
memori
cell
demonstr
sever
eae
induc
tem
tcm
associ
increas
prolifer
high
product
ifng
respons
mog
peptid
vitro
costimulatori
signal
blockad
cell
model
demonstr
suppress
effector
eae
significantli
inhibit
diseas
induc
memori
cell
contrast
antiicosl
treatment
worsen
effector
cellinduc
eae
inhibit
memori
cellinduc
diseas
data
suggest
presenc
specif
mechan
diseas
mediat
memori
cell
relev
treatment
human
autoimmun
diseas
costimulatori
signal
block
agent
therapeut
effect
glycosyl
b
interferon
bifn
childhood
adrenoleukodystrophi
ald
ccer
g
moviglia
e
pereyra
g
shuster
c
ruggilo
immunotherapi
regina
mater
foundat
bueno
air
argentina
mri
medic
imag
bueno
air
argentina
childhood
cerebr
adrenoleukodystrophi
ald
ccer
genet
diseas
base
bibliograph
research
experi
conjectur
lesion
caus
central
nervou
system
cn
result
autoimmun
demyelin
reaction
resembl
multipl
sclerosi
ms
inflammatori
reaction
bifn
shown
posit
therapeut
action
ms
reason
develop
clinic
trial
test
effect
ald
ccer
thirteen
boy
affect
diseas
divid
three
group
group
patient
behavior
perform
index
bpi
point
receiv
bifn
group
b
patient
bpi
point
receiv
bifn
group
c
patient
bpi
point
receiv
medic
bifn
suppli
aresserono
intern
dosag
schedul
iu
bifn
intramuscular
inject
pm
three
consecut
day
everi
week
patient
follow
month
via
monthli
neurolog
psycholog
immunolog
evalu
telephon
followup
thereaft
assess
surviv
gener
clinic
neuropsycholog
perform
result
small
clinic
trial
strongli
suggest
bifn
chang
natur
histori
ald
ccer
bifn
improv
clinic
condit
patient
first
group
almost
three
year
maintain
condit
two
patient
present
six
year
stop
bifn
treatment
treatment
also
slow
evolut
diseas
second
group
mri
immunolog
psychometr
data
confirm
find
support
theori
interact
immun
cell
nervou
tissu
cell
play
crucial
role
cn
repair
well
bifn
may
therapeut
agent
multipl
sclerosi
ms
common
neurolog
autoimmun
disord
diagnos
young
adult
character
repeat
occurr
demyelin
lesion
within
central
nervou
system
pohlau
et
al
part
mechan
ms
abnorm
product
autoantibodi
specif
produc
crossreact
epitop
lead
autoimmun
reaction
myelin
belief
ivig
act
neuroimmun
modul
patient
diagnos
ms
current
research
demonstr
relaps
ms
associ
exist
high
dose
ivig
reduct
relaps
rate
exacerb
number
size
brain
lesion
well
increas
function
improv
recent
studi
research
univers
california
found
antimyelin
antibodi
found
virtual
patient
progress
multipl
sclerosi
brown
theoriz
antimyelin
antibodi
may
use
marker
treatment
patient
diagnos
progress
ms
high
dose
ivig
treatment
studi
report
patient
diagnosi
progress
multipl
sclerosi
diseas
result
rapid
regress
past
year
subject
present
clinic
histori
countless
treatmentt
therapi
fail
improv
condit
stall
regress
extens
immun
workup
reveal
extrem
low
number
along
low
lymphocyt
stimul
function
subclass
defici
posit
antimyelin
antibodi
past
record
indic
presenc
posit
antimyelin
antibodi
year
upon
complet
thorough
physic
examin
workup
patient
start
high
dose
ivig
divid
three
consecut
day
subsequ
test
conduct
short
period
time
reveal
neg
antimyelin
patient
ivig
three
month
result
treatment
begin
display
increas
energi
decreas
muscl
spastic
improv
abil
walk
base
upon
preliminari
data
suggest
ivig
may
immunomodulatori
effect
ms
antimyelin
ab
may
serv
marker
immunomodul
effect
crossreact
activ
high
affin
nonself
ligand
cell
potenti
recogn
self
may
import
break
selftoler
tcr
transgen
mous
show
broad
crossreact
number
ligand
previous
shown
hyperstimul
superagonist
ligand
induc
unrespons
selfligand
proteolipid
protein
plp
peptid
examin
role
crossreact
superagonist
autoimmun
respons
demonstr
superagonist
ligand
break
toler
induc
lower
affin
cognat
antigen
propos
balteredq
hierarch
anergi
model
cell
toler
cognat
ligand
respond
superagonist
prolifer
product
mainli
vitro
contrast
cell
toler
superagonist
unabl
respond
peptid
crossreact
transgen
tcr
vivo
lowdos
immun
superagonist
abl
break
toler
cognat
ligand
result
blunt
prolif
respons
cytokin
product
follow
rechalleng
vitro
combin
differ
cell
respons
may
thu
provid
multilevel
defens
autoimmun
cell
respons
crossreact
highaffin
foreign
antigen
may
serv
import
regulatori
mechan
prevent
autoimmun
diseas
agonist
antibodi
inhibit
cell
expans
cytokin
product
develop
autoimmun
k
miyamoto
l
vijayakrishnan
e
greenfield
b
carreno
sharp
v
kuchroo
center
neurolos
diseas
bwh
harvard
medic
school
boston
usa
patholog
bwh
harvard
medic
school
boston
usa
neurolog
kinki
univers
osakasayama
osaka
japan
gener
novel
agonist
monoclon
antibodi
immun
loum
rat
fusion
protein
screen
hybriboma
supernat
bind
elisa
cho
express
surfac
three
antibodi
thu
gener
one
antibodi
agonist
inhibit
cell
expans
ifng
secret
vitro
vivo
contrast
previous
describ
antibodi
promot
cell
clonal
expans
ifng
secret
presum
block
inhibitori
signal
deliv
compar
effect
antibodi
murin
relaps
remit
autoimmun
diseas
experiment
autoimmun
encephalomyel
eae
demyelin
diseas
mediat
specif
cell
sjl
j
mice
wherea
administr
antibodi
vivo
exacerb
eae
agonsit
antibodi
amelior
diseas
understand
molecular
basi
differ
function
effect
two
antibodi
undertook
epitop
map
bind
studi
demonst
tyrosin
residu
mypppi
domain
util
bind
molecul
also
crucial
bind
block
antibodi
agonist
antibodi
crossblock
studi
show
agonist
antibodi
recogn
close
relat
distinct
epitop
molecul
thu
bind
two
antibodi
close
relat
distinct
epitop
give
distinct
function
cell
respons
tumor
necrosi
factora
tnfa
import
immun
regul
inflammatori
cytokin
implic
pathogenesi
multipl
sclerosi
ms
singl
nucleotid
polymorph
g
posit
promot
previous
shown
polymorph
associ
tnfa
product
level
studi
effect
polymorph
suscept
multipl
sclerosi
screen
genom
dna
sampl
definit
ms
patient
unaffect
ethnic
match
individu
healthi
control
use
sequencespecif
primer
pcrssp
result
indic
frequenc
gg
genotyp
relat
low
product
tnfa
significantli
increas
ms
patient
compar
control
frequenc
ga
aa
genotyp
relat
high
product
tnfa
decreas
df
p
find
suggest
polymorph
posit
product
level
tnfa
could
influenc
suscept
ms
corticotropinreleas
hormon
crh
hypothalam
neuropeptid
thought
peripher
proinflammatori
effect
outsid
central
nervou
system
studi
shown
lymphocyt
produc
crh
crh
bind
site
present
macrophag
lymphocyt
upregul
crh
peptid
product
shown
peripher
site
acut
chronic
inflamm
object
studi
peripher
role
crh
lymphocyt
antigenpres
cell
apc
activ
immun
mediat
diseas
model
experiment
autoimmun
encephalomyel
eae
materi
method
crh
mice
genet
background
immun
mog
peptid
togeth
complet
freundt
adjuv
pertussi
toxin
sever
eae
score
scale
describ
previous
elimin
antiinflammatori
effect
corticosteron
astressin
peripher
crh
antagonist
glucocorticoid
inhibit
effect
given
wildtyp
mice
day
post
immun
comparison
crh
crh
cell
cell
prolifer
assay
elisa
assay
cytokin
product
conduct
either
narv
cell
tcr
stimul
mogspecif
cell
immun
mice
respons
girradi
mogload
apc
stimul
antigen
present
function
examin
mogspecif
wildtyp
cell
prolifer
respons
mogload
crh
crh
apc
stimul
inba
phosphoryl
crh
splenocyt
test
western
blot
analysi
result
found
crh
mice
well
astressin
treat
wildtyp
mice
resist
eae
decreas
clinic
score
well
decreas
cellular
infiltr
central
nervou
system
furthermor
antigenspecif
respons
prime
cell
well
tcr
costimul
respons
narv
cell
decreas
crh
mice
decreas
product
cytokin
ifng
increas
product
cytokin
wildtyp
mice
treat
vivo
crh
antagonist
astressin
show
decreas
ifng
product
prime
cell
vitro
effect
crh
independ
abil
increas
corticosteron
product
sinc
adrenalectom
wildtyp
mice
similar
diseas
cours
sever
control
mice
furthermor
decreas
antigenspecif
cell
respons
observ
wildtyp
mogspecif
cell
incub
mogload
crh
apc
compar
mogload
crh
apc
found
inba
phosphoryl
induc
tcr
crosslink
delay
compromis
crh
cell
conclus
peripher
crh
exert
proinflammatori
effect
eae
select
increas
respons
effect
crh
like
result
optim
activ
cell
activ
nfnb
pathway
rational
oral
hmgcoa
reductas
inhibitor
differ
abil
treat
hypercholesterolemia
recent
studi
shown
certain
statin
promot
bia
prevent
revers
relaps
chronic
paralysi
experiment
autoimmun
encephalomyel
eae
howev
clear
whether
statin
effect
other
treat
autoimmun
diseas
furthermor
studi
shown
purifi
statin
administ
either
oral
parenter
ip
also
immunomodulatori
effect
studi
examin
whether
statin
differ
abil
modul
autoimmun
eae
investig
whether
differ
formul
prescript
vs
purifi
rout
administr
oral
vs
parenter
effect
treatment
develop
bia
method
relapsingremit
eae
induc
plj
sjlj
mice
immun
mbp
prescript
formul
atorvastatin
rosuvastatin
lovastatin
simvastatin
pravastatin
placebo
administ
oral
pb
vehicl
one
time
daili
prescript
form
administ
one
ten
time
equival
highestapprov
human
dose
purifi
atorvastatin
administ
oral
parenter
cytokin
profil
cell
isol
treat
mice
evalu
elisa
phosphoryl
stat
signal
molecul
measur
western
blot
result
control
placebotr
mice
develop
eae
similar
incid
sever
statin
test
amelior
eae
atorvastatin
rosuvastatin
effect
administ
oral
prescript
formul
statin
inhibit
antigenspecif
prolifer
secret
cytokin
phosphoryl
atorvastatin
rosuvastatin
induc
cytokin
associ
increas
phosphoryl
immunodulatori
effect
revers
treatment
lmevalon
rout
administr
test
use
prescript
purifi
atorvastatin
oral
administ
prescript
atorvastatin
superior
purifi
atorvastatin
administ
either
parenter
oral
conclus
result
show
statin
amelior
eae
progress
although
individu
statin
appear
vari
strength
immunomodulatori
effect
statin
induc
bia
atorvastatin
rosuvastatin
potent
statin
lower
cholesterol
robust
amelior
eae
well
induct
cell
phenotyp
like
reflect
differ
enzymat
bind
effici
halflif
lipophob
drug
formul
rout
administr
import
factor
determin
vivo
immunomodul
atorvastatin
studi
highlight
import
select
type
statin
test
treatment
multipl
sclerosi
autoimmun
diseas
recent
work
use
function
magnet
reson
imag
fmri
indic
patient
multipl
sclerosi
ms
show
alter
brain
activ
motor
cognit
task
rel
control
howev
studi
examin
ms
patientst
brain
activ
pattern
fmri
probe
execut
cognit
function
present
studi
use
modifi
version
tower
london
task
examin
potenti
alter
neural
circuitri
strateg
plan
ms
six
ms
patient
four
healthi
control
administ
fmri
tower
london
task
includ
easi
move
solut
hard
move
solut
control
condit
hard
greater
easi
contrast
particular
interest
analys
fmri
data
obtain
ge
scanner
data
analyz
use
random
effect
model
ms
particip
control
activ
predict
region
task
perform
includ
right
dorsolater
prefront
cortex
ms
patient
show
increas
anterior
right
hemispher
activ
rel
control
p
b
contrast
control
tend
show
posterior
right
hemispher
activ
patient
p
b
behavior
control
tend
perform
better
patient
across
task
condit
preliminari
find
support
previou
report
alter
brain
activ
pattern
associ
cognit
ms
group
other
engag
longitudin
research
determin
relationship
chang
neural
activ
cognit
task
perform
examin
potenti
util
fmri
track
progress
brain
chang
associ
cognit
declin
ms
nathali
arbour
rejean
lapoint
philipp
saikali
jack
p
antel
intro
human
selfreact
cell
postul
play
import
role
mani
autoimmun
diseas
although
detect
selfreact
cell
directli
exvivo
achiev
indepth
function
character
cell
imped
low
precursor
frequenc
henc
research
expand
selfreact
cell
vitro
order
character
compar
cell
autoimmun
patient
control
antigen
specif
cell
need
restimul
regular
basi
new
antigen
present
cell
apc
antigen
ag
usual
achiev
use
autolog
fresh
frozen
irradi
peripher
blood
mononuclear
cell
pbmc
ebvimmort
b
cell
dendrit
cell
presenc
ag
approach
requir
either
one
larg
blood
sampl
cell
frozen
later
use
repetit
blood
draw
evalu
selfreact
cell
mani
donor
thu
hinder
larg
volum
blood
necessari
explor
method
success
appli
tumor
antigen
present
myelin
antigen
cell
use
vitro
expand
autolog
b
cell
lapoint
et
al
goal
assess
feasibl
expand
human
myelin
specif
cell
one
small
blood
draw
method
myelin
specif
cell
expand
ml
blood
pbmc
put
cultur
myelin
basic
protein
mbp
myelin
oligodendrocyt
glycoprotein
mog
peptid
week
first
round
stimul
cell
separ
use
bead
miltenyi
prior
restimul
parallel
fraction
donort
pbmc
stimul
irradi
fibroblast
presenc
b
cell
prolifer
round
stimul
cell
type
cultur
express
high
level
mhc
molecul
costimulatori
molecul
essenti
hallmark
effici
apc
expand
b
cell
load
ag
irradi
use
apc
stimul
cell
multipl
subsequ
round
stimul
cell
line
restimul
everi
day
cell
line
everi
day
prolifer
measur
thymidin
incorpor
cytokin
releas
elisa
result
second
third
round
stimul
cell
test
specif
compar
prolifer
ifng
secret
supernat
put
cultur
agload
b
cell
vs
unload
b
cell
cell
line
exhibit
agspecif
prolifer
andor
ifng
secret
least
two
time
higher
absenc
ag
consid
agspecif
expand
mbp
mog
specif
cell
line
obtain
multipl
donor
compar
number
obtain
tradit
approach
fresh
pbmc
kept
cultur
mani
week
conclus
human
myelin
specif
cell
line
expand
vitro
rel
small
blood
sampl
facilit
immunolog
studi
cell
multipl
donor
object
investig
effect
therapi
fusion
protein
experiment
autoimmun
encephalomyel
eae
background
peripher
cell
activ
migrat
central
nervou
system
cn
involv
pathogenesi
eaetarget
receptor
share
gand
h
portion
suppress
immun
responsesth
chain
specif
express
natur
killer
macrophag
endotheli
cell
tissu
brain
spleen
thymu
use
two
fusion
protein
induc
protect
eae
bind
activ
cell
induc
cytolysi
bind
method
mice
immun
cfa
induc
eae
daili
ip
inject
either
dose
control
given
day
start
either
day
day
postimmun
target
prime
effector
stage
diseas
respect
outcom
measur
includ
clinic
diseas
cell
prolifer
measur
thymidin
incorpor
cytokin
profil
measur
elispot
assay
immunohistolog
stain
cn
day
post
immun
result
earli
treatment
combin
fusion
protein
decreas
diseas
sever
mmg
incid
p
significantli
compar
control
ig
group
inject
alon
also
attenu
diseas
mmg
mmg
show
diseas
attenu
treatment
infus
protein
induc
high
background
prolifer
splenocyt
mog
peptidespecif
prolifer
suppress
splenocyt
p
well
combin
therapi
treat
mice
protect
mice
show
increas
mogspecif
product
compar
control
group
pb
stain
inflammatori
cell
cn
show
decreas
macrophag
infiltr
protect
group
particularli
receiv
combin
therapi
scarc
infiltr
posit
contrast
ifng
highli
express
cn
control
mice
well
treat
alon
inject
fusion
protein
effector
stage
diseas
show
protect
conclus
result
suggest
block
specif
protect
eae
effect
combin
cytolyt
effect
fusion
protein
protect
associ
increas
cytokin
peripheri
cn
addit
effect
combin
therapi
may
due
cytolyt
effect
mogspecif
cell
decreas
cell
migrat
cn
mediat
blockad
studi
need
done
order
fulli
understand
mechan
molecul
protect
eae
oral
exposur
solubl
antigen
lead
induct
system
hyporespons
phenomenon
known
oral
toler
studi
isol
dentrit
cell
dc
peyert
patch
pp
mesenter
lymph
node
mln
spleen
fed
mice
measur
abil
support
cell
prolifer
cytokin
product
differenti
found
abil
dc
support
cell
prolifer
appear
pp
first
follow
mln
spleen
moreov
pp
dc
promot
signific
increas
cytokin
ifng
tnfa
increas
cytokin
howev
mln
dc
promot
signific
increas
cytokin
although
dc
lymphoid
tissu
abl
induc
narv
cell
express
surfac
tgfb
determin
upregul
latencyassoci
peptid
lap
mln
dc
effici
peak
time
last
feed
mln
dc
induc
increas
cell
studi
demonstr
mln
dc
acquir
fed
antigen
induc
expans
cell
situ
may
particip
specif
toler
fed
antigen
regul
autoimmun
process
associ
oral
toler
autoantigen
multipl
sclerosi
ms
chronic
autoimmun
disord
affect
central
nervou
system
although
aetiolog
progress
neurolog
loss
yet
fulli
elucid
believ
genet
determin
suscept
environment
trigger
implic
detriment
immun
respons
compon
myelin
sheath
myelinspecif
cell
thought
play
central
role
anim
model
diseas
experiment
autoimmun
encephalomyel
eae
induc
mice
eae
inflammatori
demyelin
diseas
primarili
mediat
cell
share
clinic
histopatholog
aspect
ms
due
dendrit
cell
dc
profession
antigen
present
cell
import
activ
selfreact
cell
interest
evalu
therapeut
potenti
regul
autoimmun
respons
dc
central
role
maintain
peripher
toler
self
alter
physiolog
like
respons
defect
immun
regulatori
mechan
first
observ
immatur
dc
abl
promot
toler
eae
model
enhanc
tolerogen
capac
cell
use
drug
interfer
nfkb
activ
andrographolid
bicycl
diterpenoid
lacton
rosiglitazon
pparg
agonist
vitro
molecul
abl
interfer
dc
matur
abil
present
antigen
cell
cell
activ
dc
complet
abolish
expos
dc
andrographolid
rosiglitazon
antigen
puls
inject
immatur
dc
treat
either
andrographolid
rosiglitazon
show
enhanc
capac
reduc
eae
symptom
result
indic
inject
immatur
dc
prevent
myelinspecif
cell
activ
eae
data
suggest
pharmacolog
approach
promot
tolerogen
phenotyp
dc
could
use
potenti
strategi
design
new
therapi
prevent
treat
detriment
immun
respons
sjlj
mice
immunodomin
encephalitogen
epitop
induc
relapsingremit
form
eae
report
regulatori
cell
play
role
affect
onset
progress
eae
transfer
cell
stage
amelior
diseas
role
regulatori
cell
natur
recoveri
diseas
well
defin
show
eaerecov
sjlj
mice
increas
number
forkhead
box
express
cell
cell
anerg
inhibit
prolif
respons
cell
stimul
deplet
cell
prior
recoveri
phase
exacerb
diseas
result
expans
ia
cell
enhanc
ifng
product
addit
transform
growth
factor
tgfh
shown
involv
recoveri
eae
percentag
cell
express
tgfh
latenc
associ
peptid
lap
cell
surfac
increas
significantli
blood
spleen
eaerecov
mice
compar
narv
mice
p
b
p
b
respect
vivo
neutral
tgfh
abolish
recoveri
diseas
result
demonstr
regulatori
cell
mediat
recoveri
eae
sjlj
mice
tgfh
play
import
role
multipl
sclerosi
ms
multifactori
polygen
diseas
manifest
chronic
inflamm
cn
addit
influenc
presenc
absenc
diseas
genet
may
also
play
signific
role
individu
variat
prognosi
differenti
respons
therapi
among
patient
order
better
understand
genet
variat
involv
heterogen
aspect
diseas
select
snp
gene
associ
risk
sever
ms
least
one
publish
studi
loci
genotyp
use
dna
larg
ms
patient
registri
establish
longitudin
studi
aim
find
biomark
diseas
risk
prognosi
respons
therapi
casecontrol
associ
analysi
util
patient
enrol
date
ethnicallymatch
cohort
healthi
control
n
compar
patient
benign
vs
malign
diseas
cours
n
vs
observ
associ
mbp
diseas
prognosi
ci
paradox
allel
also
associ
presenc
benign
diseas
p
ci
therefor
risk
factor
time
provid
better
prognosi
comparison
respond
vs
nonrespond
betainterferon
glatiram
acet
therapi
n
vs
show
signific
associ
respons
ci
linear
regress
analysi
genotyp
associ
age
onset
reveal
potenti
involv
p
analys
control
gender
among
sever
marker
exhibit
signific
sexspecif
associ
tnf
associ
malign
diseas
femal
patient
p
significantli
associ
risk
diseas
male
p
result
illustr
complex
genet
etiolog
ms
involv
varieti
sometim
genderspecif
factor
combin
influenc
presenc
progress
diseas
marker
may
eventu
improv
understand
diseas
provid
better
clinic
diagnost
indic
diseas
risk
prognosi
multipl
sclerosi
ms
chronic
inflammatori
diseas
central
nervou
system
cn
although
caus
ms
still
uncertain
ongo
autoimmun
respons
myelin
antigen
seem
like
myelin
oligodendrocyt
glycoprotein
mog
consid
promis
candid
autoantigen
ms
mog
induc
experiment
autoimmun
encephalomyel
sever
rat
mous
strain
recent
find
ms
suggest
develop
antibodi
mog
associ
progress
diseas
earli
ms
howev
studi
human
anim
model
base
fragment
mog
protein
express
e
coli
achiev
physiolog
mog
express
proper
glycosyl
clone
human
mog
isoform
gene
lentivir
express
vector
transduc
primari
cell
sever
human
murin
tumor
cell
line
transduc
cell
line
express
high
level
mog
surfac
stabl
express
achiev
murin
lymphoma
sever
human
glioma
cell
line
transgen
line
allow
fast
reliabl
detect
antimog
antibodi
lower
nanogram
concentr
compar
sensit
elisa
assay
studi
ongo
determin
antimog
antibodi
ms
patient
control
obtain
insight
role
antimog
antibodi
multipl
sclerosi
l
astier
hafler
center
neurolog
diseas
brigham
woment
hospit
boston
usa
act
costimulatori
molecul
human
cell
colig
promot
cell
prolifer
furthermor
addit
induc
phenotyp
character
larg
product
regulatori
cytokin
howev
murin
transgen
model
two
intracytoplasm
isoform
produc
altern
splice
antagonist
role
vivo
cellmedi
inflamm
decreas
inflamm
increas
differ
link
differenti
effect
cell
prolifer
ctl
cytotox
well
product
henc
crucial
regul
cell
activ
depend
ratio
intracytoplasm
isoform
present
differ
outcom
cell
activ
might
result
human
multipl
sclerosi
ms
autoimmun
diseas
direct
involv
cell
investig
role
ms
previous
describ
could
induc
upon
stimul
healthi
donor
cell
patient
ms
produc
much
lesser
extend
investig
ratio
two
intracytoplasm
isoform
cell
patient
ms
compar
healthi
donor
interestingli
found
upon
costimul
ratio
alter
ms
patient
compar
healthi
individu
might
correl
lack
secret
observ
upon
stimul
preliminari
data
suggest
dysregul
activ
human
cell
may
involv
ms
etiolog
autoimmun
diseas
disproportion
affect
women
unfortun
anim
model
vitro
studi
show
steroid
hormon
estrogen
androgen
suppress
autoreact
respons
rais
question
evid
heighten
autoimmun
respons
women
would
help
explain
increas
suscept
autoimmun
diseas
address
question
examin
sex
differ
antigeninduc
cytokinesecret
cell
untreat
relapsingremit
multipl
sclerosi
rrm
patient
control
studi
ifng
tnfa
cytokin
respons
msrelev
epitop
myelin
mbp
plp
mog
well
irrelev
epitop
observ
signific
femal
skew
p
v
ifng
respons
plp
peptid
plp
show
simultan
male
skew
respons
plp
result
ratio
ms
femal
wherea
ms
male
ratio
similarli
plp
ms
femal
ratio
ms
male
ratio
mbp
respons
also
show
strong
gender
interact
ms
femal
strong
mbpifng
respons
virtual
mbp
respons
p
revers
true
ms
male
high
extrem
low
ifng
respons
p
mbp
gave
ratio
ms
femal
compar
ratio
ms
male
mog
ms
femal
gave
ratio
wherea
ms
male
gave
ratio
contrast
mitogenstimul
gave
ratio
less
fold
differ
ms
femal
ms
male
control
femal
show
slightli
elev
ifng
respons
compar
control
male
howev
ratio
result
show
msrelev
myelin
protein
induc
femal
ms
patientst
lymphocyt
secret
inflammatori
cytokin
wherea
myelin
epitop
induc
male
secret
antiinflammatori
cytokin
interact
suggest
diseas
gender
independ
factor
immun
respons
rather
interact
promot
gender
bia
cytokin
respons
may
explain
women
suscept
ms
gender
bia
cytokin
respons
could
implic
design
clinic
trial
involv
antigenspecif
therapi
ms
develop
approach
test
new
hypothesi
intrathym
pathogenesi
myasthenia
gravi
hypothesi
posit
acetylcholin
receptor
alpha
subunit
achra
specif
cell
escap
central
delet
migrat
thymu
cours
nonspecif
inflammatori
reaction
activ
intrathym
express
autoantigen
approach
entail
express
torpedo
achra
tachra
neoselfantigen
thymu
adult
mice
achra
cell
see
immunodomin
tachra
peptid
crossreact
mous
achra
thu
epitop
encount
mous
thymu
express
tachra
howev
wide
regard
membran
express
achr
requir
proper
assembl
fold
constitu
subunit
tachr
subunit
assembl
express
reason
even
though
tachra
would
assembl
mous
subunit
c
possibl
small
amount
tachra
could
express
surfac
mammalian
cell
vivo
murin
bodi
temperatur
transient
transfect
line
mammalian
vector
express
tachra
cdna
addit
experi
cell
transfect
either
mous
achra
alon
tachra
mous
achrh
achri
achr
mous
achr
mous
achrh
achri
achr
posit
control
express
achra
protein
investig
flow
cytometri
use
mab
rat
igg
mab
see
epitop
extracellular
domain
torpedo
well
mammalian
achra
follow
fitcgoat
antirat
igg
antibodi
detect
express
transfect
protein
also
use
fitcabungarotoxin
independ
marker
detect
alpha
subunit
mocktransfect
cell
serv
neg
control
observ
low
albeit
statist
signific
number
viabl
cell
surfac
stain
mab
transfect
mous
achra
rel
mock
transfect
cell
similar
magnitud
tachra
express
cell
transfect
tachra
augment
tachra
express
mous
achrh
achri
achr
subunit
cotransfect
mani
posit
control
cell
transfect
murin
achr
h
e
subunit
express
mous
achra
transfect
cell
permeabil
treatment
saponinparaformaldehyd
express
consider
amount
tachra
intracellularli
thu
despit
temperatur
requir
uniqu
assembl
tachr
subunit
membran
express
small
amount
tachra
like
mous
achra
transport
cell
membran
express
singl
entiti
greater
amount
unassembl
tachra
mous
achra
subunit
detect
intracyoplasm
result
indic
unassembl
tachra
inde
express
onin
mammalian
cell
vivo
lay
groundwork
determin
whether
tachraspecif
cell
activ
encount
cognat
autoantigen
thymu
context
promot
activ
dressel
vogelgesang
peter
f
weber
depart
neurolog
univers
greifswald
greifswald
germani
section
neurolog
maxplanckinstitut
psychiatri
munich
germani
background
multipl
sclerosi
ms
frequent
disabl
neurolog
diseas
young
adult
glatiram
acet
ga
synthet
amino
acid
copolym
shown
reduc
relaps
rate
patient
relapsingremit
ms
propos
mechan
action
ga
function
suppress
autoreact
cell
specif
myelin
antigen
ga
reactiv
tcell
gener
mspatient
control
us
other
cell
may
involv
pathogenesi
ms
establish
experiment
system
gener
human
ga
reactiv
tcell
line
clone
demonstr
antigen
specif
dose
depend
prolifer
und
ifn
gamma
product
aim
current
studi
investig
cytokin
profil
gareact
cell
line
deriv
ms
patient
control
result
far
cell
line
healthi
volunt
line
ga
treat
ms
patient
line
untreat
ms
patient
gener
ga
reactiv
cell
untreat
ms
patient
produc
ifn
gamma
p
b
p
b
less
p
b
cell
deriv
healthi
volunt
cell
deriv
ga
treat
ms
patient
show
less
tnf
alpha
p
b
lower
level
p
b
less
p
b
p
b
product
cell
line
gener
untreat
ms
patient
conclus
data
present
demonstr
cytokin
spectrum
secret
ga
reactiv
cell
differ
untreat
ms
patient
healthi
control
cytokin
shift
may
partli
correct
initi
ga
treatment
patient
suffer
rrm
acknowledg
work
part
support
teva
pharma
deutschland
gmbh
fw
ad
gesellschaft
fqr
nervenheilkund
mecklenburgvorpommern
av
ad
multipl
sclerosi
ms
chronic
diseas
central
nervou
system
character
inflamm
area
demyelin
role
innat
immun
system
diseas
emerg
one
critic
famili
molecul
innat
immun
tolllik
receptor
tlr
famili
play
fundament
role
pathogen
recognit
activ
innat
immun
respons
tlr
implic
sever
autoimmun
diseas
role
ms
remain
unclear
present
initi
explor
role
two
molecul
use
retrospect
studi
immunophenotyp
captur
ms
natur
histori
databas
partner
ms
center
boston
analyz
data
fortyfour
patient
ms
mcdonald
criteria
subject
data
three
differ
visit
ms
center
cours
one
year
visit
peripher
blood
mononuclear
cell
pbmc
collect
stain
use
monoclon
antibodi
express
molecul
pbmc
measur
ex
vivo
stimul
lipopolysaccharid
lp
ionomycin
data
correl
associ
clinic
phenotyp
avail
databas
includ
diseas
subtyp
cours
activ
well
mri
volumetr
data
larg
interindividu
intraindividu
variabl
express
cell
observ
despit
precis
measur
clinic
laboratori
variabl
could
explain
sole
diseas
activ
subject
report
databas
role
cell
ms
remain
unclear
howev
data
demonstr
express
cell
may
undergo
larg
intraindividu
fluctuat
time
fact
need
taken
account
futur
associ
molecul
human
diseas
matrix
metalloproteinas
mmp
famili
proteas
includ
membranebound
mmp
mtmmp
physiolog
inhibitor
tissu
inhibitor
metalloproteinas
timp
mmp
thought
mediat
cellular
infiltr
cn
inflamm
integr
part
pathogenesi
multipl
sclerosi
ms
anim
model
experiment
autoimmun
encephalomyel
eae
mmp
may
also
mediat
infiltr
possibl
repair
cn
injuri
investig
differenti
express
select
mmp
spinal
cord
mice
adopt
transfer
eae
model
cn
axon
injuri
hippocampu
use
realtim
rtpcr
profil
chang
express
secret
mmp
virtual
absent
uninflam
cn
highli
upregul
eae
express
almost
exclus
infiltr
macrophag
axon
transect
express
correl
kinet
macrophag
infiltr
measur
flow
cytometri
lesionreact
hippocampu
cc
chemokin
defici
mice
macrophag
infiltr
absent
consist
upregul
lesionreact
hippocampu
defici
mice
axon
transect
upregul
prior
leukocyt
infiltr
lesionreact
hippocampu
implic
endogen
sourc
may
express
counteract
potenti
damag
effect
mmp
wherea
major
secret
mmp
upregul
eae
mtmmp
downregul
convers
none
mtmmp
investig
far
affect
lesionreact
hippocampu
sort
microglia
cn
mice
eae
found
express
mtmmp
downregul
suggest
activ
microglia
cours
neuroinflamm
correl
reduc
express
mtmmp
activ
microglia
lesionreact
hippocampu
may
differenti
regul
mmp
express
possibl
axon
transect
lead
activ
microglia
absenc
inflamm
work
fund
ms
societi
canada
cihrihrt
grant
need
natur
histori
studi
multipl
sclerosi
ms
chronic
autoimmun
diseas
whose
main
pathophysiolog
featur
lymphocyt
infiltr
inflamm
demyelin
axon
damag
central
nervou
system
diseas
heterogen
clinic
manifest
prognosi
respons
differ
treatment
although
sever
therapi
avail
treat
patient
ms
tool
predict
cours
diseas
success
particular
treatment
still
miss
combin
differ
therapeut
strategi
direct
differ
pathophysiolog
process
diseas
might
necessari
order
achiev
goal
need
develop
reliabl
biomark
diseas
activ
respons
treatment
studi
examin
immunolog
biomark
analyz
relev
molecul
peripher
blood
mononuclear
cell
pbmc
patient
ms
ex
vivo
vitro
stimul
use
flow
cytometrybas
assay
measur
batteri
cytokin
chemokin
receptor
activ
marker
costimulatori
molecul
longitudin
one
hundr
patient
ms
enrol
multipl
sclerosi
natur
histori
studi
partner
ms
center
boston
patient
differ
categori
diseas
differ
treatment
subgroup
recruit
follow
prospect
three
year
consecut
measur
immunolog
marker
clinic
assess
mri
measur
chang
biomark
correl
clinic
mri
measur
respons
treatment
preliminari
analysi
show
differenti
effect
variou
therapi
differ
immunolog
target
increas
antiinflammatori
respons
other
dramat
reduc
proinflammatori
respons
differ
time
point
initi
therapi
prospect
multiparamet
analysi
immun
marker
clinic
respons
mri
support
repres
systemat
approach
identif
surrog
marker
diseas
activ
treatment
respons
patient
ms
purpos
iodoform
metabol
cytochrom
oxid
system
co
co
vivo
antiinflammatori
effect
co
previous
demonstr
lpsinduc
shock
graft
reject
lung
injuri
model
eae
increas
co
varieti
potenti
benefici
effect
includ
protect
nitric
oxid
synthas
cellular
infiltr
macrophag
activ
inflammatori
process
includ
tnfa
product
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
chosen
studi
effect
compound
acut
inflammatori
autoimmun
encephalomyel
method
eae
induc
lewi
rat
immun
day
myelin
basic
protein
mbp
guinea
pig
day
rat
develop
inflammatori
encephalomyel
lymphocyt
infiltr
subsequ
progress
paralysi
rat
inject
mbp
random
receiv
vehicl
iodoform
mgkgday
oral
gavag
daili
clinic
score
determin
scale
brain
spinal
cord
sampl
obtain
earli
peak
clinic
sign
vehicl
control
group
correspond
treat
group
cytokin
histolog
analysi
addit
pharmacokinet
blood
chemistri
also
determin
result
iodoform
reduc
sever
eae
dose
depend
fashion
signific
reduct
sever
evid
day
therapi
p
iodoform
amelior
patholog
damag
determin
imag
analysi
carboxyhemoglobin
level
peak
within
hour
administr
normal
within
hour
without
cumul
pharmacokinet
consequ
analysi
brain
cytokin
level
indic
iodoform
increas
eae
anim
effect
tnfa
ifng
conclus
result
demonstr
power
comedi
amelior
eae
suggest
studi
halothan
would
warrant
defin
potenti
benefit
treatment
human
autoimmun
diseas
ms
inflamm
import
aspect
autoimmun
diseas
contribut
patholog
condit
multipl
sclerosi
anim
model
experiment
autoimmun
encephalomyel
eae
process
underli
inflamm
cn
includ
migrat
cell
releas
effector
molecul
coordin
network
cytokin
chemokin
releas
resid
brain
cell
well
infiltr
immun
cell
follow
induct
eae
mice
lack
ifng
receptor
develop
sever
diseas
progress
rapidli
paralysi
death
compar
milder
relapsingremit
phenotyp
wildtyp
litterm
sever
diseas
observ
ifngdefici
mice
character
lesion
spinal
cord
brainstem
larger
diffus
wildtyp
mice
furthermor
inflammatori
cn
infiltr
consist
primarili
macrophag
microglia
cell
wildtyp
mice
includ
larg
number
polymorphonuclear
cell
mainli
neutrophil
ifngdefici
mice
clear
ifng
defici
result
neutrophil
infiltr
cn
hypothes
due
chang
cytokin
network
two
possibl
candid
molecul
promot
neutrophil
migrat
activ
induc
eae
wildtyp
ifngdefici
mice
activ
immun
peptid
cfa
investig
express
two
cytokin
realtim
pcr
mrna
detect
spinal
cord
unimmun
anim
induc
onset
eae
mrna
express
significantli
higher
level
spinal
cord
ifngdefici
mice
compar
wildtyp
mice
mrna
protein
express
constitut
spinal
cord
unimmun
mice
chang
onset
eae
also
investig
express
bind
protein
endogen
potent
inhibitor
regul
ifngamma
mrna
dramat
upregul
onset
eae
spinal
cord
wildtyp
ifngdefici
mice
studi
demonstr
ifngamma
defici
could
result
aberr
action
due
failur
upregul
thu
enhanc
neutrophil
infiltr
could
due
enhanc
express
lack
inhibit
elucid
pathway
help
understand
perturb
cytokin
network
impact
cellular
infiltr
cn
patholog
background
myelinoligodendrocyt
glycoprotein
mog
potent
encephalitogen
antigen
experiment
allerg
encephalomyel
eae
anim
model
multipl
sclerosi
ms
known
target
pathogen
demyelin
antibodi
respons
eae
human
antimog
antibodi
describ
prognost
marker
earli
ms
howev
antimog
antibodi
specif
found
high
proport
healthi
individu
analyz
differ
method
object
valid
novel
easi
perform
liquidphas
base
immun
assay
detect
serum
antimog
antibodi
assess
differ
immunolog
properti
mog
solutionand
solidphas
immun
assay
designmethod
sera
ms
patient
differ
diseas
stage
healthi
control
subject
hc
chosen
accord
reactiv
recombin
extracellular
human
mog
rhmog
determin
solidphas
elisa
test
presenc
antirhmog
igg
incub
biotinyl
rhmog
solut
immunecomplex
captur
platebound
protein
g
detect
peroxidaselabel
streptavidin
biotinyl
tetanu
toxoid
tt
use
posit
control
panel
monoclon
fab
fragment
fab
sera
nonhuman
primat
c
jacchu
marmoset
immun
either
human
whole
white
matter
hwm
recombin
ratmog
linear
mog
peptid
n
per
group
use
valid
assay
result
reactiv
solutionphas
rhmog
detect
human
contrast
high
antitt
reactiv
elisa
sera
react
equal
rhmog
tt
antitt
reactiv
correl
lp
elisa
highli
signific
p
b
pearsont
correl
valid
assay
technic
marmoset
eae
model
sera
mog
peptid
immun
anim
react
significantli
weaker
solutionphas
rhmog
compar
sera
ratmogor
hwmimmun
marmoset
mean
bind
ratio
vs
ratmogimmun
hwmimmun
respect
p
b
snk
ttest
bind
ratio
ratmogand
hwmimmun
sera
indistinguish
solutionor
solidphas
assay
mean
monoclon
antibodi
fab
fragment
abl
detect
fold
lower
antibodi
affin
solubl
rhmog
compar
solidphas
rhmog
conclus
conclud
inflammatori
myopathi
put
autoimmun
disord
character
muscl
weak
presenc
inflammatori
infiltr
skelet
muscl
inclus
bodi
myositi
ibm
inflammatori
cell
infiltr
muscl
character
predomin
cytotox
lymphocyt
appear
signific
b
cell
infiltr
indic
immunohistochemistri
recent
demonstr
presenc
signific
muscl
infiltr
plasma
cell
examin
immunoglobulin
variabl
region
sequenc
cell
b
cell
immunoglobulin
variabl
region
gene
librari
ibm
muscl
creat
revers
transcriptasepolymeras
chain
reaction
follow
sequenc
whole
immunoglobulin
cdna
variabl
region
allow
identif
somat
mutat
signific
oligoclon
expans
found
ibm
muscl
contrast
librari
peripher
blood
mononuclear
cell
show
oligoclon
expans
moreov
pattern
b
cell
affin
matur
evid
clone
share
accumul
vari
number
common
uniqu
somat
mutat
within
cdr
region
clonal
variat
also
observ
within
group
compris
b
cell
data
suggest
local
inflammatori
respons
occur
within
muscl
tissu
patient
ibm
may
indic
presenc
humor
antigenspecif
respons
present
muscl
interest
examin
genet
natur
singl
cell
share
investig
differ
field
limit
amount
genet
materi
singl
cell
specimen
present
technic
challeng
even
effici
specif
pcr
protocol
present
report
show
applic
recent
develop
method
whole
genom
amplif
wga
multipl
displac
amplif
mda
dean
gen
re
singl
cell
facssort
human
blood
procedur
allow
interrog
singl
cellt
genet
inform
product
sever
copi
singl
cell
genom
follow
specif
pcr
experi
small
fraction
mda
product
also
compar
mda
whole
genom
amplif
singl
cell
use
primer
extens
preamplif
pep
method
techniqu
appli
analysi
clonal
antigenspecif
tcell
bcell
infiltr
tissu
autoimmun
diseas
fact
allow
sequenc
chain
immunoglobulin
tcell
receptor
v
j
rearrang
gene
singl
cell
isol
frozen
human
tissu
singl
cell
dissect
stain
tissu
use
laser
captur
microdissect
devic
dna
amplifi
mda
small
fraction
amplif
product
use
templat
specif
pcr
furthermor
combin
laser
captur
microdissect
mda
allow
studi
singl
cellscel
type
paraffinembed
tissu
rna
mostli
degrad
dna
remain
intact
notion
process
b
cell
affin
matur
ensu
product
potenti
pathogen
autoantibodi
may
occur
insid
cn
patient
multipl
sclerosi
ms
support
presenc
within
lesion
oligoclon
b
cell
cell
surfac
marker
capabl
support
local
immun
respons
although
b
cell
carri
somat
mutat
ig
variabl
v
region
gene
detect
csf
cn
tissu
patient
ms
direct
evid
process
b
cell
affin
matur
confin
within
compart
need
character
b
cell
ig
variabl
v
region
gene
deriv
multipl
lesion
within
white
matter
patient
ms
analysi
variabl
region
gene
librari
reveal
evid
signific
oligoclon
expans
local
b
plasma
cell
control
tissu
pbmc
reveal
oligoclon
expans
moreov
pattern
b
cell
affin
matur
evid
clone
share
accumul
vari
number
common
uniqu
somat
mutat
within
cdr
region
clonal
variat
also
observ
within
group
compris
b
cell
data
suggest
local
inflammatori
respons
occur
within
cn
tissu
patient
ms
includ
differenti
affin
matur
autoor
exogen
antigen
resid
cn
need
consid
drive
respons
sjl
mice
highli
suscept
induct
experiment
autoimmun
encephalomyel
eae
myelin
proteolipid
protein
plp
peptid
wherea
congen
mice
resist
immunodomin
suscept
plp
eae
found
associ
high
precursor
frequenc
plp
cell
naiv
repertoir
sjl
mice
understand
mechan
diseas
resist
mice
determin
precursor
frequenc
plp
cell
strain
mice
use
ia
plp
tetram
sjl
mice
similar
frequenc
tetramerreact
cell
narv
peripher
repertoir
howev
sjl
mice
major
plp
tetramerposit
cell
wherea
tetramerposit
cell
popul
mice
suggest
plp
cell
regulatori
popul
deplet
cell
vivo
facilit
expans
plp
cell
product
cytokin
eaeresist
mice
furthermor
deplet
cell
antibodi
treatment
prior
immun
encephalitogen
peptid
result
induct
eae
otherwis
resist
mice
data
indic
role
autoantigenspecif
cell
genet
resist
autoimmun
yearold
femal
system
onset
juvenil
idiopath
arthriti
sojia
present
univers
hospit
right
knee
arthriti
pharyng
previous
treat
naproxen
penicillin
respons
deni
flare
past
year
vancomycin
ceftriaxon
start
bilater
arthrocentes
appear
inflammatori
perform
follow
second
arthrocentesi
experienc
right
shoulder
pleurit
chest
pain
naproxen
prednison
start
lab
show
crp
mgdl
normal
liver
renal
function
wbc
normal
band
increas
hemoglobin
fell
gram
sinc
admiss
hiv
ana
doubl
strand
dna
rpr
rf
neg
hospit
day
hd
report
fatigu
malais
nausea
vomit
new
cervic
inguin
adenopathi
splenomegali
abdomin
distent
right
upper
quadrant
pain
note
light
erythemat
nonprurit
macular
rash
cover
anterior
neck
shoulder
three
day
acut
renal
failur
liver
function
abnorm
develop
nonsteroid
discontinu
bilater
infiltr
evolv
chest
radiograph
hd
gener
tonicclon
seizur
intub
transfer
intens
care
unit
icu
next
day
mark
hypotens
tachycardia
persist
fever
f
develop
clonu
asymmetr
plantar
reflex
obtund
laboratori
data
reveal
pancytopenia
band
mark
coagulopathi
cultur
viral
studi
return
neg
despit
condit
esr
crp
ferritin
macrophag
activ
syndrom
ma
complic
sojia
consid
high
dose
solumedrol
cyclosporin
start
blood
product
support
hemodialysi
pressor
manag
institut
hd
extub
hd
downgrad
icu
discharg
home
hd
prednison
taper
cyclosporin
bone
marrow
biopsi
icu
cours
show
promin
hemophagocytosi
tnfa
level
markedli
elev
critic
ill
normal
time
discharg
ma
secondari
hemophagocyt
syndrom
commonli
associ
sojia
symptom
attribut
activ
prolifer
welldifferenti
macrophag
precipit
chang
medic
infecti
caus
present
symptom
includ
pyrexia
chang
mentat
organomegali
lymphadenopathi
bleed
bruis
purpura
paradox
arthriti
seros
improv
laboratori
abnorm
includ
pancytopenia
transaminas
elev
coagulopathi
decreas
esr
hypofibrinogenemia
hypertriglyceridemia
hyponatremia
hypoalbuminemia
hyperferritenemia
histolog
evalu
bone
marrow
show
macrophag
hemophagocytosi
mortal
exce
rapid
diagnosi
institut
high
dose
steroid
cyclosporin
immunomodul
good
outcom
achiev
background
follow
activ
antigenpres
cell
apc
costimulatori
pathway
includ
recogn
play
key
role
activ
autorreact
lymphocyt
also
ligand
express
activ
cell
consid
critic
tcell
marker
increas
express
might
contribut
cognat
tb
cell
interact
autoantibodi
product
succeed
appropri
interact
b
cell
requir
appropri
signal
costimulatori
molecul
broadli
studi
crucial
pathway
product
toler
induct
object
aim
studi
explod
prefer
costimulatori
via
apc
interact
cell
correl
activ
diseas
system
lupu
erythematosu
rheumatoid
arthriti
patient
method
cross
section
studi
carri
sle
ra
patient
activ
diseas
proport
peripher
mononuclear
cell
studi
use
flow
cytometri
order
measur
percentag
surfac
molecul
cell
antigen
present
cell
result
cell
show
high
express
lupu
patient
type
cell
show
increas
level
molecul
predominantli
lupu
patient
conclus
costimulatori
molecul
play
essenti
role
activ
regul
cell
immun
respons
lupu
arthriti
patient
trough
could
use
monitor
activ
diseas
also
could
target
therapeut
manipul
costimulatori
system
order
benefici
effect
clinic
autoimmun
diseas
keyword
pbmc
costimulatori
molecul
diseas
activ
system
lupu
erythematosu
rheumatoid
arthriti
testuroh
okano
koya
kubo
yutaka
tajima
osamu
nakajima
takahiro
nobukawa
immunologyah
kitasato
univ
sagamihara
kanagawa
japan
infectiom
control
scienc
juntendo
univ
bunkyo
tokyo
japan
rheumatolog
institut
chem
therapi
chiba
chiba
japan
med
re
institut
kanazawa
med
univ
kanazawa
isikawa
japan
extract
taxu
yunnanensi
ty
mani
benefici
effect
certain
clinic
set
physician
easili
use
patient
without
interrupt
therapi
show
longterm
effect
ty
patient
sever
pain
due
rheumatoid
arthriti
ra
prescrib
ty
extract
extent
morn
stiff
joint
swell
pain
reduc
lower
patientst
qualiti
life
due
sever
pain
caus
ra
significantli
improv
increas
daili
life
activ
howev
benefici
effect
ty
appear
shortli
although
ty
immedi
reliev
effect
allerg
diseas
plasma
cytokin
level
decreas
promptli
although
walk
abil
patient
got
better
day
took
around
day
month
improv
morn
stiff
joint
pain
respect
therefor
longer
prescrib
period
seem
necessari
demonstr
benefici
effect
ty
follow
two
patient
good
respond
ty
prescrib
ty
extract
addit
usual
therapeut
ra
noteworthi
plasma
level
reduc
normal
level
take
ty
case
class
disabl
plasma
level
dramat
reduc
normal
level
week
prescrib
ty
crp
becam
neg
simultan
rf
also
becam
neg
week
case
class
disabl
plasma
decreas
ml
normal
level
week
prescrib
ty
crp
level
also
decreas
within
week
rf
activ
serum
improv
complement
adapt
cell
b
cell
immun
respons
upon
bind
ligand
lower
threshold
b
cell
activ
howev
function
cell
unknown
mice
defici
demonstr
alter
humor
immun
respons
foreign
self
antigen
well
alter
natur
antibodi
repertoir
collageninduc
arthriti
cia
model
autoimmun
arthriti
depend
upon
complement
activ
effect
collagen
present
antigen
present
cell
autoantibodi
product
b
cell
cytokin
product
cell
therefor
cia
provid
model
role
lineagespecif
express
autoimmun
diseas
may
dissect
mice
immun
bovin
type
ii
collagen
cii
emulsifi
complet
freundt
adjuv
cfa
day
establish
cia
day
drain
lymph
node
mice
cia
demonstr
greater
percentag
cell
express
compar
narv
mice
vs
p
respect
suggest
role
express
cell
autoimmun
diseas
determin
import
develop
cia
f
mice
backcross
gener
onto
strain
gener
mice
immun
cii
cfa
day
evalu
blind
fashion
develop
arthriti
n
significantli
reduc
sever
f
vs
f
p
incid
vs
arthriti
compar
f
mice
n
howev
antibovin
antimurin
cii
antibodi
differ
significantli
two
group
mice
cellular
prolifer
cytokin
product
respons
cii
restimul
ex
vivo
differ
two
group
deposit
within
joint
significantli
reduc
suggest
activ
complement
mice
alter
result
demonstr
requir
robust
develop
cia
like
alter
cell
activ
traffick
joint
defect
within
anticii
antibodi
repertoir
leptin
adipocytokin
link
metabol
statu
sever
import
immun
function
other
recent
shown
leptin
similarli
proinflammatori
cytokin
promot
differenti
helper
cell
contribut
onset
progress
organspecif
autoimmun
sever
anim
model
autoimmun
diseas
nonetheless
role
leptin
system
autoimmun
particular
system
lupu
erythematosu
sle
remain
elus
studi
whether
leptin
exert
influenc
develop
progress
system
autoimmun
lupuspron
nzb
nzw
f
mice
found
elisa
circul
level
serum
leptin
increas
progress
age
untreat
femal
mice
p
b
week
vs
week
age
increas
correl
develop
autoantibodi
kidney
diseas
importantli
treatment
mice
recombin
leptin
promot
autoreact
indic
predomin
rather
antidoubl
strand
ds
dna
antibodi
respons
histolog
studi
indic
leptin
acceler
product
autoantibodi
favor
deposit
immun
complex
kidney
glomerular
damag
mice
treat
leptin
compar
salinetr
control
mice
interestingli
intraperiton
inject
singl
dose
ag
antileptin
antibodi
sever
nephrit
mice
proteinuria
z
mgdl
delay
progress
renal
diseas
significantli
prolong
surviv
treat
mice
p
b
mannwhitney
u
test
six
week
posttreat
taken
togeth
studi
point
import
role
leptin
develop
progress
lupu
mice
rais
possibl
consid
leptin
antagonist
novel
therapeut
tool
immun
intervent
system
autoimmun
background
hyperhomocysteinemia
risk
factor
trombosi
recurr
pregnanc
loss
similar
mechan
appear
mediat
thrombosi
pregnanc
loss
associ
hyperhomocysteinemia
antiphospholipid
antibodi
object
report
case
patient
associ
hyperhomocysteinemia
antiphospholipid
hugh
syndrom
assess
preval
increas
level
homocystein
group
patient
hugh
syndrom
materi
result
old
woman
previou
histori
migrain
placent
abrupt
arteri
hipertens
unstabl
angina
multinodular
goitr
admit
two
consecut
transitori
ischem
attack
laboratori
investig
reveal
presenc
elev
titr
anticardiolipin
antibodi
gplunitsml
signific
hyperhomocysteinemia
homocystein
concentr
umol
normal
valu
umol
genotyp
termolabil
allel
methylen
tetrahydrofol
reductas
studi
polimeras
chain
reaction
patient
found
carrier
homozyg
genotyp
treat
anticoagul
show
radiolog
clinic
improv
patient
start
treatment
folic
acid
vitamin
hyperhomocysteinemia
normal
perform
retrospect
studi
patient
clinic
laboratori
featur
hugh
syndrom
comparison
patient
unexplain
fetal
loss
without
antiphospholipid
antibodi
patient
thrombot
event
without
antiphospholipid
antibodi
rate
hyperhomocysteinemia
statist
similar
patient
hugh
syndrom
diseas
control
group
respect
use
cutoff
point
umol
four
patient
hugh
syndrom
hyperhomocysteinemia
three
patient
thrombot
event
includ
present
case
patient
consecut
unexplain
abort
homocystein
level
similar
patient
hugh
syndrom
diseas
control
f
f
f
umol
respect
patient
thrombosi
without
antiphospholipid
antibodi
significantli
higher
level
plasma
homocystein
women
abort
p
conclus
result
present
studi
suggest
hyperhomocysteinemia
significantli
increas
patient
hugh
syndrom
howev
antiphospholipid
antibodi
may
coexist
high
level
plasma
homocystein
individu
case
hugh
syndrom
zhongji
marc
monesti
robert
eisenberg
depart
medicin
univers
pennsylvania
philadelphia
pa
depart
microbiolog
immunolog
templ
univers
philadelphia
pa
introduct
acceler
develop
atherosclerosi
increas
risk
cardiovascular
diseas
young
women
system
lupu
erythematosu
sle
disturb
featur
diseas
well
understood
combin
mous
model
sle
atherosclerosi
begin
elucid
mechan
diseas
synergi
method
chronic
graftversushost
cgvh
diseas
induc
young
apoeko
mice
inject
coisogen
spleen
cell
mice
maintain
normal
chow
diet
mice
sacrif
heart
aorta
collect
week
induct
cgvh
histolog
cholesterol
level
measur
enzymat
colorimetr
method
frozen
heart
tissu
stain
oil
red
hematoxylin
aorta
stain
sudan
iv
en
face
lesion
area
calcul
imagepro
softwar
system
serum
igg
antidsdna
antichromatin
antioxldl
anticardiolipin
level
measur
elisa
proteinuria
detect
uristix
reagent
strip
sixteen
week
induct
gvh
spleen
cell
stain
immunofluoresc
detect
fac
result
plasma
cholesterol
level
apoeko
mice
greatli
increas
significantli
chang
cgvh
cgvh
induc
increas
level
igg
antichromatin
antidna
antioxldl
anticardiolipin
well
proteinuria
apoeko
mice
apoeko
mice
without
cgvh
substanti
lesion
aortic
root
aorta
tree
well
lesion
coronari
arteri
slightli
increas
cgvh
apoeko
mice
increas
number
splenic
margin
zone
b
cell
deplet
cgvh
conclus
result
indic
induc
cgvh
lupuslik
autoimmun
apoekomic
alter
manifest
associ
atherosclerot
cardiovascular
diseas
ascvd
extend
approach
mous
lupu
model
object
demonstr
previous
singl
nucleotid
polymorph
protein
tyrosin
phosphatas
gene
associ
rheumatoid
factor
rf
posit
subset
patient
known
rheumatoid
arthriti
studi
perform
investig
associ
polymorph
presenc
rf
healthi
popul
method
healthi
subject
recruit
denver
colorado
part
ongo
studi
etiolog
rheumatoid
arthriti
sera
project
time
interim
analysi
subject
avail
mean
age
rang
nonhispan
white
femal
subject
provid
epidemiolog
inform
underw
interview
physic
examin
ensur
subject
includ
analysi
evid
ra
serum
sampl
drawn
presenc
rf
determin
use
nephelometri
polymorph
n
identifi
use
mgbeclipsek
probe
system
epoch
bioscienc
inc
perform
benaroya
research
institut
seattl
washington
statist
analysi
perform
use
logist
regress
sa
version
result
healthi
popul
subject
posit
rf
least
one
variant
allel
adjust
age
gender
race
smoke
statu
share
epitop
statu
polymorph
margin
associ
presenc
rf
confid
limit
cl
p
conclus
preliminari
analysi
healthi
subject
n
missens
singl
nucleotid
polymorph
margin
associ
presenc
rf
size
odd
ratio
similar
report
previous
polymorphismt
associ
rf
posit
ra
patient
like
becom
statist
signific
complet
patient
accrual
estim
subject
spring
gene
may
contribut
preclin
immun
dysregul
initi
develop
raspecif
autoimmun
anti
histon
antibodi
posit
mean
titer
f
uml
avail
sln
sera
oln
show
augment
serum
level
mean
titer
f
anti
dsdna
elev
sln
patient
mean
titer
f
uml
oln
individu
mean
titer
f
uml
preval
mean
titer
three
autoantibodi
significantli
differ
encount
control
sera
p
b
addit
sln
patient
serum
level
anti
anti
histon
antibodi
significantli
correl
anti
dsdna
level
increas
activ
index
renal
tissu
p
b
previuosli
report
sln
show
class
ii
kidney
lesion
sln
detect
anti
antibodi
igg
deposit
found
conclus
first
report
detect
anti
anti
histon
autoantibodi
sln
furthermor
signific
correl
anti
dsdna
antibodi
increas
activ
index
renal
tissu
suggest
earli
simultan
particip
complex
lupu
nephriti
introduct
granulocyt
apheresi
gcap
novel
hemoadsorpt
treatment
current
use
treatment
autoimmun
diseas
inmunomodulatori
properti
gcap
report
associ
emerg
evid
clinic
improv
patient
object
assess
efficaci
safeti
adacolumnr
gcap
patient
refractori
rheumatoid
arthriti
ra
method
patient
activ
ra
fail
respond
least
one
dmard
biolog
tnfalpha
antagonist
treat
weekli
gcap
five
week
clinic
assess
respons
therapi
analyz
week
open
multicent
pilot
trial
primari
outcom
measur
therapeut
respons
improv
american
colleg
rheumatolog
criteria
week
eular
respons
criteria
base
diseas
activ
score
joint
disabl
healt
assess
questionnair
haq
also
analyz
result
twenti
seven
patient
enrol
women
mean
diseas
durat
year
mean
number
previou
dmard
fail
biolog
intent
treat
basi
analysi
patient
achiev
improv
patient
therapeut
eular
respons
week
percentag
patient
complet
trial
four
patient
complet
trial
previous
fail
biolog
respons
achiev
week
signific
decreas
note
differ
acr
respons
compon
includ
tender
joint
count
swollen
joint
count
pain
score
patientt
physici
global
assess
also
index
improv
sinc
week
esr
crp
haq
significantli
decreas
week
treatment
well
toler
one
seriou
advers
event
relat
studi
therapi
document
sepsi
due
cathet
infect
conclus
treatment
gcap
led
signific
clinic
improv
subset
patient
ra
previous
fail
dmard
biolog
therapi
safe
well
toler
larg
placebo
control
studi
requir
assess
exact
role
therapi
refractori
ra
gene
express
studi
demonstr
increas
interferon
ifn
induc
gene
ifig
express
peripher
blood
mononuclear
cell
pbmc
mani
patient
system
lupu
erythematosu
sle
recent
data
implic
predomin
type
ifn
effect
ifig
express
observ
sle
object
studi
examin
hypothesi
increas
diseas
sever
activ
well
distinct
autoantibodi
specif
character
sle
patient
type
ifn
pathway
activ
order
freshli
isol
pbmc
sle
patient
diseas
control
dc
healthi
donor
hd
subject
realtim
pcr
ifig
preferenti
induc
ifna
data
use
deriv
ifna
score
individu
express
ifig
significantli
higher
sle
patient
compar
dc
hd
sle
patient
high
h
low
l
ifna
score
compar
clinic
manifest
diseas
diseas
sever
diseas
activ
serolog
featur
potenti
confound
bivari
multivari
analysi
found
sle
patient
h
ifna
score
significantli
higher
preval
renal
diseas
greater
number
acr
criteria
sle
higher
slicc
damag
index
di
score
sle
patient
l
ifna
score
patient
h
score
show
increas
diseas
activ
measur
lower
hemoglobin
absolut
lymphocyt
count
albumin
higher
antidsdna
titer
esr
score
presenc
antibodi
specif
rnabind
protein
rbp
ro
sm
dsdna
phospholipid
significantli
associ
h
ifna
score
logist
regress
analysi
confirm
renal
diseas
higher
slicc
di
score
low
complement
level
presenc
antirna
bind
protein
rbp
autoantibodi
independ
associ
h
ifna
score
suggest
might
true
absenc
treatment
hydroxychloroquin
hcq
conclus
activ
ifna
pathway
defin
subgroup
sle
patient
character
increas
diseas
sever
includ
renal
diseas
increas
serolog
diseas
activ
autoreact
rbp
data
provid
support
examin
role
ifna
score
potenti
biomark
lupu
diseas
activ
suggest
pathogen
link
rbp
ifna
product
rheumat
joint
contain
hyperreact
null
cell
e
r
fasth
k
ulfgren
l
klareskog
c
trollmo
v
malmstrom
rheumatolog
unit
depart
medicin
karolinska
institutet
stockholm
sweden
background
subpopul
unusu
cell
lack
costimulatori
molecul
found
subpopul
patient
chronic
inflamm
lesser
extent
healthi
individu
null
cell
potent
secretor
tnf
ifng
prolifer
vigor
upon
stimul
other
previous
demonstr
circul
null
cell
constitut
cell
peripher
blood
pb
patient
chronic
rheumat
diseas
aim
null
cell
present
also
inflam
joint
rheumat
patient
function
profil
proinflammatori
method
mononuclear
cell
isol
pb
synovi
fluid
sf
inflam
knee
joint
patient
differ
rheumat
diseas
cell
sort
null
convent
cell
stimul
vitro
without
presenc
antigen
present
cell
result
null
cell
could
found
synovi
fluid
patient
individu
display
popul
also
peripher
blood
cell
inflam
joint
confirm
null
cell
sinc
restrict
tcr
vbeta
repertoir
correspond
cell
circul
joint
deriv
null
cell
prolif
prone
secret
proinflammatori
cytokin
null
cell
pb
conclus
present
joint
null
cell
like
contribut
inflamm
easili
expand
secret
proinflammatori
cytokin
ongo
effort
includ
investig
synovi
tissu
null
cell
link
presenc
hyperreact
cell
joint
clinic
featur
absenc
b
cell
decreas
prolifer
cytokin
secret
aim
analyz
reduc
prolifer
cytokin
secret
mononuclear
cell
system
lupu
erytematosu
sle
patient
treat
b
cell
deplet
therapi
rituximab
explain
absenc
b
cell
background
method
rituximab
anti
antibodi
therapi
origin
develop
lymphoma
increasingli
use
autoimmun
diseas
earlier
studi
rituximab
treat
sle
patient
shown
shortli
treatment
prolifer
cytokin
secret
decreas
vitro
cultur
increas
return
b
cell
circul
investig
lack
b
cell
immunosupress
treatment
given
togeth
rituximab
account
dramat
effect
establish
vitro
system
b
cell
deplet
anti
magnet
bead
peripher
blood
mononuclear
cell
pbmc
three
healthi
subject
cell
stimul
pha
antibodi
without
costimul
cytokin
secret
prolifer
measur
cytometr
bead
array
hthymidin
incorpor
result
similar
ex
vivo
patient
data
prolifer
cytokin
secret
reduc
b
cell
deplet
pbmc
cultur
compar
intact
pbmc
cultur
true
pha
stimul
cell
mainli
tnfa
also
secret
lesser
extent
discuss
vitro
experi
indic
immunosuppress
treatment
account
decreas
immun
respons
seen
rituximab
treat
sle
patient
per
se
effect
lack
b
cell
futur
experi
delin
potenti
costimul
present
antigen
secret
cytokin
import
activ
cell
natur
killer
cell
nkt
popul
regulatori
cell
coexpress
invari
cell
receptor
well
nk
cell
marker
sever
studi
shown
nkt
cell
decreas
dysfunct
autoimmun
condit
insulindepend
diabet
mellitu
system
sclerosi
system
lupu
erythematosu
multipl
sclerosi
signific
therapeut
effect
agalactosylceramid
agalc
synthet
antigen
nkt
cell
demonstr
anim
model
autoimmun
nkt
cell
therefor
implic
particip
regulatori
immun
mechan
control
autoimmun
howev
role
pathogenesi
rheumatoid
arthriti
ra
remain
unclear
end
studi
frequenc
cytokin
profil
heterogen
nkt
cell
peripher
blood
mononuclear
cell
pbmc
ra
patient
healthi
control
includ
pair
pbmcsynovi
fluid
sf
sampl
pair
pbmcsynovi
tissu
st
sampl
ra
patient
respect
use
flow
cytometri
decreas
nkt
cell
frequenc
observ
blood
ra
patient
compar
healthi
control
addit
direct
ex
vivo
elispot
analysi
reveal
reduc
ratio
nkt
cell
ra
patient
invari
cell
receptor
sequenc
detect
pair
sf
st
sampl
nkt
cell
healthi
control
ra
patient
respond
expand
upon
vitro
stimul
howev
reactiv
toward
agalc
observ
nkt
cell
isol
sf
respond
nonrespond
ra
patient
intracellular
fac
analysi
cytokin
profil
deriv
nkt
cell
line
ra
patient
reveal
produc
significantli
less
compar
healthi
control
contrast
sf
deriv
nkt
cell
line
display
phenotyp
compar
healthi
control
find
suggest
sf
nkt
cell
function
even
patient
nonrespond
nkt
cell
blood
conclus
data
demonstr
nkt
cell
decreas
bias
toward
phenotyp
blood
impair
sf
ra
patient
indic
nkt
cell
might
function
relat
resist
progress
rheumatoid
arthriti
neutral
agent
tnf
success
mean
amelior
system
autoimmun
inflamm
neutral
tnf
howev
often
associ
develop
autoantibodi
particular
nuclear
antigen
mechan
unknown
analyz
effect
tnf
neutral
mhc
class
ii
express
function
antigen
present
myeloid
cell
rheumatoid
arthriti
ra
monocyt
isol
peripher
blood
ra
patient
antitnfmab
treatment
control
neg
select
differenti
vitro
macrophag
analyz
flowcytometri
hladr
express
cell
respons
activ
myeloid
cell
assess
prolifer
assay
mrna
level
class
ii
transactiv
ciita
determin
semiquantit
rtpcr
hladr
express
significantli
reduc
myeloid
cell
ra
patient
activ
diseas
increas
normal
level
tnf
mab
treatment
concordantli
vitro
applic
tnf
monocyt
healthi
individu
reduc
abil
upregul
hladr
differenti
macrophag
importantli
inhibit
abil
stimul
cell
mix
lymphocyt
reaction
molecular
analysi
reveal
effect
tnf
hladr
express
mediat
via
suppress
transcript
factor
ciita
data
indic
tnf
decreas
hladr
express
reduc
ciita
mrna
level
myeloid
cell
function
result
decreas
stimulatori
capac
myeloid
cell
cell
concordantli
amelior
diseas
activ
chronic
inflammatori
diseas
neutral
tnf
restor
hladr
express
myeloid
cell
abil
stimul
cell
thu
antitnf
treatment
might
lead
augment
cell
activ
myeloid
cell
therebi
promot
immun
respons
auto
antigen
develop
antinuclear
antibodi
frequent
associ
antitnf
therapi
isol
type
antimitochondri
autoantibodi
associ
histori
thrombocytopaenia
foetal
loss
antimitochondri
ama
type
antibodi
initi
describ
patient
autoimmun
diseas
identifi
sera
patient
antiphospholipid
antibodi
recurr
foetal
loss
haemolyt
anaemia
thrombocytopaenia
controversi
associ
thrombosi
date
scarc
literatur
exist
regard
type
ama
ama
type
direct
toward
unknown
antigen
locat
inner
membran
mitochondria
kda
inde
type
ama
alway
report
context
antiphospholipid
syndrom
strictli
link
antiphospholipid
antibodi
report
caucasian
woman
diagnos
autoimmun
polyglandular
syndrom
ap
iiic
type
name
autoimmun
thyroid
pernici
anaemia
recurr
idiopath
thrombocytopaen
purpura
clinic
histori
also
relev
two
foetal
loss
gestat
month
respect
associ
persist
type
ama
high
titr
antinuclear
antidna
antiphospholipid
antibodi
anticardiolipin
persist
neg
followup
period
coagul
studi
repeatedli
normalconclus
patient
type
ama
marker
thrombocytopenia
recurr
miscarriag
without
antiphospholipid
antibodi
isol
case
ab
appear
diagnost
marker
clinic
manifest
antiphospholipid
syndrom
background
natur
regulatori
cell
usual
identifi
two
way
mrna
express
transcript
factor
level
surfac
express
human
never
immunolog
narv
result
cell
express
also
due
activ
thu
frequenc
determin
base
express
regulatori
cell
never
rough
estim
studi
investig
presenc
regulatori
cell
differ
compart
patient
rheumat
joint
diseas
compar
peripher
blood
site
inflamm
analyz
synovi
fluid
synovi
tissu
materi
method
mrna
level
investig
sort
peripher
blood
synovi
fluid
cell
popul
sort
popul
express
differ
densiti
rna
also
prepar
synovi
tissu
biopsi
addit
cell
activ
vitro
investig
possibl
induct
result
discuss
could
find
messag
compart
investig
even
biopsi
synovi
tissu
synovi
fluid
cell
markedli
enrich
compar
differ
two
popul
less
appar
blood
interestingli
also
cell
neg
could
common
synovi
fluid
blood
thu
studi
show
regulatori
cell
restrict
sole
cell
especi
inflammatori
environ
like
synovi
fluid
cell
found
induct
could
mimick
vitro
perhap
suggest
regulatori
cell
origin
cell
downregul
shed
express
scenario
support
studi
show
presenc
solubl
sera
synovi
fluid
rheumat
patient
object
abnorm
host
defens
pathogen
implic
pathogenesi
spondyloarthropathi
spa
diseas
character
abund
synovi
infiltr
innat
immun
cell
consid
role
tolllik
receptor
tlr
activ
innat
inflamm
occur
tlrdepend
infect
tnfalpha
blockad
analyz
tlr
spa
modul
tnfalpha
blockad
method
peripher
blood
monocyt
obtain
spa
rheumatoid
arthriti
ra
infliximab
therapi
healthi
control
hc
express
tnfalpha
product
upon
lp
stimul
analyz
flowcytometri
differ
monocyt
subset
synovi
biopsi
spa
infliximab
etanercept
treatment
ra
analyz
immunohistochemistri
result
express
increas
monocyt
spa
wherea
tlr
increas
ra
macrophag
subset
increas
inflammatori
site
spa
particularli
increas
tlr
express
accordingli
express
tlr
significantli
higher
spa
ra
synovium
infliximab
decreas
express
monocyt
spa
ra
lead
lower
level
hc
impair
tnfalpha
product
upon
lp
stimul
parallel
system
effect
synovi
tlr
downregul
follow
infliximab
well
etanercept
indic
classeffect
tnfalpha
blocker
conclus
spa
inflamm
character
increas
express
sharpli
reduc
tnfalpha
blockad
data
emphas
central
role
innat
immunemedi
inflamm
spa
provid
addit
clue
efficaci
well
potenti
sideeffect
tnfalpha
blockad
background
previous
demonstr
antinuclear
antibodi
ana
antidsdna
antibodi
induct
week
infliximab
therapi
rheumatoid
arthriti
ra
spondyloarthropathi
spa
aim
assess
detail
clinic
biolog
correl
autoantibodi
induct
longerterm
tnfalpha
blockad
either
monoclon
antibodi
infliximab
solubl
receptor
etanercept
method
spa
ra
patient
treat
infliximab
two
year
addit
spa
patient
treat
etanercept
one
year
provid
uniqu
headtohead
comparison
autoantibodi
induct
tnfalpha
blockad
human
diseas
model
low
baselin
autoimmun
sera
blindli
analys
ana
antidsdna
antiena
antihiston
anticardiolipin
antibodi
antidsdna
antibodi
isotyp
gamma
muand
alphachain
specif
conjug
result
infliximabtr
spa
ra
cohort
observ
high
number
newli
induc
ana
antidsdna
antibodi
one
year
increas
year
year
contrast
induct
ana
antidsdna
antibodi
occasion
found
etanercepttr
spa
cohort
neither
infliximab
etanercept
antiena
antihiston
antibodi
clinic
relev
lupuslik
symptom
describ
isotyp
reveal
predominantli
igm
andor
iga
antidsdna
antibodi
similarli
infliximab
etanercept
select
increas
igm
igg
anticardiolipin
titer
conclus
studi
indic
promin
ana
antidsdna
autoantibodi
respons
pure
class
effect
tnfalpha
blocker
independ
diseas
background
associ
clinic
relev
lupussymptom
system
lupu
erythematosu
sle
chronic
autoimmun
diseas
immun
function
sle
paradox
character
activ
cell
help
autoantibodi
product
along
impair
cell
prolif
cytokin
respons
vitro
recent
evid
reveal
chemokin
well
chemokin
receptor
close
involv
initi
hyperreact
studi
design
investig
express
level
variou
chemokin
receptor
relat
diseas
activ
juvenil
sle
compar
pattern
chemokin
elev
normal
individu
serum
level
chemokin
includ
analyz
chemokin
cytomer
bead
array
cba
wherea
express
chemokin
receptor
peripher
blood
mononuclear
cell
pbmc
assess
realtim
rtpcr
andor
western
blot
demonstr
differ
chemokin
receptor
express
juvenil
sle
patient
compar
normal
individu
significantli
higher
serum
level
mig
found
sle
patient
analyz
chemokin
receptor
express
rel
low
patientst
pbmc
analysi
clinic
manifest
sledai
system
lupu
erythematosu
diseas
activ
index
level
chemokin
express
level
reveal
strong
correl
howev
decreas
serum
level
appear
patient
high
level
antidsdna
compar
patient
low
antidsdna
overal
four
chemokin
elev
sle
proinflammatori
characterist
activ
monocyt
macrophag
lineag
case
also
neutrophil
data
suggest
major
role
cellmedi
immun
respons
occur
pathophysiolog
sle
modul
murin
lupu
inhibitori
gpg
oligonucleotid
k
l
graham
l
lee
p
teo
l
steinman
p
j
utz
p
p
ho
depart
medicin
divis
immunolog
rheumatolog
stanford
univers
school
medicin
stanford
ca
usa
depart
neurolog
stanford
univers
school
medicin
stanford
ca
usa
activ
innat
immun
system
dna
contain
hypomethyl
cpg
motif
implic
pathogenesi
system
lupu
erythematosu
sle
previous
describ
immunomodulatori
oligodeoxynucleotid
odn
contain
singl
base
switch
cpg
gpg
amelior
murin
experiment
autoimmun
encephalomyel
eae
helper
model
human
multipl
sclerosi
examin
consequ
immunostimulatori
cpgodn
inhibitori
gpgodn
treatment
f
nzbw
murin
model
sle
begin
month
age
administ
cpg
gpg
odn
regular
interv
femal
nzbw
anim
period
week
cpgodn
treatment
appear
impact
overal
diseas
sever
gpgodn
treatment
significantli
delay
onset
proteinuria
improv
surviv
nzbw
mice
also
determin
effect
odn
administr
nzbw
lymphocyt
cytokin
profil
splenocyt
surfac
marker
express
interestingli
gpgodn
treatment
enhanc
product
tnfa
nzbw
cell
inhibit
cell
product
consist
observ
made
eae
model
splenocyt
deriv
gpgodn
treat
nzbw
mice
also
display
reduc
surfac
express
taken
togeth
data
indic
gpgodn
treatment
modul
immun
cell
function
amelior
diseas
nzbw
model
lupu
nephriti
protect
mechan
gpgodn
murin
sle
may
involv
gener
inhibitori
effect
costimulatori
molecul
express
antigen
present
cell
well
alter
cell
cytokin
profil
clinic
trial
oral
treatment
patient
autoimmun
diseas
includ
rheumatoid
arthriti
multipl
sclerosi
type
ii
collagen
myelin
respect
show
disappoint
result
may
part
due
insuffici
induct
oral
toler
respect
autoantigen
human
therefor
look
agent
facilit
induct
oral
toler
present
studi
test
hypothesi
phosphodiesteras
iv
inhibitor
rolipram
previous
report
produc
suppress
cytokin
includ
tgfbeta
facilit
suppress
antigeninduc
arthriti
aia
mice
oral
administr
induc
antigen
suppress
cytokin
shown
play
role
oral
toler
especi
induc
low
dose
oral
antigen
prove
hypothesi
mice
immun
ovalbumin
ova
emulsifi
cfa
day
aia
induc
intraarticular
inject
ova
pb
day
oral
toler
induc
oral
administr
either
mg
ova
daili
period
consecut
day
commenc
day
rolipram
mg
kg
oral
given
immedi
administr
ova
result
show
oral
administr
mg
ova
alon
follow
suppress
aia
although
extent
suppress
aia
greater
mice
fed
mg
oral
antigen
mg
ova
given
togeth
rolipram
significantli
facilit
suppress
aia
observ
coadministr
mg
ova
rolipram
fail
modul
suppress
aia
caus
oral
antigen
alon
secret
ifngamma
spleen
cell
suppress
oral
ova
alon
suppress
significantli
enhanc
mice
given
antigen
rolipram
contrast
suppress
ifngamma
secret
administr
mg
ova
alon
block
combin
dose
antigen
rolipram
differ
secret
either
mg
ova
aloneand
ova
plu
rolipramtr
group
result
suggest
rolipram
appear
facilit
suppress
aia
oral
administr
low
mg
high
mg
dose
ova
may
part
explain
significantli
acceler
decreas
ifngamma
mice
treat
lose
dose
ova
plu
rolipram
studi
facilit
suppress
aia
administr
oral
antigen
togeth
phosphodiesteras
iv
inhibitor
appear
mediat
modul
secret
agent
rolipram
facilit
induct
oral
toler
might
use
treatment
autoimmun
diseas
human
includ
rheumatoid
arthriti
oral
pathogen
autoantigen
object
rituximab
monoclon
antibodi
becom
target
immunotherapi
b
cell
lymphoma
recent
b
cellmedi
autoimmun
diseas
report
case
involv
year
old
femal
patient
sever
autoimmun
diseas
b
cell
immunodefici
treat
rituximab
find
patient
initi
present
year
age
raynaudt
phenomenon
posit
antinuclear
antibodi
ana
posit
thyroid
peroxidas
antibodi
fever
oral
vagin
ulcer
polyarthr
digit
vascul
elev
erythrocyt
sediment
rate
elev
rheumatoid
factor
rf
also
develop
mix
connect
tissu
diseas
treat
azathioprin
hydroxychloroquin
methylprednisolon
meanwhil
digit
infarct
polychondr
malar
facial
rash
occur
classic
dermatomyos
rash
confirm
skin
biopsi
subsequ
amyopath
dermatomyos
treat
intraven
immunoglobulin
ivig
gram
addit
methotrex
mg
weekli
cyclosporin
result
limit
improv
pain
debilit
digit
infarct
coomb
posit
hemolyt
anemia
pulmonari
vascul
evolv
upon
immun
evalu
lymphocyt
studi
show
low
b
cell
percentag
low
absolut
b
cell
count
cellsml
increas
narv
cell
low
memori
cell
addit
lymphocyt
mitogen
respons
markedli
decreas
stapha
b
cell
mitogen
also
increas
immun
complex
rf
elev
iuml
epstein
barr
viru
ebv
serolog
show
high
titer
viral
capsid
antigen
igg
high
titer
earli
antigen
antibodi
suggest
reactiv
ebv
diseas
treatment
dermatomyos
underli
b
cell
immunodefici
start
high
dose
ivig
gramkg
gammunex
combin
cyclophosphamid
steroid
thereaft
vitro
marker
autoimmun
includ
creactiv
protein
ana
direct
coomb
rf
normal
howev
pulmonari
upper
extrem
vascul
progress
rituximab
therapi
consid
immun
evalu
reveal
preponder
cell
five
weekli
dose
rituximab
mgm
ad
highdos
ivig
cyclophosphamid
steroid
therapi
pulmonari
vascul
improv
digit
infarct
ulcer
slowli
heal
autoimmun
marker
includ
rf
becam
normal
immun
studi
repeatedli
show
cell
week
patient
wean
cyclophosphamid
remain
ivig
low
dose
prednison
exacerb
autoimmun
diseas
week
conclus
patient
sever
refractori
autoimmun
diseas
underli
b
cell
defect
respond
success
addit
rituximab
specif
target
bcell
mediat
autoimmun
process
favor
respons
rituximab
patient
support
recent
publish
report
show
b
cell
deplet
rituximab
led
sustain
clinic
respons
methotrexateresist
rheumatoid
arthriti
purpos
determin
sever
dmard
bblocker
acei
aspirin
associ
presenc
coronari
calcif
electron
beam
comput
tomographi
ebct
sle
patient
method
one
hundr
thirti
seven
patient
sle
age
fulfil
least
american
colleg
rheumatolog
criteria
classif
sle
recruit
studi
histori
physic
exam
ekg
ebct
measur
coronari
calcium
perform
result
ebct
use
independ
measur
current
cardiovascular
diseas
inform
regard
current
past
number
year
medic
record
analysi
inculd
standard
studentt
ttest
perform
data
result
ttest
analysi
data
show
compar
patient
sle
current
azathioprin
patient
sle
current
take
drug
drug
lower
ebct
calcium
score
p
result
unchang
beverq
user
ad
analysi
comparison
sle
patient
take
hydroxycholoroquin
never
hydroxycholoroquin
show
differ
ebct
calcium
score
p
comparison
sle
patient
prednison
sle
patient
never
prednison
show
differ
ebct
score
p
sle
patient
receiv
intraven
cyclophosphamid
also
show
differ
ebct
score
compar
never
expos
drug
p
sle
patient
take
mycophenol
mofetil
methotrex
similarli
show
differ
ebct
score
expos
versu
expos
p
p
respect
sle
patient
statin
higher
ebct
calcium
score
drug
p
sle
patient
bblocker
also
higher
ebct
score
drug
p
patient
acei
aspirin
show
differ
ebct
score
compar
drug
p
p
respect
discuss
ever
current
azathioprin
use
associ
lower
ebct
calcium
score
sle
patient
azathioprin
associ
decreas
inflamm
endothelium
may
affect
extent
coronari
calcif
weigel
et
al
thrombosi
research
apr
gao
et
al
circul
pt
nov
dmard
studi
associ
lower
coronari
calcif
higher
ebct
score
associ
bblocker
statin
use
like
associ
previous
identifi
cardiovascular
risk
factor
patient
rheumatoid
arthriti
ra
autoimmun
synov
character
heterogen
patient
diseas
manifest
clinic
outcom
therapeut
respons
appli
synovi
antigen
microarray
beadbas
multiplex
cytokin
assay
profil
autoantibodi
cytokin
respons
ra
object
identifi
profil
secret
protein
blood
provid
diagnost
inform
delin
diseas
subtyp
demonstr
autoreact
b
cell
respons
target
deimin
epitop
elev
serum
concentr
proinflammatori
cytokin
tnfa
present
subset
earli
ra
patient
featur
predict
develop
sever
ra
contrast
autoimmun
target
nativ
epitop
contain
synovi
array
includ
human
glycoprotein
collagen
type
ii
v
low
concentr
serum
cytokin
associ
predictor
lesssever
ra
proteom
analysi
secret
protein
enabl
molecular
stratif
patient
earli
ra
clinicallyrelev
diseas
subset
ligat
death
receptor
induc
cell
death
activ
b
cell
trail
ligand
reduc
diseas
manifest
anim
model
thu
attract
target
therapeut
elimin
pathogen
lymphocyt
autoimmun
diseas
determin
lymphocyt
express
subset
b
cell
human
blood
tonsil
spleen
identifi
surfac
marker
analyz
bind
mab
germin
center
b
cell
tonsil
spleen
express
plasmablast
tissu
blood
cell
blood
consist
phenotyp
character
transit
cell
increas
plasmablast
circul
sle
subject
result
increas
percentag
blood
b
cell
express
small
reproduc
increas
express
postnaiv
subset
observ
cell
healthi
subject
howev
express
significantli
greater
subset
cell
lupu
subject
compar
subset
healthi
control
thu
express
appear
modul
differenti
factor
possibl
includ
diseaseassoci
factor
type
ifn
therapeut
target
cell
would
spare
rest
b
cell
naiv
cell
potenti
elimin
activ
cell
degre
would
determin
diseasespecif
mechan
backgroundpurpos
anticitrullin
antibodi
highli
specif
serolog
marker
ra
immun
respons
citrullin
link
express
ra
share
epitop
previous
demonstr
tg
mice
immun
citrullin
develop
arthriti
citrullin
polypeptid
influenc
peptidyl
arginin
deiminas
pad
shown
unregul
normal
mice
follow
induct
inflamm
streptococc
cell
wall
scw
induc
mice
develop
immun
respons
citrullin
chronic
arthriti
sought
investig
arthritogen
properti
immun
respons
citrullin
protein
follow
acut
scw
arthriti
induct
mice
method
ag
streptococc
cell
wall
antigen
streptococcu
pyogen
group
pgp
lee
laboratori
grayson
georgia
usa
al
pb
inject
one
knee
joint
tg
wt
mice
knee
joint
mice
receiv
al
pb
mice
sacrif
variou
time
point
investig
patholog
chang
bcell
immun
respons
result
patholog
inject
joint
day
demonstr
massiv
influx
leukocyt
start
synovi
prolifer
approxim
leukocyt
infiltr
dissip
day
day
synovi
hyperplasia
first
sign
eros
bone
cartilag
surfac
prolifer
synoviocyt
deplet
approxim
proteoglycan
normal
present
articular
cartilag
observ
splenic
tcell
prolifer
observ
tg
mice
variou
time
point
citrullin
peptid
chain
fibrinogen
qdf
tncit
ink
lkn
evid
wt
mice
tcell
prolifer
detect
either
group
mice
stimul
unmodifi
version
peptid
conclus
scw
expect
induc
acut
inflammatori
arthriti
normal
wt
tg
mice
follow
strong
citrullin
specif
tcell
respons
tg
mice
presum
inflammatori
induc
express
pad
citrullin
fibrinogen
observ
consist
previou
studi
indic
tcell
respons
citrullin
restrict
mhc
class
ii
molecul
express
share
epitop
scw
induc
arthriti
tg
mice
repres
good
model
evalu
immunogenet
effect
citrullin
invivo
includ
develop
citrullin
induc
arthriti
homozyg
type
defici
evidenc
old
girl
found
also
posit
young
girl
anteced
recurr
otiti
media
admit
hospit
polyarticular
arthriti
fever
signific
inflammatori
syndrom
increas
esr
creactiv
protein
fibrinogen
mild
normocyt
anaemia
abnorm
liver
function
test
eye
inflamm
found
antinuclear
antibodi
cell
speckl
pattern
nuclear
dot
antibodi
extract
nuclear
antigen
ndna
found
complement
analys
show
absenc
serum
hemolyt
activ
normal
elev
level
undetect
homozyg
type
defici
confirm
pcr
analysi
gene
delet
factor
b
allotyp
show
patient
typic
homozyg
bf
complotyp
complotyp
link
one
chromosom
typic
hlaa
b
bancestralq
haplotyp
chromosom
hlaa
b
repres
unusu
associ
complotyp
upon
serum
immunoglobulin
determin
igd
immunoglobulin
could
detect
iga
igm
level
close
lower
normal
rang
altogeth
clinic
syndrom
patient
relat
homozyg
defici
posit
although
defici
compon
classic
pathway
complement
activ
among
first
identifi
risk
factor
system
lupu
erythematosu
sle
studi
address
signific
patient
cutan
lupu
erythematosu
cle
among
environment
factor
postul
cigarett
smoke
might
interven
pathogenesi
le
retrospect
studi
patient
cle
individu
screen
andor
defici
among
defici
heterozyg
five
defici
heterozyg
two
combin
heterozyg
defici
serum
level
decreas
patient
defici
patient
defici
level
normal
patient
high
proport
complementdefici
patient
male
fm
ratio
mean
age
diagnosi
year
particular
interest
detect
combin
heterozyg
type
heterozyg
defici
two
male
patient
combin
defici
rare
report
expect
frequenc
caucas
popul
european
descent
approxim
frequenc
patient
le
unknown
seri
patient
smoker
male
patient
cle
smoker
comparison
frequenc
smoke
normal
french
men
women
respect
recent
suggest
smoke
behaviour
could
relat
specif
major
histocompat
complex
haplotyp
chromosom
character
presenc
null
allel
find
seem
corrobor
hypothesi
need
confirm
larg
prospect
studi
pregnanc
outcom
ten
japanes
women
mix
connect
tissu
diseas
k
abe
r
matudaira
takasaki
h
hashimoto
intern
medicin
rheumatolog
juntendo
univers
school
medicin
tokyo
japan
object
studi
pregnanc
outcom
patient
mix
connect
tissu
diseas
mctd
avail
result
contradictori
purpos
studi
examin
pregnanc
fetal
outcom
mctd
patient
method
retrospect
studi
follow
ten
mother
mctd
pregnanc
sinc
juntendo
univers
hospit
result
pregnanc
observ
live
birth
term
prematur
birth
spontan
abort
artifici
abort
one
case
interstiti
pneumonia
high
titer
sialyl
carbohydr
antigen
follow
therapi
level
decreas
pregnanc
week
gestat
laboratori
find
suggest
earli
hellp
syndrom
pregnanc
termin
two
pregnanc
renal
involv
result
spontan
abort
serum
antiphospholipid
antibodi
determin
either
activ
nephriti
recogn
pregnanc
conclus
sinc
mctd
rel
good
prognosi
therapi
chang
requir
pregnanc
prematur
deliveri
spontan
abort
high
rate
studi
consid
organ
involv
flare
possibl
risk
pregnanc
mctd
women
manifest
ap
antibeta
glycoproteini
anticardiolipin
antibodi
autoimmun
condit
et
transcript
factor
function
regul
hematopoiesi
hemostasi
requir
earli
develop
also
implic
regul
immun
system
autoimmun
express
thymu
spleen
overexpress
mice
result
develop
immunolog
renal
diseas
similar
observ
system
lupu
erythematosu
elev
express
observ
spleen
lupu
mous
model
nzbnzw
mrllpr
furthermor
elev
level
peripher
blood
monocyt
lupu
patient
correl
diseas
activ
interestingli
mrllpr
mice
heterozyg
knockout
subsequ
reduct
express
significantli
reduc
renal
diseas
prolong
surviv
studi
strongli
indic
play
import
role
pathogenesi
lupu
understand
role
immun
system
examin
regul
normal
lupu
mice
preliminari
result
show
express
higher
cell
prediseas
mrllpr
lupu
prone
mice
cell
late
diseas
mrllpr
mice
compar
balbc
mice
transient
transfect
promoterreport
construct
b
cell
line
indic
highest
level
express
driven
bp
region
encompass
exon
posit
regulatori
element
necessari
express
local
within
bp
region
furthermor
examin
promot
upstream
regulatori
region
balbc
mrllpr
spleen
identifi
polymorph
exon
transient
transfect
analys
indic
polymorph
region
contribut
posit
regul
promoterreport
construct
interestingli
region
highli
homolog
human
sequenc
locat
adjac
regulatori
element
found
necessari
express
leukemia
cell
line
analys
regulatori
region
includ
polymorph
allow
insight
element
bind
factor
necessari
normal
express
well
aberr
express
lupu
prone
mice
shown
ssc
suggest
alloimmun
could
contribut
pathogenesi
exposur
breeder
mice
vinyl
chlorid
shown
result
prolifer
microchimer
cell
parallel
develop
skin
fibrosi
herein
describ
immunolog
find
male
patient
lymphocyt
infiltr
fibrosi
involv
skin
lung
digest
tract
highli
reminisc
cgvhd
follow
exposur
organ
solvent
provid
evid
matern
microchimer
could
involv
diseas
process
patient
lymphopen
ratio
lymphocyt
phenotyp
reveal
high
proport
circul
cell
bear
activ
marker
among
includ
cell
popul
oligoclon
expans
cell
demonstr
flow
cytometri
immunoscop
analysi
involv
cell
belong
cell
cell
famili
cell
popul
stain
neg
perforin
high
resolut
hla
type
patient
mother
demonstr
nearli
ident
mhc
class
ii
patient
mother
mhc
class
molecul
search
microchimer
cell
matern
origin
fish
peripher
blood
reveal
presenc
xx
cell
among
total
analys
cell
patient
bidirect
mix
lymphocyt
cultur
mlc
perform
use
cell
patient
irradi
nont
cell
mother
vice
versa
explor
potenti
function
consequ
matern
microchimer
patient
presenc
patient
nont
cell
matern
cell
show
increas
hladr
express
vs
cultur
alon
neither
prolifer
ifngamma
product
wherea
cell
remain
quiescent
contrast
cell
deriv
patient
activ
presenc
matern
nont
cell
shown
increas
hladr
express
vs
absenc
matern
nont
cell
cell
vs
cell
secret
ifngamma
remov
patient
cell
cultur
result
decreas
overal
activ
patient
cell
respons
matern
nont
cell
indic
effector
regulatori
cell
observ
suggest
chronic
activ
lymphocyt
relat
long
term
persist
matern
cell
exposur
organ
solvent
might
lead
gvhlike
diseas
reminisc
ssc
swr
mice
resist
collageninduc
arthriti
cia
despit
carri
arthriti
suscept
haplotyp
abl
produc
anticollagen
type
ii
cii
antibodi
follow
ciiimmun
igg
anticii
antibodi
gener
pathogen
trigger
joint
inflamm
via
interact
igg
fc
receptor
fcgr
notabl
fcgriii
howev
swr
mice
resist
arthritogen
properti
antibodi
consid
present
studi
investig
possibl
fcgr
polymorph
involv
suscept
cia
studi
gener
mice
carri
fcgriii
gene
arthriti
suscept
mous
swr
mous
ciiimmun
mice
mice
develop
progress
sever
arthriti
addit
direct
effect
igg
anticii
antibodi
arthriti
develop
studi
passiv
transfer
cocktail
monoclon
anticii
antibodi
mice
like
activ
induc
arthriti
mice
develop
sever
arthriti
contrast
mice
almost
protect
diseas
consequ
gene
fcgriii
sequenc
swr
mice
well
addit
mous
strain
balbc
cba
nzw
nzb
bxsb
nod
mrl
found
fcgriii
exhibit
three
differ
haplotyp
mice
fcgriii
v
fcgriii
h
fcgriii
swr
fcgriii
v
mice
fcgriii
h
inde
differ
fcgriii
gene
interestingli
mous
share
fcgriii
h
haplotyp
autoimmunepron
strain
nzw
nzb
bxsb
nod
mrl
also
demonstr
swr
mice
differ
level
fcgriib
display
haplotyp
respect
result
suggest
polymorph
fcgr
may
form
basi
one
aspect
suscept
autoimmun
arthriti
introduct
system
lupu
erythematosu
sle
develop
childhood
clinic
manifest
rang
mild
constitut
symptom
progress
involv
target
organ
aim
studi
describ
clinic
manifest
outcom
nation
cohort
pediatr
patient
sle
patient
method
collect
retrospect
data
case
meet
acr
diagnost
criteria
childhood
onset
sle
regist
isra
nation
registri
children
rheumat
diseas
diagnos
follow
examin
diseas
activ
damag
use
sle
diseas
activ
index
sledai
sle
collabor
clinicsacr
sliccacr
diseas
damag
result
patient
identifi
femal
mean
age
diagnosi
f
year
rang
initi
clinic
manifest
includ
renal
involv
cn
hematolog
malar
rash
oral
nasal
ulcer
musculoskelet
seros
mean
sledai
f
rang
children
start
therapi
corticosteroid
immunosuppress
drug
children
year
follow
mean
sledai
f
rang
still
corticosteroid
immunosuppress
drug
children
year
follow
mean
sledai
f
rang
corticosteroid
immunosuppress
drug
mean
sliccacr
damag
index
f
children
year
follow
mean
sledai
f
steroid
immunosuppress
drug
mean
sliccacr
damag
index
f
five
patient
develop
chronic
renal
failur
one
die
conclus
nation
cohort
outcom
pediatr
sle
good
damag
index
low
rel
low
activ
patient
possibl
rel
earli
prolong
use
immunosuppress
medic
mani
patient
led
good
outcom
dyslipoproteinemia
common
lupu
patient
studi
investig
dyslipoproteinemia
cours
activ
sle
focu
role
antidsdna
antibodi
possibl
contributori
factor
fortysix
lupu
patient
year
old
fulfil
american
colleg
rheumatolog
revis
criteria
classif
sle
select
exclus
criteria
consist
renal
failur
nephrot
syndrom
thyroid
liver
diseas
diabet
mellitu
obes
pregnanc
take
drug
induc
dyslipidemia
diseas
activ
measur
system
lupu
erythematosu
diseas
activ
index
criteria
control
fortyon
healthi
indivisu
match
age
f
year
sex
accord
lipid
profil
activ
inact
control
group
found
high
level
serum
triglycerid
vldl
low
level
serum
hdl
activ
group
compar
inact
group
p
b
pattern
dyslipoproteinemia
observ
patient
posit
antidsdna
antibodi
compar
patient
neg
antidsdna
antibodi
p
b
pattern
dyslipoproteinemia
activ
sle
attribut
autoimmun
mechan
especi
relat
presenc
antidsdna
antibodi
rna
edit
coor
posttranscript
modif
rna
result
insert
delet
substitut
nucleotid
rna
edit
correct
extend
diversifi
inform
encod
within
correspond
genom
sequenc
frequent
alter
function
affect
rna
therefor
rna
edit
play
import
role
regul
gene
express
induct
phenotyp
variabl
occurr
high
circul
level
type
interferon
ifn
sle
well
document
previou
experi
demonstr
upregul
type
ifn
induc
rna
edit
gene
express
sle
cell
goal
experi
identifi
role
type
ifn
induc
edit
protein
kinas
pka
gene
transcript
normal
sle
patient
cdna
synthes
cell
sle
normal
control
group
amplifi
use
pka
adar
specif
primer
amplifi
product
pka
transcript
clone
vector
sequenc
analysi
pka
transcript
demonstr
increas
g
transcript
mutat
sle
compar
control
novel
g
edit
site
identifi
pka
gene
transcript
sle
lymphocyt
gene
upregul
suggest
possibl
caus
pka
gene
transcript
edit
sle
cell
addit
ay
g
novel
u
c
edit
also
observ
pka
gene
transcript
normal
sle
cell
enzym
respons
edit
mechan
underli
edit
unknown
sequenc
analysi
pka
transcript
demonstr
increas
u
c
transcript
mutat
sle
compar
control
taken
togeth
result
clearli
indic
increas
occurr
mrna
edit
pka
gene
transcript
sle
lymphocyt
mutant
gene
transcript
pathophysiolog
signific
encod
divers
aberr
form
includ
truncat
dominantneg
result
abnorm
gene
function
therefor
propos
defici
andor
abnorm
activ
gene
pka
contribut
pathogenesi
sle
impair
cell
function
determin
b
cell
lupu
prone
nzb
mice
possess
intrins
defect
directli
lead
contribut
cell
hyperrespons
inject
age
sex
mhc
ii
match
nzb
balbc
mice
histon
peptid
repres
domin
th
cell
epitop
histon
nucleosom
cocultur
purifi
b
cell
narv
peptid
prime
nzb
balbc
mice
presenc
peptid
found
b
cell
nzb
mice
express
high
level
surfac
follow
antigen
prime
antigen
present
exclus
autoimmun
b
cell
nzb
mice
induc
hyperrespons
normal
cell
balb
c
mice
cell
hyperrespons
result
costimul
b
cell
nzb
mice
induct
nasal
toler
nzb
mice
suppress
surfac
express
led
downregul
cell
prolif
respons
cytokin
product
interestingli
b
cell
purifi
nasal
toler
nzb
mice
induc
cell
anergi
antibodi
stimul
vitro
anerg
cell
possess
suppress
function
cocultur
narv
cell
produc
suppress
cytokin
interleukin
transform
growth
factorbeta
tgfb
upon
antibodi
stimul
vitro
lj
petrovicrackov
clinic
rheumatolog
clinic
immunolog
militari
medic
academi
belgrad
belgrad
serbia
yugoslavia
immunolog
reaction
major
amplif
factor
pathogenes
rheumatoid
arthriti
ra
rheumatoid
arthriti
destruct
synov
autoimmun
natur
cytokin
lymphocyt
product
synoviocyt
disrupt
natur
balanc
cytokin
network
insid
synovi
tissu
lead
inflammatori
reaction
joint
damag
carri
divers
modif
hydroxylysin
hyl
side
chain
design
synthes
explor
fine
specif
bciireact
cell
involv
initi
andor
regul
collageninduc
arthriti
cia
mous
model
rheumatoid
arthriti
ra
requir
hdgalactosyl
correspond
mimet
conveni
protect
solid
phase
synthesi
obtain
diverg
rout
featur
enantiopur
key
intermedi
three
bciispecif
hybridoma
use
studi
well
recurr
pathogen
cell
clone
isol
bciiimmun
mice
recogn
galactosyl
form
immunodomin
bcii
epitop
cell
extrem
sensit
chang
qamino
group
differ
pattern
recognit
analogu
hyl
side
chain
modifi
ie
invers
stereochemistri
methyl
data
document
import
collagen
posttransl
modif
autoimmun
cia
model
particular
provid
new
insight
molecular
interact
glycopeptid
tcr
pathogen
cell
monocyt
may
aggrav
immunecomplex
mediat
diseas
bind
mhc
class
enhanc
tnf
product
j
gib
befu
medicin
univers
alberta
edmonton
ab
canada
express
monocyt
macrophag
mo
rat
accord
avail
evid
mice
previou
studi
date
suggest
human
mo
express
convincingli
demonstr
mo
present
sever
rat
model
diseas
involv
immun
complex
glomerulonephr
arthriti
ischaemia
deplet
cell
mitig
patholog
diseas
model
mo
express
may
partial
respons
patholog
diseas
rat
human
previous
ascrib
cell
tnf
therapeut
target
mani
diseas
releas
larg
quantiti
mo
hypothes
human
mo
may
involv
tnfmediat
patholog
immun
complex
diseas
six
mab
recogn
human
monocyt
hi
flow
cytometri
ten
percent
monocyt
express
high
amount
remain
monocyt
express
low
amount
proport
mo
lymphocyt
difficult
distinguish
method
includ
cell
morpholog
flow
cytometri
fscssc
gate
potenti
mab
label
moreov
mani
mab
use
sold
clinic
evalu
eg
avoid
confus
hi
mo
hi
lymphocyt
clinic
research
set
care
definit
cell
eg
antitcr
mab
may
necessari
protein
found
surfac
mo
cell
line
continu
cultur
also
express
mrna
absenc
anoth
sourc
like
mo
transcrib
translat
function
mo
may
use
fcgr
bind
tissu
contain
immun
complex
establish
mo
bind
tetram
mhc
class
independ
bound
peptid
account
mhc
class
tetram
bind
mo
partial
inhibit
mab
agreement
literatur
mab
block
bind
mhc
class
demonstr
mab
bind
surfac
mo
indiscrimin
block
bind
mhc
class
tetram
select
mab
nonspecif
mab
imbed
immun
complex
enhanc
mo
tnf
product
similar
studi
mab
induc
tnf
product
suggest
particular
epitop
activ
mo
mab
specif
surfac
protein
mo
indiscrimin
enhanc
tnf
product
abil
mo
bind
mhc
class
releas
tnf
show
mo
could
involv
initi
aggrav
patholog
induc
immunecomplex
possibl
effect
attribut
cell
cell
inadequ
character
due
part
mo
introduct
sever
studi
shown
diagnost
use
anticycl
citrullin
peptid
ccp
antisa
antibodi
rheumatoid
arthriti
ra
studi
assess
autoantibodi
simultan
cohort
patient
object
determin
sensit
specif
posit
ppv
neg
npv
predict
valu
anticcp
antisa
monograph
outpati
clinic
cictd
method
crosssect
studi
studi
patient
ra
cictd
espondyloarthritid
polymyalgia
rheumat
pmr
juvenil
idiopath
arthriti
anticcp
antisa
antibodi
identifi
elisa
immunoblot
techniqu
respect
result
anticcp
antibodi
detect
ra
sensit
specif
ppv
npv
pmr
palindrom
rheumat
pr
system
lupu
eritematosu
undifferenti
connect
tissu
diseas
uctd
ankylos
spondyl
undifferenti
espondyloarthritid
sensit
specif
posit
predict
valu
neg
predict
valu
antisa
antibodi
detect
patient
ra
sensit
specif
ppv
npv
uctd
sjfgrent
syndrom
pr
juvenil
idiopath
arthriti
conclus
specif
predict
valu
anticcp
antisa
antibodi
diagnosi
ra
compar
howev
sensit
anticcp
antibodi
higher
given
higher
sensit
elisa
techniqu
compar
immunoblot
introduct
modifi
extracellular
matrix
ecm
protein
hydrolyz
elastin
collagen
fibronectin
thrombospondin
etc
polymer
protein
collagenpvp
shown
regul
inflammatori
process
due
evalu
effect
osteoarthr
oa
rheumatoid
arthriti
ra
diseas
relat
chronic
inflamm
result
special
interest
object
evalu
effect
hydrolyz
collagen
elastin
b
collagenpvp
c
mixtur
hydrolyz
collagen
elastin
plu
collagenpvp
cocultur
cartilag
synovi
tissu
ra
oa
knee
hip
materi
method
cartilag
synovi
tissu
cocultur
patient
ra
acr
patient
oa
acr
perform
prescrib
total
knee
hip
replac
surgeri
tissu
fragment
segment
approxim
tissu
cultur
sfb
antibiot
antimicot
day
follow
condit
rpmi
control
b
collagenpvp
c
hydrolyz
collagen
elastin
hydrolyz
collagen
elastin
collagenpvp
order
determin
effect
differ
cultur
condit
ecm
turnov
elastin
collagen
sulfat
proteoglycan
hyaluron
acid
tissu
stain
hematoxilin
eosin
verhoeff
alcian
blue
stain
techniqu
proinflammatori
cytokin
tnfa
ifng
supernat
quantifi
elisa
data
normal
total
protein
concentr
evalu
folinlowri
micromethod
tnfa
express
determin
histochemistri
statist
analysi
made
tstudent
test
u
mannwhitney
result
histolog
analysi
show
remodel
tissu
relat
increas
highli
sulphat
proteoglycan
sialomucin
hyaluron
acid
scarc
increment
elastin
fiber
tissu
tread
mixtur
hydrolyz
collagenpvp
vs
control
cultur
observ
increment
determin
tissu
treat
vs
control
cultur
tnfa
determin
lower
level
treat
cultur
vs
control
level
decreas
supernat
treat
cocultur
ra
patient
howev
supernat
oa
tissu
treat
hydrolyz
protein
statist
decreas
vs
control
determin
conclus
modifi
protein
induc
tissu
remodel
promot
recoveri
cartilag
proteoglycan
downregul
express
proinflammatori
cytokin
promot
chondroid
cell
prolifer
introduct
afodrin
localis
plasma
membran
mammalst
cell
cell
breakdown
apoptosi
action
cleavageproduct
alphafodrin
kd
act
neoantigen
recognis
sera
patient
ss
patient
ss
present
posit
iga
antiafodrin
antibodi
object
assess
frequenc
clinic
associ
iga
antialphafodrin
antibodi
patient
primari
secondari
ss
environ
materi
method
studi
patient
diagnos
ss
primari
ss
secondari
ss
rheumatoid
arthriti
ra
system
lupu
eritematosu
le
scleroderma
polymyos
iga
antiafodrin
antibodi
test
elisa
result
antiafodrin
antibodi
detect
patient
primari
ss
secondari
ss
ra
sle
polymyos
signific
differ
observ
compar
patient
without
antiafodrin
antibodi
neither
epidemiolog
data
time
diseas
evolut
clinic
manifest
conclus
environ
iga
antialphafodrin
antibodi
common
patient
ss
vs
literatur
associ
specif
clinic
manifest
sensit
iga
antialphafodrin
antibodi
higher
secondari
ss
ra
system
autoimmun
diseas
character
chronic
synovi
joint
inflamm
lead
cartilag
bone
destruct
etiolog
pathogenesi
diseas
still
unsolv
although
evid
reveal
tnf
play
central
role
pathogen
role
tnf
evidenc
observ
plasma
synovi
fluid
tissu
patient
ra
high
concentr
tnf
found
transgen
mice
overexpress
human
tnf
gene
develop
polyarthr
similar
ra
administr
human
tnf
monoclon
antibodi
birth
prevent
articular
lesion
diminish
incid
murin
arthriti
probabl
notabl
piec
evid
come
studi
demonstr
clinic
benefit
patient
ra
treat
antitnf
monoclon
antibodi
solubl
receptor
tnf
object
purpos
work
studi
histor
evolut
ra
would
consid
increas
diseas
rel
new
favor
specif
mutat
promot
region
tnf
gene
method
singl
nucleotid
polymorph
snp
determin
polimerasechain
reaction
pcr
restrict
fragment
length
polymorph
result
snp
determin
higher
express
cytokin
frequenc
polymorph
caucas
popul
studi
associ
de
ra
posit
find
caucas
popul
allel
time
higher
patient
ra
healthi
control
relat
presenc
extraarticular
manifest
rheumat
nodul
swedish
patient
demonstr
individu
bear
heterozyg
form
develop
sever
diseas
earlier
age
signific
associ
bad
prognosi
found
turkish
patient
ra
conclus
snp
seem
particip
evolut
ra
object
low
mannan
bind
lectin
mbl
associ
system
lupu
erythematosu
sle
ask
whether
low
mbl
might
predispos
sle
member
multicas
sle
famili
overal
increas
frequenc
method
low
mbl
detect
measur
serum
level
elisa
genotyp
mutant
structur
promot
lx
allel
rtpcr
detect
protein
electrophoresi
twentyfour
sle
patient
nine
iceland
famili
compar
firstdegre
seconddegre
nonsl
rel
unrel
famili
member
serv
control
result
mbllow
wildtypeo
mbldefici
oo
lxo
genotyp
associ
mbl
level
agl
low
mbl
observ
five
nine
famili
n
five
famili
sle
patient
firstdegre
seconddegre
rel
carri
mbllowdefici
genotyp
p
b
compar
control
p
patient
carri
mbllow
allel
lx
andor
p
b
sle
patient
also
combin
mbllowdefici
genotyp
often
nonsl
rel
p
control
p
accord
mbl
genotyp
patient
famili
also
lower
mbl
level
rel
p
b
control
p
low
mbl
predispos
sle
independ
statu
evid
mbl
consumpt
conclus
mbllowdefici
genotyp
low
mbl
serum
level
predispos
sle
independ
low
mbl
absent
four
nine
famili
highlight
heterogen
sle
h
zhuang
c
nacional
narain
e
sobel
p
lee
circul
peripher
blood
mononuclear
cell
pbmc
sle
patient
express
high
level
type
interferon
ifni
induc
gene
ifni
produc
plasmacytoid
dendrit
cell
pdc
promot
matur
myeloid
dendrit
cell
mdc
play
key
role
antigen
present
investig
interrelationship
ifni
product
circul
pdc
mdc
subject
sle
n
autoimmun
diseas
n
healthi
control
n
express
ifninduc
gene
oa
realtim
pcr
increas
sle
pbmc
vs
group
p
b
anova
high
express
seen
lupu
patient
compar
mean
sd
control
contrast
circul
pdc
mdc
count
flow
cytometri
decreas
sle
patient
compar
control
p
b
anova
product
autoantibodi
dsdna
snrnp
smnrnp
ro
la
posit
associ
high
ifni
product
neg
number
circul
pdc
mdc
wherea
antiphospholipid
antibodi
product
neg
associ
ifni
product
patient
low
pdcmdc
count
fulfil
greater
number
acr
criteria
higher
preval
renal
diseas
better
understand
basi
low
number
circul
dendrit
cell
precursor
sle
ask
whether
pdcmdc
count
persist
intermitt
low
longitudin
studi
show
individu
sle
patient
ifni
induc
gene
express
fluctuat
much
differ
independ
respiratori
infect
sledai
medic
use
howev
pdc
mdc
count
tend
remain
low
sle
regardless
ifni
level
healthi
subject
exhibit
differ
pattern
ifni
express
gener
much
lower
baselin
increas
dramat
within
day
respons
viral
upper
respiratori
infect
return
baselin
within
day
interestingli
number
circul
pdcsmdc
decreas
viral
infect
studi
mous
model
suggest
low
circul
pdcmdc
count
lupu
due
enhanc
dendrit
cell
matur
increas
express
migrat
circul
pool
site
inflamm
propos
ifni
produc
abnorm
activ
pdc
stimul
mdc
matur
present
selfantigen
culmin
autoimmun
abnorm
dendrit
activ
sle
could
reflect
either
intrins
dendrit
cell
defect
exagger
respons
extrins
microbi
activ
margin
zone
malt
lymphoma
aris
stomach
sometim
bear
immunoglobulin
receptor
specif
helicobact
pylori
antigen
erad
infect
may
lead
tumor
regress
margin
zone
lymphoma
also
aris
salivari
gland
patient
sjogrent
syndrom
ss
known
ssassoci
tumor
also
antigen
specif
studi
two
ss
patient
b
cell
neoplasm
consist
margin
zone
lymphoma
origin
within
parotid
gland
patient
posit
autoantibodi
use
recombin
human
base
elisa
first
patientt
lymphoma
exhibit
typic
lymphoepitheli
lesion
h
e
stain
k
lchain
flow
cytometri
solitari
tumor
excis
surgic
igg
autoantibodi
level
fell
unit
unit
contrast
total
igg
exhibit
kl
ratio
kl
ratio
antibodi
k
lchain
antibodi
level
decreas
surgeri
wherea
l
lchain
remain
unchang
indic
excis
tumor
specif
decreas
k
lchain
antibodi
second
patientt
lymphoma
l
lchain
surfac
marker
compat
margin
zone
lymphoma
neoplasm
widespread
time
diagnosi
permit
local
excis
ratio
kl
lchain
total
immunoglobulin
patient
wherea
kl
ratio
autoantibodi
thu
tumor
antibodi
l
lchain
data
suggest
product
antibodi
depend
presenc
tumor
cell
patient
antibodi
exhibit
nonrandom
usag
lchain
patient
consist
possibl
neoplast
b
cell
produc
autoantibodi
analog
margin
zone
lymphoma
aris
stomach
specif
h
pylori
antigen
specul
margin
zone
lymphoma
origin
salivari
gland
may
stimul
selfantigen
case
rais
possibl
autoantibodi
specif
characterist
sjogrent
syndrom
produc
margin
zone
b
cell
cell
may
occas
undergo
neoplast
transform
background
prototyp
proinflammatori
cytokin
induc
express
varieti
gene
synthesi
sever
protein
turn
induc
acut
chronic
inflammatori
chang
polymyos
dermatomyos
chronic
inflammatori
muscl
disord
character
proxim
muscl
weak
inflammatori
cell
infiltr
skelet
muscl
increas
express
endotheli
cell
capillari
mononuclear
inflammatori
cell
consist
find
muscl
tissu
myositi
patient
pathophysiolog
role
cytokin
myositi
yet
clarifi
hypothesi
could
neg
effect
muscl
fibr
metabol
regener
contribut
persist
muscl
weak
muscl
fatigu
often
seen
patient
aim
investig
muscl
fibr
express
receptor
healthi
inflam
muscl
tissu
differ
receptor
express
symptomat
nonsymptomat
muscl
tissu
method
muscl
biopsi
polymyos
patient
dermatomyos
patient
healthi
control
includ
studi
muscl
biopsi
patient
taken
two
differ
site
one
symptomat
muscl
nonsymptomat
muscl
express
investig
immunohistochemistri
local
express
also
investig
doubl
stain
confoc
microscopi
laminin
identifi
muscl
fibr
membran
marker
identifi
nuclei
result
express
membran
nuclei
muscl
fibr
well
inflammatori
cell
endotheli
cell
muscl
biopsi
myositi
patient
healthi
control
scatter
pattern
express
endotheli
cell
nuclei
muscl
fibr
differ
symptomat
asymptomat
muscl
membran
nuclear
express
ii
confirm
doubl
stain
confoc
microscopi
express
endotheli
cell
inflammatori
cell
patient
conclus
first
time
describ
membran
human
muscl
fiber
furthermor
local
cell
nuclei
implic
known
known
intracrin
pathway
could
possibl
mediat
nuclear
receptor
observ
express
muscl
fiber
membran
support
hypothesi
could
direct
effect
muscl
fibr
therebi
affect
muscl
function
trail
member
tnf
famili
proapotot
activ
increas
cell
associ
solubl
trail
strail
level
serum
patient
system
lupu
erythematosu
sle
previous
report
studi
set
character
upregul
cell
associ
strail
vivo
modul
trail
express
solubl
protein
releas
follow
cell
activ
ifna
exposur
vitro
lastli
function
abil
two
form
trail
mediat
apoptosi
compar
use
flow
cytometri
ex
vivo
express
membran
bound
trail
higher
cell
ten
lupu
patient
compar
ten
healthi
control
particularli
activ
cell
strail
level
determin
elisa
sera
lupu
patient
control
significantli
elev
patient
activ
sle
correl
diseas
activ
level
ifn
particular
clinic
featur
vitro
cell
associ
strail
maxim
induc
cell
activ
plu
ifn
patient
control
western
blot
analysi
immunoprecipit
sera
demonstr
presenc
kd
monomer
form
multimer
form
strail
although
tcell
associ
strail
function
vitro
induc
apoptosi
trail
sensit
jurkat
cell
determin
annexin
v
stain
releas
assay
apoptot
activ
membran
trail
fold
higher
compar
strail
conclus
increas
cell
associ
strail
featur
activ
diseas
lupu
patient
like
reflect
vivo
cell
activ
ifn
product
ifn
induc
enhanc
trail
express
trail
mediat
apoptosi
may
amplifi
abnorm
apoptot
process
sle
rational
collagenpolyvinylpyrrolidon
collagenpvp
shown
downmodul
proinflammatori
mediat
express
synovi
tissu
rheumatoid
arthriti
ra
patient
collagenpvp
subcutan
administr
ra
patient
safe
welltoler
drug
short
termtreat
aim
determin
efficaci
toler
safeti
intramuscular
inject
porcin
type
collagenpvp
patient
ra
long
termtherapi
method
protocol
approv
committe
medic
ethic
nation
institut
medic
scienc
nutrit
patient
gave
inform
consent
particip
recruit
studi
doubl
blind
placebocontrol
includ
patient
fulfil
american
rheumat
associ
acr
criteria
activ
ra
patient
stabl
therapi
methotrex
andor
nonsteroid
antiinflammatori
drug
nsaid
enrol
year
prospect
compar
longitudin
studi
patient
treat
accord
freyberg
scheme
intramuscular
inject
ml
collagenpvp
mg
collagen
ml
placebo
month
primari
endpoint
done
accord
ritchi
index
ri
count
joint
count
diseas
activ
score
da
erythrocyt
sediment
rate
esr
creactiv
protein
crp
secondari
endpoint
includ
morn
stiff
pain
intens
visual
analog
scale
va
spanishhealth
assess
questionnair
haqdi
improv
determin
use
american
colleg
rheumatolog
respons
criteria
statist
analysi
perform
nonparametr
doubl
tail
mannwhitney
u
test
data
express
mean
f
sd
p
valu
smaller
equal
consid
signific
result
collagenpvp
safe
well
toler
advers
event
patient
statist
signific
improv
p
b
collagenpvptr
vs
placebo
month
treatment
swollen
joint
count
f
vs
f
vs
ri
f
vs
f
vs
morn
stiff
conclus
collagenpvp
shown
safe
welltoler
drug
longterm
treatment
ra
combin
collagenpvp
plu
methotrex
efficaci
methotrex
alon
drug
could
use
treatment
ra
dermatomyos
dm
belong
group
idiopath
inflammatori
myopathi
character
bimod
pattern
agespecif
incid
rate
peak
age
group
year
juvenil
dm
age
group
year
adult
dm
aim
studi
evalu
clinic
characterist
patient
juvenil
dm
method
nation
registri
patient
juvenil
dermatomyos
jdm
elabor
author
hungari
summar
data
regist
accord
sign
symptom
diseas
cours
frequenc
relaps
surviv
patient
jdm
analysi
perform
use
data
patient
diagnos
accord
bohan
petert
criteria
surviv
probabl
calcul
kaplanmei
method
data
juvenil
patient
compar
data
patient
adult
dm
result
children
symmetr
weak
proxim
muscl
frequent
cutan
featur
facial
erythema
gottront
papul
extramuscular
extraskelet
manifest
diseas
frequent
adult
patient
common
extramuscular
featur
arthralgia
one
patient
juvenil
dm
interstiti
lung
diseas
ild
cardiac
manifest
diseas
respiratori
muscl
involv
observ
juvenil
patient
respiratori
muscl
involv
ild
frequent
among
adult
dm
patient
cardiac
manifest
myositi
view
diseas
cours
author
found
frequenc
polycycl
monophas
subtyp
diseas
similar
hazard
relaps
found
higher
first
year
remiss
none
juvenil
patient
die
among
adult
patient
diseasespecif
death
occur
conclus
patient
jdm
usual
admit
dermatolog
depart
therefor
paediatr
dermatologist
familiar
clinic
present
jdm
report
first
studi
clinic
characterist
diseas
cours
patient
juvenil
dm
diagnos
treat
followedup
hungari
best
knowledg
one
largest
studi
compar
clinic
data
juvenil
adult
patient
studi
earli
vertebr
provid
clue
develop
adapt
immun
system
even
primit
anim
phyla
porifera
express
molecul
precursor
mammalian
innat
immun
gain
new
insight
potenti
mechan
autoimmun
human
studi
cytokinelik
molecul
preb
cell
coloni
enhanc
factor
pbef
protein
produc
spong
respons
xenogen
cell
nicotinamid
nam
phosphoribosyl
transferas
activ
bacteria
mammal
pbef
induc
b
lymphocyt
activ
surfac
immunoglobulin
receptor
stimul
product
proinflammatori
mediat
monocyt
nfkb
depend
pathway
consist
homolog
nam
phosphoribosyl
transferas
pbef
induct
inhibit
nam
determin
whether
pbef
might
overexpress
patient
autoimmun
diseas
pbef
mrna
measur
quantit
realtim
pcr
pbmc
patient
system
lupu
erythematosu
sle
patient
rheumatoid
arthriti
ra
healthi
donor
hd
mean
pbef
express
significantli
increas
sle
rel
express
compar
housekeep
control
f
ra
f
compar
hd
f
p
comparison
consist
vitro
induct
pbef
express
pbef
posit
correl
express
sle
pbmc
r
p
b
summari
data
demonstr
pbef
cytokinelik
induc
proinflammatori
mediat
util
nicotinamid
adenin
dinucleotid
nfkb
pathway
stimul
innat
immun
system
activ
increas
product
pbef
autoimmun
diseas
may
repres
mechan
promot
inflamm
tissu
damag
may
ration
target
therapeut
inhibit
object
compar
genotyp
ra
versu
healthi
control
investig
associ
radiolog
progress
rate
serolog
marker
patient
method
genotyp
innolipa
innogenet
ghent
belgium
perform
ra
patient
healthi
control
radiolog
progress
rate
ra
assess
modifi
larsen
score
divid
diseas
durat
ra
patient
test
anticycl
citrullin
peptid
antibodi
antibodi
eurodiagnostica
arnhem
netherland
rheumatoid
factor
rf
latex
fixat
assay
difcolaboratori
detroit
mi
share
epitop
innolipa
ordrb
decod
amplif
kit
innogenet
ghent
belgium
mannwhitney
u
test
use
compar
differ
combin
haplotyp
pvalu
consid
signific
result
conclus
studi
neither
ra
suscept
radiolog
prognosi
associ
specif
genotyp
furthermor
raassoci
serolog
marker
equal
found
differ
genotyp
mani
studi
indic
role
type
interferon
system
human
murin
system
lupu
erythematosu
sle
cell
receptor
transgen
lupu
mous
model
sle
model
singl
posit
cell
transgen
balbc
donor
induc
lupuslik
syndrom
transfer
irradi
balbc
nunu
recipi
diseas
mice
character
presenc
antidsdna
antibodi
proteinuria
immun
complex
glomerulonephr
immunoprecipit
studi
reveal
promin
target
serum
autoantibodi
sle
mice
interferoninduc
antigen
identifi
member
interferoninduc
famili
therefor
hypothes
ifninduc
protein
also
target
serum
autoantibodi
deriv
human
lupu
patient
screen
panel
monoclon
polyclon
antibodi
direct
wellcharacter
lupu
autoantigen
western
blot
found
express
protein
induc
cell
upon
treatment
ifna
express
protein
peak
hour
follow
treatment
human
homolog
mous
previous
shown
ifnginduc
target
antinuclear
antibodi
sle
patient
express
also
induc
follow
treatment
ifnh
anoth
type
ifn
cell
treat
ifna
hour
lyse
probe
western
blot
sera
deriv
sle
patient
serum
singl
patient
uniqu
target
unidentifi
kdinterferon
induc
protein
final
express
induc
protein
involv
type
type
ii
ifn
signal
elev
pbmc
deriv
sle
patient
compar
normal
control
taken
togeth
data
suggest
ifninduc
protein
repres
novel
class
autoantigen
reveal
potenti
link
type
ifn
system
autoimmun
nuclear
receptor
recogn
regul
inflamm
pparg
nuclear
receptor
previous
consid
orphan
receptor
studi
role
mani
biolog
process
pparg
agonist
inhibitor
inflammatori
mediat
includ
nitric
oxid
tnfalpha
interleukin
earli
report
thiazoledinedion
tzd
synthet
pparg
agonist
studi
anim
model
human
patient
effect
inflammatori
diseas
system
lupu
erythematosu
sle
multipl
sclerosi
recent
report
pparg
necessari
reduct
inflammatori
mediat
ino
synthet
pparg
agonist
howev
intrins
pparg
function
absenc
synthet
agonist
appear
play
endogen
role
inflammatori
modul
thought
pparg
compet
nuclear
factor
like
nfkb
common
cofactor
activ
molecul
mechan
call
transrepress
interest
determin
transrepress
occur
nuclear
hormon
receptor
specif
estrogen
receptor
er
ppar
inflammatori
condit
competit
estrogen
receptor
ppar
may
partial
account
gender
differ
inflammatori
diseas
current
studi
demonstr
like
activ
pparg
activ
ppari
effect
significantli
reduc
product
lp
stimul
macrophag
sinc
macrophag
report
express
pparg
suggest
ppari
may
effect
regul
inflamm
elect
use
murin
model
lupu
studi
due
fold
higher
incid
lupu
femal
compar
male
bred
erh
genotyp
onto
mrllpr
lupu
mous
background
gener
collect
periton
macrophag
stimul
lp
induc
product
treatment
ppari
agonist
measur
effect
product
reduc
product
macrophag
concentr
reduct
effect
macrophag
erh
mice
least
effect
erh
mice
result
suggest
nuclear
receptor
like
erh
may
interfer
antiinflammatori
properti
exhibit
ppar
addit
result
demonstr
antiinflammatori
properti
ppari
competit
nuclear
receptor
may
use
pharmacolog
target
treatment
inflammatori
diseas
like
sle
heavi
metal
induc
autoimmun
reaction
direct
linkag
mhc
molecul
modifi
membran
protein
present
cryptopeptid
bcrushingq
autoantigen
toxic
radic
oxygen
increas
activ
enzym
nuclein
exchang
statement
form
basi
studi
concentr
fe
cu
zn
co
mn
cr
sr
pb
ba
blood
serum
patient
system
sclerosi
induct
coupl
plasma
icp
method
establish
patient
system
sclerosi
defici
zn
fe
mn
observ
increas
valu
cu
co
cr
indic
clear
correl
deseas
durat
level
activ
charact
clinic
sympthom
immunolog
paramet
copper
concentr
mostli
express
increas
time
comparison
norm
zinc
decreas
time
method
treatment
use
system
sclerosi
case
particular
penicylamin
promot
zinc
exhaust
blood
serum
cellular
level
receiv
result
point
trace
element
disbal
pathogenet
basi
deseas
gene
express
profil
activ
system
lupu
erythematosu
sle
mononuclear
cell
show
signific
granulopoiesi
signatur
trace
presenc
immatur
blood
neutrophil
precursor
inde
use
antibodi
neutrophil
separ
three
stage
immatur
neutrophil
stage
stage
ii
stage
iii
matur
neutrophil
healthi
individu
cell
neg
either
found
blood
blood
neutrophil
sle
patient
contain
cell
belong
three
stage
success
obtain
rna
highli
pure
popul
immatur
stage
matur
stage
iii
sle
well
matur
healthi
blood
neutrophil
rna
amplif
label
hybrid
affymetrix
gene
chip
array
detect
gene
specif
transcrib
immatur
versu
matur
neutrophil
ii
neutrophil
gene
contribut
slespecif
gene
signatur
furthermor
found
presenc
immatur
neutrophil
correl
sle
diseas
activ
develop
renal
diseas
suggest
relev
diseas
pathogenesi
sever
presenc
immatur
neutrophil
sle
blood
could
reactiv
process
due
apoptosi
matur
cell
inde
found
number
immatur
neutrophil
sle
blood
mononuclear
fraction
correl
abil
patientst
serum
induc
apoptosi
healthi
matur
neutrophil
whether
antineutrophil
antibodi
andor
deathinduc
molecul
like
trail
respons
proapoptot
effect
sle
serum
healthi
neutrophil
current
investig
also
found
matur
sle
neutrophil
display
acceler
spontan
apoptosi
compar
healthi
matur
neutrophil
cultur
despit
increas
apoptosi
rate
matur
sle
neutrophil
promptli
releas
much
healthi
cell
stimul
agonist
lipopeptid
agonist
impli
cell
function
releas
cytokin
proapoptot
sle
neutrophil
could
contribut
inflammatori
environ
would
facilit
matur
antigenpres
cell
process
apoptot
materi
immunogen
manner
explain
key
pathogen
event
sle
object
determin
whether
oral
contracept
ocp
use
cigarett
smoke
associ
presenc
rheumatoid
factor
rf
cohort
reproduct
age
women
without
rheumatoid
arthriti
ra
materialsmethod
subject
women
parent
children
enrol
cohort
origin
establish
prospect
studi
develop
type
diabet
mellitusrel
autoimmun
parent
popul
select
enrich
suscept
marker
type
diabet
mellitu
ra
subject
interview
examin
rule
current
diagnosi
ra
exam
histori
consist
possibl
diagnosi
ra
subjectt
medic
record
review
subject
met
american
colleg
rheumatolog
criteria
ra
exclud
analys
questionnair
administ
obtain
data
current
past
histori
tobacco
ocp
use
serum
sampl
obtain
adult
time
interview
test
rf
nephelometri
logist
regress
model
perform
determin
associ
rf
pack
year
smoke
well
ocp
use
adjust
odd
ratio
confid
interv
ci
use
measur
associ
result
subject
age
rang
year
mean
median
women
report
ever
use
ocpt
mean
durat
ocp
use
year
categori
smoke
never
n
packyear
n
packyear
n
conclus
data
suggest
ocp
use
may
protect
develop
rf
individu
without
ra
addit
heavi
cigarett
smoke
may
risk
factor
rf
seroposit
individu
without
ra
previou
studi
propos
smoke
risk
factor
ra
develop
ocp
use
invers
associ
ra
develop
result
suggest
environment
exposur
may
act
earli
develop
clinic
appar
diseas
efficaci
apratastat
novel
dual
inhibitor
tnfa
convert
enzymemetalloproteinas
murin
collageninduc
arthriti
model
enzym
tace
oral
bioavail
small
molecul
inhibitor
block
releas
tnfa
present
highli
desir
strategi
treat
ra
object
determin
effect
apratastat
novel
dual
tacemetalloproteinas
inhibitor
two
cia
model
compar
apratastat
one
cia
model
broadspectrum
metalloproteinas
inhibitor
signific
tace
activ
method
collageninduc
arthriti
cia
induc
mice
immun
base
tail
bovin
type
ii
collagen
cii
emulsifi
complet
freundt
adjuv
boost
either
lipopolysaccharid
lp
cii
emulsifi
incomplet
freundt
adjuv
day
later
result
apratastat
evalu
cia
mous
model
either
lp
boost
collagen
boost
prophylact
regimen
lp
boost
apratastat
administ
oral
dose
mgkg
bid
day
post
inocul
minimum
efficaci
dose
mgkg
bid
second
cia
model
collagen
boost
therapeut
treatment
initi
mous
diseas
sever
score
least
apratastat
mgkg
bid
mgkg
qd
po
mgkg
bid
po
broadspectrum
metalloproteinas
inhibitor
signific
tace
activ
evalu
therapeut
regimen
apratastat
mgkg
bid
mgkg
qd
produc
signific
reduct
clinic
microscop
diseas
sever
score
contrast
show
activ
lower
dose
apratastat
similar
vehicl
control
conclus
data
show
potent
tacemetalloproteinas
inhibitor
apratastat
reduc
clinic
histolog
manifest
joint
destruct
murin
cia
model
immunemedi
arthriti
system
lupu
erythematosu
sle
character
product
autoantibodi
glomerulonephr
chronic
gvh
cgvh
model
sle
induc
allorecognit
foreign
major
histocompat
complex
mhc
class
ii
determin
studi
use
mice
show
endogen
cell
requir
emerg
autoreact
b
cell
cgvh
new
studi
attempt
character
subset
b
cell
prone
lose
toler
cgvh
use
bknockinq
tg
model
chromosom
jh
locu
replac
rearrang
v
b
cell
subset
character
phenotyp
express
specif
cell
surfac
protein
thu
immatur
b
cell
sort
hsa
hi
igm
hi
igdwhil
matur
b
cell
sort
hsa
lo
igm
lo
differ
b
cell
subset
adopt
transfer
irradi
rad
jht
recipi
lack
endogen
b
cell
target
delet
jh
segment
cgvh
induc
challeng
recipi
spleen
cell
data
show
matur
b
cell
lose
toler
produc
antidsdna
autoantibodi
sooner
immatur
b
cell
determin
subset
transfer
matur
b
cell
popul
suscept
loss
peripher
toler
gvh
util
addit
cell
surfac
marker
igm
int
igd
hi
int
hi
lo
sort
follicular
fo
recircul
b
cell
igm
hi
igd
lo
hi
hi
consid
mz
b
cell
normal
locat
junction
white
red
pulp
similar
adopt
transfer
experi
follow
induct
gvh
data
indic
mz
b
cell
lost
toler
secret
autoantibodi
sooner
fo
b
cell
mz
b
cell
recent
propos
play
critic
role
host
defens
tindepend
bloodborn
pathogen
spontan
develop
autoantibodi
expand
mz
b
cell
popul
character
sever
lupuspron
strain
mice
data
show
mz
b
cell
particularli
vulner
loss
toler
cgvh
model
sle
thu
may
attract
target
therapeut
intervent
system
lupu
erythematosu
sle
multisystem
autoimmun
diseas
character
great
divers
clinic
manifest
accompani
larg
number
autoantibodi
present
studi
investig
chang
antidsdna
autoantibodi
antioxldl
autoantibodi
progress
sle
twentyseven
patient
sle
defin
accord
american
colleg
rheumatolog
criteria
monitor
year
diseas
activ
antidsdna
autoantibodi
measur
farr
assay
antioxldl
autoantibodi
determin
standard
eia
antibodi
measur
twice
year
time
result
show
subject
posit
n
iuml
subject
neg
vari
borderlin
level
antidsdna
autoantibodi
subject
posit
n
unitml
subject
neg
subject
vari
posit
neg
level
antioxldl
autoantibodi
detect
monitor
period
six
patient
allneg
level
autoantibodi
level
autoantibodi
substanti
decreas
one
patient
markedli
increas
patient
time
level
antioxldl
autoantibodi
significantli
higher
p
b
antidsdna
autoantibodi
posit
group
f
unitml
compar
antidsdna
autoantibodi
neg
group
f
unitml
signific
correl
level
antidsdna
autoantibodi
level
antioxldl
autoantibodi
antidsdna
antibodi
posit
group
r
p
b
correl
autoantibodi
antidsdna
antibodi
neg
group
r
studi
suggest
oxid
damag
involv
pathogenesi
sle
antioxldl
autoantibodi
similar
antidsdna
autoantibodi
relev
sle
progress
could
use
associ
marker
monitor
diseas
activ
sle
mechan
elev
level
antioxldl
autoantibodi
activ
sle
subject
studi
object
pregnancyderiv
microchimer
implic
pathogenesi
autoimmun
diseas
resembl
graftversushost
diseas
gvhd
evid
fetal
microchimer
fmc
found
blood
organ
women
system
sclerosi
sle
mous
model
gvhd
parent
lymphocyt
induc
slelik
glomerulonephr
autoantibodi
suggest
matern
microchimer
mmc
may
also
involv
sle
found
matern
cell
tissu
patient
autoimmun
diseas
control
form
lymphocyt
renal
tubular
cell
hepatocyt
cardiac
myocyt
thu
persist
mmc
impli
normal
immun
toler
matern
antigen
loss
toler
could
lead
inflamm
direct
mmc
within
tissu
altern
clonal
prolifer
matern
lymphocyt
reactiv
host
antigen
could
lead
elev
mmc
peripher
blood
studi
investig
mmc
level
well
toler
matern
antigen
childhood
onset
sle
method
pediatr
subject
studi
avoid
potenti
confound
factor
fmc
use
realtim
quantit
pcr
specif
nonshar
matern
hla
allel
quantifi
matern
dna
peripher
blood
subject
sle
agematch
healthi
control
lymphocyt
reactiv
evalu
intracellular
cytokin
assay
flow
cytometri
stimul
probandt
peripher
blood
mononuclear
cell
macrophag
mother
unrel
donor
urd
result
matern
dna
detect
sle
patient
control
p
mean
level
mmc
sle
genom
equival
geq
million
rang
compar
geqmillion
rang
control
stimul
urd
macrophag
lymphocyt
healthi
child
produc
interferong
wherea
respond
matern
produc
respons
urd
matern
contrast
toler
matern
cell
observ
pediatr
sle
patient
lymphocyt
produc
ifng
respons
urd
macrophag
compar
matern
produc
urd
compar
matern
conclus
mmc
common
healthi
subject
test
contrast
previou
studi
fmc
mmc
increas
autoimmun
diseas
trend
toward
decreas
mmc
pediatr
sle
patient
one
sle
patient
increas
reactiv
matern
antigen
present
cell
observ
suggest
mmc
could
clear
circul
host
cell
preliminari
result
suggest
hypothesi
immunolog
toler
mmc
intrins
normal
biolog
may
lost
chronic
inflammatori
diseas
lead
tissuespecif
inflamm
addit
studi
need
investig
mmc
tissu
frequenc
morpholog
phenotyp
extend
initi
observ
suggest
loss
toler
mmc
sle
present
year
old
male
histori
retroperiton
mediastin
fibrosi
case
complic
renal
ureter
obstruct
superior
inferior
vena
cava
obstruct
signific
collater
flow
childt
symptom
began
age
notic
increas
fatigu
activ
time
renal
function
test
abnorm
ultrasound
show
right
hydronephrosi
ct
scan
show
stenosi
inferior
vena
cava
ivc
infraren
portion
ivc
hepat
portion
extens
collater
circul
ureter
stent
place
puls
dose
solumedrol
administ
obstruct
persist
previou
report
shown
drug
tamoxifen
promot
activationindepend
shed
lselectin
neutrophil
lymphocyt
use
adult
treat
diseas
decid
add
medic
treatment
regimen
along
prednison
tamoxifen
result
resolut
ureter
obstruct
remov
stent
cours
complic
larg
deep
venou
thrombosi
lower
extrem
thrombosi
svc
continu
take
warfarin
prophylact
patient
evid
recurr
second
month
sinc
discontinu
tamoxifen
continu
hypoxem
oxygen
depend
physic
activ
pulmonari
function
test
indic
sever
restrict
diseas
make
case
uniqu
hypogammaglobulinemia
igg
rang
mgdl
treatment
cours
although
absolut
b
cell
count
low
percentag
total
count
normal
addit
identifi
sourc
protein
loss
bodi
lack
immunoglobulin
product
patient
point
toward
possibl
earli
diagnosi
combin
variabl
immunodefici
cvi
treat
intraven
immunoglobulin
ivig
order
replac
defici
prevent
infect
first
report
cvi
retroperiton
fibrosi
dendrit
cell
dc
antigen
present
cell
play
import
role
immunopathogenesi
rheumatoid
arthriti
dc
genet
modifi
shown
reduc
sever
arthriti
murin
model
collagen
induc
arthriti
cia
addit
dc
express
differenti
level
mch
class
ii
costimul
molecul
demonstr
interfer
induct
cia
defici
present
antigen
cell
aim
assess
capac
dc
puls
peptid
deriv
type
ii
bovin
collagen
cii
modul
antigenspecif
immun
respons
mice
activ
arthriti
method
five
day
cultur
gmcsf
bone
marrowderiv
dc
incub
lp
puls
h
cii
lacj
mice
activ
arthriti
subcutan
inocul
either
ciipuls
dc
dc
alon
clinic
histopatholog
paramet
follow
day
first
cii
administr
result
previou
immun
procedur
dc
phenotip
function
character
mhc
class
ii
costimul
marker
phagocytosi
assay
respect
analys
dc
display
semimatur
pattern
observ
group
mice
cia
immun
dc
alon
show
higher
score
clinic
sign
control
group
cia
p
b
howev
group
cia
mice
immun
ciipuls
dc
show
signific
lower
clinic
score
cia
control
p
b
conclus
immun
semimatur
dc
puls
type
ii
bovin
collagen
interfer
immunolog
cours
murin
arthriti
antigenspecif
manner
financ
fondecytchil
fondefchil
mecesup
signal
statdepend
pathway
essenti
induct
ifng
differenti
cell
mice
express
absenc
endogen
class
ii
molecul
develop
sever
collageninduc
arthriti
cia
anim
model
rheumatoid
arthriti
develop
arthriti
mice
cell
depend
profil
understand
role
collageninduc
arthriti
gener
transgen
mice
lack
mice
could
mount
respons
collagen
vitro
immun
strain
mice
type
ii
collagen
led
develop
arthriti
howev
incid
cia
significantli
higher
mice
compar
mice
develop
arthriti
depend
cytokin
transgen
mice
produc
tnfa
mice
produc
low
level
ifng
suggest
control
product
ifng
pathway
develop
milder
arthriti
delay
onset
observ
mice
cia
absenc
ifng
suggest
cytokin
might
regul
sever
diseas
mice
carri
nonsuscept
transgen
produc
lower
amount
cytokin
develop
milder
cia
lower
incid
compar
mice
suggest
mhc
major
predispos
factor
cytokin
produc
respons
antigen
present
mhc
molecul
may
determin
sever
diseas
system
lupu
erythematosu
sle
caus
autoantibodi
eg
anti
dna
immun
complex
caus
organ
damag
nzbnzw
fl
femal
mice
toler
artifici
peptid
pconsensu
pcon
base
antidna
igg
sequenc
contain
mhc
class
class
ii
cell
determin
develop
regulatori
cell
inhibitori
cell
suppress
autoab
product
present
studi
use
affymetrix
gene
chip
array
analyz
murin
gene
one
one
comparison
white
blood
cell
wbc
cell
subset
toler
vs
nontoler
mice
show
gene
differenti
express
least
twofold
respect
cell
array
confirm
upregul
sever
gene
use
realtim
pcr
increas
express
pattern
two
fold
real
time
pcr
gene
cell
toler
mice
repeatedli
found
immunophenotyp
cell
sort
reveal
signific
expans
pcon
treatment
mice
signific
increas
mrna
express
tgfb
found
stimul
pcon
treatment
suggest
role
tgfb
suppressor
function
cell
antitgfb
abrog
suppress
antidna
product
vitro
cell
cocultur
syngen
helper
b
cell
intracellular
stain
reveal
increas
express
ifng
splenic
cell
toler
mice
compar
untreat
mice
furthermor
annexin
v
stain
show
significantli
less
apoptosi
toler
cell
naiv
ti
toler
mice
expos
si
rna
lost
abil
suppress
antidna
product
vitro
confirm
role
suppress
associ
model
immun
toler
role
upregul
molecul
studi
similar
fashion
conclud
suppress
function
toler
cell
relat
increas
surviv
secret
tgfb
upregul
gene
product
upregul
cell
may
also
relat
abil
surviv
suppress
autoimmun
studi
molecular
mechan
suppress
lupu
mice
may
potenti
therapeut
valu
human
sle
impact
gender
immun
nephriti
background
recent
report
coadministr
antiglomerular
sera
lp
lead
sever
nephriti
gaug
proteinuria
azotemia
glomerular
crescent
format
prolif
lesion
focu
work
ascertain
gender
might
impact
nephriti
model
male
femal
mice
defici
estrogen
receptor
challeng
antiglomerular
serum
plu
lp
monitor
evid
renal
diseas
addit
mice
subcutan
implant
releas
estradiol
pellet
subject
nephrotox
insult
result
lp
antiglomerular
antibodi
challeng
femal
mice
exhibit
significantli
wors
proteinuria
vs
peak
diseas
p
b
blood
urea
nitrogen
vs
mgdl
peak
diseas
p
b
n
mice
per
group
compar
agematch
male
mice
moreov
estradioltr
male
exhibit
significantli
wors
proteinuria
earli
vs
p
b
n
mice
per
group
compar
placebotr
male
importantli
estradioltr
male
defici
estrogen
receptor
exhibit
significantli
lower
proteinuria
compar
estradiol
treat
male
p
b
n
per
group
conclus
clear
gender
profoundli
influenc
immunemedi
nephriti
action
estrogen
studi
progress
determin
cellular
molecular
base
differ
object
pathogeni
primari
sjfgrent
syndrom
pss
still
poorli
understood
sinc
pss
multifactori
diseas
approach
focus
singl
gene
gene
product
could
restrict
comprehens
systemat
studi
gene
express
repress
salivari
gland
one
main
targetorgan
patient
pss
ever
report
aim
compar
geneexpress
profil
salivari
gland
patient
pss
subject
without
autoimmun
featur
patient
method
patient
pss
accord
europeanamerican
consensu
group
criteria
includ
studi
well
patient
withss
rheumatoid
arthriti
subject
without
featur
autoimmun
autoantibodi
focu
score
b
total
rna
isol
labial
salivari
gland
rna
level
qualiti
puriti
assess
use
rna
nano
assay
agil
bioanalyz
rna
amplifi
oneround
amplif
ampliamp
ambion
uk
control
bioanalyz
cdna
fluoresc
probe
prepar
ng
amplifi
rna
cdna
fluoresc
probe
hybrid
custom
chip
contain
cdna
spot
manufactur
commissariat
ltenergi
atomiqu
cea
franc
rna
pool
normal
parotid
sampl
amplifi
use
common
refer
sampl
hybrid
twice
dyeswap
intens
valu
normal
use
lowess
whole
procedur
geneexpress
profil
fulfil
miam
standard
microarray
data
p
valu
correct
multipl
comparison
accord
benjaminihochberg
fals
discoveri
rate
procedur
result
thirtytwo
microarray
hybrid
use
salivari
gland
patient
pss
subject
without
featur
autoimmun
patient
ss
rheumatoid
arthriti
take
account
featur
present
microarray
gene
gene
upregul
gene
downregul
differenti
express
patient
pss
subject
without
featur
autoimmun
gene
differenti
express
group
algorithm
evalu
miss
valu
hierarch
cluster
show
patient
pss
cluster
tightli
togeth
well
subject
without
featur
autoimmun
gene
mainli
belong
cellcycl
oxid
burst
apoptosi
protein
metabol
chemokin
famili
valid
result
use
quantit
rtpcr
immunohistochemistri
current
way
conclus
geneexpress
profil
studi
target
organ
pss
fulfil
best
standard
microarray
data
demonstr
transcriptom
approach
could
help
unravel
new
pathogen
pathway
autoimmun
autoantigen
identifi
librari
screen
object
determin
character
autoantigen
stimul
autoantibodi
product
system
lupu
erythematosu
sle
screen
human
express
librari
patient
sera
materi
method
forti
pediatr
sle
patient
nephriti
screen
high
titer
antinuclear
antibodi
ana
immunofluoresc
western
blot
use
leukemia
acut
lymphocyt
myelocyt
leukemia
normal
cell
two
sera
yield
extrem
hightit
ana
columnpurifi
immunoglobulin
g
igg
sampl
two
pediatr
patient
diffus
prolif
glomerulonephr
use
screen
cell
line
express
librari
made
zap
ii
cdna
synthesi
kit
stratagen
immunoscreen
phagemid
lambda
zapii
vector
excis
amplifi
pcr
character
agaros
gel
electrophoresi
sequenc
sequenc
sampl
identifi
nation
center
biotechnolog
inform
ncbi
blast
program
result
seventeen
clone
isol
seven
identifi
sera
screen
vector
repeat
sequenc
four
uniqu
antigen
identifi
melanoma
antigen
gene
mage
ribosom
protein
ribosom
protein
ribosom
protein
conclus
four
autoantigen
system
lupu
erythematosu
identifi
express
librari
screen
screen
differ
tissu
express
librari
patient
sera
may
character
sle
autoantibodi
antigen
specif
improv
understand
pathogenesi
autoantibodi
product
endorgan
damag
sle
may
lead
develop
novel
therapeut
intervent
object
extern
applic
extract
two
herb
two
genera
axonopu
ludwigia
abbrevi
al
extract
use
treat
patient
second
third
degre
burn
injuri
high
efficaci
decad
l
extract
work
enhanc
heal
burn
injuri
unknown
main
symptom
sever
burn
red
pain
blister
swell
due
inflamm
therefor
antiinflammatori
medic
basic
critic
treatment
henc
aim
studi
determin
whether
al
extract
antiinflammatori
activ
method
nonadher
peripher
blood
leukocyt
napbl
monocyt
isol
human
whole
blood
collect
three
healthi
donor
human
napbl
monocyt
stimul
pha
without
presenc
filtersteril
al
extract
supernat
collect
hr
measur
tnfalpha
elisa
cell
also
stain
mtt
prolifer
assay
three
group
mice
nd
rd
degre
burn
boil
water
treat
placebo
al
extract
al
extract
daili
result
vitro
studi
human
napbl
monocyt
stimul
pha
show
incub
cell
al
extract
reduc
product
napbl
monocyt
hr
tnfalpha
napbl
monocyt
hour
napbl
monocyt
hour
prolifer
assay
show
cell
prolifer
stimul
pha
inhibit
presenc
al
extract
result
mice
burn
injuri
show
dose
respons
took
mice
n
treat
placebo
month
heal
week
group
n
treat
al
extract
day
group
n
al
extract
independ
experi
treatment
al
extract
mice
sever
inflamm
whole
back
whole
limb
also
reduc
symptom
inflamm
red
swell
within
hour
result
volunt
pain
joint
conclus
result
vitro
vivo
studi
suggest
extern
applic
al
extract
abl
reduc
superfici
subderm
inflamm
extern
applic
treat
subderm
inflamm
rheumatoid
arthriti
greatli
reduc
risk
side
effect
effort
made
studi
effect
al
extract
synoviocyt
safeti
oral
usag
treat
system
inflamm
identif
diseaseregul
cell
determin
within
antigen
target
autoimmun
diseas
would
signific
better
understand
mechan
natur
remissionrecoveri
acut
phase
diseas
develop
antigenspecif
immunotherapeut
approach
diseas
although
pathogen
epitop
identifi
sever
self
foreign
antigen
bare
inform
regard
bona
fide
regulatori
cell
epitop
use
lewi
rat
adjuvantinduc
arthriti
aa
model
human
rheumatoid
arthriti
ra
defin
diseaseregul
cell
epitop
within
aarel
antigen
mycobacteri
heatshock
protein
self
homolog
rat
epitop
resid
within
ctermin
region
interestingli
despit
sequenc
differ
correspond
homolog
ctermin
epitop
foreign
mycobacteri
self
epitop
immunogen
crossreact
also
possess
compar
aaregul
properti
intriguingli
ctermin
epitop
self
well
process
present
domin
nativ
antigen
wherea
foreign
poorli
process
present
cryptic
hidden
howev
like
also
good
immunogen
show
lewi
rat
toler
either
result
support
model
immunoregul
autoimmun
arthriti
arthrit
lewi
rat
inflammatori
acut
aa
upregul
express
well
present
endogen
self
lead
prime
ambient
ctermin
epitopereact
cell
cell
contribut
downregul
acut
aa
concurr
cryptic
epitop
effici
process
inflammatori
milieu
acut
aa
therebi
activ
subset
cell
direct
ctermin
epitop
cell
activ
expand
ctermin
epitop
vice
versa
result
reinforc
regulatori
cell
activ
aa
result
describ
novel
diseaseregul
featur
cryptic
antigen
determin
contrari
wellknown
pathogen
attribut
observ
antigen
thu
cryptic
epitop
autoimmun
diseasesrel
antigen
exploit
immunotherapeut
purpos
ra
autoimmun
diseas
system
lupu
erythematosu
sle
debilit
autoimmun
diseas
affect
women
nearli
nine
time
often
men
estrogen
implic
import
risk
factor
weakli
estrogen
organochlorin
pesticid
chlordecon
acceler
onset
sever
immun
complex
glomerulonephr
femal
nzb
nzw
mous
model
moreov
chlordecon
exposur
caus
earlier
onset
serum
igg
antidsdna
antichromatin
ovariectom
mice
similar
effect
caus
exogen
exposur
estradiol
murin
model
sle
character
spontan
develop
germin
center
gc
play
key
role
matur
humor
immun
respons
chemokin
receptor
import
gc
dark
light
zone
organ
cell
adhes
molecul
icam
may
play
import
role
reduc
gc
b
cell
apoptosi
therefor
examin
effect
chlordecon
estradiol
germin
center
b
cell
use
twomonth
old
ovariectom
mice
mice
subcutan
implant
sustainedreleas
pellet
contain
estradiol
kgday
chlordecon
control
mice
receiv
pellet
matrix
mice
sacrif
six
week
implant
spleen
cell
studi
flow
cytometr
analysi
splenic
b
cell
also
purifi
prolifer
assay
use
hthymidin
apoptosi
test
annexinv
estradiol
chlordecon
caus
signific
increas
spleen
sizeweight
p
estradiol
p
b
chlordecon
anova
also
found
chlordecon
estradiol
increas
percentag
b
cell
express
gc
marker
p
b
anova
b
cell
costimulatori
molecul
p
b
activ
marker
p
b
estradiol
p
b
chlordecon
express
p
b
p
b
estradiol
p
b
chlordecon
icam
p
b
p
b
estradiol
p
b
chlordecon
splenic
b
cell
upregul
well
hand
neither
chlordecon
estradiol
produc
signific
increas
b
cell
prolifer
significantli
reduc
splenic
b
cell
apoptosi
find
suggest
chlordecon
estradiol
may
enhanc
autoimmun
effect
germin
center
respons
spondyloarthropathi
spa
heterogen
group
diseas
character
axial
well
peripher
enthes
arthriti
less
frequent
rang
extraarticular
manifest
strong
associ
spa
particularli
ankylos
spondyl
gener
popul
first
degre
rel
affect
individu
confer
allel
signific
role
diseas
suscept
yet
fact
approxim
individu
develop
small
proport
patient
carri
allel
suggest
gene
particip
diseas
suscept
special
interest
gene
codifi
potent
immun
modul
thu
aim
present
studi
investig
allel
distribut
promot
polymorph
spa
mexican
patient
one
hundr
twentysix
patient
spa
undifferenti
spa
uspa
reactiv
arthriti
rea
healthi
control
studi
promot
polymorph
determin
polymeras
chain
reactionrestrict
fragment
length
polymorph
statist
method
includ
mantelhaenzel
x
fishert
exact
test
woolf
method
odd
ratio
allel
genotyp
frequenc
three
polymorph
site
similar
whole
group
spa
patient
healthi
control
clinic
subgroup
uspa
rea
compar
healthi
control
result
reveal
signific
differ
allel
genotyp
frequenc
data
suggest
promot
polymorph
involv
genet
suscept
spa
mexican
patient
congenit
heart
block
passiv
transfer
autoimmun
diseas
antibodi
transport
mother
fetu
rossa
posit
women
diagnosi
mother
may
sle
sjfgrent
syndrom
fetu
affect
mild
symptom
may
develop
lifethreaten
heart
block
shown
antibodi
necessari
diseas
develop
immun
rat
mother
deriv
peptid
result
heart
block
pup
howev
fact
mother
affect
children
later
give
birth
healthi
children
despit
persist
autoantibodi
indic
anoth
factor
gene
involv
penetr
diseas
aim
studi
investig
ascertain
mhc
nonmhc
genet
influenc
heart
block
develop
immunizationinduc
rat
model
congenit
heart
block
four
rat
strain
share
mhc
region
haplotyp
da
similar
background
gene
differ
mhc
gene
lewl
studi
femal
rat
immun
control
protein
mate
result
pup
immun
mother
control
immun
mother
analys
congenit
heart
block
extremitylead
electrocardiographi
consciou
pup
serum
sampl
taken
throughout
studi
mother
pup
epitop
map
antibodi
specif
use
recombin
panel
overlap
mutat
peptid
perform
analysi
ecg
born
pup
four
strain
show
strain
share
mhc
region
haplotyp
da
av
block
develop
pup
respect
lewl
strain
pup
affect
av
block
result
indic
gene
mhc
region
import
penetr
diseas
p
b
signific
differ
gener
antibodi
epitop
specif
rat
strain
heart
rat
mother
pup
heart
collect
immunohistochem
investig
inflammatori
marker
studi
first
explor
genet
influenc
develop
congenit
heart
block
anim
model
result
show
gene
found
rat
mhc
region
signific
import
penetr
congenit
heart
block
nonmhc
gene
appear
littl
influenc
diseas
identif
diseas
profil
rheumatoid
arthriti
use
antibodi
antigen
array
autoimmun
maladi
rheumatoid
arthriti
difficult
diagnos
like
repres
collect
patholog
give
rise
symptom
diseas
furthermor
definit
set
marker
diseas
monitor
real
time
predict
assess
effect
treatment
simultan
serial
measur
hundr
protein
blood
synovi
fluid
need
make
differenti
diagnosi
discov
novel
pattern
would
stratifi
diseas
protein
microarray
well
suit
type
proteom
approach
despit
fact
limit
specif
affin
reagent
ie
antibodi
measur
accuraci
depend
array
perform
sampl
prepar
assay
reproduc
demonstr
improv
method
fabric
antibodi
antigen
microarray
use
thermal
inkjet
printer
function
glass
slide
address
qualiti
issu
check
puriti
integr
protein
prior
deposit
print
array
qualiti
crossreact
affin
reagent
need
remov
high
abund
protein
use
optim
array
platform
develop
antibodi
array
detect
marker
inflamm
includ
autoantibodi
cytokin
chemokin
solubl
receptor
enzym
forti
sampl
synovi
fluid
serum
ra
patient
control
run
array
array
demonstr
increas
level
known
inflammatori
marker
ra
sampl
among
matrix
metalloproteas
cytokin
identif
diseas
profil
rheumatoid
arthriti
use
antibodi
antigen
array
autoimmun
maladi
rheumatoid
arthriti
difficult
diagnos
like
repres
collect
patholog
give
rise
symptom
diseas
furthermor
definit
set
marker
diseas
monitor
real
time
predict
assess
effect
treatment
simultan
serial
measur
hundr
protein
blood
synovi
fluid
need
make
differenti
diagnosi
discov
novel
pattern
would
stratifi
diseas
protein
micoarray
well
suit
type
proteom
approach
despit
fact
limit
specif
affin
reagent
ie
antibodi
measur
accuraci
depend
array
perform
sampl
prepar
assay
reproduc
demonstr
improv
method
fabric
antibodi
antigen
micoarray
use
thermal
inkjet
printer
function
glass
slide
address
qualiti
issu
check
puriti
integr
protein
prior
deposit
print
array
qualiti
crossr
affin
reagent
need
remov
high
abund
protein
use
optim
array
platform
develop
antibodi
array
detect
marker
inflamm
includ
autoantibodi
cytokin
chemokin
solubl
receptor
enzym
forti
sampl
synovi
fluid
serum
ra
patient
control
run
array
array
demonstr
increas
level
known
inflammatori
marker
ra
sampl
among
matrix
metallaproteas
cytokin
background
pediatr
system
lupu
erythematosu
sle
multisystem
diseas
significantli
impact
qualiti
life
qol
children
slet
impact
school
attend
import
outcom
potenti
predictor
outcom
receiv
littl
attent
object
examin
relationship
school
attend
qol
physic
function
sle
activ
damag
children
sle
designmethod
crosssect
studi
children
sle
year
parent
complet
childpar
version
childhood
health
assess
questionnair
chaq
pediatr
qol
inventori
pedsql
gener
rheumatolog
modul
physician
complet
sle
diseas
activ
index
sledai
system
lupu
intern
collabor
clinicsacr
damag
index
slicc
number
day
prior
child
miss
school
due
physicalment
health
reason
record
use
pedsql
famili
inform
form
spearman
correl
determin
number
miss
school
day
variabl
result
children
girl
sle
mean
age
f
year
mean
educ
th
grade
mean
sle
durat
f
month
sledai
slicc
median
chaq
mean
pedsqlgener
f
parent
median
chaq
mean
pedsqlgener
f
particip
children
exclud
school
attend
inapplic
day
prior
particip
children
miss
school
mean
f
day
mean
number
day
ill
play
f
mean
number
day
need
someon
f
day
number
miss
school
day
moder
correl
decreas
qol
report
parent
measur
pedsqlgener
modul
r
p
correl
significantli
rheumatolog
modul
chaq
sledai
slicc
child
report
score
conclus
number
miss
school
day
correl
decreas
gener
qol
children
sle
perceiv
parent
howev
parallel
correl
miss
school
day
overal
qol
perceiv
children
identifi
discrep
percept
parent
children
warrant
investig
larger
cohort
lack
correl
school
attend
scale
suggest
gener
scale
captur
less
tangibl
element
sle
categori
background
pediatr
system
lupu
erythematosu
sle
chronic
fluctuat
diseas
significantli
impact
qualiti
life
qol
pediatr
slespecif
healthrel
qol
tool
sle
heterogen
childrent
evolv
need
expect
parentproxi
respond
complic
qol
measur
object
develop
brief
valid
easili
understood
slespecif
pediatr
qol
tool
designmethod
develop
simpl
measur
impact
lupu
erythematosu
youngster
smileyn
base
qualit
research
pediatr
slea
item
tool
parallel
childpar
version
scale
item
children
year
parent
complet
childpar
version
smileyn
pediatr
qualiti
life
inventori
pedsql
gener
scale
childhood
health
assess
questionnair
chaq
children
also
complet
piersharri
selfconcept
scale
correl
childpar
smileyn
version
correspond
version
scale
determin
spearman
rank
test
result
children
girl
sle
mean
age
f
year
mean
sle
durat
f
month
sle
diseas
activ
index
mean
selfconcept
f
particip
mean
smileyn
score
f
parent
mean
smileyn
score
f
signific
correl
indic
asterisk
tabl
subject
complet
smileyn
minut
correl
childpar
smileyn
n
signific
r
p
result
demonstr
smileyn
brief
easili
understood
valid
pediatr
slespecif
qol
scale
lack
signific
correl
childpar
report
suggest
may
measur
differ
inform
childrenpar
childrent
percept
qol
may
differ
parentt
percept
accrual
addit
subject
necessari
confirm
result
fractal
analysi
use
model
bind
dissoci
kinet
biomed
analyt
like
connect
tissu
interstiti
glucos
adipos
tissu
interstiti
glucos
insulin
relat
analyt
analysi
provid
insight
diffusionlimit
analytereceptor
reaction
occur
heterogen
biosensor
surfac
fractal
analysi
appli
bind
glucos
relat
analyt
solut
glucos
deriv
immobil
biosensor
chip
fractal
analysi
provid
use
lump
paramet
analysi
diffusionlimit
reaction
occur
heterogen
surfac
via
fractal
dimens
rate
coeffici
demonstr
fractal
loglog
plot
made
larg
amount
avail
data
conveni
mean
make
degre
heterogen
exist
surfac
quantit
fractal
approach
provid
addit
inform
interact
may
obtain
convent
analysi
biosensor
data
numer
valu
obtain
bind
dissoci
rate
coeffici
link
degre
heterogen
rough
fractal
dimens
f
present
biosensor
chip
surfac
bind
dissoci
rate
coeffici
sensit
degre
heterogen
surfac
exampl
bind
adipos
tissu
interstiti
glucos
fractal
dimens
valu
increas
factor
equal
equal
bind
rate
coeffici
increas
factor
k
equal
k
equal
increas
degre
heterogen
probe
surfac
lead
increas
bind
rate
coeffici
dual
fractal
analysi
give
better
fit
case
bind
kinet
singl
fractal
analysi
adequ
describ
dissoci
kinet
affin
ratio
bind
dissoci
rate
coeffici
valu
also
present
valu
bind
rate
coeffici
k
link
degre
heterogen
exist
biosensor
surfac
provid
complet
pictur
reaction
kinet
occur
sensor
chip
surfac
dual
fractal
analysi
use
singl
fractal
analysi
provid
adequ
fit
done
regress
analysi
provid
quattro
pro
suggest
rough
surfac
lead
turbul
enhanc
mix
glucos
decreas
diffusion
limit
lead
increas
bind
rate
coeffici
glucos
type
diabet
mellitu
consid
typic
autoimmun
disord
result
loss
pancreat
betacel
consequ
develop
absolut
insulin
defici
howev
exact
chang
compon
immun
system
includ
impair
differ
cytokin
level
preced
develop
clinic
overt
type
diabet
mellitu
remain
fulli
understood
therefor
aim
studi
investig
serum
level
patient
newli
diagnos
type
diabet
mellitu
studi
patient
clinic
overt
type
diabet
mellitu
age
year
old
initi
insulin
therapi
agedmatch
healthi
control
subject
serum
level
measur
specif
immunoenzym
assay
found
serum
level
significantli
decreas
patient
type
diabet
mellitu
compar
control
f
pgml
vs
f
pgml
mean
f
sem
respect
p
b
data
could
explain
decreas
number
tlymphocyt
subject
newli
diagnos
type
diabet
mellitu
reveal
earlier
studi
lymphocyt
repres
target
cell
may
hypothes
reveal
signific
decreas
product
could
play
role
pathogenesi
autoimmun
insul
consequ
clinic
manifest
type
gdiabet
mellitu
organspecif
autoimmun
diseas
becom
manifest
welladvanc
intervent
therapi
must
inhibit
latestag
diseas
process
use
panel
immunogen
peptid
variou
gcell
antigen
evalu
factor
influenc
efficaci
antigenbas
therapi
diabetespron
nod
mice
advanc
diseas
abil
major
gcell
autoantigen
target
determin
td
prime
respons
declin
week
age
abil
immunogen
ignor
determin
id
gcell
antigen
prime
respons
unaffect
diseas
process
differ
pattern
td
id
immunogen
even
gcell
antigen
may
due
exhaust
uncommit
td
id
reactiv
cell
pool
recruit
autoimmun
cascad
therapeut
efficaci
associ
peptidet
immunogen
abil
promot
spread
late
diseas
process
affin
express
pattern
gcell
specificnonspecif
rareabund
character
id
reveal
babsoluteq
cryptic
determin
determin
littl
impact
cell
select
leav
larg
precursor
cell
pool
avail
prime
synthet
peptid
tradit
antigenbas
therapeut
use
whole
autoantigen
td
prime
respons
determin
find
suggest
new
strategi
design
efficaci
antigenbas
therapeut
latestag
autoimmun
diseas
object
nonalcohol
steatohepat
nash
common
chronic
liver
diseas
lead
cirrhosi
hepatocellular
carcinoma
consid
tumor
necrosi
factor
adipocytokin
import
pathogenesi
nash
featur
metabol
syndrom
although
nash
character
necroinflammatori
chang
essenti
role
inflammatori
cell
yet
identifi
clarifi
role
inflammatori
reaction
pathogenesi
nash
analyz
composit
liverinfiltr
cell
isol
liver
biopsi
specimen
nash
method
patient
nash
fatti
liver
fl
analyz
perform
immunohistochem
stain
use
antibodi
oxid
stress
assess
express
hne
count
number
popul
liverinfiltr
cell
mm
diagnos
liver
histolog
use
score
system
propos
brunt
et
al
examin
correl
histolog
score
number
popul
liverinfiltr
cell
moreov
analyz
surfac
marker
isol
liverinfiltr
cell
flow
cytometri
antibodi
lineag
marker
hladr
case
addit
local
express
also
examin
analyz
associ
cell
immunohistochem
method
result
among
variou
popul
number
cell
significantli
higher
nash
fl
nash
fl
f
f
p
nash
number
cell
tend
decreas
fibrosi
progress
r
p
express
hne
number
cell
show
posit
correl
cell
hne
r
p
r
p
moreov
flow
cytometr
analysi
show
nkt
cell
rather
nk
cell
increas
liver
nash
furthermor
flow
cytometr
analysi
show
molecul
found
express
antigen
present
cell
macrophag
dendrit
cell
lineagedr
addit
express
significantli
increas
liver
nash
compar
fl
normal
liver
importantli
part
express
recogn
around
cell
conclus
show
nkt
cell
prolifer
activ
earli
stage
nash
liver
nash
hepatocyt
contain
lot
fat
lipid
peroxid
gener
oxid
stress
antigen
present
cell
might
uptak
peroxid
lipid
deriv
degener
hepatocyt
present
process
lipid
antigen
nkt
cell
would
recogn
lipid
antigen
lead
releas
variou
cytokin
process
could
contribut
pathogenesi
nash
type
diabet
case
result
cellmedi
autodestruct
pancreat
hcell
shown
previous
dna
code
proapoptot
bax
protein
promot
diabet
prevent
prediabet
nod
mice
codeliv
intramuscularli
dna
code
secret
form
hcell
antigen
glutam
acid
decarboxylas
gad
furthermor
codeliveri
bax
recruit
dendrit
cell
contain
plasmidencod
protein
peripher
lymphoid
organ
report
dna
vaccin
revers
new
onset
diabet
deliv
intraderm
induc
immunosuppress
regulatori
cell
treg
femal
nod
mice
receiv
vaccin
time
diabet
onset
second
time
case
relaps
varieti
respons
treatment
observ
mice
respond
either
initi
relaps
treatment
initi
treatment
fifti
percent
treat
mice
overtli
diabet
fast
blood
glucos
n
mgdl
age
week
contrast
untreat
mice
mice
treat
plasmid
vector
alon
overtli
diabet
age
immunolog
analysi
reveal
drain
lymph
node
mice
treat
proapoptot
dna
vaccin
contain
higher
number
treg
enhanc
immunosuppress
function
compar
control
anim
result
indic
deliveri
dna
vaccin
alon
revers
symptom
autoimmun
diseas
suggest
real
clinic
potenti
proapoptot
dna
vaccin
treatment
immunemedi
inflammatori
disord
recent
studi
concern
h
cell
turnov
suggest
continu
process
h
cell
death
renew
effect
autoimmun
process
well
studi
regen
potenti
islet
cell
suggest
recent
studi
anim
model
examin
chang
h
cell
mass
replic
presenc
islet
inflamm
toler
induct
regulatori
cell
mean
percentag
replic
h
cell
higher
femal
prediabet
nod
mice
age
wk
compar
age
match
nodscid
mice
f
n
vs
f
n
p
b
signific
differ
h
cell
mass
two
group
f
mg
n
vs
f
n
p
ns
upon
diabet
onset
femal
nod
mice
percentag
replic
h
cell
increas
f
n
data
consist
compensatori
respons
inflamm
demonstr
increas
h
cell
replic
respons
antiislet
autoimmun
process
h
cell
replic
measur
nodscid
mice
week
posttransf
diabetogen
splenocyt
data
show
increas
mean
percentag
replic
h
cell
time
f
n
f
n
p
b
week
post
transfer
respect
contrast
chang
h
cell
replic
seen
nontreat
agematch
nodscid
mice
f
n
f
n
p
ns
cotransf
regulatori
cell
treg
harvest
nod
mice
treat
mab
prevent
develop
diabet
nodscid
mice
adopt
transfer
diabetogen
splenocyt
four
week
adopt
transfer
diabetogen
cell
treg
nodscid
mice
develop
diabet
contrast
nodscid
mice
receiv
cell
diabetogen
cell
develop
diabet
p
mice
protect
treg
h
cell
mass
significantli
greater
receiv
f
mg
n
vs
f
mg
n
respect
p
percent
replic
h
cell
mice
receiv
treg
f
n
wherea
h
cell
mass
small
determin
replic
rate
recipi
find
suggest
nod
mice
islet
inflammatori
lesion
play
role
stimul
h
cell
replic
nevertheless
heighten
h
cell
replic
initi
respons
autoimmun
insuffici
overcom
rate
autoimmunemedi
beta
cell
destruct
treatment
treg
lead
improv
preserv
h
cell
mass
mainten
heighten
h
cell
replic
prevent
develop
diabet
nod
mice
nod
mous
key
anim
model
type
diabet
major
femal
nod
mous
develop
immun
mediat
diabet
week
age
subset
remain
nondiabet
week
age
lack
diabet
develop
mice
could
due
failur
immun
system
complet
target
destroy
beta
cell
presenc
insulin
produc
cell
resist
destruct
order
distinguish
two
hypothes
studi
pancreat
histolog
nondiabet
femal
nod
mice
remain
nondiabet
week
age
mice
rang
age
week
pancrea
obtain
h
e
section
well
doubl
immunofluoresc
stain
antibodi
insulin
glucagon
eleven
mice
sever
islet
lymphocyt
infiltr
affect
major
islet
mice
insulin
stain
mice
islet
cell
exhibit
doubl
posit
insulin
glucagon
one
mous
could
detect
singl
insulin
posit
cell
neg
glucagon
cell
doubl
posit
mice
studi
glucagon
posit
cell
preserv
mice
insulin
posit
subset
glucagon
posit
cell
express
posit
insulin
transfer
diabet
analyz
six
nod
mice
inject
splenocyt
week
old
scidnod
recipi
splenocyt
rapidli
induc
diabet
b
week
data
show
older
nondiabet
nod
femal
show
insul
loss
beta
cell
splenocyt
capabl
transfer
diabet
furthermor
surviv
insulin
posit
cell
show
unusu
phenotyp
character
posit
glucagon
studi
elucid
origin
cell
hypothes
doubl
posit
cell
resist
immun
mediat
beta
cell
destruct
though
altern
may
repres
unusu
recent
develop
insulin
express
cell
previous
demonstr
program
pathway
play
critic
role
regul
develop
diabet
nod
mice
present
studi
explor
mechan
involv
regul
util
variou
knockout
transgen
nod
congen
strain
mice
observ
b
cell
defici
nod
mice
normal
resist
diabet
develop
diseas
follow
blockad
wherea
defici
nod
mice
resist
blockad
therebi
suggest
cell
play
import
role
mediat
acceler
diabet
util
tcr
tg
mice
clearli
dissect
role
regul
autoreact
cell
blockad
precipit
earli
onset
diabet
expans
tcr
tg
cell
decreas
apoptosi
nod
congen
mice
variabl
degre
resist
autoimmun
diabet
usual
develop
diabet
incid
respect
util
studi
role
diabet
resist
mab
treatment
acceler
diabet
congen
strain
albeit
differ
acceler
pattern
interestingli
congen
mice
blockad
acceler
time
onset
well
increas
incid
diabet
util
mice
shown
blockad
result
precipit
diabet
chang
local
cytokin
milieu
cell
upregul
ifngamma
tnfalpha
conclud
regul
autoimmun
diabet
limit
expans
autoreact
cell
thu
play
critic
role
mediat
diseas
resist
result
provid
rational
develop
novel
therapi
reestablish
toler
autoimmun
diabet
type
diabet
immunemedi
diseas
character
autoimmun
destruct
pancreat
hcell
varieti
environment
genet
factor
involv
develop
diseas
previous
develop
experiment
autoimmun
diabet
ead
model
insulin
peptid
immun
andor
polyinosinicpolycytidyl
acid
polyi
c
viral
rna
mimic
tolllik
receptor
tlr
activ
transgen
mice
express
costimulatori
molecul
islet
drivenli
rat
insulin
promotor
rip
peptid
immun
induc
diabet
insulin
autoantibodi
iaa
ia
mice
express
major
goal
develop
bhumanizedq
mice
develop
immun
mediat
diabet
known
nativ
autoantigen
stimulu
report
marron
et
al
human
leukocyt
antigen
hla
transgen
nod
mice
progress
diabet
rapidli
neg
mice
combin
transgen
human
transgen
balbc
mice
origin
mice
gift
dr
l
wen
mice
provid
dr
bl
kotzin
mice
immun
without
polyi
c
overal
mice
week
n
rang
diabet
onset
week
develop
diabet
follow
poli
ic
inject
alon
fortythre
percent
develop
diabet
week
n
rang
week
p
b
immun
polyi
c
inject
studi
indic
human
permiss
develop
diabet
ead
acceler
diseas
model
follow
either
activ
peptid
immun
studi
underway
defin
potenti
islet
peptid
restrict
antigen
present
use
elispot
analysi
model
immun
mediat
hcell
destruct
similar
differ
autoimmun
respons
type
type
diabet
patient
type
diabet
lada
compris
approxim
caucasian
adult
phenotyp
type
diabet
patient
islet
reactiv
autoantibodi
cell
found
type
diabet
patient
suggest
autoimmun
pathogenesi
studi
ask
cell
reactiv
phenotyp
compar
type
versu
type
diabet
identifi
type
diabet
patient
n
autoantibodi
cell
respons
islet
protein
cell
reactiv
islet
protein
measur
cellular
immunoblot
peripher
cell
popul
measur
fac
compar
type
patient
versu
type
type
normal
control
cell
type
type
diabet
patient
respond
similarli
islet
protein
molecular
weight
region
contrast
islet
protein
molecular
weight
region
significantli
p
b
less
stimulatori
cell
respons
type
diabet
patient
versu
type
patient
number
cell
significantli
lower
p
b
peripher
blood
type
patient
compar
type
patient
type
patient
normal
control
cell
significantli
lower
peripher
blood
type
patient
compar
subject
group
cell
receptor
posit
gd
cell
significantli
p
b
decreas
peripher
blood
type
type
patient
result
suggest
type
type
diabet
immunolog
similar
respect
way
differ
differ
may
import
slower
diseas
progress
type
diabet
diseas
process
diseas
process
sever
viral
infect
includ
cytomegaloviru
cmv
infect
implic
associ
develop
type
diabetesrel
autoimmunityth
aim
studi
explor
whether
correl
cmv
infect
type
diabetesassoci
autoimmun
young
children
hlaconf
diseas
suscept
case
diabetesassoci
autoantibodi
hla
age
sexmatch
control
particip
diabet
predict
prevent
dipp
studi
run
univers
turku
tamper
oulu
finland
accord
studi
protocol
newborn
infant
carri
suscept
hla
genotyp
observ
month
interv
regularli
test
primarili
ica
posit
also
gada
iaa
fortyon
prospect
follow
antoantibodi
posit
subject
girl
boy
age
month
median
month
sex
age
hlamatch
control
analyz
cmv
igg
class
antibodi
eia
time
seroconvers
autoantibodi
posit
within
next
month
signific
differ
seen
preval
cmv
antibodi
time
seroconvers
autoantibodi
posit
subject
control
posit
cmv
igg
class
antibodi
p
chisquar
test
differ
either
found
ica
gada
iaa
posit
subject
control
subject
autoantibodi
analyz
separ
conclus
data
suggest
earli
cytomegaloviru
infect
increas
probabl
develop
type
diabetesassoci
autoimmun
rotaviru
infect
implic
possibl
trigger
elucid
connect
compar
peripher
blood
tcell
respons
rotaviru
children
newli
diagnos
n
children
autoantibodi
n
control
children
carri
hlaconf
suscept
without
autoantibodi
n
lymphocyt
prolifer
assay
base
stimul
antigen
perform
use
freshli
isol
peripher
blood
mononuclear
cell
measur
also
childrent
igg
iga
class
rotaviru
antibodi
plasma
sampl
drawn
time
tcell
sampl
differ
observ
strength
tcell
respons
rotaviru
children
overt
multipl
autoantibodi
control
children
furthermor
also
frequenc
posit
tcell
respons
rotaviru
close
similar
three
group
result
remain
similar
children
serolog
evid
earlier
rotaviru
infect
studi
differ
observ
respons
control
antigen
ppd
tetanu
toxoid
tcell
respons
purifi
coxsacki
viru
stronger
children
autoantibodi
control
children
conclus
cellular
immun
studi
provid
evid
support
associ
rotaviru
infect
presenc
autoantibodi
young
children
diabet
associ
infring
endogen
opioid
system
opposit
alter
variou
type
opioid
receptor
sensit
howev
clear
whether
membran
lipid
modif
process
take
part
develop
disord
well
possibl
role
etiolog
neurolog
complic
patient
order
evalu
process
mention
involv
suppos
investig
effect
select
deltaopioid
receptor
agonist
deltorphin
ii
antagonist
receptor
antagonist
naltriben
aspect
phosphoinositid
cycl
function
lymphocyt
regul
role
process
mention
initi
membranebound
step
studi
opioid
agonist
antagonist
inform
transloc
demonstr
diabet
nondiabet
cell
evid
exist
alter
lipidmedi
signal
transduct
pathway
receptor
lipid
microenviron
may
respons
alter
nocicept
diabet
condit
amplif
free
radic
process
known
one
pathogen
mechan
form
basi
neuropatholog
complic
diabet
condit
howev
clear
whether
membran
lipid
free
radic
oxid
process
enzym
antirad
defens
system
take
part
disord
order
evalu
involv
mention
process
alter
nocicept
diabet
condit
intens
lipid
peroxid
process
investig
well
activ
enzym
cell
antirad
protect
superoxid
glutathion
reductas
dismutas
diabet
patient
erythrocyt
membran
condit
opioid
receptor
blockad
sensit
correl
intens
enzymat
lipid
peroxid
opposit
chang
receptor
sensit
well
possibl
particip
cell
antirad
protect
enzym
demonstr
evid
exist
studi
lipid
mediat
transduct
pathway
togeth
receptor
microenviron
modif
appear
possibl
biochem
target
alter
nocicept
diabet
condit
combinatori
treatment
recentonset
type
diabet
induct
isletantigen
specif
treg
rational
central
issu
use
immunesuppress
therapi
transplant
autoimmun
balanc
benefit
system
side
effect
administr
non
fcbind
shown
good
efficaci
temporarili
maintain
cpeptid
level
recentonset
diabet
year
timefram
immunosuppress
side
effect
limit
higherdos
regimen
continu
administr
one
novel
attract
avenu
type
diabet
islet
autoantigenspecif
induct
adapt
regulatori
cell
treg
act
vivo
bystand
suppressor
autoaggress
respons
select
within
pancreat
drain
lymph
node
pdln
hand
cell
induc
via
oral
intranas
administr
insulin
proinsulin
peptid
dna
vaccin
express
islet
antigen
efficaci
associ
product
site
specif
strong
clinic
advantag
attribut
fact
autoantigen
lead
expans
activ
present
pdln
sinc
known
increas
number
intrins
treg
well
tgfh
product
reason
would
creat
favor
system
milieu
isletantigen
specif
induct
autoreact
adapt
treg
synergi
could
expect
approach
combinatori
therapi
recentonset
diabet
nod
riplcmv
mous
model
use
fabt
intranas
proinsulin
result
least
increas
revers
recentonset
diabet
observ
nod
ripnp
mice
treat
combin
proinsulin
compar
intervent
given
alon
particular
mice
rapid
beta
cell
loss
benefit
synergist
effect
mechanist
observ
increas
number
proinsulin
specif
antigeninduc
treg
produc
mice
receiv
combinatori
therapi
compar
receiv
alon
furthermor
found
much
higher
number
tgfbeta
produc
treg
mice
treat
compar
mice
receiv
alon
conclus
antigenspecif
induct
treg
synerg
system
immun
modulatori
approach
revert
recentonset
synergi
evidenc
enhanc
clinic
efficaci
increas
number
intrins
tgfbeta
produc
well
adapt
autoantigenspecif
produc
treg
popul
strategi
consid
clinic
mayb
also
transplant
db
support
jdrf
postdoctor
fellowship
mgvh
support
prevent
center
grant
cell
thought
essenti
maintain
toler
self
antigen
cell
known
regulatori
cell
r
classifi
two
main
categori
natur
r
deriv
thymu
adapt
r
aris
peripheri
import
cell
control
respons
foreign
antigen
begun
describ
previous
report
activ
human
cell
led
express
cell
acquisit
cell
contactdepend
cytokineindepend
regulatori
activ
result
laboratori
reveal
invitro
deriv
r
could
gener
memori
naiv
cell
activ
cell
alloantigen
foreign
antigen
ha
ha
system
mhc
class
ii
tetram
use
identifi
antigenspecif
cell
antigen
activ
two
popul
cell
tetram
tetramercel
antigen
specif
suppress
occur
tetram
cell
ha
gener
r
requir
cognat
antigen
activ
activ
subsequ
suppress
noncogn
bystand
cell
respons
well
reason
start
test
abil
diabet
autoantigen
gener
antigenspecif
r
gadspecif
r
gener
normal
diabet
subject
activ
r
also
suppress
bystand
cell
respons
rais
possibl
antigenspecif
r
may
use
therapeut
autoimmun
diseas
local
gener
suppress
activ
tissu
express
select
target
antigen
tgfh
produc
varieti
cell
type
exhibit
strong
immun
dampen
function
surprisingli
model
virallyinduc
autoimmun
diabet
local
express
tgfh
hcell
control
doxycyclinedepend
promot
result
increas
islet
infiltr
diseas
incid
attribut
select
antiapoptot
effect
tgfh
differenti
memoryeffector
ctl
convers
mice
lack
function
tgfhreceptor
cell
exhibit
enhanc
apoptosi
fewer
memori
lymphocyt
effect
tgfh
clearli
depend
cell
differenti
statu
effect
suppress
activ
narv
antivir
ctl
result
highlight
novel
aspect
pleiotrop
natur
tgfh
implic
design
immunotherapi
involv
cytokin
invari
natur
killer
inkt
cell
compris
subset
regulatori
cell
character
coexpress
nk
cell
marker
invari
tcr
recogn
lipid
antigen
manner
previous
report
activ
inkt
cell
sphingoglycolipid
alphagalactosylceramid
agalc
protect
type
diabet
nod
mice
protect
involv
polar
toward
immun
respons
accompani
increas
potent
activ
inkt
cell
also
transactiv
immun
cell
analyz
whether
inkt
cell
influenc
function
regulatori
cell
found
cell
defici
inkt
cell
function
similarli
vitro
cell
wildtyp
nod
mice
suppress
prolifer
nod
respond
cell
upon
stimul
agalc
adopt
transfer
nod
diabetogen
cell
nod
cell
pretreat
vivo
multipl
low
dose
agalc
indic
activ
inkt
cell
influenc
regulatori
capac
cell
inhibit
transfer
contrast
protect
mediat
adopt
transfer
activ
inkt
cell
requir
presenc
cell
splenocyt
pretreat
agalc
deplet
cell
unabl
confer
protect
data
suggest
even
though
inkt
cell
may
influenc
cell
activ
inkt
cellmedi
protect
appear
requir
presenc
cell
support
cihr
grant
mop
tld
alter
peptid
ligand
apl
correspond
amino
acid
region
insulin
b
chain
b
epitop
recogn
interferon
ifn
gproduc
lymphocyt
type
diabet
patient
immunomodulatori
effect
recentonset
type
diabet
patient
phase
clinic
trial
measur
use
elispot
assay
peripher
blood
mononuclear
cell
ifng
respons
b
observ
patient
receiv
placebo
nondiabet
untreat
control
subject
administr
five
biweekli
biweeklymonthli
sc
inject
led
dosedepend
reduct
percentag
patient
ifng
respons
b
concomit
increas
percentag
respons
b
similar
trend
observ
elispot
respons
phase
clinic
studi
demonstr
treatment
enhanc
rather
suppress
pathogen
ifng
respons
recentonset
type
diabet
patient
dosedepend
fashion
enhanc
respons
treatment
consist
induct
helper
th
immunolog
phenotyp
signific
find
clinic
outcom
diseas
investig
phase
ii
multidos
studi
excess
heterozyg
individu
among
caucasian
patient
incid
rise
mani
countri
mhc
haplotyp
composit
patient
also
chang
past
sever
decad
earlier
propos
polygen
diseas
mix
two
popul
reciproc
differ
frequenc
suscept
gene
differ
loci
incid
mix
offspr
much
higher
origin
popul
suscept
gene
complement
differ
loci
propos
appar
increas
risk
heterozygot
compar
homozygot
either
heterozygot
overrepresent
among
patient
parent
appear
come
differ
previous
isol
popul
thu
diseas
popul
marker
evid
hladr
parent
genotyp
distribut
deviat
hardyweinberg
equilibrium
way
opposit
patient
parent
pauciti
heterozygot
b
parent
differ
frequenc
untransmit
hla
haplotyp
transmit
c
parent
differ
in
allel
frequenc
parent
parent
patient
greater
selfreport
ethnic
mix
control
parent
thu
specif
kind
intrafamili
popul
admixtur
explain
three
phenomena
diseas
type
diabet
tid
concord
approxim
monozygot
twin
approxim
mhcident
sib
approxim
sib
gener
thu
mhc
suscept
gene
nonmhc
gene
also
requir
suscept
popul
distribut
certain
mhc
marker
analysi
affect
sib
pair
mhc
suscept
gene
must
express
recess
frequenc
gener
popul
approxim
mhc
marker
embed
within
conserv
extend
haplotyp
fix
dna
least
hlab
interv
around
megabas
length
identif
true
suscept
locu
difficult
presenc
low
frequenc
socal
protect
hladrdq
haplotyp
patient
strongli
suggest
marker
suscept
true
mhc
suscept
gene
remain
discov
intrins
penetr
concord
rate
monozygot
twin
rate
complet
suscept
person
popul
necessari
suscept
gene
penetr
suscept
gene
like
due
differenti
environment
effect
sinc
concord
rate
dizygot
twin
rate
sib
fact
homozygot
mhcdetermin
dominantli
express
igd
defici
twice
frequenc
defici
heterozygot
conclud
penetr
situat
stochast
properti
mhc
suscept
gene
seem
like
similar
mechan
oper
rare
xlink
syndrom
known
ipex
immun
dysregul
polyendocrinopathi
enteropathi
xlink
inherit
character
earlyonset
iddm
type
diabet
sever
enteropathi
eczema
variabl
autoimmun
phenomena
ipex
gene
map
chromosom
encod
put
dnabind
protein
signific
homolog
forkheadwingedhelix
transcript
factor
famili
observ
ipex
phenotyp
one
patient
age
one
month
intract
diarrhea
dermat
elev
ige
autoantibodi
pancrea
thyroid
gut
neg
mutat
analysi
gene
reveal
three
distinct
nucleotid
substitut
mutat
consist
known
splicesit
mutat
exon
boundari
two
aberr
within
intron
second
within
exon
previous
describ
interestingli
express
studi
mrna
detect
product
smaller
compar
normal
control
sequenc
analysi
product
reveal
absenc
exon
molecular
analysi
extend
member
famili
show
mutat
one
two
healthi
brother
patient
addit
mother
identifi
carrier
mutat
present
patient
month
old
diarrhea
remiss
without
treatment
routin
monitor
order
control
diseas
progress
ipex
syndrom
usual
associ
overwhelm
autoimmun
sever
phenotyp
present
atyp
case
ipex
manifest
unusu
mild
clinic
featur
correspond
novel
set
mutat
studi
import
clarifi
link
phenotyp
patient
specif
molecular
aberr
gene
moreov
whether
gene
product
without
exon
normal
splice
variant
mrna
result
multipl
mutat
found
patient
investig
purpos
human
glycoprotein
secret
type
ii
alveolar
cell
lung
serum
level
increas
pneumonia
variou
caus
member
famili
express
cornea
conjunctiva
well
lung
purpos
present
studi
investig
clinic
use
quantifi
serum
level
diagnos
follow
sarcoidosi
patient
uveiti
patient
method
sera
obtain
uveiti
patient
diagnos
sarcoidosi
uveiti
patient
etiolog
healthi
control
subject
patient
consid
indic
sarcoidosi
concentr
exceed
uml
within
criterion
healthi
subject
neg
sarcoidosi
serum
concentr
determin
human
electrochemiluminesc
immunoassay
eclia
result
averag
level
sera
uveiti
patient
sarcoidosi
etiolog
healthi
control
f
mean
f
sd
uml
f
f
respect
level
uveiti
patient
sarcoidosi
significantli
higher
patient
etiolog
uveiti
measur
identifi
sarcoidosisposit
patient
result
combin
serum
angiotensinconvert
enzym
ace
concentr
sarcoidosi
patient
identifi
compar
use
ace
result
alon
combin
measur
identifi
nonsarcoid
patient
healthi
subject
posit
fals
posit
signific
correl
serum
ace
level
patient
sarcoidosi
moreov
serum
concentr
less
affect
system
corticosteroid
administr
ace
never
affect
ace
inhibitori
drug
system
hypertens
conclus
combin
measur
serum
ace
may
use
screen
sarcoidosi
uveit
patient
also
may
valuabl
follow
diagnos
sarcoidosi
concentr
serum
less
fluctuat
ace
patient
treat
system
corticosteroid
andor
antihypertens
drug
support
jsp
research
fellowship
young
scientist
japan
societi
promot
scienc
tokyo
jae
kyoun
ahn
hyeong
gon
yu
hum
chung
sungpyo
park
young
joo
kim
ophthalmolog
seoul
nation
univers
colleg
medicin
seoul
seoul
republ
korea
recent
report
demonstr
intraocular
infiltr
bright
cell
distinct
featur
activ
behcett
uveiti
bd
etiolog
endogen
uveiti
howev
phenotyp
natur
effector
function
bright
cell
activ
bd
remain
elus
studi
conduct
determin
phenotyp
function
characterist
bright
cell
investig
cytotox
mechan
these
subset
forti
five
patient
bd
activ
inact
healthi
control
recruit
studi
phenotyp
analysi
fresh
pbmc
perform
use
mab
mab
conjunct
threeor
fourcolor
immunofluoresc
test
express
level
follow
molecul
hladr
flow
cytometr
measur
intracellular
cytokin
ifng
cytotox
molecul
intracellular
perforin
surfac
fasl
perform
vitro
pma
ionomycin
pi
stimul
ex
vivo
cytolyt
capac
purifi
bright
cell
raji
human
umbil
vein
endotheli
cell
line
huvec
measur
standard
cr
releas
assay
modul
cytotox
done
use
treatment
huvec
rhifng
treatment
effector
cell
concanamycin
cma
brefeldin
bfa
downregul
peripher
bright
cell
patient
activ
bd
contrast
upregul
hladr
interestingli
upregul
peripher
bright
cell
bd
contrast
downregul
furthermor
patient
activ
uveiti
subset
polar
produc
ifng
contain
high
amount
preform
intracellular
perforin
exclus
express
surfac
fasl
upon
stimul
pi
moreov
vitro
cytolyt
function
bright
cell
activ
bd
upregul
raji
effect
inhibit
cma
interestingli
vitro
cytolyt
activ
subset
huvec
also
upregul
effect
suppress
bfa
rather
cma
cytolyt
function
pistimul
bright
cell
greatli
enhanc
huvec
augment
pretreat
ifng
huvec
bright
cell
character
cytotox
effector
memori
phenotyp
function
nk
receptor
play
immunopathogen
role
bd
exhibit
strong
cytolyt
function
vascular
endotheli
cell
fasldepend
pathway
experiment
autoimmun
uveiti
eau
model
human
uveiti
induc
mice
immun
retin
antigen
complet
freundt
adjuv
pertussi
toxin
describ
new
eau
model
induc
vitromatur
retin
antigenpuls
dc
dc
expand
vivo
hydrodynam
inject
ag
ligand
dna
day
size
spleen
doubl
popul
tripl
averag
total
increas
background
combin
stimul
dc
lp
enhanc
express
costimulatori
molecul
secret
ifng
tnfa
puls
uveitogen
peptid
cell
induc
vigor
immun
respons
vivo
furthermor
inject
dc
day
apart
plu
pertussi
toxin
elicit
typic
eaulik
inflamm
eye
suscept
mice
incid
sort
subpopul
exhibit
differenti
cytokin
product
stimul
releas
tnfa
popul
wherea
dc
produc
ifng
express
similar
current
work
aim
examin
differ
abil
splenic
dc
subpopul
induc
eau
altern
eau
model
allow
direct
manipul
dc
vitro
permit
better
character
role
cell
autoimmun
retina
may
help
devis
new
approach
therapi
solubl
factor
releas
cultur
rpe
cell
previous
shown
suppress
cell
prolifer
confer
cell
regulatori
properti
studi
perform
investig
possibl
molecul
surfac
rpe
cell
exert
similar
effect
cell
function
cell
activ
via
solubl
cultur
presenc
absenc
fix
rpe
cell
serum
free
medium
prolifer
well
abil
suppress
prolifer
bystand
cell
assess
via
thymidin
incorpor
latter
cell
irradi
end
cocultur
period
rpe
cell
wash
replat
freshli
isol
cell
activ
antibodi
cell
viabil
quantifi
use
alamar
blue
bioassay
order
investig
whether
surfac
play
role
mediat
contactdepend
effect
rpe
cell
cell
function
experi
repeat
use
fix
rpe
cell
recov
eye
knockout
mice
studi
complement
immunohistochemistri
western
blot
order
confirm
express
cultur
rpe
cell
final
begin
address
potenti
receptor
cell
involv
mediat
effect
examin
import
integrin
use
naiv
activ
cell
attach
molecul
done
prevent
bind
rpe
cell
cell
block
antibodi
block
function
associ
potassium
channel
margatoxin
mgtx
result
show
fix
rpe
cell
suppress
prolifer
activ
cell
turn
confer
similar
abil
suppress
bystand
prolifer
cultur
rpe
cell
express
homogen
throughout
cell
surfac
fix
rpe
cell
lack
gene
fail
suppress
cell
prolifer
similarli
inhibit
bind
receptor
cell
block
function
associ
potassium
channel
prevent
cell
becom
regulatori
conclud
asid
solubl
factor
rpe
cell
also
exhibit
contactdepend
mechan
mediat
interact
suppress
prolifer
activ
cell
confer
regulatori
properti
protect
antiretin
autoimmun
elicit
activ
regulatori
mechan
l
cort
avichez
p
b
silver
c
c
chan
r
r
caspi
laboratori
immunolog
nation
eye
institut
nation
institut
health
bethesda
md
usa
identifi
alter
peptid
ligand
apl
capabl
immunomodul
experiment
autoimmun
uveiti
eau
diseas
induc
mice
immun
retin
antigen
irbp
complet
freundt
adjuv
alaninesubstitut
peptid
major
pathogen
epitop
residu
synthes
test
immunogen
crossreact
nativ
epitop
pathogen
abil
prevent
eau
given
incomplet
freundt
adjuv
ifa
week
eau
challeng
nativ
two
peptid
unabl
elicit
diseas
crossreact
lymphocyt
prolifer
mice
pretreat
either
put
apl
fail
develop
eau
reduc
cellular
respons
lymphocyt
prolifer
delay
hypersensit
cytokin
respons
profil
show
reduc
ifng
enhanc
serum
antibodi
titer
reveal
reduc
elev
isotyp
suggest
shift
respons
protect
transfer
lymphoid
cell
protect
donor
narv
recipi
subsequ
immun
eau
thu
apl
pretreat
appear
prevent
induct
eau
skew
subsequ
respons
toward
nonpathogen
effector
phenotyp
well
elicit
regulatori
cell
introduct
granulocyteapheresi
gcap
novel
treatment
capabl
modul
innat
immun
respons
autoimmun
diseas
ulcer
coliti
crohn
diseas
rheumathoid
arthriti
behcet
diseas
present
result
treatment
period
year
case
ocular
behcet
diseas
object
evalu
gcap
efficaci
control
uveiti
activ
number
relaps
steroid
spare
effect
year
period
materi
method
patient
ocular
behcet
diseas
resist
convent
medic
treatment
select
gcap
treatment
one
patient
present
activ
other
clinic
inact
patient
demograph
age
f
male
time
diagnos
f
month
averag
relapsesyear
f
patient
steroid
depend
need
cyclosporin
azathioprin
andor
micophenol
mofetil
control
diseas
inform
consent
obtain
patient
gcap
treatment
approv
spanish
ministri
health
compassion
use
perform
induct
treatment
gcap
sessionweek
consecut
week
patient
maintain
gcap
session
month
year
gcap
procedur
consist
extracorpor
blood
circul
column
fill
cellulos
diacet
bead
procedur
last
hour
liter
blood
process
mlh
visual
acuiti
intraocular
inflamm
degre
prednison
requir
assess
studi
period
advers
event
report
result
induct
treatment
uveiti
control
patient
none
present
relaps
visual
acuiti
stabil
eye
improv
prednison
dose
taper
f
f
mgday
complet
year
mainten
treatment
mean
number
uveiti
relaps
f
daili
prednison
dose
reduc
f
visual
acuiti
stabl
mainten
treatment
conclus
gcap
treatment
safe
effect
treatment
ocular
behcet
diseas
refractori
convent
medic
treatment
one
year
mainten
regimen
reduc
uveiti
relaps
preserv
visual
acuiti
reduc
prednison
requir
background
eye
especi
highli
vascular
tissu
uvea
conjunctiva
consid
special
btargetq
immunopatholog
reaction
uveiti
refer
inflamm
uveal
tract
includ
iri
ciliari
bodi
choroid
uveiti
potenti
blind
condit
predominantli
occur
work
age
group
although
aetiolog
unknown
case
mani
patient
associ
underli
system
diseas
uveiti
initi
manifest
autoimmun
system
diseas
may
appear
year
diagnosi
primari
diseas
retrospect
studi
conduct
patient
uveiti
determin
frequenc
associ
autoimmun
system
diseas
assess
valu
limit
laboratori
screen
patient
materi
patient
male
femal
uveiti
anterior
posterior
intermedia
panuv
studi
patient
underw
standard
diagnost
protocol
includ
follow
immunolog
test
serum
immunoglobulin
complement
compon
circul
immun
complex
cic
antinuclear
antibodi
ana
antineutrophil
cytoplasm
antibodi
anca
anticardiolipin
antibodi
aca
major
histocompatibilti
complex
antigen
result
overal
patient
least
one
detect
immunolog
abnorm
patient
detect
level
ana
titer
igm
aca
igg
aca
rise
anca
posit
rheumatoid
factor
relationship
subclin
autoimmun
system
disord
could
presum
case
defin
presenc
autoantibodi
ana
anca
aca
presenc
complement
comsumpt
hypergammaglobulinemia
increas
cic
anterior
uveiti
observ
patient
posterior
uveiti
vogtkoyanaguiharada
syndrom
birdshot
retinochoroidopathi
definit
associ
system
autoimmun
diseas
determin
patient
lupu
like
diseas
lld
lld
plu
antiphospholipid
syndrom
sjfgren
syndrom
system
vascul
presenc
system
autoimmun
diseas
suspect
prior
eye
involv
recognis
subsequ
diagnost
procedur
conclus
proport
patient
uveiti
autoimmun
system
disord
may
present
system
autoimmun
diseas
frequent
undiagnos
onset
ocular
diseas
uveiti
consult
studi
immunolog
profil
therefor
help
assess
patient
uveiti
purpos
evalu
abil
computerbas
algorithm
silico
identifi
put
autoantigen
peptid
evalu
predict
bind
put
autoantigen
peptid
differ
popul
diseas
method
three
internetaccess
computerbas
algorithm
use
predict
bind
tyrosinas
tyr
tyrosinaserel
deriv
peptid
result
compar
publish
studi
vitro
immunogen
respons
tyr
peptid
cell
patient
vogtkoyanagiharada
vkh
diseas
three
websit
syfpeithi
mhcthread
propr
use
determin
rel
likelihood
bind
score
immunogen
tyr
peptid
determin
vitro
hla
molecul
confer
risk
vkh
diseas
differ
popul
result
found
use
three
websit
togeth
least
one
silico
fragment
overlap
vitro
peptid
least
nine
amino
acid
except
overlap
fragment
predict
propr
seven
amino
acid
peptid
immunogen
vitro
patient
tyr
identifi
three
websit
tyr
tyr
tyr
found
propr
high
likelihood
bind
tyr
tyr
predict
propr
high
likelihood
bind
conclus
silicopredict
bind
put
immunogen
peptid
specif
hladr
allel
hold
promis
high
throughput
evalu
put
autoantigen
suggest
correl
hla
bind
immunogen
predict
bind
immunogen
peptid
consist
clinic
studi
found
allel
confer
risk
vkh
diseas
mestizo
individu
convers
differ
likelihood
bind
immunogen
peptid
relev
hla
molecul
suggest
may
differ
well
peptid
induc
diseas
mestizo
asian
popul
purpos
evalu
killer
immunoglobulinlik
receptor
kir
gene
patient
uveiti
method
individu
diagnos
birdshot
chorioretinopathi
bcr
n
vogtkoyanagiharada
vkh
diseas
n
evalu
activ
inhibitori
kir
gene
well
class
human
leukocyt
antigen
hla
specif
use
polymeras
chain
reaction
protocol
presenc
absenc
appropri
hla
ligand
inhibitori
gene
establish
individu
genotyp
pattern
gene
inherit
ratio
activ
inhibitori
gene
hla
ligand
compar
local
publish
caucasian
bcr
mestizo
vkh
control
result
ratio
activ
inhibitori
kir
gene
hla
ligand
elev
compar
control
form
uveiti
addit
pattern
activ
genotyp
found
control
found
conclus
ratio
activ
inhibitori
kir
gene
increas
individu
bcr
vkh
diseas
fact
similar
pattern
found
two
differ
form
uveiti
distinct
clinic
syndrom
known
hla
associ
impli
increas
activ
inhibitori
kir
gene
may
marker
risk
uveiti
object
system
monitor
infecti
diseas
outbreak
potenti
essenti
contain
thu
control
erad
nation
refer
laboratori
nrl
philippin
shall
establish
partnership
nation
epidem
sentinel
surveil
system
nesss
nation
epidemiolog
centerdepart
health
philippin
materi
method
network
hospit
sentinel
region
epidemiolog
surveil
unit
sentinel
site
hospit
least
bed
capac
hospit
laboratori
capac
malari
smear
blood
stool
cultur
hepat
serolog
particip
author
surveil
personnel
avail
commun
mean
sentinel
site
region
epidemiolog
surveil
unit
hospit
admiss
basi
monitor
occur
diseas
thu
rapid
time
accur
inform
earli
warn
diseas
outbreak
qualiti
assur
procedur
ensur
sampl
collect
transport
nrl
laboratori
result
sole
basi
confirm
clinic
diagnosi
laboratori
manag
includ
qualiti
control
sampl
monitor
accuraci
precis
exist
procedur
result
sixteen
resu
involv
nationwid
five
design
nrlsphilippin
conduct
screen
specificconfirmatori
test
data
surveil
qualiti
evalu
extens
use
util
depart
health
polici
formul
program
evalu
thu
abl
contain
infecti
diseas
identifi
conclus
qualiti
assur
survey
essenti
contain
infecti
diseas
outbreak
potenti
establish
nation
refer
laboratoryphilippin
system
enabl
monitor
precis
accur
screen
confirmatori
test
diseas
therefor
readi
detect
contain
erad
background
tuberculosi
one
common
infecti
diseas
world
recent
year
genet
approach
develop
one
interest
gene
investig
aim
determin
suscept
tuberculosi
polymorph
gene
materi
method
studi
prospect
casecontrol
fifthi
patient
smear
cultur
posit
tuberculosi
chosen
randomli
match
healthi
control
histori
tbpolymorph
codon
gene
detect
newport
method
data
analyz
spss
version
result
mean
age
patient
control
f
f
year
respect
demograph
characterist
differ
within
two
group
pvalu
one
patient
case
group
heterozygot
mutat
gene
control
group
mutat
conclus
genet
suscept
tb
codon
iranian
tb
sampl
polymorph
loci
occur
tb
patient
total
studi
popul
irina
andreeva
clinic
immunolog
rostov
state
medic
univers
rostovon
russian
feder
background
polyclon
activ
blymphocyt
one
basic
mechan
hiv
pathogenesi
howev
result
antihiv
antibodi
show
protect
effect
connect
expedi
studi
function
properti
antibodi
particular
affin
method
observ
patient
age
infect
patient
stage
gener
lymphoadenopathi
lap
person
stage
preaid
stage
aid
elisa
use
determin
antihiv
antibodi
titer
degre
affin
ak
result
found
lap
stage
content
immunoglobulin
stage
diseas
f
f
f
antihiv
antibodi
titer
lg
f
degre
affin
ak
f
unit
hiv
infect
progress
preaid
stage
content
immunoglobulin
f
f
f
well
increas
degre
antihiv
specif
antibodi
lg
f
accompani
reduct
degre
affin
ak
f
unit
hiv
infect
progress
aid
stage
content
immunoglobulin
f
f
f
antihiv
specif
antibodi
lg
f
accompani
reduct
degre
affinityak
f
unit
conclus
thu
develop
infect
process
character
aggrav
insuffici
function
activ
antihiv
specif
antibodi
confirm
mark
reduct
affin
object
viru
c
hepat
hcv
often
favor
cours
younger
patient
consid
involut
thymic
function
age
investig
output
recent
thymic
emigr
hcv
patient
matheri
method
evalu
recent
thymic
emigr
use
competit
quantit
pcr
order
determin
percentag
cell
cjt
cell
receptor
exciss
circl
trec
studi
perform
hcv
patient
diagnosi
antihcv
treatment
result
obtain
group
compar
obtain
gruop
agematch
control
result
found
hcv
patient
naiv
antihcv
treatment
percentag
trec
could
detect
correl
percentag
trec
patientst
viremia
contrast
agematch
control
percentag
trec
detect
us
p
conclus
studi
describ
novel
immun
defect
hcv
patient
addit
studi
need
get
insight
possibl
role
trec
defect
pathogenesi
prognosi
diseas
background
ige
antibodi
play
major
role
pathogenesi
typ
allergi
half
life
serum
ige
short
plasma
cell
continu
secret
larg
amount
ige
maintain
serum
titer
long
period
time
current
debat
whether
igesecret
plasma
cell
shortliv
end
product
chronic
activ
b
cell
longliv
maintain
support
nich
bone
marrow
inflam
tissu
method
analyz
prolifer
lifetim
igesecret
plasma
cell
ovalbumin
ova
specif
murin
allergi
model
time
point
origin
plasma
cell
turnov
spleen
lung
lymph
node
bone
marrow
ova
allerg
mice
determin
accord
incorpor
brdu
dna
prolifer
cell
organ
sera
analys
use
elispot
elisa
fluoresc
microscopi
flow
cytometri
result
week
old
mice
sensit
ova
continu
fed
brdu
week
suppli
via
drink
water
igesecret
plasma
cell
spleen
ova
allerg
mice
brduposit
indic
prolifer
within
time
brdufeed
igesecret
splenic
plasma
cell
gener
time
period
thu
lifetim
week
antiprolif
immunosuppress
therapi
cyclophosphamid
elimin
cell
produc
ovaspecif
ige
antibodi
indic
respect
plasma
cell
divid
longliv
conclus
igesecret
plasma
cell
longliv
longliv
igesecret
plasma
cell
provid
allergenspecif
ige
independ
presenc
allergen
resist
immunosuppress
mansoni
praziquantel
antifibrot
studi
aim
evalu
effect
drug
combin
praziquantel
ca
embay
biltricid
antifibrot
agent
b
amino
propionitril
mono
fumar
salt
upon
transmiss
hepat
electron
microscop
find
chronic
experiment
murin
schistosomiasi
mansoni
studi
group
swiss
albino
mice
use
group
subdivid
four
small
subgroup
subgroup
constitut
infect
untreat
challeng
contol
mice
sacrific
done
week
later
time
need
infect
develop
chronic
one
subgroup
ii
infect
mice
treat
praziquantel
bodi
weight
oral
two
success
day
week
post
primari
infect
sacrific
done
week
later
subgroup
iii
infect
mice
given
bamino
propionitril
daili
powder
salin
success
day
sacrific
done
week
post
primari
infect
subgroup
iv
mice
given
pzq
bapn
sacrific
done
week
post
primari
infect
mice
given
beta
aminopropionitril
bapn
alon
compar
given
praziquantel
sole
combin
reveal
amelior
mitochondri
chang
reappear
crista
absenc
alreadi
deposit
collagen
nucleu
regain
regular
nuclear
membran
condens
chromatin
chang
less
evid
previous
mention
group
key
word
chronic
schistosomiasi
mansoni
primari
infect
challeng
secondari
infect
beta
amino
propionitril
praziquantel
transmiss
electron
microscopi
mansoni
praziquantel
antifibrot
studi
aim
explor
repercuss
drug
combin
praziquantel
ca
embay
biltricid
antifibrot
agent
b
amino
propionitril
mono
fumar
salt
upon
transmiss
hepat
electron
microscop
find
acut
experiment
murin
schistosomiasi
mansoni
studi
group
swiss
albino
mice
use
group
subdivid
four
small
subgroup
subgroup
infect
untreat
challeng
contol
mice
subgroup
ii
infect
mice
treat
praziquantel
b
weight
oral
two
success
day
subgroup
iii
infect
mice
given
bamino
propionitril
daili
powder
salin
success
day
subgroup
iv
mice
given
pzq
bapn
sacrific
done
twelv
week
post
primari
infect
mice
given
combin
regimen
praziquantel
beta
aminopropionitril
pzq
bapn
compar
given
drug
sole
reveal
amelior
previous
swollen
mitochondria
roughen
endoplasm
reticulum
agaim
resorpt
previous
deposit
collagen
fibr
intercellular
matrix
find
main
stigmata
hepat
cellular
regenerationthes
data
less
salient
mice
given
praziquantel
beta
aminopropionitril
alon
studi
trial
evalu
effect
combin
anthelmint
drug
praziquantel
ca
embay
biltricid
antifibrot
agent
bamino
propionitril
mono
fumar
salt
also
trial
elucid
repercuss
drug
combin
upon
worm
load
percent
resist
reinfect
moreov
aim
studi
liver
enzym
level
alanin
aminotransferas
aspart
amino
transferas
alt
ast
experiment
murin
schistosomiasi
mansoni
studi
group
swiss
albino
mice
use
group
subdivid
six
small
subgroup
subgroup
constitut
infect
untreat
control
mice
subgroup
ii
infect
untreat
challeng
contol
mice
subgroup
iii
challeng
control
mice
subgroup
iv
infect
mice
treat
praziquantel
b
weight
oral
two
success
day
subgroup
v
infect
mice
given
bamino
propionitril
daili
powder
salin
success
day
subgroup
vi
mice
given
pzq
bapn
sacrific
done
day
post
primari
infect
mice
given
combin
regimen
praziquantel
beta
aminopropionitril
pzq
bapn
compar
given
drug
sole
reveal
absenc
worm
recoveri
perfus
highest
score
percent
resist
reinfect
iul
serum
alanin
aminotransferas
aspart
aminotransferas
level
respect
data
less
salient
mice
given
praziquantel
beta
aminopropionitril
alon
key
word
chronic
schistosomiasi
mansoni
primari
infect
challeng
secondari
infect
beta
amino
propionitril
praziquantel
serum
transaminas
level
alt
ast
goal
studi
evalu
effect
combin
anthelmint
drug
praziquantel
ca
embay
biltricid
muramyl
dipeptid
deriv
adamantylamid
dipeptid
addp
ca
amantadin
potenti
toler
schistosoma
mansoni
infect
egginject
mice
also
trial
elucid
repercuss
drug
combin
upon
worm
tissu
egg
load
oogram
pattern
group
mice
use
experi
group
subdivid
five
small
subgroup
subgroup
constitut
infect
control
mice
subgroup
ii
receiv
four
intraven
dose
via
tail
vein
solubl
egg
antigen
sea
infect
subgroup
iii
includ
infect
mice
given
addp
mg
subcutan
ml
salin
subgroup
iv
infect
mice
given
antigen
sea
addp
subgroup
v
includ
mice
given
antigen
sea
addp
pzq
mgkg
two
success
day
sacrific
done
week
post
infect
egginject
mice
given
combin
regimen
praziquantel
adamantylamid
dipeptid
pzq
addp
compar
infect
untreat
control
reveal
absenc
worm
recoveri
perfus
dead
ova
oogram
evid
reduct
hepat
intestin
tissu
egg
load
record
group
compar
infect
untreat
wether
egg
inject
control
mice
larg
amount
cpg
odn
well
bacteri
dna
could
trigger
inflammatori
respons
even
sepsi
therefor
import
balanc
activ
cpg
odn
reduc
releas
cytokin
induc
cpg
odn
despit
compar
level
unmethyl
cpg
dinucleotid
dna
serotyp
adenoviru
dna
immunestimulatori
dna
serotyp
dna
dna
nonstimulatori
even
inhibit
activ
bacteri
dna
base
differ
krieg
found
neutral
cpg
odn
cpgn
odn
howev
zhao
found
cpgn
odn
inhibitori
effect
even
concentr
ration
reach
therefor
seem
cpgn
odnt
sequenc
investig
present
experi
search
cpgn
odn
dna
dna
compar
sequenc
differ
dna
dna
dna
escherichia
coli
dna
ec
dna
nineteen
specif
cpg
motif
sequenc
dna
ascertain
number
frequenc
kind
cpg
motif
ec
dna
calcul
howev
none
found
properti
cpgn
odn
assay
tnfa
releas
induc
cpg
odn
accident
found
exist
relationship
free
energi
bioactiv
therefor
put
cpgn
odn
rediscov
investig
got
six
cpgn
odn
activ
inhibit
tnfa
releas
induc
cpg
odn
among
cpgn
strongest
one
vitro
experi
cpg
without
cellular
toxic
inhibit
tnfa
releas
hpbmc
induc
cpg
odn
doseand
timedepend
manner
vivo
experi
cpgn
could
markedli
protect
mice
lethal
challeng
cpg
odn
significantli
decreas
tnfa
releas
mice
result
suggest
exist
relationship
free
energi
bioactiv
cpgn
odn
strong
inhibitori
cpgn
odn
could
screen
base
kind
relationship
background
viscer
leishmaniasi
fatal
diseas
caus
leishmnia
spp
inocul
promastigot
sand
fli
individu
develop
immun
respons
control
infect
other
may
involv
acut
form
diseas
seem
inhibit
immun
respons
caus
sever
form
diseas
aim
studi
evalu
serum
level
differ
cours
diseas
method
thirti
two
patient
viscer
leishmaniasi
includ
studi
blood
sampl
collect
patient
three
phase
time
diagnosi
medic
therapi
patient
becam
afebril
time
discharg
sera
separ
store
cytokin
assay
level
determin
use
elisa
method
result
mean
serum
level
significantli
differ
three
phase
sampl
p
mean
f
se
serum
level
three
phase
f
pgml
f
pgml
f
pgml
respect
conclus
accord
result
higher
level
time
diagnosi
may
act
inhibitori
factor
cellular
immun
role
develop
viscer
leishmaniasi
seem
medic
therapi
serum
level
decreas
significantli
may
associ
recoveri
gene
polymorph
suscept
brucellosi
background
brucella
spp
gramneg
facult
intracellular
bacterium
caus
agent
brucellosi
clarifi
immun
import
control
brucella
infect
regard
macrophag
critic
role
cytokin
inhibit
macrophag
activ
known
product
affect
gene
promot
polymorph
studi
investig
relationship
gene
promot
polymorph
suscept
brucellosi
method
one
hundr
nineti
patient
brucellosi
healthi
individu
member
patientst
famili
healthi
anim
husbandmen
infect
anim
brucella
includ
studi
individu
genotyp
three
biallel
gene
promot
polymorph
posit
g
tc
ac
use
pcrrflp
result
genotyp
allel
frequenc
ac
tc
significantli
differ
patient
anim
husbandmen
group
p
b
conclus
report
show
allel
posit
gene
associ
lower
product
invitro
invivo
accord
result
higher
frequenc
allel
posit
anim
husbandmen
may
caus
individu
resist
diseas
background
although
correl
kalaazar
diseas
sever
factor
determin
unknown
factor
also
exist
need
recogn
protect
immunolog
respons
leishmaniasi
character
strong
cellmedi
immun
respons
ifng
import
compon
immun
sinc
cytokin
gene
polymorph
may
associ
differ
abil
cytokin
product
aim
studi
investig
relationship
ifng
gene
polymorph
kalaazar
method
genotyp
patient
kalaazar
patientst
sibl
healthi
healthi
individu
resid
endem
area
posit
leishmanin
skin
test
genom
dna
extract
blood
sampl
ifng
gene
polymorph
posit
ta
determin
allel
specif
polymeras
chain
reaction
aspcr
method
result
frequenc
tt
genotyp
patient
significantli
less
sibl
respect
p
signific
differ
detect
patient
healthi
individu
resid
endem
area
p
discuss
cellmedi
immun
respons
effect
immun
leishmania
ifng
play
fundament
role
cellular
immun
induct
result
show
tt
genotyp
increas
patient
compar
sibl
research
report
associ
ifng
tt
genotyp
higher
ifng
product
therefor
seem
higher
product
ifng
patientst
sibl
may
help
resist
infect
polymorph
gene
promot
patient
kalaazar
background
viscer
leishmaniasi
caus
mostli
leishmania
infantum
south
iran
manifest
rang
asymptomat
infect
fatal
dissemin
viscer
diseas
protect
immun
respons
leishmania
cellmedi
immun
known
downregul
kind
respons
research
show
polymorph
gene
promot
regul
product
aim
studi
determin
relationship
gene
polymorph
outcom
diseas
method
one
hundr
twenti
pediatr
patient
involv
kalaazar
healthi
individu
patientst
sibl
healthi
individu
live
endem
area
without
histori
kalaazar
cutan
leishmaniasi
posit
leishmanin
skin
test
includ
studi
polymorph
gene
promot
determin
use
pcrrflp
result
signific
differ
genotyp
allel
frequenc
investig
gene
polymorph
group
conclus
document
protect
immun
leishmaniasi
cellmedi
immun
therefor
presenc
cytokin
diseas
worsen
condit
patient
sinc
result
show
signific
differ
genotyp
allel
distribut
group
studi
cytokin
profil
cytokin
gene
polymorph
recommend
infect
trypanosoma
cruzi
etiolog
agent
chaga
diseas
cellular
humor
immun
respons
essenti
control
parasitemia
immun
respons
necessari
protect
also
respons
morbid
caus
infect
regulatori
cell
treg
repres
uniqu
lineag
cell
import
role
control
immun
respons
self
foreign
antigen
want
investig
treg
play
role
control
immun
respons
tcruzi
infect
mice
deplet
cell
inject
monoclon
antibodi
inject
isotyp
match
control
infect
parasit
strain
colombiana
strain
elicit
intens
myocard
group
evalu
amount
circul
parasit
mortal
rate
immunolog
paramet
histolog
analysi
heart
throughout
cours
infect
result
show
treg
role
infect
tcruzi
anim
deplet
cell
decreas
level
parasit
bloodstream
decreas
mortal
rate
associ
augment
activ
cell
better
product
proinflammatori
cytokin
deplet
anim
also
display
sever
inflamm
cardiac
tissu
compar
control
anim
dendrit
cell
mediat
immun
respons
impair
mycobacterium
tuberculosi
mannosylatedlipoarabinomannan
manlam
may
counteract
effect
dc
toward
fulli
protect
inflammatori
respons
investig
impact
manlam
pilam
lam
smegmati
cap
phosphoinositid
residu
dc
matur
function
use
combin
approach
phenotyp
cytokin
releas
nk
cell
activ
tcell
prime
contact
manlam
dc
display
pattern
partial
matur
includ
intermedi
express
mhc
class
class
ii
molecul
low
express
costimulatori
molecul
compar
fulli
lpsmatur
dc
consid
immatur
dc
lost
fitcdextran
phagocyt
activ
opposit
present
fulli
matur
phenotyp
inde
manlamincub
dc
still
sensit
autolog
nk
lysi
abl
prime
naiv
tcell
respons
absenc
nk
lysi
notic
manlamdc
incub
antigen
confirm
partial
matur
dc
manlam
need
second
signal
complet
matur
altogeth
overal
effect
could
impair
innat
immun
respons
toward
tuberculosi
pokkali
supriya
rajavelu
priya
da
sulochana
depart
immunolog
tuberculosi
research
centr
chennai
tamil
nadu
india
background
macrophag
polymorphonuclear
neutrophil
pmn
profession
phagocyt
involv
antibacteri
defens
pmn
influx
first
line
defens
occur
earli
respons
curtail
mycobacteri
infect
chemokin
stimul
migrat
pmn
circul
site
infect
mycobacterium
tuberculosi
mtb
induc
activ
lead
proinflammatori
respons
apoptosi
pmn
object
characteris
two
preval
strain
mycobacteria
show
differenti
immun
respons
ppd
posit
popul
aim
studi
efficaci
strain
induc
apoptosi
modul
express
surfac
molecul
cytokin
secret
pmn
tb
patient
method
pmn
isol
rbc
pellet
obtain
ficolhypaqu
gradient
centrifug
subject
sediment
dextran
pmn
infect
variou
mycobacteri
strain
multipl
infect
moi
incub
phagocyt
index
percentag
apoptot
neutrophil
annexin
vfitc
posit
fac
cell
phenotyp
fac
cytokin
tnfa
elisa
assess
result
signific
increas
annexin
v
posit
cell
correspond
decreas
express
observ
strain
compar
uninfect
control
infect
decreas
express
observ
signific
chang
annexin
v
posit
compar
show
high
express
time
point
high
express
conclus
clinic
strain
downregul
express
inhibit
de
novo
synthesi
earli
activ
marker
tbpmn
strain
also
show
signific
increas
apoptosi
infect
therebi
reduc
number
phagocyt
escap
intracellular
lytic
microenviron
thu
clinic
isol
abl
inhibit
earli
activ
neutrophil
thin
kill
mechan
surviv
comparison
region
system
humor
immun
respons
parasit
infect
kinet
humor
immun
respons
trichinella
spirali
ts
character
immunofluoresc
assay
mesenter
lymph
node
mln
spleen
infect
rat
examin
concurr
express
multipl
antibodi
ab
isotyp
day
day
infect
tissu
process
stain
either
panb
cell
marker
conjug
rhodamin
xritc
combin
dual
monoclon
ab
probe
plu
secondari
ab
conjug
xritc
fluorescein
fitc
compar
uninfect
control
mln
spleen
show
signific
prolifer
dualab
express
b
cell
debc
day
respect
region
immun
respons
proceed
ahead
system
respons
immun
respons
minim
number
b
cell
express
singl
ab
isotyp
b
cell
express
one
isotyp
ab
combin
number
debc
within
tissu
respect
day
compar
number
total
number
b
cell
serial
section
tissu
specimen
combin
debc
spleen
time
higher
label
b
cell
day
debc
mln
n
time
higher
b
cell
day
result
thu
indic
debc
like
express
two
isotyp
surfac
peak
day
humor
immun
respons
pathogen
phenomenon
occur
immunolog
tissu
pressur
symptom
also
increas
patientt
complianc
ishaq
sameera
allergypulmonolog
aljunaid
hospit
nowshera
pakistan
purpos
patient
tubercul
mening
atd
regimen
alon
though
associ
improv
clinic
manifest
still
sporad
incid
residu
manifest
complet
atd
concern
cerebr
edema
chronic
inflammatori
chang
tuberculoisiscncomit
administr
cs
significantli
improv
clinic
outlook
method
patient
tubercul
mening
complain
even
rise
temperatur
manifest
rais
intracrani
pressur
ie
confus
anorexia
diffus
head
ach
irrit
lethargi
ophthalmoscop
edema
optic
disc
one
group
n
patient
medic
atd
alon
atd
anoth
group
n
patient
atd
cs
atd
adultt
prednisolon
divid
dose
follow
divid
dose
taper
dose
accord
therapeut
respons
mg
weekli
children
prednisolon
bodi
weight
anoth
trial
dexamethason
dose
bodi
weight
four
timesday
discontinu
taper
fashion
also
found
benefici
complet
treatment
patient
atd
uniform
therapeut
respons
almost
insignific
incid
residu
symptom
patient
atd
alon
compar
associ
occasion
head
ach
alter
sensorium
etc
result
cs
therapeut
trial
benefici
role
resolv
portent
csf
result
inflammatori
chang
also
improv
patient
complianc
concern
intak
atd
conclus
later
follow
patient
incid
relaps
either
group
n
patient
treat
atd
still
medic
head
ach
convuls
etc
clinic
implic
patient
atd
provid
steroid
medic
card
complet
treatment
wang
haibin
dept
clinic
immunolog
hospit
beij
beij
china
object
investig
rrelationship
statu
innat
immunolog
infect
sar
method
person
includ
follow
six
group
studi
group
case
doctor
nurs
contact
close
sar
patient
without
care
prevent
infect
group
b
case
doctor
nurs
infect
sar
work
despit
care
prevent
group
case
pneumonia
treat
hospit
sar
patient
sar
group
intens
sar
patient
group
e
mild
sar
patient
group
f
case
healthi
children
antibodi
respons
hbsag
inject
machin
array
use
detect
gross
igm
igg
iga
plasma
lymphocyt
subtyp
assay
flow
cytomet
number
erythrocyt
detect
cellelisa
pcr
rflp
use
analysi
genom
densiti
polymorph
immun
reactiv
lymphocyt
foreign
antigen
observ
dynam
microscop
result
gross
igm
iga
igg
group
c
f
lower
level
normal
individu
especi
igm
p
reactiv
lymphocyt
antigen
also
lower
level
percent
nk
cell
significantli
higher
normal
contrari
level
igm
group
b
e
significantli
higher
normal
individu
lymphocyt
easili
destroy
antigen
stimuli
number
low
level
number
intens
sar
patient
significantli
lower
mild
sar
patient
former
hh
genotyp
conclus
signific
relationship
higher
immun
respons
sar
infect
immun
destroy
may
main
pathogenesi
sar
u
bielinska
k
w
janczak
j
j
lander
j
r
baker
jr
intern
medicin
center
biolog
nanotechnolog
univers
michigan
ann
arbor
mi
usa
rational
current
live
viru
vaccin
smallpox
unaccept
side
effect
use
nanoemuls
ne
soyoil
base
antimicrobi
virucid
activ
toward
vaccinia
viru
vv
adjuv
kill
viru
nasal
vaccin
nanoemuslion
work
first
remov
viral
envelop
protein
trigger
phagocytosi
protein
antigen
present
cell
mucosa
method
ne
approv
human
use
mix
vv
western
reserv
serotyp
mixtur
ne
vv
appli
nare
mice
system
mucos
antibodi
cellular
immun
respons
evalu
anim
sera
test
abil
neutral
viru
result
brief
incub
nanoemuls
led
greater
sixlog
reduct
viru
titer
em
analysi
suggest
ne
disrupt
viral
lipid
membran
antivv
mucos
iga
serum
igg
detect
three
week
singl
intranas
administr
nevaccinia
mixtur
immun
respons
optim
anim
vaccin
time
high
titer
vv
neutral
antibodi
detect
mice
immun
nekil
viru
virusspecif
immun
infg
product
observ
splenocyt
immun
anim
evid
protect
immun
observ
control
anim
immun
formalinkil
viru
anim
evid
viral
replic
vaccin
document
complet
inactiv
viru
ne
conclus
vv
inactiv
ne
immunogen
serv
kill
viru
mucos
vaccin
small
pox
presenc
ne
necessari
develop
robust
protect
mucos
system
immun
background
immunocompromis
host
adenoviru
caus
fatal
infect
especi
stem
cell
transplant
specif
antivir
therapi
proven
valu
current
exist
sever
adenovir
infect
potenti
form
treatment
adopt
therapi
infus
adenoviru
specif
tcell
donor
aim
studi
identifi
target
epitop
adenoviru
captur
character
adenoviru
specif
tcell
method
eleven
protein
adenoviru
type
select
use
comput
algorithm
design
predict
hla
pandr
bind
tcell
epitop
select
peptid
base
predict
high
affin
multipl
hladr
allel
high
degre
homolog
adenoviru
serotyp
peripher
blood
mononuclear
cell
pbmc
healthi
adult
isol
incub
peptid
prolifer
express
stimul
index
si
determin
six
peptid
highest
si
select
ten
subject
cytokin
chemokin
profil
induc
epitop
determin
multiplex
immunoassay
mia
addit
pbmc
cultur
complet
inactiv
adenoviru
restimul
differ
peptid
subsequ
mia
cytokin
product
measur
moreov
use
tcell
captur
method
result
six
pandr
bind
epitop
adenoviru
select
base
posit
prolifer
respons
larg
percentag
donor
name
protein
donor
peptid
hexon
protein
dnapolymeras
fiber
protein
epitop
induc
predomin
proinflammatori
cytokin
chemokin
profil
also
cultur
complet
inactiv
adenoviru
restimul
adenovir
peptid
cytokin
profil
show
proinflammatori
pattern
suggest
peptid
natur
process
use
tcell
captur
method
adenovir
peptid
specif
tcell
identifi
sort
preliminari
data
show
adenoviru
specif
tcell
display
high
express
beta
ifn
gamma
tbet
respons
remark
also
express
respons
conclus
pandr
bind
comput
algorithm
possibl
identifi
hlaclass
ii
restrict
tcell
epitop
adenoviru
type
peptid
induc
predomin
proinflammatori
cytokin
profil
also
seem
natur
process
tcell
captur
method
possibl
captur
character
adenoviru
specif
tcell
import
step
toward
adopt
immunotherapi
infus
adenoviru
specif
tcell
inflamm
usual
occur
extravascular
tissu
follow
invas
microorgan
bacteria
bodi
site
also
contain
immunomodul
eg
chemokin
cytokin
acut
phase
protein
leukocytederiv
extracellular
matrixspecif
enzym
heparanas
elastas
modifi
composit
tissu
probabl
also
degrad
certain
inflammatori
mediat
thu
yield
put
bioactiv
product
postul
new
small
molecular
weight
mediat
exert
effector
function
need
evok
termin
inflamm
herein
identifi
novel
immunoregulatori
compound
degrad
product
human
bodi
fluid
especi
wound
fluid
chronic
leg
ulcer
diabet
patient
thu
far
abl
isol
identifi
sever
amino
acid
sequenc
synthes
examin
vitro
vivo
among
peptid
two
deriv
apolipoprotein
two
fibrinogen
treatment
purifi
human
cell
peptid
downregul
nuclear
factornb
activ
reduc
secret
tnfa
interferong
vivo
peptid
markedli
inhibit
dth
reaction
conainduc
hepat
mice
suggest
peptid
may
termin
inflammatori
reaction
transmit
neg
signal
inflammationinduc
leukocyt
result
indic
use
approach
may
found
first
set
novel
antiinflammatori
peptid
hope
peptid
use
downregul
inflammatori
reaction
vivo
human
patient
suffer
chronic
inflammatori
diseas
children
ishaq
sameera
allergypulmonolog
aljunaid
hospit
nowshera
pakistan
purpos
outbreak
mycoplasma
infect
associ
school
childrencamp
earli
late
winter
season
sometim
consider
number
hospit
admiss
loss
school
day
amongst
children
adolesc
method
develop
commun
bunch
school
children
adolesc
age
year
mean
f
year
present
featur
ie
rais
temperatur
case
malais
cough
headach
medium
fine
rale
laboratori
investig
leucocytosi
case
rais
esr
variabl
pulmonari
segmentallobar
consolid
seen
cold
agglutinin
level
titer
appear
blood
children
case
rais
indirect
fluoresc
antibodi
rang
also
isol
organ
ie
pneumonia
result
ignoredl
treat
case
distant
locat
almost
transvers
myeliti
enceph
menangoenceph
prove
csf
pcr
cultur
studi
hematolog
complic
thrombocytopenia
hemolyt
anemia
renal
failur
cardiac
complic
ie
myopericard
haemopericardium
heart
block
etc
mucocutan
manifest
ie
erythemat
maculopappul
errupt
steven
jhonsont
syndrom
joint
manifest
ie
mimick
rheumat
arthriti
complic
case
nausea
vomit
alter
bowel
habit
etc
clinic
implic
mycoplasma
pneumonia
held
respons
case
commun
acquir
pneumonia
object
establish
experiment
system
war
yeast
cell
hemaimmun
reaction
road
map
method
suspens
yeast
cell
ml
ns
control
ad
fresh
anticoagul
citric
acid
whole
blood
white
blood
cell
ad
plasma
ns
control
incub
ad
ml
red
blood
celll
tube
abovement
respect
incub
hemaimmun
reactionari
activ
assess
check
blood
cell
adher
rate
yeast
cell
darc
gene
activ
gene
et
al
result
yeast
cell
activ
hemammun
reaction
road
map
experiment
system
show
chang
variou
index
yeast
cell
activ
method
use
method
studi
relationship
whole
blood
cell
plasma
relationship
red
blood
cell
white
blood
cell
hemaimmun
reaction
conclus
provid
use
method
innat
adapt
immun
studi
immun
regul
studi
theori
studi
hemaimmun
reaction
road
map
clinic
caus
pediatr
diarrhea
identif
character
antigen
immunogen
mimotop
earlier
public
laboratori
two
toxin
pet
kda
pic
member
spate
serineproteas
autotransport
enterobacteriacea
famili
describ
molecular
agent
associ
pediatr
diarrhea
caus
enteroaggreg
ecoli
especi
develop
countri
despit
differ
locat
gene
chromosom
pic
plasmid
pet
protein
show
high
level
sequenc
ident
protein
identifi
patient
immunogen
howev
neither
epitop
immunolog
relationship
diseas
known
collect
peptid
properti
immunodomin
epitop
elicit
immun
respons
patient
would
benefici
research
advanc
immunolog
protein
relationship
diseas
identif
peptid
screen
random
phagedisplay
linear
constrain
librari
sera
patient
rabbit
antisera
obtain
pet
pic
protein
screen
two
highli
complex
phage
librari
result
collect
peptid
share
welldefin
consensu
motif
although
motif
show
similar
protein
carri
peptid
phage
reactiv
sera
induc
mice
rabbit
antibodi
reactiv
pet
pic
elisa
denatur
western
blot
result
indic
mimic
epitop
contain
immunogen
determin
loss
antigen
activ
upon
denatur
addit
antisera
petrel
peptid
show
crossreact
pic
vice
versa
ie
toxin
structur
also
immunolog
similar
conclud
peptid
phage
librari
specif
epitop
enterotoxin
allow
elucid
role
pathogenesi
diarrhea
use
laboratori
diagnosi
patient
sera
ongo
experi
peptid
best
immunogen
antigen
potenti
use
serolog
studi
patient
abil
induc
neutralizationeffect
respons
anim
model
nicotin
major
activ
compon
tobacco
report
modul
process
inflamm
apoptosi
chlamydia
pneumonia
cpn
oblig
intracellular
pathogen
common
caus
respiratori
tract
infect
worldwid
consid
among
risk
factor
involv
coronari
arteri
diseas
cpninfect
cell
report
resist
apoptosi
clear
compon
cpn
respons
action
present
studi
investig
role
nicotin
chlamydia
heat
shock
protein
individu
combin
viabil
prolifer
apoptosi
human
epitheli
cell
line
result
studi
show
treatment
cell
nicotin
significantli
increas
cell
count
viabil
compar
untreat
control
treatment
cell
result
signific
chang
cell
count
viabil
interestingli
apoptosi
induc
cell
tnfalpha
fact
significantli
increas
cell
count
viabil
order
ascertain
whether
increas
reflect
protect
apoptosi
caspas
activ
assess
result
show
activ
caspas
downregul
cell
treat
either
nicotin
combin
treatment
nicotin
result
even
downregul
activ
caspas
antiapoptot
action
nicotin
block
dtubocurarin
chlorid
nicotin
receptor
antagonist
high
preval
cpn
infect
readi
avail
nicotin
popul
lead
concern
possibl
combin
exposur
agent
impact
combin
exposur
nicotin
paramet
immun
statu
normal
immunocompromis
host
warrant
investig
twentyeight
patient
stage
diseas
accord
cdc
center
diseas
control
atlanta
criteria
studi
found
patient
increas
number
circul
cell
lymphocyt
healthi
donor
three
patient
also
display
increas
number
peripher
cell
vs
healthi
donor
moreov
cell
bright
dull
among
subset
cell
cell
clone
transmigr
across
endotheli
monolay
respons
interferong
induc
stromalderiv
accord
express
specif
receptor
fraction
cell
clone
coexpress
homeostat
chemokin
effect
drive
transendotheli
migrat
cell
cell
driven
effici
transmigr
inhibit
kinas
blocker
wortmannin
support
coupl
confirm
activ
serin
kinas
aktpkb
obtain
upon
ligat
addit
occup
led
camkii
activ
accordingli
camkii
inhibitor
could
decreas
transmigr
final
show
protein
tat
found
sera
patient
interfer
chemotact
activ
inhibit
due
cysteinrich
domain
protein
contain
cxc
cxc
chemokinelik
sequenc
mechan
may
contribut
redistribut
two
gy
cell
subset
resid
increas
peripher
blood
earli
aid
remov
intestin
advanc
diseas
support
import
gy
cell
first
defenc
infect
adenoviru
infect
usual
harmless
healthi
children
adult
seriou
potenti
fatal
immunocompromis
individu
like
cmv
ebvinfect
adopt
transfer
specif
tcell
also
discuss
adenovir
infect
howev
main
adenoviru
deriv
antigen
target
adenovirusspecif
tcell
respons
yet
defin
identifi
main
immunodomin
protein
adenovirusspecif
tcell
respons
function
character
adenovirusspecif
tcell
respect
cytokin
profil
three
major
adenovir
protein
includ
two
structur
capsid
protein
hexon
penton
polymeras
recombinantli
express
tcelllin
specif
entir
set
adenovirusderiv
protein
gener
stimul
pbmc
healthi
adult
adenoviruslys
accord
antigeninduc
surfac
express
specif
adenovirusspecif
tcelllin
evalu
restimul
adhexon
adpenton
adpolymeras
accord
intracellular
express
direct
qualit
cytokin
profil
adspecif
tcell
assess
shortterm
stimul
whole
blood
healthi
adult
adhexon
coexpress
analysi
tnfa
ifng
tcelllin
easili
gener
accord
show
high
specif
adenoviru
deriv
hexon
capsid
protein
specif
tcell
respond
adpenton
none
adpolymeras
qualit
assess
cytokin
profil
adhexon
specif
thcell
prove
profil
express
domin
express
tnfa
ifng
hexon
capsid
protein
main
target
protein
adenovirusspecif
tcell
respons
adult
character
cytokin
profil
result
envisag
adenovirusderiv
hexon
protein
candid
antigen
ex
vivo
gener
adenovirusspecif
tcell
cellular
therapi
object
sar
sever
infecti
diseas
caus
viru
identifi
gene
sequenc
serolog
analysi
new
strain
human
coronaviru
sar
coronoviru
sarscov
caus
sever
acut
respiratori
symptom
patient
result
high
mortal
rate
antigen
peptid
recogn
sar
viru
specif
ctlt
use
tool
studi
ctl
respons
infect
enabl
research
better
monitor
diseas
develop
tcell
mediat
vaccin
order
identifi
potenti
immunogen
epitop
sar
nprotein
use
beckman
coultert
itopia
epitop
discoveri
system
analyz
protein
across
mhc
class
allel
materi
method
itopia
epitop
discoveri
system
use
screen
sar
n
protein
analyz
overlap
nonam
peptid
across
differ
hlaab
allel
hla
hla
hla
hla
hla
hla
hla
hla
peptid
bind
assay
first
assay
system
rapid
screen
test
peptid
across
allel
identifi
binder
character
affin
rate
dissoci
assay
previous
identifi
binder
serial
dilut
analyz
affin
assay
ed
valu
determin
repres
concentr
peptid
need
achiev
bind
binder
also
analyz
rate
assay
peptid
incub
hr
time
point
taken
specifi
interv
result
analyz
use
one
phase
exponenti
decay
curv
express
valu
hr
repres
amount
time
need
achiev
dissoci
peptid
mhc
complex
rate
affin
valu
test
peptid
evalu
use
multiparametr
calcul
gener
iscor
iscor
allow
peptid
systemat
rank
subsequ
function
studi
newli
identifi
peptid
use
manufactur
hla
class
itag
mhc
tetram
import
tool
visual
quantifi
precis
vivo
sar
ctl
respons
result
identif
sar
candid
epitop
follow
epitop
hla
epitop
hla
epitop
hla
epitop
hla
epitop
hla
epitop
hla
epitop
hla
epitop
hla
base
itopia
rank
candid
epitop
sar
itagk
mhc
tetram
manufactur
use
stain
cryopreserv
pbmct
sar
infect
donor
conclus
use
itopia
epitop
discoveri
system
sar
n
protein
amino
acid
screen
potenti
immunogen
epitop
identifi
base
experiment
bind
affin
rate
determin
sar
result
demonstr
capac
itopia
system
screen
larg
number
mhc
class
restrict
peptid
priorit
epitop
greatest
potenti
produc
immun
respons
object
studi
famili
two
twin
suspect
symptom
bone
marrow
aspir
sign
hlh
neg
serolog
bacteria
viru
parasit
twin
twin
present
differ
degre
clinic
sever
twin
sever
twin
method
famili
studi
perforin
express
analys
fourcolor
multiparametr
flow
cytometri
coulter
epic
xl
tm
flow
cytomet
beckmancoult
coulter
corpor
perforin
express
studi
cell
cell
genet
analys
carri
identifi
put
perforin
mutat
genom
dna
prepar
pbmc
use
standard
protocol
inform
consent
obtain
exon
perforin
gene
amplifi
use
polymeras
chain
reaction
famili
sever
control
quantif
plasma
level
perform
triplic
use
commerciallyavail
elisa
kit
bender
medsystem
viena
austria
result
famili
studi
show
decreas
perforin
express
cd
cell
cytotox
cell
father
twin
normal
express
mother
twin
compar
healthi
control
similar
age
sequenc
disclos
one
mutat
previous
describ
clementi
blood
twin
father
codon
exon
gcggtg
chang
val
heterozyg
mutat
other
sampl
includ
twin
mutat
detect
although
sequenc
entir
gene
unlik
twin
anoth
perforin
mutat
sinc
express
normal
flow
cytometri
twin
higher
level
healthi
control
similar
age
twin
show
higher
level
ngml
twin
ngml
contrast
level
progenitor
normal
leishmania
parasit
visual
electron
microscop
examin
liver
tissu
twin
final
treatment
began
antimoni
patient
recov
complet
quickli
twin
conclus
viscer
leishmaniasi
associ
hlh
syndrom
caus
addit
consider
etiolog
diagnosi
difficulti
howev
result
indic
could
conveni
analysi
perforin
defect
concomit
infect
type
hlh
leishmania
infect
abl
trigger
haemophagocyt
syndrom
perforin
defect
may
worsen
erad
leishmania
infect
fc
receptor
fcr
mediat
phagocytosi
requir
activ
rho
gtpase
howev
recruit
fcr
unknown
show
ca
promot
ra
inactiv
capri
ra
gtpaseactiv
protein
function
adaptor
fcrmediat
phagocytosi
capridefici
macrophag
exhibit
impair
fcgrmediat
phagocytosi
oxid
burst
well
defect
activ
capri
interact
constitut
transloc
phagocyt
cup
fcgrmediat
phagocytosi
importantli
capridefici
mice
impair
innat
immun
respons
bacteri
infect
result
suggest
capri
provid
link
fcgr
essenti
host
innat
defens
case
report
year
old
caucasian
girl
present
five
year
histori
recurr
dermatom
vesicular
lesion
affect
face
back
year
age
patient
develop
primari
gingivostomat
pain
vesicular
lesion
entir
oral
mucos
surfac
continu
mucos
outbreak
everi
month
year
age
complain
facial
irrit
sore
fever
subsequ
vesicular
lesion
origin
corner
mouth
follow
dermatom
lesion
never
cross
midlin
occur
sever
time
year
trigger
respiratori
infect
stress
continu
acut
outbreak
despit
prophylact
acyclovir
dose
mgkgday
patient
also
histori
recurr
respiratori
tract
infect
sinc
six
week
life
infect
resolv
standard
cours
oral
antibiot
histori
lower
respiratori
tract
bone
joint
deep
tissu
fungal
infect
famili
histori
remark
recurr
viral
infect
father
two
sibl
physic
examin
unremark
evid
lymphadenopathi
hepatosplenomegali
chronic
rash
direct
fluoresc
antibodi
test
perform
subsequ
outbreak
posit
herp
simplex
viru
neg
varicella
viru
perilesion
skin
multipl
viral
cultur
lesion
differ
time
posit
herp
simplex
viru
evalu
possibl
defect
innat
cellmedi
immun
system
reveal
decreas
natur
killer
cell
lysi
intracellular
cytokin
assay
icc
interferongamma
product
neg
varicella
cytomegaloviru
epstein
barr
viru
influenza
delay
type
hypersensit
dth
skin
test
reactiv
tetanu
mump
lymphoprolifer
assay
lpa
mitogen
tetanu
normal
dth
skin
test
reactiv
lpa
candida
nonreact
hiv
test
neg
evalu
stat
defici
neg
flow
cytometri
reveal
elev
ratio
humor
immun
function
evalu
immunoglobulin
level
igg
iga
igm
ige
normal
mildli
decreas
diphtheria
tetanu
haemophilu
antibodi
titer
protect
zero
twelv
pneumococc
antibodi
level
ugml
vaccin
hsv
igg
titer
posit
varicella
viru
igg
titer
equivoc
flow
cytometri
reveal
elev
number
cd
cell
discuss
patient
present
recurr
dermatom
vesicular
lesion
caus
herp
simplex
viru
health
care
provid
typic
associ
recurr
dermatom
outbreak
herp
zoster
consid
cultur
hsv
viral
etiolog
although
rare
recurr
dermatom
hsv
lesion
may
hallmark
yet
undefin
immunodefici
may
elucid
field
clinic
immunolog
matur
innat
immun
defenc
encompass
number
cellular
humor
compon
among
latter
complement
system
play
import
role
also
involv
establish
adequ
specif
clonal
immun
respons
recent
establish
mannanbind
lectin
mbl
mannosebind
lectin
complement
pathway
reli
recognit
microorgan
pathogenassoci
molecular
pattern
pamp
oligomer
structur
mbl
provid
cluster
ctype
lectin
domain
allow
high
avid
bind
suitabl
space
sugar
residu
bind
trigger
activ
mblassoci
serin
proteas
turn
activ
gener
convertas
level
mbl
plasma
vari
less
ng
agml
determin
polymorph
exon
one
promot
region
numer
studi
found
associ
mbl
defici
increas
suscept
infect
appear
alon
mbl
defici
predispos
infect
also
element
immun
system
suboptim
thu
eg
leukaemia
patient
chemotherapi
high
risk
seriou
infect
mbl
defici
peterslund
et
al
mbl
defici
colorect
cancer
patient
increas
risk
postop
infect
ytting
h
et
al
cancer
immunol
immunotherapi
onlin
pub
mbl
defici
also
report
associ
autoimmun
manifest
surprisingli
increas
risk
atherosclerot
diseas
recombin
mbl
produc
human
cell
line
natimmun
copenhagen
methodolog
modifi
vorupjensen
et
al
int
immunopharmacolog
jenseniu
et
al
biochem
soc
tran
purifi
yield
prepar
certifi
clinic
trial
rmbl
show
physic
biolog
characterist
similar
plasmaderiv
mbl
preclin
phase
trial
conduct
current
evalu
safeti
concern
observ
signal
transduct
upon
infect
renal
epithelium
initi
site
contact
pathogen
host
interact
epitheli
cell
may
opportun
detect
respond
pathogen
lead
activ
inflammatori
respons
recruit
leukocyt
initi
phase
inflammatori
respons
infect
often
involv
activ
innat
immun
system
particular
complement
seri
fluid
phase
cell
surfac
inhibitor
includ
membran
cofactor
protein
exist
prevent
excess
complement
activ
also
known
receptor
variou
type
pathogen
investig
potenti
mediat
signal
transduct
subsequ
internalis
human
renal
epitheli
cell
found
apic
basolater
surfac
cell
stain
antibodi
fluorochrom
introduct
secondari
antibodi
brought
cluster
receptor
incub
led
internalis
antibodi
seen
incub
extracellular
antibodi
detect
greenlabel
fluorochrom
cell
fix
permeablis
redlabel
fluorochrom
use
detect
intracellular
extracellular
antibodi
previous
shown
src
kinas
activ
crosslink
howev
internalis
independ
src
kinas
activ
present
data
demonstr
antibodi
internalis
specif
bind
receptor
suggest
may
play
activ
role
mediat
signal
event
interest
investig
whether
serv
receptor
mediat
internalis
opsonis
pathogen
upon
infect
access
entir
human
antigenspecif
tcell
respons
accord
antigenreact
express
marco
frentsch
olga
arbach
denni
kirchhoff
thoma
schneider
alexand
scheffold
andrea
thiel
clinic
immunolog
german
arthriti
research
centr
berlin
berlin
germani
immunmodul
german
arthriti
research
centr
berlin
berlin
germani
gastroenterolog
infecti
diseas
charitecampu
benjamin
franklin
berlin
berlin
germani
either
access
restrict
activ
cell
react
express
secret
cytokin
could
perform
far
rare
select
specif
peptid
mhcii
multim
report
new
method
assess
entir
fraction
tcell
specif
particular
antigen
independ
cytokin
memori
employ
intracellular
extracellular
detect
antigeninduc
express
vitro
stimul
variou
antigen
cmv
tt
adenoviru
birch
allergen
seb
mycobacterium
tuberculosi
cours
antigendriven
vitro
activ
tcell
specif
express
antigenspecif
tcell
antigenspecif
express
detect
intracellularli
fix
tcell
stimul
perform
presenc
brefeldin
facilit
coexpress
analysi
cytokin
moreov
develop
strategi
circumv
rapid
internalis
reactiv
surfac
express
interact
counterpart
enabl
us
isol
live
antigenspecif
tcell
simpl
singl
cell
surfac
stain
vitro
stimul
fast
gener
highli
specif
tcell
line
approach
offer
strike
option
assess
entir
pool
tcell
defin
specif
allow
combin
quantit
qualit
analysi
thcell
immun
isol
specif
thcell
target
cellular
immunotherapi
katsuharu
hirano
yukihiro
shimizu
yasuhiro
nakayama
masami
minemura
yoshinari
atarashi
satoshi
yasumura
toshiro
sugiyama
third
depart
intern
medicin
toyama
medic
pharmaceut
univers
toyama
japan
backgroundaim
although
liver
diseas
known
exacerb
bacteri
infect
mechan
still
unclear
mice
model
p
acn
prime
mice
show
granuloma
format
respons
bacteria
massiv
hemorrhag
liver
injuri
observ
lipopolysaccharid
lp
inject
howev
whether
antigenspecif
respons
granuloma
format
requisit
injuri
unknown
therefor
examin
whether
antigennonspecif
accumul
dc
macrophag
liver
overexpress
gmcsf
could
prime
sever
liver
injuri
lp
inject
method
inject
recombin
adenoviru
encod
gmcsf
adgm
contain
plaqueform
unit
one
mg
per
mous
lp
administ
seven
day
later
mice
via
tail
vein
composit
hepat
mononuclear
cell
analyz
flow
cytometri
concentr
gmcsf
tnfa
ifng
serum
mice
measur
elisa
liver
histolog
serum
alanin
aminotransferas
alt
level
apoptosi
hepatocyt
also
examin
examin
role
fa
pathway
tnfa
apoptosi
hepatocyt
use
fasldefici
mice
type
mice
per
mous
neutral
antitnfa
antibodi
intraven
inject
minut
lp
inject
result
liver
histolog
adgmprim
mice
show
mark
infiltr
mononuclear
cell
macrophag
ia
b
myeloid
dc
without
granuloma
format
day
express
tolllik
intrahepat
mononuclear
cell
isol
adgmprim
mice
upregul
although
serum
alt
level
within
normal
rang
lp
inject
level
elev
earli
hour
lp
inject
adgmprim
mice
peak
level
f
iul
reach
hour
lp
inject
mice
die
within
hour
serum
tnfa
concentr
elev
lp
inject
peak
hour
lp
inject
hemorrhag
liver
injuri
histolog
recogn
adgmprim
mice
tunelposit
hepatocyt
nuclei
alreadi
observ
one
hour
lp
inject
liver
injuri
histolog
appar
rate
tunelposit
apoptot
hepatocyt
increas
three
hour
lp
inject
adgm
lp
inject
fasldefici
mice
serum
alt
level
elev
pretreat
neutral
antitnfa
antibodi
conclus
present
studi
provid
new
model
sever
liver
injuri
massiv
accumul
innat
immun
cell
dc
macrophag
liver
overexpress
gmcsf
enhanc
suscept
lp
lead
hemorrhag
liver
injuri
massiv
hepatocyt
apoptosi
lp
inject
tnfa
fasmedi
signal
thought
import
hepatocyt
apoptosi
introduct
neonat
sepsi
lifethreaten
diseas
incid
per
live
birth
mortal
rate
clinic
sign
nonspecif
indistinguish
caus
varieti
neonat
infect
disord
aim
studi
determin
sensit
specif
positc
neg
predict
valu
neutrophil
marker
earli
diagnosi
neonat
sepsi
method
studi
compris
neonat
gestat
age
week
suspect
sepsi
within
day
life
ml
whole
blood
obtain
neonat
determin
express
peripher
blood
neutrophil
flow
cytometri
neonat
classifi
two
group
classif
base
posit
blood
cultur
sepsi
group
n
neonat
posit
blood
cultur
clinic
symptom
suspect
group
n
neonat
least
clinic
sign
neg
blood
cultur
healthi
term
neonat
physiolog
hyperbilirubinemia
classif
control
group
result
elev
sepsi
group
increas
signific
specif
sensit
respect
neg
posit
predict
valu
identifi
sepi
respect
discuss
high
sensit
specif
indic
evalu
neutrophil
marker
help
clinician
earli
diagnosi
neonat
sepsi
object
whipplet
diseas
wd
rare
system
infecti
diseas
prefac
replic
actinomycet
tropheryma
whipplei
macrophag
intestin
mucosa
possibl
predispos
immun
defici
discuss
wd
reduc
reactiv
could
explain
rariti
diseas
despit
ubiquit
exist
pathogen
alreadi
shown
wd
patient
howev
due
lack
bacteri
prepar
whippleispecif
intestin
peripher
immun
reaction
wd
patient
analys
till
method
whippleispecif
stimul
perform
peripher
blood
lamina
propria
lymphocyt
lpl
sonic
whipplei
cultur
follow
facsanalysi
express
cytokin
ifng
activ
marker
tcell
sever
common
bacteri
viral
antigen
tetanu
toxoid
cytomegaloviru
tuberculin
use
control
gener
antigenspecif
reactiv
result
establish
specif
stimul
recent
evolv
laboratori
strain
whipplei
compar
first
time
immun
reaction
wd
patient
healthi
control
agematch
young
patient
tuberculosi
mycobacteri
model
infect
everi
control
patient
tuberculosi
analys
far
abl
detect
whippleispecif
tcell
blood
well
duoden
mucosa
howev
wd
patient
show
significantli
reduc
reactiv
pathogen
reactiv
seb
wd
patient
slightli
reduc
compar
control
wherea
reactiv
common
antigen
compar
addit
use
system
vitro
gener
autolog
dendrit
cell
load
whipplei
antigen
abl
enhanc
reactiv
healthi
control
still
could
induc
antigenspecif
reaction
wd
patient
conclus
henc
conclud
whippleispecif
reactiv
occur
healthi
control
frequent
exposur
bacteria
seem
activ
immun
reaction
wherea
result
hint
significantli
reduc
antigenspecif
reaction
wd
patient
result
insuffici
protect
pathogen
onset
wd
kunkel
v
moo
c
stahlhennig
f
j
kaup
zeitz
schneider
medic
clinic
charitecampu
benjamin
franklin
berlin
germani
german
primat
center
gottingen
germani
background
sever
inflammatori
patholog
condit
mucos
surfac
thought
consequ
alter
cell
home
aim
studi
migrat
tcell
condit
nonhuman
primat
system
transfer
alloor
congen
fluoresc
label
cell
provid
use
techniqu
visual
cell
activ
prolifer
migrat
vivo
well
establish
applic
mous
model
howev
equival
techniqu
nonhuman
primat
system
sever
diseas
avail
anim
model
patholog
develop
similar
human
method
describ
establish
autolog
transfer
system
rhesu
macaqu
model
mononuclear
cell
isol
peripher
blood
label
carboxyfluorescein
diacetat
succinimidyl
ester
cfse
track
reinject
result
flowcytometr
analysi
transfer
reveal
distinct
popul
label
lymphocyt
peripher
blood
lymph
node
well
intestin
mucosa
anim
percentag
label
cell
peripher
blood
remain
almost
stabl
week
wherea
fluoresc
intens
whole
popul
decreas
slightli
probabl
due
physiolog
turnov
intracellular
protein
preliminari
result
indic
increas
frequenc
cell
migrat
mucosa
transfer
vitro
activ
cell
compar
migrat
nonactiv
cell
conclus
well
establish
transfer
cfse
label
cell
mous
system
success
adapt
rhesu
macaqu
system
allow
us
analys
migratori
behaviour
cell
diseas
avail
anim
model
nonhuman
primat
system
eg
hivsiv
infect
psycholog
stress
known
affect
immun
function
influenc
infecti
diseas
suscept
previou
studi
demonstr
chronic
stress
impair
humor
immun
respons
influenza
vaccin
data
avail
posttraumat
stress
disord
ptsd
ptsd
accord
diagnost
statist
manual
mental
disord
dsmiv
condit
anxieti
disord
occur
exposur
extrem
traumat
experi
accompani
intens
fear
helpless
horror
exposur
trauma
result
immun
deregul
increas
number
evid
suggest
immun
alter
associ
ptsd
aim
studi
determin
effect
psycholog
stress
immun
respons
influenza
vaccin
war
relat
ptsd
patient
n
peripher
blood
mononuclear
cell
pbmc
sera
obtain
day
vaccin
agripp
chiron
itali
patient
control
subject
winter
season
detect
specif
antivir
antibodi
titr
sera
viral
strain
contain
vaccin
perform
inhibit
hemagglutin
ih
assay
ex
vivo
tetram
stain
recent
activ
lymphocyt
use
monitor
cell
respons
specif
hlaa
influenza
matrix
antigen
haemaglutinin
antigen
anew
ha
ha
influenza
vaccin
sixteen
patient
show
increas
antibodi
titr
day
vaccin
four
total
ten
hlaa
patient
increas
frequenc
recent
activ
influenzaspecif
cell
observ
vaccin
howev
ptsp
patient
show
diminish
frequenc
influenzaspecif
cell
vaccin
compar
healthi
control
gener
humor
respons
patient
argu
hypothesi
posttraumat
stress
might
influenc
protect
follow
vaccin
diminish
cellular
respons
ptsd
patient
could
indic
immun
dysregul
observ
earlier
patient
select
affect
cellular
immun
respons
larbi
g
dupui
c
fortin
lymphocyt
function
impair
human
age
explain
increas
suscept
diseas
observ
defect
tcell
receptor
signal
transduct
could
explain
agerel
immun
senesc
lipid
raft
critic
compon
membran
serv
signal
transduct
enhanc
hypothesi
chang
lipid
raft
properti
could
explain
defect
signal
transduct
cholesterol
major
compon
cell
membran
especi
lipid
raft
connect
found
elev
two
fold
lipid
raft
associatedcholesterol
tcell
age
increas
associ
defect
lipid
raft
coalesc
impair
lck
lat
associ
lipid
raft
sought
determin
role
cholesterol
immun
senesc
modul
cholesterol
content
peripher
tcell
normolipem
young
donor
use
mixtur
cyclodextrin
cholesterol
cholesterol
content
whole
cell
extract
well
lipid
raft
measur
hplc
abl
increas
cellular
cholesterol
content
fold
fold
observ
chang
cell
shape
size
microscopi
flow
cytometri
well
dramat
loss
membran
fluiditi
analyz
tcell
prolifer
protein
phosphoryl
westernblot
follow
stimul
found
vitro
increas
membran
cholesterol
similar
consequ
signal
transduct
observ
human
age
could
establish
tcell
model
age
cholesterol
modul
altogeth
data
suggest
signal
transduct
critic
depend
membran
cholesterol
content
chang
lipid
raft
properti
may
taken
account
explain
immun
senesc
well
patholog
diseas
program
ligand
member
superfamili
play
import
role
modul
adapt
immun
experiment
autoimmun
encephalomyel
eae
diabet
asthma
transplant
studi
pathway
eae
found
multipl
inject
either
ligand
block
antibodi
standard
eae
induct
caus
shock
syndrom
multipl
mous
strain
includ
sjlj
mice
anim
show
piloerect
cyanosi
drop
bodi
temperatur
eventu
dead
within
hour
antibodi
inject
interestingli
balbc
mice
strain
known
prone
rel
resist
develop
shock
syndrom
addit
blockad
pathway
enhanc
ova
peptid
induc
anaphylaxi
balbc
mice
patholog
studi
shock
mice
found
massiv
neutrophil
infiltr
lung
liver
skin
suggest
pathway
blockad
directli
indirectli
activ
neutrophil
model
consist
freshli
isol
neutrophil
normal
mice
found
express
neutrophil
isol
treat
mice
show
enhanc
acceler
superoxid
product
upon
pma
stimul
current
studi
role
pathway
anim
model
known
involv
neutrophil
pathogenesi
sepsi
ischemiareperfus
injuri
helper
lymphocyt
play
major
role
infecti
diseas
cell
driven
least
two
differ
subpopul
accord
cytokin
product
pattern
lymphocyt
implic
resolut
infect
caus
intracellular
pathogen
leishmania
speci
cell
thought
import
establish
infect
balanc
previous
show
abl
drive
antibodi
isotyp
switch
base
knowledg
elisa
test
perform
measur
plasma
level
antileishmania
specif
ige
antibodi
isotyp
product
ifng
peripher
blood
mononuclear
cell
pbmc
subject
live
endem
area
american
cutan
leishmaniasi
bahia
state
brazil
analys
patient
group
activ
lesion
n
cure
lesion
scar
n
asymptomat
n
pbmc
cultur
hour
stimul
leishmania
braziliensi
antigen
analysi
igg
isotyp
respons
show
abl
differenti
group
patient
present
activ
lesion
other
kruskal
walli
p
p
respect
moreov
analysi
cytokin
product
reveal
ifng
level
significantli
higher
patient
activ
cure
leishmaniasi
asymptomat
group
kruskal
walli
correl
product
ifng
pbmc
stimul
l
braziliensi
antigen
plasma
level
antibodi
isotyp
patient
present
activ
lesion
spearman
correl
p
p
respect
level
significantli
higher
patient
present
activ
lesion
other
kruskal
walli
p
b
result
confirm
ifng
produc
human
cutan
leishmaniasi
activ
lesion
concomit
high
product
observ
result
also
point
use
antibodi
differenti
patient
activ
lesion
manoochehr
rasouli
amin
abbasian
simin
kiani
brucellosi
endem
mani
middl
east
countri
includ
iran
undermin
anim
human
health
immun
respons
brucella
involv
humor
cellmedi
immun
cytokin
ratio
seem
involv
suscept
resist
brucella
infect
cytokin
confer
resist
cytokin
predispos
brucellosi
cytokin
product
affect
gene
polymorph
posit
ct
aim
studi
investig
associ
gene
promot
polymorph
suscept
brucellosi
one
hundr
nineti
seven
patient
brucellosi
healthi
individu
member
patient
famili
healthi
anim
husbandmen
anim
involv
brucellosi
includ
studi
individu
genotyp
gene
promot
polymorph
posit
ct
use
pcrrflp
result
show
distribut
cc
genotyp
significantli
anim
husbandmen
patient
group
p
statist
signific
differ
genotyp
distribut
shown
patient
healthi
famili
trend
toward
increas
frequenc
cc
genotyp
famili
group
p
data
shown
distribut
ct
tt
genotyp
associ
product
increas
patient
compar
anim
husbandmen
p
patientst
famili
member
p
suggest
individu
carri
allel
produc
cytokin
induc
immun
respons
could
import
develop
fullpictur
brucellosi
individu
cc
genotyp
probabl
induc
immun
respons
effect
control
brucella
develop
diseas
fereshteh
sahebfosul
farzad
oreizi
zohr
pessaran
ahmad
ghavaminejad
immunolog
medic
school
isfahan
isfahan
isfahn
islam
republ
iran
immunolog
medic
school
isfahan
isfahanisfahan
islam
republ
iran
immunolog
medic
school
isfahan
isfahanisfahan
islam
republ
iran
immunolog
medic
school
isfahan
isfahanisfahan
islam
republ
iran
intoduct
tuberculosi
chronic
mycobacteri
infect
main
effect
cell
mycobacterium
tuberculosi
lymphocyt
object
object
research
evalu
quantiti
lymphocyt
subpopul
treatment
combin
drug
recommend
dot
protocol
sputumposit
tuberculosi
patient
materi
method
patient
case
healthi
peopl
select
control
flow
cytometri
done
lymhocyt
use
monoclon
antibodi
result
result
show
defect
cell
mediat
immun
tuberculosi
show
decreas
lymphocyt
increas
lymphocyt
chang
revers
month
treatment
conclus
result
studi
studi
confirm
defect
cell
mediat
immun
infect
mycobacterium
tuberculosi
although
decreas
lymphocyt
main
cell
defens
tuberculosi
establish
consensu
decreas
increas
lymphocyt
tuberculosi
immun
cruzi
complex
minim
involv
substanti
antibodi
respons
activ
cell
respons
recent
shown
chronic
chagas
patient
mild
clinic
diseas
significantli
higher
frequenc
ifng
produc
cell
specif
parasit
lysat
individu
sever
diseas
howev
difficult
identifi
specif
epitop
recogn
cruzispecif
cell
thu
quantifi
respons
cell
infect
individu
cruziinfect
mice
peptid
transsialidas
famili
protein
ts
domin
target
cell
respons
present
studi
investig
respons
cell
cruziinfect
individu
ts
famili
epitop
gene
annot
encod
ts
famili
protein
screen
homologu
two
tsderiv
peptid
previous
found
recogn
low
frequenc
cell
infect
subject
screen
yield
total
homologu
encod
ts
thirtytwo
peptid
elicit
ifng
product
cell
transgen
mice
chronic
infect
cruzi
peptid
highest
frequenc
occurr
highest
predict
affin
stimul
greatest
respons
antigen
ts
peptid
fairli
associ
capac
bind
multipl
molecul
supertyp
ascertain
whether
epitop
recogn
lymphocyt
cruziinfect
subject
ifng
elispot
respons
evalu
pbmc
chronic
chagas
patient
ifng
secret
demonstr
patient
mild
diseas
peptid
assay
recogn
least
one
patient
respond
frequenc
peptid
capabl
elicit
recal
ifng
respons
vari
test
test
peptid
frequent
recogn
contrast
patient
sever
clinic
stage
show
posit
respons
data
demonstr
frequenc
ifng
produc
cell
chronic
chagas
patient
determin
part
clinic
statu
patient
also
frequenc
occurr
epitop
cruzi
genom
identifi
specif
set
class
mhc
restrict
peptid
target
immun
respons
patient
capabl
control
cruzi
infect
identif
cell
target
natur
infect
cruzi
may
applic
develop
vaccin
cruzi
human
parvoviru
ubiquit
dna
viru
caus
erythema
infectiosum
polyarthropathi
transient
aplast
crisi
fetal
death
ifngamma
elispot
intracellular
cytokin
stain
hlapeptid
tetramer
complex
dtetramert
stain
use
identifi
lymphocyt
respons
nonstructur
protein
understand
origin
respons
potenti
role
diseas
prospect
analys
evolut
virusspecif
cell
respons
five
individu
acut
infect
individu
respond
tetram
frequenc
cell
surprisingli
respons
increas
first
year
post
infect
despit
resolut
clinic
symptom
control
viremia
parvovirusspecif
cell
rapidli
develop
maintain
activ
phenotyp
strong
express
perforin
downregul
cell
possess
strong
effector
function
intact
prolif
capac
demonstr
ifngamma
elispot
releas
assay
tetram
stain
cell
line
remot
infect
individu
lower
frequenc
cell
specif
individu
epitop
observ
typic
cell
low
although
also
low
like
explan
strike
persist
expans
activ
matur
effector
cell
acut
resolut
infectionanalog
cmv
infectioni
low
level
antigen
exposur
cell
may
contribut
long
term
control
signific
pathogen
substanti
evid
bcg
provid
partial
protect
pulmonari
tuberculosi
evid
convincingli
demonstr
bcg
prevent
tuberculosi
tb
develop
avail
mycobacterium
tuberculosi
genom
sequenc
thrown
open
new
opportun
design
ration
vaccin
tb
identif
cell
epitop
immun
relev
antigen
remain
critic
step
develop
vaccin
discoveri
two
multigen
famili
pe
ppe
make
mycobacterium
tuberculosi
genom
kindl
interest
use
protein
potenti
vaccin
candid
possibl
nonamer
peptid
sequenc
pe
ppe
protein
analys
comput
abil
bind
allel
class
hla
pe
ppe
protein
signific
number
peptid
predict
high
affin
hla
binder
irrespect
length
protein
structur
basi
peptid
bind
hla
carri
molecularmodel
studi
structur
studi
correl
well
bind
predict
two
protein
pe
ppe
famili
mycobacterium
tuberculosi
genom
select
studi
protein
show
high
percentag
bind
peptid
recombin
protein
test
abil
elicit
immun
respons
mous
model
recombin
good
induc
antibodi
respons
poor
induc
cell
respons
shown
induc
good
cell
respons
term
invitro
cell
prolifer
ifng
secret
dth
respons
predict
epitop
experiment
verifi
identif
cell
specif
recogn
natur
process
epitop
hlarestrict
fashion
peptid
may
use
vaccin
cocktail
keep
mind
hla
haplotyp
profil
popul
hepatocirrhosi
sever
liver
function
destroy
chi
wang
haibin
object
studi
relationship
chang
express
erythrocyt
patient
hepatocirrhosi
sever
liver
function
destroy
method
onestep
detect
method
use
case
hepatocirrhosi
follow
percent
glutaraldehydefix
red
blood
cell
rbc
analyz
v
well
microst
plate
cell
button
well
compound
ap
ad
mix
thoroughli
microtitr
incub
follow
three
wash
sbsa
substrat
ad
incub
supernat
transfer
clean
u
microtitr
plate
facilit
read
plate
reader
number
calcul
standard
red
cell
anoth
detect
alt
che
alb
glo
tbil
gam
assay
machin
au
result
number
patient
hepatocirrhosi
significantli
lower
healthi
individu
patient
divid
two
group
accord
level
result
show
patient
low
activ
che
decreas
alb
almost
low
number
group
level
glo
tbil
gam
increas
accordingli
obvious
relationship
chang
alt
conclus
result
suggest
quantiti
erythrocyt
may
involv
pathogeni
develop
prognosi
hepatocirrhosi
detect
quantiti
mayb
use
import
assay
liver
function
introduct
identifi
group
patient
recurr
respiratori
infect
normal
total
immunoglobulin
normal
respons
protein
antigen
fail
develop
igg
antibodi
pneumococc
conjug
vaccin
serotyp
rational
investig
mechan
unrespons
vaccin
could
due
defect
isotyp
switch
method
retrospect
studi
patient
refer
clinic
evalu
recurr
respiratori
infect
receiv
complet
immun
vaccin
age
accord
acip
guidelin
patient
evalu
total
immunoglobulin
igg
subclass
concentr
immun
histori
document
measur
igg
igm
antipneumococc
polysaccharid
pp
antibodi
titer
serotyp
standard
elisa
test
data
analyz
use
epi
info
spss
sampl
obtain
patient
alreadi
immun
primari
care
physician
patient
assembl
group
unimmun
group
laboratori
data
prior
vaccin
two
immun
group
respond
nonrespond
accord
igg
antipp
antibodi
titer
nonrespond
patient
defin
igg
antipp
antibodi
titer
serotyp
includ
vaccin
statist
differ
unimmun
control
result
despit
differ
igg
antipp
antibodi
titer
respond
nonrespond
patient
igm
antibodi
titer
serotyp
significantli
higher
unimmun
control
conclus
result
suggest
defici
igm
igg
antibodi
switch
may
explan
failur
patient
respond
conjug
pneumococc
polysaccharid
cellular
molecular
mechan
underli
defect
investig
k
r
low
c
p
mikita
allergyimmunolog
walter
reed
armi
medic
center
washington
dc
usa
allerg
bronchopulmonari
aspergillosi
abpa
complex
hypersensit
reaction
includ
igeand
iggmedi
immun
respons
follow
aspergillu
colon
asthmat
airway
cystic
fibrosi
cf
multisystem
diseas
character
disord
exocrin
gland
function
diseas
manifest
includ
respiratori
gastrointestin
hepatobiliari
pancreat
reproduct
dysfunct
abpa
extrem
difficult
recogn
context
cf
clinic
radiograph
immunolog
featur
frequent
overlap
year
old
caucasian
femal
past
medic
histori
steroiddepend
asthma
allerg
rhiniti
abpa
frequent
pneumonia
present
acut
maxillari
sinus
pediatr
medic
histori
unremark
asthma
first
diagnos
patientt
third
decad
life
past
medic
histori
addit
remark
infertil
intermitt
episod
hemoptysi
year
age
mycobacterium
intracellular
pneumonia
diagnos
symptom
respiratori
distress
hemoptysi
two
year
later
apba
diagnos
subsequ
year
patient
multipl
hospit
basthmaq
exacerb
hemoptysi
pneumonia
daili
oral
steroid
intermitt
cours
antibiot
given
control
asthma
symptom
infect
year
age
patient
hospit
pseudomona
pneumonia
symptom
respiratori
distress
hemoptysi
year
age
present
acut
sinus
chest
sinu
ct
perform
sinu
ct
remark
chronic
sinus
chang
chest
ct
demonstr
multifoc
bilater
cylindr
bronchiectasi
multipl
mucousinspiss
dilat
bronchi
sweat
chlorid
test
genet
test
consist
diagnosi
cf
mutat
case
illustr
delay
diagnosi
cf
set
adult
patient
recurr
infect
atyp
pneumonia
asthma
abpa
demonstr
import
clinic
suspicion
cf
patient
age
present
histori
asthma
frequent
sinopulmonari
infect
sweat
chlorid
test
noninvas
test
modal
may
dramat
alter
manag
prognosi
patient
cf
outersurfac
protein
peptid
bind
hladr
molecul
associ
antibioticrefractori
antibioticrespons
lyme
arthriti
object
clinic
correl
link
antibioticrefractori
lyme
arthriti
certain
hladr
molecul
b
burgdorferi
cell
epitop
outer
surfac
protein
ospa
previous
molecul
associ
antibioticrefractori
arthriti
shown
bind
peptid
wherea
molecul
associ
antibioticrespons
patient
studi
determin
rel
bind
affin
ospa
hladr
molecul
correl
peptid
bind
mhc
frequenc
antibioticrefractori
antibioticrespons
arthriti
patient
method
cdna
extracellular
domain
dra
drh
attach
leucin
zipper
sequenc
cotransfect
purifi
drosophila
cell
dr
molecul
purifi
affin
chromatographi
mhcpeptid
bind
detect
captur
hladreuospa
complex
dr
antibodi
coat
plate
dilut
peptid
test
half
maxim
bind
concentr
max
determin
bind
affin
correl
frequenc
mhc
molecul
antibioticrefractori
antibioticrespons
patient
result
mhc
molecul
test
bound
ospa
peptid
molecul
bound
peptid
strongli
max
molecul
bound
moder
well
molecul
bound
weakli
max
addit
test
link
equal
express
molecul
show
molecul
molecul
bound
peptid
moder
well
altogeth
patient
antibioticrefractori
arthriti
least
one
ospa
peptidebind
hladr
molecul
compar
antibioticrespons
arthriti
odd
ratio
contrast
molecul
show
bind
ospa
peptid
antibioticrefractori
patient
one
allel
compar
antibioticrespons
patient
odd
ratio
p
b
moreov
patient
two
ospa
bind
allel
time
like
ci
antibioticrefractori
cours
patient
two
nonospa
bind
allel
conclus
highli
signific
correl
ospa
peptid
bind
implic
hladr
molecul
support
hypothesi
cell
recognit
bacteri
epitop
import
autoimmun
pathogenesi
antibioticrefractori
lyme
arthriti
form
chronic
inflammatori
arthriti
ident
compon
diseaseassoci
trimolecular
mhcpeptidetcr
complex
deciph
cell
migrat
adhes
import
control
mycobacteri
infect
critic
depend
reorgan
cytoskeleton
mycobacteria
elicit
rapid
morpholog
chang
cell
spread
process
relev
vivo
chang
macrophag
shape
extravas
migrat
studi
investig
bcg
mycobacteriainduc
signal
event
lead
macrophag
cytoskelet
rearrang
employ
specif
pharmacolog
inhibitor
suppress
distinct
kinas
pathway
known
elicit
infect
viabl
lyse
mycobacteria
well
purifi
cell
wall
lipoprotein
agonist
induc
cell
extend
actinrich
pseudopod
impart
circular
spread
within
min
substitut
persist
cell
polar
posttreat
bcg
induc
rapid
phosphatidylinositol
activ
becom
recruit
activ
receptor
suppress
inhibitor
abrog
gener
cell
protrus
polar
demonstr
involv
pathway
actin
reorgan
essenti
cell
motil
inhibit
kinas
reduc
number
polar
cell
prevent
filopodia
lamillopodia
format
suggest
role
pathway
stabil
lead
lamillopodia
nfn
b
activ
bcg
import
cytoskelet
rearrang
observ
although
suppress
inhibit
chemokin
growth
factor
secret
activ
macrophag
could
promot
cell
motil
autocrin
manner
h
blockad
correspond
antibodi
inhibit
macrophag
spread
polar
effect
pseudopod
protrus
activ
demonstr
downstream
posit
integrinmedi
adhes
signal
pathway
lead
motil
phenotypeth
data
obtain
demonstr
direct
effect
mycobacteria
macrophag
shape
least
part
mediat
activ
financi
support
cnpq
faperj
cape
chlamydia
pneumonia
cpn
oblig
intracellular
bacterium
known
caus
acut
upper
respiratori
tract
infect
recent
studi
show
cpn
also
involv
varieti
chronic
inflammatori
diseas
includ
atherosclerosi
possibl
autoimmun
diseas
like
multipl
sclerosi
well
arthriti
asthma
fact
report
organ
detect
pcr
cpn
specif
r
rna
human
peripher
blood
mononuclear
cell
associ
subclin
chronic
bacteri
infect
even
though
organ
grow
preferenti
epithelium
cell
respiratori
tract
present
studi
show
bacteria
infect
replic
human
monocyt
cell
line
human
cell
line
also
human
peripher
blood
mononuclear
cell
vitro
detect
fitcconjug
antichlamydia
monoclon
antibodi
specif
chlamydia
lp
stain
pcr
cpn
rrna
cpn
mrna
level
upregul
compar
infect
assess
realtim
pcr
cpn
rrna
p
b
also
found
cpn
infect
cell
evinc
mark
alter
cytokin
product
import
immun
respons
microbi
infect
cpn
infect
human
immun
cell
modul
varieti
cytokin
particular
cpn
infect
cell
suppress
tgf
product
compar
uninfect
cell
assess
elisa
p
b
contrast
cpn
infect
human
cell
line
vitro
markedli
stimul
product
proinflammatori
cytokin
includ
tnf
il
interestingli
cpn
infect
pbmc
enhanc
product
tnf
ifn
g
il
pha
induc
il
il
compar
lower
tgf
infect
viabl
cpn
stimul
il
ifn
g
cytokin
less
il
cytokin
well
tgf
cytokin
compar
stimul
heat
kill
cpn
pbmc
may
relat
antibacteri
immun
common
opportunist
bacterium
studi
warrant
assess
role
chlamydia
immun
respons
sinc
cpn
consid
import
induct
progress
atherosclerosi
neurolog
autoimmun
diseas
cytokin
profil
differ
observ
appear
relat
antibacteri
immun
perhap
autoimmun
thu
infect
human
immun
cell
cpn
may
result
signific
immun
deregul
homeostat
chemokin
organ
cellular
interact
requir
cell
prime
pulmonari
environ
influenza
infect
secondari
lymphoid
organ
slo
addit
earli
embrionari
step
develop
tissu
organ
recruit
induc
cell
facilit
interact
organ
popul
vcamicam
cellular
event
promot
second
wave
chemokin
product
respons
latter
recruit
immun
cell
futur
home
band
cell
zone
addit
hc
also
detect
site
inflamm
contribut
format
ectop
tertiari
lymphoid
structur
rational
murin
model
influenza
infect
detect
hc
local
product
northern
blot
taqmanpcr
immunohistochemistri
find
encourag
us
explor
particip
molecul
pulmonari
immun
respons
influenza
virus
method
pltplt
lt
alpha
mice
infect
influenza
viru
sacrif
differ
time
point
collect
spleen
lung
analysi
immun
respons
cours
infect
cellular
interact
distribut
immun
cell
evalu
immunohistochemistri
immunofluoresc
taqman
pcr
use
tool
measur
chemokin
product
final
use
flow
cytometri
determin
phenotyp
immun
cell
function
cell
migrat
blymphocyt
spleen
uninfect
mice
result
found
absenc
homeostat
chemokin
highli
associ
gener
alter
cellular
interact
local
environ
modifi
cours
infect
appear
product
play
import
role
organ
band
cell
microenviron
lung
similar
way
slo
interestingli
appreci
absenc
drain
lymph
node
adequ
apct
cell
interact
pltplt
influenzainfect
mice
still
abl
mount
adequ
primari
cell
respons
kill
vast
major
virus
even
though
viral
clearanc
littl
bit
delay
knockout
mice
compar
fast
kill
viru
found
wild
type
mice
conclus
find
reinforc
idea
lung
work
altern
place
cell
prime
local
cellular
interact
could
enough
initi
cell
respons
influenza
virus
cell
heterogen
vari
term
phenotyp
function
capabl
histori
antigenencount
deriv
function
relev
model
classifi
cell
hamper
limit
number
paramet
may
measur
use
classic
flow
cytometri
purpos
studi
develop
detail
function
meaning
scheme
classifi
human
cell
achiev
taken
advantag
introduct
reagent
flow
cytometri
perform
multicolour
fac
analysi
rest
polyclonallyactiv
antigenstimul
prepar
peripher
blood
mononuclear
cell
taken
healthi
individu
show
cell
predominantli
distribut
six
eight
possibl
subset
identifi
express
one
subset
correspond
previous
describ
naiv
compart
one
phenotyp
properti
describ
central
memori
compart
two
remain
four
subset
includ
antigenexperienc
cell
express
find
clear
differ
cell
within
differ
subset
term
express
cytolyt
mediat
capac
secret
cytokin
abil
prolifer
furthermor
find
cell
specif
differ
viru
infect
accumul
within
differ
subset
impli
protect
immun
differ
pathogen
involv
cell
differ
phenotyp
function
properti
basi
result
propos
crosssect
model
classif
peripher
cell
knowledg
cell
lie
model
inform
function
capac
reflect
histori
antigenexposur
object
work
character
directli
ifng
cytokin
pattern
induc
spleen
cell
balbc
mice
presensibil
intranas
rout
restimul
diphtheria
toxin
mutant
differenti
cytokin
induc
spleen
cell
measur
quantifi
elisa
found
set
toxin
prime
differ
effector
cell
measur
wild
type
toxin
prime
mostli
cytokin
produc
wherea
dtb
quimer
toxin
prime
cytokin
produc
cell
suggest
eight
b
fragment
diphtheria
toxin
motif
exchang
domain
toxin
influenc
capac
toxin
modul
th
cellular
immun
respons
addit
data
support
assumpt
helic
topolog
domain
contribut
cellular
properti
cri
protein
act
like
epitop
cell
subset
agreement
theoreth
predict
use
antheprot
program
hand
observ
toxin
abil
induc
regulatori
cell
aspect
toxin
repres
good
model
studi
sever
aspect
immunoregul
molecular
cellular
level
mice
proteaselik
activ
factor
promot
clearanc
pulmonari
c
trachomati
infect
ashlesh
k
murthi
yu
cong
guangm
zhong
bernard
p
arulanandam
biolog
univers
texa
san
antonio
san
antonio
tx
usa
microbiolog
immunolog
univers
texa
health
scienc
center
san
antonio
tx
usa
chlamydia
trachomati
gramneg
bacterium
infect
human
conjunctiva
respiratori
genit
tract
caus
signific
morbid
worldwid
chlamydia
evolv
variou
immun
evas
mechan
pose
complex
problem
develop
efficaci
antichlamydi
vaccin
hela
cell
infect
c
trachomati
display
progress
reduct
immunostain
mhc
class
parallel
accumul
intracellular
chlamydi
proteaselik
activ
factor
cpaf
therefor
neutral
cpaf
activ
vivo
may
viabl
vaccin
approach
c
trachomati
infect
end
shown
efficaci
potent
mucos
adjuv
balbc
mice
immun
intranas
cpaf
challeng
c
trachomati
cpaf
immun
anim
display
significantli
greater
reduct
lung
bacteri
load
day
c
trachomati
challeng
compar
mice
immun
cpaf
pb
alon
cpaf
immun
induc
significantli
higher
titer
serum
anticpaf
total
ab
antibodi
compar
anim
immun
cpaf
pb
alon
furthermor
pulmonari
anticpaf
total
ab
iga
induc
higher
level
anim
receiv
cpaf
compar
immun
group
addit
cpaf
immun
mhc
class
defici
mice
display
reduc
bacteri
clearanc
pulmonari
c
trachomati
challeng
compar
vaccin
wild
type
anim
togeth
result
demonstr
cpaf
immun
induc
robust
system
mucos
antibodi
respons
may
enhanc
clearanc
c
trachomati
lung
via
cell
mediat
mechan
support
nation
institut
health
grant
identif
ssrna
sequenc
stimul
innat
immun
tlr
viral
infect
mammalian
host
trigger
immun
system
innat
adapt
immun
respons
recognit
conserv
pathogenassoci
molecular
pattern
pamp
direct
mostli
tolllik
receptor
tlr
ten
tlr
famili
member
report
human
respond
nucleic
acid
deriv
intraendosom
locat
potenti
allow
viral
pamp
recognit
recent
discov
singlestrand
rna
ssrna
stimul
human
mous
immun
cell
secret
cytokin
chemokin
respons
ssrna
human
pbmc
releas
ifnalpha
ifngamma
tnfalpha
cytokin
chemokin
detect
monocyt
main
sourc
tnf
product
pdc
main
sourc
ifnalpha
nk
nktcell
main
sourc
ifngamma
product
upon
stimul
viral
deriv
ssrna
sequenc
identifi
genom
region
sequenc
ssrna
virus
stimulatori
show
respons
sequenc
specif
ssrna
sequenc
current
preclin
investig
may
serv
potenti
vaccin
adjuv
immun
modul
human
pathogen
tuberculosi
respons
death
infecti
diseas
public
health
problem
pose
tuberculosi
grown
seriou
consequ
global
aid
epidem
emerg
multidrug
resist
strain
tuberculosi
combat
ongo
worldwid
scourg
vaccin
develop
tuberculosi
continu
global
prioriti
infect
individu
develop
longliv
protect
immun
abl
control
contain
tuberculosi
manner
celldepend
thu
consider
interest
understand
differ
cell
subset
contribut
primari
immun
respons
follow
infect
whether
cell
elicit
vaccin
mediat
protect
tuberculosi
inform
requir
ration
design
best
vaccin
advanc
human
trial
excel
experiment
evid
cell
particip
immun
respons
tuberculosi
gener
interest
vaccin
strategi
elicit
tuberculosisspecif
cell
activ
cell
mycobacteri
antigen
need
enter
process
mhc
class
pathway
target
use
dna
vaccin
live
attenu
vaccin
strain
unfortun
evalu
role
cell
host
resist
determin
whether
vaccin
elicit
protect
cell
hamper
mycobacteri
antigen
identifi
recogn
cell
thu
even
basic
question
concern
function
cell
tuberculosi
infect
remain
unansw
identifi
epitop
protein
recogn
cell
lung
mice
follow
tuberculosi
infect
interestingli
delet
region
mycobacteri
genom
encod
origin
event
result
attenu
bovi
bcg
also
attenu
tuberculosi
furthermor
tuberculosi
infect
peopl
evid
immun
antigen
predict
cell
detect
mice
infect
erdman
tuberculosi
strain
mice
infect
bcg
importantli
cell
recogn
tuberculosi
infect
macrophag
previous
shown
vivo
cytolyt
activ
cell
specif
mycobacteri
antigen
could
detect
spleen
pulmonari
ln
lung
infect
mice
present
studi
cytolyt
activ
mediat
includ
find
independ
pathway
process
determin
whether
perforin
requir
vivo
cytotox
follow
infect
studi
highlight
cytolyt
function
antigenspecif
cell
elicit
tuberculosi
infect
enabl
us
determin
whether
cytotox
function
cell
requir
optimum
pulmonari
immun
tuberculosi
infect
pathway
tcell
activ
use
bacteri
superantigen
mechanist
therapeut
implic
autoimmun
current
paradigm
explain
activ
matur
cell
follow
engag
tcell
antigen
receptor
tcr
peptid
mhc
molecul
reli
earli
activ
src
famili
kinas
lck
lck
phosphoryl
tyrosinebas
activ
motif
subunit
tcr
complex
provid
site
recruit
activ
syk
famili
kinas
phosphoryl
transmembran
adapt
lat
provid
dock
site
assembl
multimolecular
complex
signalosom
trigger
sever
signal
cascad
caus
transloc
activ
transcript
factor
lead
chang
gene
express
despit
requir
lck
condit
cell
activ
proceed
absenc
lck
circumst
one
involv
activ
cell
superantigen
sag
type
stimuli
implic
develop
autoimmun
also
other
shown
tcr
partial
agonist
capac
induc
cell
toler
also
use
lckindepend
tcr
signal
pathway
dissect
lckindepend
tcr
signal
human
cell
upon
stimul
sag
contrast
lckdepend
tcr
signal
earli
tcr
signal
absenc
lck
character
lack
phosphoryl
lat
phospholipas
plc
found
sag
induc
signific
activ
mitogenactiv
protein
kinas
mapk
influx
transloc
nfat
nfnb
transcript
factor
lckdefici
cell
lead
product
lckindepend
cell
respons
block
protein
kinas
c
pkc
mapk
inhibitor
inhibitor
kinas
addit
observ
product
lckdefici
cell
enhanc
lithium
chlorid
licl
minim
inhibit
pertussi
toxin
sinc
licl
stabil
gener
involv
influx
explor
involv
altern
plc
particular
plch
found
inhibit
plch
block
lckindepend
activ
suggest
enzym
involv
tcr
signal
conclus
data
provid
initi
character
lckindepend
tcr
signal
induc
sag
pathway
depend
activ
plch
pkc
sinc
activ
plch
regul
heterotrimer
gprotein
data
suggest
saginduc
cell
activ
involv
g
proteindepend
pathway
find
implic
design
inhibitor
cell
activ
context
saginduc
diseas
introduct
intens
immun
respons
well
predisposit
mani
diseas
includ
infecti
ill
associ
specif
hla
phenotyp
object
investig
relationship
specif
hla
phenotyp
patient
predisposit
chronic
cours
urogenit
chlamydiosi
addit
vitro
product
ifng
interleukin
il
peripher
blood
mononuclear
cell
pbmc
studi
design
seventyeight
patient
urogenit
chlamydiosi
includ
studi
hla
phenotyp
determin
standard
terasaki
microlymphocytotox
test
util
panel
antihlaa
b
sera
cytokin
express
assess
commerci
elisa
immunotec
franc
supernat
follow
vitro
cultur
pbmc
without
mitogen
result
patient
chronic
urogenit
chlamydiosi
found
significantli
greater
preval
hla
antigen
individu
analysi
hla
phenotyp
demonstr
ifng
product
independ
presenc
hla
riskassoci
antigen
convers
significantli
greater
vitro
level
observ
patient
hla
riskassoci
antigen
chronic
urogenit
chlamydiosi
compar
studi
control
subject
conclus
hla
antigen
consid
risk
antigen
associ
develop
chronic
cours
urogenit
chlamydiosi
vitro
product
pbmc
patient
chronic
urogenit
chlamydiosi
hla
riskassoci
antigen
significantli
greater
control
subject
contrast
ifng
product
depend
upon
hla
phenotyp
chronic
cours
urogenit
chlamydiosi
patient
may
associ
immunosuppress
effect
induc
probiot
essenti
adjunct
therapi
c
difficil
enter
recurr
c
difficil
gastroenter
increas
incid
sever
especi
young
elderli
although
antibiot
flagyl
vancomycin
effect
amelior
acut
symptom
often
follow
recurr
discontinu
antibiot
also
kill
normal
flora
addit
intend
pathogen
also
exacerb
induc
relaps
c
difficil
carrier
otherwis
asymptomat
follow
case
demonstr
need
replac
normal
flora
suitabl
probiot
hasten
remiss
prevent
recurr
elimin
carrier
state
case
mg
age
admit
third
time
assist
care
intens
care
intraven
fluid
parenter
antibiot
month
suffer
relaps
requir
extend
hospit
rehabilit
confin
isol
sever
abdomin
pain
suicid
depress
thrush
persist
diarrhea
temporarili
reliev
flagyl
vancomycin
therapi
stool
persist
posit
c
difficil
altern
longterm
antibiot
therapi
famili
investig
probiot
ask
doctor
start
declin
obtain
legal
control
patient
discontinu
vancomycin
flagyl
start
probiot
four
enter
coat
capsul
trio
natren
co
contain
live
organ
l
acidophilu
strain
b
bifidum
myeloff
strain
l
bulgaricu
given
qid
stool
gradual
becam
form
patientt
symptom
disappear
unexpect
remmiss
arthriti
allow
prednison
methotrex
discontinu
dose
gradual
reduc
capsul
bid
diarrhea
recur
probiot
inadvert
discontinu
c
difficil
elimin
fece
month
remain
monthli
test
past
year
case
bp
age
admit
nurs
home
diabet
leg
ulcer
soon
develop
recurr
c
difficil
diarrhea
treat
flagyl
vancomycin
recur
whenev
therapi
discontinu
next
year
long
leg
ulcer
heal
nurs
home
retreat
c
diff
final
probiot
ad
symptom
abat
abl
discharg
home
also
continu
take
prophylact
probiot
capsday
remain
well
past
year
similar
case
one
child
present
suggest
c
difficil
increas
problem
immun
defici
also
increas
use
antibiot
kill
normal
bowel
commens
bacteria
normal
gut
bacteria
perform
vital
immunoregulatori
function
also
close
tight
junction
endotheli
cell
c
difficil
toxin
open
thu
allow
unregul
absorpt
toxin
allergen
remark
improv
arthriti
case
fit
theori
certain
antigen
epitop
gut
bacteria
may
crossreact
synovi
cell
gut
becom
permeabl
probiot
consid
essenti
recurr
c
difficil
either
use
alon
adjunct
therapi
posttrauma
alter
tcell
surfac
marker
function
suggest
correl
increas
time
recoveri
develop
multipl
organ
dysfunct
syndrom
mod
recent
dysfunct
costimul
shift
tcell
subset
ratio
emerg
regulatori
tcell
suggest
contributor
immunolog
dysfunct
howev
definit
link
trauma
patientst
tcell
immun
alter
clinic
outcom
still
undefin
trauma
patient
divid
two
group
base
sever
clinic
cours
averag
injuri
score
time
recoveri
mod
versu
assess
surfac
express
costimulatori
subset
reflect
shift
tcell
popul
decreas
activ
regulatori
cell
receptor
levelsdu
also
assess
indic
evid
immunosuppress
paramet
correl
sever
clinic
outcom
versu
addit
cell
intracellular
cytokin
ifng
gmcsf
level
respons
ex
vivo
pmaionomycin
stimul
assess
patient
n
three
differ
clinic
center
follow
day
postinjuri
sampl
day
sampl
normal
subject
n
simultan
process
surfac
express
significantli
decreas
dual
express
significantli
increas
tcell
trauma
patient
compar
normal
subject
unchang
similarli
stimul
intracellular
cytokin
ifng
level
significantli
reduc
tcell
trauma
patient
compar
normal
subject
adapt
cell
postinjuri
alter
may
occur
patient
select
aberr
alter
may
contribut
clinic
patholog
consequ
compar
alter
immun
paramet
patientst
group
sever
versu
less
sever
clinic
cours
ifng
day
postinjuri
express
significantli
reduc
patient
poor
clinic
cours
compar
less
sever
injur
subject
howev
signific
differ
two
patient
group
data
suggest
select
defect
popul
sever
injur
patient
rather
simpl
expans
cell
select
defect
sever
injur
patient
could
contribut
increas
clinic
patholog
determin
capac
immunebas
therapi
ibt
boost
hivspecif
immun
random
control
phase
ii
trial
test
im
alvac
f
daili
lowdos
sq
analyz
accord
ibt
regimen
highest
proport
rs
observ
vaccin
group
placebo
vaccin
placebo
vaccin
data
indic
dti
valid
clinic
trial
design
test
ibt
support
notion
therapeut
immun
may
improv
vivo
antivir
host
respons
c
smith
e
rabellino
j
wilkinson
dtcosta
biomed
research
divis
beckman
coulter
inc
miami
fl
usa
dendrit
cell
dc
potent
antigen
present
cell
play
import
role
induct
immun
respons
microorgan
tumor
also
vital
player
induct
toler
autoimmun
due
uniqu
featur
dc
promis
therapeut
tool
use
manipul
immun
system
form
basi
number
ongo
clinic
trial
biolog
adjuv
modul
cancer
infecti
diseas
autoimmun
order
studi
biolog
rel
rare
dc
well
evalu
efficaci
variou
clinic
trial
easi
identif
enumer
cell
whole
blood
prefer
autom
standard
format
pivot
current
studi
design
develop
autom
standard
methodolog
phenotyp
identif
enumer
dc
whole
blood
beckman
coulter
inc
dc
phenotyp
reagent
use
conjunct
coulterr
prepplu
autom
pipet
instrument
tqprep
autom
lyse
fix
instrument
cellprep
autom
noncentrifug
wash
instrument
cytom
flow
cytomet
total
autom
instrument
setup
data
acquisit
data
analysi
normal
abnorm
whole
blood
sampl
evalu
identif
enumer
dc
result
compar
recommend
valid
manual
techniqu
autom
methodolog
enabl
precis
standard
bhand
offq
identif
enumer
dc
whole
blood
signal
nois
ratio
improv
maintain
similar
cell
recoveri
compar
manual
method
normal
abnorm
blood
specimen
therefor
use
valid
reagent
precis
pipet
autom
prepar
autom
cytomet
setup
defin
gate
strategi
autom
data
analysi
data
reduct
techniqu
enabl
standard
phenotyp
evalu
enumer
rare
dendrit
cell
event
whole
blood
osmel
gaspar
guerra
segura
barbara
eliascal
fernadez
immunolog
lab
teachand
gen
hosp
dr
neto
guantanamo
guantanamo
cuba
ozonetherapi
dept
teach
gen
hosp
dra
neto
guantanamo
guantanamo
cuba
done
prospect
longitudin
studi
posit
hiv
patient
admit
sanatori
live
guantanamo
provinc
period
two
year
sampl
includ
patient
wich
divid
three
aleatori
group
th
e
first
one
treat
ozon
second
convent
treatment
third
ozon
therapyconvent
treatment
evalu
immunohematolog
biochemist
paramet
clinic
success
begin
patient
eritro
high
lymphocyt
subset
within
normal
limit
oxid
stress
moder
sever
good
evolut
without
opportunist
infect
eungsoo
hwnag
jung
heon
kim
ye
jin
kwon
hye
jin
jung
suyeon
kim
chunggyu
park
changyong
cha
depart
microbiolog
immunolog
seoul
nation
univers
colleg
medicin
seoul
republ
korea
immun
respons
regul
cell
prolifer
differenti
also
apoptosi
malfunct
apoptosi
implic
mani
form
human
diseas
mani
viral
infect
disturb
normal
regul
apoptosi
variou
cell
although
fasmedi
apoptosi
one
immun
effector
pathway
lead
elimin
virusinfect
cell
virus
may
escap
immun
surveil
express
fa
ligand
fasl
infect
cell
human
cytomegaloviru
hcmv
infect
report
induc
fasl
retin
epitheli
cell
studi
perform
find
induct
fasl
variou
cell
line
elucid
characterist
fasl
express
human
fibroblast
upon
hcmv
infect
constitut
fasl
express
found
cell
line
jurkat
cem
b
cell
line
osteogen
sarcoma
cell
line
ho
astrocytoma
cell
ine
lung
cancer
cell
line
human
fetal
lung
fibroblast
flf
epstein
barr
virustransform
lymphoid
cell
line
lcl
human
kidney
cell
line
flow
cytometri
analysi
upon
hcmv
infect
multipl
infect
fasl
express
found
flf
lcl
although
cell
line
could
infect
hcmv
timecours
analysi
fasl
express
flow
cytometri
show
fasl
express
found
fibroblast
surfac
immedi
hcmv
infect
fasl
express
downregul
hr
upregul
hr
thereaft
downregul
hr
fasl
express
rate
flf
increas
depend
increas
titer
hcmv
apoptot
death
jurkat
cell
measur
propidium
iodid
stain
flow
cytometri
detect
fasl
express
cell
surfac
flf
jurkat
cell
cocultur
flf
infect
hcmv
variou
infecti
dose
found
apoptot
death
rate
jurkat
cell
hcmvinfect
flf
proport
infecti
dose
hcmv
flf
rel
chang
mrna
express
fasl
hcmv
immedi
earli
ie
earli
protein
measur
real
time
polymeras
chain
reaction
flf
hcmv
infect
sequenti
time
point
hcmv
infect
upregul
fasl
mrna
less
hr
downregul
basal
level
hr
hr
upregul
fasl
mrna
thereaft
downregul
hr
similar
chang
fasl
express
report
hcmv
activ
promot
fasl
experi
hcmv
mrna
increas
persist
continu
except
hr
hcmv
mrna
increas
persist
result
mean
factor
hcmv
involv
regul
fasl
express
conclus
function
activ
fasl
could
induc
restrict
cell
type
hcmv
infect
would
regul
mani
cellular
viral
factor
addit
earlier
report
hcmv
vaccin
consist
five
synthet
peptid
harbor
relev
tcell
epitop
hepat
c
viru
hcv
synthet
adjuv
polylarginin
recent
multicent
studi
novel
vaccin
investig
subject
monitor
immunogen
pbmc
cryopreserv
tcell
respons
assess
interferongamma
elispot
lymphoprolifer
addit
highli
sensit
fivecolor
hla
class
tetramerbind
assay
develop
quantit
phenotyp
hcvspecif
cytotox
cell
hlaa
mous
refer
standard
establish
longterm
qualiti
control
custommad
hcv
tetram
use
clinic
longitudin
studi
present
detail
analysi
well
known
hcv
epitop
part
includ
stain
panel
differ
surfac
marker
hladr
intracellular
interferon
gamma
perforin
evolut
hcvspecif
tcell
respons
compar
recal
respons
cmv
moreov
cell
respons
epitop
seen
tetram
elispot
analys
correl
prolif
cell
respons
importantli
sever
chronic
hcv
patient
cell
respons
epitop
show
concomit
yet
transient
declin
hcv
rna
summari
data
indic
therapeut
vaccin
induc
cellular
immun
hcv
result
studi
provid
first
insight
mode
action
human
lymphocyt
hepat
b
viru
x
c
protein
induc
transcript
prothrombinas
gene
object
fibrinogenlik
protein
play
pivot
role
pathogenesi
experiment
human
fulmin
viral
hepatiit
previous
report
nucleocapsid
protein
murin
hepat
viru
caus
massiv
hepatocellular
necrosi
balbcj
mice
induc
transcript
aim
studi
investig
key
factor
hepat
b
viru
hbv
induc
transcript
human
cisact
element
involv
method
three
eukaryot
express
plasmid
hbv
structur
gene
encod
c
x
protein
respect
construct
express
plasmid
eukaryot
cell
detect
immunohistochemistri
western
blot
seri
truncat
promot
gene
subclon
luciferas
report
vector
form
promoterreport
construct
chines
hamster
ovari
cell
cell
cotransfect
construct
express
hbv
x
c
protein
respect
promot
construct
upstream
luciferas
report
gene
result
hbv
x
protein
c
protein
protein
activ
transcript
gene
show
averag
increas
rel
luciferas
activ
seri
delet
array
gene
promot
show
strong
regulatori
domain
rel
transcript
start
site
respons
regul
gene
transcript
respons
hbv
protein
conclus
result
indic
hbx
hbc
protein
viral
factor
involv
express
promot
region
may
contain
cisel
respons
viral
protein
c
x
studi
provid
new
insight
understand
interact
viru
host
gene
express
contribut
pathogenesi
viral
fulmin
hepat
work
support
nation
scienc
fund
regulatori
cell
treg
critic
control
protect
immun
respons
foreign
organ
hypothes
bcg
vaccin
newborn
induc
specif
treg
dynam
equilibrium
specif
regulatori
convent
immun
exist
incub
whole
blood
old
south
african
infant
routin
vaccin
bcg
birth
bcg
determin
mrna
express
tregspecif
marker
real
time
rtpcr
median
rang
upregul
strongli
suggest
presenc
specif
treg
treg
may
suppress
convent
immun
either
tgfh
therefor
incub
whole
blood
vaccin
infant
bcg
presenc
neutral
antibodi
molecul
show
median
increas
solubl
ifng
product
elisa
suggest
treg
effector
molecul
inde
control
convent
bcginduc
immun
effector
molecul
may
made
cell
treg
correl
bcginduc
mrna
express
molecul
express
correl
tgfh
express
p
b
express
suggest
tgfh
may
effector
molecul
mycobacteriaspecif
treg
determin
whether
treg
cell
present
measur
bcginduc
cellspecif
express
cytokin
flow
cytometri
low
frequenc
cell
made
median
howev
individu
cell
either
ifng
doubl
suggest
presenc
specif
specif
convent
cell
subset
tgfh
could
measur
assay
final
found
bcginduc
ifng
mrna
express
correl
express
p
b
suggest
dynam
equilibrium
specif
regulatori
convent
immun
conclud
newborn
vaccin
bcg
induc
specif
treg
may
control
convent
effectormemori
cell
immun
introduct
monocyt
locomot
inhibitori
factor
mlif
antiinflammatori
pentapeptid
metglncysasns
produc
entamoeba
histolytica
inhibit
vitro
vivo
locomot
human
monocyt
pbmn
without
affect
neutrophil
eosinophil
mlif
also
virtual
cancel
product
reactiv
oxygen
nitrogen
intermedi
roi
rni
pbmn
npmn
spare
eosinophil
effect
mlif
also
inhibit
delay
hypersensit
skin
reaction
guinea
pig
gerbil
may
contribut
regener
without
scar
affect
organ
ie
liver
skin
found
recoveri
treatment
determin
effect
mlif
profil
inflamm
woundheal
gene
express
human
cell
line
use
microarray
devic
pure
construct
mlif
human
cell
line
employ
cell
line
expand
mem
contain
bovin
fetal
serum
reach
adequ
cell
count
cell
adjust
ml
place
plate
incub
co
pmaionomicin
cellsml
cellsml
pmaionomicinemlif
cellsml
cellsml
cellsml
control
consist
cell
incub
without
stimulu
cell
expos
cellsml
mlif
alon
cell
treat
lyse
trizolr
total
rna
isol
follow
instruct
dna
remov
dnaas
rna
integr
confirm
agaros
gel
electrophoresi
synthesi
label
cdna
p
start
total
rna
human
cytokin
label
primersr
purifi
sephadex
column
cdna
hybrid
gene
microarray
membran
panorama
human
cytokin
gene
arraysr
membran
expos
use
biomax
mr
xray
filmr
spot
quantifi
digit
analysi
averag
valu
housekeep
gene
neg
control
use
adjust
valu
gene
membran
use
confiabl
z
valu
binvariantq
tcra
noninvari
divers
ah
gy
cell
subset
dnktt
cell
distinct
locat
function
cell
rapidli
produc
larg
amount
anti
proinflammatori
cytokin
chemokin
depend
microenviron
stimulu
system
stimul
invari
nkt
cell
lead
transient
protect
numer
diseas
indirect
activ
variou
antigen
present
cell
apc
b
cell
express
well
nk
cell
cell
activ
rapidli
stimul
apc
proinflammatori
product
model
direct
ligat
human
apc
vitro
vivo
invari
nkt
cell
activ
ligat
could
protect
acut
picornaviru
infect
suggest
reexamin
result
involv
bblockingq
cell
also
essenti
optim
physiolog
respons
picornaviru
augment
product
nk
cell
activ
case
report
support
antivir
role
human
invari
nkt
cell
howev
excess
activ
local
cell
lead
directli
indirectli
tissu
damag
high
level
ifng
produc
resid
hepat
cell
may
protect
acut
infect
yet
contribut
patholog
chronic
infect
hepat
c
amplifi
modifi
respons
tissu
analog
result
found
model
viral
myocard
invari
nkt
cell
also
essenti
optim
model
antitumor
respons
spontan
cancer
metastas
tumor
vaccin
cancer
progress
correl
failur
patient
invari
nkt
cell
activ
protect
antitumor
respons
defect
respons
correct
vitro
phase
trial
design
final
presenc
nk
cell
marker
essenti
function
therefor
cell
divers
multifunct
cell
innateadapt
immun
respons
interfac
therapeut
approach
exploit
distinct
cell
popul
explor
exampl
graftversustumor
respons
graftversushost
diseas
suppress
model
applic
sar
studi
object
establish
substitut
murin
model
sever
acut
respiratori
syndrom
sar
murin
hepat
viru
type
investig
interact
sar
viru
host
immun
respons
prothrombinas
gene
repres
host
gene
method
balbcj
mice
infect
via
trachea
balbcj
mice
inject
steril
salin
serv
control
surviv
rate
patholog
featur
organ
observ
viru
titer
differ
organ
determin
monolay
cell
standard
plaqu
assay
viru
distribut
cellular
local
studi
situ
hybrid
proinflammatori
gene
express
measur
lung
situ
hybrid
immunohistochemistri
investig
role
pathogenesi
diseas
result
mice
infect
via
trachea
develop
typic
interstiti
pneumonia
patholog
characterist
leukocyt
infiltr
hyalin
membran
format
exud
fibrin
fluid
within
lung
presenc
vascular
thrombosi
pulmonari
vessel
die
within
day
mice
control
group
surviv
inflamm
lung
moder
histolog
chang
also
found
liver
spleen
mild
organ
examin
particl
identifi
cytoplasm
alveolar
epithelia
infiltr
cell
lung
serou
gland
epithelium
tracheabronchu
cell
lymphocyt
other
peripheri
germin
center
spleen
hepatocyt
brain
neuron
epithelia
distal
renal
tubul
epithelium
small
intestin
myocardium
cell
express
evidenc
lymphocyt
mononuclear
inflammatori
infiltr
within
stroma
termin
respiratori
bronchiol
associ
fibrin
deposit
microvascular
thrombosi
conclus
patholog
chang
substitut
sar
murin
model
mimic
characterist
sar
human
addit
physic
damag
viru
replic
lung
immun
organ
includ
spleen
liver
upregul
novel
gene
lung
associ
fibrin
deposit
microvascular
thrombosi
may
play
vital
role
develop
recognit
microbi
infect
initi
host
defens
respons
control
multipl
mechan
b
cell
provid
import
link
innat
adapt
branch
immun
system
howev
direct
involv
b
cell
impart
potenti
protect
respons
unclear
focus
relev
naiv
b
cell
via
innat
immun
secret
essenti
germlin
encod
polyreact
antibodi
prolifer
memori
b
cell
higher
b
cell
cpg
dna
stimul
report
prolifer
naiv
b
cell
extrem
higher
memori
b
cell
cpg
dna
mab
stimul
expans
cell
size
dramat
increas
combin
cpg
dna
signal
signal
increas
express
life
span
naiv
b
cell
prolong
mab
cpg
dna
plu
mab
total
immunoglobulin
staphylococcu
pneumonia
specif
igg
igm
product
adult
naiv
cord
blood
b
cell
ware
recogn
presenc
cpg
mab
interestingli
enhanc
product
staphylococcu
pneumonia
specif
iggigm
howev
differenti
b
cell
plasma
cell
affect
mab
stimul
signal
activ
nfkb
pathway
naiv
b
cell
activ
via
pathway
may
play
benefici
role
profound
expans
gener
antigen
specif
low
affin
antibodi
innat
immun
system
naiv
b
cell
may
detect
infect
trigger
antimicrobi
host
defens
respons
resumen
la
con
n
inmunoreguladora
ampliament
caracterizada
son
lo
linfocito
bright
cuyo
papel
en
la
n
de
enfermedad
inflamatoria
autoinmun
es
preponderant
por
otro
lado
la
tuberculosi
es
una
enfermedad
causada
por
el
bacilo
micobacterum
tuberculosi
se
caracteriza
por
cursar
con
tisular
severo
en
el
n
debido
principalment
la
propia
respuesta
inmun
del
enfermo
por
lo
que
posiblement
lo
mecanismo
de
n
de
esta
respuesta
inmun
alterado
en
est
estudio
analizamo
el
numero
de
inmunoreguladora
en
sangr
de
pacient
con
tuberculosi
en
n
con
sujeto
sano
como
la
n
del
gen
gitr
el
cual
se
ha
reportado
que
esta
present
en
esta
que
abat
su
n
supresora
objetivo
en
raton
la
reguladora
tienen
un
papel
preponderant
en
la
n
de
meno
de
autoinmunidad
esta
reguladora
se
han
descrito
en
humano
en
est
trabajo
investigamo
la
presencia
el
fenotipo
de
esta
en
la
sangr
de
individuo
con
tuberculosi
pulmonar
activa
en
sujeto
sano
se
estudiaron
doce
pacient
con
tuberculosi
doce
sujeto
sano
se
el
numero
de
la
diferent
subpoblacion
de
linfocito
en
sangr
por
citometria
de
flujo
como
la
n
de
gitr
por
rtpcr
en
mononuclear
de
sangr
resultado
lo
nivel
de
lo
diferent
tipo
celular
tanto
en
pacient
como
en
lo
sujeto
control
en
la
sangr
tienen
un
rango
de
valor
muy
amplio
diferencia
significativa
entr
ambo
grupo
n
de
la
productora
de
que
en
lo
pacient
es
ma
grand
comparado
con
lo
control
conclusion
para
la
treg
la
que
producen
tgfb
la
nuestro
resultado
muestran
valor
similar
tanto
en
pacient
como
en
sujeto
sano
que
no
indica
que
esta
se
ven
afectada
con
la
presencia
de
la
enfermedad
solo
la
que
son
muestran
valor
ma
elevado
en
el
grupo
de
lo
pacient
aunqu
est
estudio
se
llevo
cabo
en
sangr
en
dond
el
numero
de
esta
es
muy
con
lo
que
pensamo
que
seria
de
gran
importancia
el
desarrollar
el
mismo
estudio
pero
directament
en
el
sitio
de
la
collymoreslovak
gilb
c
robert
jone
w
h
hildebrand
microbiolog
immunolog
univers
oklahoma
health
scienc
center
oklahoma
citi
ok
usa
major
histocompat
complex
mhc
class
molecul
bind
intracellular
peptid
present
cytotox
lymphocyt
ctl
ctl
respond
foreign
peptid
present
class
virusinfect
cancer
cell
identif
peptid
present
class
molecul
yellow
fever
viru
yfv
infect
import
understand
vivo
immum
respons
infect
compar
respons
aris
vaccin
yellow
feverasibi
yfv
belong
famili
flavivirida
positivesens
singlestrand
encapsul
rna
viru
viru
enter
cell
receptormedi
endocytosi
viral
rna
synthesi
occur
cell
cytoplasm
viral
protein
synthesi
proce
endoplasm
reticulum
virion
matur
endoplasm
reticulum
releas
cellt
plasma
membran
exocyt
fusion
yfv
spread
human
host
saliva
infect
femal
mosquito
mix
capillari
blood
meal
viru
infect
vascular
endotheli
cell
abl
spread
reticuloendotheli
system
replic
secondari
viremia
may
occur
caus
immun
system
overwhelm
understand
peptid
epitop
distinguish
class
mhc
yfvinfect
cell
select
human
macrophag
cell
line
character
transfect
hlaa
b
cell
line
infect
cell
line
yfv
strain
cell
secret
either
b
cultur
hollow
fiber
bioreat
unit
class
hla
harvest
infect
uninfect
cell
peptid
epitop
uniqu
yfv
infect
cell
identifi
compar
mass
spectrometr
map
msm
sequenc
peptid
uniqu
yfv
infect
cell
identif
mhc
class
epitop
uniqu
yfv
infect
cell
use
understand
epitop
avail
infect
cell
yfv
vaccin
elicit
fail
elicit
immun
respons
clonal
organ
cell
memori
paradigm
bfocus
diversityq
contribut
repertoir
flexibl
yuri
n
naumov
shalyn
c
clute
elena
n
naumova
jack
gorski
human
memori
cell
receptor
tcr
repertoir
specif
influenza
viru
epitop
analyz
btcr
clonotyp
sequenc
tetramerselect
cell
cell
bulk
cultur
reveal
clonal
divers
popul
respond
cell
cell
use
almost
exclus
focus
similar
structur
paradigm
refer
bfocus
diversityq
observ
four
differ
individu
determin
strong
clonal
select
base
atcr
usag
express
atcr
origin
multipl
av
av
other
famili
furthermor
motif
identifi
util
aga
g
n
gg
similar
amino
acid
sequenc
differ
length
run
gli
residu
thu
pattern
tcr
repertoir
context
bfocus
diversityq
extend
tcr
chain
complex
repertoir
structur
highli
resist
stabl
time
persist
condit
highli
variabl
antigen
stimul
vitro
result
suggest
abtcr
repertoir
flexibl
context
bfocus
diversityq
might
allow
antigenspecif
immun
respons
accommod
extrem
antigen
challeng
nih
grant
lymphocyt
recogn
antigen
present
antigen
present
cell
apc
peptid
present
mhc
system
endogen
peptid
present
mhc
class
exogen
peptid
present
mhc
class
ii
contrast
mhc
system
molecul
survey
differ
intracellular
compart
lipid
antigen
present
apc
surfac
lipidreact
cell
recent
saposin
shown
mediat
import
step
present
transfer
lipid
antigen
lysosom
lipid
bilay
molecul
howev
mechan
exogen
lipid
antigen
deliveri
antigen
load
compart
known
serum
lipoprotein
primari
mediat
extracellular
lipid
transport
metabol
need
howev
role
lipid
antigen
present
investig
defin
pathway
mediat
exogen
lipid
antigen
deliveri
apolipoprotein
e
apo
achiev
antigen
present
human
serum
lipid
antigen
sequest
low
densiti
lipoprotein
vldl
fraction
antigen
depend
upon
apoemedi
uptak
dendrit
cell
addit
found
dendrit
cell
secret
apo
effici
captur
lipid
antigen
apoelipid
antigen
complex
intern
receptor
mediat
uptak
result
rapid
effici
antigen
deliveri
endosom
lipid
antigen
load
compart
enabl
restrict
cell
activ
immun
system
thu
coopt
import
compon
lipid
metabol
present
lipid
antigen
major
histocompat
complex
mhc
protein
encod
highli
polymorph
gene
play
crucial
role
immun
polymorph
distinguish
mhc
molecul
predominantli
posit
modifi
peptid
bind
howev
recent
studi
seem
indic
genet
divers
mhc
molecul
function
differ
classif
mhc
molecul
function
supertyp
basi
overlap
peptidebind
specif
becom
import
issu
direct
implic
develop
epitopebas
vaccin
wide
popul
coverag
unfortun
direct
experiment
valid
multipl
member
supertyp
tremend
difficult
lack
high
qualiti
human
leukocyt
antigen
hla
molecul
studi
describ
direct
biochem
approach
classifi
hla
molecul
supertyp
use
recombin
solubl
hla
shla
protein
set
singlespecif
shla
receptor
screen
bind
capac
toward
seri
unrel
fluorescentlabel
peptid
ligand
process
peptid
candid
incub
activ
shla
peptidehla
interact
monitor
time
data
analysi
show
variou
degre
overlap
peptid
bind
capac
among
allel
test
reflect
abil
mhc
class
allel
genet
less
distinct
peptid
bind
site
share
bind
ident
peptid
result
studi
abl
better
defin
supertyp
classif
also
includ
addit
allel
current
character
taken
togeth
novel
hla
screen
procedur
repres
versatil
tool
supertypebind
analysi
profound
use
understand
antigen
peptid
select
degener
discrimin
tcell
mediat
immun
respons
complet
knowledg
phenomenon
find
util
epitop
design
develop
hla
base
vaccin
immunotherapeut
polarizationbas
competit
peptid
bind
assaysnew
screen
tool
epitop
discoveri
variou
approach
current
propos
success
develop
therapi
prevent
treatment
infecti
diseas
cancer
one
promis
approach
develop
vaccin
elicit
cytotox
lymphocyt
ctl
respons
order
facilit
ctlspecif
epitop
discoveri
valid
develop
stateoftheart
biochem
hla
class
peptidebind
assay
includ
b
b
b
b
b
b
b
cw
techniqu
base
competit
use
fitclabel
class
bind
refer
peptid
combin
highli
purifi
recombin
solubl
hla
class
molecul
quantit
measur
bind
capac
nonlabel
peptid
candid
fluoresc
polar
allow
direct
realtim
measur
solut
without
separ
step
assay
show
excel
reproduc
sensit
dynam
rang
mp
optim
load
synthet
peptid
fulli
assembl
solubl
hlaa
complex
enabl
thermal
destabil
minut
demonstr
effici
peptid
exchang
requir
remov
endogen
peptid
reaction
environ
multipl
assayspecif
paramet
determin
show
bind
select
fluoresc
peptid
solubl
hla
effect
mani
molecul
bind
exogen
ad
peptid
explor
specif
bind
demonstr
immunolog
relev
fpbase
competit
assay
panel
hla
natur
process
peptid
test
bind
shlaa
valid
approach
panel
peptid
select
repres
binder
reflect
sever
order
magnitud
bind
affin
obtain
ic
valu
directli
compar
valu
publish
direct
cellfre
radioligand
assay
cellular
base
fluoresc
assay
system
result
prove
excel
agreement
also
allow
formul
fpbase
categori
system
peptid
fpbase
ic
valu
lower
consid
high
affin
bind
ic
valu
consid
mediumaffin
bind
ic
valu
judg
lowaffin
bind
abil
exactli
determin
molecular
affin
paramet
fpbase
hla
competit
assay
prime
import
develop
immunomodul
compound
built
highthroughput
screen
platform
new
assay
approach
bridg
current
screen
gap
consider
shorten
rout
clinic
develop
consid
myriad
possibl
peptid
sequenc
coupl
genet
variabl
mhc
molecul
among
individu
cleret
quesnelhellmann
j
mathieu
vidal
j
n
tournier
immunolog
unit
crssa
la
tronch
franc
anthrax
lifethreaten
diseas
present
futur
concern
especi
sinc
use
bioterrorist
weapon
bacillu
anthraci
agent
anthrax
secret
two
critic
virul
factor
lethal
toxin
lt
edema
toxin
et
investig
role
toxin
physiopatholog
inhal
anthrax
evalu
function
murin
lung
dendrit
cell
ldc
upon
infect
b
anthraci
strain
secret
lt
et
toxin
non
toxinogen
strain
briefli
isol
ldc
balbc
mice
perform
digest
collagenas
dnase
follow
posit
select
microbead
purifi
three
cell
popul
gate
express
high
low
ii
int
int
iii
low
high
popul
upon
infect
lt
express
strain
observ
downregul
mhc
class
ii
express
int
cell
ldc
infect
non
toxinogen
strain
induc
secret
tnfalpha
low
level
lt
produc
strain
select
inhibit
product
tnfalpha
wherea
et
produc
strain
inhibit
tnfalpha
affect
increas
significantli
product
compar
non
toxinogen
strain
result
suggest
anthrax
toxin
produc
infect
impair
ldc
function
suppress
innat
immun
respons
may
repres
new
strategi
develop
b
anthraci
escap
host
respons
spread
alveolar
wall
rheumat
fever
inflammatori
autoimmun
condit
follow
non
treat
group
streptococci
pharyng
certain
serotyp
strain
heart
valv
perman
damag
inflamm
lead
heart
valv
replac
surgeri
addit
cellular
heart
valv
attack
antibas
ganglia
autoantibodi
aris
later
autoimmun
process
target
caudat
subthalam
nuclei
antigen
respons
neurolog
symptom
sydenhamt
chorea
antibodi
target
heart
antigen
protein
found
blood
affect
patient
protein
cardiac
valv
deriv
protein
shown
recogn
cell
clone
obtain
lymphocyt
infiltr
rheumat
patient
cardiac
valv
guilherm
et
al
circul
therefor
antigen
mimicri
streptococc
protein
epitop
heart
compon
propos
trigger
factor
lead
heart
autoimmun
attack
understand
diseas
process
therapeut
advanc
hamper
lack
adequ
anim
model
diseas
inject
lewi
rat
streptococcu
recombin
protein
day
follow
boost
day
sacrific
day
order
reproduc
recent
describ
anim
model
rheumat
fever
quinn
et
al
infectimmun
rat
heart
subject
histopatholog
analyz
spleen
lymph
node
lymphocyt
cell
well
sera
harvest
probe
abc
domain
complet
extracellular
protein
ab
domain
nterminu
c
domain
cterminu
myosin
control
protein
ratimmun
cell
use
fac
analysi
studi
phenotyp
profil
cytokin
product
obtain
specif
lymphoprolif
humor
immun
respons
abc
ab
c
domain
spyogen
protein
prolifer
index
reach
antibodi
titer
significantli
higher
control
fold
dilut
could
detect
prolif
humor
respons
myosin
anathomopatholog
evalu
rat
heart
display
presenc
lymphomononuclear
infiltr
sign
lesion
suggest
rheumat
fever
immun
anim
current
analyz
differ
immun
protocol
order
reproduc
diseas
lewi
rat
believ
definit
protein
minim
epitop
respons
rf
certainli
contribut
better
understand
diseas
process
major
studi
done
mainli
murin
show
result
alter
zinc
defici
stimulu
protect
induc
metal
cell
cultur
howev
evid
demonstr
zinc
supplement
vitro
vivo
caus
disturb
immun
system
studi
object
establish
influenc
zinc
matur
viabil
differ
cellular
line
human
monocyt
mice
bone
marrow
macrophag
well
effect
ident
stimulu
proport
zinc
gener
cellular
line
differ
origin
monocyt
obtain
vein
blood
healthi
individu
boyqm
method
bone
marrow
cell
obtain
femur
balbc
mice
week
old
cell
aliquot
maintain
cultur
cellwel
ad
steril
plastic
micro
plate
ad
medium
requir
cellular
line
without
stimulant
factor
requir
differenti
supernat
l
cell
granulocyt
macrophag
coloni
stimul
factor
bone
marrow
cell
mous
pma
human
monocyt
cell
without
zinc
differ
dose
metal
mm
cultur
day
co
microscop
observ
done
day
morpholog
analysi
cellular
differenti
viabil
total
recount
cell
determin
day
viabil
cell
bone
marrow
mous
mononuclear
phagocyt
cell
incub
mm
zinc
similar
control
without
zinc
mm
metal
viabil
decreas
consider
p
b
mous
bone
marrow
cell
human
mp
cell
number
cell
increas
cellular
differenti
morpholog
characterist
observ
begin
cultur
small
round
cell
modifi
state
laps
time
day
deleteri
effect
induc
dose
zinc
observ
three
cellular
line
variat
number
size
morpholog
viabil
cell
observ
differ
concentr
metal
andor
dose
differ
time
suggest
effect
exert
zinc
depend
use
dose
also
period
interact
cell
sepsi
repres
signific
health
problem
worldwid
present
effect
therapeut
approach
treatment
septic
patient
mortal
rate
still
remain
high
present
studi
elucid
potenti
role
recent
discov
heterodimer
cytokin
pathogenesi
septic
shock
acut
polymicrobi
sepsi
first
seri
experi
inject
mice
defici
subunit
wt
control
intraperiton
mgkg
e
coli
lp
result
defici
mice
surviv
significantli
longer
wt
mice
follow
endotoxin
administr
furthermor
cecal
ligat
punctur
model
clp
polymicrobi
sepsi
defici
mice
display
improv
longterm
surviv
compar
control
mice
almost
die
within
h
post
clp
system
administr
recombin
ko
mice
immedi
clp
mice
die
within
day
suggest
pathogen
role
immun
patholog
diseas
minilaparoscop
analysi
demonstr
defici
mice
significantli
reduc
inflammatori
respons
periton
caviti
compar
wildtyp
control
clp
next
investig
cytokin
level
serum
periton
lavag
differ
timepoint
induct
septic
periton
result
ko
mice
show
markedli
attenu
proinflammatori
cytokin
respons
indic
decreas
express
blood
periton
lavag
wherea
bacteri
concentr
blood
similar
control
mice
subsequ
analyz
kinet
express
clp
quantit
realtimepcr
express
subunit
strongli
induc
liver
spleen
lung
peritoneum
h
post
clp
interestingli
periton
macrophag
major
sourc
express
determin
cellstissu
target
biolog
function
sepsi
analyz
express
receptor
chain
cell
implic
pathogenesi
diseas
found
mast
cell
neutrophil
granulocyt
coexpress
receptor
chain
suggest
induc
releas
proinflammatori
mediat
cell
conclus
data
implic
critic
role
earli
pathogenesi
septic
periton
may
potenti
new
therapeut
target
diseas
structur
function
integr
bbb
alter
variou
diseas
cn
hiv
aid
dementia
enter
cn
via
transmigr
infect
monocyt
across
bbb
drug
abus
patient
lead
greater
fluiditi
cellular
membran
increas
permeabl
bbb
immunocompet
cell
efflux
transport
pglycoprotein
pgp
import
compon
bbb
induc
increas
pglycoprotein
express
could
one
mechan
reduc
intracellular
accumul
resist
antiretrovir
agent
result
progress
morphin
transport
pgp
therefor
bbb
permeabl
morphin
may
alter
base
level
pgp
express
endotheli
cell
bbb
hypothes
one
mechan
morphin
increas
transmigr
infect
monocyt
across
bbb
via
modul
pgp
express
brain
microvascular
endotheli
cell
bmvec
constitut
bbb
use
invitro
bbb
model
studi
effect
morphin
transmigr
infect
monocyt
pgp
gene
protein
express
bmvec
monocyt
infect
iiib
strain
use
transmigr
assay
pgp
gene
express
quantit
use
real
time
quantit
pcr
protein
level
measur
use
western
blot
analysi
result
show
morphin
significantli
increas
transendotheli
migrat
uninfect
monocyt
p
b
compar
control
enhanc
transmigr
infect
monocyt
addit
morphin
concentr
alon
combin
tat
significantli
increas
pgp
gene
protein
express
bmvec
increas
pgp
express
bmvec
result
enhanc
bbb
permeabl
infect
monocyt
contribut
neuropathogenesi
drug
abus
rheumat
fever
rf
postinfecti
autoimmun
diseas
preval
million
children
mostli
develop
countri
trigger
streptococcu
pyogen
affect
suscept
individu
follow
nontreat
throat
infect
thirti
patient
develop
carditi
seriou
diseas
manifest
lead
sever
perman
valvular
lesion
develop
chronic
rheumat
heart
diseas
rhd
studi
mechan
lead
patholog
autoimmun
rheumat
fever
rhd
last
year
studi
contribut
better
understand
cellular
molecular
basi
rhd
open
gateway
develop
vaccin
postinfecti
autoimmun
diseas
studi
ctermin
region
protein
identifi
potenti
protect
epitop
recogn
b
lymphocyt
healthi
individu
rf
rhd
patient
order
verifi
potenti
autoimmun
epitop
analyz
overlap
ctermin
peptid
mer
differ
two
amino
acid
residu
ntermin
peptid
previous
describ
hearttissu
crossreact
prolifer
cytokin
secret
assay
use
heartinfiltr
cell
line
hil
obtain
rheumat
heart
diseas
rhd
patient
result
show
hil
abl
recogn
ctermin
peptid
among
peptid
four
result
indic
peptid
differ
amino
acid
capabl
gener
diverg
immun
respons
could
key
issu
defin
vaccin
epitop
relat
lymphocyt
subset
nk
activ
infect
beta
thalassemia
patient
hthalassemia
multipl
transfus
therapi
use
maintain
nearli
normal
hemoglobin
level
partial
suppress
increas
ineffect
erythropoiesi
unfortun
transfus
associ
alloimmun
risk
exposur
infecti
pathogen
accumul
iron
major
caus
morbid
mortal
thalassemia
infect
assum
result
immunolog
chang
contaversi
relat
immunolog
statu
transfus
therapi
regimen
frequencuy
infect
date
quit
clear
patient
susept
infectin
studi
lymphocyt
immunophenotyp
tcell
thelper
cell
tcytolyt
bcell
natur
killer
cell
detect
whole
blood
beta
thalassem
patient
use
three
color
flow
cytometr
techniqu
nnatur
killer
cell
activ
also
determin
flow
cytometr
assay
nk
cytotox
use
target
cell
serum
ferritin
measur
ria
iron
statu
recruit
healthi
children
compar
age
never
gone
blood
transfus
inform
first
date
transfus
histori
infect
age
adminestr
chalat
therapi
obtain
interview
archiv
file
relat
physician
result
show
increas
lymphocyt
p
b
without
alter
lymphocyt
ratio
number
cell
decreas
nk
activ
p
result
correl
tendenc
infect
studi
factor
need
detect
susept
infect
immunooncolog
object
like
gene
inhibit
neg
regul
cell
cycl
dna
methyl
frequent
observ
patient
acut
myelogen
leukemia
aml
silenc
thought
close
relat
onset
progress
tumor
recent
relationship
dna
methyl
histon
modif
acetyl
methyl
highlight
treatment
target
chang
devis
present
studi
undertaken
examin
relationship
dna
methyl
gene
histon
modif
aml
method
tumor
cell
isol
bone
marrow
peripher
blood
patient
aml
case
primari
aml
case
recurr
aml
boy
girl
age
rang
year
isol
cell
confirm
leukem
cell
bone
marrow
peripher
blood
mononuclear
cell
healthi
individu
use
control
leukem
blood
cell
line
express
gene
whose
silenc
methyl
also
examin
acetyl
histon
methyl
histon
lysin
ly
analyz
chromatin
immunoprecipit
methyl
statu
gene
immunoprecipit
dna
evalu
pcr
use
methyl
specif
primer
know
possibl
role
dnmt
aml
examin
express
level
competit
pcr
result
bone
marrow
peripher
blood
mononuclear
cell
cell
show
acetyl
histon
methyl
ly
hand
cell
methyl
histon
ly
also
histon
acetyl
aml
case
show
histon
acetyl
well
methyl
ly
interestingli
promot
dna
immunoprecipit
antibodi
specif
acetyl
histon
unmethyl
allel
methyl
allel
coexist
methyl
allel
unmethyl
allel
observ
methylationspecif
pcr
sequenc
case
methyl
ly
dnmt
express
level
overexpress
aml
compar
level
normal
bone
marrow
peripher
blood
conclus
result
suggest
unbal
histon
modif
dna
methyl
gene
patient
aml
biolog
recent
year
focus
identifi
specif
gene
term
protooncogen
express
appear
underli
process
carcinogenesi
protooncogen
becom
activ
oncogen
varieti
mechan
viral
transduct
promot
insert
amplif
point
mutat
chromosom
transloc
oncogen
classifi
accord
sequenc
homolog
function
similar
site
action
gene
product
rasgen
belong
gprotein
relat
kd
locat
inner
face
plasma
membran
play
import
role
detect
wide
varieti
normal
tumour
tissu
protein
bind
guanin
nucleotid
high
affin
present
work
aim
studi
distribut
rasoncogen
human
epitheli
cancer
precancer
lesion
confirm
histolog
examin
lesion
oral
caviti
respiratori
tract
gastrointestin
tract
liver
breast
kidney
urinari
bladder
ovari
skin
cryostat
section
tissu
prepar
primari
antibodi
ra
kiha
lyophil
obtain
commerci
peroxidaseantiperoxidas
method
use
local
antigen
stain
predominantli
cytoplasm
appear
fine
granular
diffus
squamou
cell
carcinoma
variou
site
show
posit
case
adenocarcinoma
anaplast
carcinoma
show
posit
wherea
case
verruca
transit
cell
pagett
diseas
show
posit
premalign
lesion
oral
leukoplakia
submuc
fibrosi
show
posit
case
benign
lesion
show
posit
normal
tissu
oral
caviti
respiratori
tract
skin
show
positivitythi
studi
help
compair
normal
abnorm
tissu
also
provid
excel
class
tumor
marker
target
therapi
use
immunolog
pharmacolog
radiolabel
agent
inhibit
function
cancer
defect
tcr
associ
protein
relat
immun
impair
oral
cancer
patient
v
cheriyan
c
dutt
krishna
p
balaram
divis
cancer
research
region
cancer
centr
trivandrum
kerala
india
divis
radiotherapi
region
cacner
centr
trivandrum
kerala
india
cancer
oral
caviti
easili
detect
curabl
earli
stage
howev
recurr
nodal
metastasi
frequent
often
due
late
diagnosi
diseas
limit
understand
biolog
tumour
immunosuppress
report
cancer
patient
even
though
mechan
remain
illdefin
recent
report
suggest
tlymphocyt
princip
effector
cell
process
modif
signal
transduc
molecul
respons
impair
tcrzeta
protein
essenti
compon
tcr
complex
bind
zap
protein
transduc
signal
follow
tcr
activ
tcell
activ
also
lead
transloc
nfkb
compon
like
relb
crel
nucleu
activ
transcript
varieti
gene
includ
studi
address
express
statu
signal
transduc
protein
role
immun
impair
patient
cancer
oral
caviti
oral
cancer
patient
collect
studi
obtain
inform
consent
healthi
normal
individu
select
control
percentag
popul
cell
enumer
surfac
phenotyp
use
fac
calibur
capac
respond
mitogen
assess
thymidin
incorpor
assay
tcell
function
assess
quantit
level
product
stimul
express
statu
signal
molecul
tcr
p
lck
pkc
relb
crel
evalu
western
blot
follow
stimul
lymphocyt
presenc
absenc
surfac
phenotyp
cell
show
signific
decreas
posit
cell
ratio
signific
increas
cell
cell
prolifer
assay
clearli
demonstr
defect
cell
prolifer
cell
specif
mitogen
major
oral
cancer
patient
show
decreas
respons
pha
product
lymphocyt
also
found
reduc
exogen
could
increas
transform
respons
control
patient
differ
degre
vari
low
level
signal
molecul
tcr
p
lck
pkc
relb
crel
impair
transduct
relb
nucleu
observ
lymphocyt
decreas
ratio
increas
suppressor
cell
reduc
lymphocyt
prolifer
product
suggest
defect
immun
regul
cancer
oral
caviti
impair
transloc
relb
nucleu
reduc
level
signal
transduc
protein
might
reason
decreas
product
immun
impair
oral
cancer
patient
bubanov
najman
obgyn
medica
centr
ni
serbia
yugoslavia
depart
byolog
medic
univers
school
ni
serbia
yugoslavia
microevolut
tumor
accompani
almost
element
character
evolut
darwinian
sens
evolut
tumor
progress
time
scale
month
year
within
limit
popul
alter
cell
involv
phenomena
observ
longterm
evolut
speci
phenomena
includ
random
chang
genom
tumor
cell
variou
form
select
pressur
select
tumor
cell
mutat
key
gene
endow
tumor
cell
select
growth
advantag
presenc
unstabl
genom
cell
mutat
undergo
progress
dclonal
evolutiont
albeit
model
tumor
surviv
wide
accept
possibl
emerg
dfirstt
alter
cell
gener
follow
axiom
mention
phenomena
tumor
growth
escap
effect
shift
normal
cell
tumor
cell
might
bi
explain
activ
adapt
mechan
cell
surviv
thank
larg
genet
potenti
search
dbetter
solutiont
dendang
cellt
cell
abnorm
dconditionsselect
pressuret
may
wend
malign
alter
altern
way
surviv
exampl
epigenet
factor
dchemic
distressest
virusinfect
may
activ
silenc
gene
respons
malign
alter
vertebr
evolutionari
accumul
genet
potenti
associ
phenomena
epigenet
induc
adapt
abil
speci
surviv
differ
condit
way
shift
cell
normal
alter
might
conceiv
epigenet
induc
adapt
cell
surviv
well
mechan
tumor
escap
strategi
treatment
malign
diseas
bubanov
najman
obgyn
medica
centr
ni
serbia
yugoslavia
institut
biolog
medic
univers
school
ni
serbia
yugoslavia
import
cytokin
phenomena
tumor
growth
escap
even
carcinogenesi
cytokin
essenti
tumor
cell
prolifer
neutral
decreas
clonogen
malign
cell
wherea
addit
recombin
increas
cell
prolifer
autocrin
paracrin
loop
play
import
role
resist
certain
tumor
chemotherapeut
drug
addit
immunomodulatorysuppress
natur
play
signific
role
mechan
tumor
escap
immun
monitor
nevertheless
clear
strategi
treatment
malign
diseas
fact
hypothes
small
number
experimentalclin
studi
propos
strategi
treatment
malign
diseas
exampl
ammonium
trichloro
dioxoethyleneo
ot
tellur
inhibit
synthesi
tumor
transcript
level
therefor
treatment
combin
chemotherapi
may
effect
treatment
certain
malign
anoth
possibl
treatment
malign
patient
antibodi
unpredict
consequ
complic
relat
autoimmun
immun
complex
diseas
strategi
suggest
base
extracorpor
blood
filtrationpurif
method
view
remov
molecul
patientt
blood
antibodi
attach
filter
wall
present
strategi
provid
method
enhanc
immun
respons
tumor
suffer
facilit
elimin
andor
immunosuppress
cytokin
molecul
method
involv
remov
immun
system
inhibitor
circul
tumor
suffer
thu
enabl
vigor
immun
respons
tumor
particularli
use
strategi
absorb
matrix
compos
inert
biocompat
substrat
join
coval
bind
partner
antibodi
capabl
specif
bind
tnfalpa
pleiotrop
cytokin
induc
apoptosi
sensit
cell
also
regul
cell
prolifer
cellular
activ
differenti
better
estim
role
tnf
pc
cell
line
origin
develop
patient
myelodisplast
syndrom
institut
oncolog
sremska
kamenic
novi
sad
monitor
kinet
chang
vitro
treatment
without
tnfalpha
presenc
moab
gmcsf
analyz
cell
viabil
cell
enumer
intracellular
metabol
activ
determin
total
ldh
activ
cell
sonic
cell
prolifer
cell
membran
molecul
express
apoptosi
necrosi
use
flow
cytometri
becton
dickinson
san
jose
usa
analys
perform
treatment
experiment
condit
result
show
comparison
untreat
cell
tnfalpha
induc
significantli
increas
apoptosi
necrosi
pc
cell
express
high
level
tnf
alpha
receptor
immunophenotyp
cell
also
exclud
b
cell
cell
charactrist
presenc
earli
hematologyc
marker
found
pretreat
pc
cell
anti
monoclon
antibodi
modul
cell
death
induc
tnf
addit
presenc
tnf
cell
cultur
medium
induc
significantli
decreas
cell
prolifer
stimul
gmcsf
howev
chang
antigen
express
follow
cell
prolifer
determin
day
cultur
stimul
comparison
percentag
antigen
express
treatment
chang
intracellular
ldh
activ
cell
prolifer
induc
tnf
differ
cytokin
kombin
conclud
sensit
apoptosi
evid
increas
limit
cell
prolifer
estim
cell
line
introduct
abil
cell
recogn
tumor
antigen
import
step
immun
activ
degre
event
occur
cn
remain
matter
open
debat
present
studi
sought
determin
whether
peripher
cell
prime
occur
respons
intracrani
tumor
evalu
whether
degre
prime
offer
surviv
advantag
design
way
improv
specif
deliveri
cell
intracrani
tumor
method
metastat
melanoma
cell
line
transduc
b
restrict
siy
peptid
cell
implant
flank
brain
b
restrict
mice
elispot
assay
perform
spleen
isol
tumor
implant
assess
endogen
lymphocyt
respons
separ
set
experi
narv
cell
recogn
siy
peptid
isol
neg
select
stimul
day
coincub
replicationincompet
mastocytoma
cell
ratio
cell
inject
mice
harbor
intracrani
tumor
without
local
intracrani
deliveri
vari
time
point
result
tumor
grew
flank
mice
associ
poor
cell
prime
siy
antigen
grow
mice
cell
respons
promin
contrast
intracrani
deliveri
uniformli
fatal
anim
model
spite
peripher
cell
prime
siy
antigen
mice
treat
tumorspecif
cell
either
intracrani
tumor
implant
exhibit
statist
signific
increas
surviv
day
control
day
cell
p
b
cotherapi
cell
exhibit
strong
synerg
day
control
day
cell
deliveri
prior
tumor
establish
p
b
day
cell
tumor
establish
p
b
twentyperc
mice
treat
cell
long
term
survivor
greater
day
immunohistochem
analysi
anim
brain
reveal
local
infiltr
intracrani
tumorbear
mice
treat
either
cell
alon
cell
conclus
result
confirm
cell
prime
inde
occur
respons
cn
tumor
howev
strength
respons
correl
surviv
use
tumor
specif
cell
offer
surviv
advantag
local
deliveri
site
tumor
augment
immunotherapeut
respons
studi
repres
first
report
cell
direct
intracrani
antigen
along
exhibit
synergi
significantli
prolong
surviv
anim
intracrani
tumor
angiogenesi
lead
neovascular
exist
blood
vessel
associ
tumor
growth
metastasi
regul
pro
antiangiogen
molecul
well
character
antiangiogen
molecul
current
clinic
trial
cancer
treatment
last
year
clone
sequenc
express
trypanosoma
cruzi
cruzi
calreticulin
gene
tccrt
product
tccrt
protein
ident
human
crt
hucrt
vertebr
crt
known
chaperon
properti
recent
demonstr
tccrt
present
surfac
trypomastigot
bind
collagen
portion
mannan
bind
lectin
inhibit
classic
activ
pathway
human
complement
j
immunolog
sinc
tccrt
highli
homolog
function
antiangiogen
fragment
hucrt
aa
recombin
r
nativ
n
tccrt
test
antiangiogen
effect
chick
embryon
chorioallantoid
membran
cam
assay
protein
mediat
highli
signific
antiangiogen
effect
vivo
cam
assay
effect
substanti
experi
show
genet
plasmid
construct
psectagtccrt
also
display
signific
antiangiogen
properti
compar
empti
vector
thu
indic
parasit
gene
transfect
vertebr
host
like
fact
antiangiogen
substanc
act
preferenti
grow
neoplas
tissu
alreadi
establish
tumor
due
effect
emerg
blood
vessel
thu
virtu
capac
specif
bind
laminin
crt
may
interfer
assembl
endotheli
cell
consequ
gener
new
blood
vessel
synthesi
result
indic
tccrt
like
human
counterpart
antiangiogen
properti
properti
may
explain
least
partli
report
antineoplas
effect
experiment
mhc
class
chainrel
molecul
mic
ligand
particip
immun
surveil
cancer
engag
cell
surfac
mic
trigger
nk
cell
activ
antigenspecif
ctl
immun
howev
releas
solubl
form
mic
smic
tumor
may
impair
respons
decreas
surfac
express
molecular
basi
mic
express
tumor
unknown
demonstr
first
direct
relationship
oncogen
mic
express
chronic
myeloid
leukemia
malign
caus
bcrabl
fusion
oncoprotein
diagnosi
around
one
third
patient
show
increas
serum
level
smica
correl
white
blood
cell
count
decreas
upon
therapi
imatinib
mesyl
im
specif
bcrabl
inhibitor
cell
line
im
decreas
surfac
micab
express
lysi
nk
cell
upregul
micabexpress
bcrabl
confirm
silenc
bcrabl
gene
express
im
affect
mica
mrna
level
decreas
mica
protein
express
smica
releas
likewis
mica
express
reduc
upon
treatment
inhibitor
mtor
activ
bcrabl
result
suggest
posttranscript
regul
mica
bcrabl
oncogen
via
mediat
pathway
object
studi
effect
mtxload
process
innat
immun
adher
activ
tumor
cell
adult
cord
blood
erythrocyt
method
mtx
load
erythrocyt
use
modifi
hypoton
preswel
techniqu
use
erythrocyt
undergo
wash
swell
drugload
treatment
adult
cord
blood
erythrocyt
measur
rate
rosett
format
result
observ
innat
immun
adher
activ
erythrocyt
adult
cord
blood
hypoton
swell
treatment
significantli
increas
compar
group
p
b
rate
rosett
format
f
f
respect
howev
mtxload
treatment
signific
chang
untreat
carrier
erythrocyt
conclus
mtxload
treatment
affect
innat
immun
adher
activ
tumor
cell
erythrocyt
significantli
object
research
potenti
role
erythrocyt
leucocyt
reactiv
neoplasm
method
suspens
inactiv
cancer
cell
ml
ns
control
ad
fresh
anticoagul
whole
blood
white
blood
cell
treat
citric
acid
incub
h
use
monoclon
antibodi
compar
differ
express
level
leucocyt
comput
activ
index
treat
groupcontrol
groupcontrol
group
result
found
cancer
cell
could
activ
hematogen
immun
normal
blood
donor
cancer
patient
activ
index
whole
blood
cell
significantli
higher
white
blood
cell
p
b
cancer
group
modulu
f
whole
blood
cell
treat
group
significantli
higher
f
whole
blood
cell
control
group
p
b
conclus
result
indic
road
map
blood
immun
reaction
erythrocyt
requisit
erythrocyt
promot
express
granulocyt
erythrocyt
play
vital
role
leucocyt
reactiv
neoplasm
object
establish
detect
method
darc
applic
studi
cancer
cell
activ
hemeimmun
reaction
line
map
theori
method
use
elisa
method
flow
cytometri
detect
experiment
system
hemaimmun
reaction
road
map
cancer
cell
ml
ns
ad
fresh
anticoagni
whole
blood
treat
citric
acid
red
blood
cell
white
blood
cell
plasma
ns
incub
see
result
result
cancer
cell
deathli
cell
activ
hemaimmun
reaction
road
map
experiment
system
cancer
cell
ad
whole
blood
group
level
higher
ns
ad
whole
blood
group
cancer
cell
ad
whole
blood
group
level
red
cell
lower
ns
ad
whole
blood
group
cancer
cell
ad
whole
blood
cell
group
level
activ
index
higher
cancer
cell
ad
white
blood
cell
group
cancer
cell
ad
white
blood
cell
group
level
higher
ns
ad
white
blood
cell
group
conclus
result
suggest
red
blood
cell
complement
play
vital
role
regul
hema
immun
reaction
road
map
hemaimmun
reaction
antigen
cancer
cell
activ
complement
adher
complement
adher
red
blood
cell
adher
white
blood
cell
activ
hemaimmun
reaction
furthermor
provid
use
experiment
system
hemaimmun
reaction
road
map
theori
studi
apoptosisbas
therapi
hematolog
malign
apoptosi
intrins
cell
death
program
play
critic
role
tissu
homeostasi
especi
organ
high
rate
daili
cell
product
offset
rapid
cell
turnov
hemopoiet
system
provid
numer
exampl
attest
import
cell
death
mechan
achiev
homestat
control
much
learn
mechan
apoptosi
lymphoid
hematopoiet
cell
sinc
semin
observ
glucocorticoid
induc
dna
fragment
apoptosi
thymocyt
demonstr
depriv
coloni
stimul
factor
csf
factordepend
hematopoiet
cell
caus
program
cell
death
understand
core
compon
apoptosi
machineri
molecular
structur
level
mani
potenti
new
therapi
leukemia
lymphoma
emerg
present
introduc
drug
discoveri
target
thu
far
identifi
within
core
apoptot
machineri
describ
progress
date
toward
translat
grow
knowledg
target
new
therapi
cancer
leukemia
cell
may
play
import
role
mediat
immun
toler
regul
cell
caus
autoimmun
diseas
evid
murin
system
suggest
hese
cell
inhibit
immun
respons
tumour
order
investig
hypothesi
decid
assess
role
leukemia
relaps
either
bone
marrow
transplant
andor
chemotherapeut
treatment
leukemia
patient
select
project
immunophenotyp
analysi
indic
patient
cml
relaps
allogen
bmt
higher
proport
cell
compar
diseas
free
find
suggest
proport
cell
cml
patient
relaps
inhibitori
therefor
result
may
reveal
relaps
chemotherapeut
treatment
may
caus
increas
regulatori
popul
may
lead
enhanc
inhibit
graft
versu
leukemia
effect
gluten
intoler
system
immunolog
disord
character
part
presenc
antigliadin
antibodi
sometim
also
direct
calreticulin
aim
work
determin
immunoreact
serum
iga
gladin
tissu
transglutaminas
small
group
patient
myeloma
multiplex
three
patient
iga
patient
igg
myeloma
multiplex
patient
igg
iga
compon
serum
patient
nonhodgkin
lymphomalymphoplasmocyticum
healthi
peopl
includ
studi
determin
level
immunoreact
antigliadin
iga
antibodi
home
made
elisa
test
use
microgram
crude
gliadin
sigma
antigen
bovin
serum
albumin
use
blocker
immunoreact
iga
antigliadin
antibodi
determin
predilut
serum
blank
well
coat
blocker
bsa
without
gliadin
incub
correspond
serum
dilut
treat
secondari
hrp
label
goat
antihuman
iga
antibodi
addit
well
coat
gliadin
treat
secondari
goat
antihuman
iga
antibodi
immunoreact
iga
antitransglutaminas
antibodi
determin
predilut
human
serum
use
commerci
elisa
test
bind
site
recombin
tissu
transglutaminas
antigen
result
work
show
high
intens
interact
serum
iga
gliadin
two
patient
iga
plasmocytoma
patient
iga
compon
serum
serum
dilut
interact
serum
iga
gliadin
healthi
person
sera
ie
serum
dilut
limit
experiment
error
b
level
reaction
less
pronounc
intens
one
patient
iga
plasmocytoma
serum
compon
antigliadin
iga
immunoreac
also
found
patient
igg
myeloma
multiplex
od
one
patient
nonhodgkin
lymphomalymphoplasmocyticum
antigliadin
iga
immunoreact
high
surprisingli
patient
two
compon
show
iga
immun
reactiv
blocker
bovin
albumin
gliadin
intens
reaction
serum
iga
tissu
transglutaminas
examin
patient
indic
immun
disturb
characterist
celiac
diseas
develop
patient
conclus
preliminari
result
first
show
antigliadin
iga
immunoreact
patient
myeloma
multiplex
set
question
import
gluten
intoler
parasiticor
bacteri
infect
could
induc
anticalreticulinantigliadin
immun
emerg
develop
myeloma
multiplex
ikaro
gene
famili
encod
group
kruppellik
zincfing
protein
act
lymphoidspecif
transcript
factor
apart
ikaro
group
includ
aiolo
helio
eo
pegasu
knockout
studi
mice
shown
ikaro
aiolo
helio
function
transcript
regul
play
import
role
differenti
particular
subset
lymphocyt
member
ikaro
gene
famili
share
similar
overal
structur
four
ntermin
zincfing
motif
respons
sequencespecif
dnabind
ctermin
zincfing
pair
act
dimer
domain
homoand
heterodim
ikaro
helio
aiolo
bind
dna
high
affin
sequencespecif
manner
complex
activ
repress
transcript
certain
promot
dnabind
domain
member
complex
intact
howev
mechan
altern
splice
differ
isoform
creat
lack
one
ntermin
zincfing
nondna
bind
isoform
act
dominantneg
complex
contain
least
one
molecul
bind
dna
effici
possibl
regul
product
shorter
isoform
could
result
phenotyp
seen
knockout
mice
includ
complet
partial
arrest
differ
stage
lymphocyt
develop
lead
develop
leukemia
lymphoma
therefor
decid
correl
express
long
short
isoform
protein
bone
marrow
peripher
blood
lymphocyt
lymph
node
patient
differ
lymphoprolif
disord
use
reversetranscriptionpolymeras
chain
reaction
rtpcr
analyz
lymph
node
patient
differ
type
leukemia
eight
human
hematolog
cell
line
also
screen
express
aiolo
helio
preliminari
result
show
heterogen
pattern
express
aiolo
helio
among
sampl
shorter
isoform
probabl
gener
smaller
amount
fulli
function
molecul
detect
sensit
realtim
pcr
differ
subpopul
cell
analyz
use
flow
cytometri
result
could
improv
understand
mechan
normal
lymphocyt
differenti
possibl
pathway
develop
human
lymphoprolif
disord
heterogen
effector
function
display
rituximab
mab
appar
recogn
suggest
addit
mechan
probabl
relat
mab
fine
specif
respons
b
cell
deplet
improv
understand
rituximab
function
investig
fine
specif
biopan
rituximab
eptapeptid
cysteinconstrain
phage
display
peptid
librari
pdpl
eptapeptid
linear
pdpl
dodecapeptid
linear
pdpl
result
isol
clone
respect
specif
react
rituximab
elisa
western
blot
pdplderiv
clone
insert
sequenc
express
motif
np
match
amino
acid
stretch
anp
two
cyclic
peptid
bear
anp
snp
motif
specif
recogn
rituximab
paratop
reactiv
observ
peptid
bear
mous
snss
pdplderiv
clone
insert
sequenc
express
motif
wpxwle
could
align
reverseori
amino
acid
wpkwle
acid
sphingomyelinaselik
phosphodiesteras
precursor
though
linear
peptid
bear
motif
compet
cyclic
peptid
rituximabparatop
bind
test
reactiv
mab
linear
cyclic
peptid
show
display
reactiv
profil
similar
though
ident
rituximab
furthermor
rituximab
react
peptid
suggest
possibl
interact
enzym
precursor
result
indic
uniqu
fine
specif
rituximab
suggest
possibl
mechan
explain
recent
report
abil
rituximab
increas
acid
sphingomyelinas
activ
raft
microdomain
ponyi
aleksza
l
gerg
garami
constantin
k
danko
object
dermatomyos
character
immunemedi
muscl
inflamm
lead
progress
weak
skelet
muscl
presenc
cutan
symptom
patient
dermatomyos
higher
risk
malign
diseas
normal
popul
exact
pathomechan
associ
obscur
less
known
autoimmun
meet
tumor
immun
patient
aim
character
differ
lymphocyt
subset
cancerassoci
dermatomyos
patient
compar
healthi
control
patient
primari
dermatomyos
fifteen
patient
cancerassoci
dermatomyos
primari
dermatomyos
patient
includ
studi
differ
lymphocyt
subpopul
measur
phenotyp
character
monoclon
antibodi
intracellular
cytokin
express
peripher
lymphocyt
assess
vitro
incub
activ
cocktail
cell
label
antibodi
intracellular
accumul
ifng
detect
frequenc
differ
tcell
subset
measur
within
lymphocyt
popul
flow
cytometri
concern
phenotyp
character
detect
differ
percentag
cell
compar
control
cell
decreas
vs
cell
elev
vs
cancerassoci
dermatomyos
patient
primari
dermatomyos
patient
ratio
activ
hladr
cell
elev
cancerassoci
primari
dermatomyos
case
signific
differ
ratio
cell
compar
control
untreat
treat
cancerassoci
dermatomyos
patient
vs
hand
significantli
decreas
ratio
found
activ
primari
dermatomyos
patient
vs
percentag
cell
normal
cancerassoci
primari
dermatomyos
patient
well
decreas
inact
primari
dermatomyos
patient
compar
healthi
control
conclus
lymphocyt
primari
dermatomyos
less
polar
toward
cell
observ
cancerassoci
dermatomyos
patient
cancerassoci
dermatomyos
differ
primari
myositi
mani
aspect
clinic
immunolog
featur
better
understand
precis
interact
host
immun
system
malign
diseas
shed
light
associ
autoimmun
diseas
malign
bacteriophag
molecular
basi
antitumour
activ
previous
investig
interact
bacteriophag
mammalian
cell
unexpect
bind
phage
cancer
cell
antitumour
activ
select
vitro
mutant
abl
bind
cell
much
stronger
parent
also
effect
melanoma
tumour
metastas
vivo
dabrowska
et
al
acta
virol
dabrowska
et
al
anticanc
re
propos
possibl
molecular
basi
interact
reaction
integrin
target
cell
capsid
protein
probabl
contain
kgdaminoacid
motif
ie
rgd
homologu
abl
bind
receptor
gorski
et
al
medic
immunol
present
result
may
highlight
nonantibacteri
properti
phage
direct
sequenc
phagehead
gene
found
nonsens
mutat
hoc
gene
phage
particl
size
morpholog
observ
electron
micrograph
determin
dynam
light
scatter
pc
differ
gener
morpholog
head
smaller
head
line
welldescrib
morphogenesi
capsid
incorpor
hoc
protein
phage
head
becom
visibl
larger
indic
lack
gp
hoc
normal
hoc
protein
balloonshap
extend
nm
away
capsid
surfac
regularli
arrang
unit
per
one
capsid
special
localis
gp
hoc
imped
access
extern
factor
head
surfac
without
gp
hoc
import
spatial
disturb
diminish
interact
head
compon
extern
target
also
appli
gp
propos
activ
protein
differ
interact
platelet
also
observ
kniotek
et
al
immunolog
may
suggest
hoc
could
involvedhoc
protein
necessari
viabil
structur
exact
function
unknown
howev
interest
report
reveal
related
eukaryot
immunoglobulinlik
domain
similar
result
rather
diverg
common
ancestor
converg
evolut
bateman
et
al
viru
gene
immunoglobulin
superfamili
engag
adhes
process
mhc
function
tcell
receptor
other
hand
know
higher
organ
strongli
expos
bacteriophag
becom
ban
environmentq
phage
life
cycl
dabrowska
et
al
j
appl
microbiol
one
expect
phage
adapt
consider
suggest
bacteriophag
molecul
predict
interact
eukaryot
organ
influenc
import
immunolog
process
andor
modul
interact
hoc
protein
seem
one
molecul
object
although
immun
respons
thought
regul
progress
variou
cancer
cancer
often
progress
escap
hostst
immun
surveil
present
studi
investig
chang
immun
statu
progress
mous
leukemia
materi
method
establish
leukemia
model
inject
balbc
mice
cell
intraperiton
mononuclear
cell
isol
peripher
blood
pb
bone
marrow
bm
everi
day
analyz
cell
composit
flow
cytometri
cell
separ
use
magnet
microbeadsconjug
antibodi
result
discuss
number
peripher
white
blood
cell
leukem
cell
dramat
increas
day
follow
inject
cell
reach
ml
day
progress
leukemia
dendrit
cell
dc
ia
show
mark
increas
pb
although
cell
type
increas
therefor
focus
kinet
function
two
cell
popul
increas
dc
express
lower
level
ia
dc
normal
mice
low
allo
tcell
stimulatori
activ
bm
leukem
mice
continu
increas
despit
progress
leukemia
cell
rapidli
increas
pb
increas
cell
bm
thought
induc
solubl
factor
leukem
cell
cocultur
cell
normal
bone
marrow
cell
transwel
show
select
increas
cell
morpholog
circul
cell
leukem
mice
larg
granular
lymphocyt
surfac
marker
cell
shown
bright
ckit
dim
data
suggest
cell
immatur
nk
cell
isol
circul
nk
cell
leukem
mice
abl
downregul
express
ia
normal
bmderiv
dc
possibl
mediat
tgfh
produc
cell
moreov
nk
cell
significantli
suppress
allo
tcell
stimulatori
activ
dc
requir
celltocel
contact
nk
cell
dc
thought
involv
direct
interact
nk
cell
dc
induc
product
might
associ
inhibitori
effect
bone
marrow
cell
report
immunoregulatori
function
bone
marrow
transplant
without
analys
immatur
nk
cell
immunosuppress
activ
identifi
present
studi
might
popul
cell
conclus
identifi
circul
immatur
nk
cell
immunosuppress
activ
develop
leukemia
import
understand
develop
diseas
also
effect
immunotherapi
maha
h
f
seow
k
cheong
c
f
leong
high
percentag
acut
leukaemia
patient
relaps
initi
respons
treatment
current
riskadapt
therapi
use
fraction
patient
novel
marker
need
identifi
provid
therapeut
direct
reduc
overtreat
undertreat
patient
furthermor
mechan
regul
earli
relaps
identifi
studi
vitro
viabil
use
mtt
assay
blast
de
novo
acut
myeloid
leukemia
patient
fab
compar
durat
surviv
month
patient
signific
correl
r
p
viabil
durat
surviv
observ
select
sampl
low
vitro
viabil
longer
surviv
period
anoth
sampl
high
viabil
short
surviv
period
subtract
hybrid
perform
enrich
amplifi
differenti
express
gene
two
sampl
nucleotid
sequenc
four
preliminari
clone
show
one
differenti
express
gene
mitochondri
gene
cytochrom
c
oxidas
gene
upregul
sampl
show
high
vitro
viabil
shorter
surviv
period
mitochondri
gene
indic
leukaemia
patient
refractori
convent
chemotherapi
may
play
role
earli
relaps
thu
conclud
vitro
cell
viabliti
may
use
prognost
marker
studi
biolog
differ
acut
leukemia
patient
may
lead
understand
mechan
control
cell
surviv
relaps
background
cervic
carcinoma
human
papilloma
viru
hpv
relat
malign
escap
tumor
hostst
immun
respons
thought
play
import
role
carcinogenesi
may
involv
alter
express
immuneregulatori
molecul
gene
purpos
present
studi
evalu
relationship
express
level
cytotox
induc
costimul
ico
icosl
granzym
b
grb
gene
respons
treatment
cervic
cancer
materi
method
mrna
level
determin
quantit
realtim
rtpcr
cervic
cancer
specimen
patient
collect
prior
radiotherapi
radiotherapi
plu
chemotherapi
month
patient
divid
two
group
accord
diseas
persist
n
persist
n
target
mrna
level
normal
mrna
level
refer
gene
dhp
express
rel
unit
ru
result
grb
mrna
level
significantli
higher
biopsi
patient
persist
without
persist
median
valu
ru
grb
p
ru
p
respect
differ
observ
regard
molecul
conclus
besid
prognost
potenti
concern
respons
treatment
find
also
suggest
associ
aggress
tumor
process
particular
immun
activ
profil
intratumor
bcg
administr
erad
local
well
metastas
cancer
cell
suggest
develop
immun
tumor
administr
bcg
noncancer
normal
tissu
howev
result
signific
effect
tumor
potent
inflammatori
agent
bcg
normal
tissu
activ
membran
phospholipas
releas
lysophospholipid
effici
activ
macrophag
cancer
tissu
contain
alkylphospholipid
bcginduc
inflamm
produc
alkyllysophospholipid
alkylglycerol
activ
macrophag
approxim
time
effici
lysophospholipid
yamamoto
et
al
cancer
re
result
impli
highli
activ
macrophag
kill
cancer
cell
inflammationprim
macrophag
activ
process
princip
macrophag
activ
cascad
requir
serum
vitamin
bind
protein
known
gc
protein
particip
b
lymphocyt
stepwis
hydrolysi
gc
protein
hgalactosidas
inflammationprim
b
cell
sialidas
cell
yield
potent
macrophag
activ
factor
maf
protein
nacetylgalactosamin
remain
sugar
stepwis
treatment
highli
purifi
gc
protein
immobil
hgalactosidas
sialidas
gener
potent
maf
termin
gcmaf
ever
discov
produc
side
effect
human
administr
pg
gcmaf
per
mous
ng
gcmaf
per
human
result
maxim
activ
macrophag
develop
enorm
variat
receptor
human
macrophag
treat
vitro
pg
gcmafml
hr
macrophag
highli
activ
macrophag
bind
varieti
cancer
cell
cancer
cell
big
phagocyt
macrophag
membran
spread
cancer
cell
attach
macrophag
membran
surfac
phagosom
membran
secret
superoxid
lytic
enzym
trypan
blue
begin
penetr
attach
site
eventu
stain
entir
cell
time
cours
studi
cell
death
perform
effectortarget
ratio
hr
prostat
cancer
cell
lncap
breast
cancer
cell
kill
hr
lncap
mda
kill
prostat
breast
colon
lung
cancer
patient
treat
less
weekli
administr
ng
gcmaf
major
cancer
patient
exclud
advanc
exhibit
healthi
control
level
serum
prognost
index
indic
erad
tumor
vitro
cancer
cellkil
studi
macrophag
activ
gcmaf
perform
presenc
serum
igg
fraction
gcmaftreat
prostat
breast
cancer
patient
greatli
acceler
cellkil
cell
hr
observ
result
suggest
macrophag
activ
gcmaf
kill
cancer
cell
via
fcreceptor
mediat
preferenti
gcmaftherapi
develop
igg
antibodi
tumor
light
chain
amyloidosi
al
plasma
cell
neoplasia
clonal
expans
termin
differenti
b
cell
plasma
cell
within
bone
marrow
bm
monoclon
immunoglobulin
light
chain
form
insolubl
amyloid
fibril
deposit
system
previous
shown
bia
light
chain
variabl
vl
gene
usag
clonal
plasma
cell
rare
use
e
light
chain
gene
account
al
light
chain
v
gene
repertoir
show
peripher
blood
bone
marrow
patient
contain
clonal
relat
b
cell
matur
b
cell
nonplasma
cell
phenotyp
absenc
plasma
cell
evalu
light
chain
v
gene
repertoir
clonal
isotyp
compart
n
e
al
patient
pbl
bm
healthi
control
bm
mononuclear
cell
enrich
separ
b
cell
plasma
cell
peripher
clonal
isotyp
repertoir
onethird
onehalf
b
cell
use
v
j
gene
clonal
popul
bm
sequenc
align
blood
b
cell
bm
plasma
cell
use
vj
gene
evid
intraclon
variat
blood
b
cell
compar
bm
cell
also
restrict
divers
vl
gene
repertoir
al
patient
use
differ
gene
compar
vl
gene
healthi
control
though
clonal
expans
within
specif
isotyp
compart
chang
global
number
n
e
b
cell
blood
bm
popul
patient
test
plasma
cell
b
cell
popul
three
patient
onethird
greater
twothird
b
cell
bm
use
vj
gene
clonal
plasma
cell
popul
patient
sequenc
align
show
clonal
homolog
vj
junction
remain
patient
one
evid
clonal
relat
b
cell
show
popul
b
cell
use
v
gene
differ
j
gene
latter
patient
unabl
identifi
domin
clonal
plasma
cell
popul
interestingli
greater
number
clonal
b
cell
bm
popul
restrict
vl
gene
divers
sort
popul
bm
healthi
control
show
typic
polyclon
repertoir
vn
gene
repres
plasma
cell
vn
gene
b
cell
presenc
clonal
b
cell
bm
blood
al
patient
relev
understand
pathobiolog
diseas
also
signific
implic
therapi
data
preliminari
suggest
need
paradigm
shift
al
pathogenesi
bind
efficaci
sever
immunotherapeut
adjuv
limit
specif
activ
andor
undesir
ligand
bind
properti
use
dna
shuffl
gener
larg
librari
chimer
adjuv
protein
costimulatori
molecul
select
improv
variant
base
ligand
bind
function
properti
present
describ
one
chimera
bind
protein
dna
shuffl
version
preferenti
bind
interestingli
demonstr
adjuvant
membranebound
form
yet
inhibitori
activ
solubl
combin
dna
encod
dna
encod
silico
shuffl
cancer
antigen
induc
immun
respons
crossreact
epitheli
cell
adhes
molecul
epcam
form
basi
cancer
vaccin
candid
nonhuman
primat
studi
show
approach
achiev
goal
augment
epcamspecif
immun
excel
safeti
profil
importantli
demonstr
presenc
vaccin
construct
requir
detect
epcamspecif
cell
ifngamma
product
base
find
believ
novel
vaccin
approach
potenti
break
immunolog
toler
epcam
limit
current
colorect
carcinoma
vaccin
approach
moreov
broader
applic
gener
dna
vaccin
adjuv
contrast
solubl
protein
capac
inhibit
mix
lymphocyt
reaction
antigenspecif
cell
respons
vitro
make
suitabl
candid
autoimmun
therapeut
applic
activ
narv
cell
two
signal
necessari
besid
cognat
recognit
antigen
context
mhc
molecul
costimulatori
signal
essenti
effect
cell
respons
receptor
ligand
system
best
character
role
antitumor
immun
respons
still
controversi
induc
k
b
melanoma
specif
cell
respons
dc
vaccin
compar
efficaci
control
either
subcutan
pulmonari
metastas
melanoma
wildtyp
mice
model
tumor
develop
faster
mice
subcutan
metastas
differ
promin
certain
time
window
tumor
challeng
wherea
areal
tumor
burden
pulmonari
metastas
significantli
enhanc
ko
mice
furthermor
influenc
signal
prime
home
effector
function
k
b
reactiv
circul
tumor
infiltr
cell
phenotyp
investig
k
b
reactiv
cell
could
detect
dc
vaccin
compar
frequenc
circul
well
among
cellular
infiltr
subcutan
tumor
geneotyp
clonotyp
map
tumor
infiltr
lymphocyt
show
subcutan
tumor
anim
either
genotyp
harbor
oligoclon
infiltr
function
analysi
k
b
reactiv
cell
howev
reveal
number
ifngproduc
cell
substanti
lower
ko
mice
henc
model
prime
home
k
b
reactiv
cell
seem
affect
ko
mice
seem
essenti
effector
function
tumor
specif
cell
selvaggi
liau
mich
g
mantileselvaggi
special
diagnost
immunolog
laboratori
hackensack
univers
medic
center
hackensack
nj
usa
rational
hypothes
malign
b
cell
signific
autocrin
function
induc
replic
sought
establish
role
surviv
evalu
cytokin
profil
compar
b
cell
phenotyp
normal
nl
peripher
blood
pb
bone
marrow
aspir
bm
hypothes
immunolog
profil
differ
type
b
cell
malign
method
discard
bm
pb
specimen
patient
diagnos
morpholog
immunophenotyp
n
cll
n
evalu
induc
express
tumor
necrosi
factor
alpha
tnf
compar
nl
bm
pb
specimen
n
specimen
wash
resuspend
fc
incub
pma
ngml
ionomycin
mcgml
brefeldin
hour
co
cell
wash
resuspend
pb
incub
monoclon
antibodi
mab
beckman
coulter
hialeah
fl
minut
fix
permeabil
intraprep
kit
beckman
coulter
incub
mab
tnf
becton
dickinson
san
jose
ca
minut
cell
wash
resuspend
pb
analyz
coulter
xl
flow
cytomet
use
standard
right
angl
side
scatter
employ
logic
gate
strategi
use
pe
fitc
conjug
isotyp
control
antibodi
establish
histogram
region
neg
fluoresc
percentag
cell
express
tnf
record
specimen
mean
cll
group
compar
nl
group
use
standard
test
unequ
varianc
result
stimul
cell
show
statist
signific
increas
percentag
cell
express
tnf
compar
nl
stimul
b
cell
p
similarli
stimul
cll
cell
show
statist
signific
increas
express
tnf
compar
nl
stimul
b
cell
p
differ
tnf
express
stimul
cell
cll
cell
reach
statist
signific
p
within
cll
group
specimen
b
cell
express
less
n
mean
tnf
express
specimen
express
greater
n
mean
tnf
express
signific
differ
percentag
tnf
express
cll
cell
express
greater
compar
express
less
p
differ
nl
cell
cll
cell
induc
express
conclus
stimul
cll
b
cell
express
tnf
suggest
possibl
role
cytokin
pathogenesi
malign
cll
degre
tnf
express
may
prognost
signific
given
correl
express
find
support
initi
investig
possibl
role
avail
antitnf
therapi
clinic
studi
cll
work
support
grant
nation
leukemia
research
associ
effort
enhanc
antitumor
immun
led
identif
numer
tumorassoci
antigen
vaccin
antigen
shown
limit
efficaci
studi
focus
abil
melanoma
escap
immun
destruct
select
downregul
antigen
target
tumor
vaccin
even
vaccin
abl
rais
highli
specif
cellular
humor
immun
immunemedi
destruct
requir
continu
express
target
antigen
melanoma
vaccin
melanocytespecif
antigen
tyrosinas
show
extens
heterogen
respect
express
level
tumor
cell
search
agent
retain
enhanc
melanoma
antigen
express
show
map
kinas
pathway
inhibitor
capabl
enhanc
express
mrna
protein
sever
antigen
melanoma
cell
line
treatment
melanoma
agent
induc
dramat
morpholog
chang
time
induc
apoptosi
approxim
day
dose
timedepend
enhanc
antigen
express
viabl
cell
melanoma
specif
braf
mutat
detect
high
frequenc
result
constitut
activ
braf
activ
map
kinas
signal
pathway
data
obtain
map
kinas
inhibitor
therefor
suggest
possibl
link
braf
function
antigen
express
howev
observ
simpl
relationship
braf
mutat
statu
antigen
express
level
melanoma
cell
line
furthermor
western
blot
show
clear
correl
phosphoerk
level
melanoma
antigen
express
braf
mutat
statu
data
togeth
mek
inhibitor
enhanc
antigen
express
indic
multipl
influenc
mapkinas
signal
influenc
level
antigen
express
transient
overexpress
braf
offer
direct
mean
modul
map
kinas
signal
seri
melanoma
accordingli
found
four
antigenposit
cell
line
variabl
braf
mutat
statu
two
heterozyg
wildtyp
mutant
one
homozyg
wild
type
one
homozyg
mutant
transient
overexpress
mutant
braf
result
increas
erk
activ
reduct
antigen
level
conclud
inhibit
erk
activ
map
kinas
pathway
inhibitor
promot
antigen
express
melanoma
cell
line
irrespect
origin
antigen
express
statu
high
low
absent
express
melana
convers
erk
activ
induc
transient
constitut
activ
mutant
braf
transfect
antigen
express
declin
data
indic
sever
factor
may
influenc
level
antigen
express
melanoma
block
map
kinas
activ
enhanc
express
sever
melanocyteassoci
antigen
indic
map
kinas
inhibit
may
prove
help
target
melanoma
immunotherapi
trial
patient
advanc
colorect
cancer
limit
option
treatment
immunotherapi
especi
dendrit
cell
dc
base
vaccin
appear
one
promis
therapi
identifi
peptid
cea
mage
stimul
ctl
vitro
develop
previous
use
normal
healthi
donor
develop
larg
scale
manufactur
process
produc
adequ
number
autolog
dc
load
immunogen
peptid
use
clinic
trial
process
cultur
mononuclear
cell
mnc
serumfre
vaccellr
media
contain
gmcsf
day
dc
enrich
elutri
first
puls
klh
matur
bacteri
membran
fraction
klebsiella
pneumonia
fmkp
ifng
puls
peptid
matur
dc
final
cryopreserv
manufactur
process
capabl
gener
vaccin
dose
per
batch
qualif
studi
normal
healthi
donor
n
process
simplifi
use
gambro
elutrak
cell
separ
system
perform
elutri
step
singleus
close
system
steril
dispos
set
present
qualif
modifi
manufactur
procedur
three
full
scale
collidemk
process
run
three
apheresi
product
three
normal
healthi
donor
overnight
ship
contain
f
mnc
monocyt
rang
mnc
cultur
day
vaccel
media
contain
gmcsf
enrich
elutri
gener
f
dc
mean
viabil
puriti
f
f
respect
upon
matur
peptid
puls
dc
show
typic
pattern
phenotyp
matur
regul
regul
secret
tnfa
process
gener
f
viabl
dc
equival
f
vaccin
dose
per
process
base
data
process
manufactur
collidem
vaccin
amend
use
close
system
elutri
method
phase
ii
clinic
trial
underway
evalu
collidem
peptid
puls
dc
vaccin
treatment
colorect
cancer
patient
qin
ning
fang
chen
hani
sun
weim
yan
wenli
liu
object
immun
coagul
microthrombu
fibrin
deposit
within
microvasculatur
major
contributor
pathogenesi
xenograft
reject
viral
induc
hepatocellular
injuri
cytokin
induc
fetal
loss
syndrom
investig
contribut
novel
gene
fibrinogen
like
protein
prothrombinas
mediat
immun
coagul
cancer
potenti
clinic
signific
method
malign
tumor
tissu
obtain
patient
colon
cancer
patient
cervic
cancer
patient
breast
cancer
patient
esophag
cancer
patient
lung
cancer
patient
gastric
carcinoma
immunohistochemistri
situ
hybrid
use
detect
prothrombinas
mrna
tumor
tissu
antibodi
vwf
also
use
seri
histolog
section
determin
cellular
type
express
result
prothrombinas
mrna
express
almost
cancer
evidenc
highli
express
cancer
cell
also
interstiti
infiltr
cell
includ
macrophag
nk
cell
lymphocyt
vascular
endotheli
cell
conclus
express
cancer
cell
activ
interstiti
infiltr
cell
may
contribut
characterist
statu
hypercoagul
turn
induc
tumor
angiogenesi
metastasi
molecul
may
serv
potenti
therapeut
target
manag
tumor
develop
work
support
nation
scienc
object
although
pathogenesi
primari
central
nervou
system
lymphoma
pcnsl
remain
unclear
hypothes
specif
chemokinechemokin
receptor
interact
contribut
local
malign
b
lymphocyt
brain
eye
one
candid
mediat
lymphoid
chemokin
stromal
cellderiv
although
initi
work
focus
critic
role
hematopoiesi
recent
particip
neural
develop
recogn
constitut
express
brain
neuron
endothelium
neuroglia
mening
cell
consequ
studi
express
chemokin
pcnsl
method
formalinfix
paraffinembed
specimen
patient
pcnsl
cut
micron
thick
stain
standard
indirect
immunohistochem
method
use
goat
polyclon
antihuman
antibodi
santa
cruz
biotechnolog
concentr
agml
follow
deparaffin
tissu
antigen
retriev
perform
boil
section
minut
mm
citrat
buffer
ph
normal
tonsil
astrocytoma
meningioma
biopsi
also
immunostain
neg
control
prepar
substitut
goat
igg
sigma
specif
antibodi
result
posit
stain
identifi
pcnsl
biopsi
specimen
express
local
neuron
endotheli
cell
mening
cell
weaker
stain
also
observ
lymphoma
cell
either
diffus
distribut
throughout
brain
tissu
present
perivascular
infiltr
neuron
mening
express
note
astrocytoma
meningioma
biopsi
tonsil
stain
posit
crypt
outer
epithelium
within
tonsil
proper
neg
control
show
posit
stain
interestingli
mous
monoclon
antihuman
antibodi
r
system
recogn
tonsil
show
reactiv
either
normal
brain
pcnsl
biopsi
specimen
conclus
express
occur
within
pcnsl
lesion
brain
well
normal
brain
tissu
studi
examin
function
relev
express
indic
assess
possibl
involv
pathogenesi
pcnsl
phase
evalu
differ
immunotherapi
protocol
gbm
glioblastoma
multiform
gbm
cell
escap
immun
recognit
two
major
mechan
cell
produc
strong
antiinflammatori
substanc
local
tumor
micro
environ
fail
express
mhc
ii
protein
well
costimulatori
adhes
molecul
surfac
mix
leukocyt
cultur
cytoimpl
mlc
previous
shown
function
power
intratumor
proinflammatori
cytokin
pump
revers
antiinflammatori
activ
tumor
microenviron
cancer
cancer
cancer
tumorb
cell
hybridoma
vaccin
tbh
shown
function
antigen
present
cell
facilit
cell
recognit
tumor
antigen
transfu
sci
use
therapi
singl
agent
combin
test
success
clinic
trial
other
tumor
pancreat
adenocarcinoma
asco
proceed
breast
cancer
asco
proceed
phase
one
studi
evalu
toxic
possibl
antitumor
effect
treatment
combin
preliminari
studi
consecut
patient
gbm
accord
standard
select
criteria
divid
three
treatment
group
patient
group
aliv
non
sign
relaps
howev
moment
kaplan
meyer
analysi
show
signific
differ
surviv
three
group
treatment
mlc
strong
rapid
therapeut
effect
limit
durat
gener
sever
enceph
treatment
tbh
slow
last
therapeut
effect
gener
enceph
treatment
mlc
tbh
act
synerg
provok
rapid
strong
last
therapeut
respons
patient
gener
enceph
three
immunotherapi
regimen
seem
strong
antitumor
effect
differ
veloc
risk
develop
secondari
sever
brain
inflamm
complic
seem
relat
mlc
procedur
start
around
day
done
major
toxic
effect
observ
lymphoblast
cell
antiprolif
action
interferon
alpha
chan
p
j
utz
medicin
stanford
univers
stanford
ca
usa
studi
effect
lck
suppress
sensit
acut
lymphoblast
cell
antiprolif
action
interferon
alpha
short
interf
rna
sirna
mediat
lck
ablat
reduc
activ
downstream
signal
pathway
indic
lck
constitut
activ
lymphoblast
cell
despit
absenc
cell
receptor
stimul
lckdefici
lck
sirnatr
jurkat
cell
drastic
sensit
antiprolif
effect
interferon
alpha
wildtyp
untreat
cell
reduct
rate
sphase
progress
interestingli
lck
defici
cell
sensit
proapoptot
action
interferon
alpha
exposur
panel
acut
lymphoblast
cell
lckspecif
inhibitor
similarli
sensit
cell
antiprolif
effect
interferon
alpha
work
provid
ration
basi
combin
use
lckspecif
inhibitor
interferon
alpha
treatment
cell
acut
lymphoblast
leukemia
current
employ
revers
phase
protein
microarray
technolog
explor
mechan
lck
inhibit
sensit
interferon
alpha
activ
waziri
ogden
r
ce
anderson
j
n
bruce
e
anderson
isol
analyz
tumor
cell
tumor
infiltr
lymphocyt
til
present
ex
vivo
central
nervou
system
cn
tumor
specimen
use
flow
cytometri
examin
immunolog
import
cell
surfac
molecul
glioblastoma
multiforma
gbm
tumor
cell
prior
cultur
vitro
screen
supernat
ex
vivo
gbm
secret
cytokin
tumor
cell
express
moder
high
level
hla
class
class
ii
molecul
suggest
tumor
cell
could
directli
interact
influenc
til
addit
major
gbm
examin
n
secret
high
amount
immunosuppress
cytokin
base
observ
hypothes
gbm
tumor
cell
promot
differenti
andor
expans
type
regulatori
cell
turn
suppress
tumor
immun
situ
consist
hypothesi
addit
preliminari
observ
suggest
popul
til
appear
repres
effector
cell
activ
situ
infiltr
gbm
cell
notabl
secret
contrast
til
lack
express
notabl
secret
ifng
absenc
data
suggest
novel
mechan
tumor
microenviron
gbm
influenc
function
til
hinder
abil
mount
effect
tumor
respons
introduct
cancer
diseas
affect
million
individu
everi
year
pathogenesi
cancer
yet
complet
understood
consid
multifactori
although
wide
rang
behavior
differ
cancer
cancer
cell
present
atyp
morpholog
bizarr
mitot
cycl
uncontrol
growth
rate
ultim
lead
invas
kill
host
human
immun
system
repres
power
mechan
detect
destroy
cancer
cell
immun
recognit
mediat
major
histocompat
complex
class
mhc
molecul
scan
cellt
proteom
carri
small
peptid
intracellular
origin
cell
surfac
effector
tlymphocyt
ctl
survey
mhcpeptid
complex
target
cell
display
cancerspecif
peptid
epitop
differenti
cancer
cell
normal
cell
recogn
mhcpeptid
phenotyp
cancer
cell
critic
step
develop
ctlactiv
vaccin
andor
design
new
therapi
object
process
epitop
discoveri
cancer
cell
requir
larg
amount
hla
extract
identifi
peptid
present
mhc
therefor
immedi
goal
transfect
express
solubl
human
mhc
molecul
shla
b
two
cancer
cell
line
allow
product
larg
quantiti
shla
facilit
elucid
mhcepitop
present
cancer
cell
materi
method
breast
cancer
cell
line
well
lung
cancer
cell
line
transfect
shlaa
shlab
shla
construct
lack
intracellular
transmembran
domain
achain
modifi
end
ad
last
carboxitermin
amino
acid
rat
vldl
receptor
vldlr
shlavldlr
clone
mammalian
express
vector
geneticin
zeocin
invitrogen
use
fugen
transfect
reagent
roch
transfect
cell
line
select
specif
antibiot
assay
product
transfect
b
molecul
use
inhous
elisa
sever
posit
clone
obtain
form
cell
line
high
produc
select
sequenti
subclon
elisa
test
shla
protein
product
result
two
breast
cancer
two
lung
cancer
cell
line
success
transfect
shlaa
shlab
stabl
clone
produc
shla
ngml
avail
product
high
quantiti
shla
futur
detect
uniqu
peptid
epitop
distinguish
cancer
cell
normal
cell
conclus
stabl
high
shlaproduc
cancer
cell
line
import
preliminari
step
cancer
epitop
discoveri
process
fulfil
immedi
goal
enabl
us
tool
proceed
discoveri
uniqu
epitop
character
mhcpeptid
phenotyp
cancer
cell
serolog
studi
use
gstcaptur
elisa
determin
antibodi
tunisian
women
achour
p
sehr
zeghal
l
kochbati
f
zouari
pawlita
r
oueslati
biolog
faculti
scienc
bizert
zarzouna
tunisia
dkfz
heidelberg
germani
hospit
la
rabta
tuni
tunisia
institut
salah
azaiz
tuni
tunisia
hospit
la
rabta
tuni
tunisia
dkfz
heidelberg
germani
biolog
faculti
scienc
bizert
zarzouna
tunisia
cervic
cancer
second
tumor
tunisian
women
breast
cancer
human
papillomaviru
hpv
infect
consid
main
caus
invas
cervic
cancer
espaci
moreov
antibodi
protein
hpv
type
found
strongli
associ
cervic
cancer
mani
assay
use
defin
presenc
antibodi
major
low
sensit
present
work
first
one
tunisia
use
gstcaptur
elisa
order
estim
antibodi
respons
antigen
overexpress
ecoli
gst
fusion
protein
describ
research
group
pawlita
use
system
analys
sera
case
cervic
cancer
case
inflamm
cervix
control
result
show
among
cancer
posit
respect
inflamm
control
involv
autoimmun
retin
antigen
determin
diseas
sever
toxoplasmosi
l
vallochi
c
silveira
r
belfort
jr
l
v
rizzo
immunolog
univers
sao
paulo
sao
paulo
paulo
brazil
ophthalmolog
feder
univers
sao
paulo
sao
paulo
paulo
brazil
purpos
ocular
lesion
frequent
variou
individu
infect
toxoplasma
gondii
diseas
intens
ocular
toxoplasmosi
vari
greatli
patient
autoimmun
suggest
possibl
compon
retin
destruct
method
immunolog
paramet
respons
retina
antigen
evalu
infect
person
without
ocular
lesion
infect
control
subject
divid
group
basi
titer
serum
antibodi
gondii
presenc
sever
ocular
lesion
clinic
histori
result
peripher
blood
mononuclear
cell
patient
mild
diseas
respond
one
retin
antigen
significantli
higher
frequenc
patient
without
diseas
sever
diseas
interestingli
cytokin
produc
prolifer
mononuclear
cell
follow
specif
patter
except
fact
seldom
detect
conclus
result
suggest
although
presenc
immun
respons
toward
autoantigen
protect
develop
ocular
lesion
toxoplasma
gondii
may
protect
develop
sever
diseas
ling
shiqi
hu
yanhua
ocular
surfac
center
sun
yatsen
univers
guangzhou
guangdong
china
ophthalmolog
tongji
medic
colleg
huazhong
univers
scienc
technolog
object
investig
use
ipsilater
lymphadenectomi
therapi
inhibit
immun
reject
rat
corneal
transplant
method
corneal
allogen
transplant
model
establish
rat
femal
wister
rat
use
donor
femal
spragu
dawley
sd
rat
use
recipi
corneal
penetr
transplant
recipi
randomli
divid
group
group
control
group
group
b
bilater
lymphadenectomi
group
group
c
ipsilater
lymphadenectomi
group
among
rat
group
cornea
rat
group
use
patholog
studi
day
transplant
rat
use
studi
corneal
immun
reject
slit
lamp
point
time
allograft
reject
occur
record
mean
surviv
time
mst
compar
addit
reject
index
clariti
edema
vascular
graft
examin
compar
day
transplant
result
mst
graft
group
b
c
f
day
f
day
respect
increas
significantli
p
b
comparison
group
mst
f
day
differ
mst
group
b
c
significantli
p
n
patholog
studi
show
day
transplant
cornea
group
state
edema
show
disturb
collagen
fiber
signific
neovascularityhowev
cornea
group
b
c
signific
chang
detect
compar
nomal
cornea
except
reduc
densiti
endotheli
cell
day
corneal
transplantationth
reject
index
group
b
c
much
lower
group
c
conclus
bilater
ipsilater
lymphadenectomi
therapi
signific
effect
prevent
corneal
allograft
reject
ipsilater
lymphadenectomi
less
complex
surgic
procedur
effect
prevent
reject
introduct
glaucomat
optic
neuropathi
one
first
caus
blind
around
world
exact
caus
glaucoma
known
howev
recent
year
suggest
aqueou
humor
ah
relat
gener
glaucoma
human
anim
model
order
understand
particip
mainten
differ
type
glaucoma
determin
concentr
ah
plasma
glaucoma
patient
materi
method
inform
consent
blood
ah
sampl
taken
patient
glaucoma
treat
trabeculectomi
primari
openangl
glaucomapoag
acut
closedangl
glaucomaacag
pseudoexfoli
glaucomapg
patient
senil
cataract
treat
phacoemulsif
without
anteced
glaucoma
control
group
cg
determin
made
chemiluminesc
immunoassay
result
analyz
mannwhitney
rank
sum
test
consid
differ
statist
signific
p
b
result
concentr
ah
glaucoma
patient
f
cg
group
f
plasma
concentr
glaucoma
patient
f
cg
group
f
p
find
statist
differ
concentr
ah
differ
group
glaucoma
patient
poag
f
acag
f
pg
f
pg
find
statist
differ
compar
group
cg
group
also
find
statist
differ
concentr
plasma
sampl
differ
group
glaucoma
patient
poag
f
acag
f
pg
f
pg
howev
compar
concentr
plasma
group
glaucoma
patient
cg
group
found
poag
patient
differ
statist
signific
p
conclus
result
suggest
group
patient
poag
could
associ
plasma
concentr
glaucoma
consid
divers
clinic
present
glaucoma
studi
consequ
differ
molecular
process
could
play
minimum
role
present
time
develop
drug
endothelin
treat
glaucoma
howev
differ
observ
studi
consider
order
guarante
success
new
therapi
glaucoma
yonathan
garfia
marisela
linar
raul
suarez
alejandra
sancheznavarro
macarmen
jimenezmartinez
research
unit
institut
ophthalmolog
cond
de
valenciana
mexico
df
mexico
df
mexico
introduct
littl
known
express
natur
immun
receptor
toll
like
receptor
corneal
epithelium
function
ocular
immun
respons
controversi
object
sought
determin
extracellular
express
human
limbal
epitheli
cell
cultiv
vitro
determin
cellular
function
lp
stimul
matheri
method
scleracorn
rim
limbal
epitheli
cell
isol
grown
presenc
supplement
hormon
epitheli
medium
confluenc
passag
one
two
cell
expos
differ
dose
lp
e
coli
h
stimul
cell
recov
stain
peconjug
monoclon
antibodi
human
analyz
flow
citometri
mrna
obtain
rtpcr
perform
identif
gadph
use
intern
control
secret
tnfalpha
cell
evalu
elisa
supernat
pbmc
use
lp
activ
control
result
limbal
epitheli
cell
expand
vitro
express
constitut
low
densiti
stimul
lp
express
augment
take
account
medium
fluoresc
intens
similar
behavior
observ
mrna
level
express
augment
stimulu
tnfalpha
evalu
interestingli
cytokin
detect
concentr
lp
even
h
stimulu
pbmc
secret
optim
concentr
tnfalpha
lp
stimul
conclus
although
extra
cellular
express
limbal
epithelium
stimul
vitro
upregul
function
seem
associ
secret
tnfalpha
limbal
epithelium
express
corneal
epitheli
cell
infect
adenoviru
macarmen
jimenez
herlinda
mejia
marisela
linar
alejandra
sancheznavarro
raul
suarez
yonathan
garfia
research
unit
institut
ophthalmolog
fundacion
cond
de
valenciana
mexico
df
mexico
df
mexico
introduct
belong
famili
protein
name
molecul
costimul
cell
immun
activ
normal
corneal
epitheli
cell
express
molecul
surfac
object
studi
determin
corneal
epitheli
cell
induc
viral
infect
materi
method
corneal
epitheli
cell
isol
human
cornea
treat
dispaseii
grown
presenc
supplement
hormon
epitheli
medium
co
confluenc
passag
one
two
cell
expos
differ
dose
adenoviru
h
infect
cell
wash
three
time
cultur
differ
time
cell
recov
stain
peconjug
monoclon
antibodi
mab
human
fitcconjug
mab
human
cytokeratin
result
analyz
flow
citometri
result
non
infect
corneal
epitheli
cell
express
time
howev
infect
epitheli
cell
posit
sinc
rais
maximum
level
h
express
epitheli
corneal
cell
detect
also
rais
maximum
level
conclus
result
suggest
corneal
epitheli
cell
express
viru
infect
adamantiadesbehcett
diseas
trend
time
l
kump
k
l
moeller
kurup
g
f
reed
r
b
nussenblatt
laboratori
immunolog
nation
eye
institut
nih
bethesda
md
usa
purpos
analyz
differ
respons
treatment
ocular
adamantiadesbehcett
diseas
abd
method
medic
record
thirti
six
patient
uveiti
due
adamantiadesbehcett
diseas
follow
nation
eye
institut
nei
review
result
patient
divid
group
accord
time
followup
first
group
follow
until
second
group
until
third
group
visual
acuiti
degre
inflamm
group
record
visit
patient
affect
eye
group
patient
eye
group
patient
eye
recent
group
mean
followup
group
year
year
recent
year
mean
time
diagnosi
abd
present
nei
year
group
year
group
year
recent
group
therapeut
agent
use
group
includ
system
steroid
methotrex
azathioprin
cyclophosphamid
chlorambucil
agent
use
group
includ
system
steroid
cyclosporin
chlorambucil
colchicin
medic
use
recent
group
includ
system
steroid
cyclosporin
azathioprin
daclizumab
mycophenol
mofetil
methotrex
infliximab
statist
analysi
show
averag
logmar
chang
per
year
group
group
recent
group
conclus
adamantiadesbehcett
diseas
sever
blind
disord
though
trend
clinic
improv
notic
chang
visual
outcom
reach
statist
signific
larger
studi
may
empow
demonstr
trend
improv
due
introduct
newer
agent
direct
therapi
purpos
analys
visual
outcom
children
juvenil
idiopath
arthritisassoci
uveiti
method
chart
children
jiaassoci
uveiti
review
result
among
children
uveit
syndrom
refer
tertiari
eye
center
children
juvenil
idiopath
arthriti
associ
uveiti
process
bilater
children
seventi
three
patient
femal
patient
caucasian
mean
age
onset
uveiti
year
mean
followup
year
ana
posit
detect
patient
femal
patient
jiaassoci
uveiti
develop
numer
complic
cours
diseas
among
affect
eye
develop
cataract
develop
increas
intraocular
pressur
eye
develop
band
keratopathi
posterior
synechia
present
eye
among
children
immunomodul
treat
nonsteroid
antiinflammtori
agent
alon
combinaion
immunomodul
treat
topic
orsystem
steroid
among
children
requir
immunomodul
one
chemotherapeut
agent
use
children
two
agent
children
three
children
visual
acuiti
patient
document
compar
standard
interv
mix
model
linear
regress
visual
acuiti
improv
averag
logmar
unit
twomonth
visit
p
conclus
spite
sever
jiaassoci
uveiti
much
childrent
vision
preserv
patient
treat
appropri
toler
induct
tgfbtreat
antigen
present
cell
antigen
introduc
anterior
chamber
eye
process
present
resid
antigen
present
cell
apc
manner
result
antigenspecif
peripher
toler
character
suppress
immun
respons
delay
type
hypersensit
dth
similarli
convent
apc
periton
exud
cell
pec
macrophag
hybridoma
clone
treat
tgfh
vitro
induc
compar
peripher
toler
tgfhtreat
apc
known
express
uniqu
set
gene
essenti
toler
induc
abil
suppress
two
gene
regul
nfnb
critic
toler
properti
inb
protein
prevent
nuclear
transloc
nfnb
dimer
therefor
also
support
suppress
express
antigen
present
cell
treat
tgfh
found
upregul
express
inba
seri
experi
assess
contribut
inba
toler
promot
properti
apc
macrophag
hybridoma
stabli
express
antiinba
sirna
ectop
overexpress
inba
examin
abil
express
inba
protein
use
western
blot
suppress
ovaspecif
dth
secret
cultur
supernat
apc
puls
ovalbumin
ova
cultur
overnight
presenc
absenc
ngml
nfnb
activ
apc
assess
measur
nuclear
level
use
transam
chemiluminesc
assay
activ
motif
ca
increas
level
inba
protein
detect
tgfhtreat
inba
overexpress
howev
apc
express
antiinba
sirna
fail
inhibt
secret
tgfh
treatment
found
revers
apc
express
antiinba
sirna
tgfhtreat
overexpress
inba
suppress
ovaspecif
dth
suppress
induc
tgfhtreat
express
antiinba
sirna
nuclear
level
significantli
decreas
tgfhtreat
inba
overexpress
apc
decreas
prevent
tgfhtreat
antiinba
sirna
express
result
demonstr
tgfhtreatment
apc
increas
express
inba
prevent
express
proinflammatori
molecul
prevent
nuclear
transloc
nfnb
increas
express
inba
permit
toler
induct
apc
thrombospondin
interact
essenti
toler
induc
properti
tgfbtreat
antigen
present
cell
antigen
present
cell
apc
anterior
chamber
eye
known
induc
antigenspecif
system
toler
immun
respons
delay
type
hypersensit
dth
suppress
activ
tgfh
abundantli
avail
ocular
environ
confer
toleranceinduc
properti
resid
apc
similarli
vitro
treatment
convent
apc
tgfh
convert
function
phenotyp
toler
apc
investig
molecular
mechan
underli
convers
reveal
signific
involv
variou
molecul
tnfa
product
gene
via
variou
pathway
contribut
system
toler
induc
tgfhtreat
apc
recent
detect
increas
express
extracelluar
matrix
protein
thrombospondin
tsp
tgfhtreat
apc
report
assess
molecular
interact
tsp
lead
tolerogen
phenotyp
apc
convent
apc
either
hybridoma
cell
line
thioglycollateelicit
periton
exud
cell
pec
express
tsp
receptor
well
macrophag
hybridoma
periton
exud
cell
collect
wild
type
wt
null
ko
mice
use
apc
apc
puls
ovalbumin
ova
treat
ngml
examin
abil
suppress
ovaspecif
dth
respons
inhibit
secret
elisa
rtpcr
enhanc
tsp
tnfa
express
rtpcr
wt
apc
treat
tgfh
treat
tsp
suppress
ovaspecif
dth
defici
apc
fail
respons
tgfh
treatment
case
defici
apc
exogen
ad
tsp
restor
abil
acquir
tolerogen
properti
upon
tgfh
exposur
unlik
wt
apc
tsp
defici
apc
treat
tgfh
secret
increas
level
exogen
ad
tsp
mimick
tgfh
inhibit
secret
wt
pec
enhanc
tnfa
express
absenc
pec
also
prevent
abil
increas
express
tsp
result
support
possibl
tsp
express
tgfhtreat
apc
contribut
significantli
toler
induc
properti
facilit
inhibit
secret
express
tnfa
interact
tsp
receptor
essenti
toler
phenotyp
tgfhtreat
apc
antiinflammatori
cytokin
shown
exhibit
stimulatori
function
includ
upregul
human
monocyt
cell
signal
follow
lp
stimul
monocyt
cell
result
synthesi
proinflammatori
cytokin
flow
cytometri
result
show
lpsinduc
express
monocyt
cell
may
mediat
endogen
produc
investig
molecular
mechan
enhanc
express
human
monocyt
promyelocyt
cell
use
model
system
induc
phosphoryl
phosphatidylinositol
extracellular
signalregul
kinas
erk
mitogenactiv
protein
kinas
mapk
determin
western
blot
phosphospecif
anitbodi
employ
specif
inhibitor
erk
mapk
demonstr
either
alon
conjunct
inhibit
phosphoryl
signal
transduc
activ
consequ
express
howev
phosphoryl
remain
unaffect
condit
furthermor
inhibit
bind
transcript
factor
bind
site
promot
final
transfect
cell
interf
rna
vector
inhibit
express
taken
togeth
result
suggest
upregul
human
monocyt
cell
may
mediat
activ
activ
either
alon
concert
erk
mapk
membran
signal
antigen
receptor
cell
overexpress
molecul
anil
bamezai
jennif
reed
abraham
chacko
biolog
depart
villanova
univers
villanova
pa
usa
mous
molecul
serv
excel
differenti
marker
immun
cell
hematopoiet
origin
influenc
cellular
differenti
unknown
cell
overexpress
resist
polar
either
phenotyp
understand
mechan
underli
polar
toler
overexpress
cell
examin
cytokin
profil
respons
vari
antigen
stimul
primari
cultur
condit
overexpress
cell
gener
higher
level
signatur
cytokin
dose
depend
manner
addit
cell
overexpress
show
reduc
phosphoryl
lat
control
result
suggest
express
cell
diminish
membran
proxim
signal
respons
antigen
receptor
therefor
might
contribut
alter
cytokin
profil
result
also
suggest
cell
capabl
produc
high
level
signatur
cytokin
respons
antigen
stimul
resist
polar
either
phenotyp
hypothes
proatherogen
cell
control
cytokin
network
balanc
among
tgfb
impli
atherogenesi
mechan
action
remain
unclear
taken
togeth
abrog
tgfb
signal
cell
abl
acceler
atherosclerosi
permit
suggest
tgfb
reduc
atherosclerosi
dampen
cell
activ
inhibit
cell
activ
may
therefor
repres
strategi
antiatherosclerot
therapi
goal
analyz
possibl
evid
tgfb
action
lymphocyt
function
g
chromatin
topographi
chang
vitro
cerebr
coronari
atherosclerosi
object
patient
origin
research
techniqu
use
ad
tgfb
achiev
final
concentr
ngml
whole
blood
sampl
pdgfab
achiev
final
concentr
whole
blood
sampl
ngml
follow
incub
plastic
tube
sampl
lymphocyt
chromatin
nuclei
behavior
estim
min
sampl
chromatin
lymhocyt
nuclei
studi
use
comput
tv
morphodensitometri
system
bdiamorphq
russia
smear
dy
especi
dna
result
contraind
habitu
opinion
common
atherogen
mechan
without
evalu
organtarget
influenc
first
sight
seem
possibl
mechan
sensit
pdgf
switch
ie
pdgf
cerebr
atheroslerosi
act
manner
assembl
factor
could
known
howev
complex
manner
chromatin
chang
lymphocyt
implic
atherogenesi
shown
underw
involv
compon
cytokin
network
factor
revers
time
main
detect
featur
cerebr
comparison
coronari
atherosclerosi
consist
initi
heteroand
euchromatin
rebuild
obtain
result
conflict
becom
fix
opinion
cerebr
coronari
atherosclerosi
common
process
unifi
atherosclerosi
without
locat
evalu
possibl
detect
chang
result
dissemin
vascular
implic
cerebr
atherosclerosi
comparison
coronari
one
conclus
obtain
result
controversi
describ
dampen
lymphocyt
activ
induc
tgfb
satisfi
result
evidenc
tgfb
suppress
manner
lymphocyt
function
atherosclerosi
receiv
result
opinion
reflect
complic
interact
tgfb
lymphocyt
function
chang
confirm
fact
g
lymphocyt
chromatin
depend
concentr
exposit
time
chang
portray
biphas
manner
pdgfab
ad
initi
short
period
time
detect
nuclear
activ
gene
express
activ
correspondingli
follow
stabl
chromatin
topographi
chang
reflect
stabl
lymphocyt
function
chang
patholog
manner
need
detail
investig
integrin
activ
singlemolecul
level
r
h
eibl
institut
patholog
technic
univers
munich
munich
germani
atom
forc
microscopi
afm
base
forc
spectroscopi
use
direct
measur
quantif
cell
adhes
forc
live
cell
singlemolecul
interact
techniqu
use
studi
physiolog
activ
alpha
integrin
chemokin
live
cell
express
chemokin
receptor
low
physiolog
concentr
ruptur
forc
singl
pair
adhes
receptor
increas
wherea
higher
concentr
lower
ruptur
forc
back
studi
confirm
arrest
chemokin
rapidli
modul
affin
integrin
receptor
date
first
direct
measur
chemokin
induc
affin
modul
singl
adhes
receptor
well
desensit
chemokin
receptor
measur
molecular
level
live
cell
afm
base
forc
spectroscopi
evolv
complet
new
pharmacolog
test
singlemolecul
interact
live
cell
techniqu
use
elucid
mechan
involv
physiolog
leukocyt
home
well
organspecif
tumor
cell
metastasi
eibl
rh
atom
forc
microscopi
measur
mediat
affin
modul
singl
bond
immunolog
network
regulatori
cell
signal
apoptosi
medimond
milano
itali
isbn
eibl
rh
benoit
molecular
resolut
cell
adhes
forc
iee
proceedingsnanobiotechnolog
multifunct
cytokin
involv
sever
immunoregulatori
process
play
critic
role
escap
cancer
host
immun
hpv
main
etiolog
agent
cervic
cancer
oncoprotein
properti
transform
cell
transregul
cellular
gene
identifi
correl
gene
express
advanc
malign
suggest
hpv
induc
gene
express
howev
mechan
hpv
induc
cervic
cancer
remain
unclear
studi
analyz
whether
oncoprotein
involv
molecular
mechan
gene
express
end
amplifi
human
promot
pcr
peripher
blood
lymphocyt
dna
clone
pbluescript
sequenc
dna
fragment
subclon
sever
construct
gener
delet
promot
cell
transfect
construct
evalu
effect
oncoprotein
cotransfect
observ
oncoprotein
induc
twofold
promot
activ
insid
core
promot
signific
effect
regulatori
region
also
observ
sever
interact
dnaprotein
oncoprotein
regulatori
element
core
promot
footprint
emsa
addit
identifi
super
shift
dnaprotein
complex
specif
associ
bind
site
core
promot
antibodi
use
result
suggest
specif
interact
viral
transcript
factor
insid
core
promot
result
may
explain
molecular
mechan
gene
regul
cervic
cancer
well
tumor
escap
mechan
host
antitumor
immun
respons
background
orexina
also
name
novel
neuropeptid
secret
specif
neuron
later
hypothalamu
recent
find
suggest
orexina
provid
critic
link
peripher
energi
balanc
central
nervou
system
mechan
coordin
sleepwak
motiv
behavior
mainli
promot
food
intak
suppress
energi
expenditur
orexina
activ
mediat
close
relat
energi
metabol
hypothes
orexina
may
undergo
fluctuat
sever
metabol
impedi
acut
inflamm
intestin
ir
injuri
materi
method
intestin
ischemiareperfus
ir
injuri
model
rat
establish
rat
divid
randomli
six
group
shamoper
group
min
min
reperfus
group
rat
group
highli
sensit
orexina
radioimmunoassay
use
check
chang
orexina
concentr
plasma
hypothalamu
tissu
rtpcr
use
detect
chang
orexina
mrna
express
hypothalamu
tissu
therefor
chang
orexina
level
peripher
blood
central
secretori
tissu
intestin
ir
injuri
could
investig
result
compar
injuri
plasma
orexina
level
group
show
signific
differ
compar
sham
group
injuri
plasma
hypothalamu
orexina
level
everi
group
show
signific
differ
compar
sham
group
injuri
orexina
mrna
express
decreas
step
step
reach
lowest
recov
gradual
level
sham
group
conclus
orexina
delay
respons
acut
inflammatori
stimuli
intestin
ir
injuri
may
particip
metabol
disord
injuri
inflammatori
cytokin
keyword
ischemiareperfus
intestin
orexina
radioimmunoassay
pcr
inflamm
acut
cytokin
increas
serum
level
subject
metabol
syndrom
activ
gener
nonspecif
inflamm
could
play
role
pathogenesi
metabol
syndrom
compon
howev
data
regard
chang
proinflammatori
interleukin
subject
metabol
syndrom
remain
controversi
therefor
aim
studi
investig
level
serum
subject
metabol
syndrom
compar
without
syndrom
studi
patient
metabol
syndrom
f
year
f
kgm
data
present
mean
f
sem
subject
metabol
syndrom
f
year
f
kgm
diagnosi
metabol
syndrom
made
base
atpiii
criteria
group
patient
metabol
syndrom
subject
type
diabet
mellitu
person
impair
glucos
toler
arteri
hypertens
diagnos
subject
person
without
metabol
syndrom
type
diabet
mellitu
regist
subject
impair
glucos
toler
found
person
arteri
hypertens
diagnos
subject
person
studi
receiv
medic
treatment
diabet
mellitu
arteri
hypertens
time
examin
clinic
sign
concomit
diseas
patient
studi
level
measur
specif
assay
found
level
significantli
increas
patient
metabol
syndrom
compar
without
f
f
pgml
respect
p
b
conclud
elev
serum
level
could
reflect
activ
gener
inflamm
patient
metabol
syndrom
could
contribut
develop
progress
atherosclerosi
high
risk
cardiovascular
diseas
patient
light
regul
express
dendrit
cell
nfkb
neither
mapk
signal
transduct
pathway
g
zou
w
hu
bone
marrow
transplant
rush
univers
medic
center
chicago
il
usa
physiolog
biophys
univers
illinoi
chicago
chicago
il
usa
member
tumor
necrosi
factor
tnf
famili
play
pivot
role
regul
immun
system
light
type
ii
transmembran
protein
belong
tnf
famili
origin
identifi
weak
induc
apoptosi
cytokin
extens
studi
role
cell
regul
recent
identifi
role
induc
matur
dendrit
cell
light
upregul
express
dendrit
cell
previou
report
howev
signal
transduct
pathway
regul
remain
unknown
studi
found
light
activ
nfkb
mapk
jnk
light
upregul
express
dc
activ
nfkb
signal
pathway
inhibit
nfkb
activ
inhibitor
could
blunt
effect
light
upregul
express
neither
inhibitor
jnk
inhibitor
effect
thu
demonstr
light
regul
express
nfkb
signal
transduct
pathway
neither
mpak
signal
pathway
conclud
nfkb
signal
play
key
role
lightmedi
upregul
express
histamin
well
known
mediat
allerg
inflamm
synthes
one
step
enzym
reaction
histidin
decarboxylas
hdc
increas
vascular
permeabl
vasodilat
stimul
nerv
termin
primari
sensori
neuron
stimulationof
conntribit
facilit
inflammatori
respons
addit
effect
histamin
demonstr
involv
regul
innat
aquir
immun
respons
previou
studi
demonstr
histamin
inhibit
express
monocyt
susequ
product
ifng
human
pbmc
histamin
also
inhibit
express
monocyt
human
mix
lymphocyt
reaction
presenc
effect
histamin
mediat
fulmin
hepat
failur
patholog
character
diffus
intrahepat
infiltr
inflammatori
cell
massiv
multilobular
necrosi
heatkil
propionibacterium
acn
pacn
follow
challeng
low
dose
lipopolysaccharid
lp
induc
acut
massiv
liver
injuri
mimick
fulmin
hepat
failur
present
studi
examin
function
role
induc
histamin
protect
hepat
injuri
lethal
pacnesprim
lpsinduc
hepat
use
hdc
knockout
knockout
mice
moreov
investig
effect
inhibitor
histamin
nmethyltransferas
hmt
hepat
lp
challeng
pacnesprim
increas
hdc
activ
liver
wildtyp
mice
associ
mark
elev
histamin
telemethylhistamin
level
western
blot
show
increas
kda
hdc
band
liver
result
strongli
indic
hdc
protein
induc
lp
liver
histamin
produc
high
turnov
rate
hdclike
immunoreact
observ
kupffer
cellsmacrophag
treatment
wildtyp
mice
famotidin
ranitidin
chlorpheniramin
augment
hepat
injuri
inhibit
surviv
rate
dose
pacn
lp
induc
sever
hepat
high
lethal
hdc
knockout
mice
former
rescu
subcutan
inject
histamin
histamin
suppress
express
tnfa
liver
lead
reduc
plasma
level
inflammatori
cytokin
hmt
inhibitor
similar
effect
histamin
find
indic
endogen
produc
histamin
play
import
role
prevent
excess
innat
immun
respons
endotoxininduc
fulmin
hepat
stimul
vegf
consid
one
import
angiogen
factor
known
chemoattract
human
monocyt
possess
immunoregulatori
influenc
tcell
aim
studi
evalu
mrna
express
vegf
receptor
murin
immunocompet
cell
isol
thymocyt
lymph
node
cell
whole
thymu
periton
macrophag
intact
mice
use
investig
periton
cell
allow
adher
hour
wash
nonadher
cell
level
mrna
express
studi
revers
transcriptionpolymeras
chain
reaction
rtpcr
total
rna
isol
help
guanidin
thiocyan
method
synthesi
cdna
templat
carri
use
ag
total
rna
oligo
primer
mmlv
revers
transcriptas
promega
accord
manufacturert
instruct
specif
primer
use
pcr
amplif
forward
revers
pcr
product
size
bp
forward
revers
pcr
product
size
bp
primer
pair
design
nucleotid
sequenc
avail
public
databas
control
housekeep
gene
rtpcr
procedur
hactin
also
deliv
whole
thymu
express
mrna
isol
thymocyt
express
mrna
periton
macrophag
well
isol
lymph
node
cell
express
mrna
receptor
incub
periton
macrophag
presenc
ngml
vegf
h
result
enhanc
mrna
express
express
gene
murin
thymocyt
shown
first
time
suggest
vegf
may
directli
influenc
thymic
cell
specif
influenc
develop
tcell
previous
shown
vegf
modul
thymocyt
mitogeninduc
prolifer
spontan
apoptosi
vitro
evok
thymic
involut
administ
vivo
ohm
et
al
express
mrna
murin
periton
macrophag
also
novel
find
data
indic
tissu
macrophag
possess
receptor
unlik
blood
monocyt
known
express
rational
polymorphonuclear
neutrophil
pmn
major
player
inflamm
first
cell
arriv
inflammatori
site
involv
inflammatori
respons
inflamm
larg
resolv
pmn
undergo
apoptosi
ingest
phagocyt
macrophag
mani
cytokin
modul
pmn
function
includ
apoptot
rate
abil
exert
phagocytosi
case
gcsf
gmcsf
particularli
known
enhanc
pmn
phagocytosi
delay
apoptosi
bind
specif
receptor
mani
cytokin
activ
intracellular
jak
stat
pathway
recent
discov
jakstat
pathway
regul
famili
protein
name
soc
suppressor
cytokin
signal
inhibit
pathway
via
feedback
loop
mechan
ci
report
express
pmn
aim
present
studi
evalu
express
soc
modul
pmn
cell
line
follow
cytokin
stimul
immatur
promyelocyt
cell
acquir
neutrophillik
phenotyp
dimethylsulfoxid
dmso
ad
cultur
medium
method
pmn
freshli
isol
venou
blood
healthi
volunt
differenti
obtain
incub
cell
dmso
day
cell
incub
either
gcsf
gmcsf
rtpcr
use
detect
soc
mrna
protein
express
studi
immunoblot
use
specif
antibodi
proteasom
inhibitor
use
investig
soc
protein
pool
rapidli
degrad
cell
cycloheximid
chx
use
inhibit
protein
synthesi
answer
whether
soc
protein
de
novo
synthes
result
gcsf
gmcsf
found
induc
mrna
express
pmn
stimul
pmn
cell
found
express
basal
level
protein
preincub
treatment
cell
gcsf
gmcsf
enhanc
level
pmn
induc
express
protein
level
stimul
also
induc
express
pmn
chx
revers
increas
pmn
follow
stimul
cytokin
ci
mrna
express
vari
pmn
observ
protein
level
conclus
mrna
protein
express
increas
pmn
stimul
gcsf
gmcsf
rapidli
degrad
pmn
sinc
increas
express
protein
better
observ
cell
preincub
proteasom
inhibitor
elev
level
protein
express
pmn
probabl
result
de
novo
protein
synthesi
sinc
inhibit
chx
ci
mrna
level
vari
cell
follow
stimul
cytokin
use
protein
express
remain
stabl
suggest
exist
anoth
mechan
govern
express
measur
express
level
cytokin
import
studi
vivo
vitro
effect
cytokin
howev
sensit
quantit
measur
mrna
difficult
perform
establish
techniqu
eg
northern
blot
labori
prone
contamin
appli
valid
realtim
quantit
pcr
cytokin
mrna
quantif
method
easi
optim
offer
sensit
reliabl
quantit
result
significantli
reduc
labour
allow
analysi
cytokin
express
larg
number
sampl
appli
method
compar
express
level
sever
cytokin
tnfa
tgfh
receptor
fa
eosinophil
neutrophil
isol
peripher
blood
result
show
signific
differ
compar
volunt
sampl
tweak
macrophagederiv
cytokin
member
tnfa
famili
ligand
origin
identifi
weak
induc
death
certain
tumor
cell
line
tnflike
weak
induc
apoptosi
tweak
exert
pleoitrop
effect
varieti
cell
type
vitro
includ
proangiogen
proinflammatori
activ
cell
express
known
receptor
tweak
fgfinduc
molecul
restrict
epitheli
mesenchym
cell
type
includ
synoviocyt
chondrocyt
highli
upregul
context
injuri
inflammatori
diseas
report
tweak
induc
human
synoviocyt
product
proinflammatori
cytokin
chemokin
mmp
osteoclastogenesi
murin
macrophag
cell
line
thu
tweak
may
promot
joint
inflamm
damag
report
neutral
tweak
mab
markedli
reduc
clinic
paw
sever
mous
rat
collageninduc
arthriti
model
inhibit
antitweak
mab
occur
challeng
phase
appear
alter
cell
prime
elicit
anticollagen
antibodi
decreas
clinic
paw
sever
correl
reduc
inflamm
protect
cartilag
bone
loss
histolog
level
studi
progress
dissect
mechan
action
wherebi
tweak
promot
joint
inflamm
cartilag
bone
loss
investig
potenti
interplay
tweak
tnf
context
antiprolif
effect
infliximab
tcell
prevent
induc
costimul
introduct
system
neutral
proinflammatori
cytokin
tnfa
shown
benefici
patient
ra
sinc
tcell
implic
pathogenesi
ra
evalu
antiprolif
effect
infliximab
could
prevent
induc
costimul
aim
aim
studi
dissect
effect
tnfa
neutral
welldefin
cell
popul
highli
standard
stimulatori
condit
effect
antitnfa
neutral
thu
examin
highli
purifi
narv
human
cord
blood
tcell
differ
stimulatori
condit
method
highli
purifi
narv
human
tcell
neg
select
cord
blood
cell
cultur
serum
free
medium
aimv
without
antihuman
tnfa
chimer
monoclon
antibodi
infliximab
without
without
cell
stimul
four
day
agml
without
analysi
cell
divis
tcell
label
cfse
result
effect
tnfa
neutral
resid
presenc
induc
costimul
antiprolif
effect
complet
lost
presenc
induc
costimul
strongli
reduc
presenc
interestingli
antiprolif
potenti
infliximab
exceed
suboptim
stimulatori
condit
without
costimul
infliximab
act
similarli
upon
tcell
wherea
earlier
work
shown
gener
affect
tcell
strongli
tcell
final
affect
prolifer
except
present
independ
costimul
conclus
primari
tcell
respons
toward
antitnfa
treatment
affect
induc
costimul
may
affect
effect
infliximab
ra
synovium
elev
level
tcell
report
object
epigenet
regul
includ
dna
methyl
profoundli
influenc
effector
cytokin
gene
express
ifng
differenti
helper
th
cell
howev
dna
methyl
statu
cinderella
immunoregul
immun
system
remain
unreveal
method
doubl
cytokin
secret
assay
allow
simultaneu
isol
cytokinesecret
cell
subset
interest
use
highli
purifi
human
ifng
ifng
th
cell
subset
shortterm
ex
vivo
polyclon
stimul
subsequ
global
quantit
dna
methyl
analysi
th
cell
differenti
relat
gene
perfom
result
strikingli
methyl
differ
detect
thcell
subset
kb
genom
locu
span
kb
upstream
complet
gene
encompass
cpg
includ
promot
well
conserv
noncod
region
contrast
hypomethyl
hypermethyl
ifng
gene
promot
exon
intron
region
notic
ifngproduc
versu
nonproduc
respect
addit
antigenspecif
thcell
subset
show
fade
fidel
upon
vitro
restimul
alreadi
week
vitro
expans
conclus
result
point
lack
epigenet
memori
express
human
th
cell
thu
clinic
applic
regulatori
th
cell
evalu
care
respect
stabl
express
transfer
tcell
popul
tnf
alpha
regul
level
transcript
messag
turnov
translat
protein
turnov
also
demonstr
strong
role
epigenet
regul
express
implic
chronic
inflammatori
diseas
epigenet
bprintq
may
alter
contribut
diseas
persist
examin
histon
acetyl
histon
methyl
dna
methyl
nuclear
local
tnf
alpha
gene
cell
line
primari
cell
stimul
understand
role
epigenet
regul
gene
express
histon
acetyl
alter
model
system
acut
stimul
increas
reproduc
increas
matur
monocyt
artifici
increas
histon
acetyl
set
increas
tnf
alpha
express
other
suggest
histon
acetyl
suffici
transcript
compet
contrast
histon
methyl
increas
compet
cell
inhibit
clearli
impair
product
tnf
alpha
suggest
epigenet
mark
critic
transcript
dna
methyl
correl
compet
produc
tnf
alpha
also
found
development
regul
critic
product
tnf
alpha
lastli
use
fish
defin
locat
tnf
alpha
locu
within
nucleu
human
centromer
probe
use
defin
heterochromatin
tnf
alpha
locu
gener
found
euchromatin
termin
differenti
cell
howev
human
stem
cell
compet
produc
tnf
alpha
tnf
alpha
locu
heterochromatin
data
conclud
tempor
sequenc
event
culmin
transcript
compet
earli
develop
tnf
alpha
gene
exit
heterochromatin
dna
becom
demethyl
monocyt
lineag
cell
undergo
modif
histon
acetyl
accord
matur
state
histon
lysin
methyl
appear
final
event
lead
transcript
compet
tnf
alpha
gene
determin
whether
epigenet
mark
could
alter
inflammatori
diseas
state
investig
patient
system
lupu
erythematosu
sle
evid
alter
chromatin
structur
patient
sle
increas
histon
acetyl
tnf
alpha
locu
monocyt
compar
control
suggest
epigenet
chang
may
particip
diseas
perpetu
conclus
data
support
strong
role
tnf
alpha
epigenet
regul
control
express
power
cytokin
cytokineschemokin
rat
serum
plasma
use
luminex
xmap
technolog
rat
anim
model
use
extens
mani
area
biomed
research
quantif
multipl
cytokin
chemokin
critic
understand
physiolog
patholog
process
inflamm
howev
limit
sampl
avail
high
cost
extra
time
labor
associ
use
multipl
convent
elisa
product
make
impract
measur
multipl
cytokin
chemokin
rat
model
previous
report
immunoassay
panel
rat
cytokin
current
avail
commerci
product
report
expans
multiplex
immunoassay
system
simultan
quantif
differ
rat
cytokin
chemokin
eotaxin
gcsf
gmcsf
grokc
ifng
leptin
rant
tnfa
vegf
singl
serumplasma
sampl
al
volum
methodolog
includ
typic
sandwich
immunoassay
surfac
polystyren
bead
use
specif
immobil
captur
antibodi
biotinyl
detect
antibodi
streptavidinphycoerythrin
report
molecul
luminex
reader
use
quantifi
fluoresc
signal
bead
antibodi
pair
use
individu
analyt
highli
specif
neglig
crossreact
cytokin
chemokin
within
panel
standard
curv
analyt
rang
pgml
overal
sensit
pgml
serum
matrix
assay
robust
demonstr
accept
precis
interassay
cv
intraassay
cv
averag
recoveri
f
linear
sampl
dilut
accuraci
f
serum
matrix
total
assay
time
hour
serumfre
sampl
overnight
serum
plasma
sampl
assay
panel
may
also
use
sampl
cell
cultur
supernat
celltissu
extract
biolog
fluid
simpl
sensit
accur
reproduc
assay
panel
offer
econom
conveni
tool
accur
simultan
quantif
multipl
rat
cytokin
chemokin
biolog
sampl
age
character
declin
function
multipl
physiolog
system
caus
declin
still
unclear
increas
oxid
stress
disturb
energi
metabol
primari
dysregul
immun
system
might
play
import
role
age
peripher
nervou
system
associ
sever
morpholog
function
chang
includ
decreas
nerv
conduct
veloc
chang
contribut
agerelateddeclin
muscl
strength
sensori
discrimin
autonom
respons
therebi
increas
risk
fall
disabl
aim
studi
investig
nerv
conduct
veloc
peripher
nervou
system
correl
immunolog
inflammatori
marker
ageassoci
diseas
measur
motor
nerv
conduct
veloc
right
superfici
peron
nerv
use
standard
neurophysiolog
techniqu
popul
base
sampl
subject
age
year
old
take
part
inchianti
studi
blood
count
standard
biochemistri
assay
sampl
obtain
cytokin
vitamin
e
measur
inchianti
studi
examin
person
live
municip
greve
chianti
bagno
ripoli
two
small
town
locat
surround
florenc
itali
randomli
select
local
popul
registri
subject
enrol
studi
male
femal
averag
ncv
declin
age
men
women
howev
agegroup
ncv
higher
women
men
ageassoci
declin
ncv
linear
histori
diabet
p
b
stroke
p
peripher
arteri
diseas
p
well
presenc
cognit
impair
associ
lower
ncv
even
sex
age
adjust
among
cytokin
consid
signific
associ
peripher
conduct
could
found
ra
tnfa
significantli
lower
ncv
measur
subject
whose
serum
level
p
b
well
solubl
receptor
p
b
lower
tertil
adjust
age
sex
differ
among
group
disappear
p
p
adjust
chang
strength
associ
multivari
analysi
besid
age
height
independ
predictor
nerv
conduct
veloc
includ
diabet
cognit
impair
atocopherol
uric
acid
number
lymphocyt
neutrophil
result
support
hypothesi
inflamm
oxid
damag
involv
age
peripher
nervou
system
independ
ageassoci
diseas
ryusuk
nakagawa
hiroko
abe
mitsuomi
hirashima
akira
yamauchi
cell
regul
kagawa
univers
school
medicin
kitagun
mikicho
kagawa
japan
immunolog
immunopathplog
kagawa
univers
school
medicin
kitagun
mikicho
kitagun
mikicho
japan
galectin
anim
lectin
exhibit
affin
hgalactosid
share
certain
conserv
sequenc
element
date
galectin
clone
mammal
shown
play
modulatori
role
divers
biolog
process
cell
adhes
prolifer
cell
apoptosi
immun
respons
structur
galectin
gal
belong
tandemrepeat
subfamili
character
presenc
two
distinct
carbohydr
recognit
domain
crd
join
linker
peptid
shown
induc
adhes
activ
superoxid
product
neutrophil
possess
eosinophil
chemoattract
activ
well
induc
superoxid
product
prolong
cell
surviv
eosinophil
studi
show
intraperiton
administr
recombin
strongli
induc
neutrophil
accumul
periton
caviti
mice
exhibit
neutrophil
chemoattract
activ
vitro
neutrophil
play
critic
role
innat
immun
respons
complic
bacteri
infect
septic
shock
septic
multipl
organ
dysfunct
syndrom
therefor
determin
whether
galectininduc
neutrophil
contribut
enhanc
septic
shock
examin
function
lpsinduc
lethal
shock
syndrom
known
gener
shwartzman
reaction
elicit
two
consecut
inject
lp
unexpectedli
treatment
first
lp
challeng
increas
mous
surviv
suppress
elev
ifng
tnfa
level
protect
effect
shwartzman
reaction
suppress
cytokin
product
diminish
deplet
neutrophil
use
monoclon
antibodi
furthermor
treatment
mutant
lack
hgalactosid
bind
activ
lp
could
suppress
elev
ifng
tnfa
level
wherea
neutrophil
accumlu
periton
caviti
mice
observ
thu
result
indic
galectin
modifi
variou
cytokin
product
induc
lp
improv
mous
mortal
shwartzman
reaction
via
neutrophil
accumul
taken
togeth
hgalactosid
bind
activ
galectin
requir
modifi
lp
induc
cytokin
product
analysi
cytokin
network
initi
immun
respons
hyperplast
thymu
associ
myasthenia
gravi
kamo
kikuchi
h
tomoyasu
n
sakuragawa
regen
medicin
school
medicin
toho
univers
sagamihara
kanagawa
japan
ultrastracutur
nation
institut
neurosci
kodaira
tokyo
japan
respiratoy
japan
red
cross
ohmori
tokyo
japan
myasthenia
gravi
mg
close
associ
thymic
abnorm
hyperplasia
thymoma
unlik
experiment
mg
thymectomi
effect
reliev
symptom
particular
hyperplast
thymu
contain
mani
express
bcell
includ
antiachr
antibodi
produc
bcell
suggest
develop
influenc
hyperplast
circumst
rather
simpli
accumul
peripheri
reservoir
present
studi
aim
analyz
thymic
environ
induct
bcell
respons
mg
thymi
use
examin
potenti
product
tcell
cytokin
regulatori
bcell
respons
analysi
bcell
stimulatori
mechan
nude
mous
splenocyt
variou
cytokin
detect
mg
thymu
use
hyperplast
thymi
associ
mg
produc
cell
ifng
produc
cell
exclus
detect
suggest
convent
matur
cell
exclus
produc
ifng
involv
less
extent
thymic
product
found
myoid
cell
condit
medium
provid
circumst
thymic
splenic
lymphocyt
produc
also
found
mani
precursor
myoid
cell
produc
haemopoiet
biglycan
achr
cell
subset
two
factor
cytokin
produc
myoid
cell
significantli
stimul
bcell
respons
synergist
fashion
result
suggest
hyperplast
mg
thymu
contain
altern
immunostimulatori
environ
may
play
import
role
breakag
anerg
state
achr
chernobyl
cleanup
worker
latvia
statement
exposur
ioniz
radiat
acceler
age
process
disput
latest
investig
confirm
age
associ
increas
inflammatori
activ
reflect
increas
level
circul
proinflammatori
cytokin
chronic
lowgrad
inflamm
follow
impair
immun
system
function
age
promot
develop
agerel
diseas
cancer
degen
infect
diseas
way
increas
inflammatori
activ
observ
radiat
exposur
cytokin
proinflammatori
also
known
particip
age
process
approxim
latviat
men
affect
ioniz
radiat
work
chernobyl
clean
aftereffect
chernobyl
power
plant
accid
morbid
increas
progress
among
year
year
significantli
exceed
popul
aim
present
work
evalu
product
sever
cytokin
peripher
blood
cell
individu
particip
cleanup
work
chernobyl
nuclear
power
plant
explos
aftereffect
depend
age
materi
method
elisa
measur
plasma
concentr
well
level
spontan
stimul
lp
pha
mitogen
peripher
blood
mononuclear
cell
cultur
supernat
determin
chernobyl
cleanup
worker
year
work
chernobyl
blooddonor
without
histori
occup
radiat
exposur
abil
peripher
blood
leukocyt
pbl
produc
ifn
determin
chernobyl
cleanup
worker
year
work
chernobyl
age
match
blooddonor
ifn
test
whole
blood
cultur
standard
viru
cytopath
inhibit
micromethod
vitro
induct
newcastl
diseas
viru
phytohemagglutinin
doublestrand
rna
individu
divid
age
group
firstag
secondag
result
abil
pbl
produc
ifn
significantli
decreas
chernobyl
cleanup
worker
age
group
comparison
blooddonor
control
group
incid
inabl
produc
ifn
nd
chernobyl
cleanup
worker
group
two
time
exce
st
p
b
concentr
significantli
higher
nd
age
group
product
well
peripher
blood
mononuclear
cell
show
signific
differ
age
group
chernobyl
cleanup
worker
donor
conclus
increas
concentr
proinflamm
cytokin
togeth
significantli
impair
antivir
defens
decreas
abil
pbl
produc
ifn
chernobyl
cleanup
worker
latvia
age
depend
spinal
cord
injuri
sci
consist
two
phase
instantan
cellular
destruct
axon
damag
caus
initi
mechan
trauma
follow
progress
injuri
term
bsecondari
injuri
q
result
exposur
surround
tissu
excitatori
amino
acid
cytokin
oxid
metabolit
cellular
debri
invad
immun
cell
known
increas
cyclic
adenosin
monophosph
camp
potent
suppress
effect
proinflammatori
action
immun
respons
critic
compon
secondari
injuri
tumor
necrosi
factora
tnfa
central
proinflammatori
cytokin
known
activ
sci
import
trigger
cell
death
neg
regul
camp
elev
camp
modul
tnfa
express
investig
studi
previou
work
perform
lab
shown
administr
rolipram
phosphodiesteras
inhibitor
pharmacolog
agent
capabl
elev
intracellular
level
camp
increas
number
spare
oligodendrocytemyelin
axon
sci
overal
goal
current
studi
elucid
put
mechan
rolipram
affect
tnfa
initi
signal
event
mediat
axopatholog
cell
death
follow
spinal
cord
injuri
femal
fischer
rat
underw
moder
contus
injuri
subsequ
rolipram
vehicl
treatment
anim
sacrif
differ
interv
injuri
accord
known
tnfa
peak
express
point
elisa
test
control
untreat
tissu
comparison
rolipram
treat
demonstr
rolipram
reduc
tnfa
product
sci
compar
vehicl
control
express
tnfa
larg
control
autoregulatori
loop
via
transcript
factor
nuclear
factor
kappa
b
nfkb
heteroor
homodimer
complex
differ
subunit
previous
demonstr
potenti
shift
balanc
nfkb
dimer
increas
homodim
caus
transcript
repress
culmin
reduc
express
tnfa
bohuslav
et
al
j
clin
invest
current
studi
role
transcript
control
mechan
roliprammedi
tnfa
inhibit
explor
western
blot
injur
spinal
cord
rolipram
vehicl
treat
anim
taken
hour
injuri
probe
subunit
nfkb
result
show
product
greatli
increas
injur
spinal
cord
rolipram
treat
anim
furthermor
rolipram
treat
anim
also
found
increas
transloc
catalyt
protein
kinas
pka
subunit
nucleu
propos
elev
level
camp
downstream
activ
pka
rolipram
treatment
lead
interact
pka
transcript
control
level
tnfa
alter
balanc
nfkb
subunitmedi
activ
repress
tnfa
promot
investig
interact
may
lead
novel
neuroprotect
therapi
spinal
cord
injuri
repair
analysi
express
ebvand
lymphoma
heterogen
express
subunit
tumor
cell
novel
heterodimer
cytokin
famili
compos
two
subunit
epsteinbarr
viru
ebv
induc
gene
express
high
level
ebvtransform
b
cell
line
induc
vitro
ebv
oncogen
nfkappab
depend
manner
show
express
upregul
cell
line
depend
leukem
cell
adultt
cell
leukemialymphoma
atl
patient
compar
normal
activ
cell
express
decreas
cell
treatment
inhibitor
nfkappab
induc
jurkat
cell
express
wildtyp
tax
oncoprotein
tax
mutant
defect
nfkappab
activ
situ
analysi
express
hodgkint
lymphoma
hl
variou
ebvassoci
lymphoprolif
disord
lpd
includ
posttranspl
lpd
nasaltyp
nktcell
lymphoma
atl
show
express
neoplast
cell
case
hl
ebvassoci
lpd
variabl
level
atl
case
rare
control
tcell
lymphoma
contrast
lymphoma
test
tumor
cell
express
consist
data
signific
express
detect
hlderiv
cell
line
ebvor
cell
line
select
overexpress
transform
cell
suggest
may
play
role
independ
associ
regul
antivir
antitumor
immun
respons
inappropri
cytokin
product
trigger
varieti
alloor
autoimmun
diseas
particularli
true
organ
transplant
immunosuppressor
like
cyclosporin
revolution
field
part
action
drug
function
peptidylpropyl
isomeras
ppias
inhibitor
third
member
ppias
famili
implic
cellcycl
progress
function
cytokin
express
investig
studi
analyz
role
cytokin
express
human
peripher
blood
mononuclear
cell
pbmc
pbmc
normal
donor
activ
pha
plu
pma
plu
inhibit
vari
concentr
juglon
irrevers
activ
site
inhibitor
juglon
strongli
inhibit
inhibit
gmcsf
tnfa
mrna
level
activ
pbmc
concentr
low
juglon
still
reduc
gmcsf
tnfa
mrna
respect
littl
effect
order
demonstr
role
cytokin
mrna
regul
transduc
ww
domain
pbmc
ww
domain
affect
interact
prevent
function
domin
neg
decreas
gmcsf
mrna
accumul
mrna
level
remain
unchang
data
suggest
critic
mitogeninduc
elabor
cytokin
inhibit
mayb
power
immunosuppress
tracheobronchi
aspir
tba
newborn
suffer
intrauterin
pneumonia
high
level
h
tnfa
p
b
determin
high
level
proinflammatori
cytokin
accompani
elev
time
neutrophil
elastas
ne
time
neutrophil
myeloperoxydas
mpo
level
studi
enzym
control
f
ngml
f
mgml
respect
group
patient
treat
includ
tradit
therapi
endotrach
intraven
infus
recombin
broncoleukinqbiotech
russia
durat
lung
mechan
ventil
period
newborn
group
decreas
time
p
b
comparison
tradit
treat
patient
group
b
durat
antibacteri
therapi
reduc
time
p
b
hospit
periodin
time
death
ratein
time
th
day
therapi
signific
decreas
tnfa
level
notic
patient
group
concentr
h
time
higher
tradit
treat
group
ne
level
decreas
f
ngml
f
ngmlin
group
b
mpo
also
decreas
control
group
f
mgl
f
mgl
accordingli
day
monitor
cytokinet
enzymet
spectrum
tba
treat
newborn
dose
differ
healthi
babi
level
control
group
remain
high
cytokin
anticytokin
therapi
sever
acut
pancreat
chooklin
perejaslov
depart
surgeri
medic
univers
lviv
ukrain
recent
studi
show
import
role
cytokin
pathophysiolog
acut
pancreat
increas
level
proinflammatori
cytokin
determin
progress
diseas
develop
system
complic
imbal
proand
antiinflammatori
cytokin
may
play
pivot
role
develop
septic
complic
sever
cours
acut
pancreat
serum
level
interleukin
il
antagonist
tumor
necrosi
factor
tnfalpha
lymphocyt
studi
patient
acut
pancreat
increas
level
proinflammatori
cytokin
time
admiss
note
patient
highest
level
cytokin
patient
sever
cours
diseas
initi
level
antiinflammatori
cytokin
higher
patient
mild
pancreat
compar
sever
develop
septic
complic
accompani
rapid
overexpress
chang
express
patient
septic
complic
may
explain
inhibit
bactericid
function
neutrophil
develop
purulentsept
complic
increas
other
antiinflammatori
cytokin
observ
combin
persist
imbal
immunoregulatori
tlymphocyt
suppress
predomin
good
result
receiv
applic
anticytokin
therapi
pentoxifyllin
dexamethason
initi
stage
diseas
remot
period
indic
applic
immunoregulatori
cytokin
interleukin
thu
therapi
direct
correct
cytokin
statu
perspect
acut
pancreat
j
roger
perkin
van
olphen
n
burdash
w
klein
h
friedman
medic
microbiolog
immunolog
univers
south
florida
colleg
medicin
tampa
fl
usa
dendrit
cell
dc
import
monocyt
phagocyt
essenti
innat
immun
especi
opportunist
intracellular
microorgan
like
legionella
pneumophila
studi
dc
stimul
vitro
either
infect
legionella
microbi
stimul
lp
e
coli
mdp
gram
posit
bacteria
product
helper
cell
activ
cytokin
proinflammatori
cytokin
tnfa
rapidli
induc
cytokin
import
antimicrobi
immun
assess
dc
cultur
elisa
assay
treatment
stimul
dc
egcg
primari
polyphenol
catechin
plant
product
inhibit
dose
depend
manner
product
import
activ
immun
cell
intracellular
bacteria
like
legionella
contrast
treatment
dc
egcg
enhanc
product
tnfa
dose
depend
manner
tnfa
import
inflamm
consid
crucial
inflammatori
respons
thu
result
studi
show
egcg
major
catechin
wide
present
plant
product
green
tea
mark
effect
product
immunoregulatori
cytokin
stimul
dc
known
involv
antimicrobi
immun
especi
innat
immun
studi
warrant
determin
mechan
effect
catechin
cytokin
product
immun
cell
dc
protein
secret
product
tnfstimul
gene
import
endogen
mediat
inflamm
femal
fertil
previou
studi
shown
protect
effect
murin
model
experiment
induc
arthriti
mechan
respons
effect
remain
elus
gain
insight
role
investig
whether
protein
affect
express
induc
key
enzym
inflamm
immun
respons
found
protein
upregul
protein
express
raw
murin
macrophag
cell
line
effect
abolish
heat
denatur
trypsin
digest
specif
antibodi
treatment
cell
also
result
rapid
increas
mrna
level
suggest
upregul
gene
express
upregul
accompani
increas
biosynthesi
prostaglandin
predomin
pgd
pgd
metabolit
pgj
act
neg
regul
inflamm
activ
nuclear
peroxisom
prolifer
activ
receptorg
inhibit
multipl
step
nuclear
factornb
signal
pathway
thu
induct
express
macrophag
preferenti
pgd
synthesi
may
underli
protect
effect
observ
experiment
model
arthriti
hyaluronan
molecul
interact
modul
activ
protein
work
provid
first
demonstr
influenc
express
gene
regul
inflamm
cell
cultur
system
may
help
gain
better
understand
physiolog
pathophysiolog
function
result
gene
introduc
success
mous
gastric
carcinoma
cell
line
mfc
oncogen
cell
obvious
lower
mfc
pmkitneo
cell
wildtyp
mfc
cell
peripher
blood
nk
cell
cell
mice
inocul
cell
notabl
mice
inocul
mfc
pmkitneo
cell
mfc
cell
cell
differ
compar
inject
cell
conclus
oncogen
cell
distinctli
declin
induc
prolifer
nk
cell
cell
tumorbear
mice
studi
provid
experiment
basi
develop
genemodifi
tumor
vaccin
object
evalu
effect
gene
modifi
murin
colon
carcinoma
cell
vaccin
macrophag
cell
materi
method
lxsn
transfect
vector
cell
treat
mitomycin
c
prepar
tumor
cell
vaccin
balbc
mice
immun
vaccin
ip
inject
griess
assay
use
detect
level
periton
macrophag
prolifer
macrophag
splenic
cell
determin
use
h
tdr
incorpor
method
macrophag
mediat
tumor
cytotox
ctl
activ
assess
radioact
h
tdr
releas
assay
ldh
assay
respect
surviv
mice
ip
immun
vaccin
also
observ
result
cytotox
macrophag
ctl
activ
tumor
enhanc
mice
ip
immun
vaccin
level
secret
macrophag
mice
inject
vaccin
higher
control
vaccin
also
promot
prolifer
macrophag
splenic
cell
increas
surviv
time
mice
challeng
wild
cell
conclus
gene
modifi
tumor
vaccin
activ
macrophag
cell
also
antitumor
effect
object
examin
whether
express
murin
colon
carcinoma
cell
could
induc
murin
macrophag
secret
tnfa
materi
method
normal
balbc
mice
inject
ip
transfect
vector
cell
respect
day
cell
implant
periton
macrophag
prepar
lavag
hbss
collect
adher
cell
nma
n
gmonomethyllarginin
lp
inhibit
induc
product
respect
product
determin
griess
assay
level
tnfa
detect
elisa
mice
use
observ
surviv
result
level
tnfa
produc
macrophag
mice
inject
cell
higher
control
mice
timepoint
nwa
inhibit
product
group
product
tnfa
lp
stimul
macrophag
mice
inject
cell
control
group
level
macrophag
mice
inject
cell
similar
control
averag
surviv
time
mice
inject
cell
longer
control
group
express
murin
colon
carcinoma
cell
induc
murin
macrophag
secret
higher
level
tnfa
antitumor
effect
object
studi
peripher
cell
homeostasi
accomplish
balanc
prolifer
apoptosi
essenti
establish
prompt
immun
respons
time
avoid
hypersensit
reaction
immunemedi
diseas
lymphoprolif
disord
apoptosi
control
via
two
differ
pathway
antigen
stimul
induc
fasdepend
cell
death
call
activationinduc
cell
death
aicd
wherea
absenc
surviv
signal
lead
activ
cell
autonom
death
acad
human
adenotonsillar
cell
critic
locat
point
entri
foreign
inhal
digest
antigen
pharynx
popul
includ
cell
show
express
activ
antigen
use
vivo
activ
adenotonsillar
cell
model
studi
homeostasi
peripher
cell
materi
method
adenotonsillar
tissu
sampl
obtain
children
age
year
underw
surgeri
adenotonsillar
hyperplasia
infect
naiv
phenotyp
memori
phenotyp
cell
purifi
homogen
tissu
ficol
centrifug
use
antibodi
conjug
magnet
bead
stimul
cell
tcr
cell
incub
differ
concentr
antibodi
involv
fasfasl
interact
determin
use
fasl
antibodi
recombin
fa
protein
inhibit
apoptosi
cell
treat
cytokin
apoptosi
detect
analyz
phosphatidylserin
transloc
dna
degrad
activ
result
adenotonsillar
naiv
phenotyp
memori
phenotyp
cell
express
high
level
activ
antigen
cell
cell
sensit
fasdepend
apoptosi
upon
stimul
high
concentr
antibodi
cell
suscept
rapid
spontan
apoptosi
vitro
could
partial
inhibit
cytokin
bind
cytokin
receptor
common
gamma
chain
chemokin
interf
fasfasl
engag
tcr
signal
elimin
reactiv
oxygen
speci
synthet
superoxid
dismutas
mimet
conclus
apoptosi
adenoid
naiv
phenotyp
cell
could
induc
high
concentr
antitcr
antibodi
fasdepend
thu
resembl
aicdtyp
cell
death
apoptosi
cell
reminisc
acadtyp
cell
death
could
inhibit
variou
cytokin
fa
tcr
depend
therebi
homeostasi
peripher
human
cell
first
achiev
delet
naiv
cell
high
concentr
antigen
autoantigen
nutrient
magnitud
immun
respons
finetun
variou
cytokin
inhibit
death
activ
memori
phenotyp
cell
ilya
sotnikov
liora
cahalon
ode
vaina
rinat
eshel
benzion
katz
neta
ilan
israel
vlodavski
irun
cohen
ofer
lider
immunolog
weizmann
institut
scienc
rehovot
israel
bone
marrow
transplant
hematolog
institut
souraski
medic
center
telaviv
israel
oncolog
hadassahhebrew
univers
hospit
jerusalem
israel
cours
inflammatori
respons
immun
cell
need
acquir
direct
migrat
phenotyp
done
mean
degrad
extracellular
mesh
enzym
promot
adhes
migrat
cell
activ
molecul
cytokin
one
enzym
heparanas
heparan
sulfat
specif
endoglycosidas
secret
immun
cell
combin
cytokinelik
properti
convent
enzymat
activ
upon
acidif
cellular
environ
heparanas
degrad
sugar
chain
wherea
basic
ph
increas
adhes
cell
extracellular
matrix
promot
movement
along
chemokin
gradient
given
versatil
function
molecul
find
prerequisit
gene
express
regul
import
major
goal
investig
induc
heparanas
gene
transcript
primari
human
tcell
respons
exogen
signal
work
util
pure
tcell
deriv
healthi
human
donor
activ
use
tnfa
major
proinflammatori
cytokin
deliv
stress
signal
cell
bear
tnf
receptor
influenc
transcript
program
tcell
expos
solubl
tnfa
cytokin
first
precomplex
fibronectin
cell
place
immobil
tnfa
measur
heparanas
mrna
level
protein
content
cell
lysat
use
realtim
quantit
pcr
heparanas
enzymat
assay
respect
cytokin
solubl
fibronectinimmobil
form
promot
accumul
heparanas
mrna
protein
strictli
defin
timeand
concentrationdepend
manner
assess
intracellular
signal
pathway
involv
tnfainduc
signal
transduct
necessari
heparanas
gene
transcript
use
chemic
compon
known
inhibit
key
player
signal
transduct
cascad
initi
tnf
receptor
ligat
show
heparanas
mrna
accumul
depend
pkc
jnk
signal
cascad
wherea
influenc
nfkb
erk
strengthen
notion
specif
tnfa
signal
also
demonstr
first
time
strong
correl
effect
activ
tnfa
concentr
upregul
relev
transcript
factor
measur
immunoblot
heparanas
mrna
accumul
final
show
effect
reproduc
although
limit
degre
member
tnf
superfamili
fasl
trail
suggest
involv
intracellular
signal
compon
share
ligand
conclus
claim
heparanas
import
agent
autoregulatori
loop
inflammatori
lesion
respons
signal
deliv
common
stress
signal
tnfa
serum
essenti
freez
test
human
pbmc
serum
contain
plethora
bioactiv
molecul
whose
variabl
concentr
make
everi
serum
batch
uniqu
uniqu
affect
cell
perform
vitro
develop
serum
free
protocol
freez
pbmc
thaw
pbmc
display
n
viabil
regardless
whether
frozen
serum
serum
free
moreov
thaw
pbmc
maintain
full
function
compar
fresh
cell
test
elispot
assay
panel
individu
peptid
protein
recal
antigen
recogn
cell
respect
strikingli
pbmc
perform
frequent
better
serum
free
condit
increas
number
cytokin
produc
cell
elicit
recal
antigen
without
increas
activ
medium
control
magnitud
signal
enhanc
serum
free
condit
consider
larger
inclus
costimulatori
antibodi
appar
serum
contain
suppress
factor
tgfbeta
interfer
cell
activ
thu
serum
free
freez
test
media
conveni
altern
bypass
need
screen
boptimialq
serum
batch
also
media
enhanc
standard
cell
monitor
introduct
hepat
c
viru
hcv
infect
lead
caus
chronic
liver
diseas
us
affect
approxim
million
peopl
impact
healthcarerel
cost
enorm
million
spent
annual
loss
work
medic
cost
immun
mechan
lead
chronic
liver
damag
cirrhosi
hepat
c
elucid
increasingli
attribut
nonapoptot
unschedul
cell
death
releas
varieti
damp
includ
uric
acid
protein
heat
shock
protein
act
cytokin
like
role
special
immunoglobulin
type
receptor
includ
rage
highli
conserv
nuclear
protein
surpris
extracellular
role
bind
dna
increas
access
transcript
factor
also
recruit
cell
across
endotheli
barrier
promot
local
product
tnf
ifng
releas
necrot
cell
activ
macrophag
nk
cell
matur
dc
neutrophil
follow
dna
damag
result
apoptot
death
ultraviolet
irradi
platin
sequest
nucleu
detect
serum
tissu
serv
leaderless
cytokin
prototyp
damp
drive
repair
previous
underappreci
role
inflamm
result
measur
highli
sensit
sandwich
elisa
develop
laboratori
correl
serum
analyt
includ
alt
ast
total
bilirubin
albumin
pretranspl
detect
serum
patient
evalu
rang
ngml
includ
three
pt
hepatoma
evalu
whether
correl
diseas
activ
baselin
month
followup
presenc
hepatoma
histolog
activ
index
hai
reject
activ
index
stage
degre
fibrosi
highest
associ
largest
hai
signific
p
pearson
correl
associ
follow
orthotop
liver
transplant
level
diminish
n
median
ratio
compar
baselin
p
b
n
median
ratio
p
b
one
pt
baselin
level
hepatoma
increas
post
transplant
reevalu
recurr
conclus
conclud
repres
independ
measur
tissu
damag
injuri
well
cancer
may
use
assess
patient
hcv
infect
control
activ
releas
approach
develop
experiment
therapi
patient
sepsi
arthriti
cancer
inflammatori
disord
f
e
gonzalez
catalan
j
c
aguillon
rational
periodont
includ
broad
spectrum
immunoinflammatori
respons
periodont
pathogen
oral
biofilm
destroy
support
tissu
teeth
patholog
balanc
pro
antiinflamm
tip
proinflammatori
activ
mediat
cytokin
includ
tnfa
object
explor
relationship
tnfa
express
aggress
periodont
ap
condit
chilean
patient
method
recruit
individu
ap
control
subject
cytokin
express
blood
cultur
stimul
lp
e
coli
p
gingivali
extract
tnfa
measur
ultrasensit
elisa
kit
result
lpsinduc
tnfa
level
ap
patient
higher
control
p
mean
serum
tnfa
concentr
patient
group
time
higher
found
control
p
although
signific
highest
mean
lpsinduc
level
obtain
ap
group
conclus
mononuclear
cell
ap
patient
express
higher
induc
tnfa
level
healthi
individu
ex
vivo
cultur
system
interleukin
il
discov
belong
famili
cytokin
whose
member
addit
structur
relat
molecul
previous
shown
mainli
produc
activ
cell
particularli
subset
data
present
surprisingli
show
unlik
act
immun
cell
conclus
base
systemat
studi
possibl
level
analysi
receptor
express
signal
transduct
effect
vitro
effect
vivo
contrast
quantit
analys
wide
rang
tissu
correspond
primari
cell
cell
line
show
mani
nonimmun
tissu
cell
target
express
chain
receptor
complex
high
level
receptor
chain
found
skin
keratinocyt
primari
human
keratinocyt
level
upregul
ifng
suggest
increas
sensit
cell
toward
action
condit
receptor
complex
cell
function
induc
tyrosin
phosphoryl
first
time
studi
also
identifi
effect
keratinocyt
name
upregul
antimicrobi
agent
bdefensin
bdefensin
effect
transcript
regul
independ
protein
de
novo
synthesi
altern
protein
secret
indic
direct
effect
addit
induct
timeand
dosedepend
enhanc
upon
cellular
differenti
extent
induct
compar
known
induc
bdefensin
skin
patient
psoriasi
high
level
highli
significantli
associ
strongli
upregul
express
suggest
protect
effect
disord
taken
togeth
serv
commun
immun
cell
cell
mediat
directli
promot
innat
nonspecif
immun
skinth
observ
activ
cell
directli
regul
nonspecif
immun
defens
tissu
demonstr
far
unknown
import
side
immun
system
human
b
cell
product
thought
differ
mous
respect
requir
mice
increas
vitro
product
b
cell
adult
murin
bone
marrow
fold
contrast
human
studi
focus
b
lymphopoiesi
fetal
precursor
show
littl
increas
b
cell
product
fold
reexamin
knockout
mice
shown
requir
gener
adultderiv
cell
product
fetallyderiv
cell
examin
role
human
b
cell
develop
hematopoiet
stem
cell
hsc
isol
human
umbil
cord
blood
cb
sourc
like
contain
hsc
give
rise
cell
well
capabl
gener
cell
fac
analysi
human
cb
show
mutual
exclus
express
prob
cell
facssort
cb
hsc
place
stromal
cell
cocultur
addit
increas
vitro
product
human
b
lineag
cell
compar
cultur
neutral
antibodi
increas
observ
human
stroma
murin
stromal
cell
line
titrat
cocultur
show
threshold
increas
human
b
cell
product
fold
lower
cocultur
human
stroma
compar
murin
stroma
surprisingli
murin
stromal
cell
provid
better
support
human
b
cell
product
absenc
murin
human
activ
data
show
presenc
human
stroma
dramat
impact
b
cell
product
least
subset
progenitor
human
cb
hand
murin
stroma
support
b
cell
product
human
cb
progenitor
use
annex
stain
examin
extent
prolifer
andor
antiapoptot
effect
prob
preb
stage
contribut
effect
seen
vitro
studi
suggest
role
human
murin
b
cell
develop
may
similar
previous
believ
remodel
object
function
polymorph
chemokin
receptor
cx
recent
associ
protect
coronari
arteri
diseas
cad
intern
carotid
arteri
ica
occlus
diseas
man
cx
function
express
monocyt
vascular
smooth
muscl
cell
vsmc
cell
type
critic
vascular
remodel
found
atherosclerosi
angioplast
restenosi
ica
occlus
diseas
object
studi
investig
whether
cx
involv
inflammatori
process
vascular
remodel
mechan
may
play
role
method
femor
arteri
cx
wild
type
mice
subject
injuri
passag
angioplasti
guidewir
sham
oper
day
mice
euthan
perfus
paraformaldehyd
tissu
harvest
immunohistochemistri
case
mice
inject
bromodeoxyuridin
brdu
hour
prior
tissu
harvest
cell
prolifer
studi
result
cx
defici
result
protect
vascular
remodel
follow
guidewireinduc
injuri
incid
vascular
inflamm
remodel
decreas
cx
mice
vs
wt
p
injur
arteri
wt
mice
mark
monocyt
infiltr
intima
compar
noninjur
arteri
control
side
anim
f
vs
f
p
wt
injur
arteri
neointim
hyperplasia
mixtur
monocyt
vsmc
intim
hyperplasia
compris
primarili
vsmc
averag
intima
media
ratio
im
f
compar
noninjur
arteri
p
cx
mice
detect
monocyt
invas
intima
decreas
compar
wt
p
decreas
number
monocyt
intima
intima
area
decreas
cx
mice
compar
wt
mice
p
concomit
decreas
number
vsmc
intima
p
expect
number
vsmc
media
declin
injuri
respons
wt
anim
declin
p
remain
unchang
media
cx
mice
declin
p
percentag
activ
prolifer
cell
injur
vessel
also
decreas
cx
mice
vs
wt
p
conclus
cx
play
critic
role
vascular
remodel
follow
femor
arteri
injuri
one
primari
mechan
involv
monocyt
recruit
andor
retent
within
injur
vessel
intima
although
vsmc
defect
seen
downstream
monocyt
defect
observ
rule
possibl
contribut
cx
prolifer
mediatointima
migrat
vsmc
cours
vascular
remodel
gener
assum
mammalian
gene
transcrib
allel
situat
clear
sever
gene
transcript
behavior
gener
gene
group
differ
class
imprint
gene
b
gene
x
chromosom
femal
cell
c
autosom
gene
stochast
monoallel
transcrib
interleukin
multifunct
cytokin
activ
array
classic
inhibit
effector
function
lymphocyt
monocyt
macrophag
regul
growth
differenti
b
lymphocyt
dendrit
cell
recent
key
role
differenti
function
regulatori
cell
year
sinc
first
describ
studi
aim
biolog
function
address
genet
regul
make
use
ki
mice
transcript
differ
allel
easili
distinguish
observ
show
pseudomonoallel
transcript
pattern
cell
cell
express
stochast
one
allel
transcrib
allel
exclus
case
seem
take
place
bia
toward
biallel
express
obtain
increas
tcr
signal
propos
pseudomonoallel
express
reflect
tightli
control
low
frequenc
express
gene
also
show
chromatin
appear
play
major
role
regul
process
thu
least
two
level
regul
seem
implic
bona
fide
regul
express
tcr
signal
activ
transcript
factor
regul
chromatin
open
seem
act
togeth
provid
effici
control
express
think
twolay
regul
might
reveal
extrem
import
mechan
control
genet
express
biolog
situat
low
frequenc
express
gene
might
appli
mani
gene
one
studi
far
one
main
mediat
involv
control
inflamm
acut
phase
respons
famili
molecul
regul
tissu
repair
inflammatori
immun
reaction
import
question
biolog
today
use
pleiotrop
highli
biolog
activ
molecul
therapi
variou
human
diseas
system
administr
induc
advers
effect
limit
therapeut
use
promis
local
applic
lesion
inflammatori
site
human
recombin
beta
use
local
therapi
patient
chronic
bacteri
purul
rhinosinus
failur
routin
antibiot
therapi
beta
solut
applic
ngml
directli
inflammatori
site
daili
day
led
clinic
improv
treat
patient
endogen
beta
receptor
antagonist
ex
vivo
product
gene
polymorph
studi
distribut
allel
perform
patient
patient
rare
allel
elev
beta
product
patient
vntr
allel
higher
antagonist
product
compar
patient
bear
normal
allel
abnorm
allel
found
patient
respect
much
frequent
compar
healthi
subject
suggest
genet
predisposit
chronic
rhinosinus
probabl
due
disregul
famili
cytokin
product
found
recombin
therapi
highli
effect
patient
carri
vntr
allel
increas
endogen
level
patient
beta
local
applic
significantli
increas
function
activ
leukocyt
isol
inflammatori
site
test
assay
neutrophil
migrat
fmlp
superoxid
product
adhes
phagocytosi
cytolog
analysi
show
reduct
inflammatori
manifest
accompani
decreas
proport
neutrophil
increas
number
monocytesmacrophag
neg
result
beta
therapi
obtain
patient
rare
combin
homozyg
normal
vntr
allel
variant
led
elev
beta
product
normal
level
accord
obtain
result
famili
cytokin
gene
polymorph
link
chronic
rhinosinus
may
influenc
result
cytokin
immunotherapi
background
hypersensit
pneumon
hp
complex
lung
syndrom
vari
intens
clinic
present
result
immunologicallyinduc
inflamm
respons
larg
varieti
inhal
antigen
hp
may
present
acut
subacut
chronic
form
hp
character
remark
tcell
alveol
howev
evalu
lymphocyt
phenotyp
primarili
cell
subset
given
inconsist
result
likewis
studi
tcell
phenotyp
human
hp
like
thelper
versu
scanti
hypothes
diverg
tcell
subset
may
play
role
analyz
varieti
tlymphocyt
phenotyp
cell
obtain
bronchoalveolar
lavag
subacut
chronic
patient
method
forti
one
patient
hp
induc
avian
antigen
classifi
subacut
patient
chronic
patient
healthi
subjectshp
bal
cell
stain
mab
surfac
stain
intracellular
ifng
antigen
specif
secret
ifng
follow
pigeon
serum
stimul
determin
cba
use
identifi
specif
subpopul
order
precis
best
cut
point
ratio
analysi
sensit
versu
roc
curv
use
test
higher
sensit
lower
consid
use
result
bal
ratio
highli
heterogen
although
higher
level
reveal
patient
exhibit
chronic
hp
result
reach
statist
signific
f
versu
f
f
subacut
patient
control
respect
howev
chronic
patient
show
valu
compar
subacut
patient
roc
curv
show
ratio
best
cut
point
separ
chronic
subacut
case
display
sensit
specif
posit
predict
valu
neg
predict
valu
signific
differ
receptor
chemokin
express
notic
thu
subacut
patient
exhibit
significantli
higher
number
tcell
express
f
versu
f
chronic
case
contrast
higher
express
chronic
patient
f
versu
subacut
f
intracellular
ratio
significantli
higher
subacut
patient
f
versu
chronic
f
antigen
specif
stimul
also
ifng
ratio
measur
supernat
cultur
significantli
higher
subacut
patient
f
versu
chronic
f
result
reveal
sever
differ
chronic
patient
compar
subacut
patient
includ
increas
ratio
increas
respons
background
chemokin
receptor
use
previou
studi
combin
antigen
tool
defin
differ
popul
memori
lymphocyt
differ
home
function
capac
differ
stage
differenti
use
approach
four
popul
memori
lymphocyt
defin
patient
subacut
chronic
hypersensit
pneumon
hp
bronchoalveolar
lavag
blood
follow
pattern
differenti
cell
demonstr
ccr
method
peripher
blood
mononuclear
cell
pbmc
bronchoalveolar
lavag
cell
balc
obtain
subacut
chronic
hp
patient
stain
mab
secret
ifng
follow
specif
stimul
determin
antigenspecif
lymphocyt
use
identifi
specif
effector
cell
result
memori
blood
lymphocyt
equal
compos
pretermin
differenti
subacut
f
chronic
f
vs
control
f
p
b
termin
differenti
subacut
f
chronic
f
vs
control
f
subacut
chronic
patient
contrast
blood
cell
compos
pretermin
differenti
subacut
f
chronic
f
vs
control
f
p
b
higher
proport
termin
diferenti
memori
lymphocyt
subacut
f
chronic
f
vs
control
f
background
natur
killer
cell
nk
play
pivot
role
innat
immun
respons
control
tumour
infectionrel
respons
cytolyt
activ
nk
cell
control
array
activ
inhibitori
cell
surfac
receptor
includ
killer
immunoglobulinlik
receptor
kir
group
common
haplotyp
group
call
b
cytokin
chang
occur
age
wonder
whether
chang
serum
cytokin
relat
group
b
kir
haplotyp
method
kir
haplotyp
avail
subject
belfast
elderli
longitudin
freeliv
age
studi
belfast
match
subset
correspond
serum
cytokin
result
subject
categor
kir
haplotyp
associ
activ
show
increas
serum
cytokin
valu
proinflammatori
cytokin
tnfa
well
increas
valu
antiinflammatori
cytokin
tnfb
appar
sexrel
differ
conclus
kir
haplotyp
b
octononagenarian
track
activ
statu
relat
cytokin
could
effector
tumour
infectionrel
respons
immunerel
chang
age
sardar
sindhu
maud
loignon
evalu
h
h
cytokin
modul
import
determin
immun
compet
andor
restor
chronic
hiv
patient
undergo
initi
highli
activ
antiretrovir
therapi
haart
intensif
gmcsf
hydroxyurea
ddi
therapeut
vaccin
remun
tm
structur
treatment
interrupt
sti
evalu
serum
level
interferon
ifn
gamma
interleukin
il
tumor
necrosi
factor
tnf
alpha
patient
enrol
canadian
hiv
pilot
studi
patient
virem
control
ie
viru
load
vl
b
copi
ml
time
baselin
sampl
nine
sampl
point
baselin
haartintensif
therapeut
vaccin
st
peak
vl
rebound
sti
st
b
vl
nd
peak
vl
nd
b
vl
rd
peak
vl
rd
b
vl
respect
cytokin
measur
competit
enzymelink
immunosorb
assay
elisa
differ
group
mean
given
timepoint
baselin
determin
ttest
found
ifngamma
level
compar
baselin
valu
pg
ml
time
point
except
nd
peak
vl
nd
b
vl
sampl
level
significantli
reduc
level
elev
significantli
p
b
st
time
vl
copi
ml
compar
baselin
valu
pg
ml
high
level
higher
agematch
hivseroneg
control
sustain
thereaft
convers
level
reduc
significantli
st
time
vl
b
copi
ml
baselin
concentr
pg
ml
low
level
maintain
subsequ
time
point
regard
tnfalpha
modul
found
statist
nonsignific
p
n
compar
baselin
mean
concentr
pg
ml
pg
ml
respect
howev
level
compar
baselin
concentr
pg
ml
higher
control
st
time
vl
b
copi
ml
level
significantli
reduc
thereaft
therefor
conclud
immunomodulatori
therapeut
intervent
abl
inducemaintain
h
cytokin
profil
patient
wherea
suppress
level
nd
peak
vl
thereaft
might
due
deregul
innat
immun
respons
monocyt
locomot
inhibitori
factor
mlif
could
contribut
spars
delay
inflamm
observ
ameb
abscess
liver
either
directli
effect
upon
mp
ie
depress
chemotaxi
respiratori
burst
indirectli
modul
product
andor
secret
cytokin
involv
recruit
mp
late
stage
inflamm
evalu
effect
mlif
product
proantiinflammatori
cytokin
cell
materi
method
lymphocyt
purifi
neg
select
use
commerci
kit
macsreag
isol
human
cell
one
pbmc
cell
place
propylen
tube
pbsalbuminedta
al
antibodi
cocktail
elimin
cell
min
lymphocyt
purifi
fraction
found
pure
mlif
pure
commerci
obtain
american
peptid
co
sunnyval
ca
usa
five
cell
place
fetal
calf
serum
fc
stimul
h
presenc
pma
ngml
mlif
agml
pmamlif
supernat
fluid
analyz
elisa
result
proinflammatori
cytokin
cell
activ
mlif
express
increas
product
constitut
proinflammatori
cytokin
ifng
pgml
respect
compar
product
constitut
basal
rpmi
cell
control
pgml
respect
pma
enhanc
induc
product
proinflammatori
cytokin
pgml
respect
express
ifng
induc
pma
significantli
inhibit
mlif
respect
occur
antiinflammatori
cytokin
mlif
increas
product
constitut
antiinflammatori
cytokin
compar
basal
pgml
respect
compar
basal
product
control
cell
rpmi
pgml
respect
pma
increas
product
induc
pg
ml
respect
mixtur
pmamlif
found
decreas
product
constitut
pma
significantli
increas
express
conclus
proantiinflammatori
cytokin
produc
mlif
amount
similar
induc
pma
pmamlif
mixtur
ifng
proinflammatori
potenti
product
inhibit
prototyp
antiinflammatori
cytokin
disclos
significantli
increas
express
thu
mlif
orchestr
antiinflamm
pattern
cytokin
contribut
exigu
inflamm
found
advanc
lesion
invas
amebiasi
conacyt
grant
interleukin
secret
activ
cell
modul
immun
cell
function
proand
antiinflammatori
effect
interleukin
receptor
homolog
beta
alpha
associ
gamma
common
chain
upon
ligand
bind
constitut
express
mani
cell
type
immun
system
upregul
rational
sinc
blockad
pathway
solubl
result
reduct
clinic
sign
arthriti
rodent
model
examin
effect
pathway
rat
murin
respons
vitro
understand
potenti
mechan
regul
arthriti
method
arthriti
induc
male
mice
bovin
type
ii
collagen
lewi
rat
freundt
complet
adjuv
anim
treat
solubl
neutral
murin
rat
bioactiv
drain
lymph
node
cell
collagenimmun
mice
cultur
vitro
collagen
either
assay
prolifer
cytokin
secret
cytokin
anticollagen
specif
igg
level
also
measur
serum
elisa
analysi
rat
con
stimul
spleen
cell
activ
splenic
cell
assay
prolifer
cytokin
secret
respons
result
compar
control
anim
weekli
treatment
result
less
sever
sign
diseas
rat
murin
prophylact
therapeut
model
cia
addit
murin
collagen
restimul
ln
cell
result
dose
depend
inhibit
prolifer
decreas
ifngamma
gmcsf
increas
cultur
supernat
convers
addit
enhanc
collagen
prolifer
respons
result
increas
ifngamma
gmcsf
decreas
product
suggest
modul
endogen
well
antigeninduc
cytokin
conclus
result
suggest
interleukin
play
role
modul
antigenspecif
cell
respons
may
contribut
patholog
arthriti
object
investig
molecular
mechan
neural
stem
cell
nsc
respons
proinflammatori
cytokin
interferong
background
selfrenew
capac
fundament
properti
nsc
stem
cell
prolifer
form
multipot
neurospher
presenc
nsc
respond
inflamm
howev
known
molecul
account
respons
diseas
hypothesi
nsc
express
function
immun
relat
gene
interact
stem
gene
control
nsc
intrins
properti
materi
method
analyz
multipl
microarray
dataset
inflammatori
gene
express
nsc
perform
gene
cluster
gene
ontolog
data
mine
use
sever
bioinformat
databas
test
selfrenew
capac
nsc
isol
differ
region
mous
brain
cultur
supplement
bfgf
ngml
gene
express
analysi
mrna
duplic
nsc
cultur
expos
interferong
h
process
affimetrix
microarray
gene
show
chang
express
pvalu
p
b
confirm
use
differ
microarray
platform
confoc
microscopi
western
blot
result
found
nsc
express
sever
interferon
relat
gene
confirm
express
vivo
germin
zone
confoc
microscopi
ifng
dose
uml
ad
nsc
cultur
newborn
adult
brain
decreas
frequenc
induc
neurospher
format
f
vs
f
p
b
neurospher
diamet
f
vs
f
p
b
determin
gene
affect
ifng
primari
nsc
treat
ifng
subject
microarray
identifi
affect
gene
cluster
group
terrain
gene
map
ifng
highli
induc
gene
absent
untreat
nsc
fold
increas
b
mhc
gene
proteosom
gene
increas
fold
c
decreas
gene
relat
stem
includ
cell
cycl
histon
lifespan
gene
confirm
express
select
gene
confoc
microscopi
western
blot
elucid
molecular
pathway
affect
ifng
analyz
downstream
pathway
ifng
found
increas
gene
express
interferong
induc
rapid
phosphoryl
nuclear
transloc
stat
nsc
min
treatment
use
nsc
isol
found
reduct
selfrenew
capac
ifng
wild
type
mice
absent
instead
contain
nsc
ifng
vitro
increas
neurospher
format
selfrenew
capac
experi
differenti
gene
express
behavior
vivo
wildtyp
mice
ifng
treatment
way
evalu
import
nsc
conclus
nsc
function
interferon
genet
program
interferong
induc
program
lead
activ
multipl
gene
includ
appear
form
central
checkpoint
nsc
selfrenew
capac
role
promot
glial
surviv
experiment
demyelin
l
remington
p
zehntner
c
hollmann
owen
neuroimmunolog
montreal
neurolog
institut
montreal
qc
canada
inadequ
repair
thought
underli
chronic
demyelin
multipl
sclerosi
ms
oligodendrocyt
precursor
cell
opc
present
adult
central
nervou
system
cn
abil
migrat
lesion
differenti
matur
oligodendrocyt
opc
prolifer
differenti
driven
growth
factor
chemokin
administr
may
enhanc
opc
function
remyelin
examin
role
receptor
corpu
callosum
femal
mice
cuprizoneinduc
demyelin
respons
demyelin
caus
astrocyt
microglia
opc
accumul
corpu
callosum
remov
toxin
cuprizon
allow
remyelin
occur
found
transient
increas
mrna
forebrain
prior
opc
accumul
earli
week
initi
cuprizon
treatment
level
mrna
peak
two
week
declin
normal
level
posit
cell
also
increas
corpu
callosum
demyelin
pdgf
receptor
alpha
posit
opc
shown
express
suggest
possibl
mechan
migrat
cell
corpu
callosum
test
inject
replicationdefect
adenoviru
encod
via
cisterna
magna
introduc
viru
cerebrospin
fluid
without
inflamm
viru
inject
week
week
initi
cuprizon
treatment
mice
sacrif
either
week
week
viral
encod
mrna
detect
cerebellum
week
viru
inject
immunohistochem
detect
posit
opc
show
effect
encod
adenoviru
number
opc
corpu
callosum
data
suggest
endogen
suffici
opc
mobil
remyelin
delet
strategi
current
underway
j
wilkinson
c
smith
dtcosta
e
rabellino
biomed
research
divis
beckman
coulter
inc
miami
fl
usa
util
evalu
cell
function
assay
well
recogn
context
determin
efficaci
vaccin
strategi
infecti
diseasescanc
toler
profil
autoimmun
transplant
well
understand
basic
mechan
cell
immun
respons
diseas
pathogenesi
howev
variabl
associ
cell
function
assay
continu
problemat
especi
studi
involv
multicent
clinic
trial
well
longitudin
studi
variabl
natur
assay
associ
varieti
factor
rang
sourc
cell
process
methodolog
isol
freez
thaw
cultur
sampl
prepar
stain
final
data
analysi
data
reduct
view
reduc
variabl
standard
target
step
assay
involv
cell
function
autom
methodolog
stain
analysi
intracellular
cytokin
via
flow
cytometri
develop
modif
avail
sampl
prepar
instrument
perform
enabl
autom
pipet
incub
stain
intracellular
surfac
molecul
human
stimul
whole
blood
pbmc
flow
cytometr
analysi
flow
cytometri
assay
surfac
marker
intracellular
cytokin
develop
character
brestrict
polyclonalq
versu
cytokin
profil
respons
cell
stimul
autom
sampl
stain
analysi
greatli
reduc
variabl
specimen
reduc
handson
sampl
prepar
analysi
time
complex
natur
cytokin
profil
interand
intrasubject
variabl
reveal
evalu
sever
cytokin
context
multiparametr
evalu
cell
respons
use
autom
thu
provid
greater
degre
standard
function
assay
allow
correl
variabl
complex
immun
respons
profil
vaccin
efficaci
diseas
progress
without
signific
interfer
due
variabl
natur
manual
assay
high
endotheli
venul
hev
special
lymph
node
blood
vessel
allow
entranc
lymphocyt
lymph
node
analysi
genet
defici
transgen
mice
previous
determin
ltah
complex
critic
express
sever
hev
gene
develop
lthr
express
hev
specif
object
studi
determin
whether
lthr
signal
crucial
hev
gene
express
adult
wild
type
mice
whether
direct
effect
endotheli
cell
induct
hev
gene
express
question
investig
vivo
mous
peripher
lymph
node
pln
vitro
cell
line
regul
hev
gene
slc
hev
specif
lthr
evalu
immunohistochemistri
real
time
pcr
use
lthr
activ
lthr
inhibitor
contact
sensit
lthr
express
constitut
hev
pln
inhibit
one
inject
lthrfc
fusion
protein
hev
gene
regul
contact
sensit
oxazolon
mice
lthr
regul
parallel
contact
sensit
oxazolon
interest
kinet
pattern
detect
sever
hev
gene
initi
decreas
gene
express
rebound
day
gene
except
exactli
opposit
effect
initi
phase
gene
regul
contact
sensit
independ
tnfri
though
optim
rebound
gene
express
partial
depend
receptor
lthr
signal
essenti
optim
rebound
gene
express
sensit
mous
endotheli
cell
line
promin
express
lthr
upon
stimul
hamster
antilthr
antibodi
show
dramat
upregul
vitro
vivo
data
taken
togeth
indic
lthr
express
endotheli
cell
signal
direcli
crucial
constitut
hev
gene
express
regul
immun
respons
data
also
provid
inform
regard
plastic
hev
gene
express
immun
respons
suggest
initi
revers
immatur
phenotyp
recoveri
development
program
adult
phenotyp
support
nih
ca
nhr
anna
fuller
fund
sl
interferona
induc
agonist
bacteri
synthet
dna
contain
cpg
dinucleotid
cpg
dna
shown
natur
ligand
molecular
pattern
recognit
receptor
cpg
dna
activ
shown
produc
type
immun
respons
includ
ifna
induct
extens
dna
structureact
relationship
studi
identifi
novel
synthet
dinucleotid
dna
structur
immunom
recogn
combin
novel
dna
structur
synthet
stimulatori
dinucleotid
provid
us
portfolio
immunomodulatori
oligonucleotid
imo
gener
imo
produc
distinct
immun
respons
high
low
cytokin
secret
profil
compar
natur
cpg
dinucleotid
motif
base
human
cell
cultur
assay
vivo
nonhuman
primat
studi
identifi
novel
imo
consist
synthet
stimulatori
motif
induc
high
level
ifna
induct
ifna
imo
depend
presenc
specif
nucleotid
sequenc
activ
plasmacytoid
dendrit
cell
novel
imo
also
induc
human
b
cell
prolifer
activ
b
cell
express
surfac
marker
secret
cytokin
imo
induc
express
number
cytokin
chemokin
gene
includ
ifna
gene
number
interferon
induc
gene
synthetas
human
pbmc
nonhuman
primat
imo
administ
sc
mgkg
dose
induc
high
level
ifna
secret
hr
result
suggest
imo
induc
high
level
ifna
may
suitabl
candid
treatment
hepat
c
cancer
recombin
ifna
therapi
commonli
use
although
regulatori
cell
treg
instrument
mainten
immunolog
toler
one
critic
question
whether
regulatori
cell
treg
gener
thymu
differenti
peripher
cell
shown
convers
narv
peripher
cell
regulatori
cell
achiev
costimul
tcr
tgfbeta
convert
regulatori
cell
unrespons
tcr
stimul
also
inhibit
normal
cell
prolifer
vitro
importantli
tgfbetaconvert
transgen
suppressor
cell
prolifer
respons
immun
inhibit
antigenspecif
narv
cell
expans
vivo
ova
peptid
tcr
transgen
adopt
transfer
model
murin
asthma
model
coadministr
tgfbetainduc
suppressor
cell
prevent
hous
dust
mite
hdm
induc
allerg
pathogenesi
lung
significantli
tgfbeta
induc
gene
express
tcrchalleng
cell
mediat
transit
toward
regulatori
cell
phenotyp
tgfbeta
induct
attribut
cell
select
expans
small
number
preexist
regulatori
cell
accordingli
tgfbeta
express
narv
cell
detect
earli
hour
stimul
tgfbeta
induc
express
cell
tcr
transgen
mous
tgfbeta
exhibit
reduc
number
peripher
cell
final
signal
involv
tgfbeta
induct
cell
data
provid
new
evid
understand
mechan
gener
develop
regulatori
cell
open
uniqu
opportun
intent
manipul
pivot
popul
cell
immun
toler
cellbas
immunotherapi
chakravarti
l
flamand
r
lalond
p
e
poubel
osteoprotegerin
opg
cytokin
tnfr
superfamili
decoy
receptor
receptor
activ
nfnb
ligand
rankl
opg
counteract
bone
resorpt
induc
interact
receptorligand
pair
rankrankl
opg
present
blood
also
implic
divers
aspect
vascular
function
immun
regul
aim
studi
better
understand
differ
function
circul
opg
elucid
role
immun
cell
regul
explor
new
aspect
interact
immun
skelet
system
object
formul
broad
framework
would
delin
subpopul
peripher
blood
mononuclear
cell
respons
synthesi
osteoprotegerin
identifi
factor
regul
studi
function
impact
opg
regul
immun
cell
appropri
physiopatholog
context
ie
hiv
infect
individu
address
issu
use
enzym
immunometr
assay
combin
immunoblot
examin
synthesi
regul
opg
subpopul
normal
human
peripher
blood
mononuclear
leucocyt
pbmc
enrich
immunomagnet
separ
differ
condit
incub
rna
synthesi
profil
studi
use
rtpcr
northern
blot
analys
provid
evid
amongst
pbmc
opg
constitut
secret
lymphocyt
cell
product
opg
upregul
antibodi
tnfa
gmcsf
vitamin
tgfh
cell
synthesi
opg
strongli
increas
unlik
inhibit
constitut
product
opg
verifi
pathophysiolog
import
cellderiv
opg
chose
studi
circul
concentr
opg
patient
infect
know
diseas
induc
specif
associ
compromis
cell
number
function
increas
incid
osteoporosi
given
opg
present
consid
one
final
compon
decid
outcom
bone
resorpt
compar
circul
concentr
opg
hivinfect
individu
agematch
normal
subject
remark
signific
decreas
opg
concentr
plasma
hivinfect
patient
addit
normal
lymphocyt
presenc
recombin
unequivoc
reduct
constitut
opg
product
moreov
nelfinavir
proteas
inhibitor
use
highli
activ
antiretrovir
therapi
significantli
inhibit
constitut
opg
synthesi
normal
cell
result
first
suggest
causal
link
hivinduc
cell
malfunct
ie
dysregul
capac
produc
opg
secondari
osteoporosi
highlight
new
role
lymphocyt
regul
circul
opg
suggest
therapeut
potenti
opg
opg
mimet
decreas
bone
miner
densiti
associ
hiv
infect
hypersensit
metal
z
venclikova
j
bartova
l
mrkla
clinic
depart
institut
dental
research
medic
faculti
guh
charl
univers
pragu
pragu
czech
republ
introduct
dental
praxi
dentist
often
confront
suspect
delay
hypersensit
reaction
variou
metal
use
prosthet
restor
dentistri
cytokin
involv
diseas
process
includ
hypersensit
studi
new
method
detect
cytokin
call
bhuman
cytokin
arrayq
use
ten
patient
suspect
delay
hypersensit
metal
compon
dental
alloy
method
clinic
part
studi
involv
examin
oral
caviti
respect
presenc
dental
alloy
includ
dental
radiograph
special
questionair
focus
gener
health
statu
also
use
immunolog
examin
mononuclear
cell
separ
peripher
blood
use
studi
product
cytokin
use
ray
bio
tm
human
inflamm
antibodi
array
iii
possibl
identifi
express
profil
cytokin
detect
cytokin
perform
day
cultiv
mercuri
nickel
chlorid
result
nickel
chlorid
stimul
product
ifngamma
alfa
tnf
alfa
tnf
beta
mercuri
chlorid
stimul
product
alfa
stnf
rii
conclus
mercuri
chlorid
activ
rather
clone
lymphocyt
nickel
chlorid
lymphocyt
metal
salt
activ
regulatori
clone
tr
human
two
highli
relat
molecul
belong
cluster
inflammatori
cc
chemokin
locat
chromosom
form
duplic
common
ancestr
gene
gener
gene
turn
present
variabl
number
addit
nonallel
copi
moreov
group
found
locu
polymorph
display
second
allel
variant
highli
repres
hiv
patient
compar
one
describ
origin
recent
evid
point
variat
gene
copi
number
play
key
role
suscept
hiv
infect
probabl
also
relat
phenomenon
similarli
gene
dosag
variat
could
involv
diseas
chemokin
play
import
role
develop
fret
probe
realtim
pcr
base
method
determin
easili
fast
reliabl
genotyp
polymorph
locu
polymorph
consist
singl
nucleotid
chang
situat
second
intron
acceptor
splice
site
approach
use
specif
primer
locu
pair
fret
hybrid
probe
test
use
sensor
probe
complementari
one
allel
variant
obtain
better
melt
resolut
specif
probe
sensor
probe
use
total
copi
number
determin
base
approach
set
protocol
determin
copi
number
gene
wherea
inform
copi
number
belong
allel
variant
mandana
sattari
saeed
khalili
leili
mehrdad
immunolog
shahe
beheshti
univers
medic
school
tehran
islam
republ
iran
aim
regard
presenc
numer
b
cell
chronic
periodont
sinc
cell
import
role
induc
humor
respons
aim
studi
determin
correl
import
cytokin
differenti
cell
cell
import
cytokin
differenti
cell
cell
chronic
periodont
materi
method
purpos
gingiv
sampl
healthi
patient
gingiv
sampl
patient
chronic
periodont
collect
periodont
surgeri
tissu
sampl
cultur
hour
elisa
use
determin
concentr
supernat
fluid
result
found
sampl
signific
differ
case
control
group
regard
concentr
signific
differ
two
group
regard
ratio
also
correl
attach
loss
conclus
conclud
chronic
periodont
probabl
number
cell
cell
activ
phase
inflamm
tissu
damag
number
cell
could
decreas
reduct
product
maintain
cell
naiv
phenotyp
ferrarilacraz
c
foster
r
chicheportich
immunolog
allergi
univers
hospit
geneva
geneva
switzerland
cytokin
biolog
zymogenet
seattl
wa
usa
larg
number
cytokin
releas
develop
immun
respons
cell
growth
factor
tcgf
play
major
distinct
part
tcell
activ
tcgf
determin
whether
activ
cell
undergo
apoptosi
persist
regulatorymemori
cell
robust
immun
activ
key
peripher
tcell
homeostasi
major
tcgf
part
innat
adapt
immun
respons
costimul
naiv
memori
cell
contrari
major
stimulu
memori
particularli
cell
unlik
signific
effect
prolifer
cell
absenc
stimuli
demonstr
play
potent
role
maintain
naiv
phenotyp
human
lymphocyt
persist
specif
cellsurfac
marker
pbmc
isol
healthi
young
donor
naiv
memori
cell
subsequ
isol
facsvantagew
sorter
select
cell
cultur
week
phenotyp
naiv
memori
cell
assess
immunofluoresc
marker
particularli
clearli
upregul
cell
cultur
compar
less
cell
cultur
cell
cultur
express
day
mean
major
naiv
cell
cultur
switch
memori
cell
phenotyp
day
express
lymphocyt
cultur
induc
migrat
cell
chemoattract
moreov
reduc
frequenc
prolifer
naiv
cell
compar
prolifer
marker
prolifer
cell
nuclear
antigen
pcna
express
equal
cellcultur
condit
therefor
uniqu
tcgf
abl
maintain
lymphocyt
naiv
phenotyp
increas
cellsurfac
express
migrat
chemoattract
find
suggest
may
play
uniqu
role
innat
adapt
immun
respons
due
persist
narv
lymphocyt
osteopontin
opn
previous
regard
adhes
bone
matrix
protein
recent
shown
pleiotrop
cytokin
regul
earli
cellmedi
immun
previou
studi
shown
opn
play
critic
role
autoimmun
demyelin
diseas
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
opn
express
significantli
increas
affect
tissu
show
opn
inhibit
tcrmediat
apoptosi
vitro
without
affect
cellcycl
progress
measur
brdu
incorpor
cfse
label
investig
effect
opn
activationinduc
cell
death
vivo
activ
cell
inject
staphylococc
enterotoxin
b
seb
opn
mice
monitor
delet
cell
found
death
stimul
cell
vivo
acceler
opn
mice
adopt
transfer
cell
opn
mice
recipi
reveal
opn
secret
cell
prolong
surviv
activ
cell
vivo
also
found
opn
mice
express
proapoptot
famili
protein
bim
increas
cell
furthermor
compar
wild
type
mice
opn
mice
display
remark
reduc
number
certain
cell
subset
opn
mice
comparison
cell
subpopul
lo
hi
lo
int
hi
hi
express
higher
level
prosurviv
protein
despit
increas
cell
death
opn
cell
activ
level
activ
lower
opn
cell
wild
type
cell
furthermor
treatment
opn
wild
type
lymphocyt
cellperm
caspas
inhibitor
reduc
death
activ
wild
type
opn
cell
suggest
activationinduc
cell
death
opn
cell
mediat
altern
caspaseindepend
pathway
studi
suggest
opn
play
role
regul
program
cell
death
activ
cell
opn
signal
promot
cell
surviv
l
asar
kolchinski
p
wood
v
l
seyfertmargoli
immun
toler
network
univers
california
san
francisco
san
francisco
ca
usa
center
human
genet
integr
biolog
univers
pittsburgh
pittsburgh
pa
usa
object
commerci
avail
blood
collect
tube
gene
express
studi
lyse
red
blood
cell
stabil
rna
ensur
detect
transcript
profil
reflect
physiolog
state
subject
assess
two
system
abil
detect
quantifi
differenti
express
cytokin
chemokin
gene
method
peripher
blood
sampl
healthi
volunt
collect
tempu
tubek
blood
collect
tube
appli
biosystem
abi
foster
citi
ca
paxgenekblood
rna
tube
preanalytix
valencia
ca
sampl
isol
accord
manufacturerst
instruct
rna
puriti
yield
assess
prior
analysi
sampl
preprocess
follow
blood
drawn
directli
tempu
k
paxgenek
tube
sampl
drawn
li
heparin
tube
stimul
pha
transfer
two
rna
collect
tube
type
analyz
transcript
detect
singl
timepoint
differenti
express
baselin
sampl
sampl
stimul
agml
pha
hr
affymetrix
genechipn
transcript
quantit
rtpcr
cytokin
chemokin
transcript
probe
primer
abi
run
result
initi
analysi
particip
gener
genechipn
analysi
set
reliabl
detect
transcript
cluster
use
standard
correl
gener
follow
differenti
express
profil
set
transcript
show
regul
use
tube
set
b
transcript
show
regul
use
tube
set
c
transcript
show
chang
elev
baselin
valu
tempusk
paxgenek
set
transcript
show
chang
elev
baselin
valu
paxgenek
tempusk
transcript
set
c
cytokin
chemokin
relat
transcript
set
greater
log
scale
express
includ
chemokin
c
motif
ligand
class
mhcrestrict
cell
associ
molecul
chemokin
cxc
motif
quantifi
differenti
express
rtpcr
show
high
similar
tube
cytokinechemokin
transcript
allergi
relev
cytokin
detect
high
level
genechipn
assay
detect
high
level
use
rtpcr
conclus
differ
kinet
tube
lyse
process
may
account
detect
level
differ
singl
timepoint
noncytokin
chemokin
relat
transcript
found
use
genechipsn
timepoint
differ
could
confirm
use
rtpcr
sinc
cytokinechemokin
rtpcr
probe
use
demonstr
select
particular
tube
rna
studi
may
depend
heavili
upon
transcript
interest
cytokinechemokin
transcript
tube
type
provid
essenti
equival
express
profil
cytokin
network
play
crucial
role
diseas
progress
multipl
sclerosi
ms
anim
model
experiment
autoimmun
encephalomyel
eae
studi
network
necessari
understand
diseas
develop
treatment
howev
cytokin
multifacet
may
fulfil
contradictori
role
depend
upon
varieti
factor
eg
stage
diseas
tumor
necrosi
factor
tnf
import
cytokin
eae
ms
mice
lack
tnf
receptor
type
ko
develop
mild
eae
express
high
level
interferon
gamma
ifngamma
spinal
cord
ifngamma
proinflammatori
cytokin
tradit
consid
detriment
ms
shown
protect
eae
present
studi
examin
mechan
lack
result
increas
ifngamma
product
use
vitro
cocultur
approach
wild
type
wt
ko
mice
immun
peptid
complet
freundt
adjuv
seven
ten
day
later
lymph
node
cell
isol
mac
use
neg
select
splenic
antigen
present
cell
apc
unimmun
mice
also
obtain
mac
use
neg
select
wt
ko
cell
cocultur
wt
ko
apc
presenc
peptid
cytokin
express
analyz
variou
time
point
elisa
realtim
pcr
wt
ko
cell
produc
significantli
ifngamma
cocultur
ko
apc
compar
wt
apc
observ
alter
addit
neutral
antitnf
antibodi
demonstr
enhanc
ifngamma
secret
due
tnf
action
furthermor
data
demonstr
signal
apc
critic
regul
ifngamma
product
apc
regul
cell
ifngamma
product
secret
ifngammainduc
factor
preliminari
result
show
mrna
express
subunit
higher
cocultur
contain
ko
apc
compar
wt
apc
suggest
absenc
apc
lead
higher
level
result
higher
ifngamma
secret
cell
subunit
compon
well
promot
ifngammasecret
cell
wherea
promot
cell
recent
shown
critic
eae
patholog
protein
array
analysi
reveal
high
level
cocultur
futur
work
investig
role
cocultur
system
conclus
studi
show
lack
apc
lead
greater
ifngamma
product
cell
potenti
due
chang
express
data
extend
understand
cytokin
network
underli
cn
inflamm
studi
fund
canadian
institut
health
research
multipl
sclerosi
societi
canada
bacteri
immun
inhibit
proteoglycaninduc
arthriti
e
berlo
c
b
ten
brink
p
j
van
kooten
r
van
der
zee
singh
b
j
prakken
glant
w
van
eden
c
p
broeren
immun
respons
heatshock
protein
seen
inflammatori
diseas
rheumatoid
arthriti
ra
diabet
atherosclerosi
although
hsp
well
describ
role
chaperon
intracellular
protein
signific
immun
respons
hsp
becom
clear
indic
hsp
target
diseas
suppress
immun
regul
experiment
diseas
model
hsp
use
therapeut
agent
prevent
arrest
inflammatori
damag
first
clinic
trial
use
hsp
peptid
shown
shift
proinflammatori
cytokin
profil
peptid
specif
cell
product
antiinflammatori
cytokin
order
analyz
mechan
lead
hsp
induc
immun
regul
set
test
possibl
protect
effect
novel
mous
balbc
arthriti
model
proteoglycaninduc
arthriti
pgia
model
induc
immun
cartilag
pg
emulsifi
adjuv
dimethyl
dioctadecyl
ammonium
bromid
dda
singl
ip
inject
ag
mycobacteri
given
day
prior
first
pg
inject
given
dda
result
twoweek
delay
arthriti
onset
furthermor
preimmun
induc
significantli
milder
arthriti
assess
clinic
score
mean
maximum
arthriti
score
f
sem
compar
f
sem
control
mice
p
b
protect
effect
accompani
cell
prolifer
ifng
product
mice
pretreat
interestingli
mice
could
also
detect
product
arthriti
induc
proteoglycan
present
control
mice
addit
joint
section
mice
show
less
leukocyt
infiltr
reactiv
synovi
cell
prolifer
cartilag
destruct
compar
control
group
conclus
modul
could
dramat
suppress
develop
inflamm
subsequ
tissu
damag
pgia
addit
demonstr
preimmun
inde
activ
cell
alter
cytokin
profil
modul
immun
regulatori
respons
region
immunoregul
use
block
synthet
peptid
andor
mab
object
previous
defin
immunoregul
occur
allow
prolong
allograft
surviv
suppress
collageninduc
arthriti
mice
follow
interact
cell
surfac
molecul
isoform
import
deliv
direct
immunosuppress
signal
group
use
biophys
approach
investig
structur
import
region
interact
suggest
ntermin
extracellular
domain
molecul
crucial
report
investig
import
interact
use
approach
investig
purturb
variou
biolog
function
follow
interact
materi
method
seri
peptid
synthes
defin
continu
sequenc
extracellular
region
murin
human
molecul
addit
peptid
map
presumpt
human
mous
molecul
synthes
assess
abil
differ
molecul
block
interact
competit
elisa
use
platebound
biotinyl
well
fac
use
fitcconjug
bind
adher
cell
peptid
also
use
modul
suppress
mlc
reactiv
vitro
follow
inclus
mlc
cultur
measur
develop
ctl
day
cultur
addit
use
newli
prepar
panel
mab
mous
human
compar
rank
activ
antibodi
bind
fac
elisa
abil
augment
immun
reactiv
mlc
result
peptid
defin
discret
region
ntermin
region
function
activ
differ
assay
includ
assay
investig
blockad
suppress
moreov
infus
vivo
mousespecif
peptid
suppress
protect
graft
reject
afford
inject
solubl
immunosuppress
use
panel
mab
observ
mab
defin
epitop
ntermin
domain
could
augment
mlc
reactiv
block
immunosuppress
solubl
mab
target
cdomain
epitop
although
reactiv
elisa
fac
target
cell
surfac
inact
mlc
final
assay
compar
rank
differ
fac
stain
express
variou
cell
type
includ
fresh
dendrit
cell
lymphoid
tumor
cell
data
suggest
exist
signific
heterogen
express
summari
data
confirm
ntermin
region
crucial
mediat
immunoregul
suggest
prove
possibl
gener
smaller
molecular
weight
antagonist
interact
may
clinic
util
introduct
antiphospholipid
syndrom
ap
autoimmun
diseas
character
thrombot
hemocytopen
manifest
patient
high
titer
autoantibodi
direct
phospholipid
phospholipid
cofactor
protein
molecular
studi
antiphospholipid
apl
perform
monoclon
autoantibodi
obtain
ebv
transform
b
cell
repres
repertoir
autoimmun
apl
use
phage
display
technolog
possibl
studi
wide
repertoir
v
h
j
h
v
l
j
l
rearrang
recogn
specif
antigen
object
studi
phage
display
v
h
j
h
v
l
j
l
rearrang
antig
gpi
antipt
patient
pap
high
titer
autoantibodi
method
cdna
synthes
rna
obtain
peripher
blood
mononuclear
cell
v
h
dj
h
v
l
j
l
n
e
rearrang
amplifi
heavi
light
chain
fragment
link
obtain
scfv
fragment
scfv
ligat
vector
e
coli
transform
product
ligat
cultur
coinfect
phage
rescu
antibodi
format
phagescfv
antibodi
four
round
select
done
g
gpi
pt
posit
clone
sequenc
analyz
result
two
clone
recogn
g
gpi
beta
one
recogn
pt
obtain
v
h
gene
belong
v
h
famili
rearrang
show
homolog
vhsp
gene
gene
identifi
j
h
gene
use
product
j
h
gene
homolog
light
chain
compos
product
gene
belong
famili
show
homolog
j
l
gene
identifi
clone
show
homolog
gene
gene
identifi
rearrang
product
j
h
gene
homolog
light
chain
use
product
gene
belong
famili
homolog
rearrang
product
j
l
gene
third
clone
carri
product
gene
belong
v
h
famili
homolog
gene
identifi
j
h
gene
identifi
product
j
h
homolog
light
chain
product
gene
belong
famili
homolog
rearrang
product
j
l
gene
show
homolog
conclus
confirm
bia
use
v
h
v
h
gene
famili
number
somat
mutat
suggest
rearrang
product
antigen
driven
clone
antibodi
format
scfv
repres
well
autoantibodi
found
patient
pap
cytokin
implic
autoimmun
dysregul
patient
multipl
sclerosi
potenti
therapeut
target
baror
niino
duddi
f
adatia
hebert
h
j
kim
neuroimmunolog
unit
montreal
neurolog
institut
mcgill
univers
montreal
qc
canada
background
beyond
role
potenti
antibodi
produc
cell
grow
interest
fundament
role
b
cell
may
play
regul
immun
respons
emerg
anim
studi
point
import
contribut
b
cell
effector
cytokin
autoimmun
set
studi
potenti
involv
human
b
cell
cytokin
immun
regul
autoimmun
result
report
profil
human
b
cell
cytokin
product
context
depend
critic
influenc
balanc
signal
b
cell
receptor
b
cell
appropri
stimul
sequenti
b
cell
receptor
stimul
prolifer
secret
tumour
necrosi
factor
tnf
lymphotoxin
lt
contribut
germin
center
reaction
therebi
amplifi
ongo
immun
respons
contrast
stimul
alonea
mimic
b
cell
receiv
bystand
cell
help
absenc
specif
antigen
recognitioninduc
significantli
less
proinflammatori
cytokin
n
p
b
significantli
enhanc
product
p
b
serv
suppress
inappropri
immun
respons
observ
novel
network
reciproc
regul
b
cell
effector
cytokin
abnorm
subgroup
patient
relaps
remit
multipl
sclerosi
b
cell
maintain
capac
prolifer
produc
proinflammatori
cytokin
tnfa
lt
n
p
compar
normal
significantli
diminish
capac
produc
n
p
b
b
cell
cytokin
network
target
therapeut
evidenc
patient
treat
mitoxantron
novantron
recent
approv
immun
suppress
ms
compar
b
cell
untreat
patient
b
cell
mitoxantron
treat
ms
patient
produc
significantli
less
proinflammatori
cytokin
tnfa
n
p
b
lt
p
b
significantli
antiinflammatori
cytokin
p
b
observ
treatment
associ
decreas
proport
circul
memori
b
cell
suggest
appar
reciproc
regul
b
cell
cytokin
mediat
mitoxantron
relat
differenti
effect
distinct
b
cell
subset
guid
studi
fundament
b
cell
cytokin
network
enabl
us
ascrib
uniqu
effector
cytokin
profil
normal
memori
naiv
human
b
cell
subset
summari
ascrib
activ
role
memori
naiv
human
b
cell
subset
appropri
promot
suppress
local
immun
respons
normal
state
product
distinct
effector
cytokin
suggest
dysregul
b
cell
cytokin
network
occur
patient
human
autoimmun
diseas
multipl
sclerosi
network
repres
potenti
therapeut
target
activ
autoreact
b
cell
pivot
initi
propag
mani
autoimmun
diseas
gener
thought
activ
reflect
breakdown
peripher
toler
although
natur
develop
cell
complet
understood
mani
studi
b
lymphopoiesi
shown
igm
receptor
drive
develop
construct
naiv
b
cell
repertoir
wherea
igg
receptor
promot
format
memori
b
cell
compart
isotyp
chang
result
gene
rearrang
process
call
class
switch
recombin
csr
thought
occur
matur
peripher
b
cell
upon
activ
provid
appropri
cell
help
absenc
cell
help
activ
b
cell
undergo
fasmedi
apoptosi
process
thought
peripher
mechan
selftoler
recent
shown
csr
spontan
occur
normal
b
lymphopoiesi
vivo
vitro
cell
acquir
memori
phenotyp
found
csr
b
lymphopoiesi
cellindepend
expans
cell
regul
cell
studi
cell
use
igmdefici
mous
model
mmt
b
cell
develop
limit
abil
cell
undergo
csr
found
isotyp
switch
b
cell
precursor
matur
peripheri
differenti
antibodyproduc
plasma
cell
b
cell
gener
ghdriven
repertoir
oligomonoclon
bear
selftissu
reactiv
studi
reveal
isotypeswitch
b
cell
precursor
neg
select
fa
signal
block
fasfasl
interact
rescu
develop
isotypeswitch
b
cell
vivo
vitro
studi
propos
novel
development
pathway
driven
ghisotyp
receptor
effect
circumv
peripher
toler
requir
pathway
howev
strictli
control
fa
signal
prevent
b
cell
autoimmun
role
selfreact
cell
fate
vascular
cell
adhes
molecul
play
role
leukocyt
migrat
adhes
found
varieti
cell
includ
endotheli
cell
thymic
epithelium
dendrit
cell
bind
princip
ligand
late
found
b
cell
cell
disrupt
signal
associ
prolong
allograft
accept
impair
cell
respons
therefor
role
establish
posit
factor
cell
activ
prolifer
hypothesi
absenc
express
dendrit
cell
antigen
specif
selfreact
cell
fail
prolifer
effect
present
also
hypothes
selfreact
cell
activ
absenc
surviv
acquir
regulatori
cell
phenotyp
test
hypothesi
use
antigen
specif
cell
recogn
hen
egg
lysozym
hel
protein
present
peptid
antigen
present
cell
transgen
mice
express
membranebound
solubl
hel
cross
onto
condit
knockout
mice
lack
function
express
subset
splenic
dendrit
cell
adopt
transfer
label
cell
either
hel
vcam
hel
recipi
mice
fate
antigen
specif
cell
follow
time
human
ldl
modifi
vitro
use
develop
antibodi
allow
detect
spontan
modifi
ldl
circul
modifi
lipoprotein
circul
antigenantibodi
complex
immun
complex
ic
character
precipit
peg
chemic
immunolog
analysi
igg
ldl
isol
ic
demonstr
human
immun
system
recogn
malondialdehyd
lysin
carboxymethyl
lysin
yet
uncharacter
epitop
igg
fraction
isol
precipit
ic
contain
antibodi
reactiv
copperoxid
ldl
oxldl
agemodifi
ldl
ageldl
predominantli
proinflammatori
subclass
comparison
igg
subclass
dissoci
constant
antibodi
contain
precipit
ic
remain
supernat
peg
precipit
show
antibodi
includ
ic
statist
signific
higher
avid
rel
higher
concentr
affin
chromatographi
isol
circul
antibodi
oxldl
age
ldl
show
igg
antibodi
predomin
igm
antibodi
igg
subclass
predomin
subclass
antigen
antibodi
activ
complement
deliv
activ
signal
phagocyt
cell
consequ
interact
fcg
receptor
pathogen
potenti
modifi
ldlic
unquestion
furthermor
clinic
studi
carri
patient
type
diabet
clearli
demonstr
high
level
modifi
ldlic
predict
cardiovascular
event
observ
also
addit
clinic
implic
one
hand
demonstr
assay
modifi
ldl
correspond
antibodi
serum
extrem
inaccur
due
interfer
ic
hand
studi
suggest
measur
modifi
ldl
ic
rather
serum
requir
evalu
pathogen
potenti
modifi
ldl
conclus
autoimmun
respons
trigger
spontan
modifi
ldl
seem
signific
factor
pathogenesi
atherosclerosi
downstream
regul
ligas
grail
l
x
wu
l
soar
c
g
fathman
depart
medicin
divis
immunolog
rheumatolog
stanford
univers
stanford
ca
usa
anergi
induc
cell
clone
strong
tcr
signal
absenc
costimulatori
signal
costimul
shown
play
critic
role
prevent
anergi
induct
two
model
propos
explain
result
one
predict
costimul
direct
inhibitori
effort
factor
involv
anergi
induct
suggest
costimul
result
product
growth
factor
turn
prevent
anergi
identifi
grail
gene
relat
anergi
lymphocyt
use
differenti
display
grail
contain
highli
conserv
zinc
bind
ring
domain
exhibit
ligas
activ
vitro
studi
shown
constitut
express
grail
enzymat
inact
form
grail
suffici
induc
anergi
narv
cell
suggest
grail
anergi
factor
furthermor
shown
pharmacolog
inhibit
downstream
target
signal
mtor
well
block
signal
use
antagonist
antibodi
result
signific
increas
grail
express
indic
grail
regul
result
suggest
grail
function
maintain
anergi
cell
ubiquitin
pathway
degrad
essenti
signal
molecul
involv
cell
immun
studi
also
shed
light
signal
transduct
pathway
downstream
involv
grail
express
therebi
elucid
basi
costimul
blockad
better
mechanist
understand
grail
regul
costimulatori
molecul
could
lead
novel
treatment
patient
suffer
autoimmun
diseas
transplant
complic
background
diabet
tid
autoimmun
diseas
caus
pathogen
action
lymphocyt
destroy
insulin
produc
beta
cell
effect
immunomodulatori
antibodi
alaala
use
treat
new
onset
tidm
direct
effect
pathogen
cell
induc
regulatori
cell
method
phase
ii
trial
sponsor
immun
toler
network
studi
effect
alaala
immun
respons
patient
new
onset
tid
six
patient
treat
alaala
iv
daili
day
immunophenotyp
cell
prolifer
cfsebas
flow
cytometri
cytokin
secret
perform
result
transient
deplet
cell
patient
follow
recoveri
cell
day
antibodi
cours
observ
one
patient
demonstr
prolong
reduct
number
circul
cell
nine
month
therapi
patientt
count
ml
return
normal
level
till
month
post
therapi
ml
contrast
cell
count
recov
rapidli
reach
baselin
day
obviou
differ
either
coat
modul
cell
observ
cell
compar
treat
individu
trough
level
drug
higher
except
differ
observ
major
treat
individu
howev
select
recoveri
cell
treg
popul
increas
treatment
spite
reduc
cell
count
cell
function
normal
per
cell
basi
demonstr
cfse
prolifer
secret
clinic
patient
unev
clinic
cours
transient
viral
syndrom
shortli
treatment
cultur
serolog
studi
neg
patient
maintain
antimicrobi
prophylaxi
count
recov
patientt
cpeptid
level
remain
high
year
baselin
maintain
normal
hemoglobin
month
compar
note
respond
discuss
present
clinic
studi
alaala
one
patient
experienc
prolong
decreas
cell
therapi
lead
impair
function
ex
vivo
opportunist
infect
unremark
clinic
cours
may
relat
lack
deplet
central
andor
failur
caus
gener
immunosuppress
sinc
higher
circul
level
result
better
clinic
respons
data
support
dose
previou
lower
phase
iii
level
help
defin
window
daniel
h
li
albert
chen
jame
tung
paulo
fontoura
larri
steinman
jane
r
parn
type
ii
transmembran
protein
express
predominantli
b
cell
act
neg
regul
b
cell
activ
bcell
receptor
bcr
howev
whether
play
role
autoimmun
unknown
found
age
mice
develop
lupuslik
autoimmun
featur
antinuclear
ab
antidna
ab
glomerulonephr
studi
mechan
spontan
autoimmun
diseas
employ
transgen
mous
model
autoimmun
elucid
b
cell
break
toler
vitro
b
cell
doubletransgen
dtg
mice
express
antihel
hen
egg
lysozym
specif
bcr
solubl
hel
circul
anerg
unrespons
hel
antigen
ag
stimul
found
b
cell
hel
dtg
mice
hyperprolif
respons
hel
ag
stimul
compar
anerg
respons
b
cell
wildtyp
wt
hel
dtg
mice
understand
signal
transduct
pathway
employ
downstream
signal
event
nfkb
nfat
erk
jnk
pathway
examin
result
show
b
cell
hel
dtg
mice
greater
nfkb
dna
bind
activ
greater
activ
greater
erk
activ
greater
jnk
activ
greater
activ
compar
b
cell
wt
hel
dtg
mice
next
examin
earli
event
signal
found
calcium
flux
respons
hel
ag
stimul
greatli
enhanc
hel
dtg
b
cell
compar
wt
hel
dtg
b
cell
identifi
target
signal
immedi
follow
stimul
examin
phosphoryl
statu
mani
earli
signal
molecul
lyn
syk
igab
blnk
vav
cbl
etc
result
show
cblb
direct
target
signal
determin
whether
effect
b
cell
toler
clinic
relev
develop
autoimmun
diseas
induc
eae
experiment
autoimmun
encephalomyel
wt
mice
found
mog
peptid
induc
earlier
onset
sever
eae
mice
compar
wt
mice
taken
togeth
find
indic
play
essenti
role
modul
b
cell
peripher
toler
identif
target
selfantigen
ischemiareperfus
injuri
ischemiareperfus
injuri
ir
potenti
lifethreaten
disord
repres
acut
inflammatori
respons
follow
period
ischemia
result
myocardi
infarct
stroke
surgeri
trauma
recent
identif
monoclon
natur
igm
initi
ir
led
identif
conserv
selfantigen
target
util
proteom
phagedisplaypeptid
librari
identifi
antigen
epitop
ir
specif
antigen
develop
peptid
inhibitor
injuri
three
differ
model
intestin
skelet
muscl
heart
result
identifi
novel
pathway
innat
respons
highli
conserv
selfantigen
result
tissu
destruct
gener
autoimmun
mechan
previou
studi
reveal
common
hla
class
ii
haplotyp
confer
predisposit
protect
iddm
ms
jca
pemphigu
vulgari
pv
sle
bulgarian
popul
order
evalu
role
hla
antigen
autoimmun
diseas
look
common
sequenc
motif
hipervari
region
molecul
encod
protect
predispos
allel
found
bchain
code
common
predispos
allel
similar
hvr
iii
motif
pocket
electr
charg
pocket
gener
residu
similar
characterist
observ
molecul
code
predispos
allel
popul
pv
ms
sle
protect
allel
code
molecul
neutral
charg
pocket
absenc
pocket
predispos
allel
encod
common
motif
part
motif
share
predispos
popul
allel
ms
sle
bchain
encod
common
protect
character
differ
hydrophob
amino
posit
similarli
protect
iddm
allel
bulgarian
conclus
base
result
suggest
one
amino
acid
region
bchain
dr
dq
molecul
predict
involv
process
antigen
bind
helic
region
import
diseas
predisposit
protect
vivo
blockad
human
receptor
induc
expans
bright
regulatori
nk
cell
patient
activ
uveiti
zhuqe
li
wee
kiak
lim
sankaranarayana
p
mahesh
robert
b
nussenblatt
laboratori
immunolog
nation
eye
institut
nih
bethesda
md
usa
singapor
nation
eye
center
singapor
singapor
vivo
blockad
human
receptor
antibodi
use
immunosuppress
transplant
therapi
leukemia
autoimmun
diseas
studi
report
administr
human
block
antibodi
induc
expans
bright
regulatori
nk
cell
uveiti
patient
time
induc
bright
regulatori
nk
cell
treat
patient
exhibit
phenotyp
normal
donor
except
lower
level
express
addit
patient
activ
uveiti
significantli
lower
level
bright
regulatori
nk
cell
peripheri
compar
normal
donor
p
b
induct
bright
regulatori
nk
subset
occur
prior
onset
clinic
therapeut
effect
observ
may
implic
potenti
role
bright
regulatori
nk
cell
autoimmun
diseas
blockad
therapi
declin
immunocompet
age
accompani
steadili
increas
incid
autoimmun
diseas
reduc
thymic
output
import
aspect
immunosenesc
induc
compensatori
autoprolifer
process
lead
prematur
senesc
cell
contribut
immun
abnorm
associ
autoimmun
age
studi
test
whether
immun
system
patient
rheumatoid
arthriti
ra
multipl
sclerosi
ms
ankylos
spondyl
show
sign
ageindepend
age
therefor
measur
two
indic
age
number
cell
receptor
excis
circl
trec
percentag
null
cell
peripher
blood
mononuclear
cell
pbmc
addit
characterist
senesc
null
cell
analyz
pbmc
isol
blood
ra
ms
patient
well
healthi
control
hc
percentag
null
cell
measur
flow
cytometri
number
trec
ng
gdna
determin
realtim
pcr
analysi
intracellular
fac
analysi
fragment
length
analysi
use
determin
cytokin
profil
clonal
origin
null
cell
respect
ra
ms
patient
trec
number
significantli
decreas
compar
agematch
hc
trec
number
compar
patient
hc
furthermor
increas
percentag
null
cell
detect
ra
patient
ms
patient
patient
versu
hc
hc
ra
patient
presenc
haplotyp
genet
risk
factor
develop
ra
found
link
percentag
null
cell
null
cell
also
detect
synovi
tissu
ra
patient
analysi
null
cell
reveal
clonal
expans
proinflammatori
properti
studi
provid
indic
prematur
senesc
immun
system
ra
ms
patient
prematur
age
associ
thymic
involut
compensatori
autoprolifer
might
play
import
role
pathogenesi
autoimmun
null
cell
tissu
damag
properti
prematur
increas
ra
ms
patient
might
therefor
play
activ
role
pathogenesi
autoimmun
diseas
studi
necessari
reveal
exact
role
age
immun
system
particular
role
null
cell
pathogenesi
autoimmun
shown
presenc
autoantibodi
patient
thyroid
immun
diseas
igg
iga
ige
antibodi
patient
helicobact
pylori
infect
chronic
bidiopathicq
urticaria
cough
present
almost
patient
either
diseas
subset
chronic
b
idiopathicq
urticaria
patient
diseas
caus
presenc
igg
autoantibodi
high
affin
ige
receptor
fcqria
antiig
autoantibodi
function
autoantibodi
stimul
normal
activ
mast
cell
basophil
via
fcqria
caus
wheal
angioedema
cough
aim
studi
evalu
patient
chronic
idiopath
urticaria
andor
cough
presenc
helicobact
pylori
antibodi
andor
thyroid
autoimmun
histamin
releas
preval
igg
autoantibodi
fceria
antiig
autoantibodi
patient
posit
thyroid
autoimmun
helicobact
pylori
infect
levothyroxin
sodium
hp
erad
therapi
method
patient
chronic
urticaria
cough
follow
investig
perform
skin
prick
test
aeroallergen
food
allergen
blood
test
antithyroid
antibodi
aat
atpo
tsh
helicobact
pylori
antibodi
igg
iga
total
ige
autolog
serum
skin
test
aspt
patient
posit
anthithyroid
hp
antibodi
histaminereleas
activ
serum
igg
antifca
ri
e
antiig
patientst
sera
result
preliminari
data
show
patient
normal
thyrotropin
level
patient
thyroid
autoimmun
cough
also
urticaria
patient
hp
posit
urticaria
also
cough
patient
aspt
antibodi
posit
aspt
histamin
releas
posit
remiss
rate
either
partial
complet
urticaria
cough
patient
treat
levothyroxin
patient
treat
hp
erad
therapi
neg
breath
test
treatment
remiss
urticaria
patient
aspt
antibodi
posit
aspt
histamin
releas
posit
conclus
result
suggest
histamin
releas
autoantidodi
import
pathogenesi
chronic
urticaria
cough
stimul
facilit
degranul
basophil
coutan
mast
cell
crosslink
cell
surfac
ige
receptor
receptor
constant
region
igg
fcgr
link
humor
cellular
arm
immun
system
dysregul
implic
develop
autoimmun
condit
particularli
system
lupu
erythematosu
sle
polymorph
posit
transmembran
domain
inhibitori
receptor
fcgriib
result
isoleucin
threonin
substitut
preval
sle
patient
use
fcgriibneg
monocyt
cell
line
assess
consequ
express
either
wild
type
wt
mutant
fcgriib
activatori
fcg
receptor
function
express
wt
prevent
lysosom
traffick
immun
complex
superoxid
gener
inhibit
phagocytosi
opsonis
pneumococci
reduc
proinflammatori
cytokin
releas
receptor
unabl
partit
lipid
raft
exclud
proinflammatori
signal
complex
primari
macrophag
homozygot
show
similar
defect
fcgr
control
correct
lentivir
introduct
wt
fcgriib
thu
receptor
polymorph
radic
alter
cellular
respons
opsonis
particl
may
predispos
develop
sle
mutat
first
describ
could
contribut
diseas
exclud
surfac
receptor
lipid
raft
potenti
repres
novel
mechan
underli
human
genet
diseas
aim
investig
studi
compar
vitro
synthesi
serum
concentr
gifn
tgfb
patient
aitg
materi
method
patient
aitd
studi
control
group
consist
healthi
volunt
similar
investig
patient
sex
age
serum
concentr
gifn
tgfb
mnc
supernat
level
h
cultur
cytokin
determin
use
elisa
method
result
increas
serum
concentr
cytokin
gifn
growth
factor
tgfb
note
studi
group
compar
control
group
increas
serum
concentr
gifn
accompani
increas
synthesi
peripher
mnc
time
comparison
control
data
averag
serum
concentr
tgfb
aitd
pgml
control
pgml
p
serum
concentr
gifn
time
higher
control
group
conclus
increas
serum
concentr
gifn
tgfb
increas
synthesi
peripher
mnc
gifn
suggest
cytokin
well
growth
factor
tgfb
play
import
role
aitd
g
j
tobon
p
vega
r
pinedatamayo
j
anaya
rheumatolog
clinica
universitaria
bolivariana
medellin
colombia
cellular
biolog
immunogenet
unit
corporacion
para
investigacion
biologica
medellin
colombia
object
current
studi
investig
presenc
autoimmun
diseas
aid
among
first
degre
rel
fdr
primari
sjfgrent
syndrom
pss
type
diabet
mellitu
patient
materi
method
purpos
casecontrol
studi
undertaken
individu
interview
person
use
questionnair
sought
inform
demograph
medic
characterist
includ
aid
famili
histori
result
pss
women
defin
accord
revis
european
criteria
match
control
without
aid
found
famili
least
one
fdr
aid
control
ci
p
aid
regist
fdr
patient
compar
fdr
control
ci
p
b
sixtyfour
aid
observ
fdr
patient
five
one
aid
fdr
among
control
one
aid
ci
p
b
patient
defin
accord
expert
committe
criteria
patient
match
control
without
aid
patient
fdr
least
one
aid
control
characterist
ci
p
among
patient
aid
regist
fdr
compar
fdr
among
control
ci
p
frequent
aid
regist
fdr
pss
patient
autoimmun
hypothyroid
rheumatoid
arthriti
fdr
patient
autoimmun
hypothyroid
conclus
result
indic
famili
autoimmun
major
trait
aid
thu
sustain
common
variantsmultipl
diseas
hypothesi
emphas
similar
immunogenet
mechan
underli
aid
experiment
autoimmun
uveoretin
eau
anim
model
autoimmun
inflammatori
eye
diseas
activ
macrophag
play
critic
role
tissu
destruct
retina
sinc
deplet
macrophag
reduc
retin
damag
without
concomit
reduct
number
infiltr
cell
macrophag
activ
modul
signal
receiv
local
microenviron
solubl
cytokin
ifng
tnfa
well
signal
receiv
cell
surfac
receptor
interact
exampl
use
mediat
product
nitrit
measur
activ
vitro
eau
studi
cours
diseas
vivo
analys
activ
wild
type
macrophag
model
multipl
sclerosi
experiment
autoimmun
encephalomyel
mice
resist
induct
eau
lower
incid
diseas
lower
diseas
score
prime
cell
modestli
impair
time
anim
reach
peak
diseas
antigen
specif
prolifer
spleen
significantli
reduc
mice
investig
macrophag
function
assess
vitro
activ
variou
stimul
respons
stimul
ifng
wild
type
mice
produc
substanti
amount
hand
mice
stimul
produc
ifng
activ
test
whether
due
autocrin
stimul
low
level
tnfa
stimul
wild
type
macrophag
ifng
presenc
stnfrig
fusion
protein
bind
free
tnfa
show
also
block
product
contrast
impair
activ
synthesi
mhc
class
ii
upregul
indistinguish
wild
type
mice
stimul
ifng
address
whether
signal
essenti
product
stimul
macrophag
lp
condit
wild
type
mice
produc
equival
amount
togeth
result
show
select
aspect
ifng
mediat
activ
macrophag
control
autocrin
secret
tnfa
control
bypass
presenc
signal
gener
pathogenassoci
molecular
pattern
recognis
receptor
macrophag
activ
proinflammatori
milieu
may
therefor
modifi
presenc
pathogen
deriv
signal
may
differ
autoimmun
diseas
inflamm
occur
absenc
foreign
immun
system
activ
impli
model
activ
suffici
prime
occur
presenc
mycobacteri
deriv
product
drain
lymph
node
macrophag
expos
ifng
alon
retina
fundament
mainten
peripher
toler
great
therapeut
potenti
howev
effort
hamper
limit
cell
number
vivo
anerg
phenotyp
vitro
rudimentari
understand
molecular
basi
function
state
treg
previous
shown
cell
activ
tcr
result
activ
bind
ligand
hyaluronan
ha
interact
use
cell
extravas
site
chronic
inflamm
show
cell
rapidli
extens
activ
function
activ
hyaluronanbind
form
act
tcr
trigger
cell
express
marker
compar
hr
activ
moreov
act
express
strikingli
correl
suppressor
activ
cell
contrast
surfac
marker
express
within
hr
vitro
activ
act
discrimin
enhanc
suppress
function
vitro
prolifer
assay
vivo
model
separ
treg
habind
nonhabind
fraction
multipl
cytokin
includ
tgf
preferenti
express
habind
cell
cell
also
show
preponder
suppress
function
vitro
two
vivo
model
allogen
gvhd
act
induc
rest
cell
vivo
antigen
stimul
similar
function
consequ
result
reveal
cell
surfac
marker
delin
function
activ
among
regulatori
cell
therebi
provid
novel
tool
aid
identifi
regulatori
activ
enrich
maxim
suppressor
potenc
main
featur
autoimmun
diseas
autoimmun
inner
ear
diseas
includ
menieret
diseas
develop
persist
inflammatori
process
appar
absenc
pathogen
lead
destruct
target
tissu
western
blot
analysi
shown
menieret
diseas
patient
produc
antibodi
kd
inner
ear
membran
neural
protein
identifi
htubulin
hear
loss
mice
induc
immun
htubulin
use
abr
dpoae
record
spiral
ganglion
well
hair
cell
damag
observ
morpholog
studi
tempor
bone
precis
immunolog
mechan
inner
ear
diseas
remain
obscur
current
studi
balbc
mice
subcutan
inject
htubulin
dosag
ag
cfa
per
mous
immun
boost
ifa
vari
dose
tubulin
twice
oneweek
interv
control
mice
underw
subcutan
inject
pb
cfaifa
well
week
last
boost
found
antibodi
activ
htubulin
increas
dose
depend
compar
control
control
subject
rel
unrespons
moreov
ifngamma
level
markedli
increas
serum
supernat
lymphocyt
protein
level
tgfh
significantli
reduc
follow
htubulin
immun
interestingli
flow
cytometr
analysi
spleen
cell
htubulin
induc
mice
control
mice
show
total
splenocyt
control
mice
regulatori
cell
treg
cell
popul
treg
cell
reduc
htubulin
induc
mice
follow
dose
depend
ag
ag
treg
cell
narv
mice
moreov
ifngamma
level
markedli
increas
supernat
treg
cell
cultur
protein
level
tgfh
significantli
reduc
follow
htubulin
immun
thu
data
indic
immun
reactiv
htubulin
might
respons
autoimmun
inner
ear
hear
loss
studi
requir
elucid
role
cell
pathogenesi
diseas
would
eventu
result
better
therapi
bnaturalq
regulatori
cell
treg
develop
thymu
appar
result
interact
cognat
antigen
previous
show
suscept
experiment
autoimmun
uveiti
eau
elicit
mice
retin
autoantigen
irbp
serv
model
human
uveiti
control
thymusderiv
treg
studi
examin
whether
endogen
express
irbp
necessari
gener
eaurelev
treg
compar
irbp
knockout
ko
wild
type
wt
mice
hypothes
endogen
irbp
need
gener
eaurelev
treg
deplet
cell
irbp
ko
mice
alter
respons
irbp
mice
deplet
cell
monoclon
antibodi
induc
eau
mice
immun
irbp
complet
freundt
adjuv
cfa
infus
cell
irbpimmun
donor
mice
immun
irbp
incomplet
freundt
adjuv
ifa
nonuveitogen
regimen
eau
score
associ
immunolog
respons
delay
hypersensit
prolifer
irbp
examin
immun
irbpcfa
deplet
wt
ko
enhanc
immun
respons
irbp
furthermor
irbp
prime
cell
deplet
ko
donor
elicit
sever
diseas
wt
recipi
cell
nondeplet
ko
donor
suggest
eaurelev
treg
remov
howev
immun
irbpifa
deplet
wt
deplet
ko
mice
enhanc
irbpspecif
immun
respons
suggest
irbp
specif
treg
present
wt
conclud
sinc
endogen
express
irbp
appear
need
gener
irbpspecif
treg
eaurelev
treg
irbp
ko
irbpspecif
propos
treg
activ
microbi
compon
present
cfa
inhibit
develop
irbpspecif
effector
cell
bystand
fashion
thu
innat
immun
stimul
need
elicit
eau
also
activ
regulatori
cell
help
control
diseas
background
current
treatment
option
autoimmun
condit
unabl
specif
prevent
stop
autoimmun
process
therefor
need
new
antigen
specif
therapi
autoimmun
diseas
evalu
effici
new
apl
technolog
refer
ligand
epitop
antigen
present
system
leapsk
prevent
treat
experiment
autoimmun
myocard
eam
conjug
peptid
chain
murin
cardiac
myosin
use
induc
eam
j
peptid
part
human
microglobulin
molecul
method
evalu
prophylact
therapeut
vaccin
week
old
femal
aj
mice
inject
emulsifi
adjuv
prior
eam
induct
sacrif
day
prophylact
inject
day
follow
eam
induct
sacrif
day
therapeut
eam
induc
immun
emulsifi
cfa
day
inject
pertussi
toxin
day
control
group
vaccin
pb
emulsifi
use
schedul
experi
repeat
least
twice
mice
per
group
myocard
sever
evalu
histolog
heart
bodi
weight
ratio
specif
antibodi
total
analyz
elisa
cytokin
evalu
lincomultiplex
cytokin
sera
well
heart
spleen
homogen
elisa
evalu
whether
mechan
action
due
gener
anergi
specif
respons
toward
peptid
examin
serum
antibodi
mycobacteri
antigen
ppd
cfa
elisa
antigen
specif
lympholifer
vitro
result
administr
reduc
incid
sever
eam
given
eam
induct
case
treatment
significantli
lower
heart
bodi
weight
ratio
prophylact
p
therapeut
p
sever
myocard
assess
histolog
prophylact
p
therapeut
p
lower
level
antibodi
decreas
immun
respons
antigen
specif
effect
antibodi
respons
mycobacteri
antigen
spleen
lymphocyt
treat
mice
reduc
prolif
respons
sever
eam
reduc
contrast
result
increas
level
decreas
level
ifng
heart
homogen
compar
control
discuss
conclus
use
leap
alter
peptid
ligand
prevent
vaccin
well
treatment
abl
significantli
reduc
incid
sever
experiment
autoimmun
myocard
protect
effect
vaccin
antigen
specif
result
treatment
observ
increas
level
found
protect
level
proinflammatori
sera
ifng
heart
decreas
support
nih
grant
activ
selfreact
cell
healthi
adult
prevent
presenc
autoantigenspecif
regulatori
cell
treg
better
understand
human
autoantigenreact
treg
select
expand
investig
thymic
treg
children
treg
cord
blood
abl
suppress
prolifer
cytokin
product
induc
specif
antigen
cell
fraction
purifi
magnet
cell
separ
prolifer
cytokin
product
analys
stimul
neural
antigen
myelin
oligodendrocyt
glycoprotein
mog
polycon
stimuli
staphylococc
enterotoxin
b
seb
prolifer
respons
mog
addit
equal
number
thymic
cell
significantli
suppress
prolifer
howev
thymic
cell
inhibit
ifng
product
induc
mog
indic
presenc
mogrespons
treg
thymu
contrast
cord
blood
treg
suppress
prolifer
ifng
product
induc
mog
interestingli
thymic
cord
blood
cell
suppress
prolifer
cytokin
product
induc
seb
cord
blood
thymic
treg
express
mrna
express
lower
cord
blood
thymic
cell
probabl
due
presenc
low
cell
addit
high
cell
cord
blood
summari
suppress
immun
respons
mog
easili
detect
cord
blood
thymu
suggest
mogreact
treg
expand
peripheri
howev
cord
blood
deriv
cell
suppress
seb
induc
respons
express
lower
level
indic
cell
cord
blood
regulatori
antigen
process
mhc
ii
compart
human
dendrit
cell
dc
poorli
understood
howev
strategi
might
interfer
process
eg
autoantigen
warrant
particular
inform
natur
sequenc
proteas
especi
cathepsin
cat
attack
given
exogen
antigen
uptak
live
human
dc
lack
monitor
uptak
beadcoupl
chemic
affin
probe
cathepsin
cat
activ
recent
demonstr
murin
dc
select
rout
probe
catscontain
compart
use
similar
approach
follow
uptak
cathepsinbind
affin
probe
live
human
dc
gener
monocyt
vitro
found
contrast
murin
dc
human
dc
poorli
intern
exogen
materi
phagozytosi
much
effici
fluid
phaseendocytosismedi
uptak
probe
compar
murin
cell
cell
lysat
activ
cat
catb
cath
catz
catl
decor
probe
intern
probe
live
human
dc
reveal
select
label
cat
catb
decor
cath
catz
endocytosi
puls
chase
analysi
signal
activ
cat
select
increas
chase
period
min
indic
exogen
ad
materi
select
rout
catsconta
compart
fluid
phase
endocytosi
human
dc
treatment
dc
chloroquin
reduc
cellular
uptak
cathepsin
label
expect
hatpaseinhibitor
concanamycin
b
select
abrog
label
catb
like
due
phdepend
activ
enzym
treatment
dc
lp
reduc
total
amount
cat
reach
probe
due
decreas
intern
also
abrog
increas
cat
label
seen
untreat
dc
without
matur
stimulu
total
amount
activ
cat
remain
unchang
suggest
intern
also
intracellular
transport
catscontain
compart
affect
dc
matur
summari
cat
liekli
present
function
domin
cystein
proteas
antigen
process
mhc
class
ii
compart
live
human
dc
exogen
pancathepinreact
probe
select
bind
cat
intern
fluidphas
endocytosi
induct
treg
suppress
activ
product
object
studi
regulatori
cell
treg
suppress
cell
activ
vitro
regul
multipl
immun
reaction
vivo
shown
requir
treg
homeostasi
show
addit
import
activ
treg
suppress
activ
moreov
sinc
treg
produc
depend
produc
activ
cell
also
provid
new
concept
regul
treg
activ
target
cell
via
materi
method
use
vitro
cultur
system
purifi
cell
popul
analys
specif
effect
treg
addit
studi
role
treg
activ
vivo
cell
transfer
system
result
other
previous
shown
vitro
blockad
receptor
treg
cocultur
respond
cell
complet
block
suppress
activ
demonstr
uptak
prime
treg
requir
induc
capac
produc
upon
restimul
induc
signific
product
narv
cell
suffici
induc
product
treg
act
synergist
furthermor
vivo
applic
genegun
immun
normal
mice
select
activ
treg
induc
complet
suppress
prolifer
transfer
popul
ovaspecif
cell
respons
vaccin
ovalbumin
conclus
result
show
potent
induc
treg
suppress
activ
includ
product
regul
treg
activ
produc
target
cell
allow
adapt
treg
effector
function
strength
immun
respons
furthermor
specif
activ
treg
suppress
activ
vivo
may
repres
new
strategi
therapeut
intervent
autoimmun
chronic
inflamm
natur
antibodi
well
antibodi
autoimmun
strain
mice
shown
mediat
mesenter
ischemiareperfus
ir
induc
tissu
injuri
intestin
injuri
initi
neoantigen
revel
ischem
apoptot
cell
bound
antibodi
complement
activ
addit
local
intestin
damag
remot
tissu
damag
lung
occur
autoimmun
mice
report
injuri
older
five
month
anim
acceler
increas
sever
mice
defici
defici
complement
compon
resist
irinduc
tissu
damag
passiv
antibodi
transfer
either
purifi
natur
antibodi
igg
serum
older
mice
defici
mice
restor
irinduc
tissu
damag
previou
studi
indic
autoantibodi
contribut
tissu
damag
complement
activ
tissu
organ
suffer
anoth
damag
event
ischemia
howev
clear
particular
neoantigen
domin
initi
irinduc
tissu
damag
relationship
local
intestin
remot
lung
tissu
damag
clear
subsequ
expand
upon
autoimmun
studi
examin
autoantibodi
specif
either
dsdna
ssdna
vari
concentr
would
caus
equival
local
remot
irinduc
tissu
damag
expect
high
concentr
passiv
transfer
antidna
antibodi
mice
result
local
intestin
remot
damag
howev
lower
concentr
antidsdna
antibodi
effici
facilit
mesenter
irinduc
tissu
damag
remot
lung
damag
evalu
transfer
antidsdna
antibodi
result
increas
septal
thicken
cellular
infiltr
lung
compar
transfer
antissdna
antibodi
wild
type
control
mice
studi
address
recruit
cellular
infiltr
level
complement
deposit
signal
control
polymorphonuclear
neutrophil
infiltr
intestin
lung
tissu
ongo
studi
may
help
clarifi
role
circul
auto
antibodi
organ
damag
patient
mice
system
lupu
erythematosi
member
superfamili
costimulatori
molecul
import
role
regul
immun
respons
broadli
express
b
cell
cell
dendrit
cell
macrophag
nk
cell
may
indic
molecul
particip
immun
regul
via
variou
cell
type
import
interact
receptor
autoimmun
clearli
address
system
lupu
erythematosu
sle
complex
autoimmun
diseas
character
product
autoantibodi
particular
antinuclear
antibodi
b
cell
hyperact
activ
selfreact
cell
genet
studi
indic
three
region
differ
mous
chromosom
sle
link
suscept
sle
differ
sever
subregion
sle
locu
mous
chromosom
includ
member
superfamili
present
studi
investig
role
toler
autoimmun
studi
spontan
autoimmun
diseas
occur
age
data
indic
elev
level
dsdna
antibodi
detect
elisa
anti
dsdna
igg
antibodi
level
higher
igm
level
least
higher
old
compar
old
mice
similarli
antibodi
could
clearli
detect
kidney
tissu
section
wt
mice
phenotyp
analysi
cell
old
mice
show
level
activ
marker
includ
also
increas
least
cell
compar
wt
counterpart
cell
clone
demonstr
presenc
antinucleosom
cell
respons
breakdown
toler
result
defect
activationinduc
cell
death
therefor
studi
requir
order
delin
mechan
underlin
regulatori
effect
pathway
overal
present
studi
present
evid
suggest
play
key
role
control
autoimmun
small
popul
cell
present
human
mice
abil
regul
immun
respons
cell
known
regulatori
cell
r
character
express
origin
r
thought
deriv
thymu
recent
data
suggest
adapt
r
gener
peripheri
previou
report
shown
activ
human
express
well
acquisit
cell
contact
depend
cytokin
independ
regulatori
activ
portion
origin
cell
recent
focus
determin
factor
involv
gener
type
r
lifecycl
result
lab
show
addit
gener
cultur
result
increas
number
result
regulatori
cell
wherea
blockad
cytokin
tgfh
addit
block
antibodi
gener
cultur
effect
number
function
result
r
demonstr
gener
r
independ
tgfh
enhanc
presenc
furthermor
result
show
r
result
gener
cultur
retain
suppress
abil
upon
restimul
reactiv
presenc
high
dose
expand
togeth
result
suggest
gener
r
may
good
candid
immunotherapi
due
abil
retain
suppress
activ
capac
expand
vaknindembinski
h
l
weiner
neurolog
center
neurolog
diseas
boston
usa
background
heterodimer
cytokin
compris
subunit
associ
subunit
like
express
predominantli
activ
dendrit
cell
dc
phagocyt
cell
cytokin
induc
ifnsecret
cell
unlik
also
function
stimul
secret
proinflammatori
cytokin
cell
central
role
autoimmun
inflamm
support
observ
induct
experiment
autoimmun
enceph
eae
occur
mice
lack
mice
target
disrupt
thu
express
dendrit
cell
dc
may
play
import
role
pathogenesi
human
autoimmun
diseas
one
way
explor
role
dc
function
regul
dc
gene
expressionth
aim
studi
investig
role
dc
function
evalu
use
specif
antisens
oligonucleotid
asolig
small
interf
rna
sirna
tool
silenc
express
method
transfect
human
monocyt
deriveddc
modc
specif
asoligo
small
interf
rna
sirna
compar
surfac
marker
fac
analysi
apc
function
modc
secret
lower
amount
modc
transfect
control
asoligo
control
sirna
result
found
modc
effici
transfect
asoligo
sirna
respect
transfect
dc
asoligo
sirna
specif
gene
result
potent
suppress
gene
express
blockad
bioactiv
product
without
affect
unrel
gene
cellular
viabil
inhibit
associ
increas
product
decreas
tnf
alpha
product
furthermor
transfect
modc
poor
allostimul
mix
lymphocyt
reaction
conclus
demonstr
asoligo
sirna
use
immun
modul
target
human
dendrit
cell
dc
gene
express
target
reduct
express
either
result
dc
less
potent
apc
secret
knock
express
asoligo
sirna
may
use
avenu
develop
therapi
target
dc
chronic
inflammatori
autoimmun
diseas
background
previou
studi
found
sever
form
eam
aj
mice
exhibit
phenotyp
block
monoclon
antibodi
mab
reduc
sever
eam
aj
mice
show
play
pathogen
role
eam
therefor
specul
anoth
import
cytokin
could
addit
effect
method
week
old
knockout
mice
ko
ko
doubl
knockout
dko
balbc
background
balbc
wild
type
wt
immun
myosin
balbc
peptid
emulsifi
cfa
day
inject
pertussi
toxin
day
confirm
previou
result
aj
mice
also
block
mab
balbc
wt
myocard
sever
evalu
histolog
heartbodi
weight
ratio
hwbw
myosin
peptid
specif
antibodi
analyz
elisa
cytokin
evalu
heart
spleen
homogen
elisa
result
absenc
ko
mice
well
dko
result
signific
increas
myocard
incid
sever
assess
histolog
hwbw
ratio
ko
mice
higher
histolog
score
p
well
hwbw
ratio
p
compar
balbc
wt
dko
mice
still
greater
eam
sever
balbc
wt
mice
howev
phenotyp
intermedi
ko
balbc
wt
challeng
show
clearli
pathogen
factor
balbc
eam
observ
aj
eam
balbc
moder
respond
eam
induct
therefor
could
show
statist
signific
lower
myocard
sever
histolog
absenc
balbc
background
howev
hwbw
ratio
significantli
lower
ko
mice
balbc
wt
p
suggest
promot
diseas
balbc
mice
next
increas
eam
sever
ko
mice
show
significantli
higher
level
antimyosin
peptid
igg
compar
balbc
wt
defici
result
increas
level
ifng
heart
homogen
compar
balbc
wt
discuss
conclus
induc
eam
ko
mice
abl
significantli
increas
incid
sever
myocard
show
protect
effect
eam
balbc
mice
protect
effect
also
observ
dko
mice
myocard
sever
intermedi
ko
balbc
wt
mice
intermedi
phenotyp
togeth
reduc
diseas
ko
balbc
block
anti
mab
suggest
pathogen
role
eam
balbc
mice
protect
effect
associ
increas
two
key
regulatori
cytokin
h
ifng
heart
homogen
ko
mice
two
main
cytokin
thu
opposit
effect
eam
major
protect
factor
pathogen
factor
support
nih
grant
costimul
via
pathway
requir
activ
naiv
cell
howev
precis
role
costimulatori
pathway
memori
cell
function
elucid
studi
directli
test
role
costimul
pathway
memori
function
assess
abil
block
memori
cell
function
expans
vitro
vivo
use
antigen
specif
cell
deriv
transgen
mice
express
transgen
encod
cell
receptor
specif
influenza
hemagglutinin
ha
peptid
ie
gener
haspecif
memori
cell
vitro
prime
ha
antigen
present
cell
follow
adopt
transfer
haactiv
cell
syngen
host
haspecif
memori
cell
harvest
adopt
host
week
post
transfer
vitro
recal
haspecif
memori
cell
ha
presenc
led
fifti
percent
reduct
number
produc
cell
ifng
product
compar
isotyp
control
treat
cell
test
effect
antigen
stimul
haspecif
memori
cell
vivo
transfer
cfse
label
haspecif
memori
cell
secondari
balbc
host
treat
recipi
mice
isotyp
control
boost
mice
ha
peptid
pb
observ
reduc
expans
haspecif
memori
cell
haboost
recipi
mice
treat
compar
treat
mice
total
antigenspecif
memori
cell
recoveri
haboost
mice
receiv
versu
control
control
spleen
control
lymph
node
result
indic
pathway
play
key
role
product
vivo
expans
restimul
memori
cell
find
suggest
key
role
promot
optim
memori
cell
respons
introduct
complement
candid
target
molecul
treatment
inflammatori
diseas
respiratori
distress
syndrom
sepsisth
particip
develop
autoimmun
diseas
investig
phagocyt
respons
two
activ
fc
receptor
fcgri
fcgriii
directli
implic
pathogenesi
antibodydepend
autoimmun
diseas
autoimmun
vitiligo
immun
thrombocytopen
purpura
autoimmun
hemolyt
anemia
contrast
howev
thought
play
signific
role
diseas
use
experiment
model
autoimmun
hemolyt
anemia
aiha
mice
show
although
nonphagocyt
receptor
promot
cellular
immun
destruct
antibodymedi
autoimmun
diseas
mechan
bidirect
interact
activ
fcgr
method
lethal
aiha
induc
singl
intraperiton
ip
inject
amrbc
autoantibodi
kupffer
cell
isol
percol
gradient
liver
homogen
follow
control
anem
mice
sort
interphas
magnet
bead
surfac
protein
analys
fac
mrna
express
taqman
rtpcr
liver
supernat
assay
chemotact
activ
result
conclus
present
studi
identifi
key
mediat
aiha
show
mice
lack
resist
igg
autoantibodyinduc
diseas
model
upon
administr
antierythrocyt
antibodi
defici
result
impair
fcgrmediat
vivoerythrophagocytosi
upregul
activ
fcgr
kupffer
cell
induc
earli
produc
also
absent
contrast
observ
wildtyp
mice
surprisingli
mice
defici
fcgri
fcgriii
antierythrocyt
antibodi
induc
product
abolish
identifi
activ
fcgr
domin
mediat
autoantibodyinduc
releas
thu
data
consist
pathogen
mechan
antibodydepend
hemolyt
anemia
iggopson
erythrocyt
trigger
fcgrmediat
releas
turn
activ
posit
cellular
feedback
signal
uopn
engag
result
increas
fcgri
fcgriii
express
requir
effect
erythrophagocytosi
show
develop
full
blown
antibodydepend
autoimmun
diseas
requir
cooper
activ
fcgr
activ
pathway
suggest
therapeut
benifit
blockad
aiha
diseas
close
relat
type
ii
autoimmun
injuri
work
support
deutsch
forschungsgemeinschaft
ge
regulatori
cell
differenti
requir
innat
adapt
immun
cell
inhibit
vitro
zelenay
caramalho
j
demengeot
lymphocyt
physiolog
unit
instituto
gulbenkian
de
ciencia
oeira
portug
regulatori
cell
r
implic
control
autoimmun
diseas
allergi
inflamm
develop
vitro
model
system
facilit
analysi
function
properti
cell
regard
inhibit
convent
cell
prolifer
r
current
use
assay
howev
r
suppressor
mechan
vitro
assay
remain
unknown
importantli
appear
differ
vivo
scenario
wherea
latter
case
inhibitori
cytokin
tgfbeta
shown
play
role
case
vitro
addit
competit
propos
main
suppressor
mechan
vitro
presenc
satur
amount
cultur
media
shown
affect
r
abil
suppress
product
target
cell
work
first
present
evid
r
consum
signific
amount
standard
suppress
assay
consumpt
posit
correl
suppressor
effici
similar
result
obtain
test
suppressor
cell
conclud
consumpt
cell
particip
nonspecif
manner
overal
suppress
prolifer
observ
cultur
next
describ
suppress
assay
reli
consumpt
monitor
inhibitori
function
r
compon
innat
immun
system
show
r
specif
suppress
tnfalpha
product
lp
activ
periton
cell
control
requir
express
mhc
class
ii
molecul
independ
inhibitori
cytokin
secret
tgfbeta
appear
cell
contact
depend
moreov
assay
regulatori
activ
abrog
satur
amount
ad
cultur
physiolog
relev
vitro
assay
current
test
vivo
immunolog
autoimmun
reaction
maxdelbruckcent
molecular
medicin
mdc
berlin
berlin
germani
laboratori
neuroimmunolog
ircc
santa
lucia
rome
rome
itali
object
identif
naiv
memori
subset
cell
fundament
current
understand
immun
system
gener
accept
regulatori
cell
central
element
peripher
toler
littl
known
howev
phenotyp
function
characterist
cell
regard
memori
aim
studi
therefor
identifi
regulatori
memori
cell
subset
determin
marker
specif
function
method
cell
purifi
facsmacssort
phenotyp
character
naiv
vs
memori
effector
vs
suppressor
carri
flow
cytometri
expressionlevel
transcript
factor
determin
real
time
rtpcr
function
studi
includ
vitro
prolifer
cell
migrat
assay
experiment
vivo
system
congen
sjl
tcrtg
eae
model
use
induct
memori
phenotyp
demonstr
vivo
adopt
transfer
experi
cfda
label
cell
result
studi
show
chemokin
receptor
express
distinct
subset
mous
treg
cell
similar
treg
cell
exhibit
marker
activ
memori
expans
indic
effectormemori
function
memorylik
cell
gener
vivo
cell
encount
antigen
convent
cell
high
turnov
rate
contrast
cell
respond
rapidli
restimul
vitro
upregul
treg
cell
enrich
peripher
blood
accumul
cn
induct
eae
importantli
cell
also
present
human
express
fulli
cosegreg
establish
marker
human
memori
cell
conclus
subset
treg
cell
seem
repres
popul
dregulatori
effectormemoryt
cell
rem
destin
control
potenti
destruct
immun
respons
directli
inflam
tissu
rem
cell
therefor
seem
natur
counterplay
effectormemori
cell
em
involv
primarili
frontlinesuppress
object
class
ii
mhc
molecul
upon
loos
peptid
ligand
rapidli
acquir
nonrecept
state
prevent
rebind
new
peptid
show
certain
small
molecul
abl
revers
process
recent
identifi
number
organ
compound
acceler
ligand
exchang
reaction
hladr
molecul
similar
fashion
natur
catalyst
hladm
contrast
hladm
howev
compound
effect
even
neutral
ph
therefor
mediat
ligandexchang
directli
surfac
live
cell
aim
studi
identifi
molecular
mechan
small
molecul
mediat
ligand
exchang
whether
compound
exhibit
allel
specif
method
experi
carri
solubl
hladr
molecul
express
insect
cell
kinet
bind
releas
peptid
ligand
determin
elisa
experi
effect
valid
cellular
vitro
cell
system
use
hladr
transfect
fibroblast
apc
flow
cytometri
base
peptid
bind
assay
result
mechan
found
base
inductionstabil
peptiderecept
state
facilit
load
class
ii
mhc
molecul
peptid
antigen
fulllength
protein
importantli
compound
activ
subset
hla
dr
molecul
catalys
effici
load
peptid
ligand
onto
allel
variant
hla
complet
fail
acceler
peptid
bind
hla
conclus
small
molecular
compound
influenc
ligand
composit
surfac
antigenpres
cell
allelespecif
manner
repres
novel
class
molecular
tool
use
therapeut
set
facilit
antigen
load
might
also
repres
environment
risk
factor
allergi
autoimmun
diseas
respect
strict
allelespecif
compound
could
even
influenc
appar
linkag
incid
certain
diseas
hla
dr
allel
object
postul
bulk
b
cell
receptor
bcr
edit
detect
peripher
b
cell
popul
human
murin
system
result
tolerogen
process
occur
earlier
ontogeni
b
cell
matur
possibl
substanti
studi
demonstr
bone
marrow
b
cell
cultur
ex
vivo
capabl
edit
bcr
face
self
antigen
purpos
current
studi
determin
whether
immatur
b
cell
isol
directli
murin
bone
marrow
display
evid
bcr
light
chain
edit
method
hybridoma
studi
mice
antidna
v
h
dj
h
transgen
insert
igh
locu
upstream
c
suggest
igk
edit
reflect
two
way
preferenti
rearrang
gene
segment
also
skew
distribut
vk
gene
usag
hybridoma
approach
howev
unabl
distinguish
event
earli
late
b
cell
ontogeni
matur
splenocyt
captur
via
cell
fusion
look
igk
gene
usag
strictli
defin
immatur
b
cell
popul
bone
marrow
mice
phenotyp
igma
igmb
express
igh
transgen
igmaigmb
express
endogen
igh
singl
cell
sort
plate
rtpcr
amplif
sequenc
express
igk
gene
perform
ident
jk
segment
vk
gene
famili
assign
use
ncbi
igblast
websit
wwwncbinlmnihgovigblast
result
evid
vivo
receptor
edit
bone
marrow
reveal
compar
igk
gene
express
igma
b
cell
n
igmb
control
popul
n
potenti
autoreact
igma
popul
j
segment
rearrang
skew
toward
downstream
element
p
furthermor
two
subset
immatur
b
cell
significantli
differ
predilect
vk
famili
gene
usag
p
particular
express
antidna
gener
gene
substanti
reduc
express
cell
versu
control
p
respect
summari
descript
igk
gene
express
primari
b
cell
bone
marrow
transgen
mice
demonstr
receptor
edit
begin
earli
immatur
b
cell
stage
develop
nonetheless
comparison
observ
sequenc
analys
b
cell
varieti
sourc
clearli
indic
select
forc
continu
shape
matur
b
cell
repertoir
beyond
stage
develop
probabl
well
migrat
murin
bone
marrow
peripher
lymphoid
tissu
introduct
igg
immun
complex
ic
induc
inflammatori
reaction
trigger
two
pathway
complement
system
especi
cellular
receptor
igg
fcgr
mice
ic
interact
either
three
cellular
receptor
two
fcgri
fcgriii
lead
cellular
activ
fcgriib
inhibitori
receptor
hallmark
immun
respons
ic
abil
modul
balanc
receptor
recent
report
identifi
depend
invers
regul
fcgriii
versu
fcgriib
lung
macrophag
mous
model
acut
alveol
object
studi
carri
analyz
underli
cellular
molecular
mechan
cooper
immuneregul
ic
lung
patholog
method
method
use
studi
includ
adapt
cell
transfer
experi
alveolar
macrophag
deplet
fcgr
defici
mice
reconstitut
exvivo
modifi
congen
mice
modul
fcgr
express
function
consequ
analyz
presenc
specif
pathway
inhibitor
quantifi
ic
injuri
chemotaxi
taqman
rtpcr
fac
analysi
result
conclus
analyz
novel
regulatori
crosstalk
domin
event
lung
arthu
reaction
classic
anim
model
immun
complex
ic
diseas
strikingli
initi
contact
ic
result
cellular
regul
lead
plasma
complementindepend
product
select
ga
depend
signal
mediat
fcgr
alter
toward
fcgriii
main
induc
tnfa
ligand
product
distinct
inhibitor
refin
inflammatori
cascad
effect
diseas
prevent
thu
indic
cellular
compon
like
ga
potenti
new
therapeut
target
treatment
inflamm
autoimmun
diseas
summari
result
impli
revis
multimolecular
model
inflammatori
cascad
remark
find
show
macrophag
function
altern
sourc
data
also
highlight
import
local
cellular
mechan
diseas
pathogenesi
support
md
phd
program
mhh
deutsch
forschungsgemeinschaft
cell
autoimmun
immunoregul
express
lymphocyt
known
play
signific
role
pathogenesi
inflamm
autoimmun
stimul
autoreact
b
cell
directli
result
autoantibodi
product
howev
recent
publish
data
indic
autoaggress
lymphocyt
also
express
includ
cell
mice
collagen
induc
arthriti
cia
lab
extens
studi
signal
b
cell
report
prompt
us
produc
mous
human
jurkat
cell
line
express
transfect
human
h
object
studi
compar
signal
b
vst
cell
well
character
possibl
costimulatori
molecul
lymphocyt
b
cell
cell
bind
cytoplasm
adaptor
protein
call
tnfr
associ
factor
traf
includ
howev
mediat
traf
degrad
less
effici
cell
compar
b
cell
counterpart
stimul
cell
lead
jnk
nfnb
activ
tnfa
product
particular
interest
abil
act
costimulatori
molecul
cell
receptor
signal
b
cell
receptor
stimul
transfect
cell
cell
express
mice
cia
alon
lead
minim
secret
ifng
howev
stimul
via
conjunct
andor
result
significantli
increas
secret
cytokin
increas
cytokin
product
parallel
increas
nfnb
activ
via
classic
altern
pathway
well
increas
activ
jnk
find
particularli
excit
suggest
cell
specif
inhibit
signal
could
mean
block
autoimmun
respons
without
alter
gener
immun
function
lab
demonstr
bcell
blast
activ
lp
antiig
transfect
retroviru
encod
iggpeptid
fusion
protein
tolerogen
normal
prime
recipi
success
achiev
multipl
antigen
differ
mous
strain
rat
preclin
model
ms
uveiti
diabet
also
demonstr
class
ii
mhc
present
b
cell
necessari
toler
ig
carrier
enhanc
degre
durat
toler
adapt
system
murin
model
hemophilia
approxim
hemophilia
patient
make
inhibitori
antibodi
block
clot
therefor
revers
potenti
therapeut
benefit
factor
viii
deliveri
know
inhibitor
direct
epitop
domain
factor
viii
thu
clinic
applic
hemophilia
insert
residu
factor
viii
domain
fviii
domain
onto
igg
heavi
chain
backbon
respect
induc
toler
hemophilia
mice
specif
toler
domain
induc
protocol
importantli
combin
express
b
cell
induc
toler
full
length
fviii
molecul
result
support
domin
domain
immun
respons
fviii
toler
manifest
term
elisa
titer
tcell
prolifer
especi
bethesda
unit
titer
reduct
importantli
similar
result
obtain
even
treatment
initi
mice
preform
antifviii
titer
indic
potenti
treatment
patient
binhibitorq
titer
recent
data
suggest
regulatori
cell
need
vivo
toler
induct
transfect
b
cell
studi
hold
promis
futur
clinic
trial
hemophilia
patient
genet
environment
factor
decis
etiolog
type
diabet
virus
propos
trigger
environment
event
evid
report
ie
type
ifn
exist
pancreata
diabet
patient
transgen
mice
express
molecul
beta
cell
develop
diabet
group
gener
first
nod
mice
express
type
ifn
ripifnbeta
islet
new
model
autoimmun
diabet
mice
develop
acceler
diabet
week
age
equival
childhood
human
cumul
incid
reach
week
age
earlyonset
diabet
character
select
destruct
beta
cell
mhc
class
hyperexpress
islet
sever
insul
high
number
natur
killer
cell
pancrea
nk
cell
innat
immun
cell
control
certain
viru
infect
tumor
recent
associ
destruct
form
pancreat
islet
autoimmun
nod
mice
signific
increas
nk
cell
nkt
cell
observ
insul
nod
riphuifnbeta
riphuifnbeta
transgen
mice
earli
onset
diabet
compar
healthi
subject
high
amount
pancreat
nk
cell
found
transgen
mice
nod
wild
type
develop
diabet
week
age
percentag
nk
cell
spleen
pancreat
region
lymph
node
alter
diabet
anim
earli
late
compar
healthi
anim
subset
nk
cell
maintain
diseas
decreas
quickli
hour
clinic
onset
imbal
nk
nkt
subset
exist
earli
onset
transgen
mice
nodscid
ripifnbeta
unabl
produc
matur
b
lymphocyt
although
unaffect
nk
subset
develop
diabet
thu
suggest
need
interact
nk
cell
lymphocyt
subset
b
autoimmun
microarray
experi
demonstr
correl
nk
cell
subset
earli
onset
diabet
islet
express
adhes
molecul
costimulatori
molecul
cytokin
ifngamma
nk
attract
chemokin
rant
lymphotactin
sinc
type
ifn
product
take
place
cell
infect
mainli
virus
transgen
model
could
interest
tool
studi
product
ifnbeta
caus
cellular
stress
gener
danger
signal
inflamm
eventu
nk
cellmedi
autoimmun
character
role
nk
cell
earli
onset
may
help
us
understand
prevent
autoimmun
diseas
dendrit
cell
dc
potent
antigen
present
cell
capabl
antigen
uptak
present
immatur
development
stage
dc
thought
induc
tcell
anergi
immatur
dc
high
rate
endocytosi
low
level
mhc
class
ii
mhcii
costimulatori
molecul
express
upon
matur
dc
downregul
mechan
antigen
captur
increas
costimulatori
molecul
express
steadi
state
mean
absenc
acut
infect
inflamm
dc
deliv
antigen
cell
without
essenti
costimulatori
molecul
induc
cell
toler
key
role
dc
induct
immun
infecti
agent
malign
transplant
allograft
mainten
cell
toler
peripheri
prompt
interest
use
immunotherapeut
agent
object
studi
examin
whether
bacteri
lipopeptid
blp
may
induc
phenotyp
function
chang
associ
dc
matur
tolllik
receptor
method
dc
gener
bone
marrow
precursor
bmdc
use
granulocytemacrophag
coloni
stimul
factor
gmcsf
day
appropri
cytokin
ad
assess
dc
matur
use
lp
tnf
blp
stimul
mhcii
surfac
molecul
express
determin
use
murin
monoclon
antibodi
conjug
phycoerithrin
pe
isocthiocyan
fitc
flow
cytometri
capac
bmdc
endocytos
antigen
determin
flow
cytometri
use
fitcconjug
dextran
result
demonstr
bmdc
gener
vitro
use
gmcsf
blp
two
day
show
high
mhcii
express
increas
yield
differenti
dc
express
molecul
affect
presenc
blp
phenotyp
featur
dc
correspond
semimatur
smdc
development
stage
contrast
bonemarrow
precursor
cultur
five
day
blp
stimulu
altern
standard
protocol
use
tnf
lp
eight
day
yield
number
differenti
dc
matur
phenotyp
demonstr
function
assay
conclus
protocol
shown
rapid
effici
gener
smdc
tolerogen
characterist
matur
dc
use
immunolog
therapi
financ
background
object
mucos
administr
antigen
establish
method
induc
immunolog
toler
mucos
administr
auto
alloantigen
effect
treatment
anim
model
autoimmun
inflamm
transplant
parenter
administr
efficaci
anim
model
autoimmun
human
approv
therapi
transplant
reject
posit
result
report
patient
new
onset
type
diabet
treat
parenter
investig
effect
mucos
administ
anim
model
autoimmun
transplant
method
oral
nasal
administ
fragment
appropri
isotyp
control
antibodi
dose
rang
result
sjl
model
plp
induc
eae
suppress
eae
given
prior
peak
diseas
plp
specif
immun
respons
fed
anim
immun
plp
demonstr
decreas
prolif
respons
reduc
secret
increas
secret
tgfb
oral
associ
increas
number
tgfb
latenc
associ
peptid
mesenter
lymph
node
lap
cell
suppress
prolifer
cell
vitro
adopt
transfer
cell
suppress
eae
tgfb
depend
fashion
modul
surfac
cell
occur
oral
similar
result
obtain
mog
induc
chronic
eae
nod
mous
patholog
less
cell
macrophag
spinal
cord
suppress
also
occur
fragment
nod
model
diabet
oral
given
neonat
period
suppress
incid
diabet
streptozocin
induc
diabet
oral
suppress
diabet
associ
cell
whose
suppress
function
increas
oral
vivo
neutral
tgfb
revers
suppress
effect
model
collagen
induc
arthriti
nasal
suppress
incid
arthriti
associ
decreas
level
tnf
joint
effect
mucos
administ
collagen
allogen
cardiac
transplant
balbc
oral
given
day
continu
day
post
transplant
cardiac
transplant
mice
receiv
oral
surviv
averag
day
vs
day
control
p
conclus
given
oral
nasal
immunolog
activ
mucos
surfac
fc
portion
ig
molecul
requir
immunolog
effect
oral
induc
regulatori
cell
character
surfac
lap
function
tgfb
depend
fashion
result
identifi
novel
physiolog
mechan
induc
regulatori
cell
clinic
applic
varieti
immun
mediat
disord
hit
seriou
complic
heparin
therapi
caus
antibodi
ab
complex
high
molecular
weight
heparin
endogen
protein
platelet
factor
lead
limb
andor
lifethreaten
thrombosi
affect
patient
interest
understand
basi
import
clinic
observ
hit
autoab
form
heparin
patient
small
percentag
develop
thrombocytopenia
andor
thrombosi
present
work
show
gel
filtrat
heparin
form
antigen
ulc
narrow
molar
ratio
reactant
ulc
stabl
visibl
electron
microscopi
dissoci
smaller
complex
sc
upon
addit
heparin
format
ulc
ineffici
incub
low
molecular
weight
heparin
none
form
pentasaccharid
fondaparinux
mutat
studi
show
format
ulc
depend
capac
form
tetram
assembl
multimolecular
lattic
heparin
scaffold
ulc
capabl
bind
hitlik
monoclon
abcomplex
antigen
sc
capabl
caus
platelet
activ
aband
fcgriiadepend
addit
human
mous
platelet
vascular
cell
lead
selfassembl
antigen
complex
presum
nucleat
membran
glycosaminoglycan
gag
evok
bind
hitlik
monoclon
ab
cell
dosedepend
manner
narrow
rang
concentr
induc
fcgriiadepend
platelet
activ
analog
ulc
conclud
capac
form
ulc
compos
multipl
tetram
array
lattic
sever
molecul
heparin
andor
gag
may
play
fundament
role
autoab
format
capac
ulc
bind
multipl
ab
crosslinktrigg
fcgriia
promot
platelet
activ
explain
propens
thrombosi
current
test
hypothesi
patient
high
steadyst
level
surfac
base
genotyp
acquir
platelet
activ
like
gener
autoab
form
ulc
develop
hit
object
compar
optim
freez
protocol
pbmc
taken
whole
blood
detect
autorect
cell
background
detect
effect
potenti
immunomodulatori
drug
autoreact
cell
clinic
trial
perform
immun
toler
network
employ
assay
quantifi
cell
respons
autoantigen
central
assay
facil
use
reduc
problem
intersit
variabl
howev
intersit
variabl
occur
prepar
pbmc
sampl
variou
geograph
locat
step
requir
freez
pbmc
prior
ship
well
thaw
sampl
prior
assay
therefor
examin
effect
freez
thaw
procedur
minim
intersit
variabl
result
cell
assay
method
pbmc
healthi
donor
ms
patient
isol
ficol
separ
part
sampl
expos
differ
dose
tetanu
toxoid
myelin
antigen
pha
antigen
part
frozen
week
use
variou
freez
media
temperatur
prior
stimul
cell
assay
prolifer
h
thymidin
incorpor
cytokin
product
elisa
flow
cytometri
fac
elispot
cell
deathapoptosi
fac
assay
parallel
fresh
frozen
sampl
subpopul
pbmc
phenotyp
fac
analysi
result
cell
viabil
recoveri
decreas
cycl
freezingthaw
respect
viabil
well
pbmc
respons
antigen
significantli
improv
human
ab
serum
dmso
use
freez
cell
viabil
pbmc
use
fetal
bovin
serum
dmso
result
fair
viabil
high
background
prolifer
cytokin
product
use
cold
freez
media
decreas
viabil
respons
cell
antigen
pbmc
better
preserv
numer
function
retain
greater
respons
antigen
temperatur
freez
medium
use
kept
use
optim
condit
find
signific
differ
cell
popul
percentag
fresh
frozen
regard
activ
memori
cell
conclus
found
expect
freez
thaw
pbmc
decreas
cell
viabil
cell
respons
decreas
count
viabil
disproportion
affect
specif
cell
popul
among
examin
best
combin
freez
condit
obtain
use
human
ab
dmso
thu
identifi
procedur
optim
pbmc
viabil
cell
respons
pha
panel
nomin
selfantigen
protocol
adopt
standard
oper
procedur
studi
conduct
itn
therefor
expand
itnt
capabl
evalu
mechan
diseas
treatment
respons
multicent
trial
mbl
member
collectin
famili
structur
similar
lung
collectin
spa
spd
addit
mbl
function
similar
activ
complement
activ
classic
pathway
mbl
lectin
pathway
like
mbl
circul
serum
protein
sequest
site
inflamm
infect
limit
report
patient
defici
mbl
rais
possibl
lack
mbl
manner
similar
defici
might
associ
autoimmun
cell
die
apoptosi
import
target
autoantibodi
develop
system
lupu
failur
remov
die
cell
implic
develop
autoimmun
defici
show
mbl
like
collectin
abl
bind
apoptot
cell
vitro
use
mice
defici
mous
mbl
gene
mbla
mblc
demonstr
mbl
null
anim
show
defect
abil
clear
apoptot
cell
confirm
role
mbl
clearanc
apoptot
cell
vivo
analysi
mbl
null
anim
demonstr
expand
cell
spontan
activ
antigen
present
cell
importantli
despit
demonstr
defect
apoptot
cell
clearanc
compar
seen
mbl
null
anim
develop
spontan
autoimmun
lymphoprolifer
germin
centr
expans
data
demonstr
import
vivo
role
mbl
clearanc
die
cell
add
mbl
null
anim
short
list
anim
demonstr
vivo
apoptot
cell
clearanc
defect
furthermor
demonstr
failur
apoptot
cell
clearanc
dissoci
autoimmun
indic
factor
must
requir
autoantibodi
gener
end
organ
damag
autoimmun
thyroid
diseas
aitd
term
includ
variou
clinic
entiti
among
hashimotot
thyroid
ht
gravest
diseas
gd
lymphocyt
infiltr
blymphocyt
dc
fdc
often
organ
function
lymphoid
follicl
germin
center
almost
constant
featur
order
investig
specif
home
recent
thymic
emigr
rte
thyroid
distribut
recent
rte
differ
subset
pbl
patient
aitd
tcr
excis
circl
trec
measur
intrathyroid
lymphocyt
itl
peripher
blood
pbmc
patient
trec
measur
realtim
pcr
lymphocyt
obtain
cell
sort
dispers
cell
prepar
thyroid
gland
n
peripher
blood
n
patient
n
healthi
control
comparison
trec
level
itl
pbmc
individu
show
two
pattern
one
half
patient
trec
itl
higher
pbmc
wherea
half
higher
pbmc
hand
trec
content
pbmc
aitd
patient
significantli
differ
control
f
cell
vs
f
cell
p
test
assess
influenc
cell
prolifer
trec
level
measur
telomer
length
band
tlymphocyt
group
patient
aitd
itl
pbmc
control
pbmc
aitd
patient
rel
telomer
length
rtl
itl
significantli
lower
pbmc
sever
autoimmun
diseas
psoriasi
multipl
sclerosi
crohnt
diseas
associ
imbal
toward
cell
creat
state
chronic
inflamm
predomin
cytokin
ifng
tnfa
contrast
cytokin
like
shown
benefici
effect
manipul
balanc
part
current
strategi
develop
immun
diseas
calcitriol
shown
exert
sever
immunomodulatori
function
cell
antigenpres
cell
apc
vitro
vivo
goal
evalu
immunomodulatori
effect
new
vitamin
analog
therapeut
treatment
autoimmun
diseas
method
assess
abil
activ
vdrrespons
gene
realtim
pcr
bind
vdr
also
examin
use
elisa
effect
compound
cytokin
human
peripher
blood
mononuclear
cell
pbmc
cytokin
secret
macrophag
use
vitamin
analog
current
limit
induct
hypercalcemia
therefor
effect
serum
calcium
level
evalu
mice
result
transcript
analysi
human
pbmc
reveal
calcitriol
strong
induc
vdrrespons
gene
indic
cell
respons
vdrmediat
gene
transcript
macrophag
cell
line
low
concentr
significantli
induc
express
interestingli
abil
analog
bind
vdr
weaker
calcitriol
calcitriol
shown
repress
ifng
gmcsf
cell
apc
effect
depend
presenc
vdr
result
reveal
significantli
decreas
proinflammatori
cytokin
product
ifng
tnfa
increas
product
cytokin
human
pbmc
analog
also
affect
macrophag
function
induc
secret
lpsstimul
cell
vivo
analog
induc
hypercalcemia
even
highest
dose
agkg
bodi
weight
conclus
result
demonstr
lowcalcem
analog
strong
induc
vitamin
ddepend
transcript
novel
compound
modul
balanc
favor
macrophag
function
suggest
potenti
treatment
autoimmun
diseas
spa
may
candid
bqiq
molecul
trigger
autoimmun
diseas
sle
found
treatment
balbc
mice
result
mark
elev
express
tgfh
vivo
tgfhinduc
suppress
tcell
prolifer
exvivo
addit
provid
evid
one
possibl
mechan
underli
tgfhinduc
inhibit
tcell
prolifer
downregul
express
therefor
function
pair
key
cell
adhes
receptor
oper
accessori
molecul
mediat
antigen
present
cell
apc
tcell
interact
inde
cell
mice
treat
show
tgfhinduc
suppress
adhes
ligand
hyaluron
acid
respect
induc
pma
latter
suppress
inhibit
erk
phosphoryl
thu
downregul
sle
treatment
may
result
influenc
upregul
tgfh
express
function
tcell
adhes
receptor
consequ
tcell
stimul
adhes
prolifer
rational
numer
studi
perform
vitro
variou
anim
model
modul
interact
dc
cell
fa
signal
delet
activ
cell
via
induct
activationinduc
cell
death
aicd
howev
similar
studi
primari
human
cell
perform
recent
could
demonstr
fa
ligand
express
bkillerdcq
gener
human
monocytederiv
matur
dc
use
adenovir
gene
transfer
evalu
whether
faslexpress
dc
dcfasl
could
elimin
human
vitro
cocultur
experi
perform
method
human
cell
ctl
clone
specif
bind
peptid
activ
first
mix
lymphocyt
reaction
mlr
matur
dc
puls
melana
peptid
activ
cell
rescu
second
mlr
establish
either
dcfasl
egfptransduc
control
dc
dcegfp
untreat
dc
load
melanaor
control
peptid
differ
ratio
readout
system
prolifer
thymidin
incorpor
apoptosi
annexin
vpi
stain
cell
determin
result
facsanalysi
label
dc
reveal
fasltransduc
dc
dc
dcegfp
load
melana
peptid
protect
cytotox
mediat
melana
specif
cell
addit
prolifer
could
observ
melana
specif
cell
cocultur
dc
dcegfp
dcfasl
load
control
peptid
contrast
prolifer
activ
melana
specif
cell
markedli
reduc
cocultur
melana
peptideload
dcfasl
wherea
strong
secondari
prolif
cell
respons
could
observ
cocultur
dcegfp
dc
inhibit
cell
prolifer
directli
relat
number
dcfasl
present
cocultur
ratio
cell
prolifer
complet
inhibit
dcfasl
due
induct
apoptosi
major
melana
specif
cell
approxim
spontan
apoptosi
detect
cell
cocultur
melana
peptideload
dc
dcegfp
low
approxim
conclus
present
result
demonstr
first
time
human
dcfasl
protect
ctlmediat
cytotox
counter
attack
addit
melana
specif
cell
effici
elimin
melana
peptideload
dcfasl
support
concept
appli
faslexpress
bkillerdcq
novel
strategi
treatment
cell
depend
autoimmun
diseas
mice
defici
format
certain
b
cell
subset
suscept
immun
dysregul
notabl
develop
inflammatori
bowel
diseas
ibd
key
issu
ident
gicoupl
receptor
mediat
requir
lymphocyt
develop
test
predict
peripher
endocannabinoid
receptor
one
receptor
b
cell
subset
isol
tissu
peripher
mucos
seros
lymphoid
compart
null
suffici
mice
quantifi
flow
cytometri
mice
bear
null
phenotyp
profound
defici
b
cell
subset
particularli
splenic
margin
zone
mz
periton
cell
well
splenic
memori
cell
intestin
nk
nkt
cell
requir
format
mani
immunoregulatori
b
cell
subset
find
phenocopi
extend
development
disord
associ
suggest
endocannabinoid
system
requir
format
b
cell
subset
involv
immun
homeostasi
background
aim
etiolog
inflammatori
bowel
diseas
ibd
still
unknown
report
show
gut
microflora
play
role
pathogenesi
ibd
microflora
gut
ibd
patient
becom
aberr
normal
microflora
decreas
harm
potenti
harm
bacteria
increas
report
close
relationship
gut
aberr
microflora
mucos
immun
function
disord
modif
intestin
microflora
may
therapeut
effect
ibd
experi
use
dextran
sulfat
sodium
dss
induc
coliti
mice
patholog
properti
human
ibd
fed
mice
bifidobacterium
induc
coliti
studi
therapeut
effect
supplement
bifidobacterium
pathogenesi
coliti
explor
possibl
mechan
method
mice
randomli
divid
four
group
control
dss
sasp
bifidobacterium
bif
short
mice
group
dss
sasp
bif
fed
dss
wv
solut
day
induc
coliti
mice
control
drink
distil
solut
diseas
activ
index
dai
calcul
everi
day
mice
sasp
fed
sasp
everi
day
induc
coliti
mice
bif
given
bifidobacterium
oral
gavag
day
experi
end
experi
express
tnfa
nfnb
fa
mpo
inflam
colon
group
mice
measur
end
experi
result
mice
group
sasp
bif
show
lower
dai
group
dss
sinc
forth
day
experi
lower
express
tnfaand
mpo
murin
inflammatori
colon
lower
nfnb
appear
nuclei
inflammatori
cell
lower
fa
express
colon
epithelia
group
sasp
bif
compar
group
dss
end
experi
conclus
treatment
bifidobacterium
benefici
effect
murin
experiment
coliti
mechan
may
involv
respect
bifidobacterium
inhibit
proinflammatori
cytokin
secret
nfnb
activ
inflammatori
cell
limit
colon
inflamm
downregul
fa
express
colon
epithelia
murin
inflam
colon
allevi
inflammatori
damag
colon
epithelia
protect
integr
intestin
mucos
barrier
key
word
probiot
experiment
coliti
dextran
sulfat
sodium
inflamm
antimurin
tnfalpha
revers
tnb
coliti
mice
oxazolon
coliti
potenti
role
apoptosi
induct
regul
mucosa
cd
well
uc
patient
howev
administr
infliximab
chimer
antitnf
mab
shown
benefici
effect
clinic
trial
cd
less
effect
uc
aim
investig
effect
antitnf
trinitrobenzenesulphon
tnb
oxazolon
oxa
coliti
mice
model
cd
uc
respect
studi
apoptosisinduc
effect
antimurin
tnf
vitro
vivo
mice
method
coliti
induc
rectal
administr
tnb
oxa
ethanol
presensit
via
skin
antimurin
tnfalpha
given
intraperiton
ip
daili
thioglycollateelicit
periton
macrophag
treat
vitro
lp
antimurin
tnfalpha
nonspecif
control
antibodi
annexin
v
propidium
iodid
use
studi
apoptosi
cell
membran
dna
level
respect
vivo
analysi
antitnf
effect
macrophag
antimurin
tnfalpha
control
antibodi
administr
scid
mice
periton
macrophag
recov
apoptoti
analyz
describ
result
tnb
coliti
model
mice
treat
antitnf
recov
rapidli
compar
control
treat
mice
histolog
analysi
reveal
less
sever
sign
coliti
contrari
benefici
effect
antitnf
found
oxa
coliti
mice
apoptosi
induc
antimurinetnf
periton
macrophag
vitro
apoptot
cell
presenc
antitnf
amount
compar
control
cultur
vivo
less
macrophag
could
harvest
antitnf
treat
group
higher
percentag
periton
macrophag
apoptot
compar
control
group
conclus
antitnf
treatment
rescu
tnb
coliti
mice
effect
oxa
coliti
result
correl
differ
efficaci
antihuamn
tnf
treatment
uc
cd
respect
apoptosi
inducingeffect
antitnf
could
demonstr
periton
macrophag
data
suggest
differ
involv
tnf
express
cell
pathogenesi
diseas
model
introduct
increas
evid
indic
granulocyteapheresi
gcap
effect
safe
therapeut
strategi
treatment
ulcer
coliti
uc
howev
ideal
treatment
scheme
establish
yet
object
studi
carri
evalu
efficaci
safeti
compar
gcap
treatment
patient
moder
activ
steroid
depend
uc
matheri
method
prospect
multicent
random
clinic
trial
patient
random
gcap
treatment
weekli
treatment
consist
apheresi
session
adacolumnr
mlh
l
blood
process
principl
efficaci
variabl
remiss
rate
defin
rachmilewitz
index
cai
week
secondari
variabl
includ
cai
week
qualiti
life
questionnair
ibdq
euroqol
endoscop
activ
index
eai
week
well
steroid
consumpt
analyt
paramet
inclus
criteria
activ
uc
cai
eai
total
colon
affect
length
cm
steroid
depend
defin
least
one
unsuccess
attempt
taper
steroid
plu
use
mg
prednison
within
week
prior
studi
start
patient
gave
written
inform
consent
clinic
remiss
defin
cai
clinic
respons
drop
cai
sinc
patient
still
followup
efficaci
treatment
regimen
well
secondari
variabl
analysi
report
complet
studi
result
male
femal
includ
mean
age
f
year
mean
diseas
durat
month
two
patient
chronic
activ
uc
wherea
mean
number
flare
up
year
prior
studi
entri
f
remain
patient
patient
previous
treat
steroid
immunosuppress
cyclosporin
patient
random
gcap
session
patient
gcap
session
global
mean
cai
f
studi
entri
n
f
week
n
f
week
n
global
mean
prednison
dose
f
baselin
f
week
f
week
five
patient
steroid
free
week
mean
ibdq
score
f
baselin
go
f
week
f
week
two
seriou
advers
event
one
commun
pneumonia
report
conclus
granulocyteapheresi
safe
effect
treatment
moder
activ
steroid
depend
ulcer
coliti
addit
show
import
steroid
spare
effect
sever
steroid
depend
popul
even
allow
complet
steroid
withdraw
cytokin
chemokin
transcript
profil
acut
pouchiti
stallmach
gies
c
schmidt
b
ludwig
meuer
gastroenterolog
cathol
clinic
essennord
essen
germani
immunolog
univers
heidelberg
heidelberg
germani
intern
medicin
ii
saarland
univers
homburg
germani
background
ileoan
pouch
anastomosi
iap
patient
ulcer
coliti
uc
patient
polyposi
coli
fap
develop
pouchiti
immunoregulatori
aborm
might
import
pathogenesi
diseas
therefor
character
cytokin
chemokin
transcript
inflam
noninflam
pouch
patient
uc
fap
method
mucos
biopsi
taken
patient
iap
uc
n
fap
n
patient
activ
ileal
diseas
cd
n
activ
uc
n
specif
coliti
infecti
coliti
ischem
coliti
n
patient
noninflammatori
condit
n
serv
control
express
proinflammatori
gene
transcript
quantifi
use
realtim
pcr
result
compar
normal
ileal
mucosa
control
biopsi
noninflam
mucosa
iap
uc
fap
patient
express
elev
transcript
level
ifng
addit
uc
patient
express
increas
uciap
patient
transript
elev
inflam
mucosa
comparison
noninflam
mucos
biopsi
differ
found
concern
tnfa
elc
level
tnfa
ifng
elev
inflam
cu
pouch
mucosa
comparison
specif
coliti
suggest
predominantli
mediat
inflamm
transcript
could
detect
good
correl
pouchiti
activ
pdai
transcript
observ
discuss
acut
pouchiti
uc
patient
iap
anastomosi
transcript
level
proinflammatori
cytokin
chemokin
predominantli
origin
found
elev
even
data
complet
explain
immunolg
etiolog
quantif
transcript
level
allow
estim
extent
mucos
inflamm
crohnt
diseas
treatment
cyclophosphamid
infliximab
b
bifidum
similar
dose
probiot
treatment
discontinu
remiss
occur
although
discov
later
probiot
need
continu
longterm
result
patient
treat
rare
except
remiss
regularli
occur
last
day
month
howev
eventu
relaps
except
four
patient
sustain
complet
remiss
year
three
contrast
relaps
pingelbm
e
coli
replac
resid
coliform
consist
cultur
stool
predomin
coliform
also
elect
continu
take
prophylact
probiot
follow
colonoscopi
biopsi
normal
one
case
ap
donor
strain
disappear
fece
follow
prophylact
ceftin
therapi
knee
replac
gradual
relaps
treatment
repeat
success
pingelbm
strain
reestablish
remain
well
year
declin
colectomi
year
old
girl
treat
remain
well
continu
take
e
coli
mutaflor
ardeypharm
co
germani
l
acidophilu
year
old
brother
also
treat
year
later
colon
improv
unlik
sister
sustain
complet
remiss
case
intermedi
result
present
suggest
approach
pursu
control
studi
especi
use
continu
prophylact
probiot
contain
nonpathogen
e
coli
interleukin
member
common
gammachain
famili
cytokin
secret
activ
cell
divers
rang
immunomodulatori
effect
depend
upon
particular
context
immun
respons
interleukin
receptor
express
mani
immun
system
cell
type
includ
activ
cell
rational
situ
hybrid
studi
shown
highli
express
lymphoid
compart
gut
human
gene
map
chromosom
within
crohnt
diseas
suscept
region
suggest
pathway
may
involv
regul
gut
homeostasi
examin
role
cell
mediat
model
intestin
skin
inflamm
method
hi
naiv
cell
transfer
sever
combin
immunodefici
scid
mice
hous
differ
cage
condit
mice
develop
coliti
coliti
skin
lesion
resembl
psoriasi
mice
treat
solubl
murin
control
antibodi
assess
develop
diseas
purifi
hi
cell
also
cultur
determin
effect
prolifer
cytokin
secret
result
cultur
stimul
hi
naiv
lo
memori
cell
prolifer
respons
secret
increas
level
ifng
tnfa
blockad
endogen
neutral
solubl
result
decreas
level
cytokin
cultur
mice
develop
skin
inflamm
treatment
thriceweekli
seven
week
hi
cell
transfer
result
reduc
erythema
scale
hair
loss
compar
control
treatment
hi
recipi
mice
ug
time
per
week
time
cell
transfer
result
signific
reduct
clinic
sign
coliti
measur
bodi
weight
loss
stool
score
compar
control
treat
mice
macroscop
evalu
colon
control
treat
hi
recipi
show
sever
thicken
swell
almost
complet
suppress
mice
treat
microscop
controltr
mice
also
exhibit
greater
degre
epitheli
hyperplasia
leukocyt
infiltr
lamina
propriasubmucosa
compar
mice
conclus
taken
togeth
result
suggest
potent
potenti
player
inflammatori
respons
model
blockad
pathway
may
therapeut
benefit
mediat
diseas
crohnt
psoriasi
induc
costimul
ico
homologu
induc
upon
cell
activ
ico
bind
ligand
icosl
express
fibroblast
endotheli
cell
epitheli
cell
constitut
low
level
rest
b
cell
macrophag
dendrit
cell
ico
ligat
enhanc
cell
prolifer
product
sever
cytokin
ifng
key
role
product
play
import
role
induct
regulatori
cell
suppress
autoimmun
use
ico
defici
mice
investig
role
ico
induct
function
regulatori
cell
function
pathogen
effector
cell
use
coliti
model
develop
powri
colleagu
coliti
model
transfer
cell
teff
normal
mice
scid
recipi
lead
develop
inflammatori
bowel
diseas
similar
ibd
human
intestin
inflamm
result
develop
respons
driven
enter
bacteria
coliti
induc
transfer
teff
cell
prevent
cotransf
cell
contain
within
popul
treg
surprisingli
found
regulatori
cell
protect
mice
coliti
indic
ico
requir
induct
function
regulatori
cell
popul
howev
found
wild
type
regulatori
cell
could
protect
ibd
induc
effector
cell
lack
ico
without
ico
balanc
appear
shift
favour
autopathogen
cell
effector
cell
control
regulatori
cell
therebi
result
sever
clinic
diseas
thu
studi
suggest
ico
critic
regul
balanc
regulatori
cell
effector
cell
studi
investig
role
cmaf
transcript
factor
known
induc
product
inflammatori
bowel
diseas
although
crohnt
diseas
cd
associ
low
product
tbetexpress
cell
lamina
propria
surprisingli
higher
express
cmaf
cell
found
compar
control
patient
relev
find
evalu
anim
model
cd
induc
adopt
transfer
cell
ragdefici
mice
model
increas
cmafexpress
lymphocyt
lamina
propria
time
observ
interestingli
adopt
transfer
cmaf
transgen
cell
mice
result
inabl
induc
coliti
suppress
coliti
activ
induc
wildtyp
cell
contrast
transfer
cell
cmaf
transgen
wildtyp
mice
induc
coliti
augment
coliti
induc
cell
wildtyp
mice
pathway
determin
macroscop
histolog
endoscop
criteria
associ
accumul
tbet
effector
cell
lamina
propria
colit
mice
result
reveal
novel
regulatori
role
cmaf
coliti
although
overexpress
cmaf
naiv
cell
prevent
coliti
overexpress
cmaf
memori
tbet
cell
regul
express
augment
coliti
target
cmaf
memori
cell
cd
appear
attract
target
therapeut
intervent
dual
immun
suppress
activ
allevi
tnbsinduc
coliti
mice
introduct
elev
product
tnfalpha
activ
cell
play
central
role
pathogenesi
crohnt
diseas
cd
recent
identifi
inhibitor
nm
explain
inhibitori
effect
lpsinduc
tnfalpha
product
vitro
nm
well
vivo
inhibit
howev
account
strong
inhibitori
effect
mix
lymphocyt
reaction
mlr
assay
nm
suggest
anoth
target
assay
latter
confirm
inabl
rolipram
specif
inhibitor
nm
inhibit
mlr
aim
investig
efficaci
trinitrobenzenesulphon
tnb
induc
coliti
mice
model
crohnt
diseas
method
coliti
induc
rectal
administr
tnb
ethanol
presensit
via
skin
mgkg
given
intraperiton
daili
result
mice
treat
less
sever
sign
coliti
recov
rapidli
evidenc
rapid
weight
recoveri
histolog
reduct
inflammatori
lesion
less
edema
reduct
goblet
cell
loss
reduc
wall
thick
cell
infiltr
especi
infiltr
neutrophil
shown
myeloperoxidas
activ
reduc
treat
anim
conclus
find
show
strong
remissioninduc
effect
tnb
coliti
experiment
clinic
studi
indic
cytokin
play
essenti
role
mediat
inflammatori
process
associ
pancreat
one
import
mediat
inflamm
glycoprotein
produc
mani
cell
type
wide
varieti
biolog
differenti
growthpromot
effect
varieti
target
cell
type
import
acut
phase
confirm
observ
stimul
synthesi
acut
phase
protein
includ
c
reactiv
protein
crp
hepatocyt
vitro
vivo
level
rais
patient
acut
pancreat
ap
correl
diseas
sever
serum
concentr
patient
first
hour
hospit
valuabl
marker
permit
differenti
variou
type
pancreat
ap
cpchronic
pancreat
cepchron
exacerb
pancreat
immunhistochem
detect
pancrea
pancreat
knowledg
previous
describ
previou
studi
presenc
human
pancreat
cell
shown
biopsi
materi
diabet
patient
normal
gland
aim
method
aim
studi
identifi
immunohistochem
local
determin
express
cp
cep
sampl
tissu
normal
pancrea
n
obtain
autopsi
cp
n
cep
n
verifi
histopatholog
local
immunohistochem
stain
use
monoclon
antihuman
antibodi
r
system
usa
test
dako
usa
visual
complex
found
scare
acinar
cell
stain
posit
normal
human
pancrea
islet
cell
show
immunoreact
slice
pancrea
deriv
patient
cp
cep
much
stronger
immunohistochem
reaction
diffus
focal
notic
compar
control
local
exocrin
islet
cell
pancrea
immunohistochem
reaction
duct
cell
also
strong
interestingli
cytokin
detect
cytoplasm
close
nucleu
moreov
case
cp
cep
inflammatori
infiltr
markedli
stronger
express
observ
specimen
without
infiltr
conclus
conclus
result
present
herein
clearli
demonstr
moder
strong
express
exocrin
endocrin
cell
patient
cp
cep
suggest
elev
level
patient
pancreat
probabl
owe
leakag
cytokin
circul
follow
massiv
pancreat
cell
destruct
recent
data
suggest
thymu
deriv
regulatori
cell
play
import
role
toler
immun
system
toward
tumor
regulatori
cell
specif
express
transcript
factor
believ
master
regul
regulatori
cell
develop
contrast
thymic
develop
recent
data
demonstr
regulatori
cell
also
induc
narv
cell
peripheri
other
provid
evid
tgfbeta
critic
peripher
induct
regulatori
cell
induc
express
demonstr
induct
regulatori
cell
tgfbeta
physiolog
event
colon
potenti
role
pathogenesi
colon
cancer
accordingli
mice
inject
singl
dose
mutagen
agent
azoxymethan
follow
three
weekli
period
dextran
sulphat
dss
drink
water
interrupt
day
recoveri
treat
anim
develop
numer
tumor
colon
recent
studi
shown
tumor
growth
coliti
associ
colon
cancer
model
driven
inflammatori
cell
infiltr
tumor
describ
human
colon
cancer
demonstr
dysplast
epitheli
cell
produc
high
amount
tgfbeta
interestingli
cell
isol
tumor
express
high
level
mrna
cell
isol
surround
nondysplast
colon
tissu
find
confirm
immunohistochem
stain
accordingli
express
cell
found
high
number
lamina
propria
tumor
close
associ
dysplast
epitheli
cell
contrast
posit
cell
detect
lamina
propria
surround
normal
colon
tissu
base
data
specul
tumor
deriv
tgfbeta
may
induc
tumor
infiltr
cell
order
function
analyz
whether
tumor
deriv
tgfbeta
may
play
role
induct
regulatori
cell
vivo
induc
colon
tumor
mice
overexpress
domin
neg
tgfbeta
receptor
specif
cell
tumor
collect
mice
show
similar
infiltr
cell
compar
wildtyp
mice
howev
cell
isol
tumor
tissu
transgen
mice
show
strongli
diminish
express
mrna
compar
tumor
wildtyp
anim
strikingli
tumor
transgen
mice
larger
wildtyp
tumor
implic
model
inflamm
depend
colon
cancer
tumor
induc
regulatori
cell
control
tumor
growth
base
find
propos
model
tumor
deriv
tgfbeta
induc
express
infiltr
cell
give
regulatori
phenotyp
tumor
induc
regulatori
cell
case
inflamm
depend
cancer
control
tumor
growth
howev
spontan
cancer
develop
tumor
induc
regulatori
cell
may
mediat
toler
toward
tumor
inhibit
antitumor
immun
accumul
studi
address
inflammatori
bowel
diseas
autoimmun
diseas
howev
known
whether
intestin
epitheli
cellderiv
antigen
involv
gener
mucos
immun
respons
target
pathogen
process
use
modifi
serolog
analysi
recombin
cdna
express
librari
serex
antigenscreen
approach
util
humor
cellular
immun
respons
herein
identifi
epitheli
cellderiv
endogen
lectin
pathogen
mediat
exacerb
intestin
inflamm
specif
stimul
product
cell
cell
type
present
diseas
colon
high
treansfer
dssinduc
coliti
model
tcra
knockout
ko
mice
contrast
unabl
stimul
product
cell
present
normal
colon
coliti
model
well
wild
type
mice
confoc
microscop
analysi
show
interact
immunolog
synaps
colon
cell
indic
specif
bind
lipid
raftaccumul
region
interestingli
bind
intens
cell
product
increas
intestin
inflammatori
condit
recent
shown
specif
bind
sulfat
nonsialyl
oglycan
structur
inde
express
member
sialyltransferas
specif
util
modif
oglycan
markedli
downregul
cell
inflammatori
condit
addit
exposur
oglycan
without
sialyl
cell
confirm
intensifi
bind
pna
specif
bind
oligosaccharid
structur
mechanist
product
cell
mediat
protein
kinas
c
pkc
uassoci
cascad
indic
fact
colon
cell
pkcu
ko
mice
treat
dss
unabl
respond
produc
function
administr
mab
led
attenu
chronic
coliti
b
celldefici
tcra
doubl
knockout
mice
also
effect
enhanc
recoveri
dssinduc
acut
coliti
studi
indic
presenc
immunogen
epitheli
lectin
contribut
exacerb
intestin
inflamm
also
provid
novel
insight
biolog
role
cell
interact
inflammatori
condit
immunohistochem
local
copper
medicin
wroclaw
poland
depart
clinic
gastointestin
gener
surgeri
wroclaw
univers
medicin
wroclaw
poland
role
oxit
stress
pathogenesi
pancreat
benefit
antioxid
suggest
variou
studi
superoxid
dismutas
sod
primari
antioxid
enzym
scaveng
reactiv
free
radic
catalyz
dismut
superoxid
anion
molecular
oxygen
peroxid
copper
zinccontain
sod
cuzn
sod
intracellular
eznym
activ
depend
metalsit
shown
metallotionein
mt
also
antioxid
protein
high
concentr
pancreasserv
function
except
sensit
indic
zn
statu
recent
studi
confirm
mt
present
exocrin
endoxrin
cell
patient
chronic
pancreat
particularli
acinar
cell
pancrea
last
year
evid
provid
appear
decreas
cuzn
sod
express
pancreat
cell
normal
pancrea
chronic
pancreat
aim
method
aim
studi
identifi
immunohistochem
distribut
pattern
cuzn
sod
chronic
pancreat
cp
chronic
exacerb
pancreat
cep
sampl
tissu
normal
pancrea
n
obtain
autopsi
cp
n
cep
n
verifi
histopatholog
cuzn
sod
local
immunohistochem
stain
use
primari
polyclon
antihuman
cuzn
sod
antibodi
calbiochem
uk
second
antisheep
peroxidas
conjug
antibodi
sigma
germani
visual
cuzn
sodab
complex
found
scare
acinar
cell
stain
posit
cuzn
sod
normal
human
pancrea
bodi
tail
pancrea
islet
cell
show
cuzn
sod
immunoreact
slice
pancrea
deriv
patient
cp
cep
much
stronger
immunohistochem
reaction
notic
compar
control
cuzn
sod
local
acinar
islet
cell
pancrea
interestingli
immunohistochem
reaction
duct
cell
consider
stronger
islet
acinar
cell
also
compar
express
cuzn
sod
metallothionein
mt
histolog
specimen
experiment
condit
wherea
cu
zn
sod
markedli
manifest
duct
cell
pancrea
mt
apear
conclus
conclus
studi
clearli
demonstr
moder
strong
express
cuzn
sod
acinar
islet
duct
cell
patient
cp
cep
suggest
pancreat
induc
express
cuzn
sod
pancrea
overexpress
enzym
duct
cell
may
function
intracellular
antioxid
compens
lack
mt
cell
pancrea
celiac
diseas
cod
intestin
damag
induc
gliadin
alcohol
solubl
fraction
gluten
peptic
fragment
gliadin
shown
activ
cell
innat
immun
includ
macrophagesmonocyt
cytokin
chemokin
product
aim
studi
examin
whether
peripher
blood
monocyt
pbmoc
respond
peptic
digest
gliadin
tnfa
product
ii
activ
depend
presenc
ifng
iii
exist
differ
respons
pbmoc
isol
blood
donor
activ
treat
gfd
coeliac
patient
includ
analysi
causal
factor
iiii
signal
pathway
mediat
via
nfnb
molecul
activ
method
pbmoc
incub
variou
dose
peptic
digest
gliadin
alon
togeth
ifng
preincub
ifng
ad
gliadin
hla
gene
type
use
pcr
sequencespecif
primer
ssppcr
nfnb
dna
bind
activ
detect
transam
nfkb
transcript
factor
assay
kit
result
capac
monocyt
isol
activ
cod
patient
patient
gfd
produc
significantli
higher
healthi
donor
simultan
addit
ifng
enhanc
effect
product
prestimul
cell
ifng
hour
result
signific
increas
product
mainli
cell
healthi
control
enhanc
tnfa
secret
detect
mainli
gliadin
stimul
monocyt
cod
patient
markedli
increas
simultan
addit
ifng
interestingli
prestimul
cell
ifng
hour
increas
gliadininduc
tnfa
product
group
healthi
donor
patient
gfd
slightli
group
activ
cod
patient
effect
reduc
differ
tnfa
product
among
test
group
signal
pathway
trigger
gliadin
mediat
via
nfnb
subunit
specif
inhibitor
suppress
dna
bind
activ
nfnb
well
gliadin
induc
tnfa
secret
impact
antigen
express
healthi
donor
keep
gfd
treat
patient
cell
respons
evalu
conclus
tnfa
produc
cell
innat
immun
could
enhanc
effect
gliadin
specif
lymphocyt
particip
cascad
lead
damag
intestin
mucosa
celiac
patient
object
ee
allerg
inflammatori
disord
esophagu
signific
recent
increas
number
report
pediatr
case
initi
esophag
inflammatori
injuri
theoriz
due
food
allergi
possibl
aeroallergen
sensit
review
case
pediatr
patient
pt
ee
order
discern
clinic
histolog
treatment
correl
acquir
better
understand
diseas
pathogenesi
method
allergi
food
aeroallergen
test
complet
pt
serial
esophag
biopsi
perform
pt
serial
clinic
score
determin
pt
clinic
score
base
upon
presenceabs
abd
pain
vomit
dysphagia
wt
lossgain
chest
pain
result
pt
demonstr
clinic
improv
base
comparison
clinic
score
baselin
month
treatment
treatment
ptselimin
diet
ed
steroid
swallow
flovent
oral
steroid
ptsed
ptssteroid
ptsnoncompli
ppi
major
pt
demonstr
diminish
esophag
eosinophil
infiltr
pt
underw
serial
biopsi
demonstr
clinic
improv
evid
diminish
esophag
eosinophil
infiltr
differ
treatment
regimen
exist
group
pt
treat
longer
averag
length
time
respect
month
conclus
ee
allerg
inflammatori
disord
case
clinic
respond
treatment
regimen
ed
steroid
subset
patient
demonstr
improv
clinic
outcom
without
diminish
esophag
eosinophil
infiltr
result
may
reflect
incomplet
therapeut
respons
requir
close
followup
order
detect
end
diseas
remiss
altern
find
may
characterist
uniqu
patient
subset
merit
investig
infect
human
immunodefici
viru
involv
sever
clinic
manifest
affect
almost
everi
organ
system
bodi
rheumat
manifest
may
develop
time
clinic
spectrum
usual
seen
late
stage
although
sometim
constitut
initi
present
viral
ill
patient
male
femal
infect
hiv
south
itali
recruit
studi
hiv
posit
detect
enzymelink
immunosorb
assay
elisa
confirm
western
blot
patient
ask
complet
questionnair
contain
question
pertain
rheumat
diseas
follow
data
collect
age
sex
durat
hiv
infect
count
rheumatolog
manifest
found
clinic
evalu
questionnair
administr
physic
examin
patient
result
arthralgia
commonest
manifest
occur
patient
pain
usual
intermitt
moder
intens
involv
joint
one
patient
reitert
syndrom
mild
oligoarthr
knee
spondyl
respond
promptli
nsaid
anoth
patient
mild
oligoarthr
involv
knee
ankl
count
f
mean
f
standard
deviat
group
patient
hiv
without
arthralgia
f
group
patient
arthralgia
without
signific
correl
count
viral
load
arthralgia
qualiti
control
sirna
optim
itt
transfect
effici
monitor
gene
silenc
effect
microfluid
chip
devic
preckel
c
buhlmann
valer
liquid
phase
analysi
agil
technolog
waldbronn
bw
germani
gene
silenc
rna
interfer
rnai
new
breakthrough
technolog
high
potenti
develop
therapeut
deliveri
small
interf
rna
sirna
cell
key
import
elucid
gene
protein
function
differ
type
interf
rna
sever
method
deliveri
cell
type
exist
requir
transfect
optim
effici
transfect
affect
mani
factor
furthermor
select
best
silenc
sequenc
optim
sirna
transfect
condit
base
integr
puriti
sirna
sirna
uptak
cell
viabil
given
complex
monitor
optim
type
experi
new
tool
requir
would
allow
minim
sampl
reagent
consumpt
fast
easi
use
format
describ
use
microfuid
chipbas
system
quickli
verifi
sirna
qualiti
determin
optim
condit
gene
silenc
experi
first
rna
integr
puriti
assess
second
fluoresc
label
sirna
use
optim
transfect
paramet
mammalian
cell
life
cell
stain
perform
onchip
reduc
overal
analysi
time
sampl
less
minut
harvest
cell
final
result
actual
handsontim
less
minut
transfect
effici
measur
percentag
cell
strong
sirna
uptak
within
live
cell
popul
third
gene
knockdown
measur
system
stain
protein
interest
eg
fluoresc
label
antibodi
demonstr
downregul
protein
sirna
transfect
gene
silenc
mechan
also
verifi
given
cell
line
use
gfptag
cotransfect
tag
protein
label
sirna
protein
success
silenc
measur
reduc
gfp
express
within
posit
cell
popul
differ
timepoint
transfect
kilic
pediatr
immunolog
uludag
univers
school
medicin
bursa
turkey
omenn
syndrom
character
gener
erythemat
skin
rash
lymph
node
enlarg
hepatosplenomegali
increas
serum
ig
e
level
eosinophilia
evid
sever
combin
immun
defici
patient
develop
fungal
bacteri
viral
infect
athreemonthold
girl
omenn
syndrom
develop
right
ventricular
thrombosi
echocardiograph
investig
reveal
round
structur
fill
apex
corpu
right
ventricl
investig
hypercoagul
state
discuss
ventricular
thrombosi
uncommon
omenn
syndrom
common
variabl
immunodefici
cvid
heterogen
group
bcell
defici
syndrom
character
hypogammaglobulinemia
impair
antibodi
product
recurr
bacteri
infect
vitamin
vit
natur
occur
antioxid
micronutri
immunomodul
effect
patient
immunodefici
includ
influenc
cytokin
product
lymphocyt
growth
function
vit
defici
associ
shift
type
cytokin
predominantli
type
cytokin
aim
studi
investig
vitamin
level
cvid
patient
effect
vit
defici
cytokin
product
nineteen
cvid
patient
healthi
control
attend
depart
pediatr
immunolog
uludag
univers
school
medicin
turkey
involv
studi
serum
vit
serum
neopterin
indic
chronic
inflammatori
state
serum
type
tnfalpha
type
cytokin
level
determin
retin
vit
deriv
ad
lymphocyt
cultur
cvid
patient
control
effect
cytokin
product
investig
serum
vit
level
cvid
patient
obvious
low
cvid
patient
serum
neopterin
level
higher
control
group
elev
serum
neopterin
level
low
vit
level
cvid
patient
suggest
serum
vit
level
lower
secondari
recurr
infect
seen
patient
serum
level
found
lower
cvid
patient
control
result
lymphocyt
cultur
cvid
patient
show
higher
retin
stimul
group
unstimul
group
howev
expect
chang
cytokin
seen
result
studi
show
cvid
patient
low
serum
vit
level
find
correl
chronic
inflammatori
condit
supplement
vit
may
role
downregul
inflammatori
respons
pulmonari
abscess
due
aspergillu
spp
patient
chronic
granulomat
diseas
kilic
pediatr
immunolog
uludag
univers
school
medicin
bursa
turkey
chronic
granulomat
diseas
cgd
common
phagocyt
disord
invas
fungal
infect
import
caus
morbid
mortal
cgd
patient
aspergillu
spp
frequent
fungal
pathogen
fifteenmonthold
boy
cavit
right
upper
lobe
present
persist
weight
loss
fever
cough
roentgenograph
evid
right
upper
lobe
abscess
resist
antibiot
therapi
lung
biopsi
led
diagnosi
pulmonari
aspergillosi
respiratori
burst
assay
reveal
diagnosi
cgd
treat
high
dose
liposom
amphotericin
b
mgkg
invas
pulmonari
aspergillu
nidulan
infect
infect
regress
week
treatment
addit
interferongamma
report
case
hodgkint
lymphoma
develop
child
hyperig
syndrom
one
case
malign
report
syndrom
white
girl
asthma
recurr
pneumonia
bronchiectasi
atop
dermat
recurr
skin
infect
growth
retard
immunolog
evalu
reveal
high
level
immunoglobulin
e
iudl
peripher
eosinophilia
found
normal
valu
serum
igg
igm
iga
sweat
chlorid
test
wbc
chemotaxi
serum
complement
function
occur
patient
hodgkint
lymphoma
suggest
individu
hyperig
syndrom
may
also
increas
risk
develop
prematur
malign
although
precis
immunolog
defect
syndrom
still
unknown
purpos
studi
develop
distribut
variant
allel
gene
hla
snp
promotor
hivinfect
patient
establish
immunolog
genet
marker
determin
resist
hivinfect
hladetect
hla
gene
hivinfect
patient
made
use
method
multiprim
amplif
sequencespecif
primer
basi
pcr
level
allel
group
set
reagent
bdnatechnologyq
moscow
variant
allel
gene
defin
help
pcr
subsequ
restrict
product
amplif
immunolog
genet
analysi
reveal
signific
protect
effect
specif
dr
rr
pf
dr
rr
pf
dr
rr
pf
strongest
posit
associ
correl
reveal
specif
dr
rr
ef
probabl
dr
rr
pf
distinct
distribut
variant
allel
promotor
gene
hivinfect
healthi
european
peopl
reveal
quantiti
hivinfect
peopl
homozyg
variant
cc
lower
healthi
european
peopl
accordingli
variant
tt
ct
essenti
higher
besid
distinct
format
immun
respons
cytokin
statu
hivinfect
patient
reveal
variou
variant
promotor
allel
gene
receiv
result
testifi
immunolog
genet
factor
essenti
influenc
process
infect
develop
diseas
use
defi
probabl
case
infect
individu
predict
diseas
develop
individu
approach
monitor
dive
adequ
immunocorrect
therapi
hivinfect
hyperig
syndrom
rare
primari
immunodefici
unknown
etiolog
character
chronic
eczema
elev
total
serum
ige
recurr
infect
skin
respiratori
tract
variabl
associ
skelet
symptom
recent
report
pyogen
bacteri
infect
patient
anim
defect
tolllik
receptor
tlr
pathway
lead
us
search
relat
defect
patient
hyperig
syndrom
cytokin
profil
six
patient
hyperig
syndrom
analyz
serum
sampl
cell
stimul
pma
ionomycin
peripher
blood
mononuclear
cell
stimul
tlr
ligand
bacteri
product
includ
lp
peptidoglycan
polyic
cpga
cpgb
zymosan
heat
kill
listeria
monocytogen
result
compar
healthi
control
reduc
percentag
ifngamma
tnfalpha
produc
cell
pma
stimul
patient
hyperig
syndrom
found
impli
impair
inflammatori
cell
respons
augment
serum
level
point
associ
shift
howev
normal
product
cytokin
tnfalpha
ifngamma
upregul
b
cell
monocyt
tlr
stimul
rule
defect
tlr
signal
pathway
conclus
dysbal
cell
respons
patient
hyperig
syndrom
detect
describ
indic
underli
defect
tolllik
receptor
pathway
observ
object
common
variabl
immunodefici
cvid
heterogen
immunodefici
characterist
recurr
bacteri
infect
due
hypogammaglobulinemia
incapac
gener
memori
b
cell
addit
dysfunct
immunoglobulin
product
patientt
tcell
activ
impair
result
low
product
cytokin
decreas
tcell
prolifer
patient
suffer
gastrointestin
infect
autoimmun
diseas
variou
bcell
neoplasm
address
whether
cvid
associ
impair
dendrit
cell
dc
compart
dc
play
central
role
develop
adapt
immun
heparin
blood
sampl
collect
cvid
patient
least
day
follow
last
infus
intraven
immunoglobulin
ivig
newli
diagnos
naiv
cvid
patient
prior
ivig
therapi
control
blood
sampl
obtain
patient
select
antibodi
defici
receiv
ivig
similar
cvid
patient
healthi
control
monocytederiv
dc
patientst
blood
control
group
gener
differenti
six
day
presenc
gmcsf
autolog
plasma
allogen
mix
lymphocyt
reaction
dc
cvid
patient
healthi
donor
expos
tcell
thirdparti
healthi
donorsth
cell
isol
magnet
cell
sorter
mac
cell
isol
kit
miltenyi
biotech
bergisch
gladbach
germani
cytokin
quantifi
quantikin
elisa
kit
immunotech
marseil
franc
result
dendrit
cell
dc
cvid
patient
sever
perturb
diiferenti
matur
although
total
number
dc
appear
normal
determin
express
express
nomin
level
hallmark
langerh
cell
complet
fail
upregul
typic
express
fulli
matur
dc
moreov
patientst
dc
express
markedli
reduc
level
costimulatori
molecul
critic
tcell
stimul
hla
class
ii
antigen
present
molecul
turn
patientst
dc
induc
weak
prolifer
allogen
cell
produc
significantli
low
amount
upon
signal
sinc
dc
play
central
role
tcell
activ
immunoglobulin
synthesi
failur
dc
matur
fulli
stimulatori
cell
present
antigen
may
provid
gener
explan
variou
symptom
cvid
patient
multipl
defect
immun
system
includ
malfunct
dc
appear
promin
featur
cvid
patient
object
describ
clinic
social
demograph
profil
patient
primari
immunodefici
diseas
follow
hcufmg
method
patient
follow
hcufmg
diagnos
primari
immunodefici
diseas
accord
intern
consesu
criteria
studi
patient
questionnair
appli
inform
consent
obtain
parent
patient
perform
nutrit
evalu
bodi
mass
index
age
statist
analysi
perform
use
epiinfo
packag
result
studi
patient
male
sex
follow
diseas
found
common
variabl
immunodefici
xlink
agammaglobulinemia
defici
igadefici
igg
subclass
defici
specif
antibodi
defici
chronic
granulomat
diseas
ciclic
neutropenia
median
age
year
old
median
age
onset
symptom
year
old
diagnosi
made
median
age
year
old
famili
histori
signific
factor
earli
diagnosi
p
patient
show
high
frequenc
infecti
diseas
hospit
need
intens
care
present
also
allerg
autoimmun
chronic
inflammatori
diseas
discuss
studi
show
need
adequ
investig
patient
increas
suscept
infect
care
investig
primari
immunodefici
character
earli
onset
recurr
sever
infect
molecular
defect
caus
cgd
heterogen
lead
absenc
low
express
malfunct
one
phagocyt
nadph
oxidas
compon
aim
work
analyz
clinic
featur
investig
molecular
genet
defect
latin
american
patient
cgd
procedur
studi
includ
patient
diagnosi
base
histori
recurr
sever
infect
impair
respiratori
burst
demonstr
underli
mutat
singl
strand
conform
polymorph
sscp
rtpcr
analysi
follow
genom
dna
cdna
sequenc
result
seven
unrel
patient
found
xlink
form
cgd
heterogen
mutat
affect
cybb
gene
insert
substitut
splice
site
defect
two
novel
seven
patient
present
one
autosom
recess
form
cgd
common
mutat
dgt
delet
exon
gene
pneumonia
frequent
clinic
featur
follow
pyodermat
sinus
otiti
liver
abscess
patient
xcgd
like
initi
infect
age
year
inflammatori
obstruct
granuloma
later
none
patient
sever
advers
reaction
bcg
immun
conclus
xcgd
patient
latin
america
show
high
degre
molecular
heterogen
includ
two
novel
mutat
clinic
characterist
includ
earli
onset
infect
eventu
obstruct
granuloma
repres
report
case
higher
preval
report
seri
hereditari
angioedema
uncommon
condit
usual
first
present
childhood
absenc
appropri
treatment
hereditari
angioedema
high
mortal
number
report
success
short
longterm
treatment
individu
agent
suffer
hereditari
angioedema
avail
agent
vari
intern
recent
publish
intern
consensu
statement
provid
guidanc
manag
patient
adulthood
remain
littl
guidanc
literatur
manag
children
adolesc
hereditari
angioedema
need
age
group
differ
adultsin
particular
symptomatolog
differ
adult
advers
effect
androgen
treatment
differ
children
adolesc
review
treatment
option
avail
children
adolesc
hereditari
angioedema
propos
simpl
evid
base
guidelin
manag
patient
abnorm
neutrophilt
chemotact
activ
children
congenit
insensit
pain
anhidrosi
cipa
role
nerv
growth
factor
chemotact
activ
congenit
insensit
pain
anhidrosi
cipa
rare
sever
genet
disord
compris
absenc
sensat
noxiou
stimuli
inabl
sweat
loss
pain
sensat
lead
skin
lacer
follow
deep
tissu
infect
cipa
rel
high
preval
consanguin
israelibedouin
popul
carri
common
mutat
trka
gene
encod
tyrosin
kinas
receptor
nerv
growth
factor
ngf
defect
ngf
receptor
result
complet
absenc
nonmyelin
small
myelin
fiber
dorsal
root
ganglia
ngf
shown
chemotact
activ
neutrophil
invitro
anim
model
analyz
neutrophil
function
children
diagnos
cipa
hypothes
neutrophil
chemotaxi
impair
result
abnorm
activ
trka
receptor
twelv
children
genet
diagnos
cipa
carri
inst
mutat
gene
encod
trka
recruit
studi
two
independ
analys
neutrophil
function
includ
chemotaxi
superoxid
gener
phagocytosi
perform
child
chemotaxi
assess
toward
fmlp
agaros
plate
superoxid
product
measur
reduct
acetylferricytochrom
c
stimul
pma
oz
fmlp
phagocytosi
assay
ingest
zymosan
particl
opson
pool
human
serum
chemotact
migrat
cipa
patientst
neutrophil
significantli
suppress
compar
control
f
superoxid
product
phagocytosi
normal
ngf
alon
act
chemoatract
neutrophil
obtain
healthi
donor
howev
presenc
ngf
neutrophil
migrat
toward
fmlp
elev
result
demonstr
impair
chemotact
activ
neutrophil
cipa
patient
chemotact
defect
account
high
preval
sever
staphylococc
skin
bone
infect
children
decreas
chemotact
migrat
attribut
molecular
defect
trka
receptor
reveal
ngf
strong
adjuv
effect
fmlpdirect
migrat
neutrophil
mab
one
clone
human
antibodi
strong
neutral
activ
broad
rang
laboratori
primari
isol
evalu
antivir
role
infect
diseas
develop
usual
meet
difficulti
law
amount
even
absenc
individu
use
synthet
peptid
contain
eldkwa
sequenc
membraneproxim
region
recogn
mab
mab
posit
control
assay
elisa
reactiv
eldkwa
igg
purifi
sera
mexican
patient
diseas
progress
prepar
prior
initi
highli
activ
antiretrovir
therapi
haart
found
sera
contain
differ
substanti
level
antibodi
react
eldkwa
addit
initi
haart
led
elev
seroreact
decreas
gradual
initi
level
therapi
serum
patient
highest
reactiv
investig
detail
shown
reactiv
level
correl
decreas
viral
load
detect
antibodi
patient
report
countri
may
either
explain
differ
infect
phase
investig
assign
local
genet
variat
found
recent
epidemiolog
survey
sinc
epitop
elicit
antibodi
conserv
clade
b
popul
epitop
linear
avail
form
synthet
peptid
antigen
explor
possibl
seroreact
eldkwa
peptid
may
diagnost
marker
infect
diseas
progress
countri
studi
progress
verifi
hypothesi
observ
elev
eldkwaseroreact
therapi
due
improv
immunolog
statu
result
suppress
viral
load
critic
phase
diseas
progress
innat
immun
defenc
import
prevent
infect
elimin
microorgan
penetr
mechan
barrier
bodi
cellbound
well
humor
molecul
particip
recogn
microorgan
pathogenassoci
molecular
pattern
pamp
among
first
group
term
pathogen
recogn
receptor
prr
tolllik
protein
collectin
ficolin
repres
latter
group
thu
belong
broader
group
pathogen
recogn
molecul
prm
one
collectin
mannanbind
lectin
mbl
two
ficolin
hand
lficolin
capabl
activ
complement
system
mbl
hficolin
lficolin
thank
oligomer
structur
provid
cluster
recognit
domain
allow
high
avid
bind
suitabl
space
pamp
mbl
mention
ficolin
three
found
complex
proenzym
name
mblassoci
serin
proteas
masp
three
masp
exist
recognit
pamp
bind
allow
activ
mblassoci
serin
proteas
turn
activ
gener
convertas
outcom
direct
kill
invad
membran
attack
complex
opson
kill
via
phagocytosi
examin
patient
suspect
immunodefici
identifi
one
patient
normal
level
mbl
capac
activ
complement
system
probe
carbohydr
surfac
patient
found
homozyg
snp
first
domain
domain
steengardpetersen
et
al
new
eng
j
med
mutat
chang
aspart
acid
glycin
prevent
associ
mbl
ficolin
sinc
observ
homozygoc
two
patient
snp
occur
caucasian
gene
frequenc
give
rise
defici
gene
frequenc
state
mention
paper
base
blood
donor
independ
verifi
howev
appear
statist
aberr
observ
snp
analyz
sampl
healthi
asian
hong
kong
innat
immun
system
factor
may
involv
poor
outcom
cystic
fibrosi
patient
age
year
screen
mbl
level
mbl
genotyp
snp
observ
higher
frequenc
snp
patient
popul
homozyg
individu
correl
lung
function
seen
snp
level
theoret
defici
seriou
condit
mbl
defici
sinc
also
requir
complement
activ
hand
lficolin
p
william
c
stephen
l
hedg
mani
e
hodg
j
smith
depart
clinic
immunolog
southampton
gener
hospit
southampton
unit
kingdom
cvid
heterogen
primari
immunodefici
disord
characteris
hypogammaglobulinaemia
repeat
bacteri
infect
whilst
mani
cellular
abnorm
describ
patient
recent
interest
focus
subtyp
patient
base
upon
presenc
absenc
peripher
b
cell
memori
subset
develop
whole
blood
assay
detect
narv
memori
b
cell
peripher
blood
compar
previous
describ
pbmc
separ
techniqu
subtyp
peripher
b
cell
addit
analys
cohort
cvid
patient
use
assay
compar
peripher
blood
memori
b
cell
subset
distribut
seen
within
peripher
secondari
lymphoid
organ
four
colour
flow
cytometri
undertaken
upon
lyse
whole
blood
densiti
centrifug
separ
peripher
blood
mononuclear
cell
seri
healthi
control
use
compar
method
control
analys
set
refer
rang
use
whole
blood
assay
cvid
patient
subtyp
method
mbo
memori
cell
class
switch
memori
cell
normal
memori
cell
classif
patient
within
classif
secondari
lymphoid
tissu
archiv
analys
immunohistochemistri
presenc
memori
b
cell
whole
blood
assay
perform
well
correl
densiti
centrifug
separ
techniqu
previous
describ
igm
memori
cell
correl
coeffici
r
two
assay
class
switch
cell
normal
refer
rang
establish
use
healthi
control
percentag
peripher
b
cell
narv
b
cell
f
total
memori
cell
f
igm
memori
cell
f
class
switch
memori
cell
f
cvid
patient
analys
subtyp
mbo
subtyp
stabl
month
period
tissu
section
analys
repres
patient
group
lymph
node
patient
show
evid
germin
centr
b
cell
compar
normal
tonsil
similarli
lymph
node
biopsi
patient
show
evid
memori
b
cell
lymph
node
final
duoden
biopsi
patient
show
evid
posit
memori
b
cell
within
tissu
whole
blood
assay
appear
inform
previous
describ
assay
assess
b
cell
memori
statu
assay
cost
effect
conveni
undertak
within
routin
laboratori
refer
rang
establish
minimum
level
total
memori
b
cell
mean
f
individu
less
total
memori
cell
igm
memori
cell
class
switch
memori
cell
b
cell
memori
subset
constant
time
adult
patient
cvid
correl
b
cell
identifi
peripher
lymphoid
tissu
object
recoveri
cell
children
haart
support
exist
homeostat
mechan
detect
low
level
tcell
activ
necessari
mechan
achiev
tcell
repopul
experi
thymu
play
key
role
repopul
thu
homeostat
mechan
like
lead
increas
thymic
product
new
cell
order
establish
role
plasma
level
haart
prognost
marker
tcell
recoveri
hivinfect
children
retrospect
longitudin
studi
perform
hivchildren
firstlin
highli
activ
antiretrovir
therapi
haart
patient
method
inclus
criteria
begin
haart
proteas
inhibitor
b
tcell
entri
studi
c
least
month
followup
one
year
age
initi
hivinfect
children
firstlin
haart
hivchildren
tcell
biolog
sampl
could
select
studi
hivinfect
children
divid
two
group
accord
percentil
plasma
low
hivchildren
haart
low
pgml
baselin
b
high
hivchildren
haart
high
n
pgml
baselin
result
hivinfect
children
plasma
level
pgml
achiev
tcell
faster
hivchildren
plasma
level
pgml
p
way
hivchildren
plasma
level
pgml
achiev
tcell
confid
interv
month
hivchildren
plasma
level
pgml
achiev
tcell
month
rp
immunolog
respons
haart
also
calcul
high
group
rp
achiev
tcell
conclus
data
indic
good
marker
tcell
recoveri
hivinfect
children
mathemat
model
transmiss
dynam
hiv
infect
lead
deeper
understand
dispar
experiment
data
identifi
therapi
like
effect
control
diseas
dynam
model
timedepend
hiv
preval
nairobi
sex
worker
cohort
lead
predict
subsequ
observ
observ
resist
immun
hiv
infect
exhibit
member
cohort
absolut
transient
thu
whatev
cellular
type
immun
respons
observ
resist
hiv
infect
strong
enough
reliabl
prevent
infect
dynam
hiv
infect
viral
densiti
threshold
infer
dynam
model
extrapol
region
model
analysi
viral
load
growth
primari
hiv
infect
lead
conclus
viral
load
doubl
time
immedi
follow
infect
vari
day
analyz
publish
model
result
steadyst
hiv
infect
chronic
infect
patient
lead
conclus
viral
load
doubl
time
immedi
follow
haart
interrupt
virtual
ident
result
primari
infect
patient
moreov
doubl
time
threshold
infect
patient
treat
vaccin
andor
therapi
andor
haart
withdraw
virtual
ident
untreat
cohort
thu
neither
prolong
familiar
hiv
infect
vaccin
andor
therapi
significantli
increas
strength
immun
systemt
humor
interferon
respons
hiv
infect
import
question
answer
vaccin
andor
therapi
fail
measur
strengthen
immun
system
respons
hiv
infect
dynam
model
rebound
hiv
infect
follow
haart
withdraw
lead
conclus
immun
systemt
inabl
reduc
viral
load
valu
threshold
due
failur
phagocyt
arm
failur
cellular
arm
clear
product
infect
cell
host
rapidli
enough
rate
failur
traceabl
exist
pool
product
infect
cell
cell
natur
killer
cell
etc
whose
halfliv
vivo
uncharacterist
long
number
easili
replac
newli
infect
similarli
longliv
cell
one
compart
pool
consist
natur
killer
cell
higher
surviv
half
live
typic
infect
cell
unaffect
haart
pool
clear
immun
system
prime
vaccin
andor
respons
observ
characterist
satur
viral
densiti
curv
viral
setpoint
thu
hiv
infect
immun
system
elimin
sourc
viral
product
ownoutsid
antivir
intervent
need
expand
haart
includ
fusion
blocker
overcom
current
defici
promis
path
take
seek
effect
therapi
hiv
infect
moreov
achiev
use
ideal
haart
prophylact
would
prevent
infect
uninfect
sebastian
newrzela
sanaz
taromi
roland
zahn
dorothe
von
laer
georgspeyerhau
chemotherapeutisch
forschungszentrum
georgspeyerhau
chemotherapeutisch
forschungszentrum
frankfurt
main
hessen
germani
transfer
genemodifi
cell
potent
option
treatment
immun
defici
major
technic
challeng
preserv
repopul
capac
cell
ex
vivo
expans
culturea
limit
surviv
transplant
genemodifi
cell
observ
sever
clinic
trial
show
transplant
ex
vivo
expand
cell
may
competit
disadvantag
nonmanipul
cell
recipi
especi
transgen
confer
strong
select
advantagew
establish
transplant
model
lymphocyt
defici
mous
strain
analyz
repopul
capac
transplant
cell
donor
cell
collect
mice
one
popul
treat
ex
vivo
expans
transduct
protocol
popul
serv
unmanipul
competitor
cell
popul
mix
sever
variat
transplant
recipi
competit
repopul
treat
untreat
cell
analyz
distinguish
surfac
antigen
express
data
predict
high
level
gene
mark
also
dfitnesst
transplant
cell
determin
effect
therapi
genemodifi
cell
bw
present
age
yr
tonsil
pneumonia
lymphadenopathi
oral
thrush
anaemia
hepatosplenomegali
investig
reveal
lymphopenia
l
neut
lymp
mono
throat
mouth
swab
reveal
h
haemolyt
group
c
strepococcu
pseudomona
aeroginosa
candida
chest
radiographi
show
right
middl
lobe
pneumonia
treat
iv
erythromycin
cefuroxim
made
good
recoveri
within
month
present
right
side
pneumonia
complic
empyema
treat
effect
intraven
azlocillin
tobramycin
four
month
later
present
strepococc
pneumonia
treat
intraven
penicillin
cefotaxim
commenc
long
term
penicillin
prophylaxi
age
year
present
vasculit
rash
lower
limb
buttock
compat
pityriasi
lichenoid
stage
assess
immunolog
reveal
normal
serum
igg
gl
igm
gl
iga
poor
respons
pneumococcu
hib
vaccin
immunophenotyp
blood
lymphocyt
show
reduc
posit
cell
l
respect
normal
b
cell
l
poor
respons
pha
bone
marrow
examin
unremark
ebv
serolog
posit
igg
consist
recent
acquir
infect
apoptot
defect
cell
shown
excess
surfac
express
cell
togeth
enhanc
apoptosi
cell
cultur
judg
propidium
iodid
annexin
v
stain
age
yr
bw
mount
good
antibodi
respons
pneumococcu
hib
lymphocyt
respons
pha
normal
howev
lymphopenia
l
respect
persist
bw
monitor
routin
age
lymphocyt
count
improv
popul
dual
posit
cell
found
first
time
lymphocyt
dual
posit
clone
identifi
associ
doubl
posit
cell
confirm
cell
sort
analysi
clone
identifi
earlier
popul
cell
evid
tcr
igh
clone
earlier
cell
prepar
bw
current
well
without
prophylact
antibiot
present
child
apoptot
defect
low
count
develop
clonal
dual
posit
cell
popul
clinic
improv
evid
caus
popul
viral
aetiolog
remain
possibl
span
cm
use
determin
haplotyp
eight
haplotyp
observ
across
famili
case
proband
carri
recur
haplotyp
common
haplotyp
carri
present
patient
case
mutat
screen
done
sscp
ptt
dhplc
direct
sequenc
cdna
subsequ
sequenc
abnorm
region
twenti
eight
differ
mutat
identifi
patient
new
aberr
splice
eight
founder
mutat
found
allel
phenotyp
featur
patient
presenc
atm
protein
atm
kinas
activ
csa
serum
afp
level
serum
ig
level
antibodi
product
pneumococc
polysaccharid
frequenc
sinopulmonari
infect
rate
progress
ataxia
outcom
compar
genotyp
gener
diseas
outcom
correl
genotyp
howev
differ
diseas
progress
note
patient
mutat
milder
diseas
infrequ
sinopulmonari
infect
longer
life
span
posit
antibodi
product
pneumococc
polysaccharid
atm
protein
undetect
test
five
patient
develop
lymphoma
two
develop
leukemia
one
develop
thyroid
carcinoma
survey
demonstr
haplotyp
effici
initi
screen
techniqu
identifi
mutat
turkish
patient
ethnic
popul
elena
dorofeeva
roman
khanferyan
immunoregul
institut
allergi
asthma
krasnodar
russian
feder
background
fungi
implic
inflammatori
reaction
immun
nonimmun
mechan
rhiniti
asthma
hypersensit
pneumon
allerg
bronchopulmonari
mycos
allerg
fungal
sinus
extrint
allerg
alveol
etc
exact
preval
fungal
allergi
known
studi
base
skin
test
suggest
least
adult
children
worldwid
affect
fungal
allergi
bush
rk
portnoy
jm
homer
et
al
apart
direct
allergen
effect
fungi
may
carri
mycotoxin
spore
produc
volatil
metabolit
miller
jd
et
al
trichotecen
mycotoxin
group
structur
toxin
produc
mainli
fusarium
fungi
found
mani
crop
varieti
fusarium
fungi
produc
number
differ
mycotoxin
class
trichothecen
three
better
known
toxin
toxin
deoxynivalenol
vomitoxin
inhal
mycotoxin
aflatoxin
secalon
acid
zearalenon
trichothecen
produc
aspergillu
penicillium
fusarium
fungi
may
affect
immunolog
respons
lung
tissu
present
hazard
human
health
aim
investig
evalu
possibl
mechan
immunosuppress
effect
toxin
differ
cell
mechan
immun
system
result
toxin
dosedepend
increas
synthesi
antiovalbuminigeab
effect
genet
restrict
mycotoxin
dosedepend
inhibit
stem
cell
prolifer
mice
phainduc
mnc
prolifer
toxin
suppress
activ
periton
spleen
bone
marrow
alveolar
macrophag
product
influenc
toxin
decreas
well
activ
differ
hydrolas
sensit
enzym
bone
marrow
macrophag
toxin
well
suppress
activ
enzym
especi
thiol
proteinasescatepsin
b
c
h
less
sensit
hydrolas
spleen
periton
macrophag
conclus
trichotecen
mycotoxin
induc
immunotox
mainli
immunosuppress
effect
differ
immun
cell
via
multipl
mechan
bone
marrow
cell
sensit
immunosuppress
effect
studi
mycotoxin
vardan
sergey
aprikyan
nata
adolf
otieva
neuroimmunolog
inst
biochemistri
yerevan
armenia
pharmacolog
state
univers
yerevan
armenia
known
acquir
neutropenia
disord
neutrophil
product
predispos
patient
acut
recurr
bacteri
infect
purpos
studi
examin
effect
new
cytogenessynthet
short
peptid
base
natur
origin
brain
bone
marrow
immunoregulatori
peptid
design
laboratori
blood
count
develop
infect
patient
acquir
neutropenia
differ
genesi
provid
hematolog
clinic
analysi
use
standard
method
patientst
object
investig
healthi
volunt
previou
cytotox
chemotherapi
radiotherapi
daili
observ
healthi
individu
without
cytogen
treatment
normal
blood
count
serv
control
found
peptid
complet
restor
quantit
qualit
index
blood
neutrophil
count
stimul
function
activ
time
observ
complic
deviat
blood
count
patient
observ
month
immunotherapi
ill
easi
form
simpl
herp
viru
result
present
studi
indic
cytogen
may
restor
differenti
blood
count
avert
develop
infect
put
complet
recoveri
patient
acquir
neutropenia
differ
genesi
introduct
acut
otiti
media
acut
inflamm
middl
ear
sign
symptom
fever
otalgia
red
tympan
membran
accumul
fluid
middl
ear
import
bacteria
caus
otiti
media
streptococcu
pneumonia
hemophilu
influenza
polysaccharid
capsul
acut
otiti
media
one
major
childhood
infect
caus
temporari
hear
loss
may
affect
languag
develop
patient
inform
level
immunoglobulin
complement
patient
otiti
media
iran
along
frequent
complic
otiti
media
encourag
us
evalu
level
immunoglobulin
complement
patient
help
defect
immun
studi
children
otiti
media
healthi
children
age
year
evalu
serum
gamma
globulin
determin
serum
electrophoresi
igm
igg
iga
serum
determin
singl
radial
immunodiffusionlevel
igg
serum
determin
sandwich
elisa
homemad
elisa
result
show
otiti
media
occur
male
time
femal
level
gammaglobulin
igm
iga
increas
patient
group
versu
health
group
year
age
group
p
b
meaning
increas
year
age
group
note
p
n
static
differ
note
level
igg
c
c
patient
health
group
age
group
p
b
igg
decreas
group
versu
health
group
year
age
group
p
b
statist
differ
note
year
year
age
group
p
n
new
composit
immunotherapi
treatment
secondari
immunodefici
accompani
viral
infecti
syndrom
among
differ
clinic
syndrom
accompani
secondari
damag
immun
systemth
viral
syndrom
lead
one
studi
last
year
demonstr
fact
person
recurr
episod
till
acut
viral
respiratori
infect
ravri
year
may
also
persist
viral
infect
cmv
veb
hsv
ii
type
often
clinic
manifest
similar
bsyndrom
chronic
fatigu
studi
patient
ravri
f
age
till
year
clinic
marker
secondari
immunodefici
accompani
viral
infect
syndrom
detect
system
ifn
plasmat
ifn
ifna
ifng
immun
system
rbtl
igg
iga
igm
neutrophyl
phagocyt
herp
viral
infect
hsv
iii
type
cmv
veb
mean
pcr
test
specif
antibodiesigg
igm
class
hsv
iii
type
cmv
veb
patient
combin
defect
ifnt
system
differ
defici
tcellt
immun
nk
cell
phagocyt
patient
suggest
herpesvir
infect
patient
treat
follow
complex
immunotherapi
differ
combin
local
system
ifn
therapi
recombin
viferon
oil
use
high
middleand
lowdos
therapi
monthbas
therapi
specif
non
specif
passiv
intraven
immunoglobulin
cytotect
pentaglobin
intraglobin
octagam
necessari
immunomodul
therapi
thymust
factor
tactivin
tymogen
imunofan
direct
restor
tcellt
immun
synthet
prepar
polyval
effect
polyoxidonium
licopidum
reconstruct
nk
neutrophyl
leucocyt
present
itt
possibl
combin
immunotherapi
therapi
synthet
antivir
drug
kind
immunoreconstruct
may
accompani
bsupport
therapyq
use
new
kind
complex
immunotherapi
treatment
secondari
immunodefici
accompani
viral
syndrom
obtain
posit
clinic
immunolog
effect
effect
shown
decreas
frequenc
acut
episod
recurr
viral
infect
till
per
year
elimin
viral
pathogen
patient
reconstruct
destroy
differ
immun
mechan
macrophag
activ
factor
hivinfectedaid
patient
n
yamamoto
ueda
molecular
immunolog
socrat
institut
therapeut
immunolog
philadelphia
pa
usa
although
human
immunodefici
viru
hiv
report
infect
macrophag
activ
macrophag
support
growth
hiv
due
lack
dna
replic
macrophag
highli
activ
via
inflamm
recogn
develop
receptor
virus
destroy
varieti
virus
infect
cell
inflammationprim
macrophag
activ
process
princip
macrophag
activ
cascad
requir
serum
vitamin
bind
protein
known
gc
protein
particip
b
lymphocyt
stepwis
hydrolysi
gc
protein
membran
hgalactosidas
bgl
inflammationprim
b
cell
sialidas
cell
yield
potent
macrophag
activ
factor
protein
nacetylgalactosamin
remain
sugar
yamamoto
mol
immunol
thu
gc
protein
precursor
princip
macrophag
activ
factor
maf
howev
maf
precursor
activ
serum
gc
protein
hivinfect
patient
lost
reduc
gc
protein
deglycosyl
serum
anacetylgalactosaminidas
nagalas
secret
hivinfect
cell
yamamoto
et
al
aid
re
hum
retroviru
thu
deglycosyl
gc
protein
convert
maf
sinc
macrophageactiv
enhanc
phagocytosi
antigen
present
b
lymphocyt
first
indispens
step
humor
cellular
immun
develop
lack
macrophag
activ
lead
immunosuppress
exogen
given
maf
howev
bypass
deglycosyl
gc
protein
directli
act
macrophag
activ
stepwis
treatment
highli
purifi
gc
protein
immobil
hgalactosidas
sialidas
gener
potent
macrophag
activ
factor
term
gcmaf
ever
discov
produc
side
effect
human
efficaci
gcmaf
sever
hivinfectedaid
patient
assess
hivspecif
serum
nagalas
activ
serum
nagalas
level
proport
amount
hivinfect
cell
viru
load
approxim
weekli
administr
ng
gcmaf
week
intramuscular
inject
patient
exhibit
insignificantli
low
serum
nagalas
level
equival
healthi
control
erad
hiv
hivinfect
cell
confirm
complet
clearanc
viral
antigen
ie
blood
stream
diseas
relaps
four
year
complet
gcmaf
therapi
anacetylgalactosaminidas
activ
found
fusion
protein
human
immunodefici
viru
type
n
yamamoto
molecular
immunolog
socrat
institut
therapeut
immunolog
philadelphia
pa
usa
serum
vitamin
bind
protein
known
gc
protein
precursor
princip
macrophag
activ
factor
maf
precursor
activ
serum
gc
protein
lost
reduc
hivinfectedaid
patient
patient
sera
contain
anacetylgalactosaminidas
nagalas
deglycosyl
serum
gc
protein
yamamoto
et
al
aid
re
hum
retroviru
deglycosyl
gc
protein
convert
maf
thu
lose
maf
precursor
activ
sinc
macrophag
activ
enhanc
phagocytosi
antigen
present
b
lymphocyt
first
indispens
step
humor
cellular
immun
develop
lack
macrophag
activ
lead
immunosuppress
opportunist
neoplasm
therefor
nagalas
activ
level
hivinfectedaid
patient
sera
regul
degre
immunosuppress
nagalas
hivinfect
patient
blood
stream
found
complex
patient
immunoglobulin
g
suggest
enzym
immunogen
seemingli
viral
gene
product
fact
nagalas
induc
treatment
hivinfect
patient
peripher
mononuclear
cell
proviru
induc
agent
mitomycin
c
glycosidas
resid
outer
envelop
protein
capabl
interact
cellular
oglycan
although
clone
exhibit
nagalas
activ
treatment
trypsin
min
express
nagalas
activ
suggest
proteolyt
cleavag
gener
requir
nagalas
activ
fact
clone
exhibit
nagalas
activ
clone
show
enzym
activ
sinc
proteolyt
cleavag
protein
requir
express
fusion
capac
nagalas
activ
nagalas
seem
enzymat
basi
promot
fusion
initi
infect
clone
treat
trypsin
min
nagalas
activ
increas
significantli
suggest
proteolyt
cleavag
site
loop
may
requir
enhanc
nagalas
activ
infect
dipeptidylpeptidas
iv
dppiv
activ
also
abl
cleav
immedi
adjac
residu
tryptic
site
loop
support
requir
infect
enhanc
capac
nagalas
activ
therefor
nagalas
appear
play
dual
role
viral
infect
immunosuppress
nagalas
activ
pathogen
signific
hiv
infect
eight
patient
primari
immunoglobulin
defici
associ
lymphadenopathi
hepatosplenomegali
pulmonari
infiltr
background
patient
common
variabl
immunodefici
cvid
present
adenopathi
hepatosplenomegali
tissu
biopsi
show
presenc
sarcoidlik
granuloma
object
evalu
underli
patholog
lymph
node
liver
lung
patient
humor
immunodefici
patholog
correl
clinic
present
immunoglobulin
level
bcell
count
microbiolog
studi
design
retrospect
chart
review
patient
evalu
primari
immun
defici
clinic
mayo
clinic
rochest
set
larg
tertiari
care
medic
center
patient
patient
immunoglobulin
defici
includ
cvid
igg
subclass
defici
select
iga
defici
adenopathi
pulmonari
infiltr
hepatosplenomegali
includ
twenti
eight
patient
identifi
total
one
hundr
fifti
humor
antibodi
defici
electron
chart
patient
review
evalu
patient
underw
clinic
peripher
blood
laboratori
studi
result
present
base
patholog
evalu
lymph
node
lung
liver
biopsi
tissu
biopsi
bronchioalveolar
lavag
also
cultur
presenc
bacteri
fungal
mycobacteri
infect
result
sixteen
patient
male
averag
age
patient
f
median
rang
gener
adenopathi
affect
splenomegali
hepatomegali
sarcoidlik
granuloma
follicular
lymphoid
hyperplasia
two
patient
develop
lymphoma
one
chronic
lymphocyt
leukemia
one
patient
nocardia
lung
infect
anoth
atyp
mycobacterium
one
osteomyel
two
sepsi
twelv
signific
autoimmun
diseas
includ
hemolyt
anemia
idiopath
thrombocytopen
purpura
inflammatori
arthriti
autoimmun
disord
includ
celiac
diseas
system
lupu
diabet
hypothyroid
antiphospholipid
syndrom
patient
autoimmun
diseas
adenopathi
splenomegali
granuloma
lymphoid
hyperplasia
compar
without
autoimmun
adenopathi
splenomegali
hepatomegali
lymphoid
hyperplasia
granuloma
patient
granulomat
diseas
significantli
higher
hepatomegali
p
hemolyt
anemia
p
averag
cell
count
median
mean
count
median
mean
count
median
subgroup
differ
immunoglobulin
level
bcell
count
note
conclus
adenopathi
andor
hepatosplenomegali
patient
immunoglobulin
defici
granulomat
natur
also
includ
nodular
lymphoid
hyperplasia
autoimmun
diseas
also
preval
among
patient
differ
immunoglobulin
level
bcell
count
two
group
note
larger
number
patient
genet
mutat
analysi
might
differenti
differ
subgroup
patient
pathway
play
critic
role
control
mycobacteri
infect
patient
mutat
pathway
show
exquisit
suscept
germ
patient
fp
bcgvaccin
birth
month
age
develop
right
arm
regionalloc
bcgiti
thereaft
year
old
present
recurr
lung
infect
partial
respons
antibiot
pyrazinamideresist
bovisbcg
isol
sputum
age
fp
receiv
multipl
antimycobacteri
drug
regim
without
clearanc
mycobacteria
clinic
improv
year
age
refer
unit
present
mild
pulmonari
insuffici
mycobacteri
suppur
cervic
aden
tradit
primari
immunodefici
hiv
rule
recombin
r
ifng
ad
treatment
sc
time
week
resolut
suppur
lesion
sputum
persist
cultureposit
anoth
year
despit
combin
antimycobacteri
treatment
enter
rout
accord
mycobacteri
suscept
plu
rifng
upon
avail
defici
confirm
age
homozyg
deletioninsert
gcntt
lead
age
fp
show
profound
clinic
deterior
sever
respiratori
insuffici
cm
thorac
mycobacteri
mass
patientt
sputum
mass
grew
multidrug
resist
bovisbcg
resist
isoniazid
rifampicin
pyrazinamid
rifabutin
ethionamid
serum
show
mycobactericid
activ
vitro
proteinloos
enteropathi
steatorrhea
also
detect
time
initi
treatment
streptomycin
ciprofloxacin
clarithromycin
amoxicillinclavulan
acid
clofazimin
linezolid
sensit
antibiogram
rifng
rais
two
month
therapeut
scheme
start
sputum
turn
cultureneg
serum
show
posit
bactericid
activ
vitro
month
treatment
present
sensit
peripher
neuropathi
optic
neuropathi
complic
streptomycin
linezolid
withdrawn
capreomycin
introduc
year
antimycobacteri
treatment
whole
regim
suspend
four
month
later
weekli
azythromycin
prophylaxi
patient
remain
cultureneg
month
thorac
mass
complet
resolv
peripher
optic
neuropathi
show
signific
complet
recoveri
lead
normal
life
combin
parenter
enter
antimycobacteri
treatment
includ
linezolid
rifng
help
clear
year
cultureposit
diseas
caus
bovisbcg
acquir
multidrugresist
defici
patient
impair
intestin
absorpt
immun
monitor
studi
hiv
vaccin
clinic
trial
whole
blood
specimen
hiv
seroposit
patient
may
collect
multipl
site
sent
central
locat
pbmc
isol
cryopreserv
evalu
clinic
research
prefer
use
cryopreserv
pbmc
enabl
batch
analysi
multipl
time
point
sampl
archiv
futur
evalu
typic
investig
two
sampl
collect
option
whole
blood
collect
vacutainerr
tube
sent
central
locat
isol
pbmc
use
ficollhypaqu
densiti
gradient
separ
whole
blood
collect
vacutainerr
cptk
cell
prepar
tube
pbmc
isol
centrifug
collect
site
ship
central
locat
collect
tube
cpt
option
advantag
ficollhypaqu
option
eas
use
less
handson
sampl
manipul
function
studi
desir
know
pbmc
sampl
handl
manner
compromis
abil
cell
respond
activ
stimuli
likewis
import
suffici
recoveri
viabil
pbmc
retain
cryopreserv
prepar
therefor
would
valu
know
pbmc
collect
process
either
method
perform
similar
manner
studi
show
comparison
pbmc
collect
option
use
whole
blood
specimen
hiv
seroposit
patient
n
viral
load
b
perform
sampl
collect
two
method
compar
assess
antigenspecif
cell
immun
respons
use
cytokin
flow
cytometri
cellular
viabil
recoveri
use
hemacytomet
trypan
blue
exclus
antigenspecif
ifng
express
measur
stimul
pbmc
cmv
hiv
peptid
mix
hour
vitro
follow
fixat
permeabil
intracellular
stain
data
comparison
nonparametr
pair
ttest
analysi
intracellular
express
ifng
viabil
cellular
recoveri
perform
result
indic
pbmc
frozen
thaw
sampl
test
cmvand
hivspecif
ifng
express
perform
compar
fresh
pbmc
collect
condit
viabil
significantli
differ
fresh
frozen
pbmc
deriv
use
ficollhypaqu
p
although
never
less
pbmc
harvest
either
collect
method
signific
differ
postfreez
ifng
respons
viabil
recoveri
pbmc
deriv
ficollhypaqu
cpt
suggest
either
collect
method
would
result
compar
yield
viabl
cell
need
perform
equival
function
studi
overal
data
suggest
cpt
effici
system
collect
cryopreserv
function
activ
hiv
seroposit
pbmc
well
viabl
altern
ficollhypaqu
background
infect
ultim
result
impair
specif
immun
function
virtu
initi
bind
virion
envelop
glycoprotein
receptor
epigallocatechin
gallat
egcg
compon
green
tea
bind
strongli
mani
biolog
molecul
respons
multipl
health
benefit
egcg
inhibit
replic
human
peripher
blood
mononuclear
cell
vitro
inhibit
biochem
activ
revers
transcriptas
result
subsequ
decreas
hiv
antigen
concentr
present
evid
egcg
physiolog
relev
level
bind
molecul
attach
site
thu
establish
potenti
use
egcg
therapeut
treatment
hiv
infect
method
cell
posit
select
immunomagnet
separ
plateletdeplet
human
leukopak
obtain
highli
purifi
tcell
popul
nuclear
magnet
reson
nmr
spectroscopi
satur
transfer
differ
std
experi
examin
bind
egcg
inhibit
bind
studi
assess
flow
cytometri
result
nmr
titrat
studi
reveal
addit
um
egcg
void
nmr
signal
egcg
control
catechin
addit
igg
egcg
effect
std
experi
addit
mm
site
mm
egcg
show
strong
satur
ring
b
egcg
catechin
igg
littl
effect
investig
whether
bind
egcg
molecul
human
lymphocyt
capabl
inhibit
bind
analyz
bind
abil
egcgtreat
untreat
cell
egcg
markedli
inhibit
bind
cell
dosedepend
manner
p
p
b
thu
physiolog
relev
level
egcg
exert
inhibitori
effect
control
catechin
alter
bind
capac
molecular
model
studi
suggest
bind
site
egcg
phe
arg
trp
domain
pocket
bind
calcul
find
concentr
egcg
achiev
drink
green
tea
nm
could
reduc
bind
conclus
demonstr
clear
evid
high
affin
bind
egcg
molecul
along
conclud
egcg
concentr
equival
obtain
consumpt
green
tea
abl
significantli
reduc
attach
reason
suspect
egcg
potenti
use
adjunct
therapi
hiv
infect
potenti
competit
bind
properti
egcg
bind
site
may
translat
prevent
strategi
possibl
green
tea
extract
may
involv
futur
treatment
infect
transient
hypogammaglobulinemia
infanc
thi
may
repres
selflimit
matur
delay
normal
immunoglobulin
synthesi
earli
manifest
primari
immunodefici
evalu
distinct
immunolog
paramet
predict
natur
outcom
highlight
relev
pathogenesi
disord
b
cell
subset
stimul
vitro
immunoglobulin
product
sivip
specif
antibodi
respons
tetanu
toxoid
hib
streptococcu
pneumonia
vaccin
evalu
patient
mean
age
mo
igg
valu
mean
age
associ
low
valu
iga
andor
igm
b
intact
cellular
immun
c
absenc
clinic
immunolog
sign
immunodefici
abnorm
distinct
b
cell
subset
document
except
patient
low
express
b
memori
unswitch
cell
compar
agematch
normal
control
versu
normal
rang
stimul
vitro
immunoglobulin
product
sivip
baselin
condit
addit
reveal
normal
respons
isotyp
patient
low
valu
siviggp
sivigmp
sivigap
identifi
respect
sivip
patient
didntt
correl
serum
ig
concentr
antibodi
respons
vaccin
antigen
show
low
antibodi
respons
streptococcu
pneumonia
children
alter
siviggp
preliminari
data
emphas
role
siviggp
sivigap
biolog
predict
andor
prognost
marker
disord
make
us
advanc
hypothesi
defect
classswitch
mechan
contribut
pathogenet
scenario
thi
extens
clinic
immunolog
evalu
need
better
defin
condit
contrast
suscept
multisystem
hepatotox
reaction
nevirapin
associ
mhc
class
ii
region
associ
hypersensit
specif
cell
pc
suggest
hla
class
ii
molecul
like
directli
involv
pathogenesi
thu
immunogenet
laboratori
like
involv
increasingli
pharmocogenom
studi
provid
practic
clinic
applic
prevent
drug
hypersensit
reaction
provid
insight
pathogenesi
immunolog
mediat
drug
hypersensit
reaction
p
william
j
otb
hourihan
e
hodg
h
b
gaspar
j
smith
describ
year
old
caucasian
male
year
histori
chronic
activ
ebv
infect
age
develop
uncompl
glandular
fever
remain
well
year
age
repres
histori
headach
hemipleg
migrain
splenomegali
ultrasound
scan
confirm
splenomegali
without
hepatomegali
lymphadenopathi
head
ct
scan
normal
one
year
later
develop
left
side
bellt
palsi
abnorm
optic
disc
appear
ophthalm
review
diagnos
bilater
pseudoopt
disc
swell
retin
periphleb
immunoglobulin
analysi
show
rais
igg
age
height
fallen
th
centil
age
th
centil
endocrinolog
assess
undertaken
bone
scan
show
bone
age
delay
year
abnorm
age
admit
week
histori
pyrexia
lethargi
hepatosplenomegali
immunolog
opinion
request
accompani
neutropaenia
thrombocytopaenia
investig
reveal
ebv
dna
copi
per
ml
serolog
consist
past
infect
ultrasound
reveal
spleen
uniform
echotextur
addit
larg
intraabdomin
node
bone
marrow
examin
normal
liver
biopsi
show
evid
lymphoma
evid
acut
necrosi
chronic
inflamm
immunolog
test
reveal
hypergammaglobulinaemia
igg
gl
normal
normal
iga
igm
anti
neutrophil
antibodi
detect
autoantibodi
identifi
cellular
immunophenotyp
shown
nk
current
immunophenotyp
show
nk
tcr
h
immunophenotyp
show
expans
cell
account
cell
popul
mainli
posit
tcr
h
clonal
studi
consist
clonal
popul
protein
blot
sap
unremark
chang
persist
clearanc
ebv
occur
day
follow
treatment
acut
ill
rituximab
anti
moab
intraven
immunoglobulin
test
outsid
acut
ill
shown
low
ebv
count
copiesml
blood
reduct
cell
demonstr
ebv
dna
liver
biopsi
individu
exhibit
divers
multisystem
featur
previous
recognis
chronic
activ
ebv
infect
underli
immunolog
defect
patient
poorli
understood
clearer
understand
underli
defect
patient
advanc
understand
chronic
latent
viral
infect
immunolog
control
improv
therapeut
approach
difficult
manag
condit
rational
infant
present
recurr
infect
low
immunoglobulin
ig
lack
evid
immun
defici
disord
often
diagnos
transient
hypogammaglobulinemia
infanc
thi
although
thi
consid
primari
immunodefici
well
defin
long
term
followup
report
purpos
studi
character
infant
recurr
infect
low
ig
analyz
characterist
correl
time
elaps
ig
normal
provid
long
term
followup
method
patient
evalu
elig
term
born
month
present
one
ig
class
sd
normal
produc
antibodi
diphtheria
tetanu
evid
intact
cell
mediat
immun
lack
featur
immunodefici
syndrom
least
one
followup
set
ig
fortynin
patient
follow
collect
ig
present
followup
age
present
ig
normal
gender
data
analyz
util
parametr
surviv
analysi
assum
logarithm
time
normal
logist
distribut
time
normal
indic
time
age
diagnosi
result
includ
male
femal
mean
age
present
month
data
evalu
gender
took
longer
femal
ig
normal
compar
male
twentyf
percent
male
normal
time
year
femal
demonstr
normal
year
likewis
male
normal
year
postdiagnosi
took
femal
year
normal
differ
statist
signific
p
b
data
evalu
respect
gender
age
diagnosi
found
younger
femal
diagnosi
longer
time
normal
male
earlier
diagnosi
shorter
time
normal
gender
age
diagnosi
interact
strong
trend
pvalu
overal
cours
patient
benign
none
seriou
infect
howev
femal
nonident
twin
met
criteria
iga
defici
half
histori
wheez
atop
sever
follow
age
greater
year
conclus
femal
present
diminish
immunoglobulin
infanc
requir
longer
time
normal
compar
male
femal
present
younger
take
longer
time
normal
male
present
low
ig
infanc
display
strong
trend
toward
longer
time
normal
older
present
children
decreas
ig
infanc
heterogen
popul
mani
especi
femal
hypogammaglobulinemia
neither
transient
limit
infanc
thu
diagnosi
thi
made
retrospect
children
low
ig
demostr
abil
produc
specif
antibodi
gener
benign
cours
fewer
infect
grew
older
excess
atopi
wiskott
aldrich
syndrom
character
immun
defici
thrombocytopenia
eczema
increas
incid
autoimmun
diseas
protein
defici
syndrom
wasp
requir
actinbas
cytoskelet
rearrang
cell
activ
recent
data
suggest
tec
kinas
itk
requir
wasp
activ
actin
polymer
addit
itkdefici
mice
show
defect
helper
cell
differenti
regul
helper
cell
differenti
cytokin
product
essenti
mount
appropri
respons
pathogen
dysregul
pathway
implic
possibl
caus
hypersensit
autoimmun
given
increas
incid
eczema
autoimmun
diseas
patient
ask
whether
wasp
might
also
involv
helper
cell
differenti
function
found
murin
cell
cultur
exhibit
mark
reduct
secret
cytokin
ifngamma
cytokin
nonetheless
intracellular
stain
reveal
waspdefici
cell
produc
normal
elev
level
ifngamma
data
suggest
wasp
may
involv
secret
product
ifngamma
cell
surprisingli
follow
challeng
induc
agent
schistosoma
mansoni
egg
mice
show
heighten
respons
includ
larger
pulmonari
granuloma
higher
product
secret
cytokin
moreov
day
postinfecti
challeng
induc
parasit
toxoplasma
gondii
mice
show
fewer
number
brain
cyst
increas
product
secret
ifngamma
thu
respons
parasit
challeng
waspdefici
mice
mount
respons
vivo
may
exagger
togeth
find
suggest
waspdefici
complex
effect
helper
cell
effector
function
may
provid
insight
develop
autoimmun
patient
wiskott
aldrich
syndrom
cyclic
lymphopenia
absenc
novel
immunodefici
present
ronit
herzog
joan
berman
shirley
fung
ary
rubinstein
allergi
immunolog
albert
einstein
colleg
medicin
bronx
ny
usa
introduct
immunodefici
lymphopenia
absenc
hiv
infect
describ
repres
heterogen
condit
potent
cell
growth
factor
produc
primarili
activ
cell
synthesi
tightli
regul
mrna
level
close
relat
cytokin
share
two
receptor
subunit
util
uniqu
receptor
chain
instead
cytokin
appear
gener
ident
intracellular
signal
howev
may
distinct
vivo
properti
report
relat
alter
regul
primari
immunodefici
human
one
case
human
immunodefici
aris
mutat
report
novel
immunodefici
accompani
cyclic
lymphopenia
undetect
high
case
report
patient
year
old
male
without
underli
hiv
infect
recurr
mucos
candidiasi
cyclic
lymphopenia
cellsul
sinc
infanc
mother
die
age
pneumocysti
pneumonia
hiv
infect
immun
evalu
shortli
death
show
igg
level
mgdl
low
cell
count
patient
present
recurr
oral
esophag
candidiasi
preced
accompani
low
cell
count
anergi
candida
clinic
cours
stabl
episod
lymphopenia
recent
exacerb
patient
present
dysphagia
oral
thrush
resolv
oral
fluconazol
follow
sever
diarrhea
weight
loss
colonoscopi
reveal
sever
descend
colon
coliti
deep
ulcer
bacteri
fungal
mycobacteri
cultur
neg
total
cell
count
low
cellsul
cell
count
low
cellsul
immunoglobulin
igm
low
mgdl
normal
mgdl
igg
subclass
low
mgdl
normal
mgdl
igg
respons
pneumococc
polysaccharid
antigen
normal
mitogen
induc
lymphoprolif
respons
decreas
pokewe
mitogen
anti
nuclear
antibodi
posit
coliti
resolv
intraven
antifung
antibiot
repeat
total
cell
count
doubl
cellsul
cell
count
increas
cell
ul
lymphocyt
phenotyp
reveal
low
naiv
cell
proport
increas
memori
cell
percentag
cell
constantli
low
undetect
mrna
undetect
level
markedli
increas
conclus
present
famili
immunodefici
patient
cyclic
lymphopenia
recurr
mucos
candidiasi
ulcer
coliti
find
defici
concomit
increas
may
suggest
compensatori
mechan
mount
incomplet
adapt
immun
respons
pathway
persist
suscept
fungal
infect
sever
tcell
immunodefici
syndrom
involv
absent
thymu
coloboma
bullou
dermat
eosinophilia
elev
ige
object
report
novel
sever
immunodefici
absent
thymu
coloboma
bullou
dermat
bd
eosinophilia
elev
ige
monoclon
cell
expans
defect
method
wm
hx
coloboma
eczema
otiti
present
bd
pseudomona
superinfect
involv
trunk
eye
due
unusu
skin
find
ocular
pathogen
immun
assess
done
delin
result
section
clinic
cours
includ
skin
improv
antibiot
immunosuppress
base
immunofluoresc
studi
immunosuppress
stop
develop
eczema
herpeticum
recurr
bd
hypertens
hsm
lymphadenopathi
despit
ivig
aggress
antibiot
therapi
deterior
clinic
viremia
parainfluenza
infect
pseudomona
bacteremia
respiratori
failur
die
enterococcu
con
bacteremia
result
skin
cultur
grew
pseudomona
con
skin
biopsi
initi
show
nonspecif
dermat
classic
featur
pemphigu
vulgari
seen
later
biopsi
direct
indirect
immunofluoresc
studi
pemphigu
conclus
serum
neg
desmoglian
ab
initi
cbc
show
anc
alc
aec
eosinophilia
persist
serum
ig
level
prior
ivig
igg
iga
igm
ige
iuml
hivab
dna
pcr
neg
nbt
complement
screen
normal
isohemagglutinin
neg
blood
type
lymphocyt
phenotyp
show
ratio
mitogen
studi
immunosuppress
show
poor
respons
pha
cona
pwm
karyotyp
xy
indic
neither
matern
engraft
aneuploidi
echocardiogram
abdomin
ultrasound
age
normal
ebv
pcr
cmv
antigenemia
neg
delet
found
fish
mutat
analysi
pend
two
monoclon
cell
expans
detect
pcr
tcr
gamma
locu
hsv
igm
present
hsv
igg
detect
ivig
given
tracheal
aspir
silver
stain
neg
autopsi
reveal
absent
thymu
hsm
diffus
massiv
lymphadenopathi
lack
normal
architectur
interfollicular
zone
deplet
scatter
dendrit
cell
plasma
cell
lymphocyt
rare
primari
follicl
increas
stromal
element
without
increas
histiocyt
evid
gvhd
found
conclus
describ
sever
immunodefici
syndrom
consist
cell
predomin
nave
cell
defici
absenc
thymic
tissu
poor
mitogen
respons
distinct
monoclon
cell
expans
eosinophilia
elev
ige
although
possibl
repres
new
form
combin
immunodefici
group
find
consist
novel
present
atyp
digeorg
syndrom
p
william
j
otb
hourihan
e
hodg
g
davi
j
smith
depart
clinic
immunolog
southampton
gener
hospit
southampton
unit
kingdom
depart
child
health
southampton
gener
hospit
southampton
unit
kingdom
molecular
immunolog
unit
institut
child
health
london
unit
kingdom
report
case
pneumocysti
cainii
pcp
pneumonia
occur
caucasian
male
infant
absenc
typic
clinic
laboratori
featur
immun
incompet
case
month
old
male
infant
present
short
histori
poor
feed
respiratori
distress
follow
cxr
characterist
pcp
brochoalveolar
lavag
bal
undertaken
confirm
presenc
pcp
child
respond
high
dose
steroid
septrin
ivig
discharg
day
immunolog
investig
admiss
follow
nk
current
nk
stimul
index
follow
pha
lymphocyt
low
admiss
normal
hiv
test
neg
ligand
express
upon
activ
cell
common
g
chain
demonstr
protein
blot
tcr
ah
immunophenotyp
normal
current
well
prophylact
septrin
scig
case
month
old
infant
admit
day
histori
poor
feed
respiratori
distress
cxr
consist
pcp
subsequ
bal
confirm
presenc
pcp
treat
discharg
home
immunolog
investig
admiss
follow
nk
stimul
index
follow
pha
admiss
recent
review
immunoglobulin
normal
hiv
test
neg
ligand
express
upon
activ
cell
protein
blot
confirm
presenc
tcr
ah
immunophenotyp
normal
interestingli
childt
mother
previous
diagnos
hyper
ige
syndrom
yet
shown
rais
ige
typic
featur
mothert
condit
child
clinic
episod
associ
immun
incompet
remain
well
septrin
scig
case
month
old
infant
present
respiratori
distress
weight
loss
enterocol
cxr
show
bilater
hilar
infiltr
bal
sampl
confirm
pcp
immunolog
investig
admiss
follow
nk
stimul
index
follow
pha
normal
immunoglobulin
normal
hiv
test
neg
tcr
ah
immunophenotyp
normal
ligand
express
upon
activ
cell
children
demonstr
suscept
pcp
without
typic
featur
immunodefici
usual
accompani
present
children
scid
higm
syndrom
long
term
manag
children
appar
singl
pathogen
sensit
interest
regard
use
watch
wait
approach
imperfect
prophylact
treatment
bone
marrow
transplant
bmt
anastassia
p
mihaylova
kalina
l
penkova
danilela
n
baltadzhieva
milena
ivanova
elissaveta
j
naumova
central
laboratori
clinic
immunolog
univers
hospit
alexandrovska
sofia
bulgaria
bare
lymphocyt
syndrom
member
rel
heterogen
class
sever
combin
immunodefici
associ
lack
express
hla
antigen
cell
hematopoiet
origin
report
case
bl
protract
pneumonia
repeat
sever
infect
upper
lower
respiratori
tract
persist
diarrhea
candidiasi
sever
month
laboratori
test
reveal
hypogammaglobulinemia
mild
anaem
syndrom
leucocytosi
peripher
blood
immunophenotyp
show
promin
decreas
tcell
invert
ratio
antigeninduc
lymphocyt
prolifer
cellmedi
lymphocytotox
absent
vitro
detect
mhc
molecul
express
flowcytometri
use
monoclon
antibodi
hladr
dq
dp
antigen
well
hla
class
antigen
reveal
lack
mhc
class
ii
molecul
express
nonstimul
ifng
stimul
pbmc
contrast
express
mhc
class
molecul
conserv
sbt
type
show
unknown
polymorph
loci
sinc
gene
code
class
ii
polypeptid
seem
unaffect
genet
defect
patient
must
concern
regul
express
hladr
gene
stud
mutat
transact
gene
rfxap
abl
detect
genet
defect
respons
failur
express
class
ii
gene
patient
introduct
intraven
infus
immunoglobulin
ivig
everi
week
standard
therapi
patient
primari
immunodefici
diseas
pid
complic
ivig
therapi
limit
use
igiv
home
weekli
selfadminist
subcutan
immunoglobulin
scig
infus
home
becom
altern
therapi
regim
evalu
pasteur
preserv
free
liquid
human
igg
prepar
intend
subcutan
use
regard
safeti
efficaci
method
two
prospect
studi
one
us
canada
na
studi
one
europ
brazil
eu
studi
pid
patient
year
age
selfinfus
scig
vivaglobinr
zlb
behr
weekli
basi
home
patient
began
scig
therapi
one
week
last
ivig
infus
enter
wash
inwash
period
follow
efficaci
period
na
studi
efficaci
period
eu
studi
clinic
endpoint
includ
rate
seriou
bacteri
infect
sbi
rate
type
infect
well
serum
igg
level
observ
studi
safeti
variabl
compris
local
system
reaction
laboratori
investig
vital
sign
result
total
infus
administ
patient
cours
two
studi
patient
receiv
weekli
man
dose
mgkg
na
studi
mgkg
eu
studi
efficaci
phase
studi
three
sbi
pneumonia
report
efficaci
phase
two
studi
two
na
studi
one
eu
studi
result
ident
annual
rate
sbi
per
patient
annual
rate
kind
infect
similar
studi
episod
patient
year
na
studi
episod
patient
year
eu
studi
upper
respir
infect
frequent
report
type
infect
mean
sigg
level
increas
mgdl
mgdl
previou
ivig
dose
eu
studi
mgdl
start
scig
mgdl
previou
ivig
dose
na
studi
studi
drug
relat
seriou
advers
event
report
studi
local
inject
site
reaction
mostli
mild
moder
intens
drop
rapidli
studi
initi
cours
na
studi
eu
studi
conclus
two
major
clinic
trial
demonstr
weekli
selfadministr
scig
igg
prepar
safe
effect
patient
pid
result
normal
stabl
sigg
level
provid
satisfactori
protect
sever
bacteri
infect
rational
select
iga
defici
common
form
primari
immunodefici
howev
differ
frequenc
caucasian
asian
popul
approxim
caucasian
japanes
affect
addit
iga
defici
individu
increas
suscept
upper
respiratori
tract
gastrointestin
infect
primari
ciliari
dyskinesia
phenotyp
genet
heterogen
condit
primari
defect
ultrastructur
function
cilia
highli
complex
organel
structur
relat
flagella
sperm
protozoa
clinic
featur
includ
recurr
sinopulmonari
infect
subfertil
later
defect
latter
due
ciliari
dysfunct
embryolog
node
describ
first
time
familiar
case
associ
iga
defici
ciliari
dyskinesia
method
clinic
laboratori
evalu
two
sibl
present
divis
histori
bronchiectasi
recurr
infect
result
describ
male
sibl
year
old
start
present
recurr
infect
childhood
mainli
sinu
lung
infect
evolut
progress
loss
pulmonari
function
one
alreadi
submit
pulmonari
transplant
famili
histori
includ
father
older
brother
similar
symptom
die
dissemin
bronchiectasi
laboratori
find
show
iga
defici
normal
igg
igg
subclass
normal
respons
polyssacharid
antigen
pulmonari
ct
scan
confirm
bronchiectasi
evalu
show
oligospermia
reduct
sperm
motil
electron
microscopi
respiratori
mucosa
compat
ciliari
dyskinesia
conclus
first
report
associ
iga
defici
ciliari
dyskinesia
reinforc
import
complet
laboratori
evalu
patient
recurr
infect
granulomat
diseas
experi
one
center
increas
incid
tuberculosi
report
cgd
patient
live
endem
countri
multipl
report
complic
follow
bacillu
calmetteguerin
bcg
vaccin
affect
patient
manifest
axillari
lymphaden
local
ulcer
also
known
sever
case
dissemin
bcg
infect
set
cgd
less
commonli
atyp
mycobacteria
vaccin
strain
recogn
caus
pulmonari
infect
cgd
describ
discuss
three
cgd
patient
one
center
follow
diagnos
atyp
mycobacteri
infect
patient
year
old
man
famili
histori
autosom
recess
cgd
diagnos
cgd
follow
myobacterium
fortuitum
pneumonia
previous
report
patient
year
old
boy
one
three
affect
sibl
defici
refer
myobacterium
avium
pneumonia
bronchiectasi
numer
bacteri
pneumonia
previous
patient
defici
year
old
boy
diagnos
cgd
shortli
present
dissemin
myobacterium
chelona
infect
three
patient
respond
antimycobacteri
antibiot
recurr
mycobacteri
diseas
date
seri
atyp
mycobacteri
infect
either
roughli
coincid
preced
diagnosi
cgd
surprisingli
patient
recess
form
cgd
defici
one
rarer
defici
despit
fact
recess
cgd
less
common
gener
thought
less
sever
xlink
defici
none
patient
interferon
gamma
ifng
antibacteri
prophylaxi
time
develop
nontubercul
infect
unlik
patient
sever
defect
interferon
gamma
receptor
none
patient
recurr
mycobacteri
diseas
although
limit
invitro
data
demonstr
differ
inhibit
intracellular
mycobacteri
growth
within
pmn
monocyt
deriv
either
patient
cgd
normal
volunt
appear
predisposit
infect
atyp
mycobacteria
base
experi
suggest
rule
cgd
patient
pulmonari
dissemin
atyp
mycobacteri
diseas
consid
mycobacteria
possibl
pathogen
infect
cgd
patient
use
subcutan
immunoglobulin
treatment
chronic
wart
patient
common
variabl
immunodefici
j
h
lin
r
l
robert
depart
pediatr
allergi
immunolog
rheumatolog
univers
california
lo
angel
lo
angel
ca
usa
describ
year
old
man
diagnosi
common
variabl
immunodefici
cvid
two
year
histori
chronic
wart
eighteen
year
age
diagnos
cvid
follow
histori
chronic
sinus
chronic
otiti
media
persist
cervic
lymphadenopathi
serum
igg
level
low
mgdl
although
b
cell
subset
within
normal
limit
monthli
infus
intraven
immunoglobulin
continu
oral
antibiot
led
improv
infecti
episod
decreas
lymphadenopathi
wart
finger
elbow
persist
becam
disfigur
attempt
laser
therapi
cryotherapi
imiquimod
remov
wart
met
littl
success
difficulttotreat
wart
common
patient
immun
defici
case
describ
patient
cellmedi
immunodefici
immunomodulatori
treatment
often
focus
enhanc
lymphocyt
function
patient
normal
delay
hypersensit
respons
topic
immunotherapi
use
dinitrochlorobenzen
dncb
also
effect
one
syndrom
call
whim
wart
hypogammaglobulinemia
recurr
bacteri
infect
myelokathexi
character
low
serum
gammaglobulin
failur
leukocyt
leav
bone
marrow
chronic
neutropenia
treatment
wart
intraven
immunoglobulin
patient
met
poor
success
patient
suffer
chronic
neutropenia
therapi
cvid
chang
monthli
infus
immunoglobulin
weekli
subcutan
immunoglobulin
infus
two
month
subcutan
immunoglobulin
therapi
wart
resolv
complet
scar
even
though
patient
receiv
specif
therapi
wart
subcutan
immunoglobulin
success
resolut
cutan
wart
subcutan
immunoglobulin
treatment
suggest
subcutan
immunoglobulin
may
provid
steadyst
level
igg
allow
enhanc
abil
combat
human
papillomaviru
hypogammaglobulinem
patient
weni
lee
jinglong
huang
mingl
kuo
syhja
lin
chengjang
wu
depart
pediatr
allergi
immunolog
rheumatolog
chang
gung
univers
childrent
hospit
kweishan
taoyuan
taiwan
depart
microbiolog
immunolog
graduat
institut
basic
medic
scienc
chang
gung
univers
kweishan
taoyuan
taiwan
recent
advanc
immunolog
techniqu
lead
increas
recognit
primari
immunodefici
pid
review
pediatr
patient
suspect
immunodefici
taiwan
jan
jan
moleculargenet
analys
done
patient
investig
base
intern
classif
diseas
ninth
revis
publish
articl
patient
pid
femal
male
identifi
antibodi
product
defici
defect
phagocyt
function
combin
b
cell
immunodefici
cell
defici
one
primari
complement
defici
secondari
immunodefici
exclud
studi
recurr
sinopulmonari
infect
common
clinic
manifest
follow
sepsi
sever
skin
infect
splenomagalyhepatomegali
central
nervou
system
dysfunct
chronic
diarrhea
failur
thrive
ten
patient
die
seven
infect
one
dissemin
intravascular
coagulopathi
one
hepatocellular
carcinoma
one
lymphoma
six
novel
mutat
found
select
patient
first
report
pid
taiwan
base
chines
popul
bidirect
interact
human
immunodefici
viru
type
protozoan
parasit
leishmania
chenqi
zhao
michel
j
tremblay
microbiologyimmunolog
centr
de
recherch
en
infectiologi
stefoy
qc
canada
microbiologyimmunolog
centr
de
recherch
en
infectiologi
stefoy
qc
canada
result
overlap
geograph
distribut
coinfect
human
immunodefici
viru
type
protozoan
parasit
leishmania
becom
common
event
present
extrem
seriou
clinic
problem
two
diseas
produc
cumul
defici
immun
respons
pathogen
destroy
immun
cell
exponenti
increas
diseas
sever
consequ
one
hand
leishmania
increas
risk
progress
acquir
immunodefici
syndrom
aid
aidsrel
death
hand
acceler
dissemin
leishmania
infect
quicken
natur
cours
parasit
diseas
optim
therapeut
approach
hivleishmania
coinfect
patient
still
uncertain
due
complex
pathogenesi
coinfect
lack
literatur
inform
studi
aim
explor
put
effect
leishmania
process
replic
transmiss
potenti
role
play
leishmania
infect
experi
perform
physiolog
experiment
model
name
human
lymphoid
tissu
ex
vivo
cultur
system
human
primari
monocytederiv
macrophag
mdm
well
dendrit
cell
includ
human
primari
monocytederiv
dendrit
cell
mddc
dcsign
transfect
cell
line
result
show
leishmania
enhanc
replic
primari
human
macrophag
human
lymphoid
tissu
leishmaniadirect
increas
product
associ
complex
network
proinflammatori
cytokin
tnfa
leishmania
also
modul
process
transmiss
competit
bind
dcsign
dendrit
cell
hand
also
abl
promot
intracellular
growth
leishmania
human
primari
macrophag
enhanc
uptak
parasit
find
help
unravel
molecular
cellular
mechan
two
microorgan
interact
provid
novel
insight
complex
relationship
human
pathogen
importantli
offer
inform
may
use
design
effect
therapeut
strategi
control
diseas
progress
person
dualli
infect
leishmania
hereditari
angioedema
hae
autosom
domin
diseas
manifest
recurr
attak
intens
massiv
local
edema
without
concomit
pruritu
case
laryng
edema
attack
lifethreaten
risk
asphyxi
treat
adequ
aim
object
studi
place
new
intron
mutat
gn
molecular
basi
hea
typei
investig
effect
sequenc
variat
within
code
region
inhibitor
gene
polymorph
n
g
diseas
express
report
recent
sa
cum
al
j
med
genet
method
studi
perform
member
algerian
famili
five
patient
hae
type
other
healthi
pcr
product
purifi
use
qia
quick
pcr
purif
kit
qiagen
crawley
uk
fragment
sequenc
direct
sequenc
pcr
amplifi
dna
accord
abi
prism
dnaanalys
biosystem
fonctionnel
test
perfom
transfect
cell
minigen
exon
region
inton
fellow
revers
transcript
rna
agaros
electrophoresi
cdna
result
discuss
five
member
famili
hae
typei
present
gn
mutat
within
isntt
canon
splicesit
region
fonctionnel
test
reveal
presenc
differ
band
first
one
migrat
posit
wt
band
includ
second
one
gn
mutat
caus
total
splice
defect
exon
conclu
new
mutat
gn
never
descib
right
caus
partial
splice
defect
neverthless
patient
hae
n
g
mutat
inherit
mother
whot
healthi
alreadi
describ
polymorph
fonctionnel
test
shown
differ
inhibitor
synthesi
dependig
presenc
n
g
mutat
sever
clinic
express
diseas
observ
one
patient
without
mutat
conclus
describ
new
intron
mutat
inhibitor
gene
associ
hae
gn
caus
partial
splice
defect
conclud
clinic
sever
hae
famili
explain
presenc
absenc
n
g
polymorph
immunodermatolog
bexaroten
gel
vs
vehicl
gel
combin
narrowband
ultraviolet
b
phototherapi
moder
sever
psoriasi
vulgari
background
psoriasi
chronic
autoimmun
dermatolog
disord
character
erythemat
hyperkeratot
plaqu
ultraviolet
b
uvb
phototherapi
fdaapprov
psoriasi
act
induc
apoptosi
lesion
tcell
howev
phototherapi
often
inconveni
less
effect
thick
plaqu
oral
retinoid
teratogen
rare
clear
psoriasi
monotherapi
retinoid
thin
epidermi
thick
plaqu
allow
better
penetr
uvb
sinc
limit
uvb
penetr
thick
plaqu
inhibit
efficaci
combin
retinoid
uvb
would
expect
yield
synergist
improv
efficaci
bexaroten
topic
retinoid
fdaapprov
treatment
cutan
tcell
lymphoma
clinic
evalu
treatment
psoriasi
object
determin
whether
bexaroten
gel
plu
narrowband
uvb
nbuvb
phototherapi
effect
moder
sever
psoriasi
nbuvb
plu
vehicl
gel
materi
method
singlecent
doubleblind
vehiclecontrol
bilater
comparison
bexaroten
gel
vs
placebo
combin
nbuvb
moder
sever
psoriasi
nine
subject
randomli
assign
gel
appli
target
lesion
right
left
side
bodi
week
subject
appli
bexaroten
placebo
assign
side
subject
receiv
nbuvb
time
weekli
week
begin
week
start
topic
treatment
evalu
done
week
baselin
weekli
week
start
initi
nbuvb
efficaci
assess
use
target
lesion
score
photographi
result
bexaroten
gel
plu
nbuvb
significantli
effect
placebo
plu
nbuvb
moder
sever
psoriasi
chang
target
lesion
score
compar
activ
drugand
placebotr
side
mean
decreas
score
baselin
drugtreat
lesion
ci
placebotr
lesion
ci
small
sampl
size
nonparametr
wilcoxon
ranksum
test
use
analyz
differ
score
chang
two
group
score
improv
drug
significantli
greater
compar
placebo
p
scale
erythema
indur
reduc
greater
extent
drug
advers
event
mild
includ
rash
skin
irrit
conclus
compar
placebo
bexaroten
gel
appear
increas
efficaci
nbuvb
phototherapi
minim
toxic
studi
warrant
includ
larger
number
subject
atop
eczema
ae
chronic
inflammatori
skin
disord
pathogenesi
ae
fulli
understood
defect
immun
system
ruptur
skin
barrier
import
ph
lesion
nonlesion
skin
patient
ae
higher
ph
compar
healthi
skin
ph
yeast
malassezia
belong
normal
human
skin
micro
flora
induc
ige
cell
reactiv
patient
ae
previous
identifi
sever
igebind
compon
includ
protein
sympodiali
extract
furthermor
base
amino
acid
sequenc
screen
igebind
clone
sympodiali
phage
display
cdna
librari
could
isol
clone
partial
sequenc
mention
allergen
also
shown
allergen
expos
cell
surfac
sympodiali
aim
studi
investig
whether
allergen
releas
differ
ph
condit
mimick
ae
skin
healthi
skin
sympodiali
cultur
dixon
broth
ph
cultur
supernat
analys
presenc
igebind
compon
immunoblot
use
serum
ae
patient
specif
ige
sympodiali
result
show
releas
allergen
substanti
enhanc
cultur
supernat
higher
ph
racepcr
clone
sequenc
use
find
complet
code
sequenc
protein
show
similar
glucos
oxidas
famili
sequenc
express
escherichia
coli
tag
recombin
protein
igebind
frequenc
recombin
allergen
sera
ae
patient
serum
igeantibodi
sympodiali
indic
protein
major
sympodiali
allergen
conclus
clone
major
sympodiali
allergen
releas
higher
extent
ph
data
suggest
skin
barrier
ae
patient
provid
environ
enhanc
releas
allergen
sympodiali
contribut
inflamm
purpos
skin
test
excludeinclud
infect
mycobacterium
tubercl
bacillu
popular
good
olden
day
limit
wide
spread
signific
method
tuberculin
skin
test
evid
tubercul
infect
practic
sinc
year
diagnost
tool
epidemiolog
studi
wholerandom
popul
judg
degre
control
tuberculosi
excludeinclud
indic
bcg
vaccin
problem
arisen
limit
valu
patient
immin
tubercul
infect
confirm
isol
organ
sputum
smearcultur
conclus
chemotherapeut
respons
clinic
evid
tubercul
infect
sinc
tubercul
condit
fals
neg
outcom
document
infect
atyp
mycobacteri
infect
advanc
age
tuberculosi
fals
techniqu
test
improp
storag
tuberculin
solut
overwhelm
tuberculosi
earli
stage
sarcoidosi
miliari
tuberculosi
hodgkin
diseas
malnutrit
aidsimmunodefici
tuberculosi
hyperpyrexia
tuberculosi
gener
skin
xanthoma
case
indur
observ
even
despit
activ
tubercul
infect
result
face
limit
ideal
diagnost
aid
detect
tuberculosi
role
support
test
absenc
bcg
conclus
evid
radiolog
clinic
ground
conclus
cellular
mechan
respons
skin
test
reactiv
relat
mainli
previous
popul
lymphocyt
attract
site
skin
test
tuberculin
test
neg
reactiv
restor
continu
chemotherapi
clinic
implic
tuberculin
test
despit
short
ideal
conclud
diagnosi
tuberculosi
still
import
place
diagnost
tool
list
mim
object
investig
ln
requir
induct
protect
immun
leishmania
l
major
infect
materi
method
util
mice
lack
peripher
ln
due
utero
blockad
membran
lymphotoxin
lt
peripher
p
ln
null
mesenter
ln
present
pln
null
mice
utero
antagon
membran
lt
transient
organogen
defect
ln
develop
irrevers
secondari
lymphoid
architectur
adult
progeni
mice
undergo
gestat
treatment
intact
also
investig
cours
leishmaniasi
mice
genet
delet
lt
ligand
lth
receptor
r
lack
skin
drain
ln
ln
distinguish
role
lt
ln
antil
major
immun
also
infect
wild
type
bone
marrow
chimera
express
lth
receptor
hematopoet
cell
addit
wild
type
mice
treat
neutral
lthrigg
l
major
infect
splenectomi
experi
perform
order
investig
role
spleen
resist
l
major
result
pln
null
mice
resist
strain
develop
system
infect
increas
reduc
ginterferon
secret
presenc
mesenter
ln
similarli
gene
defici
mice
without
local
drain
ln
lack
ln
leishmaniasi
dissemin
accompani
increas
secret
cell
clinic
cours
infect
similar
mice
wild
type
bone
marrow
chimera
similarli
secret
treatment
wild
type
mice
lthrigg
l
major
infect
abrog
resist
l
major
splenectom
mice
clear
infect
rate
sham
oper
mice
conclus
peripher
ln
critic
immun
l
major
genet
resist
mous
strain
ln
provid
milieu
stimul
induct
respons
prevent
immun
absenc
pln
mesenter
ln
andor
spleen
prime
respons
spleen
dispens
induct
resist
l
major
presenc
pln
interact
lt
ligand
ltr
requir
control
l
major
mice
glucocorticoid
gc
commonli
use
antiinflammatori
immunosuppress
drug
outstand
therapeut
effect
howev
often
accompani
sever
sometim
irrevers
side
effect
thu
goal
gc
pharmacolog
research
develop
new
drug
show
reduc
side
effect
profil
maintain
antiinflammatori
immunosuppress
properti
classic
gc
gc
affect
gene
express
either
transactiv
transrepress
mechan
antiinflammatori
effect
mediat
major
extent
via
transrepress
mani
side
effect
induc
transactiv
mechan
therefor
aim
identifi
ligand
glucocorticoid
receptor
gr
preferenti
induc
transrepress
avoid
least
strongli
reduc
transactiv
describ
select
nonsteroid
select
gragonist
segra
zk
show
signific
dissoci
transrepress
transactiv
activ
vitro
vivo
murin
model
skin
inflamm
zk
antiinflammatorili
activ
compar
prednisolon
system
topic
applic
remark
superior
side
effect
profil
found
regard
blood
glucos
induct
spleen
involut
lesser
extend
skin
atrophi
acth
suppress
accordingli
zk
lower
risk
eg
induct
diabet
mellitu
thu
segra
repres
promis
new
class
drug
candid
improv
effect
side
effect
profil
comparison
classic
gc
moreov
attract
tool
compound
investig
mechan
graction
object
hypertrophi
scar
keloid
may
ocur
burn
mast
cell
import
role
pathogensi
purpos
present
studi
determin
number
chang
mast
cell
experiment
model
third
degre
burn
method
third
degre
burn
made
rat
direct
contact
skin
boil
water
second
rat
divid
randomli
four
group
control
group
receiv
topic
applic
unboil
commerci
honey
onetim
per
day
twice
daili
group
group
receiv
topic
applic
nitrofurazon
cream
daili
sampl
extract
rat
day
anoth
rat
day
light
microscop
studi
stain
toluidin
blue
number
mast
cell
count
data
analyz
nonparametr
test
result
group
highest
number
mast
cell
day
f
day
f
control
group
lowest
number
mast
cell
day
f
group
lowest
number
mast
cell
day
f
conclus
conclud
topic
applic
honey
degre
burn
didntt
signific
effect
number
mast
cell
comparison
control
routin
treatment
group
pioneer
anticytokin
therapi
propos
remov
hyperproduc
ifn
skurkovich
natur
tnfa
togeth
certain
ifn
skurkovich
j
ifn
research
treat
variou
autoimmun
diseas
ad
cytokin
induc
ifngamma
ifng
tnfa
receptor
often
work
similarli
conduct
good
result
treat
ad
eg
ra
ms
corneal
transplant
reject
antiifng
treat
skin
diseas
cytokin
autoreact
cell
induc
ifng
cytokin
lesion
object
test
remov
ifng
diseas
method
antiifng
given
topic
im
day
result
acn
vulgari
propionibacteria
estrogen
adolesc
pregnanc
premenstru
period
ifng
induc
day
treatment
pustular
element
dri
day
infiltr
element
remain
pale
psoriasi
vulgari
group
strep
antigenreact
cell
ifng
found
skin
lesion
psoriasi
patient
pt
rapid
reduct
erythema
lead
disappear
papular
infiltr
week
clear
plaqu
complet
remiss
pt
small
infiltr
leg
given
uv
treatment
went
remiss
complet
therapi
plaqu
reduct
psoriat
arthriti
cytokin
found
synovi
fluid
pt
respond
psoriasi
vulgari
seborrh
dermat
express
ifng
mrna
detect
skin
biopsi
treatment
itchi
peel
skin
decreas
skin
turn
paler
herp
simplex
viru
type
autoreact
cell
lesion
skin
induc
ifng
hour
treatment
pt
note
rapid
reduct
burn
pain
lesion
day
scab
form
fade
day
dystroph
epidermolysi
bullosa
genet
diseas
ad
featur
inject
antiifng
temperatur
normal
day
pain
swell
hyperemia
ulcer
lesion
neck
disappear
sign
infecti
damag
skin
back
day
eros
lesion
mouth
epitheli
day
activ
epitheli
ulcer
skin
lesion
observ
genit
lesion
dysregul
product
ifng
may
exert
patholog
effect
increas
viru
replic
within
hour
topic
applic
itch
pain
disappear
day
erod
area
epitheli
conclus
diseas
connect
immun
disturb
ifng
play
key
role
could
also
treat
besid
antiifng
antitnfa
alon
togeth
solubl
receptor
ifng
tnfa
receptor
antagonist
antiifng
may
fewer
complic
antitnfa
infect
sle
demyelin
other
rosacea
may
also
treat
antiifng
buschket
scleredema
atyp
onset
evolut
case
report
victor
cristea
monica
crisan
claudia
magurici
ramona
bologa
nicola
miron
immunolog
iuliu
hatieganu
univers
medicin
pharmaci
cluj
napoca
cluj
romania
august
femal
patient
present
emerg
depart
clinic
signific
facial
edema
erythema
gener
pruritu
dyspnea
alter
gener
condit
manifest
appear
diet
rich
fat
spice
patient
report
two
previou
similar
episod
receiv
antihistamin
cortison
treatment
outpati
basi
case
interpret
quincket
edema
patient
administ
intraven
oral
cortison
antihistamin
prepar
hospit
laboratori
investig
perform
show
extrem
low
esr
along
leukocytosi
reach
shortli
patient
develop
interv
buschket
scleredema
locat
cephal
extrem
upper
thorax
confirm
histopatholog
examin
antitopoisomeras
antibodi
blood
examin
exclud
possibl
malign
hemopathi
ten
day
admiss
patient
becam
confus
present
sever
headach
impair
vision
temporospati
disorient
ct
examin
show
chang
patient
transfer
clinic
dermatolog
suspicion
tertiari
syphili
spite
neg
vdrl
test
penicillin
treatment
initi
week
patient
discharg
improv
condit
manifest
spastic
paraparesi
case
unusu
term
onset
evolut
direct
causal
connect
establish
quincket
edema
buschket
scleredema
spastic
paraparesi
manifest
background
chronic
periodont
result
immun
respons
specif
bacteri
infect
relat
oral
flora
present
studi
investig
quantit
qualit
aspect
immun
cell
oral
mucosa
correl
diseas
progress
method
investig
patient
year
chronic
adult
periodont
diagnosi
verifi
tradit
clinic
radiolog
examin
control
group
healthi
individu
without
symptom
periodont
diseas
inform
consent
obtain
biopsi
periodont
tissu
taken
approv
ethic
committe
serial
frozen
section
gingiv
mucosa
assess
use
avidinbiotineperoxidas
techniqu
monoclon
antibodi
hladr
tcr
gychain
data
assess
use
nonparametr
statist
result
investig
demonstr
interact
antigen
immun
cell
move
epithelium
lamina
propria
relat
sever
periodont
process
parallel
loss
protect
potenti
epithelium
specif
immunolog
featur
earli
stage
periodont
includ
increas
antigen
pressur
relat
increas
antigenuptak
dendrit
cell
subsequ
persist
inflamm
epithelium
immunolog
event
occur
lamina
propria
cytotox
respons
reduc
intens
inflamm
site
promot
autoantigen
induc
cell
sensit
cell
major
cell
popul
associ
tissu
damag
b
cell
signific
cell
progress
chronic
adult
periodont
conclus
chronic
adult
periodont
caus
pathogen
microorgan
may
part
relat
host
respons
immunemedi
event
therapi
sever
chronic
periodont
target
microorgan
erad
also
immun
respons
oral
mucosa
may
enhanc
diseas
progress
acquir
angioedema
coagulopathi
sever
year
syphili
angioedema
ae
rare
condit
character
recurr
episod
nonprurit
subcutan
submucos
swell
primarili
affect
face
extrem
upper
airway
gastrointestin
tract
ae
result
unrestrain
activ
complement
system
due
inherit
acquir
defici
inhibitor
acquir
ae
aae
manifest
adulthood
usual
forth
decad
low
serum
level
activ
exist
two
form
type
aae
mostli
associ
lymphoprolif
neoplast
disord
result
exuber
complement
activ
overwhelm
normal
reserv
acceler
consumpt
type
ii
aae
defin
presenc
autoantibodi
interfer
function
thu
allow
unoppos
complement
activ
report
case
old
man
distant
histori
syphili
treat
penicillin
experienc
first
episod
facial
edema
ingest
sweet
myrrh
root
subsid
spontan
develop
diffus
swell
upper
extrem
tongu
trigger
could
identifi
minim
workup
time
unrev
remain
asymptomat
experienc
two
episod
tongu
swell
preced
minor
trauma
poorli
fit
dentur
treat
local
emerg
depart
diphenhydramin
prednison
epinephrin
occas
gradual
resolut
edema
sever
day
take
medic
could
caus
angioedema
experi
concomit
urticaria
pruritu
subsequ
primari
care
physician
discov
suppress
refer
clinic
evalu
manag
recurr
angioedema
present
offic
asymptomat
normal
physic
exam
swell
age
famili
histori
angioedema
never
bleed
tendenc
thrombot
event
laboratori
evalu
reveal
markedli
decreas
complement
level
rang
detect
depress
level
function
reactiv
rpr
pallidum
particl
agglutin
elev
lupu
anticoagul
anticardiolipin
iga
igm
igg
pt
ptt
significantli
elev
correct
even
mix
pool
normal
serum
factor
xi
xii
respect
fibrin
split
product
ddimer
beyond
assay
rang
even
serial
dilut
case
demonstr
interconnect
complement
coagul
cascad
sever
level
also
indic
multipl
autoantibodi
coexist
individu
suggest
syphili
might
incit
culprit
result
aae
case
exemplifi
diagnost
therapeut
challeng
associ
aae
present
along
review
literatur
background
atop
dermat
ad
common
dermatolog
condit
character
prurit
eczemat
lesion
chronic
persist
skin
lesion
histolog
character
infiltr
activ
tcell
mechan
activ
remain
unclear
igemedi
facilit
antigen
present
igebear
dendrit
cell
dc
tcell
may
key
event
pathogenesi
ad
method
punch
biopsi
obtain
patient
chronic
ad
obtain
sign
inform
consent
approv
local
ethic
committe
ad
diagnos
accord
criteria
defin
hanifin
rajka
human
skin
biopsi
taken
patient
undergo
cosmet
surgeri
n
serv
normal
control
express
demonstr
epiderm
dendrit
cell
dc
ad
lesion
immunohistolog
analysi
result
cryosect
inflammatori
skin
immunostain
local
cell
well
cell
identifi
lesion
epidermi
dermi
epidermi
cell
express
found
suprabas
well
basal
level
scatter
throughout
epidermi
lclike
distribut
pattern
dendrit
shape
exhibit
membran
stain
pattern
suggest
dc
studi
abl
demonstr
dc
major
epiderm
cell
popul
express
costimulatori
molecul
situ
ad
patient
show
greatest
express
conclus
costimulatori
molecul
essenti
factor
gener
effect
immun
respons
failur
deliv
costimulatori
signal
antigen
present
lead
standard
procedur
diagnos
allerg
contact
dermat
perform
patch
test
sinc
sever
disadvantag
develop
new
vitro
test
system
would
immens
valu
gene
transcript
distinguish
allerg
nonallerg
may
potenti
serv
molecular
basi
diagnost
tool
studi
use
highdens
microarray
technolog
identif
differenti
express
gene
allergenstimul
peripher
blood
mononuclear
cell
pbmc
chromiumallerg
patient
versu
healthi
control
qualifi
gene
express
studi
chromiumallerg
patient
show
posit
patch
test
crcl
k
cr
mononuclear
cell
cultur
establish
patient
strong
vitro
prolif
respons
crcl
assess
hthymidin
assay
nonallerg
control
would
accept
studi
clinic
reaction
chromium
compound
cellular
vitro
respons
crcl
use
criteria
patient
control
select
studi
use
affymetrix
genechipr
gene
express
analys
pbmc
cultur
grown
gul
crcl
media
alon
h
total
gene
differenti
express
fold
p
b
allergenactiv
pbmc
patient
compar
control
upregul
wherea
downregul
use
realtim
pcr
differenti
express
confirm
three
select
gene
cish
statist
signific
p
b
cish
differenti
express
gene
identifi
studi
may
potenti
function
diagnost
marker
contact
sensit
ration
treat
chronic
skin
inflamm
ongo
challeng
children
adult
longterm
use
topic
calcineurin
inhibitor
corticosteroid
rais
concern
immunosuppress
malign
nuclear
factor
kappa
b
nfkb
transcript
factor
play
central
role
progress
mainten
chronic
skin
inflamm
studi
explor
possibl
use
topic
nfkb
decoy
nfkbd
safer
therapeut
altern
skin
inflamm
method
efficaci
skin
penetr
high
affin
specif
nfkbd
examin
nonclin
anim
model
sinc
pig
skin
similar
human
skin
topic
nfkbd
penetr
test
porcin
skin
dustmit
antigen
induc
atop
dermat
ad
ncnga
mous
model
employ
evalu
potenc
nfkbd
approv
drug
includ
corticosteroid
tacrolimu
pimecrolimu
result
topic
nfkbd
applic
pig
skin
result
effici
nuclear
local
nuclear
local
nfkbd
evid
throughout
epidermi
well
dermal
layer
dustmit
antigen
induc
ad
mous
model
topic
nfkbd
produc
dosedepend
reduct
ear
swell
similar
betamethason
treatment
topic
nfkbd
efficaci
dose
compar
topic
calcineurin
inhibitor
tacrolimu
pimecrolimu
nfkbd
therapi
resembl
betamethason
decreas
express
proinflammatori
cytokin
tnfalpha
tslp
inflam
ear
addit
topic
applic
nfkbd
decreas
inflamm
epiderm
hyperprolifer
cellular
infiltr
cessat
topic
betamethason
result
sever
rebound
inflamm
wherea
nfkbd
efficaci
maintain
least
day
treatment
termin
notabl
unlik
betamethason
induc
skin
atrophi
within
day
prolong
nfkbd
applic
fail
show
side
effect
conclus
result
show
antiinflammatori
steroidlik
efficaci
topic
nfkbd
skin
inflamm
without
side
effect
topic
steroid
henc
observ
illustr
potenti
topic
nfkbd
novel
effect
safe
therapeut
agent
inflammatori
skin
diseas
dual
diagnosi
pemphigu
vulgari
connect
tissu
diseas
mohsin
malik
razzaqu
ahm
oral
medicin
infect
immun
harvard
school
dental
medicin
boston
usa
background
patient
dual
diagnosi
pemphigu
vulgari
pv
autoimmun
connect
tissu
diseas
ctd
previous
report
report
lack
longterm
followup
clinic
detail
relationship
two
diseas
object
report
thirteen
patient
diagnos
pv
addit
ctd
diagnosi
system
lupu
erythematosu
sle
mix
connect
tissu
diseas
mctd
method
conduct
retrospect
analysi
clinic
profil
serolog
data
treatment
followup
patient
seen
one
tertiari
academ
referr
center
result
thirteen
patient
caucasian
mean
age
onset
pv
year
rang
ten
femal
three
male
three
patient
diseas
occur
simultan
remain
ten
pv
preced
slemctd
pv
sever
difficult
treat
twelv
patient
though
eventu
respond
therapi
patient
remiss
stabl
control
taper
therapi
longterm
followup
mean
year
rang
year
reveal
six
patient
ctd
stabl
control
period
need
symptomat
therapi
seven
patient
ctd
control
requir
corticosteroid
system
agent
lifethreaten
system
involv
observ
sle
mctd
renal
cardiac
neurolog
manifest
absent
conclus
thirteen
patient
report
may
genet
predisposit
develop
autoantibodi
unknown
trigger
factor
like
influenc
level
autoantiobodi
suscept
individu
result
clinic
diseas
present
differ
respons
therapi
two
diseas
pv
ctd
would
suggest
similar
differ
mechan
influenc
autoimmun
defin
extent
diseas
regul
immun
respons
pemphigu
vulgari
potenti
fatal
autoimmun
mucocutan
diseas
associ
product
igg
autoantibodi
desmoglein
kda
epiderm
protein
character
epitop
pemphigu
vulgari
antigen
establish
humanhuman
hybridoma
fusion
peripher
blood
mononuclear
cell
human
mous
heterohybridoma
hybridoma
design
stabl
cultur
demonstr
yield
monoclon
antibodi
specif
pemphigu
vulgari
immunofluoresc
immunoblot
elisa
assay
demonstr
monoclon
antibodi
bind
intercellular
cement
substanc
kda
protein
present
skin
specif
bind
recombin
desmoglein
protein
desmoglein
protein
igg
subclass
distribut
studi
demonstr
antibodi
subclass
natur
antibodi
pathogen
demonstr
vitro
abil
produc
acantholysi
normal
human
skin
mucou
membran
organ
cultur
vivo
induct
diseas
neonat
balbc
mice
relev
valu
monoclon
antibodi
pathogenesi
fo
pemphigu
vulgari
discuss
oral
pemphigoid
op
chronic
autoimmun
diseas
character
blister
eros
lesion
oral
mucosa
identifi
epitop
op
ab
within
integrin
alpha
subunit
design
four
subunit
fragment
b
c
immunofluoresc
studi
demonstr
fragment
present
oral
mucosa
sera
patient
activ
op
bound
fragment
subfrag
peptid
within
fragment
account
bind
test
sera
control
sera
sampl
healthi
volunt
patient
pemphigoid
diseas
op
patient
sera
immunoaffinitypurifi
op
sera
rabbit
antisera
fragment
mab
produc
basement
membran
separ
oral
mucosa
biopsi
oral
lesion
op
patient
show
ab
integrin
bind
roof
blister
laminin
bind
base
vitro
studi
identifi
peptid
integrin
molecul
ab
sera
op
patient
bind
may
play
import
role
pathogenesi
op
mohammad
bayat
zahra
asgarimoghadam
mohammad
rakhshan
fatemesadat
rezai
mohammadali
almasieh
anatomi
shahe
beheshti
univers
medic
scienc
tehran
tehran
islam
republ
iran
object
regard
acceler
fractur
heal
applic
microcurr
electr
stimul
studi
effect
microcurr
microamper
full
thick
incision
wound
heal
rabbit
studi
method
male
adult
rabbit
randomli
divid
control
experiment
group
group
divid
subgroup
base
durat
studi
day
gener
anesthesia
steril
condit
one
full
thick
incis
skin
rabbit
made
day
surgeri
experiment
group
receiv
electrotherapi
daili
hour
current
intens
current
densiti
frequenc
hz
polar
neg
first
day
posit
follow
day
end
rabbit
kill
choloroform
sampl
obtain
wound
tissu
adjac
normal
skin
histolog
tensiometer
studi
number
neurtrophil
fibroblast
cross
section
vessel
count
data
analyz
student
test
result
number
fibroblast
experiment
group
seventh
day
higher
significantli
p
b
relev
control
group
tensil
strength
experiment
group
fifteenth
day
higher
significantli
relev
control
group
discuss
seem
administr
microcurr
serv
boost
electromot
forc
behind
move
ion
radic
suffici
allow
enteri
injur
region
favor
metabol
repair
take
place
microcurr
increas
atp
product
could
acceler
wound
heal
process
key
word
electr
microcurr
stimul
wound
heal
histolog
tensiometeri
rabbit
object
therapeut
effect
nitrofurazon
ointment
heal
infect
noninfect
second
degre
burn
rat
studi
morphometr
tensiometr
microbiolog
examin
point
view
method
type
investig
experiment
adult
male
femal
rat
distribut
infect
non
infect
group
group
divid
control
nitrofurazon
subgroup
rat
burn
accord
standard
method
total
bodi
surfac
contact
boil
water
second
day
burn
day
zero
half
burn
contamin
standard
sampl
pseudomona
aeruginosa
burn
nitrofurazon
group
receiv
nitrofurazon
ointment
topic
one
time
per
day
th
th
day
morphometr
microbiolog
examin
day
tensiometr
test
perform
data
analyz
student
test
method
result
result
nitrofurazon
group
significantli
better
control
group
regard
result
present
investig
conclud
topic
applic
nitrofurazon
posit
signific
effect
second
degre
burn
wound
heal
rat
noninfect
burn
itt
effect
better
infect
burn
object
effect
low
power
gallium
aluminum
arsenid
laser
ga
al
ar
laser
radiat
number
degranul
mast
cell
open
skin
wound
bed
rat
quantit
histolog
point
view
studi
method
male
rat
randomli
divid
experiment
control
group
group
divid
subgroup
gener
anesthesia
steril
condit
one
full
thick
skin
circular
wound
made
dorsum
neck
rat
wound
day
day
zero
day
one
dose
anesthet
drug
inject
rat
also
experiment
rat
receiv
ga
al
ar
laser
energi
densiti
object
determin
activ
antigen
red
blood
cell
innat
immun
reaction
main
road
method
cancer
cell
ml
andor
bacillu
calmetteguerin
bcg
yeast
cell
ml
ad
whole
blood
cell
white
blood
cell
fresh
plasma
ns
treat
citric
acid
incub
see
result
main
autcom
index
elasa
method
result
found
cancer
cell
bcg
yeast
cell
activ
hemaimmun
reaction
antigen
activ
white
blood
cell
immun
reaction
ad
plasma
group
activ
index
f
antigen
ad
whole
blood
cell
plasma
group
significantli
higher
f
antigen
ad
white
blood
cell
plasma
group
p
b
conclus
result
indic
red
blood
cell
main
road
map
hemaimmun
reaction
red
blood
cell
complement
play
vital
role
hemaimmun
reaction
road
map
background
develop
biolog
drug
import
perform
immunolog
studi
patient
sampl
monitor
treatment
also
increas
understand
mechan
drug
thu
compar
analys
sampl
differ
laboratori
site
also
practic
reason
laboratori
analys
frozen
cell
option
use
howev
freez
cell
known
affect
surviv
function
select
loss
certain
popul
risk
could
significantli
affect
outcom
variou
analys
compar
usag
fresh
cell
object
evalu
effect
data
suggest
screen
elisa
borderlin
rang
could
increas
could
elimin
specif
elisa
test
borderlin
posit
sampl
without
miss
signific
number
specif
elisa
posit
sampl
laboratori
specif
elisa
posit
sampl
ena
unit
less
like
demonstr
id
reactiv
sampl
ena
unit
indic
rel
strong
elisa
reactiv
predict
posit
id
result
analysi
provid
link
elisa
id
result
facilit
interpret
ena
elisa
result
particularli
weakli
posit
sampl
protein
microarray
technolog
repres
rapidli
evolv
branch
proteom
research
antibodi
array
antibodi
attach
surfac
potenti
use
tool
varieti
experiment
question
inher
difficulti
approach
howev
limit
efficaci
address
problem
develop
assay
detect
multipl
specif
protein
analyt
complex
mixtur
without
attach
antibodi
solid
support
assay
base
linear
amplif
uniqu
oligonucleotid
tag
antibodi
indirectli
coupl
oligonucleotid
templat
oligonucleotid
tag
distinct
sequenc
downstream
common
promot
antibodi
bind
protein
interest
indirectli
indic
concentr
analyt
unbound
materi
wash
away
rna
polymeras
amplifi
label
rna
transcript
templat
order
interpret
profil
label
probe
hybrid
oligonucleotid
microarray
contain
complementari
sequenc
sever
advantag
approach
includ
greater
degre
multiplex
capabl
possibl
fluoresc
tag
linear
amplif
signal
sensit
specif
detect
protein
analyt
approach
potenti
compat
mani
experiment
design
includ
multiplex
analysi
cellsurfac
marker
lysat
prepar
rare
cell
popul
treat
trypsin
min
nagalas
activ
fraction
increas
significantli
suggest
nagalas
activ
resid
outer
structur
envelop
protein
influenza
virion
express
proteolyt
process
disrupt
influenza
virion
sodium
deoxychol
fraction
envelop
protein
mannos
specif
lectin
affin
column
along
electrophoret
analysi
nagalas
peak
fraction
reveal
nagalas
intrins
compon
hemagglutinin
ha
sinc
fusion
capac
nagalas
activ
ha
protein
express
proteolyt
cleavag
nagalas
activ
appear
enzymat
basi
promot
fusion
initi
infect
thu
nagalas
pathogen
signific
regul
infect
immnosuppress
similar
result
also
found
hiv
yamamoto
et
al
aid
re
hum
retroviru
envelop
virus
eg
sendai
rubella
measl
virus
introduct
although
nitric
oxid
major
regul
inflamm
littl
attent
focus
upstream
regul
solut
carrier
slc
famili
molecul
suppli
larginin
induc
synthas
ino
requir
sustain
product
macrophag
bacteri
lipopolysaccaharid
lp
cytokin
interferong
ifng
strong
induc
ino
macrophag
object
identifi
immun
cytokin
modul
lp
ifng
stimul
macrophag
examin
tdepend
immun
respons
defici
mice
materi
method
adult
wild
type
ino
defici
defici
mice
sex
strain
stimul
thioglycol
h
periton
macrophag
pm
prime
unitsml
ifng
cultur
media
h
ngml
lp
ad
addit
h
total
rna
isol
revers
transcript
cdna
product
use
amplif
ino
sever
cytokin
real
time
pcr
studi
mice
three
genotyp
inocul
intraperiton
ag
dnpklh
freundt
complet
adjuv
day
boost
use
ag
dnpklh
freundt
incomplet
adjuv
serum
collect
test
elisa
immunoglobulin
product
result
loss
ino
significantli
affect
express
loss
affect
ino
express
ifng
express
significantli
increas
ino
defici
pm
compar
wild
type
control
pm
express
significantli
decreas
ino
pm
compar
wild
type
control
tnfa
phospholipas
unchang
arginasei
arginaseii
upregul
specif
ino
pm
suggest
arginasei
activ
may
increas
absenc
substrat
usag
ino
serum
level
dramat
reduc
ino
defici
mice
primari
immun
respons
return
wild
type
level
boost
serum
igm
level
normal
genotyp
conclus
overal
defici
macrophag
result
similar
phenotyp
ino
defici
interestingli
larginin
metabol
ino
absent
upregul
arginasei
express
presum
util
excess
larginin
whether
effect
depend
remain
determin
despit
increas
infg
express
ino
defici
pm
product
reduc
follow
immun
suggest
increas
cytokin
domin
respons
absenc
ino
gene
modul
cytokin
level
express
thu
pm
appear
major
function
suppli
larginin
use
pathway
defin
function
inflamm
understand
molecular
pathway
control
product
macrophag
import
step
toward
develop
improv
therapi
inflammatori
diseas
primari
immunodefici
improv
immunolog
method
use
peptid
western
blot
peptid
array
kinas
assay
elisa
peptid
becom
instrument
tool
immunolog
research
use
howev
protein
array
hamper
ineffect
variabl
bind
effici
peptid
could
result
low
sensit
fals
posit
inconsist
signal
western
blot
elisa
use
limit
due
small
molecular
mass
overcom
hurdl
appli
inteinmedi
protein
ligat
ipl
peptid
possess
ntermin
cystein
link
carboxyl
terminu
reactiv
carrier
protein
via
peptid
bond
ligat
product
array
membran
use
western
blot
analysi
poster
demonstr
multipl
applic
intein
technolog
immunolog
method
easi
gener
carrierpeptid
substrat
suitabl
western
blot
analysi
b
product
peptid
array
improv
sensit
includ
defin
antibodi
epitop
c
gener
tailor
substrat
kinas
phosphatas
assay
background
enzymelink
immunospot
elispot
assay
use
measur
respons
vaccin
chang
follow
immunotherapi
develop
optim
valid
custom
bbi
elispot
kit
immunogen
assess
niaidsponsor
hiv
clinic
trial
compar
precis
fresh
frozen
sampl
collect
one
month
interv
measur
biolog
variabl
method
captur
antibodi
detect
antibodi
streptavidinhrp
substrat
titrat
optim
perform
bbi
kit
use
accord
kit
instruct
repeat
character
use
pha
cef
pool
cmv
ebv
flu
peptid
minimum
triplic
well
within
donor
variabl
determin
use
differ
donor
time
point
collect
one
month
apart
sampl
assay
elispot
use
fresh
cell
real
time
batch
assay
use
frozen
cell
end
month
first
time
point
within
donor
variabl
present
mean
sfc
per
pbmc
f
sd
cv
cef
donor
pha
sfc
given
per
cell
result
repeat
within
assay
similar
whether
cef
pha
assay
fresh
vs
frozen
vs
within
donor
measur
cef
f
f
f
fresh
f
f
f
frozen
pha
measur
f
f
f
fresh
f
f
f
frozen
cef
sfc
valu
higher
donor
fresh
vs
frozen
howev
differ
donor
variabl
among
sampl
donor
higher
batch
frozen
sampl
individu
run
fresh
sampl
pha
show
opposit
result
fresh
sampl
lower
sfc
valu
frozen
variabl
similar
except
donor
higher
frozen
sampl
conclus
fresh
individu
frozen
batch
assay
demonstr
similar
intraassay
repeat
cef
mean
valu
donor
time
point
essenti
fresh
frozen
sampl
interestingli
variabl
within
donor
greater
batch
frozen
sampl
fresh
sampl
suggest
day
day
variat
freez
procedur
may
result
greater
variabl
test
real
time
differ
day
donor
sampl
drawn
differ
time
support
niaidcontract
hlatyp
pbmc
sampl
establish
antigenpeptid
reactiv
acceler
standard
human
immunolog
research
develop
protocol
cryopreserv
human
peripher
blood
mononuclear
cell
pbmc
maintain
full
function
thaw
pbmc
display
n
viabil
test
peptid
protein
antigeninduc
cell
recal
respons
cytokin
elispot
assay
frequenc
percel
cytokin
product
thaw
cell
approxim
fresh
pbmc
sinc
serum
highli
variabl
breagentq
affect
result
develop
serum
free
freez
test
media
toward
standard
start
build
pbmc
librari
hlatyp
healthi
human
donor
pbmc
donor
character
reactiv
panel
individu
peptid
common
viral
class
irestrict
determin
protein
recal
antigen
recogn
cell
respect
vial
character
sampl
cryopreserv
made
avail
posit
neg
control
cell
monitor
elispot
elisa
cytokin
bead
array
tetramerpentam
cytokin
captur
assay
readi
access
highli
character
pbmc
facilit
human
immunolog
research
offer
refer
sampl
assay
standard
within
laboratori
differ
laboratori
cell
prolifer
index
reliabl
valid
method
quantifi
cell
prolifer
accord
cfse
dilut
j
c
crispin
vargasroja
j
alcocervarela
depart
immunolog
rheumatolog
instituto
nacion
de
ciencia
medica
nutricion
salvador
zubiran
mexico
citi
mexico
cell
prolifer
mechan
intim
link
immun
respons
sever
cellular
activationinduc
pathway
converg
take
place
synchron
acquisit
effector
function
phenotyp
thu
measur
essenti
import
marker
respons
varieti
stimuli
sever
method
quantif
cell
prolifer
avail
measur
h
thymidin
uptak
probabl
wide
use
howev
requir
handl
carcinogen
radioact
materi
moreov
one
cell
popul
cultur
method
distinguish
altern
approach
base
label
cell
carboxyfluorescein
diacet
succinimidyl
ester
cfse
cfse
membraneperm
fluoresc
dye
bind
coval
intracellular
molecul
cell
divid
fluoresc
intens
halv
two
result
cell
thu
round
cell
divis
produc
popul
cell
one
half
fluoresc
intens
cell
aros
use
fac
cell
prolifer
easili
distinguish
cell
prolifer
accord
dilut
dye
one
assum
mani
divis
round
cell
gone
princip
drawback
result
semiquantit
differ
subtl
comparison
difficult
present
work
present
algorithm
translat
semiquantit
data
obtain
fac
yield
numer
result
materi
method
pbmc
healthi
donor
jurkat
cell
use
cell
cultur
hour
stimul
either
plate
bound
plu
solubl
pha
cell
prolifer
quantifi
manual
count
live
dead
cell
accord
trypan
blue
exclus
b
h
thymidin
uptak
c
cell
prolifer
index
cpi
fac
studi
histogram
cfse
intens
vs
cell
number
drawn
target
popul
first
marker
set
accord
neg
control
nonstimul
cell
geometr
mean
record
next
marker
etc
set
progress
one
includ
daughter
popul
consid
geometr
mean
must
halv
popul
henc
cell
account
within
prolifer
cell
undergon
one
round
prolifer
cell
three
round
data
incorpor
algorithm
cpi
mn
result
obtain
method
compar
result
cell
prolifer
detect
three
method
result
obtain
cpi
correl
close
measur
cell
prolifer
h
thymidin
uptak
r
p
b
low
mitogen
concentr
cpi
sensit
h
thymidin
uptak
conclus
cpi
sensit
reliabl
mean
quantifi
cell
prolifer
wash
instrument
analysi
surfac
marker
leukocyt
subpopul
via
flow
cytometri
j
g
wilkinson
c
aparicio
c
smith
e
rabellino
dtcosta
biomed
research
divis
beckman
coulter
inc
miami
fl
usa
use
flow
cytometrybas
assay
leukocyt
subset
analysi
routin
practic
basic
research
clinic
research
set
signific
improv
reagent
procedur
instrument
allow
introduct
autom
techniqu
prepar
cell
sampl
prior
flow
cytometr
analysi
invalu
advantag
autom
standard
reduc
bhandson
timeq
compar
manual
techniqu
current
commonli
use
techniqu
centrifug
wash
cell
remov
contamin
materi
prior
flow
cytometr
analysi
lend
well
autom
addit
subject
cell
popul
gforc
intens
celltocel
contact
centrifug
may
alter
sensit
activ
signal
transduct
express
simplifi
autom
cell
wash
tube
noncentrifug
cellprep
instrument
design
develop
wash
cell
use
polysulfon
hollow
fiber
present
studi
carri
compar
scatter
profil
surfac
antigen
express
recoveri
rare
nonrar
event
unwash
centrifugewash
cellprepwash
cell
sampl
shown
cellprep
instrument
use
success
wash
peripher
blood
cell
suspens
advers
effect
phenotyp
scatter
profil
well
cell
recoveri
optim
aspir
dose
prepar
stop
inflamm
mous
respiratori
tract
ischenko
b
p
nikolaev
e
v
vorobeychikov
l
yu
yakovleva
v
kotova
l
ya
soloviova
v
g
konusova
protein
biochemistri
institut
highli
pure
bioprepar
saintpetersburg
russian
feder
new
drug
formul
institut
highli
pure
bioprepar
saintpetersburg
russian
feder
immunopharmacolog
institut
highli
pure
bioprepar
saintpetersburg
russian
feder
hyperproduct
main
factor
provok
inflamm
receptor
antagonist
may
serv
promis
therapeut
prophylact
agent
stop
inflammatori
process
includ
infecti
one
studi
prophylact
efficaci
assess
aerosol
applic
mice
inflamm
induc
instranas
instil
lp
efficaci
studi
two
rout
applicationth
aerosol
inject
one
base
theori
multifactor
analysi
aspir
dose
particl
size
distribut
aerosol
optim
demonstr
appli
form
aerosol
caus
decreas
inflamm
respiratori
tract
mous
efficaci
decreas
depend
aspir
dose
inhal
size
particl
decreas
inflamm
regist
aspir
dose
mcgmous
effect
inject
regist
dose
mcgmous
antiinflammatori
effect
finedispers
fraction
particl
mcm
size
higher
coarsedispers
fraction
particl
mcm
size
result
data
demonstr
advantag
aerosol
rout
administr
inject
one
use
argininerich
peptid
conjug
antisens
oligom
alter
immun
function
phosphorodiamid
morpholino
oligom
pmo
effect
antisens
agent
inhibit
gene
express
howev
limit
uptak
popul
immun
cell
without
use
mechan
chemic
procedur
often
detriment
cellular
function
restrict
use
strategi
shown
enhanc
cellular
uptak
pmo
fibroblast
conjug
argininerich
peptid
oligom
examin
uptak
peptideconjug
pmo
lineag
primari
cell
b
cell
nk
cell
well
bonemarrow
deriv
macrophag
dendrit
cell
use
flow
cytometri
measur
presenc
fluoresceinlink
pmo
treat
cell
uptak
oligom
cell
type
greatli
enhanc
addit
argininerich
peptid
compar
unmodifi
pmo
furthermor
differenti
uptak
differ
cell
type
observ
found
depend
amino
acid
composit
peptid
activ
statu
cell
demonstr
antisensespecif
effect
shown
target
express
cell
treat
pmo
peptid
conjug
rxr
antisens
efficaci
also
demonstr
forc
altern
splice
mrna
use
antisens
pmo
conjug
target
splice
junction
exon
success
uptak
pmo
peptid
conjug
immun
cell
target
inhibit
gene
express
suggest
pmo
modifi
argininerich
peptid
could
potenti
use
immun
modul
therapeut
strategi
multilevel
approach
analyz
immun
respons
target
cell
combin
cytom
proteom
techniqu
cell
sort
protein
fraction
dtcosta
e
betgovargez
c
snow
simonian
biomed
research
divis
beckman
coulter
inc
miami
fl
usa
order
simplifi
studi
bsystem
biologyq
facilit
transit
bcytomicsq
ie
link
genom
proteom
function
cell
multilevel
multiprong
approach
need
pursu
requir
cellbas
event
far
interrog
isol
eg
gene
express
protein
synthesi
phenotyp
function
signal
transduct
etc
need
integr
better
understand
bcomplexq
cellular
respons
continuum
extent
achiev
integr
cellular
analysi
techniqu
eg
flow
cytometri
imag
multiplex
assay
genom
proteom
techniqu
understand
variou
aspect
respons
thu
accomplish
unifi
evalu
cell
current
studi
author
attempt
evalu
integr
wellknown
techniqu
flow
cytometrybas
phenotyp
analysi
cell
sort
protein
fraction
analysi
better
understand
complex
natur
immun
respons
howev
applic
assay
identifi
specif
immun
respons
lack
thereof
complic
fact
individu
differ
hla
allel
haplotyp
furthermor
mani
hla
allel
popul
tend
differ
function
one
must
realiz
hla
type
order
determin
class
class
ii
mhc
molecul
present
particular
peptid
epitop
posit
elispot
experi
hlaa
hlab
hlac
allel
respect
loci
goal
laboratori
provid
immunologist
twoprong
hla
resourc
first
hla
resourc
provid
research
definit
class
class
ii
hla
type
use
dna
sequencebas
type
type
sampl
popul
throughout
world
identifi
new
rare
hla
allel
haplotyp
racial
unbias
precis
manner
mhc
class
class
ii
linkag
disequilibrium
haplotyp
determin
loci
type
hlab
allel
hla
type
laboratori
ashiclia
accredit
direct
abhi
certifi
laboratori
director
second
hla
resourc
hla
ligand
databas
http
hlaligand
ouhscedu
provid
onlin
resourc
wherebi
known
hla
class
class
ii
peptid
ligand
motif
catalogu
hla
ligand
databas
provid
resourc
wherebi
scientist
find
predict
peptid
epitop
bind
particular
hla
molecul
databas
contain
peptid
epitop
includ
ac
pathogen
summari
laboratori
provid
precis
hla
type
catalogu
peptid
ligandsmotif
function
role
human
mhc
molecul
easili
elucid
potassium
channel
immun
cell
gain
attent
recent
promis
target
immunotherapi
therefor
turn
attent
potassium
channel
antigenpres
cell
specif
human
dendrit
cell
whose
k
channel
profil
yet
describ
literatur
gener
popul
immatur
dendrit
cell
cultur
monocyt
blood
healthi
human
donor
vitro
gmcsf
previous
describ
stimul
cell
lp
tnfa
induc
matur
wholecel
patch
clamp
analysi
cell
reveal
inwardrectifi
k
current
earli
timepoint
stimul
replac
mix
voltageg
channel
later
stage
matur
ident
channel
establish
characterist
inactiv
curv
pharmacolog
blockad
immunofluoresc
stain
confirm
presenc
surfac
stimul
cell
coloc
hladr
order
determin
whether
channel
function
role
dc
matur
analyz
dc
stimul
presenc
pharmacolog
blocker
found
upregul
product
significantli
impair
decreas
valid
result
stabl
mean
block
function
turn
dominantneg
adenoviru
construct
ecdysoneinduc
gfptag
viru
code
molecul
mutat
poreform
region
induc
mutant
protein
associ
famili
member
membran
tetram
block
channel
function
compar
dc
infect
dominantneg
construct
dc
infect
control
viru
code
luciferas
found
matur
dc
express
viral
product
highli
reduc
less
express
control
overal
data
first
report
express
matur
human
dc
indic
channel
function
role
dc
matur
result
therefor
bolster
argument
k
channel
blockad
immunotherapeut
strategi
target
matur
antigen
present
cell
implic
treatment
wide
rang
immunemedi
diseas
therapeut
mechan
blockad
eae
exampl
yet
fulli
explor
may
includ
effect
antigen
present
prime
tcell
conjunct
direct
suppress
tcell
function
inde
immunohistochem
stain
plaqu
brain
ms
patient
reveal
microglia
offer
first
piec
evid
target
channel
may
affect
antigen
present
tcell
infiltr
within
brain
immun
modifi
therapi
continu
employ
develop
expand
treat
diseas
rheumatoid
arthriti
inflammatori
bowel
diseas
hiv
hcv
cancer
need
exist
assess
effect
immun
system
cylexr
develop
sever
cellbas
assay
measur
function
activ
lymphocyt
small
amount
whole
blood
assay
util
vitro
stimul
patientt
blood
sampl
follow
magnet
isol
specif
subset
lymphocyt
immuknow
tm
fdaclear
assay
measur
global
immunolog
respons
cell
tcell
memori
assay
research
test
measur
antigenspecif
respons
cell
examin
global
antigenspecif
cell
mediat
immun
cylex
platform
use
monitor
immun
statu
patient
receiv
immun
modifi
therapi
studi
immun
respons
appar
healthi
individu
druginduc
immunosuppress
transplant
recipi
foreign
antigen
includ
influenza
cmv
tetanu
ebv
well
global
immun
respons
pha
measur
transplant
recipi
undergo
lymphocyt
deplet
therapi
show
mark
decreas
global
antigenspecif
respons
recoveri
immunolog
respons
occur
gradual
next
month
larg
independ
absolut
lymphocyt
count
healthi
volunt
known
natur
exposur
vaccin
show
signific
respons
vaccin
antigen
wherea
expos
unvaccin
show
respons
studi
respons
tetanu
appar
healthi
adult
vitro
respons
tetanu
toxoid
transplant
recipi
hiv
individu
posit
antigen
respons
examin
global
antigenspecif
immun
respons
cylex
platform
use
monitor
effect
immunomodul
therapi
whether
design
enhanc
suppress
patientt
immun
respons
murin
model
human
diseas
establish
immunolog
tool
prompt
need
product
expand
murin
cell
ex
vivo
antigen
provid
import
cell
costimulatori
signal
dynabeadsr
coat
monoclon
antibodi
mab
use
shortterm
day
cultur
balbc
cell
vitro
order
defin
ratio
mab
bead
cell
allow
optim
upregul
activ
marker
increas
cell
volum
expans
cell
number
perform
bead
short
longterm
cultur
variou
lymphocyt
popul
evalu
expans
balbc
cell
observ
day
robust
prolifer
cell
mononuclear
cell
antigenspecif
cell
clone
could
also
achiev
without
loss
function
cell
could
expand
period
week
cell
could
expand
week
follow
initi
cultur
restimul
necessari
day
interv
summari
thu
develop
rigor
valid
product
allow
expans
divers
popul
murin
cell
vitro
r
gilb
h
hickmanmil
w
bardet
lui
watkin
k
jackson
w
h
hildebrand
microbiolog
immunolog
univers
oklahoma
health
scienc
center
oklahoma
citi
ok
usa
wisconsin
region
primat
center
univers
wisconsin
madison
wi
usa
sivinfect
indian
rhesu
macaqu
macacca
mulatta
often
use
anim
model
studi
hiv
infect
human
siv
retroviru
close
relat
nucleotid
sequenc
caus
aid
like
syndrom
rhesu
macaqu
term
antivir
immun
respons
macaqu
human
mount
strong
cytotox
lymphocyt
ctl
driven
antisiv
antihiv
immun
respons
respect
order
compar
human
macaqu
antivir
immun
respons
test
siv
vaccin
strategi
interpret
viral
escap
mutant
human
macaqu
class
major
histocompat
complex
mhc
peptid
bind
properti
must
elucid
laboratori
focus
upon
amino
acid
sequenc
pool
motif
individu
peptid
epitop
endogen
gener
traffick
load
class
mhc
present
studi
transfect
macaqu
class
molecul
mamu
b
b
human
cell
line
harvest
milligram
macaqu
class
molecul
elut
peptid
initi
subject
cycl
edman
degrad
result
data
show
macaqu
class
molecul
endogen
load
nonam
demonstr
ancillari
anchor
least
individu
ligand
sequenc
msm
macaqu
class
demonstr
variabl
length
well
variabl
sequenc
compar
pool
motif
final
anchor
motif
detect
method
appar
character
endogen
ligand
summari
character
endogen
macaqu
class
peptid
epitop
provid
thorough
understand
immun
respons
anim
model
introduct
measur
differenti
rna
express
multicent
clinic
trial
requir
special
attent
qualiti
sampl
prepar
sampl
collect
handl
advers
affect
result
therefor
qualiti
metric
requir
detect
assess
potenti
error
induc
factor
compar
reliabl
newli
devis
qualiti
metric
deriv
fit
statist
model
probe
level
data
highdens
oligonucleotid
microarray
compar
standard
genechipn
microarray
qualiti
metric
method
devis
metric
use
robust
multichip
analysi
rma
process
deriv
probe
set
summari
genechipn
microarray
first
metric
normal
unscal
standard
error
nuse
provid
measur
rel
chip
qualiti
deriv
residu
rma
model
second
metric
rel
log
express
rle
absolut
metric
gaug
variabl
express
measur
summar
distribut
rel
log
express
within
set
microarray
refer
set
rle
summari
sensit
technic
sourc
variabl
larg
compar
biolog
variat
metric
compar
standard
qualiti
metric
percent
present
call
gapdh
background
scale
factor
two
clinic
trial
sampl
set
assess
microarray
type
diabet
trial
array
ragwe
allergi
trial
set
standard
normal
human
control
sampl
sent
blind
within
patient
set
cours
itn
clinic
trial
use
refer
set
rle
assess
made
result
nuse
rle
metric
detect
systemat
variat
within
certain
particip
set
detect
use
standard
affymetrix
qualiti
metric
elev
gapdh
ratio
typic
cite
indic
poor
qualiti
rna
show
relationship
qualiti
appli
nuse
rle
cor
hybrid
wash
artifact
easili
visual
plot
nuse
residu
alway
true
percent
present
call
provid
closest
approxim
nuse
rle
case
extrem
low
percent
present
nuse
rle
advers
affect
cor
trial
metric
appli
identifi
chip
within
particip
time
seri
requir
exclus
analysi
would
discov
otherwis
conclus
differenti
nuse
rle
nuse
valu
unit
use
assess
rel
qualiti
array
within
analysi
set
rle
summari
provid
measur
reproduc
gene
express
data
compar
across
batch
experi
trial
reflect
variabl
express
measur
propos
metric
provid
better
basi
judg
qualiti
compar
standard
metric
class
class
ii
human
leukocyt
antigen
hla
mediat
adapt
immun
respons
sinc
individu
differ
combin
class
class
ii
hla
molecul
inherit
herhi
parent
immun
respons
infect
vaccin
differ
respect
person
person
addit
mani
autoimmun
diseas
arthriti
diabet
associ
particular
class
andor
class
ii
molecul
knowledg
patientspopul
hla
molecul
therefor
becom
key
element
vaccin
design
uncov
autoimmun
trigger
mechan
hla
dna
sequencebas
type
sbt
repres
method
identifi
polymorph
racial
independ
manner
laboratori
pioneer
continu
employ
precis
hla
sbt
method
studi
bone
marrow
transplant
vaccin
develop
autoimmun
class
ii
hla
sbt
process
split
three
stepspcr
dna
sequenc
data
processingand
report
evolut
step
high
resolut
sbt
individu
last
year
describ
migrat
method
solid
phase
sequenc
chemistri
capillari
dna
sequenc
discuss
locat
pcr
dna
sequenc
primer
compar
ssp
rsca
method
resolut
ambigu
discuss
softwar
packag
avail
data
process
describ
cost
associ
hla
sbt
robust
natur
costeffici
hla
sbt
support
continu
applic
studi
diseas
resist
vaccin
design
autoimmun
possibl
oral
toler
use
graft
transplant
xiaobin
zheng
research
develop
beij
zhongbangyumin
scitrad
compani
co
ltd
beij
china
oral
toler
studi
mani
decad
immunolog
mechan
reveal
oral
toler
use
treat
autoimmun
diseas
rheumatoid
arthriti
uveiti
eae
well
other
experiment
andor
clinic
mani
seem
obtain
benefici
effect
interestingli
oral
toler
also
use
reproduct
immunolog
ie
pregnant
immunolog
use
induc
matern
toler
patern
antigen
order
establish
immun
toler
semiallograft
fetu
mother
treat
abort
way
possibl
establish
antigenspecif
immun
toler
use
transplant
immunolog
tri
use
way
induc
immun
toler
transplant
graft
antigen
purpos
establish
immun
toler
avoid
graft
reject
would
like
suggest
strongli
hope
draw
special
attent
regulatori
tcell
nonhuman
primat
nonhuman
primat
nhp
often
use
preclin
model
evalu
toler
induc
therapi
regulatori
tcell
treg
may
crucial
mainten
toler
describ
identif
characteris
treg
nhp
cell
isol
peripher
blood
mononuclear
cell
pbmc
healthi
monkey
pbmc
longterm
drug
free
kidney
transplant
recipi
longterm
transplant
survivor
lt
one
lt
monkey
year
post
transplant
treatment
pretranspl
bloodtransfus
csa
year
two
monkey
year
cessat
treatment
costimul
blockad
csa
sever
characterist
known
specif
treg
human
rodent
investig
natur
occur
cell
present
healthi
monkey
well
lt
monkey
similar
tcell
human
tcell
nhp
prolifer
upon
polyclon
allogen
stimul
howev
contrast
human
prolifer
slightli
increas
upon
addit
activ
polyclon
cona
allogen
stimulu
cell
suppress
prolifer
although
prolifer
cell
inhibit
prolifer
irradi
inhibit
block
antitgfbeta
cell
accord
human
cell
intracellular
cell
present
lt
monkey
number
found
healthi
nhp
also
prolifer
upon
cona
allogen
donor
specif
parti
stimul
evalu
possibl
donor
specif
regul
subset
antitgfbeta
ad
whole
pbmc
cultur
lt
monkey
year
post
transplant
regul
seem
tgfbeta
mediat
correl
presenc
larg
amount
latent
tgfbeta
kidney
two
lt
monkey
neither
antitgfbeta
seem
uncov
prolifer
combin
antibodi
induc
increas
prolifer
donor
natur
occur
treg
similar
characterist
describ
human
present
nhp
suppress
although
cell
lt
monkey
immunosuppress
donor
specif
therefor
donor
specif
regul
may
confin
anoth
tcell
subset
object
kidney
graft
recipi
stabl
renal
function
absenc
immunosuppress
therapi
character
skew
tcr
vbeta
chain
usag
essenti
subset
therefor
present
studi
analyz
detail
phenotyp
function
alter
lymphocyt
drugfre
toler
patient
dftol
method
peripher
blood
lymphocyt
dftol
chronic
reject
cr
healthi
control
hc
patient
stabl
kidney
function
immunosuppress
sta
analys
flow
cytometri
phenotyp
cytotox
marker
apoptosi
measur
annexinv
stain
prolifer
cfse
result
phenotyp
reveal
increas
central
memori
decreas
lymphocyt
dftol
versu
cr
express
effector
effector
memori
lymphocyt
decreas
cr
high
correl
marker
profil
stabl
time
independ
treatment
cytotox
natur
indic
higher
express
perforin
granzym
cr
versu
dftol
invers
correl
marker
express
increas
expess
cytotox
marker
express
lower
level
fa
less
sensit
apoptosi
counterpart
hc
display
profil
dftol
indic
increas
lymphocyt
cr
rather
decreas
dftol
sta
display
mix
profil
patient
resembl
dftol
other
mimick
cr
conclus
strong
cytotox
differenti
cr
dftol
hc
suggest
suppress
patholog
cytotox
dftol
investig
target
cytotox
cell
evalu
profil
identifi
patient
risk
cr
warrant
relev
preform
antihla
antibodi
well
determin
less
known
role
alloantibodi
produc
cadaver
kidney
transplant
graft
outcom
aim
studi
evalu
incid
dynam
profil
develop
posttranspl
antihla
antibodi
impact
graft
outcom
kidney
recipi
retrospect
investig
patient
detect
alloantibodi
prior
first
cadaver
kidney
transplant
period
octob
patient
receiv
tripl
immunosuppress
therapi
biopsyproven
acut
reject
observ
chronic
rejectionin
recipi
alloantibodi
profil
determin
flowpra
screen
specif
test
one
lambda
usa
antihla
antibodi
transplant
detect
studi
patient
hla
class
ireact
alloantibodi
class
iireact
hla
class
class
ii
reactiv
donorspecif
reactiv
determin
alloantibodi
posit
patient
correl
triplet
mismatch
alloantibodi
product
observ
recipi
produc
alloantibodi
earli
posttranspl
period
nine
alloantibodyposit
patient
lost
graft
due
immunolog
caus
compar
detect
antibodi
alloantibodi
titr
evalu
demonstr
patient
high
titer
experienc
acut
reject
earli
graft
loss
low
stabl
titer
chronic
reject
common
conclus
data
suggest
recipi
posttranspl
hlareact
antibodi
like
develop
allograft
reject
might
predict
earli
follow
transplant
algorithm
basi
approach
could
test
influenc
posttranspl
allosensit
graft
surviv
humor
cellular
respons
influenza
vaccin
human
recipi
natur
toler
kidney
allograft
g
rousseykesl
c
ballet
j
aubin
brouard
j
p
soulil
background
rare
cohort
kidney
recipi
continu
enjoy
normal
renal
function
year
interrupt
immunosuppress
treatment
consid
btolerantq
assess
wether
state
toler
specif
graft
result
state
immunodefici
studi
immun
respons
patient
follow
influenza
vaccin
compar
respons
kidney
recipi
convent
mainten
immunosuppress
healthi
volunte
patient
method
toler
recipi
tol
immunosuppressedrecipi
healthi
volunt
hv
receiv
trival
influenza
vaccin
anewcaledonia
period
group
match
age
renal
function
mean
age
f
f
f
year
tol
hv
respect
mean
creatininemia
f
tol
f
recipi
receiv
convent
immunosuppress
treatment
associ
calcineurin
inhibitor
mycophenol
mofetil
humor
respons
measur
hemagglutin
inhibit
hi
titer
vaccin
month
posit
respons
defin
fold
increas
hi
titer
period
tol
hv
receiv
trival
influenza
vaccin
b
cellular
immun
respons
analyz
month
vaccin
frequenc
specif
cell
determin
ifngsecret
cell
detect
enzymelinkedimmunosorb
spot
elispot
assay
hour
vitro
stimul
vaccin
result
accord
viral
strain
posit
humor
respons
observ
tol
hv
thu
recipi
present
poor
humor
respons
compar
hv
reach
signific
differ
anewcaledonia
strain
p
b
wherea
humor
respons
tol
statist
differ
hv
howev
month
vaccin
present
strong
cellular
respons
influenza
vaccin
wherea
compar
posit
respons
observ
tol
hv
statist
differ
taken
togeth
data
suggest
patient
toler
kidney
respond
vaccin
addit
show
frequenc
cell
produc
ifng
follow
vaccin
unusu
high
possibl
due
repetit
stimul
conclus
tol
recipi
present
humor
cellular
respons
influenza
vaccin
similar
hv
suggest
toler
state
small
cohort
patient
relat
global
immunodefici
inhibitor
quantit
analysi
nfatregul
gene
express
gies
schoel
dengler
zeier
meuer
immunolog
univers
heidelberg
heidelberg
germani
cardiolog
univers
heidelberg
heidelberg
germani
nephrolog
univers
heidelberg
heidelberg
germani
introduct
calcineurin
inhibitor
cni
longterm
allograft
function
significantli
improv
problem
limit
therapeut
margin
toxic
cni
remain
unsolv
quantit
assess
inhibit
nfatregul
gene
express
hr
cyclosporin
csa
intak
repres
novel
approach
evalu
biolog
effect
csa
therapi
provid
mean
enabl
individu
immunosuppress
regimen
patient
carri
heart
allograft
compar
degre
inhibit
ifng
gmcsf
gene
express
peak
blood
concentr
csa
function
immunosuppress
assess
rtpcr
vari
consider
among
csa
treat
individu
stabl
graft
function
given
rel
constant
level
inhibit
broad
rang
drug
concentr
felt
consider
group
patient
unnecessarili
high
csa
dose
might
benefit
reduc
dose
drug
without
compromis
efficaci
immunosuppress
therapi
therefor
start
clinic
studi
reduc
dosag
csa
close
pharmacodynam
monitor
patient
six
patient
kidney
transplant
enrol
studi
monitor
period
one
year
far
patient
dose
csa
could
safe
reduc
without
significantli
chang
level
immunosuppress
conclus
patient
treat
calcineurin
inhibitor
might
benefit
reduc
dosag
drug
respond
cni
strong
inhibit
nfatregul
gene
express
christoph
braud
alexandr
dupont
magali
giral
jeanpaul
soulil
sophi
brouard
inserm
itertchu
hotel
dieu
nant
nant
franc
despit
discoveri
potent
immunosuppress
agent
chronic
reject
remain
main
caus
graft
loss
solid
organ
transplant
addit
exposur
immunosuppress
may
caus
infect
malign
contribut
high
level
posttranspl
morbid
achiev
clinic
toler
would
repres
major
progress
transplant
oper
toler
patient
accept
graft
imunosuppress
free
environn
clinic
organ
transplant
still
extrem
rare
repres
uniqu
opportun
identifi
toler
fingerprint
surfac
enhanc
laser
desorpt
ioniz
timeofflight
selditof
mass
spectroscopi
analysi
use
profil
sera
drugfre
toler
kidney
recipi
n
compar
recipi
undergo
chronic
reject
n
control
nongraft
patient
renal
failur
relat
bnonimmunologicq
kidney
diseas
uropathi
diabeti
n
whose
renal
function
match
recipi
chronic
reject
sera
fraction
fraction
fraction
load
differ
chromatograph
surfac
metal
affin
cation
exchang
result
cross
valid
analys
serum
sampl
individu
two
independ
experi
four
protein
peak
interest
select
fraction
chemistri
first
protein
peak
found
significantli
increas
sera
patient
chronic
reject
renal
failur
control
compar
oper
toler
patient
p
b
suggest
protein
peak
may
relat
renal
failur
howev
interestingli
fourth
protein
peak
increas
specif
sera
oper
toler
patient
p
b
neither
found
sera
patient
chronic
reject
renal
failur
control
consid
absenc
specif
toler
marker
identif
non
invas
specif
biolog
signatur
toler
would
open
new
perspect
manag
immunosuppress
drug
long
term
recipi
transplant
natur
suppressor
cell
chimer
toler
clinicahmedabad
experi
found
instanc
likewis
infect
correl
decreas
atp
releas
instanc
cni
level
stabl
patient
atp
deviat
preoper
baselin
indic
quiescenc
much
smaller
cni
level
mean
deviat
f
vs
f
conclus
immuknow
better
correl
clinic
statu
cni
level
therefor
could
recommend
posttranspl
monitor
object
acut
vascular
reject
avr
cellmedi
reject
cmr
remain
primari
immunolog
barrier
success
xenotransplant
costimulatori
pathway
shown
play
critic
role
allotransplant
heart
allograft
reject
immunoregulatori
role
fulli
dissect
xenotransplant
method
use
concord
lewi
rattomous
heterotop
heart
xenotransplant
model
character
role
xenotransplant
use
knockout
mice
background
jackson
lab
graft
function
monitor
abdomin
palpat
xenoantibodi
level
measur
flow
cytometri
incub
sera
transplant
recipi
lewi
rat
lymph
node
cell
follow
stain
antimous
igm
fitc
pe
conjug
antibodi
intragraft
deposit
character
western
blot
goatantimous
polyclon
antibodi
result
recipi
reject
xenograft
heart
show
cmravr
histopatholog
report
recipi
reject
xenograft
heart
show
avr
histopatholog
antibodi
driven
process
contrast
recipi
reject
xenograft
heart
show
predominantli
cmr
patholog
cell
driven
process
show
recipi
significantli
increas
serum
level
xenoantibodi
well
intragraft
igg
deposit
recipi
furthermor
recipi
show
increas
xenoantibodi
furthermor
recipi
show
deposit
complement
protein
graft
wherea
recipi
show
deposit
conclus
data
demonstr
suppress
xenogen
antibodydriven
avr
promot
cmr
furthermor
data
suggest
costimulatori
molecul
suppress
xenogen
humor
respons
inhibit
gener
result
activ
contend
play
distinct
role
regul
xenogen
reject
differenti
regul
b
cell
respons
complement
activationdegrad
result
highlight
import
differ
mechan
regul
xenogen
allogen
graft
reject
work
support
grant
cihr
mot
ordcf
canvac
chronic
immunosuppress
recipi
goal
establish
dendrit
cell
dc
base
protocol
vaccin
adopt
immunotherapi
refractori
ptld
encount
sotx
patient
studi
analyz
compar
abil
ebvpeptid
puls
polar
dc
ie
gener
sotx
patient
healthi
donor
boost
ifng
ebvspecif
cell
ex
vivo
method
sotx
patient
receiv
chronic
drug
mainten
therapi
n
healthi
control
n
recruit
studi
ebvspecif
ctl
gener
ex
vivo
cocultur
autolog
cell
load
mixtur
three
peptid
deriv
ebv
ag
assess
incid
function
polar
cell
respons
ebv
epitop
elispot
assay
ifng
elisa
assay
tgfb
perform
pbmc
ex
vivo
gener
ebvspecif
ctl
result
patientst
peripher
blood
circul
lymphocyt
preserv
function
polar
ebv
ag
compar
healthi
donor
day
ex
vivo
stimul
ebv
peptidepuls
patientst
cocultur
contain
lower
number
ctl
compar
healthi
control
suggest
defect
patientst
cell
prolif
potenti
howev
ifng
produc
ebvspecif
cell
success
boost
sotx
patient
normal
control
compar
frequenc
appear
reflect
expans
preexist
ebv
bmemoryq
cell
addit
patientsctl
produc
significantli
higher
level
tgfb
compar
healthi
donor
suggest
regulatori
cell
may
expand
vitro
conclus
result
show
stabl
sotx
patient
display
immun
ifng
respons
ebv
ag
peripher
blood
degre
compar
observ
normal
control
cell
boost
ex
vivo
use
ebv
agload
polar
dc
howev
patientst
expand
cocultur
contain
ebvspecif
cell
produc
data
suggest
patientst
normal
donor
dc
might
partial
impair
abil
becom
fulli
matur
sinc
elicit
ifng
product
ebvspecif
cell
current
investig
approach
expand
bias
cell
dcbase
cocultur
condit
optim
adopt
immunotherapi
ptld
sotx
patient
